Clustering O 0 6.211194886418525e-06
of O 0 3.754072963602084e-08
missense O 0 0.002217342145740986
mutations O 0 0.001520515768788755
in O 0 5.461898240355367e-07
the O 0 2.5091736461035907e-05
ataxia B-Disease 1 0.9999997615814209
- I-Disease 1 0.9999934434890747
telangiectasia I-Disease 1 0.9999982118606567
gene O 0 2.8826092602685094e-05
in O 0 4.3833338736476435e-08
a O 0 4.3625243506539846e-07
sporadic B-Disease 0 0.0019098049961030483
T I-Disease 1 0.9953203797340393
- I-Disease 1 0.5340796113014221
cell I-Disease 1 0.8326625227928162
leukaemia I-Disease 1 0.969423770904541
. O 0 2.3402596980304224e-06

Ataxia B-Disease 1 0.9999891519546509
- I-Disease 1 0.999954104423523
telangiectasia I-Disease 1 0.9999964237213135
( O 0 4.897738836007193e-05
A B-Disease 1 0.9999576807022095
- I-Disease 1 0.9999951124191284
T I-Disease 1 0.9999995231628418
) O 0 2.312464353337873e-08
is O 0 1.2123138048991677e-09
a O 0 8.082492541916508e-08
recessive B-Disease 0 0.0001502303930465132
multi I-Disease 1 0.7272011041641235
- I-Disease 1 0.9999493360519409
system I-Disease 0 0.3983369767665863
disorder I-Disease 1 0.7095039486885071
caused O 0 1.4664337868453003e-05
by O 0 7.39089998091913e-08
mutations O 0 1.965640649359557e-06
in O 0 3.017125216331351e-09
the O 0 1.0445079245968714e-09
ATM O 0 2.0059887901879847e-06
gene O 0 1.3600216064446613e-08
at O 0 6.39708108707282e-09
11q22 O 0 2.1643693060013902e-07
- O 0 1.0060097338282503e-05
q23 O 0 1.7457515468777274e-06
( O 0 2.528607545571049e-09
ref O 0 7.646734047739301e-06
. O 0 6.795498053158155e-10
3 O 0 2.3161181861297564e-09
) O 0 1.7293075860180807e-09
. O 0 8.131634388064413e-08

The O 0 8.685225907356653e-07
risk O 0 4.12596409660182e-06
of O 0 4.914685192147772e-08
cancer B-Disease 0 0.00938959140330553
, O 0 6.24240286128952e-08
especially O 0 1.8239903454286832e-07
lymphoid B-Disease 0 0.00018152882694266737
neoplasias I-Disease 0 0.006504445802420378
, O 0 3.506523427176944e-08
is O 0 1.0285247320496183e-08
substantially O 0 3.4290607686671137e-07
elevated O 0 1.8156708392780274e-05
in O 0 6.246679049581871e-07
A B-Disease 1 0.9999841451644897
- I-Disease 1 0.9999980926513672
T I-Disease 1 0.9999998807907104
patients O 0 1.139448067988269e-05
and O 0 3.2788733506095014e-07
has O 0 8.757995715313882e-07
long O 0 7.17120201443322e-07
been O 0 9.241767315870675e-07
associated O 0 5.937384912613197e-07
with O 0 4.711851943284273e-06
chromosomal O 1 0.999995231628418
instability O 1 0.9998487234115601
. O 0 9.432670049136505e-05

By O 0 3.8882367903170234e-07
analysing O 0 2.5341345462948084e-05
tumour B-Disease 1 0.9999133348464966
DNA O 0 6.160711200209334e-05
from O 0 8.515559102306725e-08
patients O 0 5.8536130609354586e-08
with O 0 9.235899156578853e-09
sporadic B-Disease 0 0.00012240291107445955
T I-Disease 1 0.8642798066139221
- I-Disease 0 0.012642591260373592
cell I-Disease 0 0.03725661337375641
prolymphocytic I-Disease 1 0.7421556711196899
leukaemia I-Disease 1 0.9542642831802368
( O 0 1.198873462726624e-07
T B-Disease 0 0.004574381280690432
- I-Disease 0 0.0004181320546194911
PLL I-Disease 0 0.00011406287376303226
) O 0 2.0721868665418697e-09
, O 0 2.78179590473826e-10
a O 0 1.4180205454294992e-08
rare O 0 6.350449552883219e-07
clonal B-Disease 0 1.6169529772014357e-05
malignancy I-Disease 0 0.010282671079039574
with O 0 1.58822288653937e-08
similarities O 0 5.354647782951361e-07
to O 0 1.3314060964830787e-08
a O 0 5.201455678616185e-06
mature B-Disease 0 4.2263567593181506e-05
T I-Disease 0 0.0021045973990112543
- I-Disease 0 0.00026579125551506877
cell I-Disease 0 0.006346687208861113
leukaemia I-Disease 0 0.14459528028964996
seen O 0 2.7676157969835913e-06
in O 0 1.9275836393717327e-07
A B-Disease 1 0.9999617338180542
- I-Disease 1 0.9999911785125732
T I-Disease 1 0.9999992847442627
, O 0 6.292287224596294e-08
we O 0 2.375891705597155e-09
demonstrate O 0 3.2619791312527013e-09
a O 0 5.623330689985551e-09
high O 0 1.4763232414338745e-08
frequency O 0 3.2010245121227854e-08
of O 0 4.410266041254829e-10
ATM O 0 0.00010992267925757915
mutations O 0 5.092374067316996e-06
in O 0 4.1933466832233535e-07
T B-Disease 0 0.03198247030377388
- I-Disease 0 0.001101712347008288
PLL I-Disease 0 0.0010004967916756868
. O 0 7.448106202900817e-07

In O 0 6.556709308824793e-08
marked O 0 1.415617418842885e-07
contrast O 0 1.1147852063686514e-07
to O 0 1.1582197423365415e-09
the O 0 1.1550936873661044e-09
ATM O 0 5.538356344914064e-05
mutation O 0 2.372095195823931e-06
pattern O 0 1.1541866342668072e-06
in O 0 7.223228948305405e-08
A B-Disease 1 0.9998996257781982
- I-Disease 1 0.999991774559021
T I-Disease 1 0.9999994039535522
, O 0 1.0990833132495936e-08
the O 0 5.774738465191831e-10
most O 0 2.0264048772311583e-10
frequent O 0 5.510464973212947e-09
nucleotide O 0 1.0643646675134733e-07
changes O 0 1.3391682207597455e-09
in O 0 3.0541287276975027e-09
this O 0 6.961234078062262e-08
leukaemia B-Disease 0 0.028257008641958237
were O 0 4.53335042038816e-06
missense O 0 0.0060118394903838634
mutations O 0 0.0001267207262571901
. O 0 9.105102094508766e-07

These O 0 3.4679917604307775e-08
clustered O 0 1.436747680827466e-07
in O 0 2.419874745029915e-09
the O 0 8.292087572137063e-10
region O 0 1.974197028076219e-09
corresponding O 0 6.371886129841187e-09
to O 0 3.255339331431628e-10
the O 0 6.619734760349161e-10
kinase O 0 2.3691464434705267e-07
domain O 0 3.42468737812851e-08
, O 0 7.323298634176467e-10
which O 0 2.037707558244506e-09
is O 0 8.333279066796706e-10
highly O 0 1.0172552800113976e-09
conserved O 0 4.177422407991571e-09
in O 0 9.960644531403773e-10
ATM O 0 6.276510248426348e-06
- O 0 4.1929051803890616e-06
related O 0 2.7029157578795093e-08
proteins O 0 1.21099652528045e-09
in O 0 1.0935894412256175e-09
mouse O 0 4.2687270251917653e-07
, O 0 2.247073416228318e-09
yeast O 0 1.0626222035625688e-07
and O 0 3.0597334443882573e-08
Drosophila O 0 3.0836375231046986e-07
. O 0 1.0886850532187964e-07

The O 0 1.0018538176836955e-07
resulting O 0 9.802992906315922e-08
amino O 0 4.124238017766402e-08
- O 0 8.294719009427354e-07
acid O 0 2.926185516116675e-08
substitutions O 0 2.053126735290789e-08
are O 0 8.078955282542211e-10
predicted O 0 2.932331177873948e-08
to O 0 7.530860379745263e-10
interfere O 0 2.7219336118378124e-08
with O 0 7.279768343693149e-09
ATP O 0 3.5336456676304806e-06
binding O 0 3.9744350033288356e-07
or O 0 7.165883175730414e-08
substrate O 0 6.7129476519767195e-06
recognition O 0 5.618106797555811e-07
. O 0 6.093879960644699e-07

Two O 0 2.4435115264509477e-08
of O 0 4.669923114875019e-09
seventeen O 0 1.3929115993960295e-07
mutated O 0 5.889129170100205e-06
T B-Disease 0 0.00012778562086168677
- I-Disease 0 4.7865460146567784e-06
PLL I-Disease 0 1.0824607670656405e-05
samples O 0 1.5640478068235097e-07
had O 0 5.635573785411907e-08
a O 0 4.626015837061459e-08
previously O 0 2.1989951619616477e-06
reported O 0 2.59958269452909e-05
A B-Disease 1 0.9998714923858643
- I-Disease 1 0.9999731779098511
T I-Disease 1 0.9999938011169434
allele O 0 4.5235119614517316e-05
. O 0 2.8744148039550055e-07

In O 0 2.721840814956522e-07
contrast O 0 1.6248499150606222e-06
, O 0 7.695569514964973e-09
no O 0 1.1249052533912618e-07
mutations O 0 6.8230895067245e-07
were O 0 1.4811821813509596e-07
detected O 0 3.055469278478995e-05
in O 0 2.370392104822372e-09
the O 0 7.757934850083359e-10
p53 O 0 3.514576629726207e-09
gene O 0 4.506526263270416e-09
, O 0 3.309506280135821e-10
suggesting O 0 4.006003706535921e-08
that O 0 6.926584639188604e-09
this O 0 1.1786792697421333e-07
tumour B-Disease 1 0.999995231628418
suppressor O 0 0.006491245701909065
is O 0 6.612093983449085e-08
not O 0 9.377121301668012e-09
frequently O 0 2.2656490017425313e-08
altered O 0 2.2090540596764185e-07
in O 0 2.0432587177765527e-08
this O 0 6.046284397598356e-07
leukaemia B-Disease 0 0.4293791651725769
. O 0 1.3624709254145273e-06

Occasional O 0 2.6489531592233106e-05
missense O 0 0.000953702547121793
mutations O 0 7.215856749098748e-05
in O 0 3.179653873530697e-08
ATM O 0 2.6526789952185936e-05
were O 0 5.755401843998698e-07
also O 0 7.166116233747744e-08
found O 0 1.1308188874181724e-07
in O 0 1.159500584435591e-07
tumour B-Disease 1 0.9999921321868896
DNA O 0 0.00013839086750522256
from O 0 6.493536375273834e-08
patients O 0 6.297377552755279e-08
with O 0 3.781929436286191e-08
B B-Disease 0 8.080031875579152e-06
- I-Disease 0 0.0001042069707182236
cell I-Disease 0 0.0008902394329197705
non I-Disease 0 9.800664884096477e-06
- I-Disease 1 0.961100697517395
Hodgkins I-Disease 1 0.9994743466377258
lymphomas I-Disease 1 0.9119194149971008
( O 0 6.370624561213845e-08
B B-Disease 0 2.363874955335632e-06
- I-Disease 0 7.125384581740946e-05
NHL I-Disease 0 4.7430680183424556e-07
) O 0 1.283421424691511e-10
and O 0 8.437590071075363e-10
a O 0 2.6988826107299246e-07
B B-Disease 0 6.977091288717929e-06
- I-Disease 0 0.00014142443251330405
NHL I-Disease 0 1.458597125747474e-06
cell O 0 5.788534053863259e-06
line O 0 2.5284025468863547e-06
. O 0 9.764141140067295e-08

The O 0 3.9444529420507024e-08
evidence O 0 2.4107636775738683e-08
of O 0 3.090865063892778e-10
a O 0 1.5097046945911075e-09
significant O 0 3.764906164605009e-09
proportion O 0 4.139558384963493e-08
of O 0 6.570776145409241e-10
loss O 0 8.473642196804576e-07
- O 0 1.069280187948607e-06
of O 0 2.8962110487640302e-09
- O 0 0.0004527644778136164
function O 0 4.826355279874406e-07
mutations O 0 3.9402129914378747e-07
and O 0 3.932267400585943e-09
a O 0 1.5343781356591535e-08
complete O 0 5.206867115248315e-08
absence O 0 1.1103496788678058e-08
of O 0 1.2431211615648863e-10
the O 0 1.489843914903588e-09
normal O 0 3.0092746072796217e-09
copy O 0 9.153753310897628e-09
of O 0 6.094370841314145e-11
ATM O 0 3.4756013178594003e-07
in O 0 1.2333347676474204e-09
the O 0 7.990896833121042e-10
majority O 0 4.7572177308552455e-09
of O 0 1.6728902707541238e-08
mutated O 0 0.0031430916860699654
tumours B-Disease 1 0.9999297857284546
establishes O 0 7.179372119026084e-07
somatic O 0 5.249747800917248e-07
inactivation O 0 1.3286786270327866e-05
of O 0 2.0667899336412887e-10
this O 0 1.117391956739766e-09
gene O 0 8.316753508097463e-09
in O 0 1.4242542700770855e-09
the O 0 3.0174647225322815e-09
pathogenesis O 0 3.017248104697501e-07
of O 0 8.38351332799192e-10
sporadic B-Disease 0 6.356491212500259e-05
T I-Disease 0 0.4011486768722534
- I-Disease 0 0.00012540542229544371
PLL I-Disease 0 1.8643566363607533e-05
and O 0 1.0283756957107926e-08
suggests O 0 7.285032133097502e-09
that O 0 7.334313711915286e-10
ATM O 0 8.025414217627258e-07
acts O 0 8.581840660326634e-08
as O 0 4.056603497559763e-09
a O 0 7.223542979772901e-06
tumour B-Disease 1 0.9999904632568359
suppressor O 0 0.029613342136144638
. O 0 1.2907847803944605e-06

As O 0 5.955282134095796e-08
constitutional O 0 5.380036327551352e-08
DNA O 0 1.9910366972908378e-06
was O 0 7.397217700599867e-07
not O 0 2.2089343687525798e-09
available O 0 5.188642848708014e-09
, O 0 3.9499378767793303e-10
a O 0 4.026802713497091e-08
putative O 0 0.00017438064969610423
hereditary O 0 0.424712210893631
predisposition O 0 0.01866634003818035
to O 0 4.099465968465665e-06
T B-Disease 0 0.39973774552345276
- I-Disease 0 0.0006043697358109057
PLL I-Disease 0 5.0620474212337285e-05
will O 0 8.669243989345432e-09
require O 0 1.4081230625961894e-09
further O 0 5.176491457703492e-10
investigation O 0 1.1430253010757951e-07
. O 0 6.389815609963989e-08
. O 0 1.605973807272676e-07

Myotonic B-Disease 1 0.9999581575393677
dystrophy I-Disease 1 0.9999808073043823
protein O 0 0.00019863179477397352
kinase O 0 0.00032682219170965254
is O 0 2.3902700263533916e-08
involved O 0 3.061787046121367e-09
in O 0 6.331262181191732e-10
the O 0 5.739544395311214e-10
modulation O 0 5.180358897405313e-08
of O 0 1.1903579510974538e-10
the O 0 5.394799718061449e-09
Ca2 O 0 7.982196621014737e-06
+ O 0 6.8583574375225e-07
homeostasis O 0 8.501766387780663e-06
in O 0 9.09550550431959e-08
skeletal O 0 0.0005753013538196683
muscle O 0 9.557772864354774e-05
cells O 0 1.301221527683083e-05
. O 0 6.838541821707622e-07

Myotonic B-Disease 1 0.9999841451644897
dystrophy I-Disease 1 0.9999967813491821
( O 0 0.0016842175973579288
DM B-Disease 1 0.9999969005584717
) O 0 4.9548187774917096e-08
, O 0 1.4968080108701542e-09
the O 0 7.481167352274554e-10
most O 0 2.782557473324232e-08
prevalent O 0 6.455920083681121e-05
muscular B-Disease 1 0.9987319111824036
disorder I-Disease 1 0.80621337890625
in O 0 1.6721407519071363e-05
adults O 0 4.9043665057979524e-05
, O 0 6.470688163062732e-08
is O 0 8.57084785366169e-08
caused O 0 3.5262490882814745e-07
by O 0 4.305042722307917e-08
( O 0 1.1378977760045927e-08
CTG O 0 2.3597081053594593e-06
) O 0 2.607484783645475e-10
n O 0 1.3155257327923664e-08
- O 0 8.2043413840438e-08
repeat O 0 6.35313952557226e-08
expansion O 0 2.6119211238295748e-09
in O 0 1.43783540629272e-10
a O 0 5.234364608419639e-10
gene O 0 5.215509135680918e-10
encoding O 0 4.438739376055878e-10
a O 0 3.965679340467432e-09
protein O 0 8.87808440097615e-08
kinase O 0 8.048729796428233e-06
( O 0 1.5082353854722896e-07
DM B-Disease 1 0.9999951124191284
protein O 0 2.198609536208096e-06
kinase O 0 2.590915755718015e-05
; O 0 6.283171671839227e-08
DMPK O 0 8.085629815468565e-05
) O 0 5.914750356161846e-10
and O 0 6.224669668597471e-10
involves O 0 8.951718810656928e-10
changes O 0 2.495537776425749e-09
in O 0 3.492964362195039e-09
cytoarchitecture O 0 6.737241619703127e-06
and O 0 1.6889049447854632e-07
ion O 0 0.0004539821529760957
homeostasis O 0 0.003025147132575512
. O 0 6.394338925019838e-07

To O 0 3.5501585671227076e-08
obtain O 0 2.6988306700559406e-08
clues O 0 3.172729918787809e-07
to O 0 1.2848426766964849e-09
the O 0 1.6138330671822132e-09
normal O 0 7.591333783807386e-09
biological O 0 3.698092854165225e-08
role O 0 1.2285171768766645e-09
of O 0 1.1724486659314692e-10
DMPK O 0 5.8044215620611794e-06
in O 0 6.712246758411311e-09
cellular O 0 1.5460310578419012e-06
ion O 0 5.7046028814511374e-05
homeostasis O 0 0.00025427149375900626
, O 0 5.329365837525302e-09
we O 0 1.5231539363114166e-09
have O 0 8.400832807176073e-10
compared O 0 3.882128396526241e-09
the O 0 9.554698143787732e-10
resting O 0 1.2933772950418643e-06
[ O 0 9.56991463851864e-09
Ca2 O 0 4.7088956733887244e-08
+ O 0 1.0577746678563926e-08
] O 0 4.283597476728573e-09
i O 0 7.610180041695003e-09
, O 0 1.1996202642361453e-11
the O 0 2.9390236772064426e-11
amplitude O 0 1.0399660688165113e-08
and O 0 2.1137542827176503e-09
shape O 0 6.368303928638852e-08
of O 0 2.2398449761595884e-10
depolarization O 0 5.947234171799209e-07
- O 0 8.669767703395337e-05
induced O 0 1.759973747539334e-05
Ca2 O 0 1.9260874069004785e-06
+ O 0 3.672842652235886e-08
transients O 0 3.836302369109035e-07
, O 0 1.2058720688656877e-10
and O 0 1.2093202828022953e-10
the O 0 1.2897576062709248e-10
content O 0 5.286195370324265e-10
of O 0 8.397801204429456e-11
ATP O 0 2.2578629454983457e-07
- O 0 1.3552797781812842e-06
driven O 0 1.487390619558937e-07
ion O 0 1.0126698271051282e-06
pumps O 0 6.951262889742793e-07
in O 0 5.296633798224093e-09
cultured O 0 2.069204128929414e-06
skeletal O 0 2.071571179840248e-05
muscle O 0 2.824226896791515e-07
cells O 0 1.6186399776074722e-08
of O 0 1.6196818886093922e-10
wild O 0 3.0740064715928384e-08
- O 0 2.307299291715026e-05
type O 0 1.1890556379512418e-05
and O 0 1.1628670648633488e-07
DMPK O 0 0.00011586054461076856
[ O 0 8.000375117944714e-08
- O 0 3.879986707033822e-06
/ O 0 2.9209352305770153e-06
- O 0 4.614521094481461e-05
] O 0 1.1735448879335308e-06
knockout O 0 0.00012128150410717353
mice O 0 0.00013086223043501377
. O 0 2.648676513672399e-07

In O 0 4.1205314005310356e-07
vitro O 0 1.534899820399005e-05
- O 0 5.168186908122152e-05
differentiated O 0 1.85878379852511e-05
DMPK O 0 0.0006674345931969583
[ O 0 3.7405791886158113e-07
- O 0 4.106912456336431e-06
/ O 0 6.613304321945179e-07
- O 0 6.561353075085208e-06
] O 0 7.402059054584242e-08
myotubes O 0 7.901302723212211e-08
exhibit O 0 3.7011268716469203e-08
a O 0 5.620070631096041e-09
higher O 0 3.2492014412355275e-08
resting O 0 5.444128987619479e-07
[ O 0 1.7696695664426443e-08
Ca2 O 0 4.936650555009692e-08
+ O 0 1.0719022114358268e-08
] O 0 6.822436837694568e-09
i O 0 1.2567808127528224e-08
than O 0 3.820430638512562e-10
do O 0 1.5396012242874235e-09
wild O 0 7.178397876117515e-09
- O 0 2.879231942642946e-06
type O 0 4.663117124437122e-06
myotubes O 0 3.721801931533264e-06
because O 0 2.865325976486588e-09
of O 0 1.5458998664508172e-11
an O 0 2.66170863127968e-10
altered O 0 2.7837465665925265e-08
open O 0 5.05892483460002e-09
probability O 0 1.8879677821104224e-09
of O 0 1.8156399994584405e-10
voltage O 0 3.4849388157454086e-06
- O 0 6.99242491464247e-06
dependent O 0 1.3637964002555236e-07
l O 0 1.315337271989847e-06
- O 0 6.671074288533418e-07
type O 0 1.2991492894798284e-06
Ca2 O 0 2.9603802431665827e-07
+ O 0 1.8907076793084343e-08
and O 0 3.2488280954368065e-09
Na O 0 8.80135019087902e-07
+ O 0 6.894637039067675e-08
channels O 0 1.540763179264104e-07
. O 0 1.1682514156063917e-07

The O 0 3.2062862942439097e-07
mutant O 0 2.8565093543875264e-06
myotubes O 0 1.01492532849079e-05
exhibit O 0 7.454167985088134e-07
smaller O 0 1.7068483515458865e-08
and O 0 4.815599474738974e-09
slower O 0 1.0172096409633014e-07
Ca2 O 0 1.6688418327248655e-06
+ O 0 2.6798463892419022e-08
responses O 0 7.0574883714868974e-09
upon O 0 2.0643089460037345e-09
triggering O 0 7.478663377469275e-08
by O 0 3.447058860572838e-09
acetylcholine O 0 2.535391649871599e-05
or O 0 6.249514967748837e-07
high O 0 3.6130884950580366e-07
external O 0 3.492636460578069e-05
K O 0 7.905703387223184e-05
+ O 0 6.39372956356965e-07
. O 0 1.1483846407145393e-07

In O 0 1.0354044377436367e-07
addition O 0 1.3074186178130276e-08
, O 0 1.5947879683508859e-09
we O 0 8.636463211253442e-10
observed O 0 1.5461962821206043e-09
that O 0 1.605827415485095e-10
these O 0 2.1782653458757295e-10
Ca2 O 0 3.8544476410606876e-07
+ O 0 5.609193465261342e-08
transients O 0 1.5366557590823504e-06
partially O 0 4.017076378204365e-07
result O 0 9.846914394984196e-09
from O 0 1.1216599871133326e-10
an O 0 4.827917926553127e-11
influx O 0 4.5922007863019587e-10
of O 0 5.891934856672165e-11
extracellular O 0 1.3102620322058556e-08
Ca2 O 0 8.428719411313068e-08
+ O 0 1.5329351121806667e-09
through O 0 5.244195008802244e-11
the O 0 5.134669911477374e-10
l O 0 1.190125090033689e-06
- O 0 1.0585395102680195e-06
type O 0 2.2562323920283234e-06
Ca2 O 0 1.9142521523463074e-06
+ O 0 7.535062707120233e-08
channel O 0 2.98630538964062e-07
. O 0 6.192205859179012e-08

Neither O 0 1.9639692254713736e-06
the O 0 8.682730978648578e-09
content O 0 1.1909269126419986e-08
nor O 0 2.0176829096385518e-08
the O 0 1.6671104774435008e-10
activity O 0 1.1810681321833272e-09
of O 0 3.271385939918048e-10
Na O 0 1.6117301129270345e-06
+ O 0 8.495782566342314e-08
/ O 0 4.9779036004338195e-08
K O 0 4.965566091641449e-08
+ O 0 1.8165840387496246e-08
ATPase O 0 1.3751562732977618e-07
and O 0 5.838333816399199e-09
sarcoplasmic O 0 4.368079771666089e-06
reticulum O 0 3.3287599308096105e-06
Ca2 O 0 2.648653662618017e-06
+ O 0 2.1437649877498188e-07
- O 0 9.298843792748812e-07
ATPase O 0 2.6169748252868885e-06
are O 0 3.2958507034663853e-09
affected O 0 4.3758139334215684e-09
by O 0 1.657751802497387e-08
DMPK O 0 0.0028522603679448366
absence O 0 1.5794734053997672e-06
. O 0 3.957226795137103e-07

In O 0 7.015792391484865e-08
conclusion O 0 3.036269902167987e-08
, O 0 8.832101716649277e-10
our O 0 5.175455064510004e-10
data O 0 3.364800438276916e-09
suggest O 0 9.904099762536589e-09
that O 0 3.091497502438756e-09
DMPK O 0 2.0404082533787005e-05
is O 0 1.4267448333882271e-09
involved O 0 5.295631155810554e-10
in O 0 8.223133285412132e-10
modulating O 0 8.116154504023143e-08
the O 0 5.285167303803462e-10
initial O 0 2.489143779982328e-09
events O 0 5.805063096886443e-10
of O 0 3.0535504680351266e-10
excitation O 0 4.238875590090174e-06
- O 0 8.146943582687527e-05
contraction O 0 6.7785986175294966e-06
coupling O 0 6.3634633988840505e-06
in O 0 1.0608178513393796e-07
skeletal O 0 0.0026936375070363283
muscle O 0 5.701057307305746e-05
. O 0 2.1868186195206363e-07
. O 0 5.143889438841143e-07

Constitutional O 0 0.0001246414758497849
RB1 O 0 0.008102711290121078
- O 0 9.106712968787178e-05
gene O 0 4.194516805000603e-06
mutations O 0 4.976666605216451e-05
in O 0 1.3363816719902388e-07
patients O 0 3.6701786143567006e-07
with O 0 1.5007027798219497e-07
isolated O 0 8.794560562819242e-05
unilateral B-Disease 0 0.0032809677068144083
retinoblastoma I-Disease 0 0.3324909508228302
. O 0 4.067455392942065e-06

In O 0 5.950910235696938e-07
most O 0 8.062645662221257e-08
patients O 0 1.8362476339461864e-07
with O 0 1.0623827151334808e-08
isolated O 0 2.299052084708819e-06
unilateral B-Disease 0 0.0002306170790689066
retinoblastoma I-Disease 0 0.08704647421836853
, O 0 1.2143595995439682e-07
tumor B-Disease 0 1.0891376405197661e-05
development O 0 3.1656857135686778e-09
is O 0 2.886950678515632e-09
initiated O 0 4.291202504447256e-09
by O 0 1.418617778803366e-09
somatic O 0 1.9438842002728052e-07
inactivation O 0 7.91486309026368e-06
of O 0 1.9611577639633282e-10
both O 0 1.2593260878546175e-09
alleles O 0 1.199342936075709e-08
of O 0 3.554120331372701e-09
the O 0 1.0775330565593322e-06
RB1 O 0 0.0009841335704550147
gene O 0 2.4535745524190133e-06
. O 0 7.16673014267144e-07

However O 0 3.394525833755324e-07
, O 0 9.094023312172794e-10
some O 0 1.9348809013330914e-11
of O 0 8.129932144163021e-11
these O 0 8.561366726667075e-09
patients O 0 9.508221410214901e-08
can O 0 1.7824698943513795e-06
transmit O 0 0.11899090558290482
retinoblastoma B-Disease 0 0.004676643759012222
predisposition O 0 0.00025937281316146255
to O 0 3.99539743511923e-08
their O 0 2.9439436843858857e-07
offspring O 0 9.871599104371853e-06
. O 0 3.3308765523543116e-07

To O 0 4.8709818400993754e-08
determine O 0 5.54974803890218e-08
the O 0 4.308186696277971e-09
frequency O 0 8.86437589997513e-07
and O 0 7.68858665622929e-09
nature O 0 2.778277696791065e-08
of O 0 2.9901747744531804e-10
constitutional O 0 8.833287665765965e-07
RB1 O 0 0.0002621283638291061
- O 0 5.752522156399209e-06
gene O 0 2.0132318923060666e-07
mutations O 0 5.465655590342067e-07
in O 0 5.5040704438624743e-08
patients O 0 6.810387276345864e-08
with O 0 1.677030603275398e-08
isolated O 0 1.8300797819392756e-06
unilateral B-Disease 0 4.682110738940537e-05
retinoblastoma I-Disease 0 0.00023765748483128846
, O 0 5.136298497632197e-09
we O 0 1.7403825047779264e-09
analyzed O 0 8.131491036067473e-09
DNA O 0 2.404710919279296e-08
from O 0 8.958944142101188e-10
peripheral O 0 2.6388636342744576e-06
blood O 0 4.1279713514086325e-06
and O 0 8.982050303529832e-08
from O 0 7.146324065843146e-08
tumor B-Disease 0 0.0007277437835000455
tissue O 0 0.0038702033925801516
. O 0 4.5653519009647425e-06

The O 0 3.076305787885758e-08
analysis O 0 1.5092936678229307e-08
of O 0 4.221403226978282e-09
tumors B-Disease 1 0.9995515942573547
from O 0 6.6553131894409034e-09
54 O 0 6.456865264681255e-09
( O 0 3.538615234166542e-10
71 O 0 1.0428954366759058e-09
% O 0 2.4376994867125745e-10
) O 0 3.1899635710708196e-11
of O 0 5.779407161177197e-11
76 O 0 1.586708897605149e-08
informative O 0 5.78599519940326e-06
patients O 0 1.3909988183513633e-06
showed O 0 0.0001182585911010392
loss O 0 1.7721880567478365e-06
of O 0 5.8987668083432254e-09
constitutional O 0 1.5551135220448487e-05
heterozygosity O 0 0.07417649775743484
( O 0 2.3630232135474216e-06
LOH O 1 0.9995112419128418
) O 0 7.89295473424545e-09
at O 0 2.111305441587774e-08
intragenic O 0 1.8033822925644927e-05
loci O 0 2.1236921838863054e-06
. O 0 3.9534924667350424e-07

Three O 0 3.467376785692977e-08
of O 0 6.169556865387449e-09
13 O 0 6.241366889980782e-08
uninformative O 0 0.008065599948167801
patients O 0 7.73227475292515e-06
had O 0 5.059400791651569e-07
constitutional O 0 4.6492399974340515e-07
deletions O 0 0.00014563853619620204
. O 0 2.883441538870102e-06

For O 0 3.340151977226924e-08
39 O 0 1.3186583380786487e-08
randomly O 0 2.5159753391790218e-08
selected O 0 1.40056692998769e-06
tumors B-Disease 1 0.9999953508377075
, O 0 1.2651884162551141e-07
SSCP O 0 0.0006908232462592423
, O 0 1.0939070982374233e-08
hetero O 0 4.704444108938333e-06
- O 0 1.0936671515082708e-06
duplex O 0 9.389718798047397e-06
analysis O 0 1.144119909923802e-08
, O 0 1.4129274139573766e-10
sequencing O 0 1.7953235564860393e-09
, O 0 3.303854967384723e-10
and O 0 5.920066104003752e-10
Southern O 0 8.452603061925856e-10
blot O 0 6.419377882593835e-07
analysis O 0 4.695905886364926e-09
were O 0 6.095853155585473e-09
used O 0 2.5502691514134312e-08
to O 0 8.247043936648879e-09
identify O 0 6.89392572894576e-06
mutations O 0 1.2240675459906925e-05
. O 0 4.968830467078078e-07

Mutations O 0 0.00028110548737458885
were O 0 1.4110092649843864e-07
detected O 0 3.8113589653221425e-06
in O 0 3.745874277427674e-09
21 O 0 2.719991121225007e-09
( O 0 3.8271039115578276e-10
91 O 0 1.4928077662901273e-09
% O 0 4.797609531870251e-10
) O 0 2.224683354201673e-10
of O 0 5.425902394051718e-09
23 O 0 0.0002115199895342812
tumors B-Disease 1 0.999998927116394
with O 0 0.006029769312590361
LOH O 1 0.9999833106994629
. O 0 4.49163380835671e-05

In O 0 1.3852348956788774e-07
6 O 0 1.7850263489549434e-08
( O 0 5.963323723712222e-10
38 O 0 8.630551828758826e-10
% O 0 5.365387023559265e-10
) O 0 2.083747063785779e-10
of O 0 5.8161049310001545e-09
16 O 0 0.00012126208457630128
tumors B-Disease 1 0.9999996423721313
without O 0 6.981116166571155e-05
LOH O 1 0.9995459914207458
, O 0 4.405711351296304e-09
one O 0 2.2119530651565356e-09
mutation O 0 1.8509761900986632e-07
was O 0 9.274559147343098e-07
detected O 0 1.4808835658186581e-05
, O 0 4.746946169476018e-10
and O 0 1.0707799091846937e-09
in O 0 9.698261083102011e-10
9 O 0 7.086246700538368e-09
( O 0 1.1589616766283228e-10
56 O 0 5.704663963435053e-10
% O 0 2.048747282934471e-10
) O 0 1.1006534572644e-10
of O 0 8.054753530828407e-10
the O 0 0.00046089073293842375
tumors B-Disease 1 0.9999998807907104
without O 0 0.0017793838633224368
LOH O 1 0.9999268054962158
, O 0 6.150675080363044e-09
both O 0 2.3557167327936668e-09
mutations O 0 1.0146417253054096e-06
were O 0 1.5286896370980685e-07
found O 0 2.5666222427389584e-06
. O 0 1.2777313713741023e-06

Thus O 0 6.101084863985307e-07
, O 0 6.35119457026434e-10
a O 0 4.2565473368227913e-10
total O 0 1.2291305473421943e-10
of O 0 1.1336290239860602e-10
45 O 0 2.669000354060813e-09
mutations O 0 2.9867723583265615e-07
were O 0 2.077721461546389e-07
identified O 0 8.217430877266452e-05
in O 0 1.0487171493878122e-05
tumors B-Disease 1 0.999991774559021
of O 0 4.114071572303146e-08
36 O 0 8.132934681270854e-07
patients O 0 1.6720006215109606e-06
. O 0 1.205503963319643e-06

Thirty O 0 1.3269993814901682e-06
- O 0 8.195472105398949e-07
nine O 0 3.7418752540929745e-09
of O 0 1.806892829803175e-10
the O 0 1.8052264127987883e-09
mutations O 0 1.2394035309171159e-07
- O 0 6.857801508886041e-07
including O 0 1.5579397771858794e-09
34 O 0 7.411234403953415e-10
small O 0 4.603340375552989e-09
mutations O 0 3.9564454823448614e-07
, O 0 9.739914430539898e-10
2 O 0 4.876470893755425e-10
large O 0 1.9306110488059858e-08
structural O 0 0.0002965688763651997
alterations O 0 1.3117472008161712e-05
, O 0 1.0819424467456429e-08
and O 0 6.830171095373316e-09
hypermethylation O 0 8.936431186157279e-06
in O 0 1.770561652847391e-07
3 O 0 1.129448355641216e-05
tumors O 1 0.9999992847442627
- O 0 0.05069170519709587
were O 0 1.9396155039430596e-05
not O 0 9.236824780600728e-07
detected O 0 6.09726748734829e-06
in O 0 8.495791292695287e-10
the O 0 9.684193447156986e-10
corresponding O 0 1.5729990821000683e-07
peripheral O 0 2.932163397417753e-06
blood O 0 7.51896322981338e-06
DNA O 0 2.0692292309831828e-05
. O 0 3.605227050229587e-07

In O 0 1.3481751182098378e-07
6 O 0 1.4635468836843302e-08
( O 0 4.1830572339307537e-10
17 O 0 5.395249802475632e-10
% O 0 9.720385607536741e-11
) O 0 6.82665686133066e-12
of O 0 1.7166797497414343e-11
the O 0 6.778866801226968e-09
36 O 0 2.6270962294461242e-08
patients O 0 1.9212880175700775e-08
, O 0 7.253305733811999e-10
a O 0 1.3837758672252676e-07
mutation O 0 1.0187130101257935e-05
was O 0 4.042635282530682e-06
detected O 0 3.5303578442835715e-06
in O 0 1.0446892240167927e-09
constitutional O 0 1.4441364548645197e-08
DNA O 0 1.5681686136304052e-06
, O 0 5.687671444931652e-10
and O 0 4.140960074838773e-10
1 O 0 2.880201077637423e-10
of O 0 1.0962181162810225e-10
these O 0 1.7238781069295328e-08
mutations O 0 3.419577296881471e-07
is O 0 9.236251763411474e-09
known O 0 1.4585837426750459e-08
to O 0 3.9865728496124575e-09
be O 0 3.9371252569253556e-07
associated O 0 3.6063955377585444e-08
with O 0 4.2548794709773574e-08
reduced O 0 1.0012031452788506e-05
expressivity O 0 0.07719580829143524
. O 0 2.1109326553414576e-06

The O 0 5.33272412894803e-08
presence O 0 1.7622257431071375e-08
of O 0 2.1799610727679664e-10
a O 0 9.434206305058979e-09
constitutional O 0 3.797995589138736e-07
mutation O 0 2.173542270611506e-05
was O 0 1.5688417533965549e-06
not O 0 2.042502700305704e-08
associated O 0 2.458938830329771e-09
with O 0 6.035021371531002e-10
an O 0 4.4549244293534684e-09
early O 0 1.6034806549214409e-06
age O 0 1.1562203781068092e-06
at O 0 1.3045993796367839e-07
treatment O 0 1.1296003776806174e-06
. O 0 6.640777314714796e-07

In O 0 5.226957568993384e-07
1 O 0 1.2029437357341521e-07
patient O 0 1.0908795502473367e-06
, O 0 2.9479645391461418e-09
somatic O 0 5.821901254421391e-07
mosaicism O 0 0.00031583142117597163
was O 0 2.01185503101442e-06
demonstrated O 0 8.525471884013314e-08
by O 0 8.932957151763787e-10
molecular O 0 8.797240980129573e-08
analysis O 0 4.909498918514998e-10
of O 0 4.750095455863246e-11
DNA O 0 2.266172600684513e-07
and O 0 1.4638149359313957e-08
RNA O 0 3.032849349438038e-08
from O 0 3.889807143053758e-09
peripheral O 0 8.621832421340514e-06
blood O 0 0.000106323670479469
. O 0 1.6694672240191721e-06

In O 0 2.71070717872135e-07
2 O 0 6.832036802961738e-08
patients O 0 4.722243573951346e-08
without O 0 1.0122525928579762e-08
a O 0 1.6715480910534097e-07
detectable O 0 0.0014202622696757317
mutation O 0 3.2896587072173133e-06
in O 0 1.5199217884287464e-08
peripheral O 0 2.2269616238190793e-05
blood O 0 5.805947876069695e-05
, O 0 3.103853529751177e-08
mosaicism O 0 1.1195855222467799e-05
was O 0 9.335808499599807e-07
suggested O 0 4.037931589095933e-08
because O 0 2.1621562318330234e-09
1 O 0 2.462824111315598e-10
of O 0 1.9227708314417669e-10
the O 0 2.7847909223055467e-07
patients O 0 1.0110070434166119e-05
showed O 0 0.22642096877098083
multifocal O 1 0.9999520778656006
tumors B-Disease 1 0.9999998807907104
and O 0 9.518433898847434e-07
the O 0 7.619402886405169e-09
other O 0 1.1602583338543582e-09
later O 0 2.939869148121943e-08
developed O 0 5.075367326412561e-08
bilateral B-Disease 0 1.8603249145598966e-06
retinoblastoma I-Disease 0 0.0003903881588485092
. O 0 1.4289058754002326e-06

In O 0 1.5837132139040477e-07
conclusion O 0 3.02663671902792e-08
, O 0 1.305872854295842e-09
our O 0 1.0637994929396655e-09
results O 0 1.5533435648862337e-09
emphasize O 0 4.4968668788669675e-09
that O 0 1.4175168816521477e-09
the O 0 1.0308573994421977e-09
manifestation O 0 8.440212013738346e-07
and O 0 2.592704007042812e-08
transmissibility O 0 7.936372412586934e-07
of O 0 3.539533111052151e-10
retinoblastoma B-Disease 0 1.2221069027873455e-06
depend O 0 4.643543771720715e-09
on O 0 5.1693209712766475e-09
the O 0 6.250295836451869e-10
nature O 0 1.1471221306180723e-08
of O 0 5.043966633255792e-11
the O 0 3.2430436114339045e-10
first O 0 2.5682961535267168e-08
mutation O 0 9.683685675554443e-08
, O 0 1.200756299946093e-10
its O 0 1.0486674723031442e-10
time O 0 1.516966996462088e-09
in O 0 1.5983752099657522e-09
development O 0 4.1940820261210376e-10
, O 0 5.059308527677331e-10
and O 0 9.516614163374015e-10
the O 0 2.5434657158207585e-10
number O 0 8.436045195736597e-10
and O 0 1.786176540008455e-09
types O 0 3.1751310469729788e-09
of O 0 2.281274613658013e-10
cells O 0 3.9032681087292076e-08
that O 0 1.0346754564238836e-08
are O 0 5.269105596283907e-09
affected O 0 6.429643928385076e-09
. O 0 1.5140193099227872e-08
. O 0 2.6317411538911983e-07

Hereditary B-Disease 1 0.9996342658996582
deficiency I-Disease 1 0.9981921315193176
of I-Disease 0 1.1239953856545526e-08
the I-Disease 0 1.0337345202060533e-08
fifth I-Disease 0 1.0557936036548199e-07
component I-Disease 0 1.2964725293329593e-08
of I-Disease 0 2.485683880948386e-10
complement I-Disease 0 1.0644052395036852e-07
in O 0 1.427203386583642e-07
man O 0 0.00018234644085168839
. O 0 5.199518682275084e-07

I O 0 0.0006653534946963191
. O 0 4.4736179916071706e-06

Clinical O 0 0.00022261279809754342
, O 0 1.1129029076073493e-07
immunochemical O 0 5.649776721838862e-05
, O 0 8.783673344225917e-09
and O 0 2.9132376511142866e-08
family O 0 2.173478748090929e-07
studies O 0 1.1880528916208277e-07
. O 0 2.5981969997701526e-07

The O 0 1.098509443409057e-07
first O 0 6.55773533253523e-08
recognized O 0 1.0257040372607662e-07
human O 0 5.937928548860327e-08
kindred O 0 1.7186574041261338e-05
with O 0 3.3649610031716293e-06
hereditary B-Disease 1 0.9998559951782227
deficiency I-Disease 1 0.9717139005661011
of I-Disease 0 3.6491969446217354e-09
the I-Disease 0 2.2587324011169585e-08
fifth I-Disease 0 4.2643205233616754e-07
component I-Disease 0 5.192229579620289e-08
of I-Disease 0 1.1317609072136747e-09
complement I-Disease 0 1.5907988881735946e-06
( O 0 7.02590199352926e-08
C5 O 0 0.00010679128899937496
) O 0 2.5774815615164925e-09
is O 0 8.693783470903327e-09
described O 0 1.7022842939695693e-06
. O 0 3.768062128983729e-07

The O 0 2.6008126496890327e-07
proband O 0 7.801932952133939e-06
, O 0 1.492927448332182e-09
a O 0 1.9481734003790052e-09
20 O 0 7.128620471696934e-10
- O 0 1.4292888863565167e-06
year O 0 5.069330555329543e-08
- O 0 2.3581924324389547e-05
old O 0 4.3747801100835204e-05
black O 0 1.1498445928737056e-05
female O 0 5.699133180314675e-05
with O 0 0.0006660335347987711
systemic B-Disease 1 0.9999997615814209
lupus I-Disease 1 0.9999788999557495
erythematosus I-Disease 1 0.9999934434890747
since O 0 0.010946786031126976
age O 0 9.614752343622968e-06
11 O 0 2.7912484767966816e-08
, O 0 1.2601796939293308e-08
lacked O 0 9.152705752057955e-05
serum O 0 0.01702793315052986
hemolytic O 0 0.0005327549297362566
complement O 0 7.267673396427199e-08
activity O 0 7.634302789938374e-08
, O 0 1.8328363271535864e-09
even O 0 1.1427589541312955e-08
during O 0 3.012150671111158e-07
remission O 0 2.8562304578372277e-05
. O 0 3.86290423648461e-07

C5 O 0 0.0288125928491354
was O 0 7.172075584094273e-06
undetectable O 0 1.5919060388114303e-05
in O 0 1.82758004285688e-08
her O 0 1.2348251630101004e-06
serum O 0 8.351809083251283e-05
by O 0 6.0222840048140824e-09
both O 0 2.277081989632279e-08
immunodiffusion O 0 0.0002960129640996456
and O 0 3.168262537656119e-06
hemolytic O 0 0.019245322793722153
assays O 0 0.0006122785271145403
. O 0 2.1728581032220973e-06

Other O 0 4.175432621877917e-08
complement O 0 5.593296137362813e-08
components O 0 1.3947007460046734e-07
were O 0 1.3404542364980898e-08
normal O 0 1.3488125283345198e-08
during O 0 2.2709317093472237e-08
remission O 0 5.223409402788093e-07
of O 0 3.175785190379088e-09
lupus O 0 6.180929631227627e-05
, O 0 1.9400461681584602e-08
but O 0 2.61042913507481e-07
C1 O 0 0.0004762109601870179
, O 0 1.8979873228630595e-09
C4 O 0 4.7954155888874084e-05
, O 0 3.414342941709947e-08
C2 O 0 3.932476829504594e-05
, O 0 2.688774092263202e-09
and O 0 4.07328251128547e-08
C3 O 0 0.010556734167039394
levels O 0 1.4868688822389231e-06
fell O 0 3.836024461634224e-06
during O 0 1.0750184173957678e-06
exacerbations O 0 0.011052201502025127
. O 0 1.4707547961734235e-06

A O 0 1.0353802508689114e-06
younger O 0 1.581633455316478e-07
half O 0 9.696156766381137e-09
- O 0 6.469937943620607e-06
sister O 0 1.4673528312414419e-05
, O 0 1.0756911805742675e-08
who O 0 2.240723802060529e-07
had O 0 2.490758561179973e-06
no O 0 1.528899883851409e-05
underlying O 0 0.4873164892196655
disease O 0 0.0010305802570655942
, O 0 1.1297211166549914e-08
was O 0 1.2097099215679918e-06
also O 0 2.089870854149467e-08
found O 0 1.4360116651346289e-08
to O 0 6.121066320474711e-09
lack O 0 1.493969875809853e-06
immunochemically O 0 0.012029722332954407
detectable O 0 0.029027361422777176
C5 O 0 0.0007287685293704271
. O 0 3.410529529901396e-07

By O 0 1.0131161616300233e-06
hemolytic O 0 0.0037529098335653543
assay O 0 0.00018071886734105647
, O 0 1.4146437798956413e-08
she O 0 7.353258268949503e-08
exhibited O 0 6.902584459567151e-08
1 O 0 1.1617021788978832e-09
- O 0 1.0815776363415353e-07
2 O 0 8.483840852058222e-10
% O 0 5.389353546769726e-11
of O 0 3.9422361208796275e-11
the O 0 1.3735094839262274e-08
normal O 0 1.0901391078732559e-06
serum O 0 0.0001109540753532201
C5 O 0 6.261462203838164e-06
level O 0 2.177212365950254e-08
and O 0 5.441738615274971e-09
normal O 0 7.43837214045584e-09
concentrations O 0 9.604918460581757e-08
of O 0 1.0259472438267636e-10
other O 0 6.960365062091967e-10
complement O 0 6.837851174168463e-08
components O 0 1.4908813454894698e-06
. O 0 2.2915324393579795e-07

C5 O 0 0.02291101962327957
levels O 0 2.48018932325067e-06
of O 0 8.233962955905838e-10
other O 0 7.277057290089317e-10
family O 0 5.0876156620915935e-09
members O 0 3.846005458552071e-10
were O 0 1.894591861173467e-08
either O 0 3.70462274190686e-08
normal O 0 1.1303462166267764e-08
or O 0 8.782395366502271e-10
approximately O 0 4.051062957310947e-11
half O 0 1.4957348692945516e-09
- O 0 9.63101501838537e-06
normal O 0 6.847405131793494e-08
, O 0 1.3768636231148434e-09
consistent O 0 5.600609043199256e-08
with O 0 2.1923098003640007e-08
autosomal O 0 0.0002520059933885932
codominant O 0 6.994842988206074e-05
inheritance O 0 1.0856260814762209e-06
of O 0 1.1534667665458187e-09
the O 0 3.608700893664718e-08
gene O 0 2.0104003851884045e-05
determining O 0 0.012196694500744343
C5 B-Disease 1 0.9999970197677612
deficiency I-Disease 1 0.9999901056289673
. O 0 5.3976091294316575e-06

Normal O 0 0.0009772423654794693
hemolytic O 1 0.8695738911628723
titers O 0 0.002208486432209611
were O 0 1.440212997749768e-07
restored O 0 7.182289323282021e-07
to O 0 6.789425910369573e-09
both O 0 5.744604436586087e-07
homozygous O 1 0.9987356066703796
C5 B-Disease 1 0.9999995231628418
- I-Disease 1 0.9999971389770508
deficient I-Disease 1 0.9999992847442627
( O 0 1.1106420060968958e-05
C5D B-Disease 1 0.9999974966049194
) O 0 2.1933471927582104e-08
sera O 0 3.4810082638614404e-07
by O 0 7.908698695935357e-10
addition O 0 2.6055919644107917e-09
of O 0 8.959183395162995e-10
highly O 0 8.092193297670747e-07
purified O 0 3.612024556787219e-06
human O 0 8.184513831110962e-07
C5 O 0 0.00018723261018749326
. O 0 2.1013266859881696e-07

In O 0 2.4893785166568705e-07
specific O 0 8.607527490767097e-08
C5 O 0 8.904244896257296e-05
titrations O 0 0.0001142197143053636
, O 0 7.318471162420792e-09
however O 0 4.6538199960366455e-09
, O 0 7.868720119930117e-10
it O 0 1.5673433662044545e-09
was O 0 2.1096919056162733e-07
noted O 0 1.0753670842689189e-08
that O 0 7.093883813702462e-10
when O 0 1.8358102815696498e-09
limited O 0 2.4921259500487736e-10
amounts O 0 9.367856490527515e-10
of O 0 2.1956050866300814e-10
C5 O 0 2.5744375307112932e-06
were O 0 4.011094123512748e-09
assayed O 0 2.2921203424175474e-07
in O 0 4.891319016486761e-10
the O 0 1.5323818602919204e-10
presence O 0 1.1923810827596526e-09
of O 0 2.028230083883642e-10
low O 0 1.4402912995592487e-07
dilutions O 0 4.186972830666491e-07
of O 0 2.629135131826388e-09
either O 0 3.257096523157088e-06
C5D B-Disease 1 0.9999934434890747
serum O 0 0.00040325260488316417
, O 0 3.947783489000045e-10
curving O 0 3.4567702034138392e-09
rather O 0 6.123094253851491e-10
than O 0 2.0708620929177357e-10
linear O 0 5.3209459061065445e-09
dose O 0 3.6146227557765087e-06
- O 0 1.3845086641595117e-06
response O 0 1.887018541424368e-08
plots O 0 6.869210551485594e-07
were O 0 3.303455571312952e-07
consistently O 0 1.8011246538662817e-06
obtained O 0 3.133798642807051e-08
, O 0 2.8492638803889747e-10
suggesting O 0 4.70069183577948e-09
some O 0 1.0798837518644078e-10
inhibitory O 0 1.0130931826779488e-07
effect O 0 2.372732694766455e-07
. O 0 1.6886811238236987e-07

Further O 0 5.972434991008413e-08
studies O 0 2.0391238919614807e-08
suggested O 0 3.901191547583949e-08
that O 0 5.686557003059534e-09
low O 0 1.0763812241521009e-07
dilutions O 0 2.430118001939263e-06
of O 0 2.4927132358243398e-08
C5D B-Disease 1 0.9999957084655762
serum O 0 0.0028692095074802637
contain O 0 8.96235263780909e-08
a O 0 2.9045768457081067e-08
factor O 0 2.481863248249283e-08
( O 0 7.799626500215595e-10
or O 0 2.410966004617876e-08
factors O 0 4.396947250739913e-09
) O 0 2.780257690737642e-10
interfering O 0 3.3555136447205314e-09
at O 0 9.555646274250762e-10
some O 0 4.1773383363530314e-11
step O 0 6.661027729393254e-09
in O 0 4.340601655883347e-09
the O 0 1.0646749259990429e-08
hemolytic O 0 1.653322033234872e-05
assay O 0 3.0274161417764844e-06
of O 0 7.0916144068178255e-09
C5 O 0 0.00010449513501953334
, O 0 9.344461870952614e-10
rather O 0 1.2919249003928712e-09
than O 0 3.778680701671533e-10
a O 0 2.9683343782949123e-08
true O 0 6.866787316539558e-06
C5 O 0 4.1804676584433764e-05
inhibitor O 0 2.7524811230250634e-07
or O 0 1.1442032388231382e-07
inactivator O 0 7.053103763610125e-05
. O 0 2.618877203985903e-07

Of O 0 1.3357409045511304e-07
clinical O 0 7.922889381006826e-06
interest O 0 1.4805482351221144e-06
are O 0 1.0483866219601623e-08
( O 0 6.163390353641773e-10
a O 0 1.5456603108532363e-08
) O 0 1.0667944305708943e-09
the O 0 4.418053978216818e-10
documentation O 0 8.418982844204947e-08
of O 0 3.4125850589816764e-08
membranous O 1 0.999567449092865
glomerulonephritis B-Disease 1 0.9999996423721313
, O 0 0.000588677532505244
vasculitis B-Disease 1 0.9999967813491821
, O 0 2.250573970741243e-06
and O 0 0.0014325558440759778
arthritis B-Disease 1 0.9999980926513672
in O 0 1.27199371036113e-07
an O 0 1.4816774474013528e-08
individual O 0 1.2189432254672283e-06
lacking O 0 0.000472156738396734
C5 O 0 0.0003801580751314759
( O 0 1.023924389720321e-09
and O 0 9.989068461280226e-10
its O 0 6.491610582415319e-10
biologic O 0 1.6291434690174356e-07
functions O 0 1.0185289278652476e-09
) O 0 3.702619877365976e-10
, O 0 5.250322954175601e-10
and O 0 9.841657266917991e-09
( O 0 2.8392832529533507e-09
b O 0 1.3600968351568099e-08
) O 0 4.3486519940572066e-11
a O 0 1.7627660442443016e-09
remarkable O 0 3.6962455851607956e-07
propensity O 0 6.326798029476777e-05
to O 0 1.567049912409857e-05
bacterial B-Disease 1 0.9999996423721313
infections I-Disease 1 0.999998927116394
in O 0 1.0596409794061401e-07
the O 0 1.2147054029298943e-08
proband O 0 2.3907814465928823e-05
, O 0 6.813447583908783e-10
even O 0 1.515081726743972e-09
during O 0 1.917018987995789e-09
periods O 0 4.081773141706435e-09
of O 0 3.2656069515191177e-10
low O 0 1.5450774526470923e-06
- O 0 5.8083587646251544e-06
dose O 0 2.3160589535109466e-06
or O 0 1.1724700321735781e-08
alternate O 0 7.0120567130516065e-09
- O 0 3.4767590477713384e-06
day O 0 1.4283240545864828e-07
corticosteroid O 0 0.009088309481739998
therapy O 0 2.8306489184615202e-05
. O 0 2.607301610169088e-07

Other O 0 1.9219625002619978e-08
observations O 0 3.5109948726130824e-07
indicate O 0 1.1573153813060344e-07
that O 0 2.447559044327363e-09
the O 0 1.0827641006017075e-08
C5D B-Disease 1 0.9999960660934448
state O 0 2.684665645347195e-08
is O 0 1.5047140200508125e-09
compatible O 0 3.097358147741147e-09
with O 0 1.8432521065037122e-09
normal O 0 5.271739045298318e-09
coagulation O 0 1.0466323807634126e-08
function O 0 5.869317920570438e-09
and O 0 1.2065376475689504e-09
the O 0 1.8168118121053567e-09
capacity O 0 8.875574053490709e-09
to O 0 1.1400609345457724e-09
mount O 0 2.5984820695157396e-06
a O 0 5.542735834751511e-06
neutrophilic O 0 0.12794508039951324
leukocytosis O 0 0.06433603912591934
during O 0 3.4058546589221805e-05
pyogenic B-Disease 1 0.8885482549667358
infection I-Disease 0 0.058430466800928116
. O 0 1.2795125314823963e-07
. O 0 2.919482824381703e-07

Susceptibility O 1 0.9805905818939209
to O 0 0.004880846012383699
ankylosing B-Disease 1 0.9999991655349731
spondylitis I-Disease 1 1.0
in O 0 0.0007956331828609109
twins O 0 0.038048963993787766
: O 0 3.967820294548119e-09
the O 0 1.5070483749823893e-10
role O 0 6.844265154626328e-10
of O 0 2.5702981409914116e-10
genes O 0 2.9076753449430726e-08
, O 0 7.281670377778937e-09
HLA O 0 2.466823843860766e-06
, O 0 4.619577165243527e-09
and O 0 1.66636180409796e-08
the O 0 3.918582791584413e-08
environment O 0 1.351386890746653e-05
. O 0 8.604464483141783e-07

OBJECTIVE O 0 2.21071559280972e-06
To O 0 1.0721844745376075e-08
determine O 0 2.3169764773456336e-08
the O 0 9.776469633848706e-10
relative O 0 6.068466262831862e-08
effects O 0 1.259545712173349e-07
of O 0 8.560530062595717e-10
genetic O 0 4.217303740006173e-06
and O 0 8.1505937998827e-08
environmental O 0 2.6786665330291726e-07
factors O 0 8.441747745280281e-09
in O 0 7.098654464243737e-08
susceptibility O 0 0.24731756746768951
to O 0 0.3369854986667633
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
( O 0 0.00016000206233002245
AS B-Disease 1 0.9969930648803711
) O 0 9.249935573052426e-08
. O 0 2.6910205974672863e-07

METHODS O 0 0.00016010126273613423
Twins O 0 0.0009223163360729814
with O 0 5.376353584551907e-08
AS B-Disease 0 0.19139084219932556
were O 0 1.3719130720346584e-07
identified O 0 2.795063664962072e-07
from O 0 9.251162613743702e-10
the O 0 5.59152235624083e-09
Royal O 0 6.686243432341143e-05
National O 0 2.918215159297688e-06
Hospital O 0 1.1576256838452537e-05
for O 0 3.3861172141769202e-06
Rheumatic B-Disease 1 0.9998340606689453
Diseases I-Disease 0 0.017184341326355934
database O 0 1.3204866263549775e-05
. O 0 1.222528908328968e-06

Clinical O 0 0.00010131623275810853
and O 0 9.530299394100439e-08
radiographic O 0 0.00034701498225331306
examinations O 0 2.2794974938733503e-05
were O 0 2.9657149980266695e-07
performed O 0 1.664339208673482e-07
to O 0 2.0105213049959048e-09
establish O 0 1.6347618725376378e-07
diagnoses O 0 0.07326680421829224
, O 0 5.011112307329313e-07
and O 0 0.00015910323418211192
disease O 0 0.0069277286529541016
severity O 0 0.008190837688744068
was O 0 1.4830163308943156e-05
assessed O 0 1.2448812469756376e-07
using O 0 1.1858540815978813e-08
a O 0 2.1047759091175067e-08
combination O 0 2.2339897043366364e-07
of O 0 2.59509702615901e-09
validated O 0 5.09087840327993e-06
scoring O 0 1.6229654420385486e-07
systems O 0 1.948562839970691e-06
. O 0 2.648640986535611e-07

HLA O 0 0.00027944662724621594
typing O 0 7.755981641821563e-06
for O 0 3.2804990723889205e-08
HLA O 0 1.7877056961879134e-05
- O 0 9.04137414181605e-06
B27 O 0 9.909052778311889e-07
, O 0 3.1529949762187925e-09
HLA O 0 3.881819736761827e-07
- O 0 9.328635428573762e-07
B60 O 0 1.417353274746347e-07
, O 0 1.1990632931002665e-09
and O 0 4.51510429044788e-09
HLA O 0 1.3684512850886676e-05
- O 0 0.02213241532444954
DR1 O 1 0.9952390193939209
was O 0 1.1800980246334802e-06
performed O 0 9.22355880561554e-09
by O 0 3.126988945556519e-10
polymerase O 0 8.128203887736163e-09
chain O 0 5.162702265693042e-08
reaction O 0 2.207885430038914e-09
with O 0 2.4058185998931947e-10
sequence O 0 2.6053235124834373e-09
- O 0 9.6718345332647e-08
specific O 0 1.3695823364301418e-09
primers O 0 4.016891125502298e-06
, O 0 2.668725240795311e-09
and O 0 2.8842923605054693e-09
zygosity O 0 2.9107218324497808e-06
was O 0 1.6089984455902595e-07
assessed O 0 7.02965579080228e-08
using O 0 4.09096436726486e-08
microsatellite O 0 2.3296084691537544e-05
markers O 0 5.423435868578963e-05
. O 0 6.412512902898015e-07

Genetic O 0 0.0011714559514075518
and O 0 1.251683272585069e-07
environmental O 0 8.543867124899407e-08
variance O 0 1.629854473605974e-08
components O 0 3.143179867493018e-07
were O 0 7.936677093312028e-08
assessed O 0 1.704321448414703e-07
with O 0 4.361564887034319e-09
the O 0 2.1374075842572893e-08
program O 0 1.8461473416664376e-07
Mx O 0 8.665261930218549e-07
, O 0 2.0808505959979406e-11
using O 0 1.1515162434694304e-10
data O 0 1.6127960078549108e-09
from O 0 5.4368367446988586e-11
this O 0 6.307096511726229e-10
and O 0 3.262669912018623e-09
previous O 0 3.9784392669162116e-08
studies O 0 1.8322979800089456e-09
of O 0 2.004268750965821e-09
twins O 0 0.00034692499320954084
with O 0 1.3656263320172002e-07
AS B-Disease 1 0.9903918504714966
. O 0 1.989497377508087e-06

RESULTS O 0 7.343975539697567e-06
Six O 0 2.2787155273817916e-08
of O 0 3.3422977718799984e-09
8 O 0 4.6458936253657157e-07
monozygotic O 0 0.03169102221727371
( O 0 2.396517686520383e-07
MZ O 1 0.7471899390220642
) O 0 1.7667657559172767e-08
twin O 0 0.006354143377393484
pairs O 0 1.814791357901413e-05
were O 0 2.263311944261659e-05
disease O 0 3.132447454845533e-05
concordant O 0 9.486385351920035e-06
, O 0 9.658834621006918e-09
compared O 0 4.4269409471553445e-08
with O 0 1.6297977412094156e-09
4 O 0 2.566541867921046e-09
of O 0 5.239798595013667e-10
15 O 0 1.1965211932363218e-08
B27 O 0 9.469342785450863e-07
- O 0 8.616145350970328e-05
positive O 0 1.2515329217421822e-07
dizygotic O 0 8.324934606207535e-05
( O 0 8.101890713874127e-09
DZ O 0 0.000662167149130255
) O 0 9.702461056804168e-10
twin O 0 4.608790277416119e-06
pairs O 0 2.509702312636364e-07
( O 0 6.073127001293699e-10
27 O 0 2.1868877819741783e-09
% O 0 1.4501272405098575e-10
) O 0 6.999168605803519e-11
and O 0 9.080434182351382e-10
4 O 0 8.427779585318262e-10
of O 0 9.260995859072807e-10
32 O 0 1.49809309846205e-07
DZ O 1 0.5288993120193481
twin O 0 0.0027519434224814177
pairs O 0 1.1749547184081166e-06
overall O 0 2.2038501867882587e-07
( O 0 4.744556414415513e-10
12 O 0 3.807663351285129e-10
. O 0 7.050004469100202e-10
5 O 0 2.875591542661482e-09
% O 0 2.4945954191224473e-09
) O 0 5.9551656939049735e-09
. O 0 1.1459985671535833e-07

Nonsignificant O 0 0.0003244157414883375
increases O 0 2.134730493708048e-06
in O 0 4.415638077404083e-09
similarity O 0 2.6273568209944642e-08
with O 0 9.736943473726e-10
regard O 0 2.1859756671460673e-08
to O 0 5.154909388238593e-08
age O 0 2.4762944121903274e-06
at O 0 7.286243430826289e-07
disease O 0 4.991869445802877e-06
onset O 0 8.695319593243767e-07
and O 0 8.98969076956746e-09
all O 0 2.9905339316016466e-10
of O 0 5.570145455990883e-10
the O 0 2.1887892671657028e-06
disease O 0 0.00031886351644061506
severity O 0 9.18510922929272e-05
scores O 0 8.873039547552253e-08
assessed O 0 1.13424425762787e-06
were O 0 4.1929504845938936e-07
noted O 0 1.5392283785331529e-06
in O 0 2.4507799025741406e-06
disease O 0 0.0005690196412615478
- O 0 0.1096375435590744
concordant O 1 0.9337692856788635
MZ O 1 0.9999723434448242
twins O 0 0.05990562587976456
compared O 0 7.728256150585366e-07
with O 0 2.868710282655229e-07
concordant O 1 0.6595768928527832
DZ O 1 0.9998675584793091
twins O 0 0.05443013459444046
. O 0 7.98576763827441e-07

HLA O 0 0.0012725070118904114
- O 0 3.721643952303566e-05
B27 O 0 1.2971399883099366e-06
and O 0 1.4597581809994153e-08
B60 O 0 1.4401153691778745e-07
were O 0 1.4510805890211032e-08
associated O 0 1.2038395169611249e-08
with O 0 7.163639459406568e-09
the O 0 1.2391250265864073e-06
disease O 0 2.1746536731370725e-05
in O 0 1.1440980607346773e-08
probands O 0 4.0950260881800205e-05
, O 0 2.9916709110011652e-09
and O 0 1.9849917265446493e-09
the O 0 2.2826380785545552e-09
rate O 0 7.111175364116207e-07
of O 0 4.639869377598416e-09
disease O 0 5.318353032635059e-06
concordance O 0 3.356742809046409e-06
was O 0 3.011733724633814e-06
significantly O 0 2.209091860549961e-07
increased O 0 5.6360256905918504e-08
among O 0 2.3006300864381046e-08
DZ O 0 0.41353437304496765
twin O 0 0.002090159337967634
pairs O 0 5.886619192096987e-07
in O 0 2.8895232873082932e-09
which O 0 1.0015038576227653e-08
the O 0 5.457299057098908e-09
co O 0 0.00012036810221616179
- O 0 0.015505701303482056
twin O 0 0.2847340703010559
was O 0 1.2308536270211334e-06
positive O 0 1.448311914842293e-09
for O 0 4.3475348321386775e-10
both O 0 9.000224565625103e-09
B27 O 0 4.603672550729243e-06
and O 0 1.8471881730874884e-06
DR1 O 1 0.9677914381027222
. O 0 2.830341600201791e-06

Additive O 0 1.3647110790770967e-05
genetic O 0 7.64507149142446e-06
effects O 0 5.63220100957551e-06
were O 0 2.1237616110170165e-08
estimated O 0 5.070149633468191e-09
to O 0 2.755728978343086e-10
contribute O 0 1.6960699511514576e-09
97 O 0 7.525575718148048e-10
% O 0 1.955327288971631e-10
of O 0 6.362953219873901e-11
the O 0 2.8388120743017e-09
population O 0 1.785505632234674e-09
variance O 0 2.5319870644580078e-08
. O 0 2.505995269075356e-07

CONCLUSION O 0 1.0071732504002284e-05
Susceptibility O 0 0.0015067581553012133
to O 0 2.6727875024334935e-07
AS B-Disease 0 0.1614449918270111
is O 0 2.146575539541118e-08
largely O 0 3.646031698778529e-09
genetically O 0 3.7307742672965105e-08
determined O 0 1.0396347533969674e-06
, O 0 2.4460704572959457e-09
and O 0 2.2381207998023456e-09
the O 0 3.2069384925392797e-09
environmental O 0 1.3918133845436387e-07
trigger O 0 4.642510020858026e-07
for O 0 6.326750678908866e-09
the O 0 7.741556373730418e-07
disease O 0 9.106114157475531e-05
is O 0 6.249145911851883e-08
probably O 0 7.978504754646565e-07
ubiquitous O 0 3.3694150260998867e-06
. O 0 2.6553635734671843e-07

HLA O 0 0.000553268298972398
- O 0 2.2452668417827226e-05
B27 O 0 5.441294774755079e-07
accounts O 0 1.2106461610983388e-08
for O 0 2.0537983813628813e-10
a O 0 6.501068572362101e-09
minority O 0 6.678863684328462e-09
of O 0 2.1113075177048302e-10
the O 0 6.791679219020352e-09
overall O 0 3.290863560323487e-06
genetic O 0 2.162676719308365e-05
susceptibility O 0 0.001991796772927046
to O 0 6.225043307495071e-07
AS B-Disease 1 0.9961193799972534
. O 0 5.060933744971408e-06

Cell O 0 0.00029853853629902005
cycle O 0 1.8158993043471128e-05
- O 0 2.3603208319400437e-05
dependent O 0 2.172138238165644e-07
colocalization O 0 1.0132974921361892e-06
of O 0 1.1050166337511769e-09
BARD1 O 0 0.00019721077114809304
and O 0 1.9873041878781805e-07
BRCA1 O 0 3.70289626516751e-06
proteins O 0 5.188582896664684e-09
in O 0 1.2432356255587251e-09
discrete O 0 2.1235980796063814e-07
nuclear O 0 0.00017465304699726403
domains O 0 2.8990866667299997e-06
. O 0 4.722477626728505e-07

Germ O 0 0.05678946524858475
- O 0 0.0003660321526695043
line O 0 5.280857749312418e-06
mutations O 0 4.6859057079018385e-07
of O 0 2.5143995219245596e-10
the O 0 4.235072736946677e-09
BRCA1 O 0 1.0646083865140099e-05
gene O 0 9.016929425342823e-08
predispose O 0 1.72235374407137e-07
women O 0 1.1478925365793202e-08
to O 0 2.2403159327666344e-09
early O 0 6.934371867828304e-07
- O 1 0.7652909159660339
onset O 0 0.4518188536167145
breast B-Disease 1 0.9999901056289673
and I-Disease 1 0.9999852180480957
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999996423721313
by O 0 3.6286176055000396e-06
compromising O 0 0.00043298749369569123
the O 0 2.408626365024702e-08
genes O 0 5.565011207409043e-08
presumptive O 0 0.000980921322479844
function O 0 8.606871659821991e-08
as O 0 2.88335733067413e-09
a O 0 5.207433559917263e-07
tumor B-Disease 0 0.0011842787498608232
suppressor O 0 0.000728642800822854
. O 0 1.1058942845920683e-06

Although O 0 3.0712203624716494e-07
the O 0 4.476696346955578e-09
biochemical O 0 1.6559969253648887e-06
properties O 0 9.184991967003953e-08
of O 0 2.8488087444600296e-09
BRCA1 O 0 0.00012258654169272631
polypeptides O 0 1.699281938272179e-06
are O 0 1.912250446878261e-08
not O 0 3.177277463350947e-08
understood O 0 1.8304587001694017e-07
, O 0 4.817654608579858e-10
their O 0 6.959847698162491e-10
expression O 0 5.974052896817739e-08
pattern O 0 3.255399008139648e-07
and O 0 5.24179055716445e-09
subcellular O 0 4.35297408785118e-07
localization O 0 8.888826386055371e-08
suggest O 0 6.3819451945335e-09
a O 0 1.5035636069526959e-09
role O 0 1.418388517748781e-08
in O 0 1.5152153309827554e-08
cell O 0 3.104892675764859e-05
- O 0 0.0001781528553692624
cycle O 0 4.624455414159456e-06
regulation O 0 9.280292374569399e-07
. O 0 2.2312154612791346e-07

When O 0 1.0965684396069264e-06
resting O 0 1.3466910786519293e-05
cells O 0 2.5121016733464785e-07
are O 0 2.095753570685588e-09
induced O 0 7.923304679025023e-07
to O 0 8.670766327156798e-09
proliferate O 0 1.2265472832950763e-06
, O 0 4.456452151746504e-10
the O 0 1.4654254198998018e-10
steady O 0 5.897565813484107e-08
- O 0 8.989322850538883e-07
state O 0 3.2642821778949838e-09
levels O 0 2.0926858024239436e-09
of O 0 8.813485358194484e-11
BRCA1 O 0 5.472153929986234e-07
increase O 0 7.839751070548573e-09
in O 0 2.4841686485643777e-09
late O 0 1.1582561398881808e-07
G1 O 0 7.787734830344561e-06
and O 0 2.3969251028432836e-09
reach O 0 9.617338037060108e-10
a O 0 4.543882159424584e-09
maximum O 0 8.059617329081448e-08
during O 0 3.7925991591691854e-07
S O 0 4.693734081229195e-05
phase O 0 5.19976140367362e-07
. O 0 2.516945585284702e-07

Moreover O 0 5.4435859055956826e-06
, O 0 9.568052128372528e-09
in O 0 2.4923410002486435e-09
S O 0 3.834897597698728e-06
phase O 0 2.801762377657724e-07
cells O 0 3.91931195053985e-07
, O 0 7.685859060302391e-09
BRCA1 O 0 1.994166495933314e-06
polypeptides O 0 1.5759511029500572e-07
are O 0 3.421173122575283e-09
hyperphosphorylated O 0 2.622040938149439e-06
and O 0 1.8303220272741783e-08
accumulate O 0 3.551208394014793e-08
into O 0 8.587742739152304e-10
discrete O 0 2.269325847237269e-07
subnuclear O 0 3.603479854064062e-05
foci O 0 3.4545158996479586e-05
termed O 0 1.559119664307218e-05
" O 0 3.408777956792619e-06
BRCA1 O 0 0.00019953784067183733
nuclear O 0 0.00015346548752859235
dots O 0 0.0010473551228642464
. O 0 1.193869593407726e-06

" O 0 3.127388481516391e-05
BRCA1 O 0 0.0008402717066928744
associates O 0 9.59341286943527e-06
in O 0 3.200279863335709e-08
vivo O 0 5.563351351156598e-06
with O 0 8.809948326415906e-09
a O 0 3.515615844662534e-06
structurally O 0 0.008913557045161724
related O 0 7.890307074376324e-07
protein O 0 4.808030098502059e-07
termed O 0 1.915237407956738e-05
BARD1 O 0 0.019715826958417892
. O 0 7.340981937886681e-07

Here O 0 4.023501958272391e-07
we O 0 5.216755472048362e-09
show O 0 5.157099636221574e-09
that O 0 1.3665650555605424e-10
the O 0 1.40416372973462e-10
steady O 0 6.57883276744542e-08
- O 0 1.4254637790145352e-06
state O 0 1.5130371400218223e-09
levels O 0 1.1159968504870221e-09
of O 0 3.266421161329802e-11
BARD1 O 0 8.574495041102637e-06
, O 0 2.853152158976968e-10
unlike O 0 1.2347752820218716e-09
those O 0 1.496207741036315e-10
of O 0 3.4350855493414656e-10
BRCA1 O 0 2.0475112251006067e-05
, O 0 8.251355154698103e-09
remain O 0 2.5387377533547806e-08
relatively O 0 9.50167322599782e-09
constant O 0 1.329995313881227e-07
during O 0 2.7866053642355837e-07
cell O 0 0.00010703218140406534
cycle O 0 8.589669050707016e-06
progression O 0 3.5243501770310104e-06
. O 0 1.668461635517815e-07

However O 0 9.311747248830216e-07
, O 0 1.1910132435843934e-08
immunostaining O 0 2.265049943162012e-06
revealed O 0 6.280180514295353e-06
that O 0 5.3260762911122583e-08
BARD1 O 0 0.0002747088728938252
resides O 0 9.653972483647522e-07
within O 0 3.5415337329425256e-09
BRCA1 O 0 9.954545021173544e-06
nuclear O 0 4.719767730421154e-06
dots O 0 5.46373485121876e-06
during O 0 5.29791002179536e-08
S O 0 1.439252059753926e-06
phase O 0 7.596113071883792e-09
of O 0 5.468619654336315e-11
the O 0 1.3113189423208382e-09
cell O 0 1.2707887435681187e-06
cycle O 0 1.565199738706724e-07
, O 0 7.982198235723104e-10
but O 0 1.54071466695882e-09
not O 0 3.963695760500485e-10
during O 0 4.398951869433176e-09
the O 0 6.487306691838057e-09
G1 O 0 2.972902439069003e-05
phase O 0 4.1997577682195697e-07
. O 0 1.7198736657064728e-07

Nevertheless O 0 4.964971958543174e-05
, O 0 6.900491200667602e-08
BARD1 O 0 1.7313190255663358e-05
polypeptides O 0 4.7589128371328115e-07
are O 0 3.034873019558404e-09
found O 0 1.6022760895850752e-09
exclusively O 0 1.6244968703560403e-09
in O 0 1.0511310710725752e-09
the O 0 7.603632168340368e-10
nuclear O 0 1.4523132563226682e-07
fractions O 0 6.867449386938063e-10
of O 0 3.633462627994355e-11
both O 0 7.301512727764248e-10
G1 O 0 7.279004421434365e-06
- O 0 3.5977400330011733e-06
and O 0 2.1924561721675673e-08
S O 0 1.3894601579522714e-05
- O 0 2.679831823115819e-06
phase O 0 1.5466666525298933e-07
cells O 0 7.478918746528507e-07
. O 0 1.2683426575677004e-07

Therefore O 0 1.7550695474710665e-06
, O 0 1.3628442374624683e-08
progression O 0 9.01999186453395e-08
to O 0 3.2691607199097916e-09
S O 0 1.1345784514560364e-05
phase O 0 9.411420620608624e-08
is O 0 2.9128861545046902e-09
accompanied O 0 4.805002173924322e-09
by O 0 2.0900360608866464e-10
the O 0 3.9608316626527085e-10
aggregation O 0 2.4011990173988806e-09
of O 0 4.1723555166406356e-10
nuclear O 0 1.6242076526395977e-05
BARD1 O 0 1.0277863111696206e-05
polypeptides O 0 6.197250712602909e-08
into O 0 2.19084270725034e-08
BRCA1 O 0 2.0663839677581564e-05
nuclear O 0 3.794428630499169e-05
dots O 0 0.00030823814449831843
. O 0 4.083333067228523e-07

This O 0 8.202448498195736e-08
cell O 0 1.251534627044748e-06
cycle O 0 2.5821975668804953e-07
- O 0 1.7033771655405872e-06
dependent O 0 3.2039505271086455e-08
colocalization O 0 7.22366280569986e-07
of O 0 7.150626202268029e-10
BARD1 O 0 7.646867743460461e-05
and O 0 1.63080684956185e-07
BRCA1 O 0 4.715160685009323e-06
indicates O 0 6.498417803868506e-08
a O 0 3.122359926166496e-09
role O 0 8.563294073837824e-09
for O 0 5.3561977075844425e-09
BARD1 O 0 0.00021744571859017015
in O 0 2.0132647193804587e-07
BRCA1 O 0 0.00033119178260676563
- O 0 0.0005438554217107594
mediated O 0 0.00043976554297842085
tumor B-Disease 0 0.01678900048136711
suppression O 0 5.2149323892081156e-05
. O 0 1.3019633797739516e-06

Ethnic O 0 8.475622053083498e-07
differences O 0 7.803902803971141e-07
in O 0 2.0132890909962953e-08
the O 0 1.4064033493355055e-08
HFE O 0 0.0006836593383923173
codon O 0 1.2368853958832915e-06
282 O 0 3.810777684520872e-07
( O 0 1.750321274585076e-07
Cys O 0 0.08324765413999557
/ O 0 0.00021099791047163308
Tyr O 0 8.913411875255406e-05
) O 0 2.6215250414907132e-08
polymorphism O 0 7.354553235927597e-05
. O 0 1.237316041624581e-06

Recent O 0 1.2934377764395322e-06
studies O 0 1.4684128757380677e-07
have O 0 3.0568870101888024e-08
shown O 0 1.136485479946714e-06
that O 0 0.002087068511173129
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
( O 0 0.08605998009443283
HH B-Disease 1 0.9999816417694092
) O 0 1.9906041259787344e-08
is O 0 1.4173203055634076e-08
likely O 0 2.8271259111534164e-08
to O 0 1.0302604103173962e-08
be O 0 1.2961877473571803e-06
caused O 0 8.038696819312463e-07
by O 0 7.124437040317844e-09
homozygosity O 0 2.0802102881134488e-05
for O 0 1.304622965214719e-09
a O 0 8.974104304115826e-08
Cys282Tyr O 0 2.084309198835399e-05
mutation O 0 3.50340201293875e-07
in O 0 9.811514933844023e-10
the O 0 5.247402068420115e-09
HFE O 0 3.0939263524487615e-05
gene O 0 4.561059441243742e-08
located O 0 1.5037050715704936e-08
4 O 0 4.2345259743115093e-08
. O 0 2.1138407646503765e-07

5 O 0 1.8567641291156178e-06
Mb O 0 0.0002262740017613396
telomeric O 0 0.0006223951349966228
to O 0 3.3451061653977376e-07
HLA O 0 0.00023576080275233835
- O 0 0.0001715128164505586
A O 0 3.2068289783637738e-06
. O 0 1.344239308309625e-06

Population O 0 4.18053303974375e-07
studies O 0 1.4299575745724269e-08
of O 0 2.6213625714532895e-10
this O 0 2.382262831446269e-09
polymorphism O 0 8.09992980066454e-06
are O 0 1.3879642990488605e-09
facilitated O 0 8.364718695474949e-09
by O 0 1.7042612876494445e-09
the O 0 3.017240457481307e-09
fact O 0 1.5185918300630874e-08
that O 0 2.8525495299192016e-09
the O 0 4.699785893791386e-09
Cys282Tyr O 0 1.1996117791568395e-05
mutation O 0 4.1715330212355184e-07
creates O 0 1.450989195461716e-08
a O 0 1.5434626021715303e-08
Rsal O 0 1.5156741710597998e-06
restriction O 0 1.7294890142238728e-07
site O 0 4.7530301117149065e-07
. O 0 1.7281352882037027e-07

We O 0 5.48443154002598e-07
have O 0 1.053407672202411e-08
studied O 0 1.5840360134689035e-08
the O 0 1.2646141911432096e-09
codon O 0 3.075941990005049e-08
282 O 0 3.809687143530027e-08
( O 0 4.000506237389345e-08
Cys O 0 0.017244504764676094
/ O 0 3.6103869206272066e-05
Tyr O 0 2.4359103917959146e-05
) O 0 1.7025361120914795e-09
polymorphism O 0 1.5020816590549657e-06
in O 0 5.4651425607232795e-09
different O 0 1.721206066562786e-09
ethnic O 0 7.096174314824566e-09
groups O 0 7.432560522602216e-08
. O 0 2.4994696445901354e-07

In O 0 1.628627899208368e-07
agreement O 0 1.8845438987113994e-08
with O 0 9.676384138401772e-10
previous O 0 3.976322560106382e-08
observations O 0 5.338616801964235e-07
the O 0 2.0480811713241565e-08
Tyr O 0 1.3980973562865984e-05
allele O 0 3.2773914426798e-07
appeared O 0 4.604071435210244e-08
to O 0 1.2925213122016999e-09
be O 0 1.4138668902319296e-08
rare O 0 1.1165514024469303e-07
or O 0 6.403211472161274e-08
absent O 0 1.910063929244643e-07
in O 0 2.4157486677722773e-08
Asiatic O 0 1.1285193295407225e-06
( O 0 9.319275351415968e-10
Indian O 0 2.090045247982175e-09
, O 0 7.901416188005328e-10
Chinese O 0 9.56450807443332e-10
) O 0 2.0236867737111197e-09
populations O 0 2.828830325540821e-08
. O 0 1.045712849645497e-07

The O 0 6.810906683085705e-08
highest O 0 3.0602066658502736e-07
allele O 0 3.892596112109459e-07
frequency O 0 4.028132138955698e-07
( O 0 3.9599779011467717e-10
7 O 0 3.3513994357470267e-10
. O 0 6.368854055249784e-11
5 O 0 1.6358357723955663e-10
% O 0 3.9668346385468567e-10
) O 0 2.923460085124674e-10
was O 0 3.09312156332453e-07
found O 0 4.6955594257269695e-07
in O 0 2.734070960741519e-07
Swedes O 0 0.013571005314588547
. O 0 4.80333710584091e-06

Saamis O 0 8.592793892603368e-05
( O 0 1.2729347353968024e-08
2 O 0 2.8599369539250574e-09
% O 0 5.305731409777081e-10
) O 0 9.215671281648241e-11
and O 0 1.271616478781823e-09
Mordvinians O 0 1.2370670674499706e-06
( O 0 5.517600265569911e-11
1 O 0 9.92498652707674e-11
. O 0 4.266347691794792e-11
8 O 0 2.8173205435244597e-10
% O 0 1.1374474973013804e-10
) O 0 1.5359928606795137e-10
had O 0 3.273998316899451e-08
significantly O 0 3.0983880350277104e-08
lower O 0 6.70582256390162e-09
frequencies O 0 8.284645858225304e-09
of O 0 1.31267968717097e-10
the O 0 2.5438271933353462e-08
Tyr O 0 4.583103509503417e-05
allele O 0 2.8507943170552608e-06
. O 0 1.3084456895740004e-07

Comparisons O 0 2.9793891371809877e-06
with O 0 4.855241186874082e-08
allele O 0 9.52515335939097e-07
frequencies O 0 3.12775028987744e-07
based O 0 9.02064201113717e-09
on O 0 1.348825833247247e-07
prevalence O 0 3.820884376182221e-05
estimates O 0 4.41039674115018e-07
of O 0 3.042298857280912e-08
HH B-Disease 1 0.999976396560669
showed O 0 0.00013344800390768796
some O 0 6.971950794465442e-10
disagreements O 0 6.626903825690533e-08
with O 0 2.1803363559058653e-09
the O 0 6.36227959205371e-09
RFLP O 0 2.119880036843824e-06
data O 0 2.9188785788392124e-07
, O 0 1.6585987028250315e-09
particularly O 0 9.986826476904298e-09
in O 0 5.93926543501766e-08
Finns O 0 0.00031079057953320444
. O 0 1.610160097698099e-06

The O 0 4.6665243758070574e-07
newly O 0 1.0785365702759009e-06
described O 0 1.0820145917023183e-06
HFE O 0 0.0001199959879158996
marker O 0 1.4280217328632716e-06
provides O 0 1.2796095738565327e-08
a O 0 3.6981471218666684e-09
new O 0 5.564793625900677e-10
approach O 0 3.584756935737232e-09
to O 0 1.4957197980169923e-10
the O 0 1.8837872928223476e-10
screening O 0 1.0416336237994983e-08
of O 0 3.1833660152358334e-09
HH B-Disease 1 0.9981277585029602
as O 0 1.4293876304805053e-08
well O 0 2.9158711001286974e-09
as O 0 8.123534067649985e-10
studies O 0 1.9264637107774263e-10
of O 0 1.474173907944909e-11
the O 0 1.1571068547766572e-09
relationship O 0 9.043643700579196e-08
between O 0 1.0057055632728407e-08
the O 0 1.5098372330157872e-07
HFE O 0 0.06954575330018997
Tyr O 0 4.672458817367442e-05
allele O 0 1.3465063375406316e-06
and O 0 3.939776505035297e-08
different O 0 8.563380049508851e-08
disorders O 0 0.0009159671026282012
including O 0 7.046932296361774e-05
cancer B-Disease 1 0.964779257774353

Autosomal B-Disease 1 0.9978079199790955
dominant I-Disease 1 0.8786181211471558
neurohypophyseal I-Disease 1 0.9995538592338562
diabetes I-Disease 1 0.9998888969421387
insipidus I-Disease 1 0.9972100853919983
associated O 0 5.3304294851841405e-05
with O 0 2.6894575455571612e-08
a O 0 6.753226671207813e-07
missense O 0 0.00014245249622035772
mutation O 0 2.913882553912117e-06
encoding O 0 1.3143248622782266e-07
Gly23 O 0 3.41275408572983e-05
- O 0 0.00010960186045849696
- O 0 0.0007632806082256138
> O 0 1.0132676834473386e-05
Val O 0 8.111068018479273e-05
in O 0 2.3719701403024374e-07
neurophysin O 0 0.0006060337764210999
II O 0 0.005698539782315493
. O 0 1.7064112398657016e-06

Autosomal B-Disease 1 0.9955204725265503
dominant I-Disease 1 0.7543321251869202
neurohypophyseal I-Disease 1 0.999085545539856
diabetes I-Disease 1 0.9997654557228088
insipidus I-Disease 1 0.9967871904373169
( O 0 2.314522134838626e-06
ADNDI B-Disease 0 0.022330747917294502
) O 0 5.552924520202396e-08
is O 0 1.7160742515898164e-07
an O 0 0.00041991000762209296
inherited B-Disease 1 1.0
disease I-Disease 1 0.9999998807907104
caused O 0 0.021975507959723473
by O 0 2.9026773518125992e-06
progressive O 0 0.06445055454969406
degeneration O 0 0.0010646836599335074
of O 0 6.430968646498059e-09
the O 0 7.747355112996956e-08
magnocellular O 0 3.840340650640428e-05
neurons O 0 3.4678902238738374e-07
of O 0 4.1124434413397637e-10
the O 0 3.248592728155586e-09
hypothalamus O 0 9.565699201630196e-07
leading O 0 3.676690596421395e-08
to O 0 2.37325581409209e-09
decreased O 0 6.499446953966981e-07
ability O 0 8.962332209705437e-09
to O 0 8.876145929370693e-10
produce O 0 1.3110144969630255e-08
the O 0 2.3775021062988344e-08
hormone O 0 2.633674512253492e-06
arginine O 0 5.558836733143835e-07
vasopressin O 0 1.416530494680046e-06
( O 0 5.188721452498157e-09
AVP O 0 3.2512417647012626e-07
) O 0 7.236381716069218e-09
. O 0 7.757898146110165e-08

Affected O 0 5.470622454595286e-06
individuals O 0 1.1135908550841123e-07
are O 0 7.85720644103094e-09
not O 0 2.7452603745814486e-08
symptomatic O 0 1.9200883798475843e-06
at O 0 3.495385954010999e-07
birth O 0 3.3227624953724444e-05
, O 0 9.836777614680159e-09
but O 0 5.643167710900343e-08
usually O 0 1.5802205552972737e-06
develop O 0 7.775756785122212e-06
diabetes B-Disease 0 0.003908168990164995
insipidus I-Disease 0 8.489325409755111e-05
at O 0 1.3970303314181365e-07
1 O 0 3.518904634347564e-08
- O 0 4.301511580706574e-05
6 O 0 3.4154609807046654e-07
yr O 0 6.112911069067195e-05
of O 0 4.61257743111787e-09
age O 0 1.545467966934666e-06
. O 0 4.401052535740746e-07

The O 0 1.6315223660967604e-07
genetic O 0 2.7984349344478687e-06
locus O 0 3.4419178973621456e-06
of O 0 1.3533634657392213e-08
the O 0 1.6509319493707153e-06
disease O 0 0.0004323634784668684
is O 0 1.4004019277535917e-08
the O 0 9.143318102644571e-09
AVP O 0 6.515360837511253e-06
- O 0 0.0007858194294385612
neurophysin O 0 0.0011929571628570557
II O 0 0.00246962602250278
( O 0 3.6802392244794646e-09
NPII O 0 3.4943834634759696e-06
) O 0 1.9759174851863293e-10
gene O 0 2.8269249163770382e-09
, O 0 4.64907140562687e-10
and O 0 3.293652994784679e-08
mutations O 0 1.918883754115086e-06
that O 0 3.2605785804662446e-07
cause O 0 1.1133504813187756e-05
ADNDI B-Disease 0 0.13121356070041656
have O 0 8.718220669834409e-07
been O 0 2.1829055185662583e-07
found O 0 5.665686941824788e-08
in O 0 1.4786699642499457e-09
both O 0 5.836928163027721e-10
the O 0 9.202010819997497e-10
signal O 0 7.240237209771294e-08
peptide O 0 5.419096726910766e-09
of O 0 4.960163182965438e-11
the O 0 1.1309408964876866e-09
prepro O 0 9.166226845991332e-06
- O 0 9.070816304301843e-06
AVP O 0 3.426628722991154e-07
- O 0 3.3564228942850605e-06
NPII O 0 5.812686595163541e-06
precursor O 0 2.904632090405812e-08
and O 0 3.0450835186712766e-09
within O 0 3.8452374617747864e-09
NPII O 0 2.9919981898274273e-05
itself O 0 2.276613599860866e-07
. O 0 9.469815154261596e-08

An O 0 1.20350719612361e-07
affected O 0 1.0621581481018438e-07
girl O 0 4.025237649329938e-05
who O 0 6.62310029042601e-08
presented O 0 1.5440868139648956e-08
at O 0 4.239631312685788e-09
9 O 0 2.6862931878923746e-09
months O 0 2.1745303335762856e-09
of O 0 8.188185129931469e-10
age O 0 1.1192075817234581e-06
and O 0 4.8728679757914506e-08
her O 0 1.5804737358848797e-06
similarly O 0 2.0155287074885564e-06
affected O 0 2.699288614849138e-08
younger O 0 7.360119980148738e-08
brother O 0 3.0086280844443536e-07
and O 0 1.315929765155488e-08
father O 0 4.408487939144834e-07
were O 0 2.5247437918096693e-08
all O 0 3.3917194053323385e-10
found O 0 1.494646184596604e-08
to O 0 1.6475285580241916e-09
have O 0 7.17352488521783e-09
a O 0 2.164678392091446e-08
novel O 0 8.346665225644756e-08
missense O 0 1.501626775279874e-05
mutation O 0 8.519796779182798e-07
( O 0 5.728400531701539e-10
G1758 O 0 4.642368267582242e-08
- O 0 9.513029908703174e-06
- O 0 0.00047323768376372755
> O 0 1.2645974720726372e-06
T O 0 1.829277152864961e-06
) O 0 1.7970552129709105e-11
encoding O 0 1.0610815004419294e-10
the O 0 1.2474606070345118e-10
amino O 0 7.641054455831409e-10
acid O 0 1.2810399407925388e-09
substitution O 0 1.7875023683444624e-09
Gly23 O 0 7.277778308889538e-07
- O 0 1.1749855730158743e-05
- O 0 6.002577720209956e-05
> O 0 9.288075375479821e-07
Val O 0 8.636149686935823e-06
within O 0 3.2283466566696006e-08
NPII O 0 0.0002798089408315718
. O 0 7.308611316148017e-07

The O 0 5.081053586764028e-07
mutation O 0 5.711200356017798e-05
was O 0 3.5553364341467386e-07
confirmed O 0 3.674769644135267e-08
by O 0 2.1089459067979988e-09
restriction O 0 8.909501048037782e-08
endonuclease O 0 2.3434588001691736e-05
analysis O 0 6.514321171380288e-07
. O 0 3.3176311831084604e-07

A O 0 1.6123396562761627e-05
T1 O 0 0.0021333128679543734
- O 0 3.4720210351224523e-06
weighted O 0 1.34847340405031e-07
magnetic O 0 6.018416911501845e-07
resonance O 0 6.522758667415474e-06
imaging O 0 2.270428740303032e-05
of O 0 2.866063830708754e-09
the O 0 2.800311733608396e-07
fathers O 0 3.669114812510088e-05
pituitary O 0 3.637539703049697e-05
gland O 0 9.496251550444867e-06
demonstrates O 0 4.5448638275047415e-07
an O 0 1.496009538470844e-08
attenuated O 0 0.00020096929802093655
posterior O 0 0.0002725547819864005
pituitary O 0 0.0024186198133975267
bright O 0 0.00022627336147706956
spot O 0 7.116651249816641e-05
. O 0 8.450223276668112e-07

This O 0 7.426594947901322e-07
mutation O 0 4.119239383726381e-05
may O 0 3.7883805248384306e-07
be O 0 2.981207058994073e-09
valuable O 0 2.13303663620934e-09
for O 0 1.7002960150946933e-10
developing O 0 3.1166238478874675e-09
models O 0 8.459949185635196e-08
of O 0 4.251770047147829e-09
dominantly B-Disease 0 0.37678202986717224
inherited I-Disease 1 0.9985664486885071
neurodegeneration I-Disease 1 0.999998927116394
, O 0 2.9754087194078238e-08
as O 0 2.137120064249487e-10
the O 0 1.795411597171892e-10
early O 0 1.3690422129286617e-08
age O 0 8.126002981612146e-09
of O 0 1.897124957128682e-10
onset O 0 6.261231533244427e-07
of O 0 3.064598530500007e-08
symptoms O 0 2.3827651602914557e-05
suggests O 0 8.81632260529841e-08
that O 0 1.1319902348816413e-08
this O 0 1.4008374016327707e-08
mutation O 0 6.6541747401061e-06
may O 0 1.4503397096632398e-06
be O 0 1.3863193260021944e-08
particularly O 0 1.4933382530557537e-08
deleterious O 0 9.72962538980937e-07
to O 0 9.368468667503294e-09
the O 0 4.5320003749793614e-08
magnocellular O 0 9.641137148719281e-05
neuron O 0 0.00011205476766917855
. O 0 3.512085555712474e-08
. O 0 5.6733210129777945e-08

Frequent O 0 6.428495544241741e-05
inactivation O 0 0.0005209565279074013
of O 0 1.1726259430133723e-07
PTEN O 0 0.029692014679312706
/ O 0 0.00021946110064163804
MMAC1 O 0 0.0017312932759523392
in O 0 3.7600532323267544e-06
primary O 1 0.9962129592895508
prostate B-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999984502792358
. O 0 0.0004898693296127021

Sporadic B-Disease 1 0.8554138541221619
prostate I-Disease 1 0.9999767541885376
carcinoma I-Disease 1 0.9999998807907104
is O 0 6.884058166178875e-06
the O 0 1.1431055213506625e-08
most O 0 7.860174733309577e-09
common O 0 4.5824802441529755e-07
male B-Disease 0 0.0018932834500446916
cancer I-Disease 0 5.320541822584346e-05
in O 0 5.9795683959862345e-09
the O 0 2.6411022258088224e-09
Western O 0 1.7579822042534943e-08
world O 0 4.3847811070918397e-07
, O 0 1.7198342749935591e-09
yet O 0 3.5878897630681195e-09
many O 0 1.0755603005452308e-11
of O 0 1.772616081696654e-11
the O 0 3.9896816406148616e-10
major O 0 2.1009884942913004e-09
genetic O 0 1.8397194878616574e-08
events O 0 6.834393495580571e-09
involved O 0 6.038340938374631e-09
in O 0 2.8724393974499662e-09
the O 0 1.8535712964506956e-09
progression O 0 2.1813484352151136e-08
of O 0 1.1255667925480495e-10
this O 0 2.7984558670368642e-08
often O 0 2.3904942281660624e-05
fatal O 1 0.9867892861366272
cancer B-Disease 0 0.19391970336437225
remain O 0 7.378616828646045e-07
to O 0 2.378155272708682e-08
be O 0 1.3094634141452843e-06
elucidated O 0 0.00026150105986744165
. O 0 1.2118772474423167e-06

Numerous O 0 2.4522014427930117e-06
cytogenetic O 0 0.004178829491138458
and O 0 7.584301897622936e-07
allelotype O 0 0.0008236697758547962
studies O 0 8.725856446289981e-07
have O 0 1.7325147894098336e-07
reported O 0 1.0688030442906893e-06
frequent O 0 2.5895292310451623e-06
loss O 0 5.170978965907125e-06
of O 0 4.842549472527935e-09
heterozygosity O 0 0.0001577752991579473
on O 0 8.80010975379264e-06
chromosomal O 0 0.15838994085788727
arm O 0 0.0017054578056558967
10q O 0 2.742985998338554e-05
in O 0 1.3278056485432899e-06
sporadic B-Disease 1 0.5734380483627319
prostate I-Disease 1 0.9999997615814209
cancer I-Disease 1 0.9999979734420776
. O 0 0.00010818089504027739

Deletion O 0 0.0002205994096584618
mapping O 0 0.00017331064736936241
studies O 0 2.0536299416562542e-06
have O 0 9.518182508827522e-08
unambiguously O 0 1.542507015983574e-05
identified O 0 1.1902716323675122e-06
a O 0 6.107167394020507e-08
region O 0 1.4316659857627201e-08
of O 0 7.319276851269763e-10
chromosome O 0 1.9206676370231435e-05
10q23 O 0 6.869288995403622e-07
to O 0 5.030367233871402e-09
be O 0 1.0397439353937443e-08
the O 0 1.4536476466986414e-09
minimal O 0 7.982310421539296e-07
area O 0 1.809681293707399e-08
of O 0 9.315441751311937e-09
loss O 0 3.935661879950203e-05
. O 0 1.2347545634838752e-06

A O 0 1.832283601288509e-06
new O 0 2.0590962890310038e-07
tumor B-Disease 0 4.0961356717161834e-05
suppressor O 0 8.936884114518762e-05
gene O 0 2.3018603769742185e-06
, O 0 7.745936869696379e-08
PTEN O 0 0.0006247184937819839
/ O 0 1.7123258658102714e-05
MMAC1 O 0 0.003357021836563945
, O 0 2.0884083795635888e-08
was O 0 6.019576517246605e-07
isolated O 0 8.66716547420765e-08
recently O 0 3.8565733007089875e-07
at O 0 3.5994118796622843e-09
this O 0 1.1762324447772698e-09
region O 0 1.608225219662529e-09
of O 0 3.6153383065062883e-10
chromosome O 0 4.0139957491192035e-06
10q23 O 0 3.0939210660108074e-07
and O 0 8.603092460646167e-09
found O 0 1.8690650804842335e-08
to O 0 2.562076328871399e-09
be O 0 5.468836761224338e-08
inactivated O 0 2.845872870693711e-07
by O 0 1.3571419543723096e-09
mutation O 0 4.858140982832992e-07
in O 0 6.442942179774036e-08
three O 0 0.00016003011842258275
prostate B-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999990463256836
cell O 1 0.6731178164482117
lines O 0 0.0008957820828072727
. O 0 1.2340163948465488e-06

We O 0 9.405351306668308e-07
screened O 0 7.636553164047655e-06
80 O 0 9.406858225702308e-07
prostate B-Disease 1 0.9942768216133118
tumors I-Disease 1 0.9999960660934448
by O 0 6.320650669522365e-08
microsatellite O 0 0.0001896154135465622
analysis O 0 5.780220249107515e-07
and O 0 2.48414124826013e-08
found O 0 7.606018215255972e-08
chromosome O 0 1.0894967772401287e-06
10q23 O 0 1.2782368230546126e-07
to O 0 2.196150816757836e-09
be O 0 1.1007069922186474e-08
deleted O 0 1.0375197234679945e-07
in O 0 1.9774878623479708e-08
23 O 0 3.871312159731133e-08
cases O 0 5.714067441431325e-08
. O 0 5.140888106325292e-07

We O 0 2.3510055768838356e-07
then O 0 3.156870320708549e-09
proceeded O 0 1.0873061340177514e-09
with O 0 5.925971519049611e-11
sequence O 0 6.72122357769922e-10
analysis O 0 1.4072443210721985e-10
of O 0 3.1215766083114715e-11
the O 0 4.4543466692914535e-09
entire O 0 1.808550109672069e-07
PTEN O 0 0.00010433025454403833
/ O 0 7.060924644974875e-07
MMAC1 O 0 8.749649168748874e-06
coding O 0 5.915782708143524e-07
region O 0 1.8678143476336118e-08
and O 0 2.8968862864076073e-08
tested O 0 1.1601680398598546e-06
for O 0 1.3594503300851102e-09
homozygous O 0 8.010649139578163e-07
deletion O 0 3.0589987431994814e-07
with O 0 3.477714338728788e-09
new O 0 7.700474036198557e-09
intragenic O 0 1.5459544329132768e-06
markers O 0 5.863211072210106e-07
in O 0 3.2384654957695602e-09
these O 0 8.866703482546257e-10
23 O 0 3.1088760454878184e-09
cases O 0 1.8158211601004837e-09
with O 0 1.7096503768243565e-08
10q23 O 0 1.2998832062294241e-05
loss O 0 1.7994541394728003e-06
of O 0 2.5098977118886978e-08
heterozygosity O 0 0.0008894882630556822
. O 0 2.1317296159395482e-06

The O 0 3.1981748804810195e-08
identification O 0 2.9657538647143156e-08
of O 0 2.5355123556281e-10
the O 0 8.847141352852361e-10
second O 0 2.7591715578978437e-08
mutational O 0 9.791285265237093e-06
event O 0 7.943398827592318e-07
in O 0 3.0344389223557755e-09
10 O 0 1.630792834106387e-09
( O 0 5.307482231486915e-10
43 O 0 6.555782139372468e-09
% O 0 2.4945586929447927e-08
) O 0 7.624333306921471e-07
tumors B-Disease 1 0.9999970197677612
establishes O 0 0.0028444849886000156
PTEN O 0 0.06171268969774246
/ O 0 7.99597182776779e-06
MMAC1 O 0 7.353464297921164e-06
as O 0 6.235436056378774e-10
a O 0 1.8714614302695054e-09
main O 0 1.3872900161970847e-08
inactivation O 0 2.408673935860861e-06
target O 0 2.4109384710868653e-08
of O 0 4.024288124959696e-10
10q O 0 9.304875447924132e-07
loss O 0 7.247974167512439e-07
in O 0 2.6765471261569473e-07
sporadic B-Disease 1 0.9333587884902954
prostate I-Disease 1 1.0
cancer I-Disease 1 0.9999990463256836
. O 0 6.500539711851161e-06
. O 0 6.101986969042628e-07

Risk O 0 6.42499653622508e-05
reversals O 0 7.883516445872374e-06
in O 0 6.169594257698918e-08
predictive O 0 4.05779292123043e-06
testing O 0 7.833341442164965e-06
for O 0 1.661655551288277e-05
Huntington B-Disease 1 0.9999924898147583
disease I-Disease 1 0.9999841451644897
. O 0 2.9735321732005104e-05

The O 0 5.931929081270937e-08
first O 0 1.58114410453436e-08
predictive O 0 7.141104561014799e-07
testing O 0 8.799419788374507e-07
for O 0 5.652815616485896e-06
Huntington B-Disease 1 0.9999986886978149
disease I-Disease 1 0.9999980926513672
( O 0 1.850564444794145e-06
HD B-Disease 0 0.12526357173919678
) O 0 5.104615841133864e-09
was O 0 1.7803925800308207e-07
based O 0 2.5039579298891113e-09
on O 0 5.741595199282301e-09
analysis O 0 2.207982463531266e-09
of O 0 2.8192878587240955e-10
linked O 0 3.657195520645473e-06
polymorphic O 0 3.360774485372531e-07
DNA O 0 4.648854314837081e-07
markers O 0 3.663538166165381e-07
to O 0 2.8821804942680274e-09
estimate O 0 1.5463651692471103e-08
the O 0 4.0663544753627434e-10
likelihood O 0 1.4207685694600514e-08
of O 0 1.9150517283073043e-10
inheriting O 0 3.1171492764769937e-07
the O 0 1.528929693961345e-08
mutation O 0 9.176129083243723e-07
for O 0 1.8780275112817435e-08
HD B-Disease 0 0.0003756211663130671
. O 0 9.803233069760608e-07

Limits O 0 7.373523658316117e-07
to O 0 8.818690666601015e-09
accuracy O 0 6.653969819581107e-08
included O 0 1.1827001600295262e-09
recombination O 0 4.431824152106856e-08
between O 0 2.2986550440862175e-09
the O 0 2.311987046255126e-09
DNA O 0 3.6248471246835834e-07
markers O 0 1.8513482018533978e-06
and O 0 9.846088389053875e-09
the O 0 5.272523750932123e-09
mutation O 0 1.6267446198980906e-06
, O 0 3.253826541538274e-09
pedigree O 0 6.6747288656188175e-06
structure O 0 6.570155051122128e-07
, O 0 4.806649522848261e-10
and O 0 2.547116406681482e-10
whether O 0 9.144116019932369e-10
DNA O 0 1.208228894711283e-07
samples O 0 2.0269789402505012e-08
were O 0 6.543901420741349e-09
available O 0 3.410598914399543e-09
from O 0 4.527874464255177e-10
family O 0 8.248051130976819e-09
members O 0 4.2602370520228305e-09
. O 0 7.483743758029959e-08

With O 0 2.5769866240921147e-08
direct O 0 2.5939604242353198e-08
tests O 0 3.4893766098775814e-08
for O 0 4.14651618596551e-10
the O 0 1.2363478241184112e-08
HD B-Disease 0 0.055037569254636765
mutation O 0 4.106160304218065e-06
, O 0 1.888558420759523e-09
we O 0 1.9101789039410733e-09
have O 0 7.00790814267549e-10
assessed O 0 3.0209947876613796e-09
the O 0 3.2191077581344985e-10
accuracy O 0 7.33839229383193e-08
of O 0 1.475992383870306e-10
results O 0 2.1212152034877363e-08
obtained O 0 1.0287915408468962e-08
by O 0 5.646230705202981e-10
linkage O 0 2.740840443493653e-07
approaches O 0 5.463610452949297e-09
when O 0 1.4354576416408804e-09
requested O 0 4.246573093169559e-10
to O 0 6.133287211440575e-10
do O 0 5.004948455678004e-09
so O 0 6.243576211595325e-10
by O 0 3.3715891190055913e-10
the O 0 4.0851220184379144e-09
test O 0 6.68539144044189e-08
individuals O 0 1.9419823971134065e-08
. O 0 2.887476284740842e-07

For O 0 1.9435423936897678e-08
six O 0 3.7934140273421235e-09
such O 0 8.550951058339251e-10
individuals O 0 1.172559471740442e-08
, O 0 5.580421014172998e-09
there O 0 1.5329710834066645e-08
was O 0 9.56123358264449e-08
significant O 0 6.964512078155849e-09
disparity O 0 1.06916651532174e-07
between O 0 1.915454461709487e-09
the O 0 1.9179413612846474e-08
tests O 0 6.652700790255039e-07
. O 0 2.2710968039518775e-07

Three O 0 3.9170434007473887e-08
went O 0 2.9458526284997788e-08
from O 0 5.237580369410466e-10
a O 0 7.09559557776629e-08
decreased O 0 1.0397724508948158e-05
risk O 0 2.1802507887969114e-07
to O 0 1.148792283522937e-09
an O 0 7.573732752064188e-09
increased O 0 1.968187689271872e-06
risk O 0 1.9214623989682877e-06
, O 0 1.561542450900788e-09
while O 0 3.2902796043288163e-09
in O 0 7.624937903294438e-10
another O 0 2.585068381577571e-09
three O 0 1.2446663699705596e-09
the O 0 7.221962050607544e-08
risk O 0 1.0080437277792953e-05
was O 0 2.69596330326749e-05
decreased O 0 2.18681543628918e-05
. O 0 2.153644089730733e-07

Knowledge O 0 4.023985411549802e-07
of O 0 1.3151086886153962e-09
the O 0 2.0813448742273977e-09
potential O 0 1.977306851586036e-08
reasons O 0 2.715264013630758e-09
for O 0 1.1610015726581935e-10
these O 0 1.856623882412478e-10
changes O 0 7.164606130594109e-10
in O 0 9.764076214224815e-10
results O 0 1.6142525538498376e-08
and O 0 7.764541010146786e-09
impact O 0 1.4206032794561452e-08
of O 0 1.5133248820742295e-10
these O 0 2.950608424256984e-09
risk O 0 1.8219070696545714e-08
reversals O 0 1.5996203472923298e-08
on O 0 2.4467668779948326e-08
both O 0 3.543021875884733e-08
patients O 0 3.0743230183816195e-08
and O 0 1.2130499271734152e-08
the O 0 7.174318916725042e-09
counseling O 0 8.658143002548968e-08
team O 0 5.655890866762547e-09
can O 0 4.590267721482633e-09
assist O 0 6.53579024234574e-10
in O 0 1.116859271732551e-09
the O 0 2.9001895329727745e-10
development O 0 4.993043825618493e-11
of O 0 2.9001658713445622e-11
strategies O 0 1.8356772768512997e-09
for O 0 2.75764300283754e-10
the O 0 1.0055482668747118e-08
prevention O 0 5.541845666812151e-07
and O 0 7.142753588595951e-08
, O 0 3.870689990748133e-09
where O 0 1.2485950051654982e-08
necessary O 0 3.77825948305599e-08
, O 0 3.811690962862713e-09
management O 0 6.682606690233683e-10
of O 0 2.5222659030821326e-11
a O 0 2.3089347678251215e-07
risk O 0 4.2555046775305527e-07
reversal O 0 1.1200238958508635e-07
in O 0 1.904126190055422e-09
any O 0 4.398196917776431e-09
predictive O 0 3.252125395647454e-07
testing O 0 6.08274319802149e-08
program O 0 2.759481887437687e-08
. O 0 5.4592041998091645e-09
. O 0 4.459449343130473e-08

A O 0 5.050076197221642e-06
novel O 0 3.861129016513587e-07
common O 0 2.835762131780939e-07
missense O 0 6.258820940274745e-05
mutation O 0 7.43413011150551e-06
G301C O 0 4.6685809707014414e-07
in O 0 2.8383031480672116e-09
the O 0 1.911119040798326e-09
N O 0 4.7723065108584706e-06
- O 0 1.1009716217813548e-05
acetylgalactosamine O 0 3.574203947209753e-05
- O 0 4.3596992327366024e-05
6 O 0 1.510489511247215e-07
- O 0 0.0001096442065318115
sulfate O 0 0.00015846581663936377
sulfatase O 0 1.085831354430411e-05
gene O 0 5.761784294122663e-08
in O 0 1.2838340168741524e-08
mucopolysaccharidosis B-Disease 0 4.0583934605820104e-05
IVA I-Disease 0 0.001556664938107133
. O 0 2.7319831588101806e-06

Mucopolysaccharidosis B-Disease 0 0.04468561336398125
IVA I-Disease 1 0.7420981526374817
( O 0 1.8675043975235894e-05
MPS B-Disease 1 0.9995365142822266
IVA I-Disease 1 0.9999750852584839
) O 0 1.5880310684224241e-06
is O 0 1.0069670253187724e-07
an O 0 3.725150179434422e-07
autosomal B-Disease 1 0.9996556043624878
recessive I-Disease 1 0.9999195337295532
lysosomal I-Disease 1 0.9999829530715942
storage I-Disease 1 0.9999949932098389
disorder I-Disease 1 0.999953031539917
caused O 0 0.00032477659988217056
by O 0 3.935255961096118e-07
a O 0 0.005819611717015505
genetic B-Disease 1 0.9999964237213135
defect I-Disease 1 0.9999940395355225
in O 0 1.2306094276937074e-06
N O 0 8.591188088757917e-05
- O 0 3.632378502516076e-05
acetylgalactosamine O 0 0.00016898999456316233
- O 0 0.0009275290067307651
6 O 0 1.4636999594586086e-06
- O 0 0.05799021199345589
sulfate O 0 0.05105803534388542
sulfatase O 0 0.0005381466471590102
( O 0 2.332495796508738e-08
GALNS O 0 1.0816022040671669e-05
) O 0 9.270332057553787e-09
. O 0 3.456903741039241e-08

In O 0 1.1629312979266615e-07
previous O 0 9.556383417930192e-08
studies O 0 1.6458082896519954e-08
, O 0 3.320186570121564e-09
we O 0 7.62834595491313e-09
have O 0 1.0787773341291995e-08
found O 0 8.362452952326294e-09
two O 0 1.516712311300239e-09
common O 0 4.1256541294387716e-08
mutations O 0 1.2464087717489747e-07
in O 0 8.38115088441782e-09
Caucasians O 0 1.8415421720874292e-07
and O 0 3.2387696080604655e-08
Japanese O 0 9.624014865039499e-07
, O 0 8.991611011310852e-09
respectively O 0 3.2453095855089487e-07
. O 0 4.4612534111365676e-07

To O 0 1.0882324374961172e-07
characterize O 0 1.5452970956175704e-06
the O 0 1.6518244549956762e-08
mutational O 0 3.427600677241571e-05
spectrum O 0 1.3199489785620244e-06
in O 0 1.2695492435099709e-09
various O 0 2.059670906051636e-10
ethnic O 0 2.1555266460637768e-09
groups O 0 3.2935758564889284e-09
, O 0 2.9191489225866007e-09
mutations O 0 1.9380010485292587e-08
in O 0 1.3838036272417753e-09
the O 0 1.7056499546086457e-09
GALNS O 0 1.8372902559349313e-05
gene O 0 1.8168266890938867e-08
in O 0 1.5992695168165483e-08
Colombian O 0 1.6315319953719154e-05
MPS B-Disease 1 0.9997735619544983
IVA I-Disease 1 0.9999935626983643
patients O 0 9.19852900551632e-05
were O 0 1.4222645177142113e-06
investigated O 0 4.023966903332621e-05
, O 0 1.168975405363426e-08
and O 0 8.116971983440635e-09
genetic O 0 3.233804193314427e-07
backgrounds O 0 1.7357199055823003e-07
were O 0 1.2517163305858503e-08
extensively O 0 5.881569009602572e-08
analyzed O 0 8.310271226719124e-08
to O 0 1.1617995454571428e-09
identify O 0 2.0567092917644914e-08
racial O 0 1.847966579759941e-08
origin O 0 2.84648553616762e-08
, O 0 2.6036331424172943e-10
based O 0 3.502128309573749e-10
on O 0 1.498414015088656e-08
mitochondrial O 0 3.595554971980164e-06
DNA O 0 8.25259030534653e-06
( O 0 1.4513157786666397e-08
mtDNA O 0 1.2273916638605442e-07
) O 0 5.620735876732397e-09
lineages O 0 1.231041011351408e-07
. O 0 2.636612066453381e-07

Three O 0 2.1085051571390068e-07
novel O 0 8.621574352218886e-07
missense O 0 0.0003996086888946593
mutations O 0 0.0001556451024953276
never O 0 1.0252214451611508e-05
identified O 0 5.700492238247534e-07
previously O 0 6.928780749149155e-08
in O 0 1.8231157694614808e-09
other O 0 1.4058419983697945e-09
populations O 0 7.455986050786123e-09
and O 0 1.2039979679911994e-08
found O 0 2.1742495803778183e-08
in O 0 2.2951458511499823e-09
16 O 0 2.389770603627994e-10
out O 0 2.940112875382539e-10
of O 0 2.579442770489493e-10
19 O 0 1.2398338355978922e-07
Colombian O 0 8.172850357368588e-06
MPS B-Disease 1 0.99181067943573
IVA I-Disease 1 0.9997546076774597
unrelated O 0 1.126232382375747e-05
alleles O 0 6.250289885656457e-08
account O 0 2.896295114851455e-08
for O 0 8.061842748929848e-09
84 O 0 1.8161463799515332e-07
. O 0 4.4472946569840133e-07

2 O 0 1.0469981504002135e-07
% O 0 3.5195073522231723e-09
of O 0 1.408436561822768e-10
the O 0 1.6541820135884677e-09
alleles O 0 4.8661622287227146e-08
in O 0 1.113420466936077e-08
this O 0 1.4849875995537332e-08
study O 0 1.4874132148179342e-07
. O 0 3.644612149855675e-07

The O 0 1.79075243522675e-07
G301C O 0 1.023402546707075e-06
and O 0 2.4487183836185977e-08
S162F O 0 3.442238778461615e-07
mutations O 0 1.1357072082773811e-07
account O 0 1.4850358276419229e-08
for O 0 4.553668997431259e-09
68 O 0 1.3155238320905482e-07
. O 0 3.2113663905875e-07

4 O 0 1.1141192999275518e-06
% O 0 8.461740463872047e-08
and O 0 5.0613500945928536e-08
10 O 0 6.111677208764377e-08
. O 0 4.377677953470993e-07

5 O 0 1.6545304504234082e-07
% O 0 8.494142278436811e-09
of O 0 8.761397718437536e-10
mutations O 0 8.809378755358921e-07
, O 0 6.359877513517631e-09
respectively O 0 1.738456774091901e-07
, O 0 1.285732520450722e-09
whereas O 0 4.829257882477123e-09
the O 0 5.709355765937119e-10
remaining O 0 3.315509866652633e-09
F69V O 0 2.7927166229346767e-05
is O 0 1.0237193315276727e-09
limited O 0 1.2865046528087731e-10
to O 0 1.9703925990821602e-10
a O 0 3.016666383359734e-08
single O 0 8.639519364805892e-06
allele O 0 2.1916614514339017e-06
. O 0 1.4093670586134976e-07

The O 0 1.707751238200217e-07
skewed O 0 2.2022986740921624e-06
prevalence O 0 3.683805744003621e-06
of O 0 1.0701816099967232e-09
G301C O 0 2.6130243213629e-07
in O 0 1.8480008634469414e-09
only O 0 2.9044591176585755e-09
Colombian O 0 1.6334153087882441e-06
patients O 0 7.68801768913363e-08
and O 0 1.1240640418463954e-08
haplotype O 0 1.3554788438341348e-06
analysis O 0 1.7283644515586616e-09
by O 0 3.1971894576265925e-10
restriction O 0 4.542148879238539e-09
fragment O 0 2.47027458044613e-07
length O 0 1.8268208634708571e-07
polymorphisms O 0 1.833636588344234e-06
in O 0 1.9009545049186727e-09
the O 0 2.478909966185938e-09
GALNS O 0 3.362967981956899e-05
gene O 0 2.294604328767491e-08
suggest O 0 1.0275051032238025e-08
that O 0 1.4600135544995396e-09
G301C O 0 5.557734539252124e-08
originated O 0 4.588228019741791e-09
from O 0 4.858200508550681e-10
a O 0 4.6498566774744177e-08
common O 0 5.686450776920537e-07
ancestor O 0 9.5651112133055e-06
. O 0 1.400160954290186e-06

Investigation O 0 5.28028579083184e-07
of O 0 2.0000643363715653e-09
the O 0 1.6052402740385219e-09
genetic O 0 1.6204444364120718e-07
background O 0 2.5205270048900275e-07
by O 0 1.5653623952616158e-09
means O 0 1.3080739824644638e-09
of O 0 1.0016441842619628e-10
mtDNA O 0 3.212707255784153e-08
lineages O 0 2.8909676874633305e-09
indicate O 0 1.878414401801365e-08
that O 0 9.754825835983638e-10
all O 0 4.357081084815917e-10
our O 0 4.728137525944476e-08
patients O 0 1.801818250157794e-08
are O 0 2.6546527198689773e-09
probably O 0 3.2089470636265105e-08
of O 0 8.396908168784023e-10
native O 0 6.72766802267688e-08
American O 0 2.856928858818719e-06
descent O 0 0.0002580581058282405

Low O 0 1.2268887076061219e-05
frequency O 0 1.0168192829951295e-06
of O 0 4.512478835039246e-09
BRCA1 O 0 3.198742342647165e-05
germline O 0 2.4581284378655255e-05
mutations O 0 2.720864813454682e-06
in O 0 2.335758964022716e-08
45 O 0 8.135962303867927e-08
German O 1 0.9996715784072876
breast B-Disease 1 0.9999982118606567
/ I-Disease 1 0.9999979734420776
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999994039535522
families O 0 0.000275708589470014
. O 0 4.586197519529378e-06

In O 0 1.22427024962235e-07
this O 0 2.078861305321311e-09
study O 0 1.5736187908288457e-09
we O 0 4.384803631296563e-09
investigated O 0 1.2232823110025492e-06
45 O 0 6.545713659988905e-08
German O 1 0.9983872175216675
breast B-Disease 1 0.9999920129776001
/ I-Disease 1 0.9999943971633911
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999996423721313
families O 0 2.3979587240319233e-06
for O 0 4.5227086076238265e-08
germline O 0 0.00010696791287045926
mutations O 0 4.205920959066134e-06
in O 0 5.633797872661717e-09
the O 0 3.688758454245544e-08
BRCA1 O 0 0.0004671634524129331
gene O 0 6.736746854585363e-06
. O 0 5.478409548231866e-07

We O 0 9.345143894279317e-07
identified O 0 2.745520362168463e-07
four O 0 3.625864719580818e-09
germline O 0 3.6465628454607213e-06
mutations O 0 3.113784941888298e-06
in O 0 1.6617850207012452e-08
three O 0 8.010282499526511e-07
breast B-Disease 1 0.9997678399085999
cancer I-Disease 1 0.8761124014854431
families O 0 9.675155610011643e-08
and O 0 3.196363351776199e-08
in O 0 6.324485468667262e-08
one O 0 0.0007272751536220312
breast B-Disease 1 0.9999953508377075
- I-Disease 1 0.9999998807907104
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
family O 0 6.211064464878291e-05
. O 0 7.702251281216377e-09
among O 0 1.9988732891107475e-10
these O 0 2.6428795263377935e-10
were O 0 1.971687879631645e-08
one O 0 1.3213491456554038e-07
frameshift O 0 0.017481017857789993
mutation O 0 8.152821465046145e-06
, O 0 1.2551895078871667e-09
one O 0 4.132724829020162e-09
nonsense O 0 1.644078474782873e-05
mutation O 0 1.2271849527678569e-06
, O 0 3.806545079143575e-10
one O 0 5.712034734095539e-10
novel O 0 8.563343811829327e-09
splice O 0 1.2713438763967133e-06
site O 0 3.7844658891117433e-06
mutation O 0 5.914173925702926e-06
, O 0 1.9826269515021977e-09
and O 0 8.36648972324383e-09
one O 0 8.151432950853632e-08
missense O 0 0.0005713371792808175
mutation O 0 0.00017119028780143708
. O 0 7.804497954566614e-07

The O 0 8.412206966568192e-07
missense O 0 0.0009887033374980092
mutation O 0 0.00029936135979369283
was O 0 1.3982061091155629e-06
also O 0 1.6840662198092105e-08
found O 0 2.005680954653144e-08
in O 0 2.05218722015843e-08
2 O 0 3.697444128647476e-07
. O 0 1.0084158930112608e-06

8 O 0 1.653774859278201e-07
% O 0 2.6159645560852596e-09
of O 0 9.868753036990086e-11
the O 0 3.153618755025178e-10
general O 0 3.2606604083440516e-09
population O 0 4.483957649625836e-10
, O 0 2.853892400178637e-10
suggesting O 0 2.5880398268895988e-08
that O 0 1.4394476721690808e-08
it O 0 9.315832549816605e-09
is O 0 6.932032192707993e-08
not O 0 1.2593646943059866e-06
disease O 0 1.87950354302302e-05
associated O 0 1.0752213484011008e-06
. O 0 1.0496889899513917e-06

The O 0 1.0550227358407938e-07
average O 0 5.799070663670136e-07
age O 0 6.496744475725791e-08
of O 0 1.3169089818632074e-08
disease O 0 0.00011793764861067757
onset O 0 5.101781789562665e-05
in O 0 2.721321834542323e-07
those O 0 4.388328278537301e-08
families O 0 1.6798965418729495e-07
harbouring O 0 0.008799471892416477
causative O 0 0.000593111733905971
mutations O 0 7.0878563747101e-06
was O 0 1.2817450567581545e-07
between O 0 1.6498029609124387e-08
32 O 0 1.1196608085128901e-07
. O 0 9.312493034485669e-07

3 O 0 6.201537416927749e-07
and O 0 5.771396871523393e-08
37 O 0 4.748553976696712e-07
. O 0 2.1981281861371826e-07

4 O 0 1.2180821613583248e-06
years O 0 1.7183914735596773e-07
, O 0 4.05732247799051e-09
whereas O 0 1.2687438655234473e-08
the O 0 3.0965903174973164e-09
family O 0 9.059734651373219e-08
harbouring O 0 2.4637185561005026e-05
the O 0 9.792561428412228e-09
missense O 0 1.544881160953082e-05
mutation O 0 2.3647094167245086e-06
had O 0 3.6774203238110204e-08
an O 0 1.3394594322591047e-09
average O 0 4.4632324147642066e-07
age O 0 1.3284483735276353e-08
of O 0 8.644142623914775e-10
onset O 0 1.6112829825942754e-06
of O 0 2.670636156665296e-08
51 O 0 1.0754819186331588e-06
. O 0 9.901382327370811e-07

2 O 0 4.232912942825351e-06
years O 0 1.4598049347114284e-06
. O 0 1.0442174698255258e-06

These O 0 6.179321587751474e-08
findings O 0 5.2889642887521404e-08
show O 0 2.070647724394803e-07
that O 0 5.916233902780732e-08
BRCA1 O 0 3.4103592042811215e-05
is O 0 4.823727906000386e-08
implicated O 0 1.8020524521489278e-06
in O 0 6.16185369395339e-09
a O 0 3.718113372741527e-09
small O 0 2.616159067159174e-09
fraction O 0 7.980089833381498e-08
of O 0 1.5089547105162637e-06
breast B-Disease 1 0.9999935626983643
/ I-Disease 1 0.9999972581863403
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999996423721313
families O 0 7.412188551825238e-07
suggesting O 0 5.597030963144789e-07
the O 0 2.220614581105451e-09
involvement O 0 2.821991706980498e-08
of O 0 6.715226708031707e-10
another O 0 1.9194608569250704e-07
susceptibility O 0 0.0018887707265093923
gene O 0 6.6512175180832855e-06
( O 0 1.81432525891978e-07
s O 0 0.00021711505542043597
) O 0 1.1723290072040982e-06

Paternal O 0 0.09068626165390015
transmission O 0 0.056173309683799744
of O 0 0.0001966658455785364
congenital B-Disease 1 0.9999938011169434
myotonic I-Disease 1 0.9999985694885254
dystrophy I-Disease 1 0.9999982118606567
. O 0 0.011617328971624374

We O 0 1.5060750229167752e-06
report O 0 2.844602065010804e-08
a O 0 4.424903998767604e-09
rare O 0 1.1198871874285032e-07
case O 0 2.6190519974989e-07
of O 0 1.6531473079339776e-07
paternally O 1 0.9687106609344482
transmitted O 1 0.9999427795410156
congenital B-Disease 1 0.9999991655349731
myotonic I-Disease 1 0.9999998807907104
dystrophy I-Disease 1 0.9999998807907104
( O 0 0.18721766769886017
DM B-Disease 1 0.9999984502792358
) O 0 9.475033380113018e-07
. O 0 4.435045752870792e-07

The O 0 1.1723541604169441e-07
proband O 0 4.479851668293122e-06
is O 0 2.7542799152513453e-09
a O 0 1.511084590788414e-09
23 O 0 3.2941538385955482e-09
year O 0 2.772803853190453e-08
old O 0 0.0036231603007763624
, O 0 0.0002807948039844632
mentally B-Disease 1 0.9999995231628418
retarded I-Disease 1 0.9999982118606567
male O 0 0.19299346208572388
who O 0 0.0016236980445683002
suffers O 1 0.937240719795227
severe O 1 0.6127362251281738
muscular B-Disease 1 0.9980102181434631
weakness I-Disease 1 0.9776792526245117
. O 0 2.3661312297917902e-05

He O 0 3.993145583081059e-06
presented O 0 2.7565051823330577e-06
with O 0 1.015847192320507e-05
respiratory O 1 0.9899612665176392
and O 0 3.924210886907531e-06
feeding O 0 4.47077582066413e-05
difficulties O 0 1.5313837138819508e-05
at O 0 7.997466013875965e-07
birth O 0 8.435781637672335e-05
. O 0 5.499547341969446e-07

His O 0 3.6214130432199454e-06
two O 0 5.542785856960109e-07
sibs O 1 0.5970680713653564
suffer O 0 0.0007332356180995703
from O 0 4.964875301993743e-07
childhood O 0 0.03179331123828888
onset O 1 0.9664115905761719
DM B-Disease 1 0.9999942779541016
. O 0 4.818532761419192e-05

Their O 0 2.075568659165583e-07
late O 0 1.8355281383719557e-07
father O 0 3.723963857282797e-07
had O 0 2.7318469264514533e-08
the O 0 9.331655448363563e-10
adult O 0 4.265117325985557e-08
type O 0 1.5174010741247912e-06
of O 0 5.586483453612345e-08
DM B-Disease 1 0.999998927116394
, O 0 2.91583379663507e-08
with O 0 8.870480350253729e-09
onset O 0 7.237806016746617e-07
around O 0 2.1044467501951658e-08
30 O 0 8.840162379897265e-09
years O 0 1.3021282541103574e-07
. O 0 1.5866974933942402e-07

Only O 0 3.802268011554588e-08
six O 0 1.3195987635938877e-09
other O 0 3.812343496445436e-10
cases O 0 7.776957411387286e-10
of O 0 1.6777463862638342e-09
paternal O 0 0.010419006459414959
transmission O 0 0.07367634773254395
of O 0 9.823496839089785e-06
congenital B-Disease 1 0.999998927116394
DM I-Disease 1 1.0
have O 0 0.0041432129219174385
been O 0 2.2819767764303833e-05
reported O 0 1.0600108907965478e-05
recently O 0 5.033344677940477e-06
. O 0 5.723894673792529e-07

We O 0 2.2842469604711368e-07
review O 0 9.30950871946834e-09
the O 0 1.1299274849108087e-09
sex O 0 1.9780920013090508e-07
related O 0 9.459940741862738e-08
effects O 0 2.84869065581006e-06
on O 0 7.553576324426103e-06
transmission O 0 0.014281351119279861
of O 0 8.855978194333147e-06
congenital B-Disease 1 0.9999964237213135
DM I-Disease 1 0.9999986886978149
. O 0 0.00022045642253942788

Decreased O 0 0.00020092522026970983
fertility O 0 1.073237399396021e-05
of O 0 7.890877284921771e-09
males O 0 1.4229074452032364e-07
with O 0 2.1735447219839443e-08
adult O 0 4.0754694055067375e-05
onset O 0 0.015074015595018864
DM B-Disease 1 0.9999988079071045
and O 0 1.0373094028182095e-06
contraction O 0 9.013281783154525e-07
of O 0 1.4386145053002508e-10
the O 0 1.4272564241579744e-09
repeat O 0 3.423675707381335e-07
upon O 0 8.261638484441391e-09
male O 0 2.0086763470317237e-06
transmission O 0 1.0545231816649903e-06
contribute O 0 1.05183506349249e-09
to O 0 4.76326200704591e-10
the O 0 1.4689268690304402e-09
almost O 0 6.102752081460494e-09
absent O 0 4.914272722089663e-08
occurrence O 0 1.41179796742108e-07
of O 0 4.035388911916016e-09
paternal O 0 0.002029739785939455
transmission O 0 0.004267411772161722
of O 0 1.106479703594232e-05
congenital B-Disease 1 0.9999897480010986
DM I-Disease 1 0.9999977350234985
. O 0 0.00015797914238646626

Also O 0 1.3548711308430939e-07
the O 0 2.1967079266715928e-09
fathers O 0 1.2557791251310846e-08
of O 0 1.4823797744867306e-10
the O 0 1.9653125349350375e-08
reported O 0 7.170507888076827e-05
congenitally O 0 0.01325256284326315
affected O 0 1.6686716719505057e-07
children O 0 6.259798368546399e-08
showed O 0 5.211291409068508e-06
, O 0 1.3601427761855689e-09
on O 0 3.6158525063001434e-08
average O 0 1.4259326519550086e-07
, O 0 8.721648958598394e-10
shorter O 0 9.808453427240238e-08
CTG O 0 3.1943588396643463e-07
repeat O 0 2.377833823175024e-07
lengths O 0 3.855304385069758e-06
and O 0 1.0990727439263992e-08
hence O 0 3.3957167744347316e-08
less O 0 1.370193558614119e-07
severe O 0 8.189034269889817e-05
clinical O 0 0.00024475916870869696
symptoms O 0 1.3239959116617683e-05
than O 0 2.4650777419310543e-08
the O 0 1.1042548919704132e-07
mothers O 0 1.5348470014941995e-06
of O 0 3.3342051342089007e-09
children O 0 4.700116278399946e-06
with O 0 0.003766537643969059
congenital B-Disease 1 0.9999966621398926
DM I-Disease 1 0.9999984502792358
. O 0 0.0001872765424195677

We O 0 7.274592803696578e-07
conclude O 0 2.0464146643917047e-07
that O 0 1.37345459449989e-08
paternal O 0 2.719424810493365e-05
transmission O 0 0.00012334775237832218
of O 0 2.135575414285995e-06
congenital B-Disease 1 0.9999992847442627
DM I-Disease 1 1.0
is O 0 2.45590945269214e-05
rare O 0 1.894514412015269e-06
and O 0 3.1592090721233035e-08
preferentially O 0 9.423038136446849e-07
occurs O 0 7.0882202329869415e-09
with O 0 9.87391723938913e-10
onset O 0 2.1232638403034798e-07
of O 0 1.218517908796457e-08
DM B-Disease 1 0.9999945163726807
past O 0 4.072187778092484e-07
30 O 0 3.212913934902417e-09
years O 0 3.6615865894873423e-09
in O 0 1.3408116839030981e-09
the O 0 4.924553653751218e-09
father O 0 6.288828899414511e-06
. O 0 3.7514030992724656e-08
. O 0 8.870450329823143e-08

The O 0 3.856532657664502e-06
RB1 O 0 0.0009011169895529747
gene O 0 2.4486960228387034e-06
mutation O 0 1.4079880202189088e-05
in O 0 1.4147193638791578e-08
a O 0 1.700478691191165e-07
child O 0 0.00012484047329053283
with O 0 4.180727046332322e-05
ectopic B-Disease 1 0.999955415725708
intracranial I-Disease 1 0.9999932050704956
retinoblastoma I-Disease 1 0.9996621608734131
. O 0 0.0001494548487244174

The O 0 8.904249284569232e-07
RB1 O 0 0.00024164689239114523
gene O 0 1.3531888498619082e-06
mutation O 0 1.6334779502358288e-05
was O 0 3.2894908486014174e-07
investigated O 0 1.4081741710469942e-06
in O 0 1.7335883839564303e-08
a O 0 1.4164143067318946e-06
child O 0 0.006898033898323774
with O 0 4.267340955266263e-06
ectopic B-Disease 1 0.9996229410171509
intracranial I-Disease 1 0.9999442100524902
retinoblastoma I-Disease 0 0.002463656011968851
using O 0 1.2599734589002765e-07
DNA O 0 5.445683655125322e-06
obtained O 0 7.653970612864214e-08
from O 0 5.453352214246365e-10
both O 0 5.96450666634496e-10
the O 0 5.806240377381755e-09
pineal B-Disease 0 6.583271897397935e-06
and I-Disease 0 5.661614181917685e-07
retinal I-Disease 0 0.0023780036717653275
tumours I-Disease 1 0.9999567270278931
of O 0 1.1655667542243009e-08
the O 0 4.6324265667863074e-07
patient O 0 0.00011243495100643486
. O 0 1.0364195759393624e-06

A O 0 6.8506906245602295e-06
nonsense O 0 7.38676535547711e-05
mutation O 0 8.346714821527712e-06
in O 0 2.8757847658766877e-08
exon O 0 1.9711013010237366e-05
17 O 0 7.034255844473591e-08
( O 0 6.733272273073965e-10
codon O 0 5.864673635613826e-09
556 O 0 4.14920009461639e-09
) O 0 6.442318206678621e-11
of O 0 3.358558223198749e-11
the O 0 2.802713083838171e-08
RB1 O 0 2.120999306498561e-05
gene O 0 1.1594448956486758e-08
was O 0 4.447930734841066e-08
found O 0 5.176572948073499e-09
to O 0 9.526547328775337e-10
be O 0 1.5911213679942193e-08
present O 0 8.062196243940889e-09
homozygously O 0 1.3582010069512762e-05
in O 0 4.293273736521996e-09
both O 0 2.1992736520815015e-09
the O 0 1.6240205624740156e-08
retinal B-Disease 0 6.516398570965976e-05
and I-Disease 0 4.6086492488939257e-07
the I-Disease 0 8.204965524782892e-07
pineal I-Disease 0 0.010982596315443516
tumours I-Disease 1 0.9999330043792725
. O 0 3.693289500006358e-06

The O 0 7.86244171990802e-08
same O 0 3.7423554033466644e-08
mutation O 0 5.604219950328115e-07
was O 0 2.756478245657945e-08
present O 0 3.2388667303706598e-09
heterozygously O 0 2.0036140995216556e-06
in O 0 7.615635899682616e-10
the O 0 2.247599467652961e-10
DNA O 0 3.871622311635292e-08
from O 0 2.695715317635461e-10
the O 0 2.9261265632740674e-10
constitutional O 0 7.40528971476806e-09
cells O 0 1.2371019764145785e-09
of O 0 3.295011485882071e-11
the O 0 7.170583682380993e-09
patient O 0 1.514417135695112e-06
, O 0 4.6731845060321575e-09
proving O 0 3.3578015745661105e-07
it O 0 8.14530221049381e-10
to O 0 3.685154126298329e-10
be O 0 7.2617951651920976e-09
of O 0 1.937164872956032e-09
germline O 0 6.162565568956779e-06
origin O 0 3.740386205208779e-07
. O 0 3.9731543211019016e-07

The O 0 6.204454194858045e-08
initial O 0 4.077554365267133e-07
mutation O 0 5.201177373237442e-06
was O 0 3.875154561683303e-07
shown O 0 1.847938904120383e-07
to O 0 4.5676040727471445e-09
have O 0 9.438313242071672e-08
occurred O 0 4.650029552522028e-07
in O 0 8.68897664929591e-09
the O 0 2.0891890883945052e-08
paternally O 0 9.409835001861211e-06
derived O 0 9.978944035538007e-07
RB1 O 0 6.0643593315035105e-05
allele O 0 4.100228125025751e-06
. O 0 2.5009765636241355e-07

The O 0 5.275463763609878e-07
mutation O 0 1.9949156921938993e-05
is O 0 9.465749073456209e-09
in O 0 6.813109520997784e-10
an O 0 5.667010194443378e-10
area O 0 8.072674972936511e-09
of O 0 2.465145587660089e-10
the O 0 2.4878055171484448e-09
gene O 0 5.590413909573044e-09
that O 0 2.6635063599123043e-10
encodes O 0 4.879541215530026e-10
the O 0 3.326872666242764e-10
protein O 0 9.88123183276457e-09
- O 0 1.5523870615652413e-06
binding O 0 5.005791194889753e-07
region O 0 5.263741442718128e-09
known O 0 2.2065131943804772e-09
as O 0 5.909607803111783e-10
the O 0 2.9669742218629835e-09
pocket O 0 0.008196045644581318
region O 0 1.336543533625445e-07
and O 0 8.21444174903263e-08
has O 0 9.058317118615378e-08
been O 0 1.1123956511482902e-07
detected O 0 2.8609258606593357e-06
in O 0 1.6976721139982942e-09
other O 0 6.356236093019163e-10
cases O 0 1.9693828789968393e-09
of O 0 3.856298391724522e-09
retinoblastoma B-Disease 0 0.00012007417535642162
. O 0 1.3437109203096043e-07
. O 0 2.1522028248455172e-07

Low O 0 0.00013215358194429427
levels O 0 5.810430820929469e-07
of O 0 8.569057130536351e-10
beta O 0 2.0264648625811787e-08
hexosaminidase O 0 3.142579089399078e-06
A O 0 2.0111595233629487e-07
in O 0 1.3588237202100117e-08
healthy O 0 1.680572836448846e-07
individuals O 0 3.232355938465048e-09
with O 0 2.5108275281127135e-07
apparent O 1 0.8665618300437927
deficiency O 1 0.7601754069328308
of O 0 4.5291033146099835e-09
this O 0 6.578255096201246e-08
enzyme O 0 1.4054212442715652e-06
. O 0 2.7252409040556813e-07

Appreciable O 0 0.0002743631193879992
beta O 0 5.485203018906759e-06
hexosaminidase O 0 6.886353367008269e-05
A O 0 1.1920369615836535e-06
( O 0 5.736330077610319e-09
hex O 0 7.710631848567573e-07
A O 0 1.8003468937877187e-07
) O 0 9.145615931238638e-10
activity O 0 9.224702779420113e-09
has O 0 7.318108341536345e-09
been O 0 2.8199631074699028e-08
detected O 0 3.7012757729826262e-06
in O 0 8.539122298145685e-09
cultured O 0 4.9340516852680594e-05
skin O 0 0.0009310564491897821
fibroblasts O 0 1.4541553809976904e-06
and O 0 7.218447535706218e-06
melanoma B-Disease 1 0.8880598545074463
tissue O 0 0.00021470239153131843
from O 0 1.262677500335485e-07
healthy O 0 1.0288827070326079e-06
individuals O 0 1.2003956051387377e-08
previously O 0 1.3476728781824932e-06
reported O 0 8.303882168547716e-06
as O 0 3.671922286230256e-07
having O 0 0.004044756293296814
deficiency B-Disease 0 0.002431740751489997
of I-Disease 0 3.6534922309705564e-10
hex I-Disease 0 6.767745048819052e-07
A I-Disease 0 5.9427438969805735e-08
activity O 0 4.17748591274858e-09
indistinguishable O 0 4.74446837372966e-09
from O 0 9.885840757117847e-11
that O 0 7.135857460482953e-10
of O 0 2.2484925032983938e-09
patients O 0 2.19289699998626e-06
with O 0 0.01738773286342621
Tay B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999991655349731
Sachs I-Disease 1 0.9999988079071045
disease I-Disease 1 0.5437830090522766
( O 0 2.312912670277001e-07
TSD B-Disease 0 0.0004939435748383403
) O 0 6.396693663646147e-08
. O 0 1.6274121605874825e-07

Identification O 0 1.2223737940075807e-05
and O 0 6.472750158081908e-08
quantitation O 0 1.759381302690599e-05
of O 0 7.725217798792983e-09
hex O 0 5.842781320097856e-06
A O 0 5.027492306908243e-07
, O 0 3.6965746019745893e-09
amounting O 0 3.02439779886754e-08
to O 0 8.346247248880445e-09
3 O 0 8.997087519446723e-08
. O 0 4.803570732292428e-07

5 O 0 4.790916250385635e-07
% O 0 1.3010186705741944e-07
- O 0 1.621641422389075e-05
6 O 0 3.0252235205807665e-07
. O 0 1.4686229121707584e-07

9 O 0 3.0485085744658136e-07
% O 0 3.2450875320222394e-09
of O 0 1.6138507197283047e-10
total O 0 1.9715213905868723e-09
beta O 0 1.5481917969850656e-08
hexosaminidase O 0 2.045744622591883e-06
activity O 0 2.8973117238706436e-08
, O 0 3.214175037236089e-10
has O 0 7.312662697600558e-10
been O 0 1.871397259378682e-09
obtained O 0 3.88773013781929e-09
by O 0 1.001554839064056e-09
cellulose O 0 6.2702756622456945e-06
acetate O 0 1.6888113805180183e-06
gel O 0 6.898384526721202e-06
electrophoresis O 0 3.6369596045915387e-07
, O 0 1.3288606881545206e-09
DEAE O 0 9.273727528125164e-07
- O 0 4.747489867895638e-07
cellulose O 0 1.0758676580735482e-06
ion O 0 4.575062121148221e-06
- O 0 1.3368790860113222e-05
exchange O 0 8.773262294425876e-08
chromatography O 0 1.5191819784377003e-06
, O 0 5.610300557457037e-10
radial O 0 4.7515161583078225e-08
immunodiffusion O 0 5.066091034677811e-06
, O 0 2.963987943971347e-09
and O 0 2.1984778442174502e-08
radioimmunoassay O 0 5.1375780458329245e-05
. O 0 4.516596732173639e-07

Previous O 0 2.866300519599463e-06
family O 0 4.0539453038945794e-07
studies O 0 1.0944309458693624e-08
suggested O 0 1.6923836554383342e-08
that O 0 3.956016847439514e-09
these O 0 6.811160524478055e-10
individuals O 0 3.3421767575703143e-09
may O 0 5.333466788215446e-07
be O 0 1.5020882315752715e-08
compound O 0 1.150475128497419e-07
heterozygotes O 0 6.016597922098299e-07
for O 0 8.889835534375834e-10
the O 0 3.151070959717117e-09
common O 0 5.841767602987602e-08
mutant O 0 1.9035079503737506e-06
TSD B-Disease 0 8.064434950938448e-06
gene O 0 5.80742813838242e-08
and O 0 7.884048081052697e-09
a O 0 1.561091380608559e-07
rare O 0 8.631400305603165e-06
( O 0 3.549467919583549e-08
allelic O 0 3.3880617138493108e-06
) O 0 1.0935774952258726e-08
mutant O 0 1.2890845937363338e-06
gene O 0 8.147180210471561e-07
. O 0 4.1320734567307227e-07

Thus O 0 8.467664542877174e-07
, O 0 5.79787418075739e-09
the O 0 8.046369126546438e-10
postulated O 0 4.332960941155761e-07
rate O 0 9.174294035574349e-08
mutant O 0 4.088873950536254e-08
gene O 0 9.723863492183682e-09
appears O 0 9.05511843285467e-09
to O 0 8.545159024819782e-11
code O 0 1.7882141600811252e-10
for O 0 3.052663677394207e-11
the O 0 1.7652515560406812e-10
expression O 0 3.149676963687398e-09
of O 0 1.0970045705160913e-10
low O 0 7.12081202891568e-08
amounts O 0 2.786528785492237e-09
of O 0 6.776678662667734e-10
hex O 0 1.4859305110803689e-06
A O 0 5.534741376322927e-07
. O 0 2.4077039029180014e-07

Heterozygotes O 0 0.00032628426561132073
for O 0 3.280612048683906e-08
the O 0 7.886063357886997e-09
rare O 0 4.5661559511245287e-07
mutant O 0 3.193408701918088e-05
may O 0 4.5867441258451436e-06
be O 0 1.3132568810192424e-08
indistinguishable O 0 1.0695744379063399e-07
from O 0 1.8495454057187999e-09
heterozygotes O 0 3.8673644553455233e-07
for O 0 1.375734859365707e-09
the O 0 1.4248310087339178e-08
common O 0 9.202524893225927e-07
TSD B-Disease 0 0.00018224857922177762
mutant O 0 1.1296238881186582e-05
. O 0 3.2726251220083213e-07

However O 0 4.380501081868715e-07
, O 0 2.850341296323222e-09
direct O 0 5.762022414756984e-09
visualization O 0 2.7944292924075853e-07
and O 0 1.3036088652995659e-08
quantitation O 0 1.3124905308359303e-05
of O 0 3.7145906350843916e-09
hex O 0 2.626876721478766e-06
A O 0 3.5469302162027816e-08
by O 0 8.542164753322368e-10
the O 0 1.7922374695444887e-09
methods O 0 2.5779311840778973e-07
described O 0 1.4334538718685508e-05
may O 0 9.369809959025588e-07
prevent O 0 4.2100435138081593e-08
false O 0 3.4029183098027715e-06
- O 0 2.6036615963676013e-05
positive O 0 1.3454651082156488e-07
prenatal O 0 0.0028379475697875023
diagnosis O 0 0.00011920189717784524
of O 0 6.933536855768807e-09
TSD B-Disease 0 0.00027971185045316815
in O 0 3.72608838006272e-07
fetuses O 0 0.00021229505364317447
having O 0 1.1262105203968531e-07
the O 0 1.0061295796504055e-08
incomplete O 0 5.638470952362695e-07
hex B-Disease 0 1.43634670166648e-05
A I-Disease 0 9.532469266559929e-05
deficiency I-Disease 0 0.0006485743797384202
of O 0 3.9908462645676934e-10
the O 0 3.957022087774931e-08
type O 0 0.0006040926673449576
described O 0 6.972974460950354e-06
in O 0 2.5603238640314885e-08
the O 0 2.2263707322167647e-08
four O 0 2.7862228080266505e-07
healthy O 0 1.2294609405216761e-05
individuals O 0 2.45828459810582e-06

The O 0 1.1116518408016418e-06
tumor B-Disease 0 0.0001163851993624121
suppressor O 0 0.00018006180471275002
gene O 0 6.898977062519407e-06
Smad4 O 0 0.00011289089161437005
/ O 0 8.02218619355699e-06
Dpc4 O 0 2.146295264537912e-05
is O 0 6.206629432625732e-09
required O 0 1.2730895226908956e-09
for O 0 4.594934155388586e-10
gastrulation O 0 3.4193161013718054e-07
and O 0 3.0822846497358114e-08
later O 0 3.647480184554297e-08
for O 0 2.2800186183502547e-09
anterior O 0 3.8208321484489716e-07
development O 0 1.099005109139739e-09
of O 0 3.167477669041574e-10
the O 0 1.0198980326947549e-08
mouse O 0 5.6275462156918366e-06
embryo O 0 7.15950091034756e-06
. O 0 4.6035097511776257e-07

Mutations O 0 0.0001231559581356123
in O 0 6.491529802588047e-08
the O 0 6.25911766860554e-08
SMAD4 O 0 0.008518774062395096
/ O 0 8.097859972622246e-05
DPC4 O 0 0.001141837565228343
tumor B-Disease 0 9.698897338239476e-05
suppressor O 0 1.5334791896748357e-05
gene O 0 1.5402812891807116e-07
, O 0 9.717110449614097e-10
a O 0 7.0857057998807704e-09
key O 0 2.4464494430276318e-08
signal O 0 4.3850820929947076e-07
transducer O 0 3.2834309422469232e-06
in O 0 9.755871666072835e-09
most O 0 5.402089442441138e-09
TGFbeta O 0 1.7660433513810858e-05
- O 0 5.0937265768880025e-05
related O 0 1.9887146152086643e-07
pathways O 0 7.794577072672837e-08
, O 0 2.733485937600477e-10
are O 0 9.248282695217824e-11
involved O 0 5.976577566180197e-10
in O 0 1.9540571383203087e-09
50 O 0 1.4139200921192696e-09
% O 0 3.1520330789902573e-09
of O 0 2.5072668563552725e-07
pancreatic B-Disease 1 0.9993100166320801
cancers I-Disease 1 0.9983713030815125
. O 0 1.145445912698051e-05

Homozygous O 0 0.0004974457551725209
Smad4 O 0 0.0009187248069792986
mutant O 0 0.0003180726198479533
mice O 0 0.003969419747591019
die O 0 0.0001700015418464318
before O 0 2.7698648707996654e-08
day O 0 2.7868118479545956e-08
7 O 0 1.006279646276198e-07
. O 0 8.415515395654438e-08

5 O 0 6.242236167963711e-07
of O 0 1.0055524768404211e-07
embryogenesis O 0 6.236437184270471e-05
. O 0 2.8270908387639793e-06

Mutant O 0 7.518647635151865e-06
embryos O 0 1.2436462384357583e-06
have O 0 4.535848674436238e-08
reduced O 0 4.390764374306855e-08
size O 0 1.676584929555247e-06
, O 0 3.1307401116009714e-08
fail O 0 1.0082543440148584e-06
to O 0 1.01590824641562e-08
gastrulate O 0 7.079599163262174e-05
or O 0 6.615120895503424e-08
express O 0 9.385781929438508e-09
a O 0 7.52921280877672e-09
mesodermal O 0 8.91946228875895e-07
marker O 0 5.579536264121998e-06
, O 0 5.381664891501714e-09
and O 0 7.169886462321529e-09
show O 0 2.6162811082031112e-06
abnormal O 0 6.5597641878412105e-06
visceral O 0 8.363317465409636e-05
endoderm O 0 0.0008328111143782735
development O 0 1.0225006263908654e-07
. O 0 2.0705806491605472e-07

Growth B-Disease 1 0.997804582118988
retardation I-Disease 1 0.9996850490570068
of O 0 2.053479164487726e-08
the O 0 8.796804706889816e-08
Smad4 O 0 0.0011387872509658337
- O 0 0.0038965658750385046
deficient O 0 2.825336196110584e-05
embryos O 0 8.447791799426341e-08
results O 0 2.0069208517270454e-08
from O 0 8.718388788686582e-10
reduced O 0 2.3940433635516456e-08
cell O 0 8.426965223407024e-07
proliferation O 0 1.0191710941853671e-07
rather O 0 2.403508503334706e-09
than O 0 1.0933077776442701e-09
increased O 0 1.1790834975045072e-08
apoptosis O 0 3.5781192764261505e-07
. O 0 3.0859499133839563e-07

Aggregation O 0 9.942506039806176e-06
of O 0 8.322088973500286e-08
mutant O 0 8.388954483962152e-06
Smad4 O 0 9.573398710926995e-05
ES O 0 3.4346744541835506e-06
cells O 0 3.745976329128098e-08
with O 0 1.961798501426415e-09
wild O 0 2.2481727057765966e-07
- O 0 4.253114457242191e-05
type O 0 5.726546805817634e-05
tetraploid O 0 4.312424061936326e-05
morulae O 0 0.00010391601972514763
rescues O 0 7.292358986887848e-06
the O 0 5.1748681784147266e-08
gastrulation B-Disease 0 9.766091534402221e-05
defect I-Disease 0 0.0005169964279048145
. O 0 6.34285356682085e-07

These O 0 1.159533766781351e-07
results O 0 1.3129994158589398e-07
indicate O 0 1.6807203451207897e-07
that O 0 4.521973018256631e-09
Smad4 O 0 2.22843686970009e-06
is O 0 2.6762592142404174e-09
initially O 0 3.777010704197892e-09
required O 0 3.8019157266866443e-10
for O 0 2.083201666724932e-11
the O 0 5.703833932946267e-11
differentiation O 0 1.1840764480020027e-10
of O 0 4.327750657839857e-11
the O 0 1.8682231317512787e-09
visceral O 0 1.8414859368931502e-05
endoderm O 0 0.00010872705024667084
and O 0 1.9592343747376617e-08
that O 0 1.2111674996262423e-09
the O 0 2.3554922456980876e-09
gastrulation B-Disease 0 6.710917546115525e-07
defect I-Disease 0 2.2075912511354545e-06
in O 0 3.738864773339401e-09
the O 0 1.2329379295294984e-08
epiblast O 0 5.277865056996234e-05
is O 0 3.5292156752575465e-08
secondary O 0 1.744873934228508e-08
and O 0 2.1802460281605818e-08
non O 0 6.71382380801333e-08
- O 0 2.895304533012677e-05
cell O 0 5.009206142858602e-05
autonomous O 0 4.809231768376776e-07
. O 0 5.534588467526191e-07

Rescued O 0 0.00028715614462271333
embryos O 0 2.1369452952058055e-05
show O 0 8.063408313319087e-05
severe O 0 0.0006313968915492296
anterior O 0 0.0006461440934799612
truncations O 0 0.0004967162967659533
, O 0 2.5884159526867734e-07
indicating O 0 6.015129088154936e-07
a O 0 1.6431860316856728e-08
second O 0 2.9029099124500135e-08
important O 0 1.1877459016318426e-09
role O 0 5.025629690180722e-09
for O 0 3.816681637403008e-09
Smad4 O 0 2.239215245936066e-05
in O 0 3.509206436547174e-08
anterior O 0 3.9201990148285404e-05
patterning O 0 0.000385171064408496
during O 0 7.947036237965222e-07
embryogenesis O 0 2.234731255157385e-05
. O 0 1.1599877325352281e-06

Prevalence O 0 0.0010568187572062016
of O 0 5.460893603981276e-08
p16 O 0 7.398709840344964e-06
and O 0 6.090742488140677e-08
CDK4 O 0 8.751618588576093e-05
germline O 0 2.5569243007339537e-05
mutations O 0 7.29478642824688e-06
in O 0 4.4814655097979994e-08
48 O 0 4.95607594075409e-07
melanoma B-Disease 1 0.999518871307373
- O 1 0.9901736974716187
prone O 1 0.9520485401153564
families O 0 1.2022055670968257e-06
in O 0 7.393662713184312e-07
France O 0 0.0002759470953606069
. O 0 2.953664306915016e-06

The O 0 2.3181935375760077e-06
French O 0 0.00017762332572601736
Familial B-Disease 1 0.9898014664649963
Melanoma I-Disease 1 0.9998923540115356
Study O 0 2.701967787288595e-05
Group O 0 4.165953214396723e-06
. O 0 4.6484510107802635e-07

Germline O 0 0.005286323372274637
mutations O 0 0.00017141505668405443
in O 0 3.632684908438932e-08
the O 0 7.779216382175491e-09
p16 O 0 1.3568316035161843e-06
and O 0 5.893157961622819e-08
CDK4 O 0 9.368824976263568e-05
genes O 0 1.6319394546826516e-07
have O 0 2.416845568120607e-08
been O 0 8.111960880796687e-08
reported O 0 4.077255368883925e-07
in O 0 1.0525735838484707e-09
a O 0 4.612841220108521e-09
subset O 0 3.934422210249977e-08
of O 0 7.284966585530128e-08
melanoma B-Disease 1 0.9966872334480286
pedigrees O 0 0.0009428198682144284
, O 0 1.0549015883043467e-08
but O 0 1.2565889662141672e-08
their O 0 3.089465394623403e-08
prevalence O 0 1.2206730389152654e-05
is O 0 1.75213088482451e-08
not O 0 1.101425173288817e-08
well O 0 2.1337132949383886e-08
known O 0 4.516510614394065e-07
. O 0 6.314239726634696e-07

We O 0 3.5808162124340015e-07
searched O 0 1.334984318646093e-07
for O 0 5.933823987724907e-10
such O 0 1.949403749534895e-09
germline O 0 3.867884515784681e-06
mutations O 0 7.381882483059599e-07
in O 0 9.382882026898187e-09
48 O 0 3.602552212100818e-08
French O 0 0.0005179906729608774
melanoma B-Disease 1 0.9999163150787354
- O 1 0.9472973346710205
prone O 0 0.10475042462348938
families O 0 8.293309150531059e-09
selected O 0 1.2724583609013962e-09
according O 0 6.664862550742612e-10
to O 0 3.064934694929633e-10
two O 0 8.713302301899262e-10
major O 0 7.703441440298775e-09
criteria O 0 3.956508720648344e-08
families O 0 6.036310895574104e-10
with O 0 1.769878021917748e-09
at O 0 1.70934395526956e-08
least O 0 1.2019301109944536e-09
three O 0 1.6271451963589811e-09
affected O 0 1.7593031476081933e-09
members O 0 1.2815135064236927e-10
( O 0 4.716297352658216e-10
n O 0 4.2729385540951625e-07
= O 0 1.6174460881757113e-07
20 O 0 2.753837435864881e-10
) O 0 5.5066243231927103e-11
or O 0 1.1279119860319042e-09
families O 0 1.511317182512073e-10
with O 0 1.1332815796905038e-09
two O 0 2.161843681847131e-08
affected O 0 1.6395638624544517e-08
members O 0 2.5582319596040293e-10
, O 0 2.222804301732495e-10
one O 0 1.4452150587374035e-10
of O 0 5.476322867403738e-11
them O 0 5.297348115718137e-10
affected O 0 6.934379737089102e-10
before O 0 3.124818737099133e-10
the O 0 1.788347109288324e-10
age O 0 8.801344653086574e-10
of O 0 8.686644285826883e-12
50 O 0 1.5450456192223072e-10
( O 0 2.0306531456348864e-10
n O 0 2.469054436460283e-07
= O 0 2.3481621269638708e-07
28 O 0 1.350067835304003e-09
) O 0 6.845658068188598e-11
, O 0 1.6960399751297928e-10
and O 0 1.9482253588165577e-09
one O 0 3.882128396526241e-09
additional O 0 9.973367909310582e-09
minor O 0 4.809176630260481e-07
criterion O 0 4.337072368798545e-06
. O 0 5.871145276614698e-07

Sixteen O 0 1.412451183568919e-06
different O 0 6.852774703247633e-08
p16 O 0 1.5439770777447848e-06
germline O 0 2.190436680393759e-05
mutations O 0 9.252806194126606e-06
were O 0 5.555169835247398e-08
found O 0 5.687915916041675e-08
in O 0 1.847057440329536e-08
21 O 0 3.822701444278209e-08
families O 0 7.674228363896418e-09
, O 0 2.320159175894787e-09
while O 0 4.632335404153309e-09
one O 0 1.1155802503992618e-08
germline O 0 5.03624460179708e-06
mutation O 0 1.2703343372777454e-06
, O 0 1.6919246004221122e-09
Arg24His O 0 1.1794555803135154e-06
, O 0 2.1310397890772492e-09
was O 0 2.906655822698667e-07
detected O 0 4.601578893925762e-06
in O 0 3.857335784118732e-09
the O 0 1.8156487868736804e-08
CDK4 O 0 0.00030171172693371773
gene O 0 5.327818826117436e-07
. O 0 1.0785781512367976e-07

The O 0 5.741707553852393e-08
frequency O 0 3.913075090622442e-07
of O 0 1.1948761979851952e-09
p16 O 0 3.027451498383016e-07
gene O 0 2.0875327777503117e-07
mutation O 0 2.6289717425243e-07
in O 0 9.994804983648464e-10
our O 0 5.105246225767246e-10
sample O 0 2.6114030937662847e-09
( O 0 1.224887552497833e-10
44 O 0 1.7981326150273702e-10
% O 0 2.918590646938668e-10
) O 0 1.403499677588016e-10
is O 0 6.353096937417035e-10
among O 0 1.1636375890633488e-10
the O 0 5.83726489367109e-09
highest O 0 8.23644131742185e-06
rates O 0 2.376773636569851e-06
yet O 0 1.511463665337942e-07
reported O 0 6.602528657140283e-08
and O 0 2.8338349444823052e-09
the O 0 3.4030676054896958e-09
CDK4 O 0 7.516063487855718e-05
mutation O 0 1.7583001010734733e-07
is O 0 2.828676459731838e-10
the O 0 8.488659775096608e-11
second O 0 4.878829429344478e-08
mutation O 0 2.911954652518034e-06
detected O 0 5.335854439181276e-06
in O 0 3.94696497707514e-09
this O 0 2.2097770280282703e-09
gene O 0 7.943734203763597e-08
worldwide O 0 7.858408679339846e-08
. O 0 3.9787130390323e-07

In O 0 2.313832681011263e-07
summary O 0 2.3677550586853613e-07
, O 0 3.28489302425794e-09
our O 0 2.950422572922662e-09
results O 0 1.1595642668282835e-08
show O 0 2.3185596376151807e-07
frequent O 0 6.932918239499486e-08
involvement O 0 5.009133730027315e-08
of O 0 6.739581115411397e-10
the O 0 5.806317648904269e-09
p16 O 0 1.713882653575638e-07
gene O 0 2.2615344263954285e-08
in O 0 4.2710599501560864e-08
familial B-Disease 1 0.8300471901893616
melanoma I-Disease 1 0.9999635219573975
and O 0 6.750059128535213e-06
confirm O 0 1.0015889529313426e-05
the O 0 2.402051002547978e-09
role O 0 3.3556799561296202e-09
of O 0 1.3187803626912853e-10
the O 0 4.179821377903181e-09
CDK4 O 0 1.114363840315491e-05
gene O 0 7.14325532058524e-09
as O 0 2.362561035695876e-09
a O 0 2.0189590941299684e-06
melanoma B-Disease 1 0.9919064044952393
- O 0 0.006179051008075476
predisposing O 0 2.6480297492526006e-06
gene O 0 3.419208951527253e-07
. O 0 2.1730139465603315e-08
. O 0 1.1011631073643002e-07

Progression O 0 3.751761687453836e-05
of O 0 6.367162086462486e-08
somatic O 0 1.2553678061522078e-05
CTG O 0 0.00011130207712994888
repeat O 0 9.0455041572568e-06
length O 0 4.301579394905275e-07
heterogeneity O 0 1.0089353281728108e-06
in O 0 9.819175694758542e-09
the O 0 1.7114905048742912e-08
blood O 0 9.650350875745062e-06
cells O 0 3.183348553648102e-06
of O 0 2.391205953244935e-06
myotonic B-Disease 1 0.999998927116394
dystrophy I-Disease 1 0.9999995231628418
patients O 0 0.022008148953318596
. O 0 4.673205694416538e-06

The O 0 5.565627247960947e-08
genetic O 0 2.6692313781495614e-07
basis O 0 7.179701100312741e-08
of O 0 1.227039888362924e-06
myotonic B-Disease 1 0.9999996423721313
dystrophy I-Disease 1 0.9999998807907104
( O 0 0.04208146035671234
DM B-Disease 1 0.9999996423721313
) O 0 8.712911636621357e-08
is O 0 3.194313924481662e-09
the O 0 1.771967850228151e-10
expansion O 0 3.727486319604623e-09
of O 0 4.260844455039603e-10
an O 0 1.377910479050115e-07
unstable O 0 0.0004531450686044991
CTG O 0 1.1870457456097938e-05
repeat O 0 6.464692887675483e-07
in O 0 1.2304447460920187e-09
the O 0 5.109727641006145e-10
34 O 0 1.028402585312449e-09
UTR O 0 3.142921300991475e-08
of O 0 1.6215057074830952e-10
the O 0 4.140332521274104e-08
DM B-Disease 1 0.999981164932251
protein O 0 2.6291348831364303e-07
kinase O 0 1.288522980757989e-06
gene O 0 5.2307967735032435e-08
on O 0 1.967570995020651e-07
chromosome O 0 6.48734494461678e-05
19 O 0 5.365611741581233e-07
. O 0 5.939383527220343e-07

One O 0 4.926134522520442e-08
of O 0 3.208172616453453e-10
the O 0 4.870466252526739e-10
principal O 0 5.671089819969666e-09
features O 0 6.854745659978789e-09
of O 0 4.6487255711546993e-10
the O 0 7.571409241791116e-07
DM B-Disease 1 0.9999996423721313
mutation O 0 0.00012192971917102113
is O 0 1.873197952306782e-08
an O 0 1.7650101380439764e-09
extraordinarily O 0 4.12458939536009e-05
high O 0 3.224113527267036e-07
level O 0 9.04759200892613e-09
of O 0 2.0001585110396292e-10
somatic O 0 4.501692387748335e-07
mosaicism O 0 8.40940629132092e-05
, O 0 1.434391005972202e-08
due O 0 8.463318046381119e-09
to O 0 2.5990847252188587e-09
an O 0 2.9846390248167154e-08
extremely O 0 9.271197086491156e-06
high O 0 3.9570531384924834e-07
degree O 0 3.429589767733887e-08
of O 0 2.5195651121023843e-10
somatic O 0 1.6812152807688108e-06
instability O 0 3.1990216484700795e-06
both O 0 5.2054343058216546e-09
within O 0 1.0202962918981484e-09
and O 0 1.2238145608023387e-08
between O 0 9.975384074323301e-09
different O 0 4.473719528164111e-08
tissues O 0 4.4260508730076253e-05
. O 0 4.6957163135630253e-07

This O 0 5.572573513745738e-07
instability O 0 2.9387531412794488e-06
appears O 0 1.851438753419643e-07
to O 0 1.3974047474718532e-09
be O 0 1.7511511130052781e-09
biased O 0 3.045467211748587e-09
towards O 0 9.769530323611164e-11
further O 0 8.26218191085637e-11
expansion O 0 6.913223882243358e-10
and O 0 2.1882010092788562e-10
continuous O 0 2.525195164082561e-09
throughout O 0 3.090240008329914e-10
the O 0 3.581693275300779e-10
life O 0 3.150428140585859e-09
of O 0 1.828309552365237e-11
an O 0 3.871743758931956e-10
individual O 0 3.2168752106542797e-09
, O 0 8.457053946031579e-10
features O 0 1.5399258757042844e-07
that O 0 1.828780114010442e-07
could O 0 1.2437507166396244e-06
be O 0 8.377990923236212e-08
associated O 0 9.682832313728795e-09
with O 0 2.50837484117028e-09
the O 0 2.2826306178558298e-08
progressive O 0 2.9046047984593315e-06
nature O 0 1.063595050254662e-06
of O 0 2.1862245347392673e-09
the O 0 1.7190894823215785e-06
disease O 0 0.00017353800649289042
. O 0 7.010186777733907e-07

Although O 0 3.3434699275858293e-07
increasing O 0 3.808023052442877e-08
measured O 0 1.8825356846718933e-06
allele O 0 6.12097551311308e-07
size O 0 5.49721391962521e-07
between O 0 6.520194517634081e-08
patients O 0 1.6281246928429027e-07
clearly O 0 1.5262308750152442e-07
correlates O 0 8.789626093630432e-08
with O 0 1.0617723367190024e-09
an O 0 4.305393819237224e-09
increased O 0 1.1836225439765258e-06
severity O 0 0.0002877569058910012
of O 0 8.277209673224206e-08
symptoms O 0 0.00010631718760123476
and O 0 5.2118849680482526e-08
an O 0 5.738059360993475e-09
earlier O 0 9.397766120855522e-07
age O 0 6.62411068219626e-08
of O 0 3.7685607412463185e-10
onset O 0 5.272376029097359e-07
, O 0 8.204114609888791e-10
this O 0 1.6160191240732757e-10
correlation O 0 5.5134535159595544e-08
is O 0 3.83773457457437e-09
not O 0 1.3191255865407925e-09
precise O 0 2.8657845518864633e-07
and O 0 1.898172818926014e-08
measured O 0 8.464277016173583e-06
allele O 0 9.67511937233212e-08
length O 0 1.3790383945888607e-07
cannot O 0 2.569558716913889e-07
be O 0 1.8372394716692497e-09
used O 0 5.770909972113714e-09
as O 0 2.206398258541853e-10
an O 0 6.394759721750631e-10
accurate O 0 1.63236416028667e-06
predictor O 0 1.720766340440605e-05
of O 0 2.469372928359803e-09
age O 0 1.755006451276131e-07
of O 0 7.534124435437661e-09
onset O 0 3.896320049534552e-05
. O 0 1.085639496523072e-06

In O 0 1.4565395645149692e-07
order O 0 2.918792318951091e-09
to O 0 2.2083938844286166e-10
further O 0 3.905766543521594e-10
characterize O 0 1.6713792660993931e-07
the O 0 6.700248356139582e-09
dynamics O 0 2.330847109988099e-06
of O 0 6.196175661443704e-08
DM B-Disease 1 0.9999878406524658
CTG O 0 4.458815237740055e-05
repeat O 0 7.930198648864462e-07
somatic O 0 9.554174766890355e-07
instability O 0 2.0773518372152466e-06
, O 0 8.943036533537452e-09
we O 0 3.3299851764923005e-09
have O 0 4.1674104167555015e-09
studied O 0 9.117213650711165e-09
repeat O 0 1.637548763255836e-07
length O 0 2.785329300536432e-08
changes O 0 4.123471009087609e-10
over O 0 3.806719384158441e-10
time O 0 3.916921897939574e-09
in O 0 5.486409193622421e-08
111 O 0 8.849655387166422e-06
myotonic B-Disease 1 0.999998927116394
dystrophy I-Disease 1 0.9999997615814209
patients O 0 4.8973186494549736e-05
with O 0 2.4679710719510695e-08
varying O 0 3.2777652450022288e-06
clinical O 0 1.6829666492412798e-05
severity O 0 0.00024465046590194106
and O 0 8.101523718551107e-08
CTG O 0 3.743080696949619e-06
repeat O 0 2.3135370952331868e-07
size O 0 3.2233504754231035e-08
over O 0 3.250109348318375e-10
time O 0 2.9623248298804583e-10
intervals O 0 1.2648916358770634e-09
of O 0 3.4112261626528806e-11
1 O 0 2.4502355699951295e-09
- O 0 4.959989837516332e-06
7 O 0 9.223825969684185e-08
years O 0 1.2759446121890505e-07
. O 0 1.872609090014521e-07

We O 0 1.1274876214883989e-06
have O 0 8.600795631252822e-09
found O 0 1.0779726000720302e-09
a O 0 4.326944080812467e-10
direct O 0 1.7243374506037412e-09
progression O 0 5.4964019113867835e-08
of O 0 3.8224475668036106e-11
the O 0 4.2585776571790745e-10
size O 0 5.793477342308506e-08
heterogeneity O 0 2.538345533764641e-08
over O 0 2.381658648076268e-09
time O 0 3.250383961983516e-09
related O 0 4.262976194269186e-09
to O 0 4.798305086595178e-10
initial O 0 3.630053058145677e-08
CTG O 0 4.6590983515670814e-07
repeat O 0 8.791856487277983e-08
size O 0 2.989082759086159e-08
and O 0 5.623230769913334e-10
the O 0 1.5581679002618642e-10
time O 0 2.8065791912723626e-09
interval O 0 2.2460417525849152e-08
and O 0 2.303087498489731e-09
always O 0 8.878588531047171e-09
biased O 0 8.979284538135346e-10
towards O 0 1.6991225093576645e-10
further O 0 1.0184512122535239e-09
expansion O 0 5.077943043829691e-08
. O 0 6.137528885119536e-08

Attempts O 0 6.517508950310003e-07
to O 0 6.49846487732475e-09
mathematically O 0 8.702156151230156e-07
model O 0 1.1915930997474788e-07
the O 0 2.646401986439173e-09
dynamics O 0 1.7507364873381448e-06
have O 0 5.147069259692216e-08
proved O 0 2.0186921290132886e-07
only O 0 1.0349334722548065e-09
partially O 0 2.1711626629894454e-07
successful O 0 1.8521443934105264e-08
suggesting O 0 1.0085104662493904e-07
that O 0 9.086116858902926e-10
individual O 0 3.5211369930898684e-10
specific O 0 9.170716963602388e-10
genetic O 0 1.3693039591089473e-07
and O 0 3.089118365551258e-07
/ O 0 6.307779131020652e-06
or O 0 1.0797199365697452e-06
environmental O 0 4.086499302502489e-06
factors O 0 2.5589374175183366e-08
also O 0 4.422179067375964e-09
play O 0 1.8737973395133167e-09
a O 0 6.792093998342352e-09
role O 0 1.9350460789269164e-08
in O 0 7.657150469242424e-09
somatic O 0 2.3497957499785116e-06
mosaicism O 0 0.00011639029980869964
. O 0 6.690570586442846e-08
. O 0 1.6709185501895263e-07

Aspartylglucosaminuria B-Disease 1 0.99837327003479
among O 0 7.404049142678559e-07
Palestinian O 0 8.57082341099158e-06
Arabs O 0 5.643098575092154e-06
. O 0 6.267062531151169e-07

Aspartylglucosaminuria B-Disease 1 0.9999374151229858
( O 0 7.809658563928679e-05
AGU B-Disease 1 0.9998258948326111
) O 0 4.184513713312299e-08
is O 0 1.0979161579882657e-08
a O 0 1.0509415915294085e-07
rare O 0 7.547134009655565e-05
disorder B-Disease 0 0.0008529265760444105
of I-Disease 0 1.282679278347132e-07
glycoprotein I-Disease 1 0.9952325224876404
metabolism I-Disease 0 0.1154002919793129
caused O 0 5.199362476560054e-06
by O 0 6.149011966272155e-08
the O 0 1.0295108950231224e-05
deficiency B-Disease 0 0.01267676055431366
of I-Disease 0 1.5618940585326868e-09
the I-Disease 0 1.7093839232984465e-07
lysosomal I-Disease 0 0.008732674643397331
enzyme I-Disease 0 6.980685157031985e-06
aspartylglucosaminidase I-Disease 0 8.822674863040447e-05
( O 0 2.4036012291617226e-08
AGA O 0 2.4670525817782618e-05
) O 0 7.217734321329772e-08
. O 0 4.5492780031963775e-07

AGU B-Disease 1 0.9999258518218994
is O 0 3.61544152838178e-05
inherited O 0 0.000516922096721828
as O 0 1.7062527390976356e-08
an O 0 1.2290409756587906e-07
autosomal O 1 0.948799192905426
recessive O 1 0.9265561699867249
trait O 0 0.280380517244339
and O 0 1.931563247126178e-06
occurs O 0 7.049231953715207e-08
with O 0 9.92955606626822e-10
a O 0 1.6360734207410133e-06
high O 0 4.824124061997281e-06
frequency O 0 3.729452510015108e-05
in O 0 1.7034358279488515e-07
Finland O 0 7.65577788115479e-05
because O 0 4.110588847083818e-08
of O 0 3.5481309557106044e-10
a O 0 1.6917131517857342e-07
founder O 0 1.3937648191131302e-06
effect O 0 4.2100037944692303e-07
. O 0 2.3181087271950673e-07

While O 0 5.609653044302831e-07
very O 0 4.324572344671651e-08
few O 0 2.2049196246598513e-08
patients O 0 5.679828518623253e-08
with O 0 4.434496077010408e-07
AGU B-Disease 1 0.999996542930603
have O 0 3.0438886824413203e-06
been O 0 4.913101179226942e-07
reported O 0 2.6892632831732044e-07
from O 0 1.6555486981317813e-09
non O 0 1.661480730774656e-08
- O 0 2.692653470148798e-05
Finnish O 0 8.626437920611352e-05
origin O 0 2.591399379525683e-07
, O 0 2.7673566549424322e-08
we O 0 7.805614927747229e-07
diagnosed O 0 0.0016219491371884942
the O 0 4.6678331955263275e-07
disorder O 0 0.00018920637376140803
in O 0 1.068088266720224e-07
8 O 0 1.7904604021623527e-07
patients O 0 1.876835042935454e-08
originating O 0 7.091952802795731e-09
from O 0 2.286559830366741e-09
3 O 0 7.940913704373997e-09
unrelated O 0 5.220456387178274e-07
families O 0 1.7754475223341615e-08
, O 0 9.678488011033437e-10
all O 0 1.8548153291053637e-10
Palestinian O 0 1.885590172889806e-08
Arabs O 0 5.498873356657441e-09
from O 0 4.967095623698015e-10
the O 0 1.411029404430053e-09
region O 0 6.0928426748319e-09
of O 0 3.437033768705078e-09
Jerusalem O 0 2.6220404834020883e-05
. O 0 8.477796882289113e-07

The O 0 1.353809693682706e-06
clinical O 0 4.9269801820628345e-05
diagnosis O 0 0.018301257863640785
of O 0 2.116504447258194e-06
AGU B-Disease 1 0.9999982118606567
is O 0 3.8604880501225125e-06
often O 0 1.5510862283463211e-07
difficult O 0 2.2190327797488862e-07
, O 0 9.533472900002948e-10
in O 0 3.4301750329035485e-10
particular O 0 1.2194566467726986e-09
early O 0 3.325402397891253e-09
in O 0 8.985503452407784e-10
the O 0 1.5082829429857725e-09
course O 0 1.0986996201722832e-08
of O 0 2.411676414126873e-10
the O 0 7.217596476039034e-07
disease O 0 6.314815254881978e-05
, O 0 3.0437830034202307e-09
and O 0 8.294890996296544e-09
most O 0 3.8076200525871684e-10
of O 0 2.0024984448419048e-10
the O 0 2.9316780114641006e-07
patients O 0 1.4290203580458183e-06
are O 0 2.7357557996765536e-07
diagnosed O 0 0.00015329568122979254
after O 0 1.230602553192739e-08
the O 0 4.491577776377653e-09
age O 0 9.643978948759013e-09
of O 0 1.202814653433748e-10
5 O 0 1.5773366612847894e-08
years O 0 1.6110895728616015e-07
. O 0 3.9304850929511304e-07

However O 0 8.854389648149663e-07
, O 0 3.983091634296443e-09
since O 0 3.2195024424197527e-09
these O 0 3.5121422437001115e-10
patients O 0 4.2506025366151334e-09
excrete O 0 6.366735139096136e-09
early O 0 6.938494778729876e-10
large O 0 8.726041555995323e-10
amounts O 0 1.3774651419495854e-09
of O 0 1.6524277779428331e-10
aspartylglucosamine O 0 1.5210143828880973e-06
in O 0 5.790723456300384e-09
urine O 0 1.3211625571329932e-07
, O 0 3.069175746883701e-10
biochemical O 0 5.839450523126288e-08
screening O 0 8.406463081200855e-09
is O 0 1.4541245985100204e-09
easy O 0 8.159207531832635e-09
by O 0 1.0324458621369104e-08
urine O 0 1.0464912520546932e-05
chromatography O 0 5.386433258536272e-05
. O 0 5.726931462390894e-08
. O 0 1.1228837593080243e-07

Detection O 0 6.514727283501998e-05
of O 0 4.914619466944714e-08
heterozygous O 0 4.089563390152762e-06
carriers O 0 3.2185405984819226e-07
of O 0 1.1792566922963488e-08
the O 0 1.1003669897036161e-05
ataxia B-Disease 1 0.9999995231628418
- I-Disease 1 0.9999948740005493
telangiectasia I-Disease 1 0.9999986886978149
( O 0 1.561267026772839e-07
ATM O 0 1.0689217560866382e-05
) O 0 5.057668173158447e-10
gene O 0 3.7124583407432965e-09
by O 0 1.6989354367780152e-09
G2 O 0 6.361345640470972e-06
phase O 0 4.02707968305549e-07
chromosomal O 0 0.00014011916937306523
radiosensitivity O 0 2.0671033780672587e-05
of O 0 8.671328544096468e-09
peripheral O 0 0.0012754093622788787
blood O 0 0.00911455787718296
lymphocytes O 0 0.0008165932958945632
. O 0 6.089493922445399e-07

In O 0 0.0005498375394381583
ataxia B-Disease 1 0.999995231628418
- I-Disease 1 0.9999885559082031
telangiectasia I-Disease 1 0.999998927116394
( O 0 9.37242730287835e-05
A B-Disease 1 0.9999837875366211
- I-Disease 1 0.9999964237213135
T I-Disease 1 0.9999996423721313
) O 0 5.217867737883353e-07
patients O 0 1.8241416910314e-07
, O 0 8.831803732789467e-09
mutations O 0 2.0826809077334474e-07
in O 0 3.0345834733935817e-09
a O 0 4.687979426876154e-08
single O 0 4.981161509931553e-07
gene O 0 2.5077921961269567e-08
, O 0 3.4472147358854954e-10
ATM O 0 3.466188218226307e-06
, O 0 5.574080308434759e-09
result O 0 9.283659352377072e-08
in O 0 4.562234039440227e-07
an O 0 0.1827990561723709
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
syndrome I-Disease 1 1.0
that O 0 5.56431677978253e-06
embraces O 0 1.2058339962095488e-06
a O 0 5.812936265670032e-08
variety O 0 9.991151017629818e-09
of O 0 1.2437668672760083e-09
clinical O 0 4.296921360946726e-07
features O 0 9.653203051129822e-06
and O 0 2.4640985429869033e-06
manifests O 0 5.846722615387989e-06
extreme O 0 2.38163374888245e-05
radiosensitivity O 0 9.686125122243538e-05
and O 0 1.8082115360584794e-08
a O 0 1.9955002983351733e-08
strong O 0 1.070809361181091e-07
pre O 0 5.464750938699581e-05
- O 0 0.0018604871584102511
disposition O 0 1.718326166155748e-05
to O 0 1.612674509487988e-07
malignancy B-Disease 0 0.02550307661294937
. O 0 8.337450481121778e-07

Heterozygotes O 0 4.687722321250476e-05
for O 0 1.374751867899704e-08
the O 0 2.096825157948956e-09
ATM O 0 4.078000074514421e-06
gene O 0 4.884993813902838e-07
have O 0 2.4293656863960678e-08
no O 0 5.4878537270042216e-08
clinical O 0 3.739501508448484e-08
expression O 0 8.383041461001994e-08
of O 0 7.0403607388414e-09
A B-Disease 1 0.9999775886535645
- I-Disease 1 0.9999961853027344
T I-Disease 1 0.9999997615814209
but O 0 0.0006103482446633279
may O 0 0.0005998156266286969
be O 0 0.00021706476400140673
cancer B-Disease 0 0.15184412896633148
prone O 0 0.0016316426917910576
with O 0 1.7290940235170638e-08
a O 0 5.234090281192039e-07
moderate O 0 5.182481800147798e-06
increase O 0 3.500065872685809e-07
in O 0 3.426608330414638e-08
in O 0 5.1448704851964067e-08
vitro O 0 5.553768278332427e-05
radiosensitivity O 0 0.0005865811835974455
. O 0 4.784337193086685e-07

We O 0 8.572708907195192e-07
performed O 0 6.877457536802467e-08
a O 0 1.8791668665585348e-08
blind O 0 7.241858952511393e-07
chromosomal O 0 4.7746165364515036e-05
analysis O 0 8.951469965268188e-08
on O 0 1.6702701088888716e-07
G2 O 0 2.456220863678027e-05
- O 0 7.296977855730802e-06
phase O 0 2.3824485140266916e-07
lymphocytes O 0 1.2005061478248535e-07
from O 0 6.252347528601376e-10
7 O 0 1.5782395834662566e-08
unrelated O 0 3.980955625593197e-06
A B-Disease 1 0.9999868869781494
- I-Disease 1 0.9999978542327881
T I-Disease 1 0.9999997615814209
patients O 0 5.363097898225533e-06
, O 0 1.2186783138190549e-08
13 O 0 4.154553590041132e-09
obligate O 0 1.8987703924722155e-06
A B-Disease 1 0.9999513626098633
- I-Disease 1 0.9999911785125732
T I-Disease 1 0.9999980926513672
heterozygotes O 0 0.00044498464558273554
( O 0 6.879081304589363e-09
parents O 0 6.593515067265798e-09
of O 0 1.0176546411111431e-10
the O 0 4.2067846095505956e-08
patients O 0 1.0828429708453768e-07
) O 0 1.2402205928907506e-09
, O 0 1.0748005818683737e-09
and O 0 5.3944910760606035e-09
14 O 0 2.2674853106252613e-09
normal O 0 7.238203814097233e-09
controls O 0 1.3429851897228673e-08
following O 0 2.232646290067919e-09
X O 0 1.4074214050197043e-05
- O 0 6.60679859265656e-07
irradiation O 0 8.243572580113323e-08
with O 0 6.699018562095205e-10
1 O 0 2.4030453182888323e-09
Gy O 0 4.171129148744512e-06
in O 0 9.430026759460475e-10
order O 0 2.757737649350389e-10
to O 0 2.1421764362372642e-10
evaluate O 0 7.139863367200405e-09
this O 0 5.32557276056167e-10
cytogenetic O 0 1.7035623613992357e-06
method O 0 5.991886986578265e-09
as O 0 4.3199674393257226e-10
a O 0 9.70205360495413e-10
tool O 0 5.864978547265309e-08
for O 0 4.380061868758389e-10
detection O 0 2.3484487599034765e-07
of O 0 3.130821824015584e-09
ATM O 0 0.0013672435889020562
carriers O 0 1.8032953903457383e-06
. O 0 1.9243876181462838e-07

Both O 0 4.908314622298349e-06
A B-Disease 1 0.9576489329338074
- I-Disease 1 0.9996823072433472
T I-Disease 1 0.9999890327453613
homozygotes O 0 0.001510676578618586
and O 0 9.223966657145866e-08
heterozygotes O 0 3.649053724075202e-06
showed O 0 1.961771658898215e-06
significantly O 0 4.303761969026709e-08
increased O 0 1.6738029628982076e-08
levels O 0 1.8237184207237078e-08
of O 0 3.850433305530032e-09
radiation O 1 0.9999330043792725
- O 0 0.20801681280136108
induced O 0 0.010164187289774418
chromatid O 0 0.32806333899497986
damage O 0 0.004062653053551912
relative O 0 2.2273809463513317e-06
to O 0 2.8223507975155826e-09
that O 0 1.487909906394691e-09
of O 0 1.0499949798514763e-09
normal O 0 1.2068194621406292e-07
controls O 0 3.9655033106100745e-06
. O 0 7.699558182139299e-07

These O 0 1.0732998845242037e-07
results O 0 4.75263099986023e-08
show O 0 4.9745718655458404e-08
that O 0 2.63120192300903e-09
the O 0 2.8162849829982406e-09
G2 O 0 1.615256223885808e-05
- O 0 5.7512547755322885e-06
phase O 0 1.006425449645576e-07
chromosomal O 0 1.6332582163158804e-05
radiosensitivity O 0 4.225330940244021e-06
assay O 0 6.760057658539154e-06
can O 0 2.5286377436373186e-08
be O 0 1.3174132895699131e-09
used O 0 4.864434188789346e-09
for O 0 3.144909055396994e-10
the O 0 2.133048848662611e-09
detection O 0 3.928984824597137e-06
of O 0 2.190303582949582e-08
A B-Disease 1 0.9999610185623169
- I-Disease 1 0.9999762773513794
T I-Disease 1 0.999987006187439
heterozygotes O 0 0.0009597853058949113
. O 0 9.95945470094739e-07

In O 0 2.0693684632533405e-07
combination O 0 3.414483558117354e-07
with O 0 1.2642507485338683e-08
molecular O 0 1.8007734979619272e-05
genetic O 0 2.563200268923538e-06
analyses O 0 6.352115065055841e-07
, O 0 2.2196660065532114e-09
this O 0 1.058399701214796e-09
test O 0 4.678724963014247e-08
may O 0 1.6126345769862382e-07
be O 0 1.3540496501818211e-09
of O 0 5.943948111486463e-11
value O 0 2.7984876638242895e-08
in O 0 2.691945555355346e-09
studies O 0 1.1189595916505368e-09
of O 0 2.874158688825901e-10
familial B-Disease 0 0.00030128745129331946
and I-Disease 0 2.607373971841298e-06
sporadic I-Disease 0 0.0011939234100282192
cancers I-Disease 0 0.043433837592601776
aimed O 0 2.400697098892124e-07
at O 0 3.002396553597464e-08
determination O 0 2.2521854248225281e-07
of O 0 2.126621101439241e-10
the O 0 7.586495320843767e-10
potential O 0 8.236150428331257e-09
involvement O 0 1.3329153780716751e-08
of O 0 6.721236345264003e-10
ATM O 0 0.00010452962305862457
mutations O 0 6.238687092263717e-06
in O 0 1.9981288801318442e-07
tumor B-Disease 0 0.041929058730602264
risk O 0 1.8922331946669146e-05
or O 0 1.5273359110778983e-07
development O 0 2.0495976471579525e-08
. O 0 1.0310274944913544e-07
. O 0 4.768502890328818e-07

Ataxia B-Disease 1 0.9999872446060181
- I-Disease 1 0.9998519420623779
telangiectasia I-Disease 1 0.999988317489624
: O 0 9.993210596803692e-07
identification O 0 5.978202466394578e-07
and O 0 8.15057443759315e-09
detection O 0 9.870740313999704e-07
of O 0 1.337715604954326e-09
founder O 0 2.608274144222378e-06
- O 0 0.00018550392996985465
effect O 0 5.914924940952915e-07
mutations O 0 2.8293572995607974e-07
in O 0 1.245017644535551e-09
the O 0 9.124968003426659e-10
ATM O 0 2.0676850454037776e-06
gene O 0 2.5599089070738046e-08
in O 0 8.703406884080778e-09
ethnic O 0 4.845167111966475e-08
populations O 0 8.981705263977346e-07
. O 0 3.8461897133856837e-07

To O 0 2.9272236190536205e-08
facilitate O 0 1.4145035365231706e-08
the O 0 1.3505468965391287e-09
evaluation O 0 2.1098673919084376e-09
of O 0 1.6629787824573583e-10
ATM O 0 3.882814780808985e-06
heterozygotes O 0 1.7237649672097177e-06
for O 0 7.253863287814966e-09
susceptibility O 0 9.437149128643796e-05
to O 0 8.401690365644754e-08
other O 0 3.9837323129177094e-07
diseases O 0 0.00045086751924827695
, O 0 1.61278379540164e-09
such O 0 4.401091935335444e-09
as O 0 3.320091764180688e-06
breast B-Disease 1 0.9990735054016113
cancer I-Disease 0 0.32445260882377625
, O 0 9.559318669971617e-08
we O 0 1.4888986932248827e-08
have O 0 2.805562226981806e-09
attempted O 0 7.906428578507985e-08
to O 0 1.1758577445064589e-09
define O 0 2.341182714360457e-08
the O 0 3.0181612764579313e-09
most O 0 4.009854670528057e-09
common O 0 3.5712119483832794e-08
mutations O 0 9.635763120741103e-08
and O 0 3.2370819358362724e-09
their O 0 7.245621880258568e-09
frequencies O 0 1.1474894563434646e-05
in O 0 1.5346611689892597e-05
ataxia B-Disease 1 0.9999985694885254
- I-Disease 1 0.9999959468841553
telangiectasia I-Disease 1 0.9999996423721313
( O 0 2.0734330973937176e-05
A B-Disease 1 0.9999940395355225
- I-Disease 1 0.9999955892562866
T I-Disease 1 0.9999983310699463
) O 0 2.135003640546529e-08
homozygotes O 0 1.2568057172757108e-06
from O 0 2.0668620148711625e-09
10 O 0 3.5930467490175033e-09
ethnic O 0 1.920027870028207e-08
populations O 0 4.0033157233665406e-07
. O 0 2.8985951416871103e-07

Both O 0 1.333641819201148e-07
genomic O 0 4.456424449017504e-06
mutations O 0 9.526903340884019e-06
and O 0 1.0906465952587041e-08
their O 0 2.9425659686665995e-09
effects O 0 3.6206836284691235e-07
on O 0 1.3557280453824205e-07
cDNA O 0 2.491917712177383e-07
were O 0 5.17475996275607e-07
characterized O 0 8.253039595729206e-06
. O 0 8.868384497873194e-07

Protein O 0 5.078832600702299e-06
- O 0 1.5538770412604208e-06
truncation O 0 4.571947158638068e-07
testing O 0 3.896075639886476e-08
of O 0 1.6531465085733998e-10
the O 0 3.373750168123024e-10
entire O 0 6.310020284061579e-10
ATM O 0 6.799951535185755e-08
cDNA O 0 1.645045699660841e-08
detected O 0 1.7820930509060418e-07
92 O 0 1.6552108572653879e-09
( O 0 1.7826191911485267e-10
66 O 0 1.9596555489442835e-09
% O 0 2.1121180360239578e-09
) O 0 5.913960432479826e-10
truncating O 0 3.667956889330526e-07
mutations O 0 1.4608480114475242e-07
in O 0 3.3027980350652797e-09
140 O 0 5.99699800929443e-09
mutant O 0 5.282300890030456e-07
alleles O 0 4.0559328340350476e-07
screened O 0 3.6800021916860715e-05
. O 0 1.2165345424364205e-06

The O 0 9.909243914307808e-08
haplotyping O 0 4.409456323628547e-06
of O 0 1.0072662703919377e-08
patients O 0 1.1116596709825899e-07
with O 0 2.0305698456013488e-08
identical O 0 0.016832031309604645
mutations O 0 9.260664228349924e-06
indicates O 0 8.135230586958642e-07
that O 0 2.421841838184946e-09
almost O 0 6.425276422028503e-10
all O 0 2.2080011430336555e-11
of O 0 4.41088623959196e-11
these O 0 7.527370393667354e-10
represent O 0 6.1920739646836864e-09
common O 0 1.5006169462594698e-07
ancestry O 0 9.709352752906852e-07
and O 0 6.898266491361937e-08
that O 0 6.026031940109533e-08
very O 0 2.6264849850576866e-08
few O 0 1.3572099888392586e-08
spontaneously O 0 7.026974202517522e-08
recurring O 0 4.3027361584790924e-07
ATM O 0 0.00015255944163072854
mutations O 0 1.364862055197591e-05
exist O 0 1.5679353282394004e-06
. O 0 4.90195304791996e-07

Assays O 0 3.1741288694320247e-05
requiring O 0 6.953948172849778e-07
minimal O 0 5.002669922760106e-07
amounts O 0 1.743955557742538e-08
of O 0 3.395959069507626e-10
genomic O 0 2.1214948731085315e-07
DNA O 0 6.843089977337513e-06
were O 0 1.0875041311919631e-07
designed O 0 1.8493470861358219e-06
to O 0 1.8004191471021613e-09
allow O 0 1.6331834773453124e-09
rapid O 0 1.309088037970696e-08
screening O 0 2.729315617955308e-08
for O 0 1.160187501625387e-09
common O 0 2.839436241686144e-08
ethnic O 0 1.7182218314815145e-08
mutations O 0 9.605944796930999e-06
. O 0 4.929668762088113e-07

These O 0 3.534921688697068e-08
rapid O 0 1.1337376548681277e-07
assays O 0 7.873928552726284e-06
detected O 0 1.2273123502382077e-05
mutations O 0 1.1622950069067883e-07
in O 0 1.4704603090720525e-09
76 O 0 2.885833350063649e-09
% O 0 4.254834540251551e-10
of O 0 6.672150609787764e-10
Costa O 0 3.0966448321123607e-06
Rican O 0 1.3792787285638042e-05
patients O 0 5.262720037535473e-08
( O 0 2.5162799621725185e-10
3 O 0 5.213609544085784e-10
) O 0 3.427550951395908e-11
, O 0 4.5417627991817255e-11
50 O 0 5.1501938130860125e-11
% O 0 5.704856725907703e-11
of O 0 5.647986522916426e-10
Norwegian O 0 0.37762901186943054
patients O 0 4.0127073930307233e-07
( O 0 5.140706194062261e-10
1 O 0 1.3345045069002026e-09
) O 0 1.082444966993279e-10
, O 0 8.728368028343425e-11
25 O 0 9.748236245998854e-11
% O 0 6.935910873417939e-11
of O 0 4.661181995935237e-10
Polish O 0 0.08261220157146454
patients O 0 6.824338925071061e-07
( O 0 4.798066943756396e-10
4 O 0 6.284017750601834e-10
) O 0 5.499770083794431e-11
, O 0 5.204178754603106e-11
and O 0 4.829817656926139e-10
14 O 0 2.9277680280159757e-10
% O 0 5.082993748128928e-11
of O 0 2.5049215479633347e-10
Italian O 0 4.1293005779152736e-05
patients O 0 6.782632340218697e-07
( O 0 2.219915806733752e-09
1 O 0 8.993669808887716e-09
) O 0 9.386027510771555e-10
, O 0 2.916765162730428e-10
as O 0 6.685641484871496e-10
well O 0 4.422878951970688e-09
as O 0 2.3857231745694207e-09
in O 0 1.1214771333811768e-08
patients O 0 5.7261746455594675e-09
of O 0 1.7041345001800323e-09
Amish O 0 7.161180838011205e-05
/ O 0 7.142152753658593e-06
Mennonite O 0 6.819186637585517e-07
and O 0 2.2669311761092104e-07
Irish O 0 2.3944371605466586e-06
English O 0 4.617888293978467e-07
backgrounds O 0 9.118031698562845e-07
. O 0 3.156378625135403e-07

Additional O 0 4.3272459038234956e-07
mutations O 0 1.1481527508294675e-05
were O 0 3.542832871517021e-08
observed O 0 1.5236987849220895e-07
in O 0 5.405140335312808e-09
Japanese O 0 1.8642840871052613e-07
, O 0 1.1753353845733727e-09
Utah O 0 6.052258250122122e-09
Mormon O 0 1.938033289405894e-09
, O 0 2.4612462068418495e-10
and O 0 6.166623878200994e-10
African O 0 7.267417223566497e-10
American O 0 9.959228464140324e-08
patients O 0 2.425944387596246e-07
. O 0 2.5494480837551237e-07

These O 0 6.534013152759144e-08
assays O 0 2.87366310658399e-06
should O 0 1.153603701453676e-08
facilitate O 0 3.1613112128070497e-09
screening O 0 1.4306947093700728e-07
for O 0 3.786461988397605e-08
A B-Disease 1 0.9998705387115479
- I-Disease 1 0.9999704360961914
T I-Disease 1 0.9999924898147583
heterozygotes O 0 2.66742044914281e-05
in O 0 6.710940692045142e-09
the O 0 6.1184515232071135e-09
populations O 0 2.0375843234887725e-08
studied O 0 5.3171845593169564e-08
. O 0 1.3893872718995226e-08
. O 0 8.795864658850405e-08

The O 0 5.145772320247488e-06
von B-Disease 1 0.9070411920547485
Hippel I-Disease 1 0.9979897737503052
- I-Disease 1 0.9644615650177002
Lindau I-Disease 1 0.9806508421897888
tumor I-Disease 0 0.009464357979595661
suppressor O 0 0.00015684589743614197
gene O 0 6.053040237929963e-07
is O 0 7.954223057993204e-09
required O 0 2.781627372883122e-09
for O 0 1.3803767018316648e-09
cell O 0 6.6886714193969965e-06
cycle O 0 2.777775307549746e-07
exit O 0 1.6228044330546254e-07
upon O 0 6.057202739384593e-08
serum O 0 7.676377572352067e-05
withdrawal O 0 4.390209142002277e-06
. O 0 3.337439409278886e-07

The O 0 3.75600023971856e-07
inactivation O 0 1.3721050891035702e-05
of O 0 8.958640940193163e-09
the O 0 1.3226716077952005e-07
von B-Disease 1 0.9982900023460388
Hippel I-Disease 1 0.9996960163116455
- I-Disease 1 0.9986788630485535
Lindau I-Disease 1 0.9987013339996338
( I-Disease 0 1.5362367093985085e-06
VHL I-Disease 0 0.0002510393096599728
) I-Disease 0 4.06505362704479e-09
tumor I-Disease 0 3.4728091122815385e-06
suppressor O 0 2.7285897886031307e-05
gene O 0 5.457894189930812e-07
predisposes O 0 1.0048322110378649e-05
affected O 0 4.68299283795659e-08
individuals O 0 3.726228214873117e-09
to O 0 5.439455996736342e-09
the O 0 3.035922418348491e-06
human O 1 0.7293120622634888
VHL B-Disease 1 0.9999964237213135
cancer I-Disease 1 0.9999959468841553
syndrome I-Disease 1 0.9999885559082031
and O 0 4.120600351598114e-06
is O 0 4.523614620666194e-07
associated O 0 2.7451409323475673e-07
with O 0 6.792600970584317e-07
sporadic B-Disease 0 0.4599677622318268
renal I-Disease 1 0.9999560117721558
cell I-Disease 1 0.9999884366989136
carcinomas I-Disease 1 0.9999998807907104
( O 0 8.914686623029411e-05
RCC B-Disease 1 0.9917802214622498
) O 0 5.7798132502284716e-08
and O 0 1.5821718761799275e-06
brain B-Disease 0 0.07532555609941483
hemangioblastomas I-Disease 0 0.011477514170110226
. O 0 1.1411294735808042e-06

VHL O 0 0.022865546867251396
- O 0 2.527808646846097e-05
negative O 0 1.058808038578718e-06
786 O 0 8.17017826193478e-06
- O 0 0.0001829872198868543
0 O 0 5.053942118138366e-07
RCC B-Disease 0 0.0006874333485029638
cells O 0 1.213693821000561e-07
are O 0 1.2894975087718308e-09
tumorigenic O 0 1.217636167893943e-06
in O 0 1.7557638898324512e-08
nude O 0 0.04382156580686569
mice O 0 0.00010722341539803892
which O 0 2.1017310558590907e-08
is O 0 2.05435579658797e-09
suppressed O 0 8.9109066792048e-09
by O 0 2.4723689762140566e-10
the O 0 1.362661539161536e-09
reintroduction O 0 2.3377518232337025e-07
of O 0 1.942312266578483e-08
VHL B-Disease 0 0.0005154808750376105
. O 0 2.545560562339233e-07

Remarkably O 0 0.000255291786743328
, O 0 2.8745290592269157e-08
this O 0 2.580241131866501e-09
occurs O 0 2.9013695890256486e-09
without O 0 1.4786080138051716e-09
affecting O 0 1.3180919689048665e-09
the O 0 8.759226122201369e-10
growth O 0 6.63788455312897e-08
rate O 0 1.1671957622638729e-07
and O 0 1.3583176805553876e-09
cell O 0 3.082626278683165e-07
cycle O 0 2.655687048047639e-08
profile O 0 2.2598397819706406e-08
of O 0 9.084864804886905e-11
these O 0 1.340573763108921e-09
cells O 0 2.7477801367581378e-08
in O 0 1.3590803149554631e-08
culture O 0 4.444488013177761e-07
. O 0 3.7580426237582287e-07

The O 0 1.7345401204238442e-07
786 O 0 2.6199516014457913e-06
- O 0 7.4757563197636046e-06
0 O 0 1.6129259705621735e-08
cell O 0 1.6863151586221647e-06
line O 0 2.1092141651024576e-06
, O 0 1.023695905821853e-09
like O 0 6.3871934408155084e-09
many O 0 2.7970774585384106e-09
cancer B-Disease 0 8.88779050001176e-06
cells O 0 4.829307087561574e-08
, O 0 1.3761389805466706e-09
fails O 0 2.726027759081262e-08
to O 0 3.3873812088636157e-10
exit O 0 1.2628264656200372e-08
the O 0 1.2753886835525918e-09
cell O 0 8.974512866188888e-07
cycle O 0 5.182177176266123e-08
upon O 0 5.753302723121578e-09
serum O 0 6.065312391001498e-06
withdrawal O 0 1.1186655228812015e-06
. O 0 2.0362756458780495e-07

Here O 0 9.256118573830463e-07
, O 0 2.6686439724699085e-09
it O 0 6.909215977124461e-10
is O 0 3.213795063405911e-10
shown O 0 4.08418721065118e-09
that O 0 4.282917076547932e-10
reintroduction O 0 9.62778656798946e-09
of O 0 6.233363825103311e-11
the O 0 1.47795375937676e-09
wild O 0 2.4267683329526335e-07
- O 0 0.000311619252897799
type O 0 0.00028805198962800205
VHL B-Disease 0 2.784549542411696e-05
gene O 0 1.4506903234234869e-08
restores O 0 5.3624354734438384e-08
the O 0 6.527380858045717e-10
ability O 0 3.056500386122707e-09
of O 0 2.2335662208661233e-09
VHL O 0 0.0011644779006019235
- O 0 0.00029600394191220403
negative O 0 5.042332850280218e-05
RCC B-Disease 1 0.9826532602310181
cancer I-Disease 0 3.5818065953208134e-05
cells O 0 1.4310462148614533e-08
to O 0 2.929426978770522e-10
exit O 0 1.309694841467035e-08
the O 0 2.5411346360471043e-09
cell O 0 1.6488927485625027e-06
cycle O 0 1.211195126415987e-07
and O 0 4.090892069541496e-09
enter O 0 2.2243927588760926e-08
G0 O 0 5.306153525452828e-06
/ O 0 3.839076327949442e-07
quiescence O 0 2.321791271242546e-06
in O 0 4.159074862286616e-08
low O 0 1.0034399565483909e-05
serum O 0 0.0003909449151251465
. O 0 4.460513309823e-07

Both O 0 4.707159405370476e-06
VHL O 0 0.00261164759285748
- O 0 8.237978909164667e-05
positive O 0 8.928621753057087e-08
and O 0 2.634586167005182e-07
VHL O 0 0.0005882823606953025
- O 0 1.4803216799919028e-05
negative O 0 9.128820579462626e-07
RCC B-Disease 0 0.0007852142443880439
cells O 0 4.999884595235926e-08
exit O 0 1.5237185735372805e-08
the O 0 1.572778463021507e-09
cell O 0 1.232136128237471e-06
cycle O 0 6.077419811845175e-08
by O 0 2.642125185303712e-09
contact O 0 3.3905755003615923e-07
inhibition O 0 3.893386292475043e-06
. O 0 4.390404342302645e-07

The O 0 1.0465603281772928e-06
cyclin O 0 0.00023735311697237194
- O 0 1.2367753697617445e-05
dependent O 0 1.4410909443540731e-07
kinase O 0 2.0879178919130936e-06
inhibitor O 0 9.788640227270662e-07
, O 0 5.247822620901843e-09
p27 O 0 1.9505246484641248e-07
, O 0 5.360865640291479e-10
accumulates O 0 2.1251837623026404e-08
upon O 0 1.2169774077364082e-09
serum O 0 1.583009634487098e-06
withdrawal O 0 1.5325170465985138e-07
, O 0 3.1874167194523295e-10
only O 0 3.457472155798946e-11
in O 0 1.093755780390282e-10
the O 0 2.150901262654159e-10
presence O 0 2.571902912862356e-09
of O 0 1.4303086492972739e-09
VHL B-Disease 0 4.539665678748861e-05
, O 0 4.322918412125176e-10
as O 0 1.6401408009514284e-10
a O 0 1.6660306467741748e-09
result O 0 3.179694729738003e-09
of O 0 3.5227001871085406e-11
the O 0 5.568870919958613e-10
stabilization O 0 1.7190282974866022e-08
of O 0 2.1144833106667704e-10
the O 0 6.6002465715087055e-09
protein O 0 3.4427705486450577e-07
. O 0 1.7866535984012444e-07

We O 0 3.55586877276437e-07
propose O 0 5.6556888949899076e-08
that O 0 2.424693557045998e-09
the O 0 1.1790468601446946e-09
loss O 0 7.839904014872445e-08
of O 0 8.844846521860461e-10
wild O 0 1.9497526864142856e-06
- O 0 0.00924768391996622
type O 0 0.0054373666644096375
VHL B-Disease 0 3.753357668756507e-05
gene O 0 2.214140693013178e-08
results O 0 1.3288588895932207e-08
in O 0 6.718493539281667e-10
a O 0 7.063347240432449e-09
specific O 0 2.2598440452270552e-08
cellular O 0 0.0001374778221361339
defect O 0 4.001790512120351e-05
in O 0 7.266980617259833e-08
serum O 0 0.000716095557436347
- O 0 0.00047874473966658115
dependent O 0 4.505974686708214e-07
growth O 0 1.2469902799239208e-07
control O 0 3.0351989721566497e-07
, O 0 7.56520002198613e-09
which O 0 4.496569161460684e-08
may O 0 4.238715973770013e-07
initiate O 0 7.713809395681892e-07
tumor B-Disease 0 0.00039849142194725573
formation O 0 3.261687652411638e-06
. O 0 4.246042806244077e-07

This O 0 1.6157595439381112e-07
is O 0 1.5087842086813907e-08
corrected O 0 1.1964210955284216e-07
by O 0 9.560417735254845e-11
the O 0 2.7880850406170055e-10
reintroduction O 0 6.241604921797261e-08
of O 0 5.506753386619323e-10
wild O 0 7.434863960043003e-07
- O 0 0.015000254847109318
type O 0 0.018257029354572296
VHL B-Disease 0 0.0019782520830631256
, O 0 6.355657777845636e-09
implicating O 0 6.237884008442052e-06
VHL B-Disease 0 1.903461634356063e-05
as O 0 6.790807915990626e-10
the O 0 2.9060698292227016e-10
first O 0 2.940227972203502e-08
tumor B-Disease 0 1.775942109816242e-05
suppressor O 0 2.291253622388467e-06
involved O 0 3.899159217723991e-09
in O 0 1.4720289431835454e-09
the O 0 4.76597927789868e-10
regulation O 0 6.661752482983729e-09
of O 0 1.7043937095007067e-10
cell O 0 1.7125132671935717e-06
cycle O 0 1.1387015774744214e-07
exit O 0 9.290673830264495e-08
, O 0 3.3913005736962987e-09
which O 0 7.891811648619296e-09
is O 0 2.2570731950111167e-09
consistent O 0 3.7148542020304376e-08
with O 0 1.8965722325958723e-09
its O 0 6.2847997917003795e-09
gatekeeper O 0 6.75906335345644e-07
function O 0 4.259846697607372e-09
in O 0 1.3444658719663494e-09
the O 0 2.2460760362719157e-08
kidney O 0 2.357816993026063e-05
. O 0 1.106536089423571e-07
. O 0 4.308673737796198e-07

Piebaldism B-Disease 1 0.9999150037765503
with O 0 0.0003818903351202607
deafness B-Disease 1 0.9999978542327881
: O 0 4.2538491129562317e-07
molecular O 0 6.52207472739974e-06
evidence O 0 1.64629568644159e-07
for O 0 1.1347140116413357e-08
an O 0 6.802357574997586e-07
expanded O 0 0.012809546664357185
syndrome O 1 0.9998693466186523
. O 0 9.548251000524033e-06

In O 0 1.8324166717320622e-07
a O 0 5.666097635526057e-08
South O 0 6.761820880996083e-09
African O 0 2.1679291695164693e-09
girl O 0 8.356300895684399e-07
of O 0 6.745998759605243e-10
Xhosa O 0 2.7681965093506733e-06
stock O 0 2.2368978136455553e-07
with O 0 6.386769513255786e-08
severe O 0 0.0003286271821707487
piebaldism B-Disease 0 0.3905946910381317
and O 0 0.000364972569514066
profound O 1 0.9005717635154724
congenital O 1 0.9999990463256836
sensorineural B-Disease 1 0.9999974966049194
deafness I-Disease 1 1.0
we O 0 0.0023491824977099895
identified O 0 3.695812210935401e-06
a O 0 2.1478205880498535e-08
novel O 0 3.043471252794916e-08
missense O 0 3.702708966102364e-07
substitution O 0 2.9177125160373407e-09
at O 0 1.5098342576180812e-09
a O 0 7.1239072418904925e-09
highly O 0 2.1059403110257335e-08
conserved O 0 5.136908498570847e-08
residue O 0 1.6934370705712354e-07
in O 0 4.6446840817893076e-10
the O 0 4.103377915232187e-10
intracellular O 0 5.253353378975589e-07
kinase O 0 2.522470197163784e-07
domain O 0 5.180820217276505e-09
of O 0 2.2251417375329652e-10
the O 0 1.3547968080729333e-08
KIT O 0 0.001332174171693623
proto O 0 0.0017812600126489997
- O 0 0.001568429172039032
oncogene O 0 2.6418892957735807e-05
, O 0 1.0350189150187816e-08
R796G O 0 7.320567760871199e-07
. O 0 1.083115606093088e-07

Though O 0 1.9233834791521076e-06
auditory B-Disease 0 5.541870268643834e-05
anomalies I-Disease 0 0.03797174617648125
have O 0 5.276037882140372e-07
been O 0 7.720596073568231e-08
observed O 0 2.110136705368859e-07
in O 0 2.3366546031411417e-08
mice O 0 8.32768182590371e-06
with O 0 2.7323054041517025e-08
dominant O 0 6.111752099968726e-06
white O 0 1.919810711115133e-05
spotting O 0 0.00010918680345639586
( O 0 3.035493989500537e-08
W O 0 0.010013873688876629
) O 0 1.2735437149302697e-09
due O 0 1.3589507297240289e-08
to O 0 7.181796490840497e-08
KIT O 1 0.8657898902893066
mutations O 0 0.005611954722553492
, O 0 4.491380423132796e-06
deafness B-Disease 1 0.9999986886978149
is O 0 6.94274945090001e-07
not O 0 3.997409692146903e-08
typical O 0 6.647310328844469e-07
in O 0 1.022851776610878e-07
human O 0 1.0163520300920936e-06
piebaldism B-Disease 0 0.00025296767125837505
. O 0 5.830119107486098e-07

Thus O 0 1.6559305322516593e-06
, O 0 5.9395568463571635e-09
the O 0 1.5378609496963236e-09
occurrence O 0 1.8725605741565232e-06
of O 0 1.2896204282242252e-07
sensorineural B-Disease 1 0.9999827146530151
deafness I-Disease 1 1.0
in O 0 4.896424798062071e-06
this O 0 1.1702407221036992e-07
patient O 0 1.4161955732561182e-06
extends O 0 4.0812302870563144e-08
considerably O 0 2.2502355534470553e-08
the O 0 3.6598180042091144e-10
phenotypic O 0 6.088291115702305e-08
range O 0 2.136792076612437e-08
of O 0 7.300148263666983e-10
piebaldism B-Disease 0 1.70862658706028e-05
due O 0 2.915878383191739e-08
to O 0 3.824763616933069e-09
KIT O 0 3.185245077474974e-05
gene O 0 1.322893581345852e-07
mutation O 0 2.4826974254210654e-07
in O 0 4.760240202017485e-09
humans O 0 2.2030615554058386e-08
and O 0 1.5489185045680642e-08
tightens O 0 1.9269531549070962e-05
the O 0 3.6292551186534183e-09
clinical O 0 3.500208478612876e-08
similarity O 0 1.1587179216121513e-07
between O 0 2.993190761912956e-08
piebaldism B-Disease 0 4.662523861043155e-05
and O 0 1.851932474039586e-08
the O 0 5.827228144461571e-10
various O 0 3.585445829124012e-10
forms O 0 2.7379093126000953e-07
of O 0 2.2261378035182133e-05
Waardenburg B-Disease 1 0.9999877214431763
syndrome I-Disease 1 0.9998745918273926
. O 0 2.0696960234545259e-07
. O 0 5.676492378370313e-07

Cycloheximide O 0 0.00012789118045475334
facilitates O 0 7.780880082464137e-07
the O 0 5.8470264185928045e-09
identification O 0 5.538982250641311e-08
of O 0 9.236633680131945e-10
aberrant O 0 4.2826846424759424e-07
transcripts O 0 7.582761440971808e-07
resulting O 0 1.6090015719782969e-07
from O 0 8.327162293042534e-10
a O 0 1.2384105296803227e-08
novel O 0 3.022045191869438e-08
splice O 0 4.261281446815701e-06
- O 0 4.776483547175303e-05
site O 0 2.0871236756647704e-06
mutation O 0 1.0664714409358567e-06
in O 0 1.1507818697964467e-08
COL17A1 O 0 6.868004857096821e-05
in O 0 2.1864426713591456e-08
a O 0 8.546830940758809e-07
patient O 0 8.133439223456662e-06
with O 0 8.579243626627431e-07
generalized O 0 0.005368388723582029
atrophic B-Disease 1 0.9989064931869507
benign I-Disease 1 0.9986376166343689
epidermolysis I-Disease 1 0.9956342577934265
bullosa I-Disease 1 0.9899348616600037
. O 0 5.126552059664391e-05

Patients O 0 0.00011900554090971127
with O 0 4.999579346076644e-07
generalized O 0 0.0006118515157140791
atrophic B-Disease 1 0.9986956715583801
benign I-Disease 1 0.9966185092926025
epidermolysis I-Disease 1 0.995428204536438
bullosa I-Disease 1 0.9408588409423828
often O 0 2.184172444685828e-06
show O 0 1.0599031838864903e-06
decreased O 0 5.422583626568667e-07
expression O 0 1.9349501556575888e-08
of O 0 2.244473273904646e-09
type O 0 0.000966750958468765
XVII O 0 0.00024797910009510815
collagen O 0 3.7608601815009024e-06
, O 0 2.6867645885886304e-09
a O 0 2.2644437436269982e-08
transmembrane O 0 1.3695766938326415e-05
hemidesmosomal O 0 2.461142003085115e-06
protein O 0 1.4899327105410975e-08
encoded O 0 1.9987991706216235e-08
by O 0 2.2699225610267604e-08
COL17A1 O 0 0.0005576722323894501
. O 0 4.6750500359848957e-07

This O 0 3.530482217684039e-07
report O 0 5.409640024822693e-08
documents O 0 9.818744928224987e-09
a O 0 7.119302480873557e-09
novel O 0 2.55765399970187e-08
splice O 0 3.1251254313247046e-06
- O 0 7.112939783837646e-05
site O 0 2.0108077478653286e-06
mutation O 0 7.137571174098412e-07
in O 0 3.6940652758943315e-09
COL17A1 O 0 3.0964594770921394e-05
in O 0 1.126218673874746e-08
a O 0 4.826212602893065e-07
patient O 0 6.1000941968814e-06
with O 0 4.5688611294281145e-07
generalized O 0 0.0004363141779322177
atrophic B-Disease 1 0.997734546661377
benign I-Disease 1 0.981381893157959
epidermolysis I-Disease 1 0.9909061193466187
bullosa I-Disease 1 0.8740965127944946
, O 0 7.80107711761957e-08
and O 0 8.06334998770808e-09
applies O 0 7.429624027111004e-09
a O 0 2.4011255206346505e-09
new O 0 9.46758449416052e-10
methodology O 0 2.4566324530184147e-09
to O 0 4.0045636251484495e-10
define O 0 1.0481829804120935e-07
and O 0 1.899534574079098e-08
characterize O 0 5.056646159573575e-07
the O 0 5.3311346448481345e-09
resulting O 0 6.647525907510499e-08
mRNA O 0 6.181102207847289e-08
splice O 0 1.5051244872665848e-06
variants O 0 6.623668014071882e-07
. O 0 3.9146573271864327e-07

Mutational O 0 0.0009592098649591208
analysis O 0 6.114242978583206e-07
of O 0 2.1415086592924126e-08
COL17A1 O 0 0.00017166956968139857
identified O 0 1.3368576219363604e-06
a O 0 2.1754509305083047e-07
maternally O 0 0.00014874029147904366
inherited O 0 0.0061430069617927074
G O 0 0.00016514067829120904
- O 0 7.000111509114504e-06
to O 0 8.726433264882871e-08
- O 0 0.001802357961423695
T O 0 6.696082709822804e-05
transversion O 0 3.203841174581612e-07
at O 0 4.1552888907503416e-10
the O 0 3.0199850953316343e-10
- O 0 1.768423629755489e-07
1 O 0 7.056220052703566e-10
position O 0 2.8984821209832035e-09
of O 0 4.076558257626317e-10
exon O 0 2.6837549285119167e-06
32 O 0 5.3528300014704655e-08
. O 0 1.2002976745861815e-07

This O 0 4.362981442795899e-08
acceptor O 0 2.3113074121283717e-07
splice O 0 4.9639174903859384e-06
- O 0 4.565653944155201e-05
site O 0 8.134796871672734e-07
mutation O 0 1.0058514590127743e-06
led O 0 4.41985159582714e-09
to O 0 8.562162645553428e-10
the O 0 1.7031792642896448e-09
formation O 0 5.376576517335252e-09
of O 0 3.415355775970852e-10
aberrant O 0 3.3921085673682683e-07
transcripts O 0 1.0891461244000311e-07
present O 0 3.6174665041244225e-08
at O 0 9.690447910770672e-08
extremely O 0 3.655424052340095e-06
low O 0 3.165332236676477e-05
levels O 0 1.6077713098638924e-06
. O 0 1.6205403596813994e-07

Based O 0 4.3107866076752543e-07
on O 0 4.968284983419835e-08
our O 0 8.926778427564841e-09
recent O 0 3.0889573121584135e-09
finding O 0 1.3829934975007063e-09
that O 0 4.067667092044758e-09
cycloheximide O 0 9.804086403164547e-06
stabilized O 0 1.2474552931962535e-05
mutant O 0 2.3022460027277702e-07
COL17A1 O 0 1.63454819812614e-06
transcripts O 0 4.985428603276887e-08
in O 0 1.6582727413450016e-09
keratinocytes O 0 9.251029808865496e-08
homozygous O 0 1.6045882489379437e-07
for O 0 2.0423847058026467e-09
a O 0 1.0000160273193615e-06
frameshift O 1 0.5363034605979919
mutation O 0 4.439447002368979e-05
, O 0 1.8240480237352585e-09
the O 0 1.3039538337977774e-09
effects O 0 1.632275541396666e-07
of O 0 5.055758589556092e-10
the O 0 1.3946682919652176e-08
splice O 0 2.5606137569411658e-05
- O 0 0.00023316587612498552
site O 0 9.434135108676855e-07
mutation O 0 9.804227119047937e-08
on O 0 1.2460843468176108e-09
splicing O 0 4.4210826111168444e-09
of O 0 4.1071365752820554e-10
COL17A1 O 0 6.134180694061797e-06
transcripts O 0 9.034867787249823e-08
were O 0 1.017048223417305e-08
determined O 0 1.6967309335313985e-08
using O 0 2.2552875122983096e-09
reverse O 0 1.3366327777930564e-07
transcriptase O 0 5.6105740497969236e-08
polymerase O 0 2.2774685248805326e-08
chain O 0 4.914609874617781e-08
reaction O 0 2.561616918583809e-09
of O 0 6.279988334911835e-11
total O 0 4.482025306451476e-10
RNA O 0 7.012123326433084e-09
from O 0 1.0848596465606875e-09
keratinocytes O 0 1.5833991540148418e-07
incubated O 0 1.780453686706096e-07
for O 0 2.795077502781851e-09
2 O 0 5.5983448987717566e-08
. O 0 1.8780998800593807e-07

5 O 0 4.780843028129311e-07
h O 0 4.141693807468982e-06
in O 0 1.7499457438674426e-09
the O 0 6.165071786412568e-10
presence O 0 1.606340660487149e-08
or O 0 8.763707981529478e-09
absence O 0 3.136990667229611e-09
of O 0 1.0981036219215312e-10
10 O 0 2.3674642246618305e-09
microg O 0 9.230774935531372e-07
cycloheximide O 0 3.312842636660207e-06
per O 0 2.4123602315739845e-07
ml O 0 1.041751602315344e-05
. O 0 1.8583482130907214e-07

Using O 0 1.7107292649143346e-07
this O 0 7.389416190051179e-09
approach O 0 4.351031535065886e-08
, O 0 1.3632490691861676e-09
an O 0 1.1492327089968057e-09
abnormally O 0 1.0710846254369244e-06
spliced O 0 2.61511854660057e-06
transcript O 0 0.00011182932212250307
was O 0 5.476891601574607e-06
identified O 0 1.0047759957387825e-07
that O 0 3.594202990786499e-10
contains O 0 4.4833567414137576e-11
an O 0 1.953455106007418e-11
extra O 0 3.110476043399757e-10
264 O 0 6.671819763326425e-10
bases O 0 1.3692269540399593e-09
upstream O 0 9.614807838786987e-10
from O 0 1.3108655827487325e-10
exon O 0 7.092510401207619e-08
32 O 0 1.4254826208315308e-09
, O 0 3.1079377960097077e-10
resulting O 0 2.5978357243161554e-09
in O 0 6.918992045967798e-09
a O 0 8.887603257790033e-07
premature O 0 2.1097566786920652e-05
termination O 0 1.0505713134989492e-06
codon O 0 1.868367007773486e-07
27 O 0 1.0623016244437622e-08
bp O 0 2.3299951124045037e-07
downstream O 0 1.4273851434154494e-08
from O 0 1.6319784412743843e-09
the O 0 9.15095998976767e-09
cryptic O 0 8.304649782076012e-06
splice O 0 1.4643040231021587e-05
site O 0 8.217752110795118e-06
. O 0 2.563994883075793e-07

Three O 0 6.920380712926999e-08
other O 0 9.527328925784673e-10
splice O 0 8.002204481272202e-07
variants O 0 4.1987647136920714e-07
, O 0 1.1666093646667264e-09
including O 0 2.54405774224864e-10
one O 0 1.1801358779095494e-09
derived O 0 1.1911148734000676e-09
from O 0 9.993275651432043e-11
the O 0 3.2071573174974333e-10
skipping O 0 3.949826687943414e-09
of O 0 1.6824465431941604e-10
exon O 0 5.588464659922465e-07
32 O 0 7.630717391293729e-09
, O 0 1.1990678450146675e-09
were O 0 4.026933098089103e-08
also O 0 1.1832241852971492e-06
identified O 0 1.937057459144853e-05
. O 0 1.1005306532752002e-06

These O 0 7.047470518273258e-08
results O 0 3.9051968769854284e-08
indicate O 0 1.4299493145131237e-08
the O 0 1.393842402608314e-10
usefulness O 0 1.096555912738495e-08
of O 0 5.683778447895804e-10
cycloheximide O 0 4.895245365332812e-05
treatment O 0 2.515496362320846e-07
in O 0 2.153422773432112e-09
evaluating O 0 7.397454648838675e-09
the O 0 1.1134368982368414e-09
abnormal O 0 1.0310467146723568e-08
processing O 0 5.096071897803256e-10
of O 0 4.6317123747474653e-11
mRNA O 0 2.8187141509761204e-09
due O 0 3.3770548579781234e-09
to O 0 7.543309865631898e-10
splice O 0 1.0119747457792982e-06
- O 0 4.543329851003364e-05
site O 0 3.4962333756993758e-06
mutations O 0 2.5105453005380696e-06
, O 0 8.043381072297962e-09
because O 0 1.553493262917982e-07
( O 0 1.1123846732630227e-08
i O 0 4.996470579499146e-06
) O 0 1.0248465409645746e-09
aberrant O 0 2.0408124967730146e-08
splicing O 0 1.367776381044905e-08
often O 0 5.853676654510309e-09
generates O 0 5.6473425935621435e-09
a O 0 4.154935950850813e-08
premature O 0 2.203962594649056e-06
termination O 0 1.8832149351055705e-07
codon O 0 3.4034716378528174e-08
, O 0 8.966722364611712e-10
( O 0 6.471175817424069e-10
ii O 0 3.941470822610427e-06
) O 0 8.240200743969694e-10
transcripts O 0 2.436600254895893e-08
with O 0 2.2876866623278147e-08
premature O 0 2.346821702303714e-06
termination O 0 1.9570182985262363e-07
codons O 0 1.1761052576275688e-08
can O 0 5.67868863043941e-09
occur O 0 2.839510626628794e-09
at O 0 1.958979201077682e-09
low O 0 2.2219071524887113e-06
or O 0 1.134099306909775e-06
undetectable O 0 0.00013999322254676372
levels O 0 1.5619252735632472e-07
due O 0 3.566051010039928e-09
to O 0 6.606263869279871e-10
nonsense O 0 1.068760298039706e-06
- O 0 4.93076868224307e-07
mediated O 0 8.86967157498475e-08
mRNA O 0 1.1542991451563012e-08
decay O 0 1.396649338403222e-07
, O 0 2.7833560456436146e-10
and O 0 1.865047227767036e-09
( O 0 7.806145174704682e-10
iii O 0 6.843748110441084e-07
) O 0 2.0783964826964763e-10
the O 0 8.448718391562693e-10
levels O 0 9.385280996809797e-09
of O 0 2.5140240583754192e-11
these O 0 2.2898932749981782e-10
transcripts O 0 6.015350439980693e-09
can O 0 1.2392233905700323e-08
be O 0 2.2744546246400432e-09
increased O 0 3.2554279272289932e-09
by O 0 1.0497632096928555e-08
cycloheximide O 0 0.00015001824067439884
. O 0 4.011620831079199e-07

A O 0 2.4642090465931688e-06
deletion O 0 3.1810865039005876e-05
mutation O 0 5.3240335546433926e-05
in O 0 5.877643971530233e-08
COL17A1 O 0 0.0001784830674296245
in O 0 1.4931076819379996e-08
five O 0 1.7690892306632122e-08
Austrian O 0 0.03083760105073452
families O 0 6.032944384060102e-07
with O 0 8.768960242377943e-07
generalized O 0 0.00337261613458395
atrophic B-Disease 1 0.9994188547134399
benign I-Disease 1 0.9991459846496582
epidermolysis I-Disease 1 0.9950278401374817
bullosa I-Disease 1 0.8049256801605225
represents O 0 2.6333657388022402e-06
propagation O 0 6.50930985557352e-07
of O 0 3.0156812602655236e-09
an O 0 1.3053803371576578e-08
ancestral O 0 8.143650484271348e-05
allele O 0 5.190571755520068e-05
. O 0 7.063867997203488e-07

Patients O 0 0.0002673290728125721
with O 0 1.3085309547022916e-06
generalized O 0 0.0018976242281496525
atrophic B-Disease 1 0.9994953870773315
benign I-Disease 1 0.9993929862976074
epidermolysis I-Disease 1 0.9985299110412598
bullosa I-Disease 1 0.995654821395874
, O 0 2.853444129868876e-07
a O 0 3.666032810656361e-08
usually O 0 5.224854149332714e-08
nonlethal O 0 2.654576007898868e-07
form O 0 1.5735563962948618e-08
of O 0 2.208960658833803e-08
junctional B-Disease 0 0.47148802876472473
epidermolysis I-Disease 1 0.8468234539031982
bullosa I-Disease 0 0.397848516702652
, O 0 5.6220248012550655e-08
have O 0 4.933146335872607e-09
generalized O 0 1.2816619232580706e-07
blistering B-Disease 0 0.0015985362697392702
, O 0 7.149116754590068e-06
nail B-Disease 1 0.9999938011169434
dystrophy I-Disease 1 0.999933123588562
, O 0 1.4612293853133451e-05
patchy B-Disease 1 0.7594663500785828
alopecia I-Disease 1 0.999745786190033
, O 0 2.573867959654308e-06
and O 0 6.011651566950604e-05
dental B-Disease 1 0.9990296363830566
abnormalities I-Disease 1 0.9982380867004395
. O 0 2.940886224678252e-05

Skin B-Disease 1 0.9634703993797302
fragility I-Disease 0 0.10940299183130264
in O 0 1.4826703420567355e-07
most O 0 8.415462993127676e-09
cases O 0 2.146436450800593e-08
is O 0 2.2489997419938845e-08
due O 0 3.6333986486170033e-08
to O 0 8.990324928959126e-09
mutations O 0 3.884700845446787e-07
in O 0 1.5080929838262591e-09
the O 0 1.3208073523784947e-09
gene O 0 3.979896234795888e-08
encoding O 0 6.279518061091949e-08
type O 0 7.178964733611792e-05
XVII O 0 0.00016728114860597998
collagen O 0 2.370273068663664e-05
( O 0 5.90930966382075e-08
COL17A1 O 0 0.00010346889757784083
) O 0 1.538677452117554e-08
. O 0 9.164062930722139e-08

Recently O 0 3.799714977503754e-05
, O 0 6.028526655654787e-08
we O 0 2.2713562586318403e-08
reported O 0 5.006249281791497e-08
five O 0 4.563049937900132e-09
Austrian O 0 0.0010140191297978163
families O 0 5.697742366805869e-08
with O 0 8.731976919307272e-08
generalized O 0 0.00021787114383187145
atrophic B-Disease 1 0.9992038607597351
benign I-Disease 1 0.9964990615844727
epidermolysis I-Disease 1 0.9829567670822144
bullosa I-Disease 1 0.7982039451599121
who O 0 4.7429688265765435e-07
share O 0 4.774446082933537e-08
the O 0 5.222878129984565e-09
same O 0 9.665453859497575e-08
COL17A1 O 0 0.0002602412714622915
mutation O 0 2.2918959075468592e-05
. O 0 1.9414608232182218e-07

Affected O 0 5.260324996925192e-06
individuals O 0 3.301867579352802e-08
in O 0 2.468393267562874e-09
three O 0 2.326607129177205e-09
families O 0 6.188070944546098e-09
are O 0 1.3003748078332933e-09
homozygous O 0 1.903644459844145e-07
for O 0 2.146545829972979e-09
4003delTC O 0 1.873850351330475e-06
, O 0 2.338699900406027e-09
whereas O 0 9.460441319220081e-09
those O 0 1.4370356016257801e-09
in O 0 2.21653118082088e-09
two O 0 5.6230406997315185e-09
others O 0 6.454922640841687e-08
are O 0 2.152602540661519e-08
compound O 0 1.4182161294229445e-06
heterozygotes O 0 3.688965807668865e-05
. O 0 6.514687811431941e-07

To O 0 6.931688290023885e-08
determine O 0 1.921358148138097e-07
if O 0 8.024334086087492e-09
the O 0 9.424201419250267e-10
occurrence O 0 3.0673680839754525e-07
of O 0 3.919430890952924e-10
4003delTC O 0 2.137303226845688e-06
in O 0 9.330858752321092e-09
these O 0 1.0514419335194702e-09
unrelated O 0 7.906760401965585e-08
families O 0 3.1732059202482787e-09
signifies O 0 2.0650070098326978e-08
propagation O 0 4.161984978878763e-09
of O 0 3.875562024080459e-11
an O 0 1.7608741131880379e-09
ancestral O 0 2.0869165382464416e-06
allele O 0 2.833577639194118e-07
or O 0 3.797012038120329e-09
a O 0 1.8650304411949037e-08
mutational O 0 2.4280641810037196e-05
hot O 0 1.0877923159569036e-05
spot O 0 1.1194551916560158e-05
, O 0 4.561039990136351e-09
haplotypes O 0 1.6696108673386334e-07
were O 0 2.0008977230645542e-07
determined O 0 2.0008146748295985e-06
for O 0 2.8379512073684054e-09
polymorphisms O 0 8.433433322352357e-06
both O 0 5.4680304728549345e-09
within O 0 1.2578695418596908e-08
and O 0 4.690971877607808e-07
flanking O 0 0.016386698931455612
COL17A1 O 0 0.2287936806678772
. O 0 1.0421005072203116e-06

Five O 0 9.41411030908057e-07
intragenic O 0 4.627574162441306e-05
polymorphisms O 0 0.00013543720706366003
were O 0 8.464969170063341e-08
chosen O 0 1.162050722314234e-08
based O 0 3.85541598646455e-09
on O 0 1.820288275666826e-08
their O 0 5.32319184287644e-08
informativeness O 0 0.00023758813040331006
. O 0 5.356118890631478e-07

One O 0 3.494151812333257e-08
of O 0 4.0280659363567395e-10
these O 0 8.890412295237127e-10
, O 0 1.2236786028907432e-09
not O 0 3.5729204039824936e-09
previously O 0 1.682307839701025e-07
reported O 0 1.3924295672040898e-06
, O 0 2.315906133532053e-09
was O 0 7.495800247170337e-08
2988 O 0 1.5985658308181883e-07
A O 0 2.585963443380024e-07
or O 0 2.110702155277977e-07
C O 0 1.1686292111789953e-07
that O 0 6.468362512279668e-10
introduces O 0 8.304971710337838e-10
a O 0 2.131129273053034e-09
new O 0 7.53294315813946e-10
restriction O 0 9.063131356512599e-10
site O 0 4.9157793391430005e-09
for O 0 2.3991295616809794e-09
Eco0109 O 0 1.334630837845907e-06
I O 0 1.2424926353560295e-05
. O 0 4.1349341728391664e-08

All O 0 3.566766793028364e-08
the O 0 6.372226302175932e-09
4003delTC O 0 2.6985327394868364e-07
alleles O 0 1.0907406533533504e-07
showed O 0 2.2453551196122135e-07
the O 0 1.0995209187569799e-09
same O 0 8.653170624484119e-09
haplotype O 0 6.617972871936217e-07
for O 0 4.0224307218394983e-10
these O 0 6.960524379096e-10
five O 0 6.275444608405678e-09
polymorphic O 0 1.9931474071199773e-06
markers O 0 8.530206105206162e-05
. O 0 2.214982714576763e-06

Fourteen O 0 5.6204130487458315e-06
microsatellite O 0 0.00017906571156345308
polymorphisms O 0 0.0005164967733435333
were O 0 1.9920517502214352e-07
selected O 0 9.931321542921978e-09
based O 0 2.030495327431936e-09
on O 0 1.1504856622934767e-08
their O 0 3.774578516413385e-08
high O 0 9.544739896227838e-07
heterozygosity O 0 5.136593699717196e-06
and O 0 1.00490211707438e-08
their O 0 1.3902269335730466e-09
location O 0 3.105025925265181e-08
within O 0 1.497870383282418e-09
10q23 O 0 4.736694734219782e-07
- O 0 5.916137070016703e-06
q25 O 0 7.576096550110378e-07
near O 0 5.020545472689264e-07
COL17A1 O 0 9.71274494077079e-05
. O 0 3.505400627545896e-07

Three O 0 3.6844625128651387e-07
families O 0 9.74328600023e-08
shared O 0 7.599101792266083e-08
microsatellite O 0 7.125601405277848e-05
polymorphisms O 0 0.0005223916377872229
covering O 0 2.1315711364877643e-06
at O 0 1.8741056706517156e-08
most O 0 6.0560338965842675e-09
19 O 0 2.1493695712138106e-08
cM O 0 1.1706839359248988e-05
, O 0 1.1963271262516173e-08
whereas O 0 3.363031098047031e-08
the O 0 4.570532396996896e-09
others O 0 5.026722593726163e-09
shared O 0 8.154166231122417e-09
smaller O 0 2.094008522135482e-08
regions O 0 5.199708663639058e-09
consistent O 0 6.707539768058268e-08
with O 0 2.7144249070687465e-09
cross O 0 4.7048109763636603e-07
- O 0 2.007772536671837e-06
over O 0 2.8837643384349576e-09
events O 0 4.5585348829035865e-09
during O 0 6.777496341925371e-09
passage O 0 2.300093449036922e-09
of O 0 5.188419485713247e-11
this O 0 8.826628872249387e-10
mutation O 0 1.3159524137051903e-08
through O 0 2.5271984505081946e-10
several O 0 1.495221502167965e-09
generations O 0 2.6647191475603904e-07
. O 0 2.1412397188669274e-07

These O 0 6.402589036724748e-08
results O 0 1.1193469617865048e-07
indicate O 0 1.7847786182301206e-07
that O 0 5.300221594950472e-09
4003delTC O 0 7.621832196491596e-07
occurs O 0 4.920441831757216e-09
on O 0 1.1066807470427875e-09
a O 0 8.783773708387344e-09
single O 0 1.4449193486143486e-07
ancestral O 0 3.112846798103419e-06
allele O 0 4.7227388222381705e-07
. O 0 8.740771662019142e-09
. O 0 6.109998906822511e-08

The O 0 6.438850732592982e-07
haptoglobin O 0 0.00017322473286185414
- O 0 1.6377392967115156e-05
gene O 0 5.059439445176395e-07
deletion O 0 4.06077333536814e-06
responsible O 0 5.944160648141406e-07
for O 0 6.341505098816924e-08
anhaptoglobinemia B-Disease 0 0.00213986006565392
. O 0 2.6563207029539626e-06

We O 0 1.5567961781925987e-06
have O 0 1.3619606775705506e-08
found O 0 4.646599993662903e-09
an O 0 4.0929895583907694e-10
allelic O 0 2.275007489060954e-07
deletion O 0 9.529596809443319e-07
of O 0 3.077994525924055e-09
the O 0 1.1751637885026867e-07
haptoglobin O 0 7.779057341394946e-05
( O 0 3.906871270942247e-09
Hp O 0 1.3155885270066392e-08
) O 0 1.5149478893583535e-10
gene O 0 1.8100119181241325e-09
from O 0 1.82899750900134e-10
an O 0 1.214121136960955e-09
individual O 0 2.5782401991136794e-08
with O 0 5.981042363600864e-07
anhaptoglobinemia B-Disease 0 0.008863975293934345
. O 0 9.694899745227303e-07

The O 0 1.6488912990553217e-07
Hp O 0 4.90966328925424e-07
gene O 0 1.6092576515802648e-07
cluster O 0 2.0828377955695032e-07
consists O 0 2.484988215201156e-09
of O 0 6.086079973322001e-10
coding O 0 9.929854059009813e-07
regions O 0 4.083400728660536e-09
of O 0 5.621075271911025e-10
the O 0 7.742181118430835e-09
alpha O 0 2.4065874626444383e-08
chain O 0 3.236151826513378e-07
and O 0 5.0714650257077665e-09
beta O 0 1.5101540018491733e-09
chain O 0 1.7873839297521954e-08
of O 0 6.398929303097489e-11
the O 0 2.474686455755659e-09
haptoglobin O 0 9.55412019720825e-07
gene O 0 1.2348772671089137e-08
( O 0 2.207446447854977e-10
Hp O 0 2.973381763027305e-09
) O 0 1.6138537728416225e-10
and O 0 5.946649839216889e-10
of O 0 1.25922453020344e-10
the O 0 5.007220860164807e-09
alpha O 0 1.8429506809525265e-08
chain O 0 3.8694381032655656e-07
and O 0 2.751591621219518e-09
beta O 0 1.2386012215870323e-09
chain O 0 7.796715273400423e-09
of O 0 8.790283778647989e-11
the O 0 7.065759088931145e-09
haptoglobin O 0 8.646326932648662e-06
- O 0 6.897760158608435e-06
related O 0 1.0211869749809921e-07
gene O 0 7.173062499532534e-08
( O 0 2.7403050939511786e-09
Hpr O 0 1.0497710718482267e-06
) O 0 6.359268112099414e-10
, O 0 4.40828956671524e-10
in O 0 1.2889123102155509e-09
tandem O 0 1.9817221073026303e-06
from O 0 3.943089854629989e-09
the O 0 3.039700402496237e-08
5 O 0 6.802909524594725e-08
side O 0 4.022660505142994e-06
. O 0 8.69657185376127e-07

Southern O 0 3.280454393461696e-06
blot O 0 3.055183697142638e-05
and O 0 2.0627867414191314e-08
PCR O 0 3.0426058401644696e-06
analyses O 0 1.191767637465091e-06
have O 0 2.3247674008075592e-08
indicated O 0 1.224321692916419e-07
that O 0 5.986686701930921e-10
the O 0 1.3667995901744945e-10
individual O 0 1.5160008803860592e-09
with O 0 6.310288735988934e-09
anhaptoglobinemia B-Disease 0 2.2149228243506514e-05
was O 0 4.2376973397040274e-07
homozygous O 0 8.046668398264956e-08
for O 0 2.5508017920117254e-10
the O 0 5.471710862181567e-10
gene O 0 5.3040341008170344e-09
deletion O 0 1.0122163729420208e-07
and O 0 1.2256506920493848e-08
that O 0 3.149617011644068e-09
the O 0 1.941729665944081e-09
gene O 0 1.835215890366726e-08
deletion O 0 1.6620677456558042e-07
was O 0 1.2257329728981858e-07
included O 0 2.3982968944125105e-09
at O 0 5.225369470451824e-09
least O 0 6.289353482458182e-10
from O 0 2.520439690290033e-10
the O 0 2.9366395981611504e-09
promoter O 0 5.864659669896355e-06
region O 0 3.2991651632841013e-09
of O 0 1.9131460304855352e-10
Hp O 0 2.631805706698742e-08
to O 0 4.6421355648362805e-09
Hpr O 0 1.1090215821241145e-06
alpha O 0 3.6806182546200716e-09
but O 0 2.2689561340882847e-09
not O 0 6.776407213138214e-10
to O 0 7.054578587961657e-10
Hpr O 0 3.5339892292540753e-06
beta O 0 2.2028640245252973e-08
( O 0 3.2267690741605293e-09
Hpdel O 0 2.487043957444257e-06
) O 0 1.4532381520382387e-08
. O 0 5.3367028129969185e-08

In O 0 9.737861716985208e-08
addition O 0 1.6819894810282676e-08
, O 0 3.5515450580447805e-09
we O 0 2.2712467462326913e-09
found O 0 3.05096725661258e-09
seven O 0 3.412913562872433e-10
individuals O 0 1.0625579582868028e-10
with O 0 2.545524679931077e-09
hypohaptoglobinemia B-Disease 0 3.483309774310328e-05
in O 0 7.795704526358804e-09
three O 0 1.876494293284736e-09
families O 0 2.6955315757248854e-09
, O 0 1.0462725130722106e-09
and O 0 1.8990444772271076e-09
the O 0 1.7332569823835797e-09
genotypes O 0 8.811380070028463e-08
of O 0 8.118774402765538e-11
six O 0 3.325984487823064e-10
of O 0 5.373966896482507e-11
the O 0 2.7250488532359896e-09
seven O 0 3.071250365138667e-09
individuals O 0 6.921153095085231e-10
were O 0 4.2507590336526846e-08
found O 0 4.0762746067457556e-08
to O 0 4.9170263416442594e-09
be O 0 9.297966130361601e-07
Hp2 O 0 0.00016473022697027773
/ O 0 1.3419244169199374e-05
Hpdel O 0 2.2607966457144357e-05
. O 0 2.703787913560518e-07

The O 0 7.574471396765148e-07
phenotypes O 0 9.677557682152838e-05
and O 0 1.3139414534180105e-07
genotypes O 0 9.192453944706358e-06
in O 0 1.0155846830173232e-08
one O 0 1.5307262124508725e-09
of O 0 1.611620559227589e-10
these O 0 4.3299161478493886e-10
three O 0 8.363820747092632e-10
families O 0 2.6446762557696957e-09
showed O 0 1.307215029555664e-06
the O 0 7.466487872420657e-09
father O 0 7.275328925970825e-07
to O 0 2.159856071770605e-09
be O 0 6.780641115256003e-08
hypohaptoglobinemic B-Disease 0 5.435514140117448e-06
( O 0 9.52969037015805e-10
Hp2 O 0 2.7475530828269257e-07
) O 0 3.0038194154258235e-10
and O 0 1.469509847140671e-09
Hp2 O 0 3.350170800331398e-06
/ O 0 2.9127858169886167e-07
Hpdel O 0 1.1276457598796696e-06
, O 0 3.228885214756616e-10
the O 0 4.325805269544958e-10
mother O 0 3.331159348363144e-07
to O 0 5.985635875838113e-10
be O 0 7.274216340391604e-09
Hp2 O 0 3.543242144132819e-07
- O 0 5.597553922598308e-07
1 O 0 1.7477341796023893e-09
and O 0 3.564113004728142e-09
Hp1 O 0 3.1373806450574193e-06
/ O 0 1.142968670819755e-07
Hp2 O 0 2.663596205820795e-07
, O 0 1.402734178812537e-10
one O 0 2.2580310884978694e-11
of O 0 1.1737705425673983e-11
the O 0 2.2228552332137497e-10
two O 0 1.3821681577042e-09
children O 0 2.5455115348904656e-08
to O 0 5.605340192005315e-09
be O 0 2.7267461177871155e-07
hypohaptoglobinemic B-Disease 0 5.3028634283691645e-05
( O 0 3.914673918359313e-09
Hp2 O 0 7.967160513544513e-07
) O 0 1.6341829278676556e-10
and O 0 2.6812818632038216e-09
Hp2 O 0 3.726177283169818e-06
/ O 0 2.266479413037814e-07
Hpdel O 0 8.881418693817977e-07
, O 0 3.506513135409506e-10
and O 0 5.571675898430328e-10
the O 0 4.525586572157181e-10
other O 0 7.782953170831775e-10
child O 0 2.2426478096804203e-07
to O 0 1.2891090417355144e-09
be O 0 3.487121347234279e-08
Hp1 O 0 1.6131525626406074e-06
and O 0 2.2331413163101388e-08
Hp1 O 0 1.334492026217049e-05
/ O 0 4.1952142737500253e-07
Hpdel O 0 8.881366966306814e-07
, O 0 4.4964273970826696e-10
showing O 0 7.788781886119978e-08
an O 0 1.1290657297990947e-09
anomalous O 0 5.380989591685648e-07
inheritance O 0 9.186514375869592e-07
of O 0 2.0491588426096996e-09
Hp O 0 5.778771310360753e-07
phenotypes O 0 8.235262612288352e-06
in O 0 2.6456159929466594e-08
the O 0 5.774039379957685e-08
child O 0 2.2179245206643827e-05
with O 0 1.2626873058252386e-07
Hp1 O 0 0.0005398496869020164
. O 0 1.2430759852577467e-06

The O 0 4.27575940875613e-07
Hp2 O 0 3.281357203377411e-05
/ O 0 3.1465556276089046e-06
Hpdel O 0 9.01388284546556e-06
individuals O 0 9.766745634465224e-09
had O 0 1.650289931376392e-07
an O 0 7.895152975834208e-09
extremely O 0 1.5707864804426208e-06
low O 0 1.4327880535347504e-06
level O 0 9.37467081740806e-09
of O 0 2.5508209433589e-10
Hp O 0 3.814282223402188e-08
( O 0 9.307303261429922e-10
mean O 0 1.5548888399052885e-08
+ O 0 7.761610021361776e-09
/ O 0 2.0086748264702692e-08
- O 0 5.623284664579842e-07
SD O 0 5.52545279788319e-05
= O 0 1.9972563336523308e-07
0 O 0 1.1328341598115799e-09
. O 0 2.8603719393061056e-10
049 O 0 6.777680283676091e-08
+ O 0 7.909728871879906e-09
/ O 0 2.3468293974815424e-08
- O 0 9.130459943662572e-08
0 O 0 1.4377210533211837e-09
. O 0 3.668540471402082e-10
043 O 0 9.027667857708366e-08
mg O 0 7.631564358234755e-07
/ O 0 9.689080116004334e-08
ml O 0 2.4537263243473717e-07
; O 0 7.745278862714144e-10
n O 0 7.142603664078706e-08
= O 0 5.04428214753716e-08
6 O 0 7.046671024468765e-10
) O 0 2.975960103346331e-11
, O 0 5.2768144020998164e-11
compared O 0 3.3214027084227382e-09
with O 0 3.226508782372406e-10
the O 0 3.832891781740955e-09
level O 0 1.069586659241395e-07
( O 0 4.1944638734525697e-11
1 O 0 7.05978400739049e-11
. O 0 2.8615599473313935e-11
64 O 0 1.5065426683946725e-10
+ O 0 9.455891625265167e-10
/ O 0 2.585586189596256e-09
- O 0 2.8587603395635597e-08
1 O 0 2.2363359775123826e-10
. O 0 3.8718031558637733e-10
07 O 0 7.687999570293869e-09
mg O 0 3.215834851744148e-07
/ O 0 6.500054183788961e-08
ml O 0 1.2042613661833457e-07
) O 0 6.581295924901198e-11
obtained O 0 9.924954191831148e-10
from O 0 5.779344780521001e-10
52 O 0 4.165177536208375e-09
healthy O 0 4.372145312458997e-08
volunteers O 0 9.56102841342954e-09
having O 0 1.7987387934681465e-07
phenotype O 0 4.459417141333688e-06
Hp2 O 0 6.25790619324107e-07
, O 0 3.3728753123796196e-10
whereas O 0 1.1725074244850475e-09
the O 0 7.891400866100184e-10
serum O 0 1.0716609040173353e-06
Hp O 0 5.203518504970361e-09
level O 0 2.471050031260802e-09
of O 0 6.425714127455961e-11
an O 0 6.058191170943417e-10
individual O 0 3.2183236076122057e-09
with O 0 1.512512604051608e-08
Hp1 O 0 6.342395499814302e-05
/ O 0 2.4779360501270276e-06
Hpdel O 0 7.1370868681697175e-06
was O 0 7.131448001018725e-07
0 O 0 8.23439449959551e-08
. O 0 1.0816292217441514e-07

50 O 0 1.3221032304500113e-06
mg O 0 1.697713196335826e-05
/ O 0 2.3026464077702258e-06
ml O 0 7.067903879942605e-06
, O 0 4.468847514260688e-09
which O 0 8.620318348029343e-10
was O 0 1.6709448047436126e-08
approximately O 0 4.7885379689249774e-11
half O 0 2.0498651387423905e-10
the O 0 4.0788838973071506e-10
level O 0 1.975081875826845e-09
of O 0 8.844808219166111e-11
Hp O 0 1.5277374032507396e-08
in O 0 6.4462462034953205e-09
control O 0 4.2055654603245785e-07
sera O 0 2.655748403412872e-06
from O 0 1.4644453427692383e-09
the O 0 2.693856249180726e-09
Hp1 O 0 4.842542693950236e-06
phenotype O 0 3.6947443504686817e-07
( O 0 1.030320273542884e-10
1 O 0 1.4872793274722795e-10
. O 0 1.8444679117379792e-10
26 O 0 1.1179142056505498e-09
+ O 0 1.7694730125583646e-09
/ O 0 5.0197956902309215e-09
- O 0 3.751567589915794e-08
0 O 0 6.64329924404683e-10
. O 0 2.3491736333980384e-10
33 O 0 1.0536140848671494e-09
mg O 0 3.4533721304796927e-07
/ O 0 7.82820421818542e-08
ml O 0 2.1158938068310817e-07
; O 0 1.2138686722451553e-09
n O 0 1.817473531673386e-07
= O 0 1.8875769569604017e-07
9 O 0 1.9616939184174953e-09
) O 0 5.215148451975793e-11
, O 0 7.495317561057036e-11
showing O 0 6.936343766028585e-08
a O 0 6.665402452199487e-08
gene O 0 4.653574023905094e-07
- O 0 0.0002864116395357996
dosage O 0 2.8223792469361797e-05
effect O 0 9.500540727458429e-07
. O 0 1.2890338041415816e-07

The O 0 7.664898049597468e-08
other O 0 7.509492583324118e-09
allele O 0 7.824769454600755e-07
( O 0 2.611517668782426e-09
Hp2 O 0 7.820681275916286e-07
) O 0 1.0009566786539636e-10
of O 0 2.7450470715950637e-11
individuals O 0 4.689647004063602e-10
with O 0 2.2215054684693314e-08
Hp2 O 0 0.0015248646959662437
/ O 0 3.731041488208575e-06
Hpdel O 0 6.283415132202208e-06
was O 0 4.2940789057865913e-07
found O 0 3.204066700845942e-08
to O 0 5.675992120757201e-09
have O 0 4.523476704321183e-08
, O 0 1.2164251828039596e-09
in O 0 7.480510655355488e-10
all O 0 2.76516948227723e-10
exons O 0 5.8244779665983515e-08
, O 0 2.263069509567117e-09
no O 0 4.83638658010932e-08
mutation O 0 7.895638987065468e-08
, O 0 2.0241334997006533e-10
by O 0 2.2421359213709025e-10
DNA O 0 2.064590205463901e-07
sequencing O 0 3.835270661056711e-07
. O 0 1.8669065582344047e-07

On O 0 1.10027293942494e-07
the O 0 1.7138155339324612e-09
basis O 0 1.0487180013285524e-09
of O 0 8.230095771555312e-11
the O 0 1.4574732531968948e-09
present O 0 2.6236159911263712e-08
study O 0 7.680319491498722e-09
, O 0 2.362307294223598e-10
the O 0 1.2607313804036124e-10
mechanism O 0 1.859584153329763e-09
of O 0 1.408452798834503e-10
anhaptoglobinemia B-Disease 0 3.1338402095570927e-06
and O 0 7.322911166340873e-09
the O 0 6.064491686608164e-10
mechanism O 0 5.093800936606385e-09
of O 0 1.5520694451875983e-10
anomalous O 0 5.549821366912511e-07
inheritance O 0 7.918575875009992e-07
of O 0 5.5161435419393e-09
Hp O 0 1.1342172001604922e-06
phenotypes O 0 1.6075524399639107e-05
were O 0 4.849817401009204e-07
well O 0 1.391343573686754e-07
explained O 0 1.790960709513456e-06
. O 0 2.2443509806180373e-07

However O 0 7.885838613219676e-07
, O 0 3.652497859718551e-09
the O 0 5.689657078811194e-10
mechanism O 0 2.2786807107877394e-08
of O 0 5.363793409429718e-09
hypohaptoglobinemia B-Disease 0 0.0021051173098385334
remains O 0 1.7333430150756612e-05
unknown O 0 2.383560422458686e-05

ATM O 0 0.003887647995725274
mutations O 0 0.005260677542537451
and O 0 3.763418362723314e-06
phenotypes O 0 0.01852581836283207
in O 0 6.007708725519478e-05
ataxia B-Disease 1 0.9999992847442627
- I-Disease 1 0.9999957084655762
telangiectasia I-Disease 1 0.9999994039535522
families O 0 5.655522727465723e-06
in O 0 2.1056029808619314e-08
the O 0 2.63733301864022e-08
British O 0 1.024191442411393e-05
Isles O 0 1.1498140111143584e-06
: O 0 5.038046091421222e-10
expression O 0 7.149399405825818e-10
of O 0 2.103352041149531e-11
mutant O 0 7.788199418712338e-09
ATM O 0 3.1817839385439584e-07
and O 0 3.7240184269649035e-09
the O 0 3.862172359703209e-09
risk O 0 5.308075401444512e-07
of O 0 2.0342066875400633e-07
leukemia B-Disease 1 0.9999709129333496
, O 0 0.13697223365306854
lymphoma B-Disease 1 1.0
, O 0 3.998151896666968e-06
and O 0 0.0003866186598315835
breast B-Disease 1 0.999966025352478
cancer I-Disease 1 0.9581766128540039
. O 0 9.00642407941632e-06

We O 0 6.796813067921903e-07
report O 0 1.3069698212575531e-08
the O 0 3.5525052344276276e-10
spectrum O 0 1.704184171558154e-08
of O 0 2.7511284916847956e-10
59 O 0 7.343836649909008e-09
ATM O 0 6.569797551492229e-05
mutations O 0 1.263973808818264e-05
observed O 0 2.2776850528316572e-05
in O 0 4.456375245354138e-05
ataxia B-Disease 1 0.9999996423721313
- I-Disease 1 0.9999978542327881
telangiectasia I-Disease 1 0.9999998807907104
( O 0 4.5961282012285665e-05
A B-Disease 1 0.9999954700469971
- I-Disease 1 0.999997615814209
T I-Disease 1 0.9999996423721313
) O 0 1.5913680329049384e-07
patients O 0 2.005512556024769e-08
in O 0 6.509108807506436e-09
the O 0 4.0656601640876033e-08
British O 0 0.00011168609489686787
Isles O 0 2.4286200641654432e-05
. O 0 7.599527975798992e-07

Of O 0 6.60536301211323e-08
51 O 0 8.745461599346527e-08
ATM O 0 2.9283430194482207e-05
mutations O 0 3.264667611801997e-05
identified O 0 1.7453786540500005e-06
in O 0 2.077407579292867e-08
families O 0 5.530576441259427e-09
native O 0 4.850712276294189e-09
to O 0 2.4307873491835608e-09
the O 0 1.0831998409344124e-08
British O 0 1.003815032163402e-05
Isles O 0 1.3708239521292853e-06
, O 0 3.9871355106413375e-09
11 O 0 1.2158846152132696e-09
were O 0 1.446214703548776e-08
founder O 0 3.0645057336187165e-07
mutations O 0 1.5991010116067628e-07
, O 0 5.705371175501739e-10
and O 0 6.462171908694359e-10
2 O 0 2.0621709895252138e-10
of O 0 6.312737832470106e-11
these O 0 3.9593834877393874e-09
11 O 0 6.4481149308903696e-09
conferred O 0 1.2939160853875364e-07
a O 0 2.2208493533071305e-07
milder O 0 2.0605786630767398e-05
clinical O 0 7.595581791974837e-06
phenotype O 0 1.023074673867086e-05
with O 0 1.1308292968692513e-08
respect O 0 6.27478868864273e-08
to O 0 4.0962973457681073e-08
both O 0 9.975043440135778e-07
cerebellar B-Disease 1 0.9598519802093506
degeneration I-Disease 0 0.274078369140625
and O 0 3.25115956911759e-06
cellular O 0 0.00017448191647417843
features O 0 4.925481334794313e-05
. O 0 2.674763436516514e-06

We O 0 1.726124082779279e-06
report O 0 6.6239465468243e-08
, O 0 4.4867126680614433e-10
in O 0 2.0240949194505475e-10
two O 0 3.1087219465320004e-09
A B-Disease 1 0.9999229907989502
- I-Disease 1 0.9999905824661255
T I-Disease 1 0.9999991655349731
families O 0 2.921746045103646e-08
, O 0 1.6673586122895045e-10
an O 0 9.295429009847922e-11
ATM O 0 6.665581622655736e-06
mutation O 0 2.5189433472405653e-07
( O 0 2.7820612480411455e-10
7271T O 0 3.099558298913507e-08
- O 0 1.1851619774461142e-06
- O 0 1.3795101949654054e-05
> O 0 8.325341696036048e-07
G O 0 1.0202977136941627e-05
) O 0 2.3217430755728685e-10
that O 0 1.4509337731283267e-08
may O 0 1.6811960676932358e-06
be O 0 3.5971005729606986e-08
associated O 0 6.841527344647602e-09
with O 0 8.466592427147646e-10
an O 0 9.615454210631924e-09
increased O 0 2.58469572145259e-06
risk O 0 1.4701968211738858e-06
of O 0 1.3652838504185638e-07
breast B-Disease 1 0.9998378753662109
cancer I-Disease 0 0.28079015016555786
in O 0 1.092177086547963e-07
both O 0 2.981950899538788e-07
homozygotes O 0 0.0006858265260234475
and O 0 3.0490582503261976e-07
heterozygotes O 0 5.130982572154608e-06
( O 0 2.9329338957495565e-09
relative O 0 6.34108118902077e-07
risk O 0 1.5700315714184399e-07
12 O 0 1.8245246424797301e-09
. O 0 1.0203256017859985e-09
7 O 0 9.901153674718444e-09
; O 0 1.2251341274804872e-08
P O 0 0.00015782585251145065
= O 0 4.474555908018374e-07
. O 0 7.75450259560273e-10
0025 O 0 7.579675553870402e-08
) O 0 4.79705788980489e-11
, O 0 5.989572726683434e-11
although O 0 1.0376137726808565e-09
there O 0 5.581208384342062e-09
is O 0 7.321737882648449e-09
a O 0 1.1954803369462752e-07
less O 0 6.725513685523765e-06
severe O 0 0.13399574160575867
A B-Disease 1 0.9999982118606567
- I-Disease 1 0.9999980926513672
T I-Disease 1 0.9999995231628418
phenotype O 0 0.0002957204997073859
in O 0 5.6728857167342994e-09
terms O 0 8.352618152684954e-09
of O 0 1.9620893798588668e-10
the O 0 5.3291118184972674e-09
degree O 0 9.604328852219624e-07
of O 0 1.938186500183292e-07
cerebellar B-Disease 1 0.9758485555648804
degeneration I-Disease 1 0.6339697241783142
. O 0 1.2706148481811397e-05

This O 0 2.1577537268058222e-07
mutation O 0 2.050076318482752e-06
( O 0 3.267826675923402e-09
7271T O 0 9.019217372951971e-08
- O 0 4.9654754548100755e-06
- O 0 4.490425999392755e-05
> O 0 1.4405827641894575e-06
G O 0 7.434243343595881e-06
) O 0 8.286359792775144e-11
also O 0 1.1028115226574542e-10
allows O 0 7.445291605456816e-11
expression O 0 9.673192247205975e-10
of O 0 2.976641502727695e-11
full O 0 4.870830849768026e-09
- O 0 4.36653238011786e-07
length O 0 1.987705289252517e-08
ATM O 0 2.0273276390980755e-07
protein O 0 2.6946731512822453e-09
at O 0 4.1477266066181073e-10
a O 0 3.783529045620071e-09
level O 0 3.842262685793685e-08
comparable O 0 5.355266239348566e-07
with O 0 8.099109827242046e-09
that O 0 1.5152824062170112e-07
in O 0 1.34198316459333e-07
unaffected O 0 9.468481948715635e-06
individuals O 0 1.0101064162881812e-07
. O 0 4.370815531729022e-07

In O 0 1.2799249304862315e-07
addition O 0 2.0205751738444633e-08
, O 0 3.6204050868349213e-09
we O 0 4.6352344185152106e-09
have O 0 3.87653420474976e-09
studied O 0 1.0033798503172875e-07
18 O 0 5.264447366926106e-08
A B-Disease 1 0.9998865127563477
- I-Disease 1 0.9999970197677612
T I-Disease 1 0.9999998807907104
patients O 0 2.808572844514856e-06
, O 0 3.017533778404413e-09
in O 0 3.1033013936365705e-09
15 O 0 2.4288502320501948e-09
families O 0 2.668236742664476e-09
, O 0 9.876446327439226e-09
who O 0 2.6819845970749157e-06
developed O 0 0.017171870917081833
leukemia B-Disease 1 0.9999662637710571
, O 0 0.018579617142677307
lymphoma B-Disease 1 0.9999998807907104
, O 0 9.622610832593637e-07
preleukemic O 0 0.004192662891000509
T O 0 0.0023032769095152617
- O 0 2.2543037630384788e-05
cell O 0 4.3506664951564744e-05
proliferation O 0 8.835697371978313e-06
, O 0 7.862306716788225e-08
or O 0 0.1068432554602623
Hodgkin B-Disease 1 0.9999997615814209
lymphoma I-Disease 1 1.0
, O 0 8.513786724506645e-07
mostly O 0 2.1099086922049537e-08
in O 0 2.84007626305538e-07
childhood O 0 0.0003656027256511152
. O 0 3.604103540055803e-06

A O 0 1.0741923688328825e-06
wide O 0 7.493370191014037e-08
variety O 0 4.644349793636593e-09
of O 0 5.099504707395397e-10
ATM O 0 0.00014220278535503894
mutation O 0 1.543200050946325e-05
types O 0 1.0921895210458388e-07
, O 0 4.302239398068508e-10
including O 0 1.1733038984829136e-09
missense O 0 8.922289271140471e-05
mutations O 0 8.738174983591307e-06
and O 0 4.4795342546422035e-08
in O 0 1.4676058590623597e-08
- O 0 7.48407983337529e-05
frame O 0 0.08328954875469208
deletions O 0 3.335146902827546e-05
, O 0 2.6683602882826563e-08
were O 0 7.436332793986367e-08
seen O 0 1.3867592087990488e-06
in O 0 9.718578830586466e-09
these O 0 2.5420908045248325e-08
patients O 0 3.697303441185795e-07
. O 0 2.43185809267743e-07

We O 0 2.1996778798438754e-07
also O 0 7.494821430142906e-10
show O 0 1.4312255824933118e-09
that O 0 1.513737746261512e-10
25 O 0 6.291797638446894e-11
% O 0 5.2297915997812083e-11
of O 0 1.1322482534881217e-10
all O 0 6.156781040544956e-08
A B-Disease 1 0.9999821186065674
- I-Disease 1 0.9999942779541016
T I-Disease 1 0.9999995231628418
patients O 0 5.874135808880965e-07
carried O 0 3.3158727319460013e-07
in O 0 1.0015764217996548e-08
- O 0 3.4012052765319822e-06
frame O 0 4.9349833716405556e-05
deletions O 0 2.587465360193164e-06
or O 0 1.653129970691225e-07
missense O 0 1.4688075680169277e-05
mutations O 0 2.0822631086048204e-06
, O 0 7.345933861202525e-10
many O 0 4.515143120498166e-11
of O 0 5.56713952715171e-10
which O 0 4.482363351598906e-07
were O 0 1.3333141168914153e-06
also O 0 1.7949892594515404e-07
associated O 0 2.1997067278789473e-08
with O 0 1.9657275807105634e-09
expression O 0 3.636497680759021e-08
of O 0 4.826484212294702e-10
mutant O 0 2.74314686521393e-07
ATM O 0 6.329569259833079e-06
protein O 0 3.549333484897943e-07
. O 0 8.675351637066342e-08

The O 0 6.301673352027137e-07
DMPK O 0 5.937732203165069e-05
gene O 0 2.4554894935135962e-06
of O 0 2.9103784981998615e-07
severely O 1 0.8135057091712952
affected O 0 0.21752458810806274
myotonic B-Disease 1 0.9999997615814209
dystrophy I-Disease 1 0.9999998807907104
patients O 0 0.007328517269343138
is O 0 3.872369234159123e-07
hypermethylated O 0 2.0215105905663222e-05
proximal O 0 1.5730095128674293e-06
to O 0 1.4339478937586136e-08
the O 0 4.87819429295655e-09
largely O 0 3.122146807754689e-08
expanded O 0 1.3949347987818328e-07
CTG O 0 1.89498550753342e-05
repeat O 0 7.88564375397982e-06
. O 0 2.882067633436236e-07

Using O 0 3.1872079375716567e-07
methylation O 0 4.80888775200583e-06
- O 0 1.1426015589677263e-05
sensitive O 0 3.201796062057838e-06
restriction O 0 4.964230981840956e-08
enzymes O 0 2.8100357596372305e-08
, O 0 1.0069950429070218e-09
we O 0 1.2180155772867352e-09
characterized O 0 4.6314343471465236e-09
the O 0 3.1310296022546424e-10
methylation O 0 4.247638685228594e-08
pattern O 0 8.601717382816787e-08
on O 0 4.86430407065086e-09
the O 0 1.070614374931722e-09
5 O 0 2.193061510169514e-09
side O 0 5.1836175352093505e-09
of O 0 1.33748540021017e-10
the O 0 6.364440086059631e-09
CTG O 0 1.4583661140932236e-06
repeat O 0 1.2376330005281488e-07
in O 0 7.182132666372354e-10
the O 0 3.2633154511962914e-10
DMPK O 0 3.741831449133315e-07
gene O 0 8.537537898867242e-10
of O 0 7.144569658112943e-11
normal O 0 1.4468382936172475e-08
individuals O 0 5.255151869221208e-10
and O 0 6.621455383992725e-09
of O 0 2.142959232287467e-08
patients O 0 1.3135298104316462e-05
affected O 0 1.0275618933519581e-06
with O 0 0.008282664231956005
myotonic B-Disease 1 0.9999998807907104
dystrophy I-Disease 1 0.9999998807907104
, O 0 1.8325721384826466e-07
showing O 0 3.352029693814984e-07
expansions O 0 1.2817780259410938e-07
of O 0 7.484322050999026e-10
the O 0 1.7510650707208697e-08
repetitive O 0 1.5944935512379743e-05
sequence O 0 2.9520379030145705e-07
. O 0 1.3001752563468472e-07

The O 0 1.2557676143387653e-07
gene O 0 1.1327801274774174e-07
segment O 0 1.6880274245067994e-07
analyzed O 0 1.3939107645910553e-07
corresponds O 0 3.160299755222695e-08
to O 0 5.552293624866422e-10
the O 0 5.631227151248197e-10
genomic O 0 1.519280488082586e-07
SacI O 0 5.9089538808621e-06
- O 0 2.8177805688756052e-06
HindIII O 0 8.964581184045528e-07
fragment O 0 2.1063746658001037e-07
carrying O 0 3.5243253648786776e-08
exons O 0 1.9775224302520655e-07
11 O 0 1.3675024668202695e-08
- O 0 3.6075145999348024e-06
15 O 0 2.414689248553259e-08
. O 0 1.0791995919134934e-07

There O 0 3.652374971352401e-07
is O 0 3.294731820702168e-09
constitutive O 0 1.0201801181608516e-08
methylation O 0 3.6997931829318986e-08
in O 0 1.7258313667056768e-09
intron O 0 2.730175538090407e-06
12 O 0 6.010303810199957e-09
at O 0 2.693891998362119e-09
restriction O 0 1.9197559097960948e-09
sites O 0 1.2193542842098282e-09
of O 0 1.1180117942544143e-10
SacII O 0 2.068556796075427e-06
and O 0 2.086139083701255e-08
HhaI O 0 1.0980774050040054e-06
, O 0 1.9736950962467859e-10
localized O 0 1.5658709884291966e-08
1 O 0 1.2053852360693895e-09
, O 0 1.8409146429476664e-10
159 O 0 1.074091593444848e-09
- O 0 1.1254282981099095e-06
1 O 0 2.988819192140113e-09
, O 0 2.0441219550360046e-10
232 O 0 1.185570752681997e-09
bp O 0 5.889561904837137e-08
upstream O 0 3.953970206804769e-10
of O 0 3.681513080500132e-11
the O 0 3.1026916591514464e-09
CTG O 0 2.911182718889904e-06
repeat O 0 3.2031169894253253e-07
, O 0 3.4435870821525327e-10
whereas O 0 9.18202347488517e-10
most O 0 1.6027858207312562e-10
, O 0 3.3993485804018064e-10
if O 0 5.210222031593048e-09
not O 0 1.3267409393336038e-09
all O 0 5.1900431868867614e-11
, O 0 4.2726017168703834e-11
of O 0 6.725230615456379e-12
the O 0 1.8874846130501055e-10
other O 0 4.0494479297548125e-11
sites O 0 9.113036436581012e-10
of O 0 1.6848711315020637e-10
SacII O 0 3.0756186788494233e-06
, O 0 2.0626558239200676e-09
HhaI O 0 3.318390611184441e-07
, O 0 3.382913393856768e-10
and O 0 9.323756211543355e-10
HpaII O 0 5.278251933305e-07
in O 0 1.6328719487646026e-09
this O 0 2.064970638926411e-09
region O 0 3.0180000720747557e-09
are O 0 1.1583610737275762e-09
unmethylated O 0 2.9180156957409054e-07
, O 0 1.4133836323537707e-09
in O 0 1.0725970112090977e-09
normal O 0 1.7977709987349044e-08
individuals O 0 5.025023730453881e-10
and O 0 2.968015833104687e-09
most O 0 4.968014888362404e-10
of O 0 6.232059313049376e-10
the O 0 1.9934959993861412e-07
patients O 0 7.6134341497891e-07
. O 0 6.761036388525099e-07

In O 0 5.7883521975554686e-08
a O 0 6.902475924164264e-09
number O 0 1.0540944783699047e-09
of O 0 8.473037826917107e-10
young O 0 1.130561827267229e-06
and O 0 6.550299985974561e-06
severely O 0 0.05445843189954758
affected O 0 4.895188681075524e-07
patients O 0 1.2784866498805059e-07
, O 0 3.593032982251998e-09
however O 0 6.706372790432624e-09
, O 0 1.3551444688619796e-10
complete O 0 6.987487255472047e-10
methylation O 0 2.8507765037488753e-09
of O 0 3.196663420079737e-11
these O 0 2.1858274912300857e-10
restriction O 0 1.2785940084469871e-09
sites O 0 5.391580071290036e-09
was O 0 2.768616411685798e-07
found O 0 1.9377791815600176e-08
in O 0 3.6687171078853e-09
the O 0 7.900440301966682e-09
mutated O 0 4.044070010422729e-06
allele O 0 1.2478948292482528e-06
. O 0 1.051936280305199e-07

In O 0 7.200890195235843e-08
most O 0 1.0532643646143924e-09
of O 0 2.2443095992752404e-10
these O 0 4.794007857356064e-09
patients O 0 1.9356773961476392e-08
, O 0 9.476618378911894e-10
the O 0 1.8034712612191584e-09
onset O 0 3.256135130413895e-07
of O 0 9.715798832132805e-09
the O 0 3.838231714325957e-05
disease O 0 0.3179023861885071
was O 0 0.21925194561481476
congenital O 1 0.9999489784240723
. O 0 4.981737583875656e-05

Preliminary O 0 1.9384247934794985e-05
in O 0 4.494254142173304e-07
vivo O 0 2.145705911971163e-05
footprinting O 0 0.00023613199300598353
data O 0 9.117060528751608e-08
gave O 0 5.58885737689252e-09
evidence O 0 2.4185919933472633e-09
for O 0 1.2264492199598465e-10
protein O 0 1.1590556958651632e-08
- O 0 5.418663022282999e-06
DNA O 0 2.1176554128032876e-06
contact O 0 3.93765844819427e-07
in O 0 2.3514937552704396e-08
normal O 0 4.9294243353870115e-08
genes O 0 4.049143242923492e-09
at O 0 1.2092792323059598e-09
an O 0 1.6914664113798494e-09
Sp1 O 0 1.817258663550092e-07
consensus O 0 2.6129527430640564e-09
binding O 0 1.4852794549824466e-08
site O 0 5.8269864489091105e-09
upstream O 0 3.9364825288323857e-10
of O 0 3.055727892942173e-11
the O 0 1.0758876012317842e-09
CTG O 0 1.126583811128512e-06
repeat O 0 2.871458377740055e-07
and O 0 1.6217787113248505e-09
for O 0 6.653985695770359e-11
a O 0 8.632049519619045e-10
significant O 0 1.0654482851535363e-09
reduction O 0 1.659656412300592e-08
of O 0 4.453085122868572e-11
this O 0 5.611178188758004e-10
interaction O 0 1.634046564724656e-09
in O 0 1.1546272382645384e-08
cells O 0 8.538471263364045e-09
with O 0 1.681311867507418e-09
a O 0 1.9235545778428786e-07
hypermethylated O 0 6.010780271026306e-05
DMPK O 0 1.9943716324632987e-05
gene O 0 6.924842921307572e-08
. O 0 8.538389550949432e-09
. O 0 7.174362792738975e-08

The O 0 7.4848085205303505e-06
hemochromatosis B-Disease 1 0.9999058246612549
gene O 0 9.813385076995473e-06
product O 0 2.755561752110225e-07
complexes O 0 2.6610547365635284e-07
with O 0 1.9180868005008733e-09
the O 0 1.158600415607225e-08
transferrin O 0 2.043321364908479e-05
receptor O 0 4.529459545210557e-07
and O 0 2.0374717024651545e-08
lowers O 0 6.803589940318489e-07
its O 0 1.4423347238778916e-10
affinity O 0 5.606110242695195e-09
for O 0 5.656880519566698e-10
ligand O 0 1.6350159057765268e-06
binding O 0 4.14921305491589e-06
. O 0 3.110657473825995e-07

We O 0 3.0885398700775113e-06
recently O 0 1.3238064866527566e-06
reported O 0 6.931568918844278e-08
the O 0 7.515577604699786e-10
positional O 0 8.217935487664363e-08
cloning O 0 1.8944328772363406e-08
of O 0 1.3141726595833347e-10
a O 0 2.9681531898972935e-08
candidate O 0 8.988947229227051e-06
gene O 0 2.5499978164589265e-06
for O 0 1.9245549992774613e-05
hereditary B-Disease 1 0.9999997615814209
hemochromatosis I-Disease 1 1.0
called O 1 0.7384074330329895
HFE O 1 0.995900571346283
. O 0 6.9156367317191325e-06

The O 0 5.346024423147355e-08
gene O 0 1.1437711577855225e-07
product O 0 3.1546569800866564e-08
, O 0 5.948305736858117e-10
a O 0 3.0095272940400264e-09
member O 0 1.97913974098185e-09
of O 0 1.9582385712979544e-10
the O 0 4.333165382064408e-09
major O 0 1.1399500010611519e-07
histocompatibility O 0 7.95198357081972e-05
complex O 0 1.1950839962082682e-06
class O 0 2.337963707077506e-07
I O 0 2.4520752504031407e-06
- O 0 1.8504007925912447e-07
like O 0 9.53605994169493e-09
family O 0 9.801119915664458e-09
, O 0 1.2047807196324811e-09
was O 0 9.592066163577329e-08
found O 0 1.17245884112549e-08
to O 0 2.685903721655336e-09
have O 0 9.769465236786345e-09
a O 0 4.363506178606258e-08
mutation O 0 9.942675660568057e-07
, O 0 3.1762394936407645e-09
Cys O 0 1.4647445141235949e-06
- O 0 1.701102974038804e-07
282 O 0 1.6731901197886145e-08
- O 0 3.915603883797303e-05
- O 0 0.0005363114178180695
> O 0 6.587333132301865e-07
Tyr O 0 7.975082212396956e-07
( O 0 5.823850290909149e-10
C282Y O 0 1.4762782107879957e-08
) O 0 4.377528894927707e-11
, O 0 2.2014872563813626e-11
in O 0 1.1538400790378489e-10
85 O 0 4.807667597361842e-10
% O 0 5.462805208189536e-10
of O 0 3.975077156326279e-09
patient O 0 3.9262606151169166e-05
chromosomes O 0 3.7751942727481946e-05
. O 0 8.699441877979552e-07

This O 0 3.218691233541904e-07
mutation O 0 2.151475428036065e-06
eliminates O 0 7.942550723782915e-07
the O 0 4.0897454312016635e-09
ability O 0 2.0908515807605e-08
of O 0 9.797189726157285e-10
HFE O 0 0.0003056308487430215
to O 0 1.2728037290798966e-08
associate O 0 1.672762550697371e-08
with O 0 5.174134898311422e-09
beta2 O 0 0.0001543178950669244
- O 0 0.00035813148133456707
microglobulin O 0 0.00012319846427999437
( O 0 3.796294834046421e-09
beta2m O 0 1.7054024965545977e-06
) O 0 3.2256594617585677e-10
and O 0 1.2878506039371018e-09
prevents O 0 1.3911984453329751e-08
cell O 0 1.6111715012812056e-05
- O 0 0.00018827593885362148
surface O 0 0.0010346758645027876
expression O 0 1.2522613360488322e-05
. O 0 5.217992224970658e-07

A O 0 1.2956193131685723e-06
second O 0 1.6355447485238983e-07
mutation O 0 1.6463707652292214e-05
that O 0 7.323919959389968e-08
has O 0 2.785993480358684e-08
no O 0 1.9396097172830196e-08
effect O 0 2.4659005504190645e-08
on O 0 8.789425010036211e-08
beta2m O 0 0.00021951507369522005
association O 0 9.804597134177584e-09
, O 0 5.934016056308167e-10
H63D O 0 2.5183867364830803e-06
, O 0 6.346472236629097e-10
was O 0 7.402990576110824e-08
found O 0 1.8467650519937706e-08
in O 0 7.577760086086016e-10
eight O 0 3.581815954945e-10
out O 0 6.812772013198298e-10
of O 0 1.768749868791275e-10
nine O 0 1.6886723130937753e-08
patients O 0 1.6775681288550004e-08
heterozygous O 0 2.9462123407597574e-08
for O 0 7.7664036313152e-10
the O 0 9.033951364756376e-09
C282Y O 0 2.3409518234984716e-06
mutant O 0 4.47369484390947e-06
. O 0 3.3840919400063285e-07

In O 0 4.1472330281067116e-07
this O 0 1.206602728842654e-08
report O 0 1.0700719421663507e-08
, O 0 2.8168423149566024e-10
we O 0 1.0417403606410858e-09
demonstrate O 0 3.4642615442948e-09
in O 0 1.1440625113934288e-09
cultured O 0 5.34332343704591e-07
293 O 0 6.848632949640887e-08
cells O 0 1.4254865732254984e-07
overexpressing O 0 9.386409374201321e-07
wild O 0 6.086236226110486e-08
- O 0 3.4086021969415015e-06
type O 0 2.7203823265153915e-06
or O 0 3.2123885773671645e-08
mutant O 0 6.21117919763492e-07
HFE O 0 5.607328148471424e-06
proteins O 0 1.7200376678516704e-09
that O 0 1.5994783275630198e-10
both O 0 7.243734778672462e-11
the O 0 7.384552414002599e-10
wild O 0 1.5953126819567842e-07
- O 0 6.734178168699145e-05
type O 0 6.0042948462069035e-05
and O 0 1.1896008800249547e-06
H63D O 0 0.003744045738130808
HFE O 0 0.00010143880354007706
proteins O 0 1.7618560832488583e-08
form O 0 4.9119112333073645e-08
stable O 0 1.1212031267859857e-06
complexes O 0 1.38354621981307e-07
with O 0 5.155811333423799e-09
the O 0 4.734463487920948e-08
transferrin O 0 9.409491758560762e-05
receptor O 0 7.164760518207913e-06
( O 0 7.027027493222704e-08
TfR O 0 0.00010502048098715022
) O 0 7.063333917756154e-09
. O 0 5.86823460935193e-08

The O 0 2.048511760222027e-07
C282Y O 0 6.184891844895901e-06
mutation O 0 2.823762997650192e-06
nearly O 0 3.4386484770720926e-08
completely O 0 1.0997442245752609e-07
prevents O 0 1.4904870226928324e-08
the O 0 1.8327489526015484e-09
association O 0 7.215842368069048e-10
of O 0 3.4997695713689936e-11
the O 0 1.775961377958879e-09
mutant O 0 9.746239584274008e-07
HFE O 0 2.9792596251354553e-05
protein O 0 3.277959592651314e-08
with O 0 3.94042087847879e-09
the O 0 2.887324797029578e-07
TfR O 0 0.003205101005733013
. O 0 4.259491959146544e-07

Studies O 0 8.571678904445434e-07
on O 0 5.269289360398943e-08
cell O 0 4.760805950354552e-06
- O 0 2.6348467144998722e-05
associated O 0 5.4636235091720664e-08
transferrin O 0 2.5409285626665223e-06
at O 0 1.3583079550016919e-08
37 O 0 4.5062082953961635e-09
degrees O 0 4.595946734298195e-08
C O 0 3.179351040216716e-07
suggest O 0 2.6380224227295912e-08
that O 0 1.3855837588394593e-09
the O 0 2.4772037754416942e-09
overexpressed O 0 3.308034365545609e-06
wild O 0 5.420628781394043e-07
- O 0 5.8534522395348176e-05
type O 0 2.8744016162818298e-05
HFE O 0 2.108483386109583e-05
protein O 0 3.596305120368015e-08
decreases O 0 2.0796276700707494e-08
the O 0 1.3197641590689813e-10
affinity O 0 1.102402524821855e-08
of O 0 5.013028325784319e-10
the O 0 4.4628446715933023e-08
TfR O 0 0.00014932492922525853
for O 0 7.193858841958445e-09
transferrin O 0 6.399467383744195e-05
. O 0 3.470752005796385e-07

The O 0 4.279271479390445e-07
overexpressed O 0 4.6450022637145594e-05
H63D O 0 4.291894583730027e-05
protein O 0 3.1000524813862285e-07
does O 0 2.550118338717766e-08
not O 0 9.824810964786934e-10
have O 0 5.266992397778836e-10
this O 0 5.861394147821386e-10
effect O 0 5.857309304246883e-08
, O 0 1.9415989649385068e-10
providing O 0 5.3640741154437066e-11
the O 0 6.4971202029529e-11
first O 0 1.2483626632420197e-10
direct O 0 7.040463767538085e-10
evidence O 0 1.7452698841680103e-08
for O 0 8.086725733491562e-10
a O 0 4.005698528430912e-08
functional O 0 9.1622460729468e-08
consequence O 0 2.8243880123568488e-08
of O 0 2.051226272170581e-10
the O 0 1.856866660432388e-08
H63D O 0 0.0015816249651834369
mutation O 0 1.3415994544629939e-05
. O 0 3.186411561273417e-07

Addition O 0 3.626288958002988e-07
of O 0 2.0273191125852463e-08
soluble O 0 1.69737159012584e-05
wild O 0 1.281054892388056e-06
- O 0 0.0007629577885381877
type O 0 0.002593997400254011
HFE O 0 0.05456274002790451
/ O 0 6.165475497255102e-06
beta2m O 0 5.763570243288996e-06
heterodimers O 0 1.7163374650408514e-06
to O 0 6.3364602453930274e-09
cultured O 0 2.5097742764046416e-06
cells O 0 2.4695867750779144e-07
also O 0 8.327817546671668e-09
decreased O 0 2.550536670753445e-08
the O 0 9.999377020841749e-11
apparent O 0 3.008977600416074e-08
affinity O 0 4.5781600732652805e-08
of O 0 6.222343196249369e-10
the O 0 3.247764013281085e-08
TfR O 0 1.4156893485051114e-05
for O 0 4.749099030698645e-11
its O 0 7.235104876324172e-11
ligand O 0 2.5767702638290757e-08
under O 0 5.740105724072464e-09
steady O 0 1.0922682349701063e-06
- O 0 0.0001221511629410088
state O 0 6.88722394670549e-08
conditions O 0 2.0101049358345335e-07
, O 0 1.7294583820604004e-10
both O 0 9.697164599087316e-11
in O 0 2.1267032579430634e-09
293 O 0 2.6827768451198608e-08
cells O 0 4.7989320961505655e-08
and O 0 2.138631138848268e-08
in O 0 7.14378955990469e-08
HeLa O 0 3.7368794437497854e-05
cells O 0 2.0827931166422786e-06
. O 0 1.8335825302528974e-07

Furthermore O 0 2.077288399959798e-06
, O 0 1.2599554732872775e-09
at O 0 6.089366233474891e-10
4 O 0 8.497086922965025e-10
degrees O 0 2.9951266355965345e-08
C O 0 5.298581982060568e-07
, O 0 5.025713734063686e-10
the O 0 2.1467301269950667e-09
added O 0 9.504920939207295e-08
soluble O 0 6.870363336020091e-07
complex O 0 2.3287348938083596e-08
of O 0 5.855262497078684e-09
HFE O 0 0.016725219786167145
/ O 0 9.670835652286769e-07
beta2m O 0 5.281766561893164e-07
inhibited O 0 4.184585478128611e-08
binding O 0 6.989877121554855e-09
of O 0 2.087741091116868e-10
transferrin O 0 1.6844250012582052e-06
to O 0 1.3134272336401409e-08
HeLa O 0 9.263613719667774e-06
cell O 0 1.759332553774584e-05
TfR O 0 5.857032010680996e-05
in O 0 1.3978579405105052e-09
a O 0 2.796726938925076e-08
concentration O 0 7.347402424784377e-05
- O 0 8.703107596375048e-05
dependent O 0 2.4199042059080966e-07
manner O 0 4.366421762824757e-06
. O 0 5.50971037682757e-07

Scatchard O 0 3.799990372499451e-05
plots O 0 1.3069519582131761e-06
of O 0 3.516608559905876e-09
these O 0 8.148068331159664e-10
data O 0 1.5154494548141884e-08
indicate O 0 1.0818727247396964e-07
that O 0 1.7382826289491504e-09
the O 0 1.0376235426434732e-09
added O 0 1.6151242121509313e-08
heterodimer O 0 1.2733763696815004e-06
substantially O 0 1.382332897037486e-07
reduced O 0 2.9476834306763067e-09
the O 0 1.419648287814823e-10
affinity O 0 1.3777416540960985e-08
of O 0 3.223588729284188e-09
TfR O 0 3.5520562960300595e-05
for O 0 9.387106203462281e-09
transferrin O 0 0.00010695016680983827
. O 0 4.2043222947540926e-07

These O 0 1.1443887615314452e-07
results O 0 2.6768271155219736e-08
establish O 0 8.924956773626036e-09
a O 0 3.1565349445372703e-08
molecular O 0 9.611067071091384e-06
link O 0 2.0584164303727448e-05
between O 0 2.1751831980054703e-07
HFE O 0 0.04453996941447258
and O 0 2.1028016661261972e-08
a O 0 1.6211858522297007e-08
key O 0 1.1130850019469563e-08
protein O 0 3.311730445432204e-09
involved O 0 1.1612103500979742e-09
in O 0 1.2530875004301834e-08
iron O 0 0.048504430800676346
transport O 0 2.137478531949455e-06
, O 0 2.6770046179791507e-09
the O 0 4.0367287290621334e-09
TfR O 0 6.86670100549236e-05
, O 0 4.3232814550542287e-10
and O 0 1.570638064052332e-09
raise O 0 5.410297987396007e-09
the O 0 4.153189181455019e-10
possibility O 0 5.182609008613781e-09
that O 0 2.3326411913160428e-09
alterations O 0 3.103805923387881e-08
in O 0 2.374437535479501e-09
this O 0 1.517030612241399e-09
regulatory O 0 5.7334457181923426e-08
mechanism O 0 2.1868395094770676e-07
may O 0 7.243868935802311e-07
play O 0 1.19630605421861e-09
a O 0 2.825243150539336e-09
role O 0 7.98033017446187e-09
in O 0 4.752447324563036e-09
the O 0 2.5477945087004628e-08
pathogenesis O 0 7.720382200204767e-06
of O 0 2.014308620346128e-06
hereditary B-Disease 1 0.9999997615814209
hemochromatosis I-Disease 1 1.0
. O 0 0.0005282578058540821
. O 0 2.757769834715873e-06

Genomic O 0 2.3507247533416376e-05
organization O 0 1.437124552694513e-07
of O 0 1.6161803007008757e-09
the O 0 2.070287408173499e-08
UBE3A O 0 0.000728911894839257
/ O 0 1.0839132301043719e-05
E6 O 0 0.00015593032003380358
- O 0 0.0021278478670865297
AP O 0 9.20841375773307e-06
gene O 0 7.389674294699944e-08
and O 0 1.6239029676512473e-08
related O 0 1.9892249270014872e-07
pseudogenes O 0 2.7670994313666597e-05
. O 0 1.0450384024807136e-06

The O 0 4.293644622066495e-07
UBE3A O 0 4.8428195441374555e-05
gene O 0 2.649813382049615e-07
encodes O 0 1.5472714665065723e-07
the O 0 1.2929880277567918e-08
E6 O 0 4.1384224459761754e-05
- O 0 0.0010542620439082384
AP O 0 6.458022198785329e-06
ubiquitin O 0 1.7825230713697238e-07
- O 0 5.638239599647932e-07
protein O 0 7.2941119810820965e-09
ligase O 0 1.0818829565550914e-07
and O 0 4.194276037594591e-09
has O 0 7.830307069411901e-09
recently O 0 4.447404933216603e-08
been O 0 1.1930504584256596e-08
shown O 0 3.054042707617555e-08
to O 0 1.6111788569972418e-09
be O 0 1.0337660114601022e-06
mutated O 0 0.0007711649523116648
in O 0 0.35281890630722046
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 0 0.00016143401444423944
who O 0 2.182257048843894e-06
lack O 0 5.966042522231874e-07
15q11 O 0 3.871346052619629e-06
- O 0 1.0820912393683102e-05
q13 O 0 3.2792550541671517e-07
deletions O 0 1.347857960354304e-06
or O 0 4.943609042129538e-07
chromosome O 0 4.442771023605019e-05
15 O 0 4.355012777068623e-07
paternal O 0 0.0005167880444787443
uniparental B-Disease 0 0.328324556350708
disomy I-Disease 0 0.01123097538948059
. O 0 4.3731647565437015e-06

Previous O 0 2.504499889255385e-06
UBE3A O 0 6.318862870102748e-05
cDNA O 0 1.6223664260905934e-06
analysis O 0 3.4950892313645454e-07
has O 0 1.079474998277874e-08
shown O 0 8.573214138607455e-09
a O 0 7.614173291869974e-09
coding O 0 2.1002928463076387e-07
region O 0 2.839450896630069e-09
of O 0 3.357509270607295e-10
approximately O 0 6.460425527876623e-09
2 O 0 4.5107427126822586e-08
. O 0 9.156759261941261e-08

6 O 0 6.942001391507802e-07
kb O 0 7.4016384132846724e-06
and O 0 2.9550534463851363e-08
a O 0 1.224071866090526e-07
3 O 0 1.2127428306030197e-07
- O 0 0.0029750140383839607
untranslated O 0 0.0002616137790028006
region O 0 1.2104987945349421e-07
( O 0 2.469702664598117e-09
UTR O 0 2.36159621636034e-07
) O 0 3.658769467951295e-11
of O 0 6.651549450120697e-11
< O 0 1.347565898868197e-07
50 O 0 1.2476135680117295e-09
bp O 0 3.2917569114943035e-07
, O 0 2.538909360527697e-10
whereas O 0 2.127267251239573e-09
Northern O 0 9.32338317660708e-10
analysis O 0 2.4128785636179373e-09
has O 0 1.4435875828056055e-09
indicated O 0 3.7401988173257905e-09
mRNA O 0 8.690745900707952e-10
sizes O 0 3.742039567100619e-09
of O 0 1.5030754418887682e-10
5 O 0 5.681526360490352e-09
- O 0 5.2953209888073616e-06
8 O 0 1.0128864147418426e-07
kb O 0 0.00013177507207728922
. O 0 1.082291191778495e-06

We O 0 3.263972985223518e-07
have O 0 2.232335427621024e-09
analyzed O 0 1.7192438583890635e-09
additional O 0 9.873045436759043e-11
cDNA O 0 4.394046460021173e-09
clones O 0 2.051752545639829e-08
and O 0 1.925682058256939e-09
provide O 0 9.070913464803709e-10
evidence O 0 5.2438702269341775e-09
for O 0 3.0998625888400966e-10
an O 0 3.3099101237610284e-10
additional O 0 7.963286030587824e-09
0 O 0 7.907755872338385e-08
. O 0 1.487267269340009e-07

5 O 0 1.594987111275259e-07
kb O 0 2.659550091266283e-06
of O 0 6.996799584157998e-09
5 O 0 3.311934193561683e-08
- O 0 2.9065609851386398e-05
UTR O 0 6.6082884586649016e-06
and O 0 4.5867407649780034e-09
> O 0 9.42665145942101e-09
2 O 0 9.424273583746867e-10
kb O 0 3.7026808286100277e-07
of O 0 3.707483875459161e-09
3 O 0 2.9512301580325584e-07
- O 0 0.011158452369272709
UTR O 0 0.0002052316121989861
. O 0 2.654690263170778e-07

We O 0 1.2358583489913144e-06
have O 0 5.008214287727242e-09
established O 0 9.81319914217238e-10
the O 0 3.945502813351709e-10
genomic O 0 3.649386925985709e-08
organization O 0 1.136767013854012e-09
of O 0 2.3167795459855256e-10
UBE3A O 0 9.277379831473809e-06
and O 0 1.4131705805553452e-09
the O 0 9.141041396043548e-11
sequence O 0 9.980403170573027e-10
of O 0 2.777538476994579e-10
intron O 0 2.416122515569441e-05
- O 0 0.00010828143422259018
exon O 0 2.6527297450229526e-05
borders O 0 1.2827896398448502e-06
. O 0 3.445904326326854e-07

We O 0 9.276204764319118e-07
have O 0 2.2195614235442918e-08
also O 0 1.6772344624271796e-09
mapped O 0 4.2135582134505967e-07
two O 0 6.081148362646616e-10
highly O 0 9.091634112223801e-09
homologous O 0 4.773407624725223e-08
processed O 0 1.201850921006553e-07
pseudogenes O 0 9.261531204174389e-07
, O 0 1.6195964569476473e-09
UBE3AP1 O 0 3.0067574243730633e-06
and O 0 5.474219300083405e-09
UBE3AP2 O 0 3.6477490539255086e-06
, O 0 1.6928726476184153e-10
to O 0 6.380270617389883e-11
chromosomes O 0 8.428683528904912e-09
2 O 0 6.777531869062159e-10
and O 0 1.0965977459420628e-08
21 O 0 7.231083731795707e-09
, O 0 1.8284926905920429e-09
respectively O 0 5.237705735794407e-08
, O 0 1.4179361018662462e-09
and O 0 7.034105742320662e-09
determined O 0 1.7481742986547033e-07
their O 0 4.827020561037898e-09
genomic O 0 3.8960538972787617e-07
organization O 0 4.232927253156049e-08
. O 0 1.021775375420475e-07

These O 0 9.604441686406062e-08
results O 0 6.767152171960333e-08
will O 0 3.1560634106142516e-09
form O 0 8.648232685537494e-10
the O 0 1.7518084205470075e-10
basis O 0 6.435591504150295e-10
for O 0 2.2171049718355818e-10
studies O 0 7.598659479413072e-10
of O 0 3.237549672796547e-10
mutation O 0 6.246452244340617e-07
and O 0 7.320620998285676e-09
imprinting O 0 3.564887492757407e-06
of O 0 3.850193053267503e-08
UBE3A O 0 0.0026168867480009794
. O 0 7.559547725577431e-07

Mutation O 0 0.000690307526383549
spectrum O 0 5.529574627871625e-05
and O 0 4.7674754455329094e-07
genotype O 0 0.012706917710602283
- O 0 0.011161187663674355
phenotype O 0 0.0009344808058813214
analyses O 0 1.3649816537508741e-05
in O 0 1.8718285446084337e-06
Cowden B-Disease 1 0.9950541257858276
disease I-Disease 0 0.055299337953329086
and O 0 1.3119523828208912e-05
Bannayan B-Disease 1 0.9981822967529297
- I-Disease 1 0.9999908208847046
Zonana I-Disease 1 0.9999842643737793
syndrome I-Disease 1 0.9999829530715942
, O 0 1.610218731684654e-07
two O 0 5.735271315643331e-07
hamartoma B-Disease 1 0.9825038313865662
syndromes I-Disease 0 0.2174815982580185
with O 0 1.500114763075544e-06
germline O 0 0.19462229311466217
PTEN O 1 0.700770378112793
mutation O 0 0.0005729967379011214
. O 0 1.7646594869802357e-06

The O 0 6.049345302017173e-06
tumour B-Disease 1 0.999764621257782
suppressor O 0 0.005547432694584131
gene O 0 5.607727143797092e-05
PTEN O 0 0.0023048368748277426
, O 0 1.8831928016993515e-08
which O 0 3.1492985996806055e-09
maps O 0 1.488382395109511e-07
to O 0 2.258043352298955e-08
10q23 O 0 2.7608102755039e-05
. O 0 5.909467404308089e-07

3 O 0 1.193216974115785e-07
and O 0 1.2541173655122861e-09
encodes O 0 9.293860792070063e-09
a O 0 4.659593599853906e-09
403 O 0 3.1103291053824478e-09
amino O 0 2.275370114546149e-09
acid O 0 1.0555556428926138e-08
dual O 0 6.273317012528423e-07
specificity O 0 7.863895916671026e-06
phosphatase O 0 0.12662777304649353
( O 0 1.3204755511253552e-08
protein O 0 1.1560270252175542e-07
tyrosine O 0 6.6636621340876445e-06
phosphatase O 0 0.09651346504688263
; O 0 6.711007216608778e-08
PTPase O 0 1.7889919035951607e-05
) O 0 1.659184012403614e-09
, O 0 1.0335349243106862e-09
was O 0 4.0979080040415283e-07
shown O 0 9.239229825652728e-07
recently O 0 2.5828921934589744e-07
to O 0 1.7719147260564228e-09
play O 0 3.4690819106231174e-09
a O 0 5.9793401341323715e-09
broad O 0 1.3595936820820498e-08
role O 0 4.7182012963276065e-08
in O 0 1.0460659183308962e-07
human O 0 8.096516239675111e-07
malignancy B-Disease 0 0.013675546273589134
. O 0 9.449550475437718e-07

Somatic O 0 0.0003765522560570389
PTEN O 0 0.0037289683241397142
deletions O 0 0.0001306909107370302
and O 0 5.75936610403005e-07
mutations O 0 5.042511020292295e-06
were O 0 5.9548394659714177e-08
observed O 0 3.721748385032697e-07
in O 0 9.385888510848872e-09
sporadic B-Disease 0 4.84228839923162e-05
breast I-Disease 1 0.9984738230705261
, I-Disease 0 2.5660236133262515e-05
brain I-Disease 1 0.834717869758606
, I-Disease 0 2.892215889005456e-06
prostate I-Disease 1 0.9899635910987854
and I-Disease 0 0.009551497176289558
kidney I-Disease 1 0.9363955855369568
cancer I-Disease 0 0.17233633995056152
cell O 0 0.0009386511519551277
lines O 0 6.806805322412401e-05
and O 0 6.771606564370813e-08
in O 0 4.448267532097816e-09
several O 0 6.282019349157508e-09
primary O 0 0.0019141947850584984
tumours B-Disease 1 0.9999918937683105
such O 0 7.373960215772968e-07
as O 0 9.519089508103207e-05
endometrial B-Disease 1 0.9999580383300781
carcinomas I-Disease 1 0.9999998807907104
, O 1 0.9501134753227234
malignant B-Disease 1 0.9999998807907104
melanoma I-Disease 1 1.0
and O 1 0.9996863603591919
thyroid B-Disease 1 0.9999924898147583
tumours I-Disease 1 0.9999959468841553
. O 0 0.00018812845519278198

In O 0 2.018376505930064e-07
addition O 0 4.584337887081347e-08
, O 0 2.1765897528780442e-08
PTEN O 0 0.00021618095343001187
was O 0 1.305311570831691e-06
identified O 0 3.7390165630313277e-07
as O 0 1.0469393130208005e-09
the O 0 1.4139821535863462e-09
susceptibility O 0 1.9107879779767245e-05
gene O 0 1.1212122785764222e-07
for O 0 1.4412800730667641e-08
two O 0 5.4137144616106525e-06
hamartoma B-Disease 1 0.9997876286506653
syndromes I-Disease 1 0.9998757839202881
Cowden B-Disease 1 0.999914288520813
disease I-Disease 1 0.9755895733833313
( O 0 1.5148648913054785e-07
CD B-Disease 0 0.000608533329796046
; O 0 3.6395096003616345e-07
MIM O 0 6.579307955689728e-05
158350 O 0 1.0610460776661057e-06
) O 0 1.877682676010295e-09
and O 0 7.092117471074744e-08
Bannayan B-Disease 0 0.0039036492817103863
- I-Disease 0 0.3940671384334564
Zonana I-Disease 0 0.01924416422843933
( I-Disease 0 1.9563291431268226e-08
BZS I-Disease 0 4.0753375287749805e-06
) I-Disease 0 1.304996222195598e-09
or I-Disease 0 1.735070576103226e-08
Ruvalcaba I-Disease 0 5.084961230750196e-05
- I-Disease 0 0.0002264164504595101
Riley I-Disease 0 3.3443477150285617e-05
- I-Disease 1 0.9606110453605652
Smith I-Disease 0 0.040933992713689804
syndrome I-Disease 1 0.9986292123794556
( O 0 1.0305300435220488e-07
MIM O 0 0.000526060932315886
153480 O 0 1.716812766971998e-05
) O 0 2.1423707252665736e-08
. O 0 1.4230784017854603e-07

Constitutive O 0 5.925335699430434e-06
DNA O 0 1.5293429669327452e-06
from O 0 1.0121309124144773e-08
37 O 0 8.150745856028152e-09
CD B-Disease 0 2.803670213324949e-06
families O 0 1.6238317357419874e-08
and O 0 1.506357349967402e-08
seven O 0 2.9195735606890594e-08
BZS B-Disease 0 2.718390169320628e-05
families O 0 8.326720646323338e-09
was O 0 5.053565388379866e-08
screened O 0 3.991919129475718e-06
for O 0 8.945838203544554e-08
germline O 0 0.0004109809233341366
PTEN O 0 0.004628210794180632
mutations O 0 3.156244201818481e-05
. O 0 6.066753712730133e-07

PTEN O 0 0.04677652567625046
mutations O 0 0.00020852507441304624
were O 0 9.763843422661012e-08
identified O 0 1.322261766745214e-07
in O 0 1.151367445828555e-09
30 O 0 3.304762574707354e-10
of O 0 6.011306730169252e-11
37 O 0 3.8308014538301904e-09
( O 0 6.911325400871249e-10
81 O 0 4.301814904295043e-09
% O 0 9.432761238770127e-10
) O 0 2.6935567665198334e-10
CD B-Disease 0 1.7757797650119755e-06
families O 0 3.492111488867522e-09
, O 0 4.947334764082711e-10
including O 0 2.3434196805283136e-09
missense O 0 2.013030825764872e-05
and O 0 4.805339699487376e-07
nonsense O 0 1.5334775525843725e-05
point O 0 1.7083537784401415e-07
mutations O 0 6.791046303078474e-07
, O 0 6.998638335531382e-10
deletions O 0 1.1602793392739841e-07
, O 0 2.344644700613685e-09
insertions O 0 8.903942898541573e-07
, O 0 1.2489563827600136e-09
a O 0 3.2503297830999145e-08
deletion O 0 6.195671630848665e-06
/ O 0 3.4825532111426583e-06
insertion O 0 3.618298478613724e-07
and O 0 2.320740861705417e-07
splice O 0 4.450659253052436e-05
site O 0 4.388092565932311e-05
mutations O 0 2.470824620104395e-05
. O 0 6.050858587514085e-07

These O 0 2.255930127148531e-07
mutations O 0 3.4507622785895364e-06
were O 0 6.674750530066831e-09
scattered O 0 6.474945024592671e-09
over O 0 1.7857848533253673e-09
the O 0 1.381245673393039e-09
entire O 0 7.765918574875741e-09
length O 0 8.912390114801383e-08
of O 0 9.499312447758257e-10
PTEN O 0 6.659149948973209e-05
, O 0 4.4998249570937787e-10
with O 0 1.6430119764709872e-10
the O 0 4.836860911794361e-10
exception O 0 1.5474884706989656e-09
of O 0 3.716251958940653e-11
the O 0 7.302808358033985e-10
first O 0 1.903012325499276e-08
, O 0 5.63947422094202e-09
fourth O 0 1.824014503881699e-07
and O 0 1.7849386324542138e-07
last O 0 8.697269322510692e-07
exons O 0 2.1476503206940833e-06
. O 0 4.314101147429028e-07

A O 0 3.2228022064373363e-06
hot O 0 7.5022599048679695e-06
spot O 0 3.478968210401945e-06
for O 0 1.6342623254672617e-08
PTEN O 0 0.0002760062925517559
mutation O 0 1.6387405139539624e-06
in O 0 4.270276132700701e-09
CD B-Disease 0 8.573299965064507e-06
was O 0 1.5480169395232224e-06
identified O 0 3.7996221635694383e-07
in O 0 1.1033991498266005e-09
exon O 0 1.1493953024910297e-06
5 O 0 3.9241228044772924e-09
that O 0 1.7400539897849399e-09
contains O 0 4.414617282844091e-10
the O 0 1.5128466257507966e-09
PTPase O 0 9.248477113033005e-07
core O 0 4.7009987014234866e-08
motif O 0 5.892708543342451e-08
, O 0 2.580523815465252e-11
with O 0 6.270448743572743e-11
13 O 0 9.890065155726546e-11
of O 0 3.103274581750526e-11
30 O 0 1.2535672500035844e-09
( O 0 4.3050138454070463e-10
43 O 0 7.924084721722124e-10
% O 0 7.975304860963206e-10
) O 0 3.485561561600292e-10
CD B-Disease 0 4.608491053659236e-06
mutations O 0 7.184536343629588e-07
identified O 0 1.7131473839526734e-07
in O 0 1.0198241362502358e-08
this O 0 1.876666821942763e-08
exon O 0 5.4134117817739025e-05
. O 0 1.3479325389198493e-06

Seven O 0 3.5494952754788756e-08
of O 0 9.498769548699215e-10
30 O 0 1.5644878725851186e-09
( O 0 3.6599157038352814e-10
23 O 0 1.2055945131095314e-09
% O 0 4.5699372064333943e-10
) O 0 2.2616875039460638e-10
were O 0 8.955087338335943e-09
within O 0 2.6128466057429023e-10
the O 0 4.333379877152765e-09
core O 0 1.0541441497480264e-06
motif O 0 1.5263574368873378e-06
, O 0 3.242153212568155e-10
the O 0 2.8630572912469177e-10
majority O 0 2.378199415176141e-09
( O 0 1.0282216050816473e-10
five O 0 5.636414945886514e-11
of O 0 6.837307109375246e-11
seven O 0 1.726756515552097e-09
) O 0 1.4288464855738425e-10
of O 0 9.427576774800883e-11
which O 0 7.447304994911974e-08
were O 0 1.9049407455895562e-06
missense O 0 0.0018381507834419608
mutations O 0 7.445212759193964e-06
, O 0 5.305572425839955e-09
possibly O 0 3.154343986011554e-08
pointing O 0 8.649065819099633e-08
to O 0 5.190560203871541e-10
the O 0 4.990656221615097e-10
functional O 0 1.4617921095805286e-08
significance O 0 1.7176027711229835e-08
of O 0 3.7852809775529295e-10
this O 0 2.5384958135532543e-08
region O 0 1.604103232466514e-07
. O 0 3.026914328074781e-07

Germline O 0 0.026582764461636543
PTEN O 0 0.07078248262405396
mutations O 0 0.00027858393150381744
were O 0 2.2359294860052614e-07
identified O 0 4.6718724888705765e-07
in O 0 3.3003610955262275e-09
four O 0 3.80919629172638e-10
of O 0 2.0813559209464927e-10
seven O 0 6.671784902323452e-09
( O 0 2.086524064637274e-09
57 O 0 1.3029824330601514e-08
% O 0 3.948922966401369e-09
) O 0 5.647137868436403e-09
BZS B-Disease 0 6.433390808524564e-06
families O 0 1.9596528844090244e-08
studied O 0 4.2088234408765857e-07
. O 0 5.238714493316365e-07

Interestingly O 0 6.070782183087431e-05
, O 0 2.176539837250857e-08
none O 0 1.0881697320996864e-08
of O 0 1.8917915844962607e-10
these O 0 2.3184341113591245e-09
mutations O 0 2.1890137702484935e-07
was O 0 5.378624905461038e-07
observed O 0 1.6505811117895064e-07
in O 0 3.9914036520372065e-09
the O 0 1.0887905688150568e-08
PTPase O 0 1.7454820408602245e-05
core O 0 4.516623903327854e-06
motif O 0 8.553357474738732e-06
. O 0 2.6168723366026825e-07

It O 0 3.154341641220526e-07
is O 0 7.607162011424862e-09
also O 0 7.249226219308014e-10
worthy O 0 1.036551999789026e-08
of O 0 2.2876449345954342e-10
note O 0 5.123180812915962e-07
that O 0 4.3088110857070205e-09
a O 0 1.2872570565036767e-08
single O 0 3.4790835456988134e-07
nonsense O 0 1.7177735571749508e-06
point O 0 2.5566151862221886e-08
mutation O 0 1.1236786434665191e-07
, O 0 2.386350006489124e-10
R233X O 0 1.4208930920744933e-08
, O 0 6.411272068795881e-10
was O 0 5.820113813115313e-08
observed O 0 1.9684788910012685e-08
in O 0 5.442545858436176e-10
the O 0 1.1745263650553284e-09
germline O 0 3.0287336016954214e-07
DNA O 0 2.780908232580259e-07
from O 0 8.319446798132901e-10
two O 0 1.274357730451925e-09
unrelated O 0 1.8256591260978894e-07
CD B-Disease 0 4.349521259428002e-05
families O 0 1.0641490355567385e-08
and O 0 1.9269251083642303e-08
one O 0 7.730026396757239e-08
BZS B-Disease 0 7.592271140310913e-05
family O 0 3.216215134216327e-07
. O 0 2.334935658154791e-07

Genotype O 1 0.9328925609588623
- O 0 0.08262878656387329
phenotype O 0 0.04386819526553154
studies O 0 8.197644660867809e-07
were O 0 3.329097353343968e-08
not O 0 1.5976779010884457e-08
performed O 0 2.9839220871963335e-08
on O 0 1.937103100146942e-08
this O 0 1.9937491657628925e-09
small O 0 5.0971054044168795e-09
group O 0 1.5356253157960964e-08
of O 0 5.692547322411201e-09
BZS B-Disease 0 0.00010911801655311137
families O 0 1.640831612803595e-07
. O 0 1.8686272085233213e-07

However O 0 1.2983205124328379e-06
, O 0 6.066707669560856e-08
genotype O 0 0.00023873057216405869
- O 0 0.0005077567766420543
phenotype O 0 6.250649312278256e-05
analysis O 0 5.850152717812307e-08
inthe O 0 1.9563087789720157e-06
group O 0 1.3834136503021455e-08
of O 0 4.878322190648987e-10
CD B-Disease 0 2.9542297852458432e-05
families O 0 2.1938618033345847e-08
revealed O 0 7.335439136113564e-07
two O 0 6.630361815140873e-10
possible O 0 1.2088509748764409e-08
associations O 0 6.70881350472996e-10
worthy O 0 1.370000912714886e-08
of O 0 1.6147157222423658e-10
follow O 0 3.4731071352211984e-09
- O 0 8.939883855418884e-07
up O 0 1.2806546934029939e-08
in O 0 2.9360682773926783e-09
independent O 0 1.6938111357944763e-08
analyses O 0 1.306758804275887e-06
. O 0 1.8203652984993823e-07

The O 0 9.290461377986503e-08
first O 0 4.865568570266987e-08
was O 0 3.95813259501665e-07
an O 0 4.86400697496947e-09
association O 0 7.706997706691254e-09
noted O 0 8.890483904622215e-09
in O 0 5.245618384108752e-10
the O 0 1.1173622027627061e-09
group O 0 1.2411577321458367e-09
of O 0 1.2065001775418693e-10
CD B-Disease 0 2.3784425138728693e-05
families O 0 3.152732119815482e-08
with O 0 2.725861804719898e-06
breast B-Disease 1 0.9991401433944702
disease I-Disease 0 0.28743481636047363
. O 0 7.96370477473829e-06

A O 0 1.1416824463594821e-06
correlation O 0 2.505515112716239e-06
was O 0 7.811042905814247e-07
observed O 0 9.907278553100696e-08
between O 0 9.252821286942492e-10
the O 0 2.68324118479768e-09
presence O 0 2.5145416771010787e-07
/ O 0 8.46787429509277e-07
absence O 0 5.300353045356587e-09
of O 0 2.054989511890426e-10
a O 0 2.5591137386982155e-07
PTEN O 0 0.000607641413807869
mutation O 0 8.216593414545059e-07
and O 0 2.293067513647884e-09
the O 0 1.957619621961726e-09
type O 0 2.9486348012142116e-06
of O 0 7.855052075456115e-08
breast O 1 0.7802654504776001
involvement O 0 0.000229984667384997
( O 0 4.3380381953284086e-07
unaffected O 0 2.915869845310226e-05
versus O 0 0.00010189824388362467
benign O 0 0.0050451867282390594
versus O 0 0.007827538065612316
malignant O 1 0.5347544550895691
) O 0 2.3251494951637142e-07
. O 0 2.872189668323699e-07

Specifically O 0 7.200615073088557e-07
and O 0 9.336110551316779e-09
more O 0 2.586216241162731e-10
directly O 0 5.647407430586782e-09
, O 0 1.127395843347756e-09
an O 0 2.978745916593084e-09
association O 0 1.583534370297457e-08
was O 0 7.834931352590502e-07
also O 0 1.576674968362113e-08
observed O 0 1.7947490604797167e-08
between O 0 2.3712409813470003e-10
the O 0 6.540392116782812e-10
presence O 0 4.219478988432002e-09
of O 0 2.918880137592339e-10
a O 0 5.450585831567878e-07
PTEN O 0 0.006711434107273817
mutation O 0 5.6190699979197234e-05
and O 0 2.0512365153990686e-05
malignant B-Disease 1 0.9999027252197266
breast I-Disease 1 0.9999669790267944
disease I-Disease 1 0.9950343370437622
. O 0 2.9454165996867232e-05

Secondly O 0 0.0004144179983995855
, O 0 2.4783675556250273e-08
there O 0 6.048507472655729e-09
appeared O 0 1.115889318725749e-07
to O 0 3.5203597814614795e-09
be O 0 9.430467429183409e-08
an O 0 3.1929268118346954e-08
interdependent O 0 0.009522980079054832
association O 0 1.0495774205310227e-07
between O 0 1.518279013623669e-08
mutations O 0 2.5491900146334956e-07
upstream O 0 3.798228842555318e-09
and O 0 8.651449556751345e-10
within O 0 9.985540172507967e-11
the O 0 1.2497808343781003e-09
PTPase O 0 2.3599848191224737e-06
core O 0 3.86241822525335e-07
motif O 0 4.315451178626972e-07
, O 0 2.826190392823946e-10
the O 0 1.302789681689731e-10
core O 0 2.2809940602996903e-08
motif O 0 3.223252065254201e-08
containing O 0 1.6203379749057945e-09
the O 0 2.4425444999920387e-10
majority O 0 6.020110521198774e-10
of O 0 4.735009606626761e-10
missense O 0 0.0005054114735685289
mutations O 0 1.429650183126796e-05
, O 0 4.305960477068993e-09
and O 0 2.093987427898014e-09
the O 0 1.147616113250649e-09
involvement O 0 4.138074416459858e-08
of O 0 1.259294779565323e-09
all O 0 2.928305598004499e-09
major O 0 4.722819824110047e-08
organ O 0 0.0005914853536523879
systems O 0 1.9674840586958453e-05
( O 0 5.101890465653014e-09
central O 0 3.101255785509238e-08
nervous O 0 1.1164730494783726e-05
system O 0 1.0073690646095201e-05
, O 0 6.969164587644627e-07
thyroid O 0 0.44157442450523376
, O 0 4.3125299953317153e-07
breast O 0 0.24365460872650146
, O 0 1.5407265891553834e-05
skin O 1 0.989929735660553
and O 0 0.014171194285154343
gastrointestinal O 1 0.9997305274009705
tract O 1 0.9761244058609009
) O 0 7.095283081071102e-07
. O 0 5.72889689465228e-07

However O 0 5.697269216398126e-07
, O 0 1.7084891279495196e-09
these O 0 1.2606519994573517e-10
observations O 0 2.016444078378754e-08
would O 0 8.136657569934869e-09
need O 0 2.9523872235870385e-09
to O 0 1.890122502956615e-09
be O 0 7.237019872263772e-08
confirmed O 0 4.873518832937407e-08
by O 0 4.6053577618110353e-10
studying O 0 1.4940070292013274e-09
a O 0 1.311436514939146e-09
larger O 0 1.265002658179526e-09
number O 0 6.352540160570186e-10
of O 0 5.650895307240944e-10
CD B-Disease 0 6.0871294408570975e-05
families O 0 1.0368648162284444e-07
. O 0 2.1898009094911686e-07

Molecular O 1 0.8231549859046936
defects O 1 0.9944347739219666
leading O 0 1.1787403764174087e-06
to O 0 2.7974310867762142e-08
human O 0 1.6094941202027258e-07
complement B-Disease 0 4.518657078733668e-05
component I-Disease 1 0.9635231494903564
C6 I-Disease 1 0.9999998807907104
deficiency I-Disease 1 0.9999985694885254
in O 0 1.2666378168546544e-08
an O 0 3.3031635204849863e-09
African O 0 6.4047482872808814e-09
- O 0 5.45966177014634e-05
American O 0 2.6029465516330674e-07
family O 0 2.7491756782183074e-07
. O 0 2.753544379174855e-07

Complement B-Disease 0 0.0010446476517245173
component I-Disease 1 0.904682993888855
C6 I-Disease 1 0.9999983310699463
deficiency I-Disease 1 0.9999978542327881
( O 0 3.656863896139839e-07
C6D B-Disease 0 0.0007279428537003696
) O 0 8.868027201458517e-09
was O 0 1.4740793631062843e-05
diagnosed O 0 0.002686849096789956
in O 0 4.365992900545734e-09
a O 0 1.778917777528477e-07
16 O 0 1.3060976300494076e-08
- O 0 6.326044967863709e-06
year O 0 5.781533474191747e-08
- O 0 1.609541413927218e-06
old O 0 1.6986500668281224e-06
African O 0 1.966282692222876e-09
- O 0 3.0325481930049136e-06
American O 0 2.3815853467112902e-07
male O 0 4.731615263153799e-06
with O 0 5.504873115569353e-05
meningococcal B-Disease 1 0.999996542930603
meningitis I-Disease 1 0.9999744892120361
. O 0 1.8191069557360606e-06

The O 0 2.4585285700595705e-06
patients O 0 5.28853342984803e-06
father O 0 1.839707579165406e-06
and O 0 2.929983011767945e-08
two O 0 1.604619548345454e-08
brothers O 0 1.4299461099653854e-06
also O 0 1.0033741659754014e-07
had O 0 5.096437121210329e-07
C6D B-Disease 0 5.947241515968926e-05
, O 0 1.2025010986960183e-09
but O 0 8.715645427592733e-10
gave O 0 1.8120913658492555e-09
no O 0 2.21711999870422e-08
history O 0 1.0725300647607128e-08
of O 0 1.524910508976518e-08
meningitis B-Disease 1 0.9999114274978638
or O 0 1.61826548605859e-07
other O 0 3.27394822363658e-08
neisserial B-Disease 0 0.049627773463726044
infection I-Disease 0 0.020930301398038864
. O 0 5.198987764742924e-07

By O 0 2.166446222418017e-08
using O 0 1.4200180586954048e-08
exon O 0 6.013735287524469e-07
- O 0 2.1540158456900826e-07
specific O 0 1.3958944000691531e-09
polymerase O 0 2.4622018202080653e-08
chain O 0 2.703431789541355e-07
reaction O 0 3.3247189890062145e-08
( O 0 6.18129658569444e-10
PCR O 0 2.2462695881131367e-07
) O 0 1.4495141753556595e-09
/ O 0 3.716881380455561e-08
single O 0 1.3825464861838554e-07
- O 0 6.6154261730844155e-06
strand O 0 1.9008593881153502e-06
conformation O 0 3.895417648891453e-06
polymorphism O 0 1.969545110114268e-06
as O 0 3.781824298165759e-10
a O 0 1.4975846118758795e-09
screening O 0 1.0137886086170056e-08
step O 0 5.323006480040249e-09
and O 0 3.200532894265251e-10
nucleotide O 0 1.6032329908099996e-09
sequencing O 0 1.933568444245637e-10
of O 0 1.6468356192622657e-11
target O 0 2.8704693733061504e-08
exons O 0 3.590965391708778e-08
, O 0 1.9068373546815565e-09
we O 0 3.94699517514141e-09
determined O 0 2.1264042970869923e-08
that O 0 2.030065449076801e-09
the O 0 1.2494519863182063e-09
proband O 0 1.9265084119979292e-05
was O 0 2.0436100101051125e-07
a O 0 1.4650271218386024e-08
compound O 0 5.142280556924561e-08
heterozygote O 0 1.8197576423517603e-07
for O 0 1.1813677813776735e-09
two O 0 2.1038928821326408e-08
C6 O 0 0.0024561407044529915
gene O 0 9.74235490502906e-07
mutations O 0 3.13267173623899e-06
. O 0 3.1299643410420686e-07

The O 0 7.608267793557388e-08
first O 0 1.6733624264020364e-08
, O 0 1.2216893052752198e-09
1195delC O 0 4.3185465870010376e-08
located O 0 1.3206764570838914e-09
in O 0 1.6428122195932815e-09
exon O 0 3.1588713227392873e-06
7 O 0 2.6928231022793625e-07
, O 0 3.120365521525059e-09
is O 0 1.086149503670697e-09
a O 0 1.0207736877987372e-08
novel O 0 2.010990698408932e-07
mutation O 0 7.649591680092271e-07
, O 0 3.705071527360104e-10
while O 0 1.5931728158946612e-10
the O 0 1.4229908917862133e-10
second O 0 2.8102874694013735e-08
, O 0 1.3710824697810153e-09
1936delG O 0 2.407074184418434e-08
in O 0 5.467026276129161e-10
exon O 0 5.701111831513117e-07
12 O 0 2.0353237317749517e-08
, O 0 2.398502951805881e-09
has O 0 1.607557464922138e-08
been O 0 6.005677022358213e-08
described O 0 5.474983026942937e-07
before O 0 5.711278205922099e-08
to O 0 2.4622959671205535e-08
cause O 0 3.3006638204824412e-06
C6D B-Disease 0 8.865956624504179e-05
in O 0 6.767937321683348e-09
an O 0 1.7968788679212366e-09
unrelated O 0 2.4206059379139333e-07
African O 0 6.1497016368150526e-09
- O 0 3.3350290777889313e-06
American O 0 7.880863961418072e-08
individual O 0 7.302327276192955e-08
. O 0 2.5644985157669e-07

Both O 0 7.164269959503144e-07
mutations O 0 1.763774525898043e-05
result O 0 5.943491601101414e-07
in O 0 1.4271066106630315e-07
premature O 0 3.984126669820398e-05
termination O 0 1.0966407899104524e-05
codons O 0 1.3963951914774952e-06
and O 0 2.3292375317396363e-07
C6 O 0 0.0017160688294097781
null O 0 8.349166819243692e-06
alleles O 0 3.882159489876358e-06
. O 0 7.712698106843163e-07

Allele O 0 0.0001192746713059023
- O 0 3.872989054798381e-06
specific O 0 1.2089178547114443e-08
PCR O 0 2.862732799258083e-06
indicated O 0 1.2756565865856828e-06
that O 0 5.14464204570686e-09
the O 0 1.86737514340507e-09
probands O 0 2.3210970539366826e-05
two O 0 1.1216803486036042e-08
brothers O 0 1.040132701746188e-06
also O 0 3.8048142414481845e-08
inherited O 0 9.347933200842817e-07
the O 0 4.166766487401219e-09
1195delC O 0 2.0321856482041767e-06
mutation O 0 1.145608479191651e-07
from O 0 3.502662881960106e-10
their O 0 3.813429128030066e-09
heterozygous O 0 1.4359630995386397e-06
mother O 0 5.821112608828116e-06
and O 0 5.287690729716132e-09
the O 0 2.2205426386534555e-09
1936delG O 0 8.849248729347892e-07
mutation O 0 7.956290204447214e-08
from O 0 7.265393842104118e-10
their O 0 6.566720056611075e-09
homozygous O 0 2.941509046650026e-05
father O 0 6.4036171352199744e-06
. O 0 4.0978132886948515e-08
. O 0 2.124564275618468e-07

PAX6 O 0 0.260450154542923
mutations O 0 0.0076211560517549515
reviewed O 0 7.784147601341829e-05
. O 0 5.720736226066947e-06

Mutations O 0 0.0008725649677217007
in O 0 3.8011191350051377e-07
PAX6 O 0 0.0002168938663089648
are O 0 1.577583397249782e-08
responsible O 0 4.3982915087781294e-08
for O 0 4.62543159329698e-09
human O 0 4.151696941789851e-07
aniridia B-Disease 1 0.9999966621398926
and O 0 1.8794054312820663e-06
have O 0 1.5067386982536846e-07
also O 0 2.1416925122252906e-08
been O 0 4.82175970262233e-08
found O 0 1.4517094371058192e-07
in O 0 3.078495751651644e-07
patients O 0 3.7765232718811603e-07
with O 0 8.946825801103842e-06
Peters B-Disease 1 0.9999986886978149
anomaly I-Disease 1 0.9999994039535522
, O 0 2.0834326278418303e-05
with O 0 0.05129662901163101
congenital B-Disease 1 0.9999997615814209
cataracts I-Disease 1 0.9999504089355469
, O 0 1.1297770470264368e-06
with O 0 8.036550752876792e-06
autosomal B-Disease 1 0.9731044769287109
dominant I-Disease 0 0.05848608911037445
keratitis I-Disease 1 0.9808362722396851
, O 0 1.0389984481662395e-06
and O 0 1.4091614275457687e-07
with O 0 4.271192665328272e-06
isolated B-Disease 0 0.17221224308013916
foveal I-Disease 1 0.9999971389770508
hypoplasia I-Disease 1 0.9999946355819702
. O 0 0.00010607202420942485

No O 0 4.4223457962289103e-07
locus O 0 5.131175271344546e-07
other O 0 5.78102010706516e-10
than O 0 1.952205508359839e-09
chromosome O 0 9.54590996116167e-06
11p13 O 0 5.306138518790249e-06
has O 0 7.126315182404142e-08
been O 0 1.522658834574031e-07
implicated O 0 1.882423930510413e-05
in O 0 4.335273843025789e-06
aniridia B-Disease 1 0.9999982118606567
, O 0 8.376920135333421e-08
and O 0 4.184705204579586e-08
PAX6 O 0 3.244153776904568e-05
is O 0 1.9123159944456347e-08
clearly O 0 8.82163497806232e-09
the O 0 9.49066866762216e-11
major O 0 3.792495206766944e-09
, O 0 3.6863792018948516e-09
if O 0 9.530932487678001e-09
not O 0 2.7556357196090175e-09
only O 0 5.941513947504973e-10
, O 0 7.293899373372881e-10
gene O 0 2.120842879094198e-08
responsible O 0 3.1640217912354274e-07
. O 0 4.184433919363073e-07

Twenty O 0 1.089908323592681e-06
- O 0 1.5863146245465032e-06
eight O 0 1.0159682872767917e-08
percent O 0 7.242236588211881e-09
of O 0 6.219021408959691e-10
identified O 0 6.620815838687122e-06
PAX6 O 0 0.0011337293544784188
mutations O 0 2.166082413168624e-05
are O 0 3.3382665520775845e-08
C O 0 4.470700787351234e-06
- O 0 0.0006601488566957414
T O 0 9.731926547829062e-05
changes O 0 1.928593285072111e-09
at O 0 1.2354749445719904e-09
CpG O 0 1.8086811337525432e-07
dinucleotides O 0 4.77474657145649e-07
, O 0 4.702123690414339e-10
20 O 0 1.6715777373388363e-10
% O 0 9.730811295627362e-11
are O 0 6.438240218731295e-11
splicing O 0 1.0317902976453297e-08
errors O 0 6.907654892529536e-08
, O 0 2.440556090554935e-10
and O 0 1.8876573915083128e-10
more O 0 5.1980281190466826e-11
than O 0 1.4510770363074244e-09
30 O 0 1.2416146999427724e-09
% O 0 8.491967684598478e-10
are O 0 7.718556904734442e-10
deletion O 0 1.0304730579946408e-07
or O 0 1.9208519219660047e-08
insertion O 0 1.5250624585405603e-07
events O 0 2.979964506266697e-07
. O 0 8.75913997333555e-07

There O 0 6.526079801005835e-07
is O 0 1.0575527120693096e-08
a O 0 1.556903939103904e-08
noticeably O 0 4.237117536831647e-06
elevated O 0 4.51768355560489e-05
level O 0 3.4258238912343586e-08
of O 0 5.944472136754086e-10
mutation O 0 5.869152346349438e-07
in O 0 1.192419607498607e-09
the O 0 3.225370248660653e-10
paired O 0 8.618633273727028e-08
domain O 0 1.6837226723964704e-08
compared O 0 2.062145654235792e-08
with O 0 5.333990471534378e-10
the O 0 3.960025640736831e-09
rest O 0 2.513302677087381e-09
of O 0 4.1033701436710146e-10
the O 0 1.6265410351934406e-08
gene O 0 3.057942876694142e-07
. O 0 1.6839481986608007e-07

Increased O 0 4.257589353073854e-06
mutation O 0 1.144160887633916e-05
in O 0 6.292572241051175e-09
the O 0 1.309849118058537e-09
homeodomain O 0 2.6530851755524054e-06
is O 0 6.315550304947237e-09
accounted O 0 6.4088174767107375e-09
for O 0 8.027556397394164e-11
by O 0 1.011956740626374e-09
the O 0 1.467465882143415e-08
hypermutable O 0 4.694190647569485e-05
CpG O 0 1.9111639630864374e-06
dinucleotide O 0 4.773471573571442e-07
in O 0 8.685579366840557e-09
codon O 0 1.3524943653919763e-07
240 O 0 2.544429023032535e-08
. O 0 8.742709667330928e-08

Very O 0 3.716084506777406e-07
nearly O 0 8.535947060295257e-09
all O 0 5.308302686302113e-10
mutations O 0 1.2290057327390969e-07
appear O 0 4.987616009088924e-08
to O 0 8.568211917747703e-09
cause O 0 5.020941443945048e-06
loss O 0 1.0465744253451703e-06
of O 0 2.697011503016711e-10
function O 0 3.661146719124986e-09
of O 0 5.732463462249093e-11
the O 0 1.4018309846264287e-09
mutant O 0 6.499893174805038e-07
allele O 0 5.413490100636409e-08
, O 0 7.480935315662407e-11
and O 0 6.780438016606993e-11
more O 0 1.4121642223641206e-11
than O 0 2.024195255856398e-10
80 O 0 5.64085618492971e-11
% O 0 8.491963382484258e-11
of O 0 1.596798943070965e-10
exonic O 0 1.5142596794248675e-06
substitutions O 0 7.766426080024758e-08
result O 0 9.41431039791496e-08
in O 0 2.3292590967116666e-08
nonsense O 0 7.138393812056165e-06
codons O 0 1.4352852986121434e-06
. O 0 1.1864202065225982e-07

In O 0 2.7787714884652814e-07
a O 0 5.50582406333433e-08
gene O 0 7.33613987335957e-08
with O 0 4.229825822932298e-09
such O 0 3.0066658496252785e-08
extraordinarily O 0 0.0019455001456663013
high O 0 7.173636618063028e-07
sequence O 0 1.7929700391050574e-08
conservation O 0 1.2141627703243785e-09
throughout O 0 8.00811916779054e-11
evolution O 0 1.2843476282498045e-09
, O 0 1.9647408699974278e-10
there O 0 8.309329335709492e-10
are O 0 6.372056216008559e-09
presumed O 0 0.0011639378499239683
undiscovered O 0 0.00041889052954502404
missense O 0 7.784860645188019e-05
mutations O 0 1.0114815268025268e-05
, O 0 1.881210076604134e-09
these O 0 3.4915700886095635e-10
are O 0 1.0113894166607906e-09
hypothesized O 0 5.27893604385099e-08
to O 0 7.872777096906702e-09
exist O 0 6.89674095610826e-08
in O 0 6.203197067122801e-09
as O 0 5.6271314718969734e-08
- O 0 0.0019234804203733802
yet O 0 6.6100028561777435e-06
unidentified O 0 0.0001245116291102022
phenotypes O 0 6.297224899753928e-06
. O 0 1.7914318917178207e-08
. O 0 6.122749596215726e-08

Genetic O 0 0.00045965539175085723
heterogeneity O 0 0.00021346255380194634
and O 0 6.348051897475671e-07
penetrance O 0 4.392974005895667e-05
analysis O 0 3.0718553034603246e-08
of O 0 4.3073300481921706e-10
the O 0 1.9674953222192926e-08
BRCA1 O 0 0.00039898636168800294
and O 0 1.2918266065753414e-06
BRCA2 O 0 0.00014221227320376784
genes O 0 1.1311657317492063e-06
in O 0 1.102116766560357e-05
breast B-Disease 1 0.999861478805542
cancer I-Disease 1 0.9726731181144714
families O 0 7.77934656071011e-06
. O 0 7.934502718853764e-06

The O 0 0.0021426109597086906
Breast B-Disease 1 0.9999948740005493
Cancer I-Disease 1 0.9999860525131226
Linkage O 1 0.6071845293045044
Consortium O 0 0.0001727869239402935
. O 0 3.418505230001756e-06

The O 0 6.30432381854007e-08
contribution O 0 9.713615867212866e-08
of O 0 6.429865084811581e-09
BRCA1 O 0 5.496852827491239e-05
and O 0 7.106402790668653e-07
BRCA2 O 0 0.009841266088187695
to O 0 0.0011078675743192434
inherited B-Disease 1 0.9999998807907104
breast I-Disease 1 0.9999997615814209
cancer I-Disease 1 0.9999998807907104
was O 0 0.02559792995452881
assessed O 0 4.266099949745694e-06
by O 0 9.12892517135333e-09
linkage O 0 2.0263436454115435e-05
and O 0 1.61295133693784e-07
mutation O 0 3.6714286011374497e-07
analysis O 0 3.1759608276615836e-09
in O 0 4.868905834065629e-10
237 O 0 2.0238952735951443e-09
families O 0 1.1957608236912165e-09
, O 0 1.9687772245813306e-10
each O 0 1.1891143625319955e-10
with O 0 1.0162507502187168e-09
at O 0 1.1562139690113327e-08
least O 0 4.056639746341517e-10
four O 0 4.0219244601402693e-10
cases O 0 2.4968613843157073e-09
of O 0 2.6023897703453258e-08
breast B-Disease 1 0.9995065927505493
cancer I-Disease 0 0.06769977509975433
, O 0 1.699437812696658e-09
collected O 0 8.475176116462535e-09
by O 0 4.2033200031710294e-08
the O 0 0.002902176696807146
Breast B-Disease 1 0.9999998807907104
Cancer I-Disease 1 0.9999947547912598
Linkage O 0 0.021388700231909752
Consortium O 0 1.3288965419633314e-05
. O 0 2.8959095743630314e-07

Families O 0 1.219426849274896e-06
were O 0 1.7457660206332548e-08
included O 0 2.7396780399868703e-09
without O 0 2.509044527698734e-09
regard O 0 2.9088720321368555e-09
to O 0 4.748802462373192e-10
the O 0 3.478928256583913e-09
occurrence O 0 2.4887119707273087e-06
of O 0 1.0587339005496688e-07
ovarian B-Disease 1 0.9934747815132141
or I-Disease 0 2.0248271539458074e-05
other I-Disease 0 1.5119090903681354e-06
cancers I-Disease 0 0.3621225655078888
. O 0 6.018628937454196e-06

Overall O 0 0.00017976881645154208
, O 0 7.741940862615593e-06
disease O 0 0.00010478750482434407
was O 0 1.321949412158574e-06
linked O 0 1.2853802218160126e-05
to O 0 3.956395744353358e-08
BRCA1 O 0 8.34881666378351e-06
in O 0 1.4457478547669211e-09
an O 0 1.1338091576718057e-09
estimated O 0 6.018907594551592e-09
52 O 0 1.0527704263907367e-09
% O 0 1.4954944227429934e-10
of O 0 1.8630198772573436e-10
families O 0 1.4615161525455278e-08
, O 0 1.5251686580342039e-09
to O 0 3.912486334911591e-09
BRCA2 O 0 4.055128215441073e-07
in O 0 1.3882157645639381e-09
32 O 0 3.4855884845086393e-10
% O 0 1.2981363206598928e-10
of O 0 1.5166422284718095e-10
families O 0 1.3707746049362868e-08
, O 0 7.955193837005936e-09
and O 0 6.697743692996028e-09
to O 0 2.12884598838059e-09
neither O 0 2.3968075524294363e-08
gene O 0 1.1334783112104674e-09
in O 0 3.632050493695971e-10
16 O 0 6.717494338559504e-10
% O 0 1.96862706691725e-10
( O 0 7.337416091379723e-11
95 O 0 5.386016632691337e-10
% O 0 3.536577419804843e-10
confidence O 0 1.7285326237015397e-07
interval O 0 5.234419973021431e-07
[ O 0 4.109162077270412e-08
CI O 0 5.302641170601419e-07
] O 0 1.419559692017458e-09
6 O 0 1.5208134751532043e-10
% O 0 5.5458027059529513e-11
- O 0 1.5457067092938814e-07
28 O 0 5.382537526799069e-09
% O 0 6.865419344137536e-10
) O 0 2.141073429662299e-10
, O 0 9.10461039893562e-10
suggesting O 0 5.159287184142158e-07
other O 0 1.6670389513251394e-08
predisposition O 0 6.086578287067823e-05
genes O 0 1.2671157492150087e-06
. O 0 4.48058528945694e-07

The O 0 1.3246420849100105e-07
majority O 0 4.1046344989581485e-08
( O 0 2.729866110939838e-09
81 O 0 2.503719009894212e-09
% O 0 2.87327633907708e-10
) O 0 2.414192804001125e-11
of O 0 1.9030357845117862e-10
the O 0 3.6830610952165443e-06
breast B-Disease 1 0.9999939203262329
- I-Disease 1 0.9999998807907104
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
families O 0 1.055224515766895e-06
were O 0 6.767577360733412e-07
due O 0 4.507078870119585e-07
to O 0 9.467304806776156e-08
BRCA1 O 0 0.0002340483188163489
, O 0 4.515207763233775e-09
with O 0 4.942677378494409e-09
most O 0 6.4179550562926124e-09
others O 0 8.98969076956746e-09
( O 0 6.347573577869525e-10
14 O 0 2.4901172235303193e-09
% O 0 1.3144465516035098e-09
) O 0 9.856493399240662e-10
due O 0 6.663838547638079e-08
to O 0 7.26168707387842e-07
BRCA2 O 0 0.0015246440889313817
. O 0 1.2692008795056609e-06

Conversely O 0 1.8174447177443653e-05
, O 0 2.5173036988235253e-09
the O 0 2.593794345973066e-10
majority O 0 4.118581864442916e-10
of O 0 1.3302293988548541e-10
families O 0 3.1674372014123264e-09
with O 0 4.562451749734464e-08
male B-Disease 0 2.722190947679337e-05
and I-Disease 0 8.624225301900879e-06
female I-Disease 1 0.8733303546905518
breast I-Disease 1 0.9998158812522888
cancer I-Disease 1 0.6749579310417175
were O 0 1.4960728549340274e-06
due O 0 8.944453497861105e-07
to O 0 1.7821524522787513e-07
BRCA2 O 0 4.919857019558549e-05
( O 0 1.0249840087794837e-08
76 O 0 2.1363725011269707e-08
% O 0 1.6692501603188248e-08
) O 0 1.569243579524482e-08
. O 0 2.7872539476447855e-07

The O 0 8.70963816623771e-08
largest O 0 4.618152260604802e-08
proportion O 0 7.450401540154417e-08
( O 0 1.146465367085625e-09
67 O 0 2.8105271443479296e-09
% O 0 4.862483748979685e-10
) O 0 8.146898433647465e-11
of O 0 8.910541055007215e-11
families O 0 9.759928865094025e-09
due O 0 6.853755252222982e-08
to O 0 4.22360191265625e-09
other O 0 2.751528782596324e-09
genes O 0 2.452242497952284e-08
was O 0 1.3004148513573455e-06
found O 0 3.192927238160337e-07
in O 0 8.031944886965903e-09
families O 0 1.2010133998430206e-09
with O 0 1.8962105219344494e-09
four O 0 5.5395288356407946e-09
or O 0 1.8321033579127288e-08
five O 0 4.492441141312753e-10
cases O 0 1.0058278654412334e-09
of O 0 7.050330985691744e-09
female O 1 0.8458336591720581
breast B-Disease 1 0.9997676014900208
cancer I-Disease 0 0.2947123944759369
only O 0 5.875166380064911e-07
. O 0 9.330343573310529e-07

These O 0 9.941540923819048e-08
estimates O 0 3.573611309093394e-07
were O 0 2.7879549335807496e-08
not O 0 1.0620281543083365e-08
substantially O 0 1.197402923480695e-07
affected O 0 2.055229764152955e-09
either O 0 9.60403090388695e-10
by O 0 1.2404097748941467e-09
changing O 0 1.9477138124557314e-08
the O 0 2.321071113087214e-09
assumed O 0 2.611604372759757e-07
penetrance O 0 1.438284584764915e-07
model O 0 2.384132180566212e-08
for O 0 1.512379332879732e-09
BRCA1 O 0 9.858773637461127e-07
or O 0 1.3805142806688764e-08
by O 0 1.7388861461853367e-09
including O 0 8.173209664619208e-09
or O 0 8.22010520096228e-07
excluding O 0 6.200329153216444e-06
BRCA1 O 0 0.0003191527503076941
mutation O 0 5.659574526362121e-06
data O 0 1.3867379493603949e-06
. O 0 2.2698323220993188e-07

Among O 0 1.9482862967379333e-07
those O 0 1.3921354735657587e-08
families O 0 1.4444421658765805e-08
with O 0 4.203344019515498e-07
disease O 0 0.0013557340716943145
due O 0 5.630630539599224e-07
to O 0 4.5489835542866786e-07
BRCA1 O 0 0.0008045533904805779
that O 0 1.7166438226468017e-07
were O 0 3.575755727069918e-07
tested O 0 1.1564387705220724e-06
by O 0 4.072750192651853e-10
one O 0 7.179434269311002e-10
of O 0 3.827584083015978e-11
the O 0 5.745601772133568e-10
standard O 0 2.452991054724407e-08
screening O 0 3.4047944463821977e-09
methods O 0 1.886428258046635e-08
, O 0 1.103083402398397e-09
mutations O 0 1.4279924798188404e-08
were O 0 3.422167083044769e-08
detected O 0 3.1247200240613893e-06
in O 0 9.953959878572505e-10
the O 0 7.775711741153657e-10
coding O 0 1.8264998402628407e-08
sequence O 0 1.9756056790498633e-09
or O 0 3.791141012232657e-10
splice O 0 4.62359706077109e-09
sites O 0 1.8130281720374342e-09
in O 0 1.333544663584263e-10
an O 0 2.2613552697059447e-10
estimated O 0 7.512915622953642e-09
63 O 0 7.957117187373797e-10
% O 0 2.8971100518582205e-10
( O 0 5.3596769383768006e-11
95 O 0 2.5022378613570595e-10
% O 0 6.032374599840296e-10
CI O 0 1.5280703564712894e-06
51 O 0 2.9579281246583378e-09
% O 0 1.1869577543066612e-09
- O 0 1.4290640137915034e-06
77 O 0 9.054669902752721e-09
% O 0 2.4753901151086666e-09
) O 0 8.308334464857126e-09
. O 0 1.1742609018483563e-07

The O 0 9.501567177494508e-08
estimated O 0 5.291820315278528e-08
sensitivity O 0 9.320133926848939e-07
was O 0 2.691567431156727e-07
identical O 0 1.0356097845942713e-07
for O 0 5.090046786837554e-11
direct O 0 2.6893676174921666e-10
sequencing O 0 3.6578031714640247e-09
and O 0 1.6241469280586784e-09
other O 0 3.7874764435841257e-10
techniques O 0 2.7690205683938984e-07
. O 0 1.7445800892801344e-07

The O 0 1.232016870744701e-07
penetrance O 0 1.5666553736082278e-05
of O 0 1.1655290066414636e-08
BRCA2 O 0 0.00012576467997860163
was O 0 6.349892487378384e-07
estimated O 0 4.3859076370722505e-09
by O 0 3.8427935833418303e-10
maximizing O 0 3.336026210831733e-08
the O 0 9.054013538900563e-09
LOD O 0 0.002164775040000677
score O 0 4.7707590766776775e-08
in O 0 2.2330732818431898e-08
BRCA2 O 0 1.3002662853978109e-05
- O 0 0.0001383758062729612
mutation O 0 4.73169257020345e-06
families O 0 7.50234807611605e-09
, O 0 6.005487773741436e-10
over O 0 1.194500276469057e-09
all O 0 1.1973309010926414e-09
possible O 0 3.080128578858421e-07
penetrance O 0 1.110434368456481e-05
functions O 0 3.967814876659759e-08
. O 0 1.4988033569807158e-07

The O 0 6.327248058823898e-08
estimated O 0 9.144559953710996e-08
cumulative O 0 5.558126758842263e-07
risk O 0 4.265361610578111e-07
of O 0 8.489640102027352e-09
breast B-Disease 1 0.9245466589927673
cancer I-Disease 0 0.025806766003370285
reached O 0 2.877195584005676e-07
28 O 0 3.3268490184923394e-09
% O 0 1.5251912233171794e-10
( O 0 3.305952386845057e-11
95 O 0 1.805166849333517e-10
% O 0 3.582362739784628e-10
CI O 0 6.750161674062838e-07
9 O 0 9.077906204524311e-10
% O 0 7.244191357891339e-11
- O 0 1.3928552533570837e-08
44 O 0 2.8579669186790113e-10
% O 0 1.0075074108328863e-10
) O 0 1.5796947083757118e-11
by O 0 2.1997591248545945e-10
age O 0 1.0987604603940326e-08
50 O 0 6.780101480252654e-11
years O 0 2.3686644312626015e-10
and O 0 3.8399949886525064e-10
84 O 0 3.3150782119406585e-10
% O 0 8.439131338189299e-11
( O 0 4.084541385673823e-11
95 O 0 2.437597346194309e-10
% O 0 3.5829778033402704e-10
CI O 0 1.5377172246644477e-07
43 O 0 3.8954250936029666e-10
% O 0 1.3946162280564778e-10
- O 0 4.549798759967416e-08
95 O 0 1.0042923159758743e-09
% O 0 4.722202628926198e-10
) O 0 6.686198816829858e-11
by O 0 1.4797703062896517e-09
age O 0 1.2395371129514388e-07
70 O 0 3.2844169606249807e-09
years O 0 1.0044904996675541e-07
. O 0 1.9851977128837461e-07

The O 0 7.092387022566982e-06
corresponding O 1 0.888093888759613
ovarian B-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999996423721313
risks O 0 0.43718940019607544
were O 0 6.890074473631103e-06
0 O 0 1.5628922938049072e-06
. O 0 3.761692539683281e-07

4 O 0 1.860694283095654e-07
% O 0 4.935103881109626e-09
( O 0 3.932572600895412e-10
95 O 0 7.716495775689225e-10
% O 0 1.0958549623296676e-09
CI O 0 4.991699711354158e-07
0 O 0 6.594467194531717e-10
% O 0 1.6392620594274376e-10
- O 0 2.8338094537616598e-08
1 O 0 1.6046066697583683e-09
% O 0 1.0011208528837301e-10
) O 0 5.630019020430588e-12
by O 0 1.0643896181106172e-10
age O 0 9.045624693726495e-09
50 O 0 4.251498111895735e-11
years O 0 2.399851706247347e-10
and O 0 2.213665362127415e-10
27 O 0 8.207088342260249e-10
% O 0 8.57973275758539e-11
( O 0 3.539598822377421e-11
95 O 0 1.0702096153725194e-10
% O 0 1.8586188144098514e-10
CI O 0 1.1151127665698368e-07
0 O 0 4.2377695796957937e-10
% O 0 6.963070398047222e-11
- O 0 4.916597973192438e-08
47 O 0 1.3208779625628608e-09
% O 0 2.8861896206322513e-10
) O 0 4.9031608634342305e-11
by O 0 1.0185891019531823e-09
age O 0 1.119989789799547e-07
70 O 0 3.5093117300988297e-09
years O 0 4.443979051416136e-08
. O 0 1.765308041967728e-07

The O 0 4.087420393261709e-07
lifetime O 0 1.3896775271859951e-05
risk O 0 2.266579713250394e-06
of O 0 5.2973138764400574e-08
breast B-Disease 1 0.9994427561759949
cancer I-Disease 1 0.5986517667770386
appears O 0 1.93775349544012e-06
similar O 0 1.5630869043548046e-08
to O 0 1.149522033117023e-09
the O 0 3.181352425940531e-08
risk O 0 1.7403158381057438e-06
in O 0 5.414295856098761e-08
BRCA1 O 0 2.6624165911925957e-05
carriers O 0 9.804264777812932e-08
, O 0 1.9970376463618322e-09
but O 0 1.1746972283788182e-08
there O 0 3.501114953508022e-09
was O 0 3.240289814243624e-08
some O 0 2.2606770622157768e-11
suggestion O 0 6.194282420324271e-09
of O 0 1.2004860994174749e-10
a O 0 1.6353466492091684e-07
lower O 0 2.285701384607819e-06
risk O 0 4.842302701035806e-07
in O 0 9.253779076345836e-09
BRCA2 O 0 1.7597521946299821e-06
carriers O 0 3.525602920717574e-08
< O 0 3.05573273351456e-08
50 O 0 5.184623841358871e-10
years O 0 8.952692476249524e-10
of O 0 1.0091618651841827e-09
age O 0 1.018093257698638e-06
. O 0 2.8632030080188997e-07

Eye B-Disease 0 0.347638875246048
movement I-Disease 0 5.8953599364031106e-05
abnormalities I-Disease 0 0.29017674922943115
correlate O 0 5.5770884500816464e-05
with O 0 6.347846124299394e-07
genotype O 1 0.6766396760940552
in O 0 6.564939667441649e-06
autosomal O 1 0.9935436248779297
dominant O 1 0.8127902150154114
cerebellar B-Disease 1 0.9994291663169861
ataxia I-Disease 1 0.9998445510864258
type I-Disease 1 0.9971223473548889
I I-Disease 0 0.24596868455410004
. O 0 1.766555442372919e-06

We O 0 1.1440214393587667e-06
compared O 0 8.897577004063351e-07
horizontal O 0 0.00011045833525713533
eye O 0 0.0015280194347724319
movements O 0 1.4740752703801263e-05
( O 0 3.363499345709897e-08
visually O 0 6.626239610341145e-07
guided O 0 1.7638114968576701e-06
saccades O 0 0.00015617106691934168
, O 0 4.5655310643155644e-09
antisaccades O 0 5.406585614764481e-07
, O 0 5.479836029387286e-10
and O 0 7.447453764797274e-10
smooth O 0 8.332714429570842e-08
pursuit O 0 1.280148694604577e-06
) O 0 1.0727074784000479e-09
in O 0 1.490301437812036e-09
control O 0 1.562464433391142e-07
subjects O 0 1.0117064448422752e-06
( O 0 2.9769169351823166e-09
n O 0 8.309525014738028e-07
= O 0 2.526941216274281e-07
14 O 0 3.444940444019551e-10
) O 0 1.7797754936488275e-10
and O 0 4.601393754910532e-08
patients O 0 2.4473409965253268e-08
with O 0 3.2870361987846763e-09
three O 0 7.139755009433202e-09
forms O 0 1.5740555170395965e-07
of O 0 1.0208287193336218e-07
autosomal O 0 0.1834898442029953
dominant O 0 0.001023386954329908
cerebellar B-Disease 0 0.10648176074028015
ataxias I-Disease 0 0.06852361559867859
type I-Disease 0 0.011498096399009228
I I-Disease 0 0.0004489012935664505
spinocerebellar B-Disease 0 0.00019126507686451077
ataxias I-Disease 0 7.180719421739923e-06
1 I-Disease 0 5.439019901132269e-09
and I-Disease 0 3.829434991331482e-09
2 I-Disease 0 4.513700968544754e-09
( O 0 9.885487983751773e-10
SCA1 B-Disease 0 6.062894499336835e-06
, O 0 1.7063169766018405e-09
n O 0 2.0319225768616889e-07
= O 0 5.396572788640697e-08
11 O 0 5.734850372363098e-10
; O 0 2.976217328143349e-10
SCA2 B-Disease 0 9.290033062825387e-07
, O 0 4.5119860625497665e-10
n O 0 4.9229413434659364e-08
= O 0 2.7604347252463413e-08
10 O 0 1.4447906759862406e-10
) O 0 5.6654621966023555e-11
and O 0 5.918638379398544e-08
SCA3 B-Disease 1 0.9999958276748657
/ O 0 5.71006748941727e-05
Machado B-Disease 0 4.353791518951766e-05
- I-Disease 0 0.01220676489174366
Joseph I-Disease 0 0.003124643350020051
disease I-Disease 0 0.002028773305937648
( O 0 1.768794675172103e-07
MJD B-Disease 1 0.9999945163726807
) O 0 1.8400985624111854e-08
( O 0 1.2622766165648613e-09
n O 0 2.5899910269799875e-06
= O 0 7.51148604649643e-07
16 O 0 9.711018655877979e-09
) O 0 6.724727885654147e-09
. O 0 4.877387382862253e-08

In O 0 6.008472723806335e-07
SCA1 B-Disease 0 1.644635085540358e-05
, O 0 4.53640014441703e-09
saccade O 0 4.3376948610784893e-07
amplitude O 0 3.0480319423986657e-07
was O 0 4.555260701977204e-08
significantly O 0 4.887948534815223e-08
increased O 0 1.8413590652244238e-08
, O 0 2.379846542055475e-09
resulting O 0 2.234615514851157e-08
in O 0 3.429720862868635e-08
hypermetria B-Disease 0 0.00011489194730529562
. O 0 1.6455217632938002e-07

The O 0 6.694259724326912e-08
smooth O 0 4.4313929947747965e-07
pursuit O 0 9.8383168278815e-07
gain O 0 2.7786040845967364e-06
was O 0 1.3938239135313779e-05
decreased O 0 2.1028508854215033e-05
. O 0 3.0436052611548803e-07

In O 0 8.545470109311282e-07
SCA2 B-Disease 0 3.649071732070297e-05
, O 0 1.2460017906334997e-08
saccade O 0 1.7179357882923796e-06
velocity O 0 9.299837415710499e-07
was O 0 6.859364702904713e-07
markedly O 0 3.096201680818922e-06
decreased O 0 3.599517867769464e-06
. O 0 1.5396835806313902e-07

The O 0 1.0976904718518199e-07
percentage O 0 2.3531006831944978e-07
of O 0 5.217379861477411e-10
errors O 0 4.1603758660357926e-08
in O 0 5.166284733348903e-09
antisaccades O 0 3.6598088627215475e-05
was O 0 5.668091489496874e-07
greatly O 0 2.073654670198266e-08
increased O 0 7.424339809602998e-09
and O 0 4.1468108946673965e-09
was O 0 6.029849828337319e-07
significantly O 0 3.5320443458886075e-08
correlated O 0 5.6272497772624774e-08
with O 0 2.3889844769087176e-08
age O 0 2.4589412532805e-06
at O 0 2.4457833660562756e-06
disease O 0 6.855616811662912e-05
onset O 0 4.6666875277878717e-05
. O 0 2.034002363870968e-06

In O 0 1.216103697743165e-07
addition O 0 9.054392791085775e-09
, O 0 2.1397385252530654e-10
a O 0 8.684151175941679e-10
correlation O 0 7.11011836074249e-08
between O 0 3.416699811964463e-09
smooth O 0 1.3341917792786262e-06
pursuit O 0 9.460259207116906e-06
gain O 0 1.701247128949035e-06
and O 0 7.04006541951685e-09
the O 0 4.1326278510389614e-10
number O 0 4.4350159655870414e-10
of O 0 4.3552614292785563e-10
trinucleotide O 0 9.971324288926553e-06
repeats O 0 1.2490426115618902e-06
was O 0 3.3079007266678673e-07
found O 0 2.7638390065476415e-07
. O 0 2.890013490741694e-07

In O 0 1.2103076187486295e-05
SCA3 B-Disease 1 0.9997010231018066
, O 0 1.6812043668323895e-07
gaze B-Disease 0 4.520868606050499e-05
- I-Disease 0 0.00013283481530379504
evoked I-Disease 0 0.00023512147890869528
nystagmus I-Disease 0 9.188718104269356e-05
was O 0 1.476516899856506e-06
often O 0 5.803582947550012e-09
present O 0 1.5370017480975662e-09
as O 0 1.702032847994417e-09
was O 0 1.1836603164283588e-07
saccade O 0 1.055575694408617e-06
hypometria O 0 8.88345141447644e-07
and O 0 1.8306701710102402e-09
smooth O 0 2.4764775119479054e-08
pursuit O 0 1.6592092322298413e-07
gain O 0 4.5072425791659043e-07
was O 0 3.029813569810358e-06
markedly O 0 3.6876299418509007e-06
decreased O 0 1.7129362959167338e-06
. O 0 2.1280075657159614e-07

Three O 0 1.125102642163256e-07
major O 0 2.1857713861095363e-08
criteria O 0 5.408484682334347e-08
, O 0 7.563926707199187e-10
saccade O 0 3.0308603982120985e-07
amplitude O 0 6.787900730387264e-08
, O 0 3.7776573535985847e-10
saccade O 0 1.0627134372498404e-07
velocity O 0 8.64743228135012e-08
, O 0 1.9759890945714176e-10
and O 0 1.2503954816001084e-10
presence O 0 1.140087024786851e-09
of O 0 8.118716809946136e-10
gaze B-Disease 0 0.0002182901225751266
- I-Disease 0 7.682630530325696e-05
evoked I-Disease 0 3.16843725158833e-05
nystagmus I-Disease 0 1.2156345974290161e-06
, O 0 1.923339404408253e-10
permitted O 0 1.5054568702765891e-10
the O 0 1.538323635141836e-10
correct O 0 1.6409622105584276e-08
assignment O 0 4.658400332147039e-10
of O 0 1.4283470239906393e-11
90 O 0 4.960484800697884e-11
% O 0 3.924433347735068e-11
of O 0 2.128657146382995e-11
the O 0 1.2031777796295273e-09
SCA1 B-Disease 0 5.286647137836553e-06
, O 0 1.0810564249341681e-10
90 O 0 1.432950459678839e-11
% O 0 1.625462264787103e-11
of O 0 1.3368903206689708e-11
the O 0 3.734788034392977e-09
SCA2 B-Disease 0 5.2623418014263734e-05
, O 0 5.068117037154707e-10
and O 0 4.1908032599735634e-10
93 O 0 2.2424781476182432e-10
% O 0 4.831363087376417e-11
of O 0 5.6836778339341976e-11
the O 0 4.6022016420010914e-08
patients O 0 1.3395154496720352e-07
with O 0 4.897565304418094e-07
SCA3 B-Disease 1 0.9999984502792358
to O 0 5.816751169618328e-08
their O 0 3.4501589141200384e-08
genetically O 0 7.07647060949057e-08
confirmed O 0 4.769567567564081e-07
patient O 0 1.0279558182446635e-06
group O 0 2.955329847509347e-08
and O 0 3.0048713739461164e-08
, O 0 3.981079021997402e-09
therefore O 0 3.2860913989907203e-08
, O 0 9.483205332116995e-09
may O 0 1.5798062236171972e-07
help O 0 4.321708768628696e-09
orient O 0 5.141711767464585e-07
diagnoses O 0 6.253835636016447e-06
of O 0 1.4454639707395245e-09
SCA1 B-Disease 0 0.0018641753122210503
, O 0 9.244430110300073e-09
SCA2 B-Disease 0 2.1284922695485875e-05
, O 0 1.796666260212021e-09
and O 0 2.9707301507642114e-08
SCA3 B-Disease 1 0.9999160766601562
at O 0 3.8320749240483565e-08
early O 0 1.5648259577005774e-08
clinical O 0 3.030969963901953e-08
stages O 0 9.412210033588053e-08
of O 0 3.611769994193992e-09
the O 0 1.950563500940916e-06
diseases O 0 0.0022849056404083967
. O 0 4.707872136577862e-08
. O 0 2.286182194666253e-07

Genetic O 0 6.679991929559037e-05
basis O 0 3.5905483741771604e-07
and O 0 1.770980446735848e-07
molecular O 0 8.821630763122812e-05
mechanism O 0 0.00010523220407776535
for O 0 0.0002154627873096615
idiopathic B-Disease 1 0.9999991655349731
ventricular I-Disease 1 0.9999765157699585
fibrillation I-Disease 1 0.9999979734420776
. O 0 0.0026952417101711035

Ventricular B-Disease 1 0.7748808264732361
fibrillation I-Disease 1 0.7800066471099854
causes O 0 0.0001074761530617252
more O 0 6.459218049315041e-09
than O 0 2.6212538806191787e-09
300 O 0 1.8728683048863104e-09
, O 0 1.2978647045969183e-09
000 O 0 4.8715649292319085e-09
sudden O 0 2.424129093014926e-07
deaths O 0 3.848878904477715e-08
each O 0 1.68977665193637e-09
year O 0 2.333007387278485e-08
in O 0 5.080420528713603e-09
the O 0 2.141602628569217e-08
USA O 0 1.1019696103176102e-05
alone O 0 1.8724925894275657e-06
. O 0 1.3328381953670032e-07

In O 0 2.9624747099887827e-08
approximately O 0 2.8556743636443116e-09
5 O 0 1.9893542368976114e-09
- O 0 9.386644705955405e-08
12 O 0 2.135104315570402e-09
% O 0 1.5570655875762895e-10
of O 0 7.797688189592478e-11
these O 0 7.636701937485668e-09
cases O 0 5.7224873728500825e-08
, O 0 1.0963343122227798e-08
there O 0 8.855687738673623e-09
are O 0 5.483435927544633e-09
no O 0 1.211762423736218e-07
demonstrable O 0 0.030427532270550728
cardiac O 0 0.0014586421893909574
or O 0 1.1179913599335123e-06
non O 0 6.142618076410145e-07
- O 0 0.1875365525484085
cardiac O 0 0.014216958545148373
causes O 0 4.30722957389662e-06
to O 0 4.3008467898175695e-09
account O 0 2.054156844621957e-08
for O 0 3.3365191165479757e-10
the O 0 1.7597662216317644e-09
episode O 0 1.1009169611497782e-06
, O 0 1.7591462508903533e-08
which O 0 2.4944444732000193e-08
is O 0 2.1411125317172264e-08
therefore O 0 8.360590442180182e-08
classified O 0 4.944905413140077e-06
as O 0 0.00044339190935716033
idiopathic B-Disease 1 0.9999994039535522
ventricular I-Disease 1 0.9999661445617676
fibrillation I-Disease 1 0.9999990463256836
( O 0 0.0024127215147018433
IVF B-Disease 1 0.9999667406082153
) O 0 9.440344115319022e-07
. O 0 6.569215429408359e-07

A O 0 7.883627972660179e-07
distinct O 0 3.359293643256933e-08
group O 0 9.082361529522132e-09
of O 0 6.072550906566221e-09
IVF B-Disease 1 0.9999966621398926
patients O 0 1.8552169422036968e-05
has O 0 5.232687954048743e-07
been O 0 8.194629685931432e-08
found O 0 3.624013444891716e-08
to O 0 2.0165737968369513e-09
present O 0 1.112573499995051e-08
with O 0 9.950187340734828e-09
a O 0 4.934193498229433e-07
characteristic O 0 2.206300814577844e-05
electrocardiographic O 0 0.00025917901075445116
pattern O 0 1.653157960390672e-05
. O 0 3.886753745518945e-07

Because O 0 1.960468409833993e-07
of O 0 4.5476164500790617e-10
the O 0 2.61239835319671e-10
small O 0 4.263209785193567e-10
size O 0 3.764498757163892e-08
of O 0 1.5951186205231949e-10
most O 0 1.5673822240103163e-09
pedigrees O 0 7.314831123039767e-07
and O 0 2.6031130584414086e-09
the O 0 1.5192486157999952e-09
high O 0 3.6061484820493206e-07
incidence O 0 2.8481221306719817e-05
of O 0 3.146584548474607e-09
sudden B-Disease 0 5.1608098146971315e-05
death I-Disease 0 1.136195169237908e-05
, O 0 1.881906408485179e-09
however O 0 1.8241036459087923e-09
, O 0 5.30337385118429e-10
molecular O 0 2.517036818971974e-07
genetic O 0 1.1164257784912479e-07
studies O 0 1.459036447215567e-09
of O 0 1.6403011171561843e-09
IVF B-Disease 1 0.9999679327011108
have O 0 1.954321078301291e-06
not O 0 6.39348556319419e-08
yet O 0 1.311129977921155e-07
been O 0 8.53028723213356e-08
done O 0 2.3502097690197843e-07
. O 0 1.2662952997288812e-07

Because O 0 7.500312494812533e-05
IVF B-Disease 1 0.9998047947883606
causes O 0 0.06449168175458908
cardiac O 1 0.9268034100532532
rhythm O 0 0.0065176039934158325
disturbance O 0 5.228595910011791e-05
, O 0 3.5694348810011434e-08
we O 0 1.4826640359899557e-08
investigated O 0 6.768132720935682e-07
whether O 0 3.4643161228586905e-08
malfunction O 0 1.9586197595344856e-05
of O 0 5.501388788964334e-10
ion O 0 2.494597720215097e-05
channels O 0 3.172020569763845e-06
could O 0 1.3899823898100294e-05
cause O 0 3.863084657496074e-06
the O 0 2.5576107987035357e-07
disorder O 0 2.9776207156828605e-05
by O 0 9.317751903381577e-09
studying O 0 1.1896038643044449e-07
mutations O 0 1.2474446009491658e-07
in O 0 2.1495571989049722e-09
the O 0 1.6320257145707728e-08
cardiac O 0 0.00014724084758199751
sodium O 0 1.1482841728138737e-05
channel O 0 1.4758537645320757e-06
gene O 0 9.94062816062069e-07
SCN5A O 0 6.0878261137986556e-05
. O 0 2.7372513500267814e-07

We O 0 1.7025879515131237e-06
have O 0 3.038720564063624e-08
now O 0 4.684383991815366e-09
identified O 0 2.102861884623053e-08
a O 0 3.559848238410268e-08
missense O 0 0.00015999138122424483
mutation O 0 7.751589691906702e-06
, O 0 6.301024702004554e-10
a O 0 3.92552257366674e-09
splice O 0 6.334798854368273e-06
- O 0 0.0001803264021873474
donor O 0 1.3871062947146129e-05
mutation O 0 4.6442539314739406e-05
, O 0 4.639728157229683e-09
and O 0 7.788124811725083e-09
a O 0 6.548823421326233e-07
frameshift O 0 0.07395331561565399
mutation O 0 2.3424368009727914e-06
in O 0 2.5327200336988653e-09
the O 0 3.626196676265181e-09
coding O 0 2.769627940324426e-07
region O 0 5.926350521434642e-09
of O 0 3.975780260567774e-10
SCN5A O 0 0.0004831745754927397
in O 0 3.2668747707020884e-08
three O 0 2.3393509707148041e-07
IVF B-Disease 1 0.9997699856758118
families O 0 1.3855178622179665e-06
. O 0 7.067769161039905e-07

We O 0 2.2554182521616895e-07
show O 0 2.9124210598752143e-08
that O 0 4.606403314344476e-10
sodium O 0 9.176915227726568e-09
channels O 0 1.311596609099297e-09
with O 0 4.532903497000973e-10
the O 0 5.502335920226642e-09
missense O 0 1.211321523442166e-05
mutation O 0 3.4187921755801653e-06
recover O 0 3.8218857412175566e-07
from O 0 1.6291482607400098e-09
inactivation O 0 1.996815626625903e-06
more O 0 2.027885637190252e-10
rapidly O 0 2.9869784423652845e-09
than O 0 3.91275317701556e-10
normal O 0 1.963146090133705e-09
and O 0 1.2778870184249058e-09
that O 0 2.4805086873413984e-09
the O 0 1.0291095087211488e-08
frameshift O 0 0.001200670376420021
mutation O 0 3.013710283994442e-06
causes O 0 1.8788336220154633e-08
the O 0 8.456892408581496e-10
sodium O 0 1.0546806095135253e-07
channel O 0 7.283521341605592e-08
to O 0 3.3589586667659432e-09
be O 0 3.276697313481236e-08
non O 0 4.0067220652417745e-08
- O 0 2.2593310859519988e-05
functional O 0 3.6918738715030486e-06
. O 0 6.015605436004989e-07

Our O 0 1.0388191640231526e-06
results O 0 1.7773999161363463e-07
indicate O 0 1.0605670297536562e-07
that O 0 5.972034422541128e-09
mutations O 0 3.243066259983607e-07
in O 0 9.50700229651602e-09
cardiac O 0 4.367622750578448e-05
ion O 0 0.0011837577912956476
- O 0 0.0020223611500114202
channel O 0 7.378539521596394e-07
genes O 0 4.915920115422523e-09
contribute O 0 3.265009096420357e-10
to O 0 1.7637573346274138e-10
the O 0 2.1913930670081072e-09
risk O 0 3.2154783724536173e-08
of O 0 5.539811387400562e-10
developing O 0 5.699839675799012e-07
IVF B-Disease 1 0.9997442364692688
. O 0 3.885515980073251e-07
. O 0 3.060402207211155e-07

Molecular O 0 5.3849849791731685e-05
heterogeneity O 0 6.57630298519507e-05
in O 0 2.704280461784947e-07
mucopolysaccharidosis B-Disease 0 0.0001573795307194814
IVA I-Disease 0 0.0014284400967881083
in O 0 3.3610052696531056e-07
Australia O 0 4.680733667328241e-08
and O 0 2.193686121643168e-08
Northern O 0 2.9315147642705597e-08
Ireland O 0 5.384213181969244e-07
: O 0 3.4597187337226387e-09
nine O 0 5.64574553774122e-10
novel O 0 5.81801318233488e-09
mutations O 0 3.785241631248937e-08
including O 0 5.805927405511113e-10
T312S O 0 1.5355351479229284e-06
, O 0 2.3902912982265434e-09
a O 0 2.3553676342658036e-08
common O 0 2.306254174300193e-07
allele O 0 3.836851192318136e-07
that O 0 8.208408175391924e-09
confers O 0 1.7105919596360764e-06
a O 0 1.7546578874316765e-06
mild O 0 0.0034579390194267035
phenotype O 0 0.008424011990427971
. O 0 1.6089107930383761e-06

Mucopolysaccharidosis B-Disease 0 0.01862248219549656
IVA I-Disease 1 0.5303956866264343
( O 0 2.3111047994461842e-05
MPS B-Disease 1 0.999581515789032
IVA I-Disease 1 0.999977707862854
) O 0 1.0560318060015561e-06
is O 0 1.4196638176144916e-07
an O 0 1.5924990748317214e-06
autosomal B-Disease 1 0.9997743964195251
recessive I-Disease 1 0.9999114274978638
lysosomal I-Disease 1 0.9999793767929077
storage I-Disease 1 0.999995231628418
disorder I-Disease 1 0.9998499155044556
caused O 0 0.0006610516575165093
by O 0 2.2135036203962954e-07
a O 0 0.0015739091904833913
genetic B-Disease 1 0.9999958276748657
defect I-Disease 1 0.999994158744812
in O 0 4.3217110601290187e-07
N O 0 4.6637956984341145e-05
- O 0 4.6208708226913586e-05
acetylgalactosamine O 0 0.0001738432329148054
- O 0 0.0007242957944981754
6 O 0 1.6504078530488187e-06
- O 0 0.02257053554058075
sulfate O 0 0.04222480207681656
sulfatase O 0 0.00043319229735061526
( O 0 2.7969829119456335e-08
GALNS O 0 9.484883776167408e-06
) O 0 7.3213191065235605e-09
. O 0 3.6643132972358217e-08

Previous O 0 3.744608875422273e-06
studies O 0 1.263277482621561e-07
of O 0 2.9177962268533975e-09
patients O 0 4.0683907798211294e-08
from O 0 1.0402610994830752e-09
a O 0 7.554447023494504e-08
British O 0 3.931471655960195e-05
- O 0 0.0005366801633499563
Irish O 0 3.153026227664668e-06
population O 0 2.717802649598866e-09
showed O 0 2.431596044516482e-07
that O 0 1.3437506662938858e-09
the O 0 6.70364541655033e-10
I113F O 0 9.626155872410891e-08
mutation O 0 2.7182551320947823e-08
is O 0 3.5780745033520134e-10
the O 0 1.2919390557364352e-10
most O 0 1.0274733286408377e-09
common O 0 1.565336305020537e-08
single O 0 5.405593583418522e-06
mutation O 0 2.000657877943013e-05
among O 0 5.028202281209815e-07
MPS B-Disease 1 0.9999254941940308
IVA I-Disease 1 0.999997615814209
patients O 0 0.0009268478606827557
and O 0 1.6265242948065861e-06
produces O 0 2.08477649721317e-06
a O 0 1.2225998943904415e-05
severe O 0 0.03539106249809265
clinical O 0 0.00040399827412329614
phenotype O 0 0.03501523658633232
. O 0 4.787267243955284e-06

We O 0 2.0518191377050243e-06
studied O 0 5.411790766629565e-07
mutations O 0 6.042807854100829e-07
in O 0 3.0264277750546853e-09
the O 0 1.947534356006031e-09
GALNS O 0 4.284770056983689e-06
gene O 0 1.0357811497385683e-08
from O 0 1.0038633257991592e-09
23 O 0 2.9319271455108264e-09
additional O 0 1.8630963438681647e-08
MPS B-Disease 1 0.9998099207878113
IVA I-Disease 1 0.9999947547912598
patients O 0 4.4521744712255895e-05
( O 0 2.3677395599719375e-09
15 O 0 4.4252645992060025e-10
from O 0 3.6442218687149364e-10
Australia O 0 9.247286492097828e-09
, O 0 3.171649054500847e-10
8 O 0 4.597582037302317e-10
from O 0 6.666909802000021e-10
Northern O 0 1.9231725545409972e-08
Ireland O 0 2.497532420875359e-07
) O 0 4.415888488207287e-10
, O 0 4.9353153508402414e-11
with O 0 1.7215037728668392e-10
various O 0 4.2626835394798945e-09
clinical O 0 2.8219215892022476e-05
phenotypes O 0 0.0017615637043491006
( O 0 2.8734828561027825e-07
severe O 0 0.00023863476235419512
, O 0 1.0365049973870555e-07
16 O 0 1.0195323696393643e-08
cases O 0 1.0510896153448357e-08
; O 0 6.239222472004258e-09
intermediate O 0 4.754253879468706e-08
, O 0 2.3869382026475705e-09
4 O 0 1.0880556011727549e-08
cases O 0 3.3400880283807055e-08
; O 0 1.2264158044672513e-07
mild O 0 5.925996447331272e-06
, O 0 1.4936144765442805e-08
3 O 0 1.7174748734305467e-08
cases O 0 2.809033539108441e-08
) O 0 4.4595687143100804e-08
. O 0 3.1377109621644195e-07

We O 0 1.2053178579662926e-06
found O 0 1.5615254866929718e-08
two O 0 5.495798816035347e-10
common O 0 2.2600683990958714e-08
mutations O 0 1.7397751150838303e-07
that O 0 8.643581961287339e-10
together O 0 7.549066927126091e-10
accounted O 0 5.19546583532815e-09
for O 0 1.6982736050774605e-10
32 O 0 3.609240961655047e-10
% O 0 1.1419254430933279e-10
of O 0 5.94800805830964e-11
the O 0 5.1414739132837894e-09
44 O 0 3.0844768961202362e-09
unrelated O 0 1.4192252706379804e-07
alleles O 0 3.280355187484929e-08
in O 0 2.025510248415685e-08
these O 0 4.821520604991747e-08
patients O 0 9.879988738248358e-07
. O 0 7.343558650063642e-07

One O 0 2.923464137438714e-07
is O 0 6.531942542409297e-09
the O 0 2.1675941042076374e-09
T312S O 0 1.8094109464072972e-06
mutation O 0 2.1014079720771406e-06
, O 0 1.00563024574285e-09
a O 0 7.193981854669573e-09
novel O 0 2.633362896631297e-07
mutation O 0 8.358038030564785e-07
found O 0 6.038110456074719e-09
exclusively O 0 1.3216245875469212e-08
in O 0 4.3532065063800474e-08
milder O 0 5.612648601527326e-05
patients O 0 5.031712589698145e-06
. O 0 1.1097250762759359e-06

The O 0 3.77429785203276e-08
other O 0 1.4178250795637837e-09
is O 0 2.220449379919387e-09
the O 0 1.322007170401207e-09
previously O 0 9.376391574278387e-08
described O 0 7.267548198797158e-07
I113F O 0 3.675204709452373e-07
that O 0 1.296408225215373e-08
produces O 0 4.5627825073779604e-08
a O 0 3.8220969145186245e-07
severe O 0 0.00040614252793602645
phenotype O 0 0.002067215507850051
. O 0 1.4848708360659657e-06

The O 0 8.61048334854786e-08
I113F O 0 5.979993034088693e-07
and O 0 5.56125234751903e-09
T312S O 0 9.756006136285578e-08
mutations O 0 4.733659864086803e-08
accounted O 0 6.6595542413949715e-09
for O 0 1.278113032077144e-10
8 O 0 1.4417192994997663e-09
( O 0 3.335602904996904e-10
18 O 0 1.0890952584219349e-09
% O 0 2.0959123325781093e-10
) O 0 1.004056282560839e-10
and O 0 6.032400801103677e-09
6 O 0 1.1203033167817011e-08
( O 0 2.819148248178749e-10
14 O 0 3.37239292047542e-10
% O 0 1.6578892425567204e-10
) O 0 2.8577690561193414e-11
of O 0 6.684630626807575e-11
44 O 0 2.00788452531242e-09
unrelated O 0 2.1964854113321053e-07
alleles O 0 1.2626450995867344e-07
, O 0 1.956123796276188e-08
respectively O 0 1.1636630006250925e-06
. O 0 4.2882589923465275e-07

The O 0 2.89606134629139e-07
relatively O 0 2.8072184932170785e-07
high O 0 1.3833205514401925e-07
residual O 0 2.189880979130976e-05
GALNS O 0 5.529163536266424e-05
activity O 0 6.96493955842925e-08
seen O 0 3.2373058900248e-08
when O 0 5.733931662810221e-10
the O 0 1.9388939065390076e-10
T312S O 0 5.793297397360675e-09
mutant O 0 6.0573279725417706e-09
cDNA O 0 5.4987476794110535e-09
is O 0 1.5474884706989656e-09
overexpressed O 0 2.4640792162244907e-07
in O 0 1.4152853333726512e-09
mutant O 0 1.36735181399672e-07
cells O 0 1.4777740808824547e-08
provides O 0 9.204643713900396e-10
an O 0 2.1734719579669104e-10
explanation O 0 1.1464965865570775e-08
for O 0 1.0583431908628427e-09
the O 0 4.0025518899255985e-08
mild O 0 0.00033342017559334636
phenotype O 0 0.00036935205571353436
in O 0 1.1166471836077108e-07
patients O 0 3.547200577713738e-08
with O 0 8.063442358263728e-09
this O 0 2.838408477146004e-07
mutation O 0 2.7261967261438258e-05
. O 0 2.9559396352851763e-07

The O 0 4.285994137376292e-08
distribution O 0 1.079279421389856e-08
and O 0 1.3203566018304969e-09
relative O 0 1.2067316035313524e-08
frequencies O 0 9.8154497862879e-09
of O 0 7.336548729641734e-11
the O 0 8.797199080312623e-10
I113F O 0 1.1965705937200255e-07
and O 0 2.1795711901972936e-09
T312S O 0 8.233296000526025e-08
mutations O 0 2.157637801758483e-08
in O 0 5.578449369103566e-10
Australia O 0 9.586881288825566e-10
corresponded O 0 8.922268257549604e-09
to O 0 1.175947561549151e-09
those O 0 2.265786225308375e-09
observed O 0 8.300544607209304e-08
in O 0 1.0284208151745133e-08
Northern O 0 2.8642729077432705e-08
Ireland O 0 9.418007493877667e-07
and O 0 4.7127958424653116e-08
are O 0 9.7058483472523e-10
unique O 0 2.6272202191535143e-09
to O 0 6.292736887125727e-10
these O 0 1.826163387175228e-10
two O 0 3.337766729671898e-10
populations O 0 2.4050674785058845e-09
, O 0 2.6285321141905627e-10
suggesting O 0 2.1216116863342904e-08
that O 0 2.108270225065212e-09
both O 0 6.90834667249618e-10
mutations O 0 5.778953138246834e-08
were O 0 4.668153508191608e-08
probably O 0 1.4664186664958834e-07
introduced O 0 1.577023844845371e-08
to O 0 5.222408061555939e-10
Australia O 0 1.3169685342262483e-09
by O 0 1.105657565503293e-09
Irish O 0 1.7174528466057382e-07
migrants O 0 1.2766713242129413e-09
during O 0 1.8882990726609705e-09
the O 0 8.233225212705975e-10
19th O 0 9.413825807769172e-08
century O 0 2.0382147170039389e-07
. O 0 3.8603337770837243e-07

Haplotype O 0 0.0005531464703381062
analysis O 0 3.504427752432093e-07
using O 0 3.532893089186473e-08
6 O 0 3.97190369483269e-08
RFLPs O 0 5.660085662384517e-07
provides O 0 1.2871630428179515e-09
additional O 0 1.5862776370223486e-10
data O 0 1.2420748873864795e-08
that O 0 9.014290980324802e-10
the O 0 1.5595541524859868e-09
I113F O 0 1.1097334891019273e-06
mutation O 0 1.733888410626605e-07
originated O 0 9.211954754562157e-09
from O 0 4.5751175070662953e-10
a O 0 3.6844902240318333e-08
common O 0 2.3410404992318945e-07
ancestor O 0 5.1847264330717735e-06
. O 0 1.0661409532986e-06

The O 0 5.7361798866395475e-08
other O 0 1.7837321619751378e-09
9 O 0 1.3222498651543901e-08
novel O 0 2.299278811790373e-08
mutations O 0 4.783095732818765e-07
identified O 0 3.1190850791062985e-07
in O 0 2.9575499826961504e-09
these O 0 5.713345352376109e-09
23 O 0 1.0020124818765908e-07
patients O 0 1.738727739564183e-08
were O 0 1.4845769946703058e-08
each O 0 1.7423456011300686e-09
limited O 0 3.3572933322290055e-09
to O 0 1.8716721505995793e-09
a O 0 8.860220646056405e-08
single O 0 4.407484539115103e-06
family O 0 1.7909590042108903e-06
. O 0 9.39439757985383e-07

These O 0 5.134028668862811e-08
data O 0 3.6267103098452935e-08
provide O 0 1.5736096870000438e-09
further O 0 2.8672322849310206e-10
evidence O 0 3.179166929712096e-09
for O 0 3.916628410483014e-10
extensive O 0 9.869538786233534e-08
allelic O 0 2.8534752345876768e-05
heterogeneity O 0 2.7976848286925815e-05
in O 0 2.3987431632122025e-06
MPS B-Disease 1 0.9995051622390747
IVA I-Disease 1 0.9999600648880005
in O 0 3.8332118492689915e-06
British O 0 0.00021555896091740578
- O 0 0.32494091987609863
Irish O 0 0.00041133799823001027
patients O 0 1.1023441004454071e-07
and O 0 4.455562141458813e-09
provide O 0 7.930646694909171e-10
evidence O 0 7.0034760213388836e-09
for O 0 6.27592033897173e-10
their O 0 3.563406236750666e-09
transmission O 0 4.3266308580314217e-07
to O 0 9.121818300705797e-10
Australia O 0 1.173755981298541e-09
by O 0 1.8143946345361428e-09
British O 0 9.312847396358848e-06
- O 0 0.0018778766971081495
Irish O 0 1.9598082872107625e-06
migrants O 0 1.2668528448500638e-08
. O 0 5.030098559899443e-09
. O 0 6.058277790543798e-08

Identification O 0 3.3300807444902603e-06
of O 0 2.295466572377336e-08
constitutional O 0 2.2778476704843342e-06
WT1 O 0 0.009527488611638546
mutations O 0 0.0001977628853637725
, O 0 2.1604259714536056e-08
in O 0 5.280849535438392e-08
patients O 0 1.1619192719081184e-07
with O 0 4.4515212493934087e-07
isolated O 0 0.038027625530958176
diffuse B-Disease 1 0.9999057054519653
mesangial I-Disease 1 0.9999995231628418
sclerosis I-Disease 1 0.9999997615814209
, O 0 5.424413984655985e-07
and O 0 6.819938835889161e-09
analysis O 0 6.107701455704273e-09
of O 0 8.881603008603633e-09
genotype O 0 0.18805161118507385
/ O 0 0.00010937979095615447
phenotype O 0 3.1197923817671835e-05
correlations O 0 8.726189548724506e-07
by O 0 2.670100140989007e-09
use O 0 1.4732065345413048e-08
of O 0 1.7560478626776899e-09
a O 0 6.935906640137546e-07
computerized O 0 0.023935016244649887
mutation O 0 7.562284736195579e-05
database O 0 4.218478352413513e-06
. O 0 3.8142209746183653e-07

Constitutional O 0 8.157488082360942e-06
mutations O 0 1.0611689504003152e-05
of O 0 8.320323097166238e-09
the O 0 1.162888718653221e-08
WT1 O 0 3.871412263833918e-05
gene O 0 1.0028460906141845e-07
, O 0 2.6655291862631714e-10
encoding O 0 4.234636641342604e-09
a O 0 1.6325869012234762e-07
zinc O 0 0.17846503853797913
- O 0 4.0186136175179854e-05
finger O 0 2.396909394519753e-06
transcription O 0 2.5394255587229964e-08
factor O 0 4.600355651973587e-09
involved O 0 5.346878495515739e-09
in O 0 2.6809820496964676e-07
renal O 0 0.03180773928761482
and O 0 1.957660060725175e-06
gonadal O 0 0.0026138117536902428
development O 0 5.273190240018266e-08
, O 0 1.4829892869272499e-08
are O 0 1.8170128734951163e-09
found O 0 1.6201502361923303e-08
in O 0 5.731092045380137e-09
most O 0 2.583655245302907e-08
patients O 0 1.1757894213815234e-07
with O 0 2.435045189486118e-06
Denys B-Disease 1 0.9999008178710938
- I-Disease 1 0.9999949932098389
Drash I-Disease 1 0.9999878406524658
syndrome I-Disease 1 0.9999912977218628
( O 0 3.062558789679315e-06
DDS B-Disease 1 0.9999964237213135
) O 0 9.817400581368929e-08
, O 0 2.575807123150753e-08
or O 0 1.6644798961351626e-05
diffuse B-Disease 1 0.9984933137893677
mesangial I-Disease 1 0.9999994039535522
sclerosis I-Disease 1 0.9999998807907104
( O 0 5.3903750085737556e-05
DMS B-Disease 1 0.8490579128265381
) O 0 1.5743129466727623e-08
associated O 0 1.0117106086227068e-07
with O 0 8.682434327056399e-07
pseudohermaphroditism B-Disease 1 0.9999984502792358
and O 0 0.0001587643928360194
/ O 0 0.0008205237099900842
or O 0 0.00023007637355476618
Wilms B-Disease 1 0.9895981550216675
tumor I-Disease 1 0.6810184121131897
( O 0 8.796652764431201e-06
WT B-Disease 1 0.9999545812606812
) O 0 1.034332512972469e-07
. O 0 2.6653700047063467e-07

Most O 0 2.0661238977481844e-06
mutations O 0 7.811483374098316e-05
in O 0 7.855192961869761e-06
DDS B-Disease 1 0.9999966621398926
patients O 0 0.00010961430962197483
lie O 0 0.00011322746286168694
in O 0 2.4064361170417214e-08
exon O 0 1.26222248582053e-05
8 O 0 2.6602345215565038e-08
or O 0 8.037123855331174e-09
exon O 0 1.6028170648496598e-06
9 O 0 2.0061477812305384e-08
, O 0 1.5250545271072724e-10
encoding O 0 4.238903450470843e-09
zinc O 0 8.150160283548757e-05
finger O 0 1.749681587170926e-06
2 O 0 1.2034745644484701e-08
or O 0 7.143626135075465e-08
zinc O 0 0.0017226326745003462
finger O 0 3.789662150666118e-05
3 O 0 2.7470203889379263e-08
, O 0 3.1494848951041376e-09
respectively O 0 2.676852872696145e-08
, O 0 2.0923414389972805e-10
with O 0 8.97574015112923e-10
a O 0 4.341196415680315e-07
hot O 0 7.613433990627527e-05
spot O 0 3.432697485550307e-05
( O 0 2.08975015070223e-09
R394W O 0 1.6255144785759512e-08
) O 0 1.0346073997524741e-10
in O 0 8.966722364611712e-10
exon O 0 3.790443543039146e-06
9 O 0 4.7477931275352603e-07
. O 0 2.4859289737833024e-07

We O 0 3.2762540058683953e-07
analyzed O 0 2.0049931492849282e-07
a O 0 2.3893935718888315e-09
series O 0 2.672306154138937e-09
of O 0 1.5694373578512e-09
24 O 0 2.776313294816646e-07
patients O 0 1.0305320330417089e-07
, O 0 4.382813667547225e-09
10 O 0 2.2199242444287393e-09
with O 0 4.560181210422343e-08
isolated B-Disease 0 0.00018936986452899873
DMS I-Disease 1 0.9925138354301453
( O 0 1.8431462933676812e-07
IDMS B-Disease 0 0.002411531750112772
) O 0 2.184178171660278e-09
, O 0 5.416407322655914e-10
10 O 0 3.677276261271345e-10
with O 0 1.1185785808720539e-07
DDS B-Disease 1 0.9999996423721313
, O 0 1.1948898759328586e-07
and O 0 1.9279616125800203e-08
4 O 0 1.6832924387699677e-08
with O 0 2.6376557116236654e-07
urogenital B-Disease 1 0.9080676436424255
abnormalities I-Disease 1 0.9995417594909668
and O 0 6.828995537944138e-05
/ O 0 0.005285205319523811
or O 0 0.003697867039591074
WT B-Disease 1 0.9999531507492065
. O 0 5.3312210184230935e-06

We O 0 3.974369974457659e-06
report O 0 2.832402685726265e-07
WT1 O 0 8.226252248277888e-06
heterozygous O 0 2.087816483253846e-06
mutations O 0 2.361948190809926e-06
in O 0 2.003065979749863e-08
16 O 0 6.635415417122204e-08
patients O 0 9.713282622669794e-08
, O 0 4.006330378558687e-09
4 O 0 5.259295665638319e-09
of O 0 1.991499187781187e-09
whom O 0 5.7073525567830075e-06
presented O 0 1.098716620617779e-05
with O 0 1.907324985950254e-05
IDMS B-Disease 1 0.9909163117408752
. O 0 6.62959200781188e-06

One O 0 7.446565177815501e-07
male O 0 1.5098054291229346e-06
and O 0 9.856836236110667e-09
two O 0 4.4125169296194144e-08
female O 0 0.12284572422504425
IDMS B-Disease 1 0.9992678761482239
patients O 0 1.191584760817932e-05
with O 0 8.349625204573385e-07
WT1 O 0 0.03884119912981987
mutations O 0 7.146030111471191e-05
underwent O 0 0.00014932293561287224
normal O 0 7.790661584294867e-06
puberty O 0 2.254445462313015e-05
. O 0 2.1642620140482904e-07

Two O 0 8.433742664237798e-07
mutations O 0 9.497754945186898e-05
associated O 0 2.2241183614823967e-06
with O 0 3.522135614275612e-07
IDMS B-Disease 1 0.6989739537239075
are O 0 2.85009278400139e-08
different O 0 5.1991605465318e-10
from O 0 1.3555070399462466e-09
those O 0 2.3886292055408376e-08
described O 0 3.175018719048239e-05
in O 0 0.00013935753668192774
DDS B-Disease 1 0.9999982118606567
patients O 0 0.00016605255950707942
. O 0 1.9947829059674405e-06

No O 0 1.7128959370893426e-05
WT1 O 0 0.0005705788498744369
mutations O 0 4.923011510982178e-05
were O 0 1.1599662030903346e-07
detected O 0 4.279208496882347e-06
in O 0 3.119294378350901e-09
the O 0 1.5581537171627247e-09
six O 0 1.980870045770189e-08
other O 0 1.357249317379683e-07
IDMS B-Disease 1 0.9128236174583435
patients O 0 8.965855613496387e-07
, O 0 4.582386026186214e-09
suggesting O 0 2.842346873421775e-07
genetic O 0 2.0810767864531954e-07
heterogeneity O 0 2.535167595851817e-07
of O 0 5.609329445377398e-09
this O 0 4.753528628498316e-06
disease O 0 0.0006120541947893798
. O 0 4.16777311329497e-06

We O 0 4.033085588162066e-06
analyzed O 0 1.816512485675048e-05
genotype O 0 0.0058592576533555984
/ O 0 3.718649168149568e-05
phenotype O 0 4.556611384032294e-05
correlations O 0 9.037934432853945e-06
, O 0 6.369346383650054e-09
on O 0 7.066918161768854e-09
the O 0 5.054215934663375e-10
basis O 0 1.0765732749717927e-09
of O 0 1.0269613631708197e-10
the O 0 8.45025294182733e-09
constitution O 0 2.9745501617384207e-09
of O 0 8.521622990587119e-11
a O 0 7.515441780014953e-08
WT1 O 0 5.9822455114044715e-06
mutation O 0 3.845210017061618e-08
database O 0 2.294681777925689e-09
of O 0 1.362065737975371e-10
84 O 0 7.014866465482328e-09
germ O 0 0.0010611467296257615
- O 0 0.0002540621208027005
line O 0 2.009051058848854e-05
mutations O 0 3.179193299729377e-07
, O 0 1.6022906612622734e-10
to O 0 8.12396400151627e-11
compare O 0 1.5310687828673508e-08
the O 0 1.938505606036145e-10
distribution O 0 4.330378555739145e-10
and O 0 2.0708867953800336e-09
type O 0 1.9022870390017488e-07
of O 0 1.2403885696343764e-09
mutations O 0 8.293469591080793e-07
, O 0 1.5952046350520277e-09
according O 0 2.0097199460167303e-09
to O 0 5.003494840671863e-10
the O 0 7.325845263750352e-09
different O 0 7.458961448492119e-08
symptoms O 0 2.0136028979322873e-05
. O 0 2.997315675656864e-07

This O 0 1.2550637507047213e-07
demonstrated O 0 2.900392246374395e-07
( O 0 1.1871208460689786e-09
1 O 0 1.0474745515409722e-09
) O 0 8.91751186782308e-11
the O 0 4.499799144408456e-10
association O 0 1.5096528471758575e-09
between O 0 2.0983694781762097e-09
mutations O 0 1.3578525681623432e-07
in O 0 2.6155855259446525e-09
exons O 0 1.7319597134246578e-07
8 O 0 6.158094034702799e-09
and O 0 5.8230087418564835e-09
9 O 0 5.894180787890946e-08
and O 0 2.150612630202886e-07
DMS B-Disease 0 0.0683508813381195
; O 0 2.327904624621624e-08
( O 0 2.7522148449143913e-10
2 O 0 2.056766978952851e-09
) O 0 4.599248204506523e-10
among O 0 5.362422950128121e-09
patients O 0 1.0287095619787578e-07
with O 0 4.3361936263863754e-07
DMS B-Disease 1 0.5760286450386047
, O 0 4.03756805766875e-09
a O 0 8.025482500784165e-09
higher O 0 1.4664474079495449e-08
frequency O 0 1.6433459038012188e-08
of O 0 1.5628706662162983e-10
exon O 0 2.030829364230158e-06
8 O 0 2.000278875868844e-08
mutations O 0 6.394570561951696e-08
among O 0 1.0678490314219857e-09
46 O 0 9.026975611448051e-09
, O 0 6.311542932735392e-08
XY O 0 7.840319449314848e-05
patients O 0 7.350341491019208e-08
with O 0 1.9655374217109056e-08
female O 0 5.2442312153289095e-05
phenotype O 0 1.1690616702253465e-05
than O 0 4.410217968597863e-09
among O 0 2.5958988292273943e-09
46 O 0 2.9121322242531278e-08
, O 0 1.016395074771026e-07
XY O 0 0.0005989224882796407
patients O 0 6.63406183321058e-08
with O 0 4.117790552982115e-09
sexual O 0 3.267049635269359e-07
ambiguity O 0 3.191015593984048e-07
or O 0 2.4673602183611365e-06
male O 0 0.0001357460714643821
phenotype O 0 0.00010137961362488568
; O 0 2.9153165215234367e-08
and O 0 3.356936417731049e-08
( O 0 2.2247903519456713e-09
3 O 0 3.485364219457665e-09
) O 0 1.8977365512373723e-10
statistically O 0 2.188890846355207e-09
significant O 0 8.256672567874546e-10
evidence O 0 1.508877005562681e-07
that O 0 4.997052727162554e-08
mutations O 0 7.931365075819485e-08
in O 0 4.2068144523454976e-09
exons O 0 1.9079338642313814e-07
8 O 0 1.1900004537324094e-08
and O 0 1.1745203032376139e-08
9 O 0 2.2638261043539387e-08
preferentially O 0 6.377968020387925e-07
affect O 0 2.800046594586547e-08
amino O 0 5.407625458531129e-09
acids O 0 4.709806988856258e-10
with O 0 9.76213554437777e-11
different O 0 1.7275067487609874e-10
functions O 0 2.456871595057919e-09
. O 0 1.1643025210616997e-08
. O 0 9.994737837359935e-08

The O 0 4.6590182023464877e-07
185delAG O 0 2.1967292923363857e-05
BRCA1 O 0 3.9166901842691004e-05
mutation O 0 1.3017374840273988e-06
originated O 0 3.806171733344854e-08
before O 0 5.569316674503e-10
the O 0 1.025743726068562e-10
dispersion O 0 6.319662304576923e-08
of O 0 2.0071523609832553e-10
Jews O 0 1.8364554321692594e-08
in O 0 2.2308883629307275e-09
the O 0 1.4609691234568345e-09
diaspora O 0 8.890687297480326e-09
and O 0 2.057572423552756e-08
is O 0 2.2788100295656477e-09
not O 0 8.989651800739296e-10
limited O 0 1.05672948169655e-09
to O 0 1.0562323460305834e-08
Ashkenazim O 0 4.281192104826914e-06
. O 0 2.653530941643112e-07

The O 0 2.6222858195978915e-07
185delAG O 0 7.70786118664546e-06
mutation O 0 5.167774361325428e-06
in O 0 3.111998481131195e-08
BRCA1 O 0 3.649677091743797e-05
is O 0 4.558024357947943e-08
detected O 0 3.3035737487807637e-06
in O 0 4.783102358629776e-09
Ashkenazi O 0 5.003538490200299e-07
Jews O 0 2.144161292960689e-08
both O 0 2.897935003076668e-09
in O 0 7.390603684598318e-08
familial B-Disease 1 0.9799224138259888
breast I-Disease 1 0.9999938011169434
and I-Disease 1 0.9999918937683105
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
and O 0 4.923325832351111e-06
in O 0 1.0861438859421924e-08
the O 0 2.336635773758644e-09
general O 0 1.0748729017961978e-08
population O 0 2.3061039300387165e-08
. O 0 1.3343618832095672e-07

All O 0 3.3728406378941145e-07
tested O 0 1.1096383786934894e-05
Ashkenazi O 0 1.559887095936574e-05
mutation O 0 8.6698928498663e-06
carriers O 0 8.2468744722064e-08
share O 0 1.7147156583519063e-08
the O 0 9.742849860217007e-10
same O 0 9.550257473733836e-09
allelic O 0 1.0617130783430184e-06
pattern O 0 1.0369552683187067e-06
at O 0 1.7281610809050107e-08
the O 0 3.44268435981121e-08
BRCA1 O 0 8.882611291483045e-05
locus O 0 0.00012279303336981684
. O 0 1.1844738310173852e-06

Our O 0 3.001506172495283e-07
previous O 0 9.571743220249118e-08
study O 0 1.1064175353681094e-08
showed O 0 4.0678560253581963e-07
that O 0 1.4626643229931346e-09
this O 0 2.319163749930908e-09
Ashkenazi O 0 1.0306042668162263e-06
mutation O 0 1.5545024325547274e-06
also O 0 1.3011024257991721e-08
occurs O 0 3.3666556209510645e-09
in O 0 3.9671826934650767e-10
Iraqi O 0 6.670146035503421e-08
Jews O 0 1.3271516330348732e-08
with O 0 1.6394910984374178e-09
a O 0 7.739821938912428e-08
similar O 0 4.0171602222471847e-07
allelic O 0 1.7581471183802933e-05
pattern O 0 2.115172173944302e-05
. O 0 2.8896360504404583e-07

We O 0 2.445069355871965e-07
extended O 0 6.3198766220295965e-09
our O 0 1.0576691744645927e-09
analysis O 0 4.3457520915168857e-10
to O 0 1.171183705572787e-10
other O 0 1.478615563321739e-10
non O 0 4.5969703599269e-09
- O 0 3.8647834799121483e-07
Ashkenazi O 0 2.8782816130501487e-08
subsets O 0 1.0754717116867596e-08
354 O 0 2.1318449228147074e-09
of O 0 1.682603778530023e-10
Moroccan O 0 1.0564942840574076e-06
origin O 0 1.8792960077007592e-08
, O 0 3.9274231089514444e-10
200 O 0 6.62349841640264e-10
Yemenites O 0 1.10270995890005e-07
and O 0 2.308004010131981e-09
150 O 0 1.792087034324652e-09
Iranian O 0 6.765229443317367e-08
Jews O 0 1.5751606952107977e-07
. O 0 1.8575828164557606e-07

Heteroduplex O 0 6.915078120073304e-05
analysis O 0 1.320051694619906e-07
complemented O 0 5.0509925131336786e-08
by O 0 8.795554840013153e-10
direct O 0 3.3805735988323704e-09
DNA O 0 3.8292252924065906e-08
sequencing O 0 1.383983772029751e-08
of O 0 1.5288064147966907e-09
abnormally O 0 1.6498364630024298e-06
migrating O 0 1.9071729084885192e-08
bands O 0 5.719737217191323e-08
were O 0 3.309458662670295e-08
employed O 0 3.9655532191318343e-07
. O 0 6.371013228090305e-08

Four O 0 2.3349260303007213e-08
of O 0 5.044642481522033e-10
Moroccan O 0 1.7647065533310524e-06
origin O 0 2.81120975387239e-08
( O 0 2.3249115133072706e-10
1 O 0 1.581223901814255e-10
. O 0 1.0029441166459208e-10
1 O 0 8.913333959803538e-10
% O 0 4.976882239660085e-10
) O 0 2.0998656979909214e-10
and O 0 7.624970876918269e-09
none O 0 2.0042659087948778e-08
of O 0 1.0632269370480785e-10
the O 0 8.38378966250275e-09
Yemenites O 0 1.3991198102303315e-06
or O 0 1.505220126318818e-08
Iranians O 0 7.3504367037458e-09
was O 0 1.8775331511733384e-08
a O 0 9.35932487067248e-09
carrier O 0 1.5428129529482248e-07
of O 0 2.4914845186962964e-10
the O 0 2.3049608444125624e-08
185delAG O 0 1.3542186025006231e-05
mutation O 0 5.5826867537689395e-06
. O 0 2.4155050937224587e-07

BRCA1 O 0 0.006395558826625347
allelic O 0 0.0008657486760057509
patterns O 0 0.0001059203059412539
were O 0 5.445957285132863e-08
determined O 0 8.40874463392538e-08
for O 0 2.050049019430844e-10
four O 0 5.258520840989434e-10
of O 0 1.2297238227709784e-10
these O 0 1.1443942460331868e-09
individuals O 0 4.4908221585870933e-10
and O 0 1.5091634608666027e-09
for O 0 4.6553802479643025e-10
12 O 0 2.447272939853917e-10
additional O 0 3.6947822579236345e-10
non O 0 8.034871434858815e-09
- O 0 7.72630392020801e-06
Ashkenazi O 0 6.448910880862968e-07
185delAG O 0 4.1582430299058615e-07
mutation O 0 1.3876558568881592e-07
carriers O 0 6.22576834530264e-08
who O 0 2.793939302137005e-07
had O 0 0.00039853513590060174
breast B-Disease 1 0.9999682903289795
/ I-Disease 1 0.9999915361404419
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999991655349731
. O 0 0.0003413801023270935

Six O 0 6.151288403088984e-07
non O 0 4.846613705922209e-07
- O 0 6.0481539549073204e-05
Ashkenazi O 0 6.166269031382399e-06
individuals O 0 4.828641042564641e-09
shared O 0 1.977442565248566e-08
the O 0 1.4557822503036277e-08
common O 0 3.624518569722568e-07
Ashkenazi O 0 7.132425707823131e-06
haplotype O 0 2.841039349732455e-05
, O 0 2.648280261752234e-09
four O 0 2.9178797156248493e-09
had O 0 4.4748117034032475e-07
a O 0 1.2519961956058978e-07
closely O 0 4.5815406224392063e-07
related O 0 1.3921253128046374e-07
pattern O 0 2.8894203296658816e-06
, O 0 2.896851869493844e-09
and O 0 2.578140367859305e-09
the O 0 1.3489688255319265e-09
rest O 0 7.2888961533124075e-09
( O 0 1.3534376952506477e-09
n O 0 1.2551395229820628e-06
= O 0 6.394936917786254e-07
6 O 0 4.2362522378880385e-09
) O 0 3.188553865385302e-10
displayed O 0 3.8709364957867365e-07
a O 0 1.7488262926690368e-07
distinct O 0 1.0735390105764964e-06
BRCA1 O 0 0.0002152886736439541
allelic O 0 0.00010473575093783438
pattern O 0 0.00011037768126698211
. O 0 1.5874102246016264e-06

We O 0 3.6940889458492165e-07
conclude O 0 6.342920499946558e-08
that O 0 9.120653121641453e-10
the O 0 1.1709899716549899e-09
185delAG O 0 1.4735186596226413e-05
BRCA1 O 0 0.00025584781542420387
mutation O 0 4.107170752831735e-06
occurs O 0 1.1409969857822944e-08
in O 0 3.3848238101263917e-10
some O 0 1.517278663820676e-10
non O 0 2.2280360667537025e-08
- O 0 0.00016242060519289225
Ashkenazi O 0 4.375951448309934e-06
populations O 0 9.837378911470296e-09
at O 0 9.597242112135973e-09
rates O 0 1.6184228002202872e-07
comparable O 0 3.71484034644709e-08
with O 0 6.629033988403421e-10
that O 0 1.0507928749348139e-08
of O 0 1.64307003558406e-08
Ashkenazim O 0 4.646996603696607e-05
. O 0 9.914458587445552e-07

The O 0 6.671914576372728e-08
majority O 0 1.4003779469362598e-08
of O 0 6.47987052904142e-10
Jewish O 0 2.0342804418760352e-07
185delAG O 0 8.331097888003569e-06
mutation O 0 7.35133335183491e-06
carriers O 0 7.82489095740857e-08
have O 0 5.103720113197596e-09
a O 0 1.2143601679781568e-08
common O 0 1.0584572152083638e-07
allelic O 0 6.53584811516339e-06
pattern O 0 2.0729507014038973e-05
, O 0 2.0374744114093346e-09
supporting O 0 5.37270183897931e-09
the O 0 1.7836776500246287e-09
founder O 0 4.104509443436655e-08
effect O 0 5.9293920884329054e-09
notion O 0 7.297590087773642e-09
, O 0 5.971108607560893e-10
but O 0 7.913542598991796e-10
dating O 0 6.348475523054731e-08
the O 0 5.106921552311405e-10
mutations O 0 1.574198904563673e-08
origin O 0 8.428486242273436e-10
to O 0 2.256525383215191e-10
an O 0 4.4146339361894604e-10
earlier O 0 2.847691149554521e-08
date O 0 1.218632377231188e-07
than O 0 2.5826585314803197e-09
currently O 0 1.4303803475002042e-08
estimated O 0 4.203287673476552e-08
. O 0 1.195125776121131e-07

However O 0 9.965002618628205e-07
, O 0 2.235936102934488e-09
the O 0 4.936588915427365e-10
different O 0 7.466940399325495e-10
allelic O 0 5.828300686516741e-07
pattern O 0 1.4137206107989186e-06
at O 0 9.147015589405783e-09
the O 0 8.10519829030909e-09
BRCA1 O 0 2.2652620828012004e-05
locus O 0 2.2074311800679425e-06
even O 0 4.5902261547325907e-08
in O 0 1.1114636988551752e-09
some O 0 2.93611163160179e-10
Jewish O 0 1.813147321172437e-07
mutation O 0 1.4658847931059427e-06
carriers O 0 7.873381946410518e-08
, O 0 2.260774456530612e-09
might O 0 2.2361419382832537e-08
suggest O 0 5.043105932855951e-09
that O 0 1.6613405096066458e-09
the O 0 2.196431259093856e-09
mutation O 0 3.7005275999035803e-07
arose O 0 2.44144313654715e-08
independently O 0 3.2024779272887827e-08
. O 0 1.0600286870499076e-08
. O 0 5.932562530119867e-08

Crystal O 0 0.0008134371018968523
structure O 0 2.5067554361157818e-06
of O 0 3.787160363089015e-09
the O 0 5.648228125210153e-07
hemochromatosis B-Disease 1 0.9999974966049194
protein O 0 9.61887781159021e-05
HFE O 0 0.002149141626432538
and O 0 1.0597213773166914e-08
characterization O 0 1.525982042949181e-07
of O 0 1.4438099327218623e-10
its O 0 2.4466582093651823e-09
interaction O 0 9.600299222256581e-09
with O 0 4.6253987306954514e-08
transferrin O 0 0.00024346903956029564
receptor O 0 6.492294232884888e-06
. O 0 3.722294934505044e-07

HFE O 0 0.013613776303827763
is O 0 2.4499010464751336e-07
an O 0 6.903002613967146e-09
MHC O 0 4.941274528391659e-05
- O 0 1.842409801611211e-05
related O 0 1.5178741818999697e-07
protein O 0 2.6139858277929306e-08
that O 0 3.870239684289345e-09
is O 0 1.9073611579045746e-09
mutated O 0 2.337251814310548e-08
in O 0 1.4934856684689635e-09
the O 0 4.94247274218651e-08
iron B-Disease 1 0.9995463490486145
- I-Disease 1 0.9999743700027466
overload I-Disease 1 0.9999386072158813
disease I-Disease 1 0.9997397065162659
hereditary B-Disease 1 0.9999995231628418
hemochromatosis I-Disease 1 1.0
. O 0 0.008209623396396637

HFE O 0 0.0025411255192011595
binds O 0 5.24026108905673e-06
to O 0 4.883661830490382e-08
transferrin O 0 1.818304372136481e-05
receptor O 0 4.245988293405389e-06
( O 0 5.4884399247612237e-08
TfR O 0 0.00022395531414076686
) O 0 2.426899514684777e-10
and O 0 3.6928660129831314e-10
reduces O 0 8.25927504166657e-09
its O 0 2.1807679273511127e-10
affinity O 0 8.794586392468773e-09
for O 0 2.5424824467989993e-09
iron O 0 0.008494113571941853
- O 0 0.00018300047668162733
loaded O 0 1.262742625840474e-05
transferrin O 0 1.7777229004423134e-05
, O 0 1.450065045816018e-08
implicating O 0 9.044055332196876e-06
HFE O 0 0.00026117838569916785
in O 0 2.815696689140168e-07
iron O 0 0.013184189796447754
metabolism O 0 9.896032133838162e-05
. O 0 3.6568428640748607e-07

The O 0 6.707487614221463e-07
2 O 0 9.500694773123541e-07
. O 0 5.665140747623809e-07

6 O 0 2.4207868136727484e-06
A O 0 6.116522968113713e-07
crystal O 0 0.003017031354829669
structure O 0 2.6942793738271575e-06
of O 0 3.6361489375025258e-09
HFE O 0 0.002137844916433096
reveals O 0 1.4745552334716194e-06
the O 0 9.8129926406898e-10
locations O 0 2.1579879216915288e-08
of O 0 4.295143085641939e-08
hemochromatosis B-Disease 1 0.9999996423721313
mutations O 0 0.0013860056642442942
and O 0 6.988533129970165e-08
a O 0 1.95067357822154e-07
patch O 0 0.0003861029981635511
of O 0 5.6710462992271005e-09
histidines O 0 0.00010685352026484907
that O 0 1.8740134066774772e-07
could O 0 1.579411588181756e-07
be O 0 7.168231785925627e-09
involved O 0 3.79295084229625e-09
in O 0 7.444108973686525e-08
pH O 0 0.0027463422156870365
- O 0 0.0006782179116271436
dependent O 0 8.928159331844654e-07
interactions O 0 1.1082105402238085e-06
. O 0 4.6677706677655806e-07

We O 0 8.25686754524213e-07
also O 0 1.4261742009580303e-08
demonstrate O 0 6.04943224402632e-08
that O 0 7.047000138982185e-08
soluble O 0 0.0006091318791732192
TfR O 0 0.0008329619886353612
and O 0 1.3493374417805626e-08
HFE O 0 1.637171044421848e-05
bind O 0 1.1473775884951465e-07
tightly O 0 2.3753045752528124e-07
at O 0 3.4835827555923515e-09
the O 0 1.2297174389885868e-09
basic O 0 3.154145744588277e-08
pH O 0 1.7214046010849415e-07
of O 0 7.197584889206965e-11
the O 0 1.7201687851908787e-09
cell O 0 8.429589797742665e-06
surface O 0 0.0001659824192756787
, O 0 4.183945190305849e-09
but O 0 5.247411838382732e-09
not O 0 9.85910686424063e-10
at O 0 1.69512237579994e-09
the O 0 9.705870773757397e-09
acidic O 0 1.4890065358486027e-05
pH O 0 4.845980129175587e-06
of O 0 4.804333375574288e-09
intracellular O 0 0.00020656776905525476
vesicles O 0 0.0009127671364694834
. O 0 1.857109509728616e-06

TfR O 1 0.79258131980896
HFE O 0 0.005343504715710878
stoichiometry O 0 7.407130033243448e-05
( O 0 3.955422300805367e-08
2 O 0 2.455002201529055e-09
1 O 0 1.5206343961793323e-09
) O 0 2.072885474380115e-10
differs O 0 8.96371776804017e-09
from O 0 5.467999386610245e-09
TfR O 0 5.6632139603607357e-05
transferrin O 0 1.4315096450445708e-06
stoichiometry O 0 1.778020362053212e-07
( O 0 1.7649484651549585e-10
2 O 0 2.75845318808976e-10
2 O 0 3.8187622508623065e-10
) O 0 1.9041104803996234e-10
, O 0 1.729395793237387e-10
implying O 0 2.731430015501246e-08
a O 0 2.253369713045572e-09
different O 0 7.12954140169586e-11
mode O 0 2.064986182048756e-09
of O 0 3.08045221275588e-11
binding O 0 3.0098501468955874e-08
for O 0 3.1447786597027516e-09
HFE O 0 7.750462100375444e-05
and O 0 7.327161455350506e-08
transferrin O 0 2.1294708858476952e-05
to O 0 1.1386472920094093e-07
TfR O 0 0.002919898834079504
, O 0 1.268854576963463e-09
consistent O 0 3.03279712454696e-08
with O 0 9.863507788310244e-10
our O 0 4.91912777178527e-09
demonstration O 0 6.478320102587531e-08
that O 0 1.250434866761907e-08
HFE O 0 1.8920960428658873e-05
, O 0 1.0179462828219243e-09
transferrin O 0 1.3614278486784315e-06
, O 0 2.910953256218818e-09
and O 0 1.931355768647336e-07
TfR O 0 0.0004763246688526124
form O 0 1.3530899067859536e-08
a O 0 1.2199929244616214e-07
ternary O 0 1.898791379062459e-05
complex O 0 2.979764303745469e-06
. O 0 4.6234140427259263e-07

Identification O 0 1.056498263096728e-06
of O 0 2.410744270875398e-09
three O 0 3.6056166941023093e-09
novel O 0 1.5117548457510566e-07
mutations O 0 9.455373515265819e-07
and O 0 2.168012791514684e-08
a O 0 1.7145153208275588e-07
high O 0 3.7963479826430557e-07
frequency O 0 1.377557055093348e-07
of O 0 1.6308634998019045e-10
the O 0 7.99155586150846e-09
Arg778Leu O 0 1.8671624275157228e-05
mutation O 0 8.503465096509899e-07
in O 0 2.6268205388646493e-08
Korean O 0 1.5405059912154684e-06
patients O 0 1.2449214636944816e-07
with O 0 8.77074228355923e-07
Wilson B-Disease 0 0.24445445835590363
disease I-Disease 0 0.001040808274410665
. O 0 1.7309472468696185e-06

Four O 0 4.767121026816312e-07
mutations O 0 1.28843630591291e-05
- O 0 5.01332942803856e-05
- O 0 2.9294771593413316e-05
R778L O 0 1.0374023986514658e-06
, O 0 1.3332934756249415e-09
A874V O 0 8.298594700306694e-09
, O 0 9.97927573909152e-11
L1083F O 0 3.798685366263044e-09
, O 0 5.985838213984351e-11
and O 0 1.1343839062538663e-10
2304delC O 0 1.3080646787955175e-08
- O 0 2.0180837623229309e-07
- O 0 1.5715130530224997e-07
in O 0 1.4002757842135338e-09
the O 0 2.4130442088932114e-09
copper O 0 0.0001333664549747482
- O 0 2.5568962769284553e-07
transporting O 0 1.1336539706974236e-08
enzyme O 0 5.574293471255487e-09
, O 0 2.7890423304199885e-10
P O 0 8.859541935635207e-07
- O 0 1.043413249135483e-06
type O 0 1.3491836398316082e-05
ATPase O 0 1.4520749573421199e-05
( O 0 5.1718060944949684e-09
ATP7B O 0 3.422178224354866e-06
) O 0 2.2725585302474371e-10
, O 0 2.4115154317883025e-10
were O 0 2.2191169790630738e-08
identified O 0 3.145286655126256e-06
in O 0 2.884143555093033e-07
Korean O 0 1.5207781871140469e-05
Patients O 0 3.6494117239271873e-07
with O 0 2.0339091406640364e-06
Wilson B-Disease 0 0.13770265877246857
disease I-Disease 0 0.0005305871600285172
. O 0 6.831085102021461e-07

Arg778Leu O 0 0.00037222012178972363
, O 0 1.9295216091563816e-08
the O 0 8.35766567064411e-10
most O 0 8.377998295117095e-10
frequently O 0 5.790913704117884e-08
reported O 0 1.307301999986521e-07
mutation O 0 3.3587298275961075e-08
of O 0 1.6936964331026871e-10
this O 0 1.198080190611961e-09
enzyme O 0 1.1072027739089663e-08
, O 0 1.2989445075106687e-09
was O 0 4.970076474819507e-07
found O 0 4.909728801294477e-08
in O 0 2.4011164168058485e-09
six O 0 7.694010428771492e-10
of O 0 2.661099673950673e-10
eight O 0 5.964717075812587e-08
unrelated O 0 1.3990802472108044e-05
patients O 0 4.032498566175491e-07
studied O 0 1.347606968238324e-07
, O 0 4.4925183018129644e-10
an O 0 4.738117675984199e-10
allele O 0 5.2248939397259164e-08
frequency O 0 8.042049870482515e-08
of O 0 8.992155908771338e-10
37 O 0 3.708496976173592e-08
. O 0 1.6483159015479032e-07

5 O 0 3.769513909901434e-07
% O 0 2.3269855375929183e-08
, O 0 1.2241547775460049e-09
which O 0 3.2546956241219505e-09
is O 0 1.957992878942605e-09
considerably O 0 2.5211441823103087e-08
higher O 0 1.4010431037547733e-08
than O 0 9.219561225570772e-10
those O 0 7.548764391351881e-10
in O 0 1.3888699079700473e-09
other O 0 6.706791788602118e-10
Asian O 0 8.328261635881518e-09
populations O 0 4.365778494275219e-08
. O 0 6.114626671660517e-08

The O 0 8.683016261556986e-08
novel O 0 6.94734652029183e-08
single O 0 2.282970257283523e-08
nucleotide O 0 1.854142084312116e-07
deletion O 0 2.564229646395688e-07
, O 0 2.2678572353385107e-09
2304delC O 0 2.0193236593968322e-07
, O 0 2.3364306045436933e-09
was O 0 2.370425562503442e-07
found O 0 9.231676045828863e-08
in O 0 2.5625272570550806e-08
one O 0 5.385568897509074e-07
patient O 0 4.6293745981529355e-05
. O 0 1.068041910912143e-06

Since O 0 7.349359520958387e-07
a O 0 2.710241275849512e-08
mutation O 0 2.043043139110523e-07
at O 0 3.7771834549005234e-09
cDNA O 0 1.0819655216209867e-07
nucleotide O 0 1.5205995396172511e-06
2302 O 0 1.0687994290492497e-05
( O 0 1.3868872716926717e-09
2302insC O 0 1.0105842562779799e-07
) O 0 8.066160517294918e-10
had O 0 3.290274719347508e-08
been O 0 8.793667660711435e-08
previously O 0 1.6947376479947707e-07
described O 0 2.584994263088447e-06
, O 0 2.414052291399571e-09
this O 0 2.6003726949497263e-10
region O 0 2.5874055675778607e-10
of O 0 8.334387346931038e-11
the O 0 7.604303853270267e-09
ATP7B O 0 0.00022222535335458815
gene O 0 2.1330912147732306e-07
may O 0 3.5963262234872673e-07
be O 0 3.571995321749455e-08
susceptible O 0 8.127980436256621e-06
to O 0 2.3701943518972257e-08
gene O 0 2.0150425825704588e-06
rearrangements O 0 0.00799049623310566
causing O 0 0.002407003426924348
Wilson B-Disease 0 0.2251601666212082
disease I-Disease 0 0.0008594527607783675
. O 0 1.5636676380381687e-06

Disruption O 0 2.0298504750826396e-05
of O 0 4.545364085117853e-09
splicing O 0 3.335466658427322e-07
regulated O 0 8.932028805475056e-08
by O 0 2.1597243993198845e-09
a O 0 9.796076483326033e-08
CUG O 0 0.00020519382087513804
- O 0 1.0136967830476351e-05
binding O 0 5.355674375095987e-07
protein O 0 1.6148088661793736e-06
in O 0 1.0979048965964466e-05
myotonic B-Disease 1 0.9999963045120239
dystrophy I-Disease 1 0.9999980926513672
. O 0 0.00013702981232199818

Myotonic B-Disease 1 0.9999892711639404
dystrophy I-Disease 1 0.9999983310699463
( O 0 0.1562848538160324
DM B-Disease 1 0.9999991655349731
) O 0 9.318694083049195e-07
is O 0 1.6978697203740012e-07
caused O 0 3.569973046069208e-07
by O 0 5.214735754321964e-09
a O 0 3.2900118185352767e-07
CTG O 0 5.784356744698016e-06
expansion O 0 9.570643833001213e-09
in O 0 3.9899708537127765e-10
the O 0 7.145745106740264e-10
3 O 0 7.345391406232693e-09
untranslated O 0 6.475021336882492e-07
region O 0 5.199212615991655e-09
of O 0 1.2955571060402349e-09
the O 0 2.0115921870456077e-06
DM B-Disease 1 0.9999910593032837
gene O 0 9.70871769823134e-06
. O 0 4.5281814209374716e-07

One O 0 2.7559323712011974e-07
model O 0 4.816906198357174e-07
of O 0 5.3845635505922473e-08
DM B-Disease 1 0.999995231628418
pathogenesis O 0 0.0010160746751353145
suggests O 0 7.83344546562148e-07
that O 0 2.428150569500076e-09
RNAs O 0 3.42417791898697e-08
from O 0 1.4309191331829396e-10
the O 0 1.7687465381222012e-10
expanded O 0 3.299133854994807e-09
allele O 0 8.271524798431074e-09
create O 0 2.2110366315608587e-10
a O 0 2.0064681027776032e-09
gain O 0 6.904598137680296e-08
- O 0 8.01465262156853e-07
of O 0 1.2819540984310152e-09
- O 0 1.3646459592564497e-05
function O 0 2.6866633362487846e-08
mutation O 0 3.052039687645447e-08
by O 0 2.276749622165397e-10
the O 0 2.4712515367397714e-10
inappropriate O 0 2.8221476711109972e-08
binding O 0 8.676058982359791e-09
of O 0 4.9494464082755485e-11
proteins O 0 3.95191213087287e-10
to O 0 7.024408832378981e-10
the O 0 1.2557983097849501e-08
CUG O 0 0.0003465091867838055
repeats O 0 6.883939931867644e-06
. O 0 1.543523637792532e-07

Data O 0 2.6845689262700034e-06
presented O 0 6.95930907568254e-07
here O 0 3.122450564774226e-08
indicate O 0 4.6157396127455286e-08
that O 0 1.0834225738776126e-09
the O 0 9.791081279075797e-10
conserved O 0 4.3484845946295536e-07
heterogeneous O 0 3.880049462168245e-06
nuclear O 0 0.0003259450604673475
ribonucleoprotein O 0 2.8480922992457636e-05
, O 0 1.346138867042157e-09
CUG O 0 1.2021827160424436e-06
- O 0 1.5772697281590808e-07
binding O 0 3.219160404910326e-08
protein O 0 9.92885862416415e-09
( O 0 3.515010782439987e-10
CUG O 0 1.7757203750079498e-05
- O 0 0.00018528189684730023
BP O 0 8.47225237521343e-05
) O 0 6.399982210858468e-10
, O 0 7.844623839403653e-10
may O 0 2.6592097412958537e-08
mediate O 0 2.561589838023792e-07
the O 0 4.0972505388481295e-08
trans O 0 1.6700580545148114e-06
- O 0 2.501351264072582e-05
dominant O 0 1.727898109038506e-07
effect O 0 6.5953389416506525e-09
of O 0 1.5963026733789576e-10
the O 0 4.381726537161512e-09
RNA O 0 2.7506862920745334e-07
. O 0 7.94194718878316e-08

CUG O 0 0.002509440528228879
- O 0 0.00037748890463262796
BP O 0 9.85131919151172e-05
was O 0 1.0009618023332223e-07
found O 0 2.885128802532222e-09
to O 0 1.5027171174075704e-10
bind O 0 3.028866046861367e-08
to O 0 1.311429076444881e-09
the O 0 8.9856619922557e-09
human O 0 1.0143523923034081e-06
cardiac O 0 0.11524109542369843
troponin O 1 0.944774329662323
T O 0 0.00039682345231994987
( O 0 1.156793549839108e-09
cTNT O 0 4.263913311319811e-08
) O 0 2.3617172106860096e-10
pre O 0 5.945476004853845e-07
- O 0 1.2316484571783803e-05
messenger O 0 1.3929049202943133e-07
RNA O 0 2.391948150659573e-08
and O 0 9.000563627736824e-10
regulate O 0 5.230295307967481e-09
its O 0 1.4656189595285696e-09
alternative O 0 2.889061967437101e-08
splicing O 0 5.953129402769264e-07
. O 0 1.2835810991873586e-07

Splicing O 0 7.295878731383709e-06
of O 0 3.796933967237237e-08
cTNT O 0 1.1981779607594945e-05
was O 0 2.2943956992094172e-06
disrupted O 0 3.9517130062449723e-05
in O 0 1.5978448573150672e-06
DM B-Disease 1 0.999996542930603
striated O 0 0.3050122857093811
muscle O 0 0.0003766190493479371
and O 0 3.196245188519242e-07
in O 0 4.3348453715452706e-08
normal O 0 1.2353959277788817e-07
cells O 0 3.4750769373204093e-08
expressing O 0 6.922041162482628e-09
transcripts O 0 3.149035876504058e-08
that O 0 7.617543040794317e-09
contain O 0 2.7534366608961136e-07
CUG O 0 0.00021437386749312282
repeats O 0 4.490879291552119e-06
. O 0 1.1382401510218187e-07

Altered O 0 1.6875355868251063e-05
expression O 0 8.625652867522149e-07
of O 0 2.6261832708485144e-09
genes O 0 5.5954306077410365e-08
regulated O 0 9.909772558103214e-08
posttranscriptionally O 0 8.608461143921886e-07
by O 0 1.0601176825275616e-08
CUG O 0 0.00031773283262737095
- O 0 0.0002104602026520297
BP O 0 3.5151573683833703e-05
therefore O 0 1.299180585334625e-08
may O 0 1.7826241816010224e-08
contribute O 0 2.2239632357923256e-09
to O 0 1.61361299433338e-07
DM B-Disease 1 0.999995231628418
pathogenesis O 0 0.0004012929566670209
. O 0 7.553322944886531e-08
. O 0 1.6573999062075018e-07

Identification O 0 2.5524211650918005e-06
of O 0 8.164157350165624e-09
a O 0 3.638599821442767e-08
novel O 0 3.4117104519282293e-07
nonsense O 0 5.6618369853822514e-05
mutation O 0 3.455372279859148e-06
and O 0 2.0084669483111384e-09
a O 0 2.563014689371812e-09
missense O 0 2.191762575876055e-07
substitution O 0 3.2259750426533174e-09
in O 0 1.1935687993513966e-09
the O 0 9.423195557189956e-10
vasopressin O 0 7.97047391642991e-07
- O 0 2.411953391856514e-05
neurophysin O 0 2.1547897631535307e-05
II O 0 2.2752708900952712e-05
gene O 0 1.9539125872825025e-08
in O 0 8.495402159525156e-10
two O 0 1.5816138398960788e-09
Spanish O 0 1.422891244828861e-07
kindreds O 0 2.4877649593690876e-06
with O 0 1.2182465525256703e-07
familial B-Disease 1 0.8467278480529785
neurohypophyseal I-Disease 1 0.9992915391921997
diabetes I-Disease 1 0.9976245760917664
insipidus I-Disease 1 0.8739916086196899
. O 0 8.670074748806655e-06

Familial B-Disease 1 0.9974767565727234
neurohypophyseal I-Disease 1 0.9996241331100464
diabetes I-Disease 1 0.9999426603317261
insipidus I-Disease 1 0.999422550201416
( O 0 0.0001116949351853691
FNDI B-Disease 1 0.9999871253967285
) O 0 6.2692265601072e-08
is O 0 1.2459781650875357e-08
an O 0 1.9202920498173626e-07
autosomal B-Disease 1 0.9988846182823181
dominant I-Disease 1 0.9999077320098877
disease I-Disease 1 0.9995786547660828
caused O 0 0.029986035078763962
by O 0 0.0007229280308820307
deficiency O 1 0.995262861251831
in O 0 1.1628636542582171e-07
the O 0 1.7385991668561473e-07
antidiuretic O 0 0.0007847310043871403
hormone O 0 1.2658532796194777e-05
arginine O 0 1.7954189388547093e-06
vasopressin O 0 1.3872552244720282e-06
( O 0 1.782779701642312e-09
AVP O 0 3.848496987757244e-08
) O 0 1.2017369044325932e-10
encoded O 0 4.4589518188864474e-10
by O 0 1.2466043475267696e-10
the O 0 1.5213248438783467e-09
AVP O 0 1.9173471628164407e-06
- O 0 0.00021164487407077104
neurophysin O 0 0.00019316270481795073
II O 0 0.0002598737773951143
( O 0 3.199295495193155e-09
AVP O 0 1.9628855341125018e-07
- O 0 9.765472896106075e-06
NPII O 0 2.4501172447344288e-05
) O 0 4.742864434525984e-10
gene O 0 3.555625349704883e-09
on O 0 4.528086350319427e-08
chromosome O 0 3.529123932821676e-05
20p13 O 0 1.5294686818378977e-05
. O 0 5.455136147247686e-07

In O 0 7.793313727688655e-08
this O 0 3.4869864773412473e-09
study O 0 5.104401790134716e-09
, O 0 1.4678430693138012e-09
we O 0 1.438585028878947e-09
analyzed O 0 1.3388367747779739e-08
two O 0 2.938430887500232e-10
families O 0 6.375298622351977e-10
with O 0 6.537863583844228e-09
FNDI B-Disease 1 0.9996738433837891
using O 0 2.012531696848896e-09
direct O 0 8.353856495446621e-10
automated O 0 7.968391741997038e-07
fluorescent O 0 7.494208603020525e-06
, O 0 4.5822265426487263e-10
solid O 0 1.589016740410898e-08
phase O 0 4.742549908343108e-09
, O 0 4.089953931085688e-10
single O 0 1.227578483309344e-08
- O 0 3.106074757397437e-07
stranded O 0 1.905997359941125e-09
DNA O 0 1.688803541455286e-09
sequencing O 0 3.676013937692346e-10
of O 0 3.891257455146402e-11
PCR O 0 7.265219323926431e-07
- O 0 5.831831458635861e-06
amplified O 0 6.984887477301527e-06
AVP O 0 1.6172439245565329e-06
- O 0 2.4068453058134764e-05
NPII O 0 2.390512418060098e-05
DNA O 0 2.6289417291991413e-06
. O 0 2.4649418151057034e-07

In O 0 1.837016583294826e-07
one O 0 3.3981639724345314e-09
of O 0 2.749921956812784e-10
the O 0 9.273780854357483e-09
families O 0 2.6067068503721202e-08
, O 0 1.222312295823258e-08
affected O 0 5.850015583064305e-09
individuals O 0 1.0043497145062474e-09
presented O 0 8.721707445147331e-08
a O 0 7.917867606010986e-08
novel O 0 7.571973981157498e-08
nonsense O 0 3.4083097943948815e-06
mutation O 0 3.373535051309773e-08
in O 0 4.003433418109381e-10
exon O 0 1.2172107233254792e-07
3 O 0 9.136095768802477e-10
of O 0 5.900729904695368e-11
the O 0 2.0544927981092087e-09
gene O 0 9.613015272691428e-09
, O 0 9.629558261892157e-11
consisting O 0 1.0711286024811528e-10
in O 0 7.447922834025178e-10
a O 0 2.303168429307334e-07
G O 0 0.0007817709119990468
to O 0 8.963635167447137e-08
T O 0 6.85401537339203e-05
transition O 0 1.155285911380588e-08
at O 0 6.058090473715083e-09
nucleotide O 0 3.355567059770692e-07
2101 O 0 6.880159162392374e-07
, O 0 5.047510742706152e-10
which O 0 1.2321967890471797e-09
produces O 0 1.5386120155724825e-09
a O 0 2.239508578583127e-09
stop O 0 1.344271716163803e-08
signal O 0 1.7537867336159252e-07
in O 0 4.118890561954913e-09
codon O 0 4.485091054107215e-08
82 O 0 7.3366259734086725e-09
( O 0 3.759387912083412e-09
Glu O 0 4.883335350314155e-06
) O 0 7.065769080938367e-10
of O 0 2.8275666252852716e-09
NPII O 0 0.0027986904606223106
. O 0 6.264444891712628e-07

The O 0 6.231470024431474e-07
premature O 0 1.0544998076511547e-05
termination O 0 9.69027837527392e-07
eliminates O 0 3.5212889315516804e-07
part O 0 2.7391866552761712e-09
of O 0 3.8084260745030463e-10
the O 0 6.66885879851975e-09
C O 0 5.620669980999082e-06
- O 0 3.914947683369974e-06
terminal O 0 1.0928980742619387e-07
domain O 0 9.689274937940695e-10
of O 0 1.7123900908355694e-10
NPII O 0 8.65101974341087e-05
, O 0 3.141288063002179e-10
including O 0 4.3913941927264943e-11
a O 0 2.564892742640268e-09
cysteine O 0 6.228272120267775e-09
residue O 0 7.688530700988849e-08
in O 0 6.816592845737546e-10
position O 0 3.8121147127867516e-08
85 O 0 5.734741015395173e-10
, O 0 7.124460466023663e-10
which O 0 1.2422431083791707e-08
could O 0 2.5068052877941227e-07
be O 0 2.706124213602834e-08
involved O 0 4.642666695531261e-09
in O 0 2.72608358109494e-09
the O 0 5.01224706184189e-09
correct O 0 8.094678491943341e-07
folding O 0 3.134295525342168e-07
of O 0 1.382877479194633e-09
the O 0 4.6288580080044994e-08
prohormone O 0 0.00012459774734452367
. O 0 5.380035190682975e-07

In O 0 1.1592562287887631e-07
the O 0 3.387286229283859e-09
second O 0 1.3437615464795272e-08
family O 0 1.530254145620802e-08
, O 0 1.9887121116557438e-10
a O 0 6.007458974721658e-10
G279A O 0 2.7810544978024154e-09
substitution O 0 4.498983963152625e-10
at O 0 1.8988734196145884e-10
position O 0 3.563446870913367e-09
- O 0 1.0962551044713109e-07
1 O 0 1.8543376556490188e-10
of O 0 1.5966793859290007e-11
the O 0 4.350487470272668e-10
signal O 0 2.0126445576806873e-07
peptide O 0 1.3337206894448173e-07
was O 0 2.3862384068706888e-08
observed O 0 8.960144626257716e-09
in O 0 6.650132666763398e-10
all O 0 1.3279941590838007e-09
affected O 0 2.9193786943437772e-08
individuals O 0 5.3339043404321274e-08
. O 0 4.616171054294682e-07

This O 0 2.702406050048012e-07
missense O 0 0.00017704369383864105
mutation O 0 0.00010299894347554073
, O 0 1.7288039444451897e-08
which O 0 3.389484959370748e-08
replaces O 0 3.3375395105395e-06
Ala O 0 1.1848275107695372e-06
with O 0 3.0267177208997964e-08
Thr O 0 0.00024823789135552943
, O 0 1.83016837240757e-08
is O 0 3.164550843592906e-09
frequent O 0 2.050896483751785e-07
among O 0 5.60644366487395e-07
FNDI B-Disease 1 0.9999995231628418
patients O 0 4.626705049304292e-06
and O 0 1.800501365778473e-07
is O 0 2.24461143005783e-08
thought O 0 8.896488878917808e-09
to O 0 7.807946511562136e-10
reduce O 0 5.655071078081164e-09
the O 0 7.452370387461826e-10
efficiency O 0 2.7394857937679262e-08
of O 0 2.8951158137502375e-10
cleavage O 0 9.363125172967557e-06
by O 0 1.108195935017875e-08
signal O 0 1.1320106523271534e-06
peptidases O 0 2.1561338598985458e-06
. O 0 1.3626986650194794e-08
. O 0 5.183818174714361e-08

Genetic O 0 4.821148468181491e-05
heterogeneity O 0 2.62739704339765e-05
of O 0 2.294526098012284e-07
Saethre B-Disease 1 0.7700484395027161
- I-Disease 1 0.999891996383667
Chotzen I-Disease 1 0.9999388456344604
syndrome I-Disease 1 0.9999839067459106
, O 0 6.968992494194026e-08
due O 0 2.9134987755696784e-08
to O 0 6.486923442849957e-09
TWIST O 0 5.929476901656017e-05
and O 0 5.2362747737788595e-06
FGFR O 0 0.0285742599517107
mutations O 0 1.2730904018098954e-05
. O 0 5.307164201440173e-07

Thirty O 0 4.734138656203868e-06
- O 0 8.262544724857435e-06
two O 0 1.5603346170678378e-08
unrelated O 0 4.452218945516506e-06
patients O 0 6.04328533881926e-08
with O 0 1.5421552923555737e-09
features O 0 1.2249960263943649e-06
of O 0 5.966082028407982e-08
Saethre B-Disease 1 0.9641751050949097
- I-Disease 1 0.9999103546142578
Chotzen I-Disease 1 0.9999277591705322
syndrome I-Disease 1 0.9999426603317261
, O 0 1.0840989439486748e-08
a O 0 2.0782404419605882e-07
common O 0 2.379862780799158e-05
autosomal B-Disease 1 0.8421594500541687
dominant I-Disease 0 0.0412026084959507
condition I-Disease 0 0.0007269709021784365
of O 0 1.0386403914708353e-07
craniosynostosis B-Disease 1 0.9798580408096313
and O 0 0.0002186252677347511
limb B-Disease 1 0.958730161190033
anomalies I-Disease 1 0.5301165580749512
, O 0 8.090312064723548e-08
were O 0 5.278583614654053e-08
screened O 0 1.2960052117705345e-05
for O 0 1.1000588528986555e-07
mutations O 0 9.664197477832204e-07
in O 0 1.246089809114892e-08
TWIST O 0 2.7254738597548567e-05
, O 0 4.902401684603319e-08
FGFR2 O 0 9.181939822155982e-05
, O 0 4.500908534765813e-09
and O 0 5.4387530923349914e-08
FGFR3 O 0 0.000377866585040465
. O 0 5.03250021210988e-07

Nine O 0 8.157107913575601e-07
novel O 0 2.2748164951735816e-07
and O 0 1.803823046486741e-08
three O 0 6.420698195341856e-09
recurrent O 0 6.60852892906405e-05
TWIST O 0 0.0004813974956050515
mutations O 0 4.6691533498233184e-05
were O 0 2.3688684791522974e-07
found O 0 2.1024091267918266e-07
in O 0 2.470401128107369e-08
12 O 0 1.8393230050151033e-08
families O 0 1.0782058978975329e-07
. O 0 5.988736688777863e-07

Seven O 0 2.981629734222224e-07
families O 0 4.545080400930601e-08
were O 0 3.113987290248588e-08
found O 0 3.946199100823833e-08
to O 0 2.4204931392546314e-09
have O 0 1.8689368275204288e-08
the O 0 5.813132197829418e-09
FGFR3 O 0 7.239186379592866e-05
P250R O 0 4.605160768278438e-07
mutation O 0 1.5383773188659688e-07
, O 0 1.3426022793527892e-10
and O 0 4.662435992841552e-10
one O 0 2.0044865767232523e-09
individual O 0 1.4379493151750466e-08
was O 0 2.2491342406283366e-06
found O 0 1.4649342006123334e-07
to O 0 6.029157173514932e-09
have O 0 4.1409169426742665e-08
an O 0 3.020107941509309e-09
FGFR2 O 0 2.50757784669986e-05
VV269 O 0 3.7358373106144427e-07
- O 0 1.5176181022980018e-06
270 O 0 8.640986237651305e-08
deletion O 0 5.569424047280336e-06
. O 0 3.1484481155530375e-07

To O 0 5.8281120374203965e-08
date O 0 1.5451274748556898e-07
, O 0 8.220201186404097e-10
our O 0 1.1542545808040927e-09
detection O 0 8.022361157600244e-07
rate O 0 1.0342142076069649e-07
for O 0 9.280672064182482e-11
TWIST O 0 5.781179766017885e-07
or O 0 4.8441410882560376e-08
FGFR O 0 2.016529833781533e-05
mutations O 0 1.1486048379083513e-07
is O 0 1.8066937945704353e-09
68 O 0 1.971412366685854e-09
% O 0 1.3388616881826465e-09
in O 0 2.472738014347442e-09
our O 0 1.861729117536015e-07
Saethre B-Disease 0 0.05475933477282524
- I-Disease 1 0.9995297193527222
Chotzen I-Disease 1 0.9999208450317383
syndrome I-Disease 1 0.9999849796295166
patients O 0 4.219622553591762e-07
, O 0 1.191617138296408e-09
including O 0 5.374072298280907e-10
our O 0 5.887933340886775e-08
five O 0 3.043279406256261e-08
patients O 0 5.6272497772624774e-08
elsewhere O 0 1.2709847396763507e-07
reported O 0 2.8526443429655046e-07
with O 0 3.911861767846858e-08
TWIST O 0 0.0009834292577579618
mutations O 0 4.475984678720124e-05
. O 0 6.774835696887749e-07

More O 0 1.8402072754497567e-08
than O 0 1.0158244245772607e-09
35 O 0 3.3798047693878175e-10
different O 0 1.3074646920685495e-10
TWIST O 0 2.100127858284395e-06
mutations O 0 2.2693482151225908e-06
are O 0 2.888327577110772e-09
now O 0 5.9319034129146075e-09
known O 0 6.359319737470059e-09
in O 0 1.7328932733207125e-09
the O 0 1.0778826720070356e-08
literature O 0 2.327691959180811e-07
. O 0 2.2388141474039003e-07

The O 0 5.0431086862090524e-08
most O 0 2.0234474096270105e-09
common O 0 2.6841011635525547e-09
phenotypic O 0 2.530853180360282e-07
features O 0 4.484155397221912e-06
, O 0 1.0469617173214374e-08
present O 0 2.555814226923303e-09
in O 0 1.8017590752705814e-09
more O 0 8.256416383911613e-11
than O 0 7.592487749619181e-10
a O 0 9.068824802227482e-09
third O 0 1.3118524933020126e-08
of O 0 8.833213605008439e-10
our O 0 1.9703011844285356e-07
patients O 0 1.1977656200201636e-08
with O 0 3.859337294187526e-09
TWIST O 0 0.0002108900953317061
mutations O 0 4.8822084863786586e-06
, O 0 2.158357270687361e-09
are O 0 8.827807373990026e-10
coronal B-Disease 0 6.622185537707992e-06
synostosis I-Disease 0 0.0001382753107463941
, O 0 7.756548292547905e-09
brachycephaly B-Disease 0 1.1149962119816337e-05
, O 0 3.5045374602304946e-08
low B-Disease 0 5.039429015596397e-05
frontal I-Disease 1 0.9998354911804199
hairline I-Disease 1 0.9999974966049194
, O 0 8.76923786563566e-06
facial B-Disease 1 0.9952667951583862
asymmetry I-Disease 0 0.23644137382507324
, O 0 3.0298656383820344e-06
ptosis B-Disease 1 0.8654081225395203
, O 0 3.922396842881426e-07
hypertelorism B-Disease 0 0.003980041015893221
, O 0 2.215885430700837e-08
broad B-Disease 0 6.118955298006767e-08
great I-Disease 0 2.855670345525141e-06
toes I-Disease 0 0.0015429777558892965
, O 0 4.503716510839695e-09
and O 0 4.6562373512415434e-08
clinodactyly B-Disease 0 4.847966556553729e-05
. O 0 2.551529973970901e-07

Significant O 0 3.878134009482892e-07
intra O 0 1.4115678368398221e-06
- O 0 1.4495595678454265e-05
and O 0 3.256944935969841e-08
interfamilial O 0 1.5144174540182576e-05
phenotypic O 0 1.3464573385135736e-05
variability O 0 0.00017043472325894982
is O 0 2.816598154709027e-08
present O 0 4.226583527611183e-09
for O 0 2.3082415978592508e-09
either O 0 2.345881284782081e-07
TWIST O 0 0.00011112328502349555
mutations O 0 8.733475624467246e-06
or O 0 7.442120590894774e-07
FGFR O 0 0.0016815419076010585
mutations O 0 1.3289701200847048e-05
. O 0 5.264768674351217e-07

The O 0 7.852835182120543e-08
overlap O 0 1.3888022465380345e-07
in O 0 2.2758747775242227e-08
clinical O 0 2.0036625869579439e-07
features O 0 1.2823456927435473e-06
and O 0 7.774414001460173e-08
the O 0 2.6473814251914973e-09
presence O 0 3.2084084722328043e-08
, O 0 1.4346202004134057e-09
in O 0 1.842755392722495e-10
the O 0 1.87732357437298e-10
same O 0 6.659452989055126e-09
genes O 0 1.8564904058493426e-09
, O 0 9.68053207039965e-11
of O 0 5.4071969124436237e-11
mutations O 0 2.0403922107448125e-08
for O 0 1.0101589703603864e-10
more O 0 1.7562612475430228e-10
than O 0 1.7579177002957636e-09
one O 0 1.0929560367856084e-08
craniosynostotic B-Disease 0 7.272820948855951e-05
condition I-Disease 0 1.8478416450307122e-06
- O 0 5.755236998084001e-07
such O 0 1.0838896447040725e-09
as O 0 5.622558418849621e-09
Saethre B-Disease 0 4.715614977612859e-06
- I-Disease 0 8.848734978528228e-06
Chotzen I-Disease 0 3.1190186291496502e-06
, I-Disease 0 9.1034463300943e-10
Crouzon I-Disease 0 5.270736664897413e-07
, I-Disease 0 1.7203789504094402e-09
and I-Disease 0 5.760465526805092e-08
Pfeiffer I-Disease 0 0.000825073104351759
syndromes I-Disease 0 5.124792369315401e-05
- O 0 1.4025010841578478e-06
support O 0 1.650495384808437e-08
the O 0 6.354978765443775e-09
hypothesis O 0 3.2304413366546214e-07
that O 0 1.627384227376183e-09
TWIST O 0 1.893064478508677e-07
and O 0 2.334053306185524e-08
FGFRs O 0 6.699330583614937e-07
are O 0 2.636998397420598e-10
components O 0 3.049320795867061e-09
of O 0 3.231157008620755e-11
the O 0 8.5012696882103e-10
same O 0 1.479810585180985e-08
molecular O 0 2.0370721642848366e-07
pathway O 0 1.2937372284582693e-09
involved O 0 5.167169470077226e-10
in O 0 5.732969099447871e-10
the O 0 1.1049070547386464e-09
modulation O 0 3.7987453538335103e-07
of O 0 3.0284617480447196e-08
craniofacial O 1 0.977893054485321
and O 0 7.67801066103857e-06
limb O 0 0.0001390283869113773
development O 0 4.736845582442584e-09
in O 0 1.5861068902722764e-08
humans O 0 5.1275112156190517e-08
. O 0 1.7116605022238218e-08
. O 0 2.0975946313228633e-07

Mutation O 0 0.00023408359265886247
analysis O 0 1.5392298564620432e-06
of O 0 3.893661926213099e-07
UBE3A O 1 0.9863263368606567
in O 1 0.5449787378311157
Angelman B-Disease 1 0.9999997615814209
syndrome I-Disease 1 0.9999998807907104
patients O 0 0.15920691192150116
. O 0 2.8221800675964914e-05

Angelman B-Disease 1 0.9999996423721313
syndrome I-Disease 1 1.0
( O 0 0.0003274431510362774
AS B-Disease 1 0.999219536781311
) O 0 4.462478742084386e-08
is O 0 9.450489812934393e-08
caused O 0 1.4736217224253778e-07
by O 0 2.596068782168004e-08
chromosome O 0 0.002659727120772004
15q11 O 0 6.348636361508397e-06
- O 0 7.225933586596511e-06
q13 O 0 1.0839712416554903e-07
deletions O 0 1.514834480076388e-07
of O 0 4.197229230840094e-09
maternal O 0 8.252162660937756e-05
origin O 0 5.148876311977801e-07
, O 0 3.6186103002933123e-09
by O 0 1.7310409106130464e-08
paternal O 0 0.0014927490847185254
uniparental B-Disease 0 0.2935849130153656
disomy I-Disease 0 0.0181058868765831
( O 0 1.3101501394885418e-07
UPD B-Disease 1 0.9993197917938232
) O 0 1.8499793918991259e-09
15 O 0 5.724523077788035e-10
, O 0 2.670918763936214e-10
by O 0 1.653214454222507e-08
imprinting O 1 0.655745267868042
defects O 1 0.9989830851554871
, O 0 2.5677232784460102e-08
and O 0 9.221429841943518e-09
by O 0 1.725275922126457e-08
mutations O 0 1.6109603393488214e-06
in O 0 2.0382453058687133e-08
the O 0 1.2202465882182878e-07
UBE3A O 0 0.0013986829435452819
gene O 0 1.5869622984610032e-06
. O 0 1.6507148359323764e-07

UBE3A O 0 0.0013191459001973271
encodes O 0 6.001359452056931e-06
a O 0 3.027099353403173e-07
ubiquitin O 0 3.137138264719397e-06
- O 0 1.4165820175549015e-05
protein O 0 1.195153060962184e-07
ligase O 0 7.413411253764934e-07
and O 0 1.5440486222928484e-08
shows O 0 1.6766712178650778e-06
brain O 0 0.000548145268112421
- O 0 1.6379799490096048e-05
specific O 0 2.2855543591049354e-07
imprinting O 0 0.00010526461846893653
. O 0 6.566214665326697e-07

Here O 0 1.8038596181213506e-06
we O 0 5.8539363578802295e-08
describe O 0 2.885967660404276e-07
UBE3A O 0 4.48165628768038e-05
coding O 0 1.1941216143895872e-05
- O 0 4.461691059987061e-05
region O 0 2.800298659622058e-07
mutations O 0 2.069002675852971e-06
detected O 0 2.8951026251888834e-06
by O 0 2.5276720716504997e-09
SSCP O 0 2.124872298736591e-05
analysis O 0 1.0462072097539021e-08
in O 0 6.6556182787280704e-09
13 O 0 2.0086748264702692e-08
AS B-Disease 1 0.8686228394508362
individuals O 0 5.1078718144026425e-08
or O 0 1.3994880418977118e-06
families O 0 2.524229216760432e-07
. O 0 8.674671221342578e-07

Two O 0 2.2939244104236423e-07
identical O 0 3.3983130833803443e-06
de O 0 4.037362373310316e-07
novo O 0 4.345914135228668e-07
5 O 0 1.7849037803330248e-08
- O 0 1.3462675951814163e-06
bp O 0 8.839674592309166e-07
duplications O 0 5.857845621903834e-07
in O 0 8.739254653278294e-09
exon O 0 3.2977502542053116e-06
16 O 0 1.6659868151691626e-08
were O 0 8.997962908097179e-08
found O 0 1.5230697272272664e-06
. O 0 1.227494067279622e-06

Among O 0 1.0085700807849207e-07
the O 0 2.631648676754139e-09
other O 0 9.616312190985354e-10
11 O 0 1.231517776645319e-09
unique O 0 4.772570605382498e-08
mutations O 0 2.0469349237828283e-06
, O 0 5.963372018413793e-09
8 O 0 3.5167024847737594e-09
were O 0 2.6969302346913082e-09
small O 0 2.905118368090598e-09
deletions O 0 4.106467770270683e-07
or O 0 7.733004991905545e-08
insertions O 0 7.647864549653605e-06
predicted O 0 3.423091811782797e-06
to O 0 8.876285484404889e-09
cause O 0 9.701226417746511e-07
frameshifts O 0 4.247448669048026e-05
, O 0 5.242180467490698e-09
1 O 0 1.5140417808368056e-09
was O 0 6.972489785539437e-08
a O 0 6.026100862754902e-08
mutation O 0 1.7460149592807284e-07
to O 0 6.39305275385027e-10
a O 0 7.215598341048235e-09
stop O 0 1.1705439284526165e-08
codon O 0 2.23941043486775e-09
, O 0 1.1441688568814001e-10
1 O 0 1.5655139684600528e-10
was O 0 1.3107669616374551e-08
a O 0 1.6140894842919806e-08
missense O 0 2.478806345607154e-05
mutation O 0 3.0476326173811685e-06
, O 0 6.900826576838881e-10
and O 0 2.9081730357205515e-09
1 O 0 8.52296544451292e-09
was O 0 7.621827080583898e-06
predicted O 0 2.7932701414101757e-06
to O 0 7.355120956731298e-09
cause O 0 2.64707523456309e-07
insertion O 0 2.1207499756314974e-08
of O 0 1.1619614159741332e-09
an O 0 3.794674796608888e-08
isoleucine O 0 8.696561417309567e-05
in O 0 2.449366265366848e-09
the O 0 6.42686959206884e-10
hect O 0 3.0212245860639086e-07
domain O 0 8.385528937893127e-10
of O 0 7.509670663097268e-11
the O 0 4.778971440799751e-09
UBE3A O 0 1.7082809790736064e-05
protein O 0 4.759044358593201e-08
, O 0 2.958027989219403e-10
which O 0 1.7930537610233444e-10
functions O 0 1.798441395806094e-10
in O 0 1.2021501571979343e-09
E2 O 0 6.156358836051368e-07
binding O 0 7.11287171384356e-08
and O 0 4.374044682009526e-09
ubiquitin O 0 2.968154149129987e-07
transfer O 0 1.4699610062507418e-07
. O 0 2.538549779274035e-07

Eight O 0 5.6592281083567286e-08
of O 0 1.4951757609793503e-09
the O 0 4.806184783490153e-09
cases O 0 3.2020871287841146e-08
were O 0 5.690715170203475e-07
familial O 0 0.042490433901548386
, O 0 4.066851602146926e-07
and O 0 5.564374561117802e-08
five O 0 9.216472030004752e-09
were O 0 3.0000839501553855e-07
sporadic O 0 3.474848926998675e-05
. O 0 1.4495142295345431e-06

In O 0 2.4351396632482647e-07
two O 0 1.5283902143892192e-08
familial O 0 0.0005246763466857374
cases O 0 1.9313533812237438e-06
and O 0 1.1518628184603585e-07
one O 0 4.975321488132067e-08
sporadic O 0 4.256228749000002e-06
case O 0 5.354185304895509e-06
, O 0 7.264704837695035e-09
mosaicism O 0 1.314937094321067e-06
for O 0 1.7725783507671622e-08
UBE3A O 0 0.0004569298180285841
mutations O 0 3.1717968340672087e-06
was O 0 8.085991112238844e-07
detected O 0 2.718820951486123e-06
in O 0 3.164876805072936e-09
the O 0 1.2124948156611026e-08
mother O 0 7.813934644218534e-06
of O 0 7.56687046354898e-10
three O 0 7.849720162766971e-08
AS B-Disease 1 0.9996994733810425
sons O 0 2.1546911739278585e-05
, O 0 1.0359841873253117e-09
in O 0 6.010312247894944e-10
the O 0 4.104334649923658e-09
maternal O 0 9.165449228021316e-06
grandfather O 0 9.169323220703518e-07
of O 0 3.186401975607822e-10
two O 0 5.724777096816069e-09
AS B-Disease 0 0.49751028418540955
first O 0 1.0410897743895475e-07
cousins O 0 1.7450207678848528e-06
, O 0 1.3827745615202502e-09
and O 0 4.730029257160595e-09
in O 0 1.1408941569257536e-09
the O 0 1.2230165324922382e-08
mother O 0 2.840086381183937e-06
of O 0 3.8294989401777e-10
an O 0 1.209755566833337e-07
AS B-Disease 1 0.9995231628417969
daughter O 0 0.07543222606182098
. O 0 2.138092213499476e-06

The O 0 5.356312371418426e-08
frequencies O 0 1.9475544377201004e-07
with O 0 2.263751630593447e-09
which O 0 7.007003421932723e-09
we O 0 9.542646672855426e-09
detected O 0 7.721846486674622e-07
mutations O 0 5.0044352661871017e-08
were O 0 6.886354153579077e-09
5 O 0 1.0004761463733303e-09
( O 0 1.8282685088077955e-10
14 O 0 3.7328345969811494e-10
% O 0 1.0364956115616053e-10
) O 0 8.575621983364368e-12
of O 0 2.303972637673901e-11
35 O 0 3.444178553468902e-10
in O 0 5.545446324362047e-10
sporadic O 0 2.517392090339854e-07
cases O 0 6.825029430501672e-08
and O 0 4.4151857281349294e-08
8 O 0 3.2632796465037472e-09
( O 0 1.333427535055165e-10
80 O 0 1.3494519390810922e-10
% O 0 1.0757352647550178e-10
) O 0 2.3563347453792183e-11
of O 0 4.002820644388727e-11
10 O 0 1.384490078137901e-09
in O 0 1.0840783382093377e-08
familial O 0 0.0006431986694224179
cases O 0 2.488187419658061e-06
. O 0 3.864006146159227e-07
. O 0 1.0039328799393843e-06

The O 0 1.7562117136549205e-05
hemochromatosis B-Disease 1 0.9997444748878479
845 O 0 9.368771861772984e-05
G O 0 0.00029915536288172007
- O 0 1.3842255611962173e-05
- O 0 8.04951287136646e-06
> O 0 8.557534414421752e-08
A O 0 9.117596455610055e-09
and O 0 4.000847653173878e-09
187 O 0 6.819925957302075e-09
C O 0 9.692703173413975e-08
- O 0 5.317008799465839e-06
- O 0 0.00010536584886722267
> O 0 2.8317131182120647e-06
G O 0 8.02989088697359e-05
mutations O 0 1.4594319281968637e-06
: O 0 9.717021853816732e-09
prevalence O 0 5.956060249445727e-07
in O 0 8.11147682355795e-09
non O 0 1.9343161739016068e-07
- O 0 0.002418768359348178
Caucasian O 0 9.028056228999048e-05
populations O 0 1.0750809451565146e-06
. O 0 2.8611557922886277e-07

Hemochromatosis B-Disease 1 0.9864822626113892
, O 0 2.6510645056987414e-06
the O 0 1.9926377717638388e-05
inherited B-Disease 1 0.9999988079071045
disorder I-Disease 1 0.9999873638153076
of I-Disease 0 2.8005254648633127e-07
iron I-Disease 1 0.9892071485519409
metabolism I-Disease 0 0.0016809945227578282
, O 0 4.365493300184653e-09
leads O 0 1.0000970718238023e-08
, O 0 6.107281791400965e-09
if O 0 2.0853561011335842e-07
untreated O 0 2.642344043124467e-06
, O 0 8.825248309918265e-10
to O 0 1.2354238521083971e-08
progressive O 0 0.0013674474321305752
iron B-Disease 1 0.9985066056251526
overload I-Disease 0 0.1036156490445137
and O 0 2.3914706162031507e-06
premature B-Disease 0 5.548750050365925e-05
death I-Disease 0 9.232235242961906e-06
. O 0 2.4305018087034114e-07

The O 0 2.073844188998919e-05
hemochromatosis B-Disease 1 0.9999599456787109
gene O 0 9.890814544633031e-05
, O 0 1.430003209179631e-07
HFE O 0 0.000977710704319179
, O 0 5.7263527253326174e-08
recently O 0 1.3849656852471526e-06
has O 0 2.38175800859608e-07
been O 0 1.144094170513199e-07
identified O 0 8.204183359339368e-07
, O 0 1.2639149726823007e-09
and O 0 7.22735760128046e-10
characterization O 0 3.423394190349427e-08
of O 0 4.7023548249702785e-11
this O 0 7.555664427449926e-10
gene O 0 7.515596145424297e-09
has O 0 8.448480137701608e-09
shown O 0 5.993992857611374e-08
that O 0 6.294444965249113e-09
it O 0 3.182247521049675e-10
contains O 0 9.851601479038408e-11
two O 0 5.206802211610295e-10
mutations O 0 4.500232719806263e-08
that O 0 1.7842969324277647e-09
result O 0 1.5907451356156344e-08
in O 0 3.850161522933604e-09
amino O 0 2.1958239670993862e-09
acid O 0 2.441600255309595e-09
substitutions O 0 1.8126686818220605e-09
- O 0 1.4317123486762284e-08
cDNA O 0 7.27250970555815e-09
nucleotides O 0 7.710761806833943e-09
845 O 0 1.286486295271061e-08
G O 0 9.120397521655832e-07
- O 0 9.062341064236534e-07
- O 0 5.3976091294316575e-06
> O 0 5.251229495684129e-08
A O 0 6.31527541372634e-08
( O 0 2.384957509260488e-10
C282Y O 0 1.033267427175133e-08
) O 0 3.5677141796419676e-11
and O 0 2.795006726064031e-10
187 O 0 2.1788397752686706e-09
C O 0 3.031160815680778e-07
- O 0 2.6626908947946504e-05
- O 0 0.0005947137251496315
> O 0 4.649289621738717e-06
G O 0 0.00011694765998981893
( O 0 6.957435072507678e-09
H63D O 0 3.4986103855771944e-05
) O 0 2.565001544496681e-08
. O 0 6.03969070311905e-08

Although O 0 0.00035895610926672816
hemochromatosis B-Disease 1 0.9999836683273315
is O 0 9.942618817149196e-07
common O 0 9.068188688843293e-08
in O 0 1.736361632254102e-08
Caucasians O 0 1.4368836218636716e-06
, O 0 3.5523719521535213e-09
affecting O 0 1.276747507716891e-08
> O 0 1.0140017536741652e-07
= O 0 4.769558259454243e-08
1 O 0 9.562063363333095e-10
/ O 0 4.5686840977055e-09
300 O 0 1.1436779995266377e-10
individuals O 0 1.7971897581237073e-10
of O 0 1.5897669292108674e-10
northern O 0 2.8671042429095905e-08
European O 0 5.5020237255121174e-08
origin O 0 4.855074564602546e-08
, O 0 8.182455268901379e-10
it O 0 1.4157957028970714e-09
has O 0 2.1400429872642235e-08
not O 0 4.648638807225325e-09
been O 0 2.6720883283815056e-08
recognized O 0 5.43045786116636e-09
in O 0 2.8837974230810914e-09
other O 0 8.619353231154037e-09
populations O 0 1.5168656375408318e-07
. O 0 2.7832800242322264e-07

The O 0 7.387926359569974e-08
present O 0 1.8779200416929598e-08
study O 0 2.4761077632717843e-09
used O 0 2.381794761419087e-09
PCR O 0 1.368249229471985e-07
and O 0 2.27022867171911e-09
restriction O 0 6.935811924790869e-09
- O 0 8.040593257874207e-08
enzyme O 0 2.3467698895274225e-09
digestion O 0 3.47283579671398e-09
to O 0 7.622636549742268e-11
analyze O 0 2.0262318489727704e-09
the O 0 1.316314973687227e-10
frequency O 0 4.77014738820003e-09
of O 0 1.2595962467498723e-11
the O 0 2.0971760439358889e-10
845 O 0 4.16537027092545e-08
G O 0 3.039740477106534e-06
- O 0 1.2734759593513445e-06
- O 0 2.4781888896541204e-06
> O 0 8.31442203974575e-09
A O 0 7.641729027341171e-09
and O 0 2.3942474669524927e-09
187 O 0 6.501502891609334e-09
C O 0 1.0183588727841197e-07
- O 0 9.950624644261552e-07
- O 0 1.0782305253087543e-05
> O 0 3.345750769767619e-07
G O 0 3.232319613744039e-06
mutations O 0 4.997024305453124e-08
in O 0 2.970728552043056e-09
HLA O 0 5.02656234857568e-07
- O 0 5.239179472482647e-07
typed O 0 7.533898838119057e-08
samples O 0 4.32077751355564e-09
from O 0 3.8563993665086116e-10
non O 0 9.2305452170649e-09
- O 0 1.5362778867711313e-05
Caucasian O 0 2.2467590952146566e-06
populations O 0 1.1379780673337336e-08
, O 0 2.714765356959248e-10
comprising O 0 3.2568672758692685e-10
Australian O 0 3.5781187790462354e-08
Aboriginal O 0 5.088054777502293e-08
, O 0 7.707876004126035e-10
Chinese O 0 3.542937332401408e-10
, O 0 3.547467875009147e-10
and O 0 8.098337112016907e-09
Pacific O 0 2.4889267535854742e-08
Islanders O 0 9.27390487959201e-07
. O 0 6.034013466660326e-08

Results O 0 5.712187430617632e-06
showed O 0 1.0405503871879773e-06
that O 0 1.4311164475699911e-09
the O 0 7.438510363222406e-10
845 O 0 2.240409600062776e-07
G O 0 3.714551712619141e-05
- O 0 1.5851737771299668e-05
- O 0 3.744163041119464e-05
> O 0 1.664586761762621e-07
A O 0 2.3114617420105787e-07
mutation O 0 1.2443747436918784e-06
was O 0 5.341682296489125e-08
present O 0 1.5469219238894993e-09
in O 0 1.4041162677003172e-09
these O 0 4.0199302220322863e-10
populations O 0 7.201968466041819e-10
( O 0 4.1381315041277844e-11
allele O 0 2.2987252101813738e-09
frequency O 0 9.146213564292793e-09
0 O 0 2.650265007453356e-10
. O 0 3.687542979302627e-11
32 O 0 1.5548545784227485e-10
% O 0 1.9085100166904567e-10
) O 0 2.364186901804288e-10
, O 0 5.900215316323454e-10
and O 0 1.3940938181633555e-08
, O 0 5.4318873843328674e-09
furthermore O 0 5.045215445420581e-08
, O 0 1.3027232625972829e-09
it O 0 2.5602344688735457e-09
was O 0 7.436416922246281e-07
always O 0 2.5739024067661376e-07
seen O 0 7.899494391949702e-08
in O 0 4.601836967044193e-10
conjunction O 0 3.186609864869183e-09
with O 0 1.0717837284346388e-08
HLA O 0 4.870415068580769e-06
haplotypes O 0 1.0870412552321795e-06
common O 0 6.519299233787024e-08
in O 0 1.0891644031119085e-08
Caucasians O 0 2.837439296854427e-07
, O 0 1.5858245827615747e-09
suggesting O 0 6.228012949804906e-08
that O 0 4.796404162732415e-09
845 O 0 1.2624981593489792e-07
G O 0 1.5295869161491282e-05
- O 0 1.032521413435461e-05
- O 0 6.982367631280795e-05
> O 0 3.510324972921808e-07
A O 0 4.316415925131878e-06
may O 0 3.852312602248276e-06
have O 0 5.842444750214781e-09
been O 0 2.3846904451119144e-09
introduced O 0 5.079829445975292e-09
into O 0 1.4543624637930463e-10
these O 0 2.1570721597807818e-10
populations O 0 9.355642927033614e-10
by O 0 3.051118468988534e-09
Caucasian O 0 2.9690363589907065e-06
admixture O 0 1.0818394002853893e-05
. O 0 9.971390682039782e-07

187 O 0 3.1649435641156742e-06
C O 0 3.402671836738591e-06
- O 0 4.94215191793046e-06
- O 0 5.560509816859849e-05
> O 0 3.550901283233543e-06
G O 0 2.3202783268061467e-05
was O 0 4.4345465965989206e-08
present O 0 2.1214365819588465e-09
at O 0 1.1834493385265432e-09
an O 0 1.0268189631901237e-09
allele O 0 4.8911847017052423e-08
frequency O 0 3.377900270606915e-08
of O 0 5.228367738752127e-10
2 O 0 5.81076307071271e-08
. O 0 5.758520273957402e-07

68 O 0 1.1755555533454753e-06
% O 0 2.2006174660305078e-08
in O 0 1.7783986505648386e-09
the O 0 7.005341862154069e-10
two O 0 1.7976364841132408e-09
populations O 0 1.0408927941796264e-08
analyzed O 0 6.302448696260399e-07
( O 0 1.9788450877911146e-09
Australian O 0 1.9789108307577408e-07
Aboriginal O 0 1.817400772097244e-07
and O 0 4.932132924295729e-08
Chinese O 0 1.1001046296144068e-08
) O 0 1.0704189534749275e-08
. O 0 4.872654457699355e-08

In O 0 3.850993479659337e-08
the O 0 3.127563097393704e-09
Australian O 0 2.210583360806595e-08
Aboriginal O 0 4.303064571331561e-08
samples O 0 1.3835667722617018e-08
, O 0 1.6038560757269948e-10
187 O 0 1.4403064296786283e-09
C O 0 2.9929850597909535e-08
- O 0 7.014547236394719e-07
- O 0 1.2327319382166024e-05
> O 0 6.752608214810607e-07
G O 0 1.4691241631226148e-05
was O 0 1.1899941654291979e-07
found O 0 5.168436345570626e-08
to O 0 1.4368088940841517e-08
be O 0 9.815190793460715e-08
associated O 0 2.0724922222825626e-08
with O 0 2.1695848673175533e-08
HLA O 0 1.1941785487579182e-05
haplotypes O 0 1.3954459063825198e-06
common O 0 1.3862153025456792e-07
in O 0 1.7341704960927018e-08
Caucasians O 0 4.776805440087628e-07
, O 0 2.188147885107128e-09
suggesting O 0 2.1708190445224318e-07
that O 0 1.7444278910261346e-08
it O 0 1.2394928639025693e-08
was O 0 4.548176235630308e-08
introduced O 0 7.983512517739655e-09
by O 0 1.0175056353034506e-09
recent O 0 5.2024994090515975e-08
admixture O 0 3.274990604040795e-06
. O 0 4.5564206629933324e-07

In O 0 4.6802782094346185e-08
the O 0 8.967799836057111e-10
Chinese O 0 4.665852149088323e-10
samples O 0 1.5956428400798472e-09
analyzed O 0 9.905913422869617e-09
, O 0 2.6011859333152643e-10
187 O 0 2.6121851348648306e-09
C O 0 3.1741397066298305e-08
- O 0 1.254116455129406e-06
- O 0 1.1176119187439326e-05
> O 0 1.1208450132471626e-06
G O 0 2.1888348783249967e-05
was O 0 1.71965226059001e-07
present O 0 1.9853903410194107e-08
in O 0 2.1093976343422582e-08
association O 0 1.8717398742040814e-09
with O 0 8.336649703899468e-10
a O 0 3.592712261024644e-08
wide O 0 2.5032999673157974e-08
variety O 0 8.132018614048775e-09
of O 0 1.981020458785565e-09
HLA O 0 6.246325483516557e-06
haplotypes O 0 1.0100724239237024e-06
, O 0 1.936599769436498e-09
showing O 0 3.3089955309151264e-07
this O 0 4.270194420286089e-09
mutation O 0 6.89279602283932e-08
to O 0 2.2754482742470827e-09
be O 0 4.505600514903563e-08
widespread O 0 6.270888519566142e-08
and O 0 5.266385869617807e-07
likely O 0 2.0458759308894514e-07
to O 0 4.588752933187834e-09
predate O 0 5.336082153917232e-07
the O 0 8.327987743861343e-10
more O 0 2.7481286690722584e-10
genetically O 0 2.2447814718162817e-09
restricted O 0 1.037932406688924e-09
845 O 0 4.193574199007344e-08
G O 0 1.2678298844548408e-05
- O 0 2.5623969122534618e-05
- O 0 9.722547110868618e-05
> O 0 4.551104950678564e-07
A O 0 7.745816787974036e-07
mutation O 0 9.916777344187722e-06
. O 0 4.878662025475933e-07

Genotype O 1 0.9746955633163452
- O 0 0.053663771599531174
phenotype O 0 0.008008205331861973
correlations O 0 0.0032604748848825693
in O 0 0.0004675729142036289
attenuated B-Disease 1 0.9996389150619507
adenomatous I-Disease 1 0.9999920129776001
polyposis I-Disease 1 0.9998908042907715
coli I-Disease 1 0.9999052286148071
. O 0 0.0003323541604913771

Germ O 0 0.023945918306708336
- O 0 0.00018916792760137469
line O 0 2.341871777389315e-06
mutations O 0 2.7018029413738986e-07
of O 0 3.39413330774363e-10
the O 0 8.684221342036835e-09
tumor B-Disease 0 0.00010725255560828373
suppressor O 0 0.0001470716088078916
APC O 0 2.8201168333907844e-06
are O 0 2.1665249150260024e-08
implicated O 0 5.316255919751711e-05
in O 0 7.671101047890261e-05
attenuated B-Disease 1 0.9999494552612305
adenomatous I-Disease 1 0.9999991655349731
polyposis I-Disease 1 0.999993085861206
coli I-Disease 1 0.9999969005584717
( O 0 0.0007269653142429888
AAPC B-Disease 1 0.9999836683273315
) O 0 9.294342362409225e-08
, O 0 3.2685685269484566e-09
a O 0 1.8660129796899128e-07
variant O 0 0.00948302075266838
of O 0 0.00015898495621513575
familial B-Disease 1 0.9999997615814209
adenomatous I-Disease 1 0.9999938011169434
polyposis I-Disease 1 0.9999982118606567
( O 0 0.00025853340048342943
FAP B-Disease 0 0.0016773941460996866
) O 0 4.5804833348483953e-07
. O 0 6.753387538083189e-07

AAPC B-Disease 1 0.9996534585952759
is O 0 1.9268277355877217e-06
recognized O 0 8.195192435778154e-08
by O 0 1.0029006514145067e-09
the O 0 3.4828122608132617e-09
occurrence O 0 4.668660835704941e-07
of O 0 2.215647887382488e-09
< O 0 1.6019461099858745e-06
100 O 0 9.361752262293521e-09
colonic B-Disease 0 0.00027203551144339144
adenomas I-Disease 0 2.884561945393216e-05
and O 0 4.621727445197621e-09
a O 0 1.5121607077617227e-08
later O 0 2.5836018835434515e-07
onset O 0 5.1128226914443076e-05
of O 0 0.013830356299877167
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
( O 0 1.3934205753685092e-06
age O 0 1.3556831390815205e-06
> O 0 2.390300153365388e-07
40 O 0 4.1586760701761705e-09
years O 0 4.60907116917042e-08
) O 0 1.9039525511743705e-08
. O 0 1.1439598779361404e-07

The O 0 3.088781852511602e-08
aim O 0 4.0831377390304624e-08
of O 0 5.154363047488175e-10
this O 0 1.5345030801583448e-09
study O 0 4.958729871162859e-09
was O 0 5.8834093152881906e-08
to O 0 4.797712449544633e-09
assess O 0 2.5774027108127484e-06
genotype O 0 0.022585295140743256
- O 0 0.028425166383385658
phenotype O 0 0.0003413428785279393
correlations O 0 9.710604354040697e-05
in O 0 9.762437002791557e-06
AAPC B-Disease 1 0.9999291896820068
families O 0 1.8926615439340821e-06
. O 0 6.102289376030967e-07

By O 0 4.831822408846165e-08
protein O 0 1.8004962498707755e-07
- O 0 1.3592691630037734e-06
truncation O 0 1.0720166301325662e-06
test O 0 5.527952566808381e-07
( O 0 2.9555482505827513e-09
PTT O 0 3.7924542084510904e-07
) O 0 2.373105045805346e-10
assay O 0 1.5828133825834811e-07
, O 0 1.5149768939348718e-10
the O 0 1.9100250547854358e-10
entire O 0 3.4344320720691712e-09
coding O 0 3.280023719298697e-08
region O 0 5.451043505466657e-10
of O 0 4.0951193824856347e-11
the O 0 3.6196456942860777e-09
APC B-Disease 0 1.6090704946236656e-07
gene O 0 1.1698854329722508e-08
was O 0 4.783269247354838e-08
screened O 0 9.73205601439986e-07
in O 0 3.9805872376064144e-08
affected O 0 2.2245878028570587e-08
individuals O 0 5.1209601004131855e-09
from O 0 8.723620936734733e-08
11 O 0 9.684877113613766e-06
AAPC B-Disease 1 0.9999289512634277
kindreds O 0 6.7751323513221e-05
, O 0 8.774463822192047e-09
and O 0 9.442607806775527e-10
their O 0 1.970074325896576e-09
phenotypic O 0 1.7275666550631286e-06
differences O 0 7.62621903049876e-06
were O 0 8.027015610423405e-06
examined O 0 0.00011237149010412395
. O 0 1.4837073649687227e-06

Five O 0 3.266918895405979e-07
novel O 0 6.801105314480083e-07
germ O 0 0.0007036444148980081
- O 0 0.00023313875135499984
line O 0 1.693113154033199e-05
APC B-Disease 0 1.2968863529749797e-06
mutations O 0 3.2557653639742057e-07
were O 0 1.4776586176878936e-08
identified O 0 7.443235290338635e-07
in O 0 1.3640872431608386e-08
seven O 0 3.321657615629192e-08
kindreds O 0 5.990351928630844e-05
. O 0 1.2196129546282464e-06

Mutations O 0 0.0006107549997977912
were O 0 7.814688984808527e-08
located O 0 1.659425308275786e-08
in O 0 1.6322180274030984e-09
three O 0 4.2762482443947647e-10
different O 0 3.2545074968304277e-10
regions O 0 4.024303390526285e-10
of O 0 7.615922476000847e-11
the O 0 1.645791725124468e-09
APC B-Disease 0 5.850822404340761e-08
gene O 0 3.846425400411135e-09
( O 0 1.220784862088209e-10
1 O 0 2.819524613784097e-10
) O 0 3.456885472319371e-11
at O 0 4.2115655407570785e-10
the O 0 2.694975076433792e-10
5 O 0 7.345009600534524e-10
end O 0 3.6322049812298474e-09
spanning O 0 5.9342344371771105e-09
exons O 0 2.0708165848759563e-08
4 O 0 7.362485621165149e-10
and O 0 1.2264358417723997e-09
5 O 0 7.323606165954288e-10
, O 0 6.050338563490243e-10
( O 0 9.12534561803291e-11
2 O 0 1.747296612952809e-10
) O 0 2.9507798982031375e-11
within O 0 2.8943965280081585e-11
exon O 0 3.5691357425093884e-07
9 O 0 2.5847592510785944e-08
, O 0 4.0214259700022126e-10
and O 0 3.751387200878753e-09
( O 0 2.605769489072429e-10
3 O 0 8.457634592673458e-10
) O 0 4.689949123504178e-11
at O 0 5.068483965864345e-10
the O 0 3.1821140167309636e-10
3 O 0 9.45955314080038e-10
distal O 0 1.1169343672179366e-08
end O 0 1.023659290666501e-08
of O 0 3.5253705510385203e-10
the O 0 1.7758031489734094e-08
gene O 0 4.800415354111465e-07
. O 0 2.1210011880157253e-07

Variability O 0 0.00031500356271862984
in O 0 2.5878868825657264e-08
the O 0 4.224197880375868e-09
number O 0 3.953627469854837e-08
of O 0 2.609438161016442e-05
colorectal B-Disease 1 1.0
adenomas I-Disease 1 0.9999994039535522
was O 0 0.017465976998209953
most O 0 1.3472646998025084e-08
apparent O 0 2.1100390767969657e-06
in O 0 3.661679315314359e-08
individuals O 0 1.565329532660087e-09
with O 0 1.644139224765695e-08
mutations O 0 8.163941060956859e-07
in O 0 1.5320063440071863e-08
region O 0 1.4849592666621447e-08
1 O 0 1.3675260035483916e-08
, O 0 6.696096566116694e-09
and O 0 7.530263701482909e-07
upper O 0 0.00368041405454278
- O 1 0.9664250612258911
gastrointestinal O 1 0.8030016422271729
manifestations O 0 0.0007200093823485076
were O 0 1.0267507377648144e-06
more O 0 2.1426732388363234e-08
severe O 0 4.7254827222786844e-05
in O 0 9.121286836943909e-08
them O 0 3.796369085762308e-08
. O 0 5.323719847183384e-07

In O 0 1.932232720491811e-07
individuals O 0 7.2423329555704186e-09
with O 0 6.509456529357749e-09
mutations O 0 7.259443464135984e-07
in O 0 7.793593326255177e-09
either O 0 2.788327257974288e-08
region O 0 1.2408884586534441e-08
2 O 0 4.221861971132057e-09
or O 0 3.9619841629701114e-08
region O 0 4.299698375120897e-09
3 O 0 1.0400924566056347e-09
, O 0 1.1751533079973342e-10
the O 0 3.036897955333018e-10
average O 0 9.000636680411844e-09
number O 0 1.6747848941012222e-10
of O 0 1.0905851222098306e-10
adenomas B-Disease 0 1.420942680852022e-06
tended O 0 1.2714855301965144e-07
to O 0 2.7190367735130394e-09
be O 0 2.6443547795906852e-08
lower O 0 1.781156022673258e-08
than O 0 1.5628595084749008e-09
those O 0 9.502266751226784e-10
in O 0 3.309128970840902e-09
individuals O 0 3.830901706969314e-10
with O 0 1.7423529286020312e-08
mutations O 0 4.016103218873468e-07
in O 0 1.137340177592705e-08
region O 0 1.3103795382107819e-08
1 O 0 6.5393721548900885e-09
, O 0 2.4521851216263713e-09
although O 0 3.335854259489679e-08
age O 0 2.2862280957269832e-07
at O 0 7.017625591743126e-08
diagnosis O 0 3.356828892719932e-05
was O 0 3.512452167342417e-06
similar O 0 2.715882146731019e-06
. O 0 1.5640255242033163e-06

In O 0 1.9029272380066686e-06
all O 0 1.470754824595133e-07
AAPC B-Disease 1 0.9994878768920898
kindreds O 0 0.00011228975927224383
, O 0 8.900324921512492e-09
a O 0 5.215412546277776e-09
predominance O 0 5.109167773298395e-07
of O 0 2.0737655148650447e-08
right O 0 0.24811694025993347
- O 1 0.9999339580535889
sided O 1 0.9999921321868896
colorectal B-Disease 1 1.0
adenomas I-Disease 1 0.9999970197677612
and O 0 0.03077586181461811
rectal B-Disease 1 0.9997038245201111
polyp I-Disease 1 0.8548756241798401
sparing O 0 7.776349775667768e-06
was O 0 1.1975643019468407e-06
observed O 0 1.0739240678958595e-06
. O 0 1.330218566408803e-07

No O 0 3.0217628591344692e-05
desmoid B-Disease 1 0.5402759909629822
tumors I-Disease 1 0.9999933242797852
were O 0 1.4422695358007331e-06
found O 0 5.957144821877591e-07
in O 0 2.5151500437914365e-08
these O 0 3.49231292773311e-08
kindreds O 0 8.522516145603731e-05
. O 0 9.494725645708968e-07

Our O 0 1.0213208270215546e-06
data O 0 2.138841637133737e-07
suggest O 0 1.4429680561534042e-07
that O 0 1.2275831018371264e-08
, O 0 2.425364131752872e-09
in O 0 1.62651062396435e-07
AAPC B-Disease 1 0.9999794960021973
families O 0 2.03924468422656e-08
, O 0 4.3842909858149426e-10
the O 0 1.0628173341409308e-10
location O 0 3.862260733455969e-09
of O 0 1.2777182090140116e-10
the O 0 4.9814463665143194e-08
APC B-Disease 0 5.869175583939068e-05
mutation O 0 1.5401417840621434e-05
may O 0 3.5155185287294444e-06
partially O 0 1.7086192656279309e-06
predict O 0 2.7821974413200223e-07
specific O 0 1.2954787464991568e-08
phenotypic O 0 8.567938493797556e-06
expression O 0 3.632465086411685e-05
. O 0 2.3065147161105415e-06

This O 0 1.55503471432894e-07
should O 0 1.505105196031309e-08
help O 0 2.0086086127690805e-09
in O 0 5.409727110716744e-10
the O 0 3.0073910028960427e-10
design O 0 1.8832436410320952e-07
of O 0 8.796158801338549e-10
tailored O 0 2.2179794541443698e-05
clinical O 0 7.753926183795556e-06
- O 0 0.006535809021443129
management O 0 5.227286337117221e-08
protocols O 0 9.347318474794974e-09
in O 0 1.695603379925359e-10
this O 0 6.75075759182242e-11
subset O 0 2.7934732305112675e-09
of O 0 9.120048716226847e-09
FAP B-Disease 0 0.000796930049546063
patients O 0 9.615106364435633e-07
. O 0 3.457721575728101e-08
. O 0 1.2454012221496669e-07

Wilms B-Disease 0 0.48112189769744873
' I-Disease 0 1.95979682757752e-05
tumor I-Disease 0 2.0150378986727446e-05
1 O 0 1.514123404433576e-08
and O 0 9.515166432549904e-09
Dax O 0 0.005383058451116085
- O 0 9.50928279053187e-06
1 O 0 5.834337457599759e-09
modulate O 0 2.1033156372141093e-07
the O 0 3.4775287094390706e-09
orphan O 0 7.02244506101124e-07
nuclear O 0 1.1069208767366945e-06
receptor O 0 2.3629772272215632e-07
SF O 0 0.0003850324428640306
- O 0 5.158681801731291e-07
1 O 0 9.054527128071754e-10
in O 0 6.818231534921892e-10
sex O 0 1.1403316335645286e-07
- O 0 9.910924063660786e-07
specific O 0 1.519078551837083e-08
gene O 0 1.336431409981742e-07
expression O 0 3.544817559486546e-07
. O 0 2.3306063212658046e-07

Products O 0 4.688927504048479e-07
of O 0 5.0682156249592936e-09
steroidogenic O 0 3.1230426884576445e-06
factor O 0 3.100812051570756e-08
1 O 0 8.264775530619772e-09
( O 0 5.0981361354729415e-09
SF O 0 0.07235078513622284
- O 0 2.626024252094794e-05
1 O 0 6.221634318848146e-09
) O 0 4.3271172756043086e-10
and O 0 7.45970183402278e-08
Wilms B-Disease 0 0.048980776220560074
tumor I-Disease 0 0.001529841567389667
1 O 0 1.392067048300305e-07
( O 0 4.297845634937403e-09
WT1 O 0 5.2768605200981256e-06
) O 0 6.269603169961613e-10
genes O 0 2.44602826882101e-09
are O 0 1.699297369484043e-10
essential O 0 5.934638891424981e-10
for O 0 4.716450563435615e-10
mammalian O 0 3.7322121215765947e-07
gonadogenesis O 0 4.3749832911998965e-06
prior O 0 1.2908836666269963e-08
to O 0 2.368268026131659e-09
sexual O 0 5.751451226387871e-07
differentiation O 0 7.364641305684927e-07
. O 0 5.445706960927055e-07

In O 0 4.670647228977032e-07
males O 0 1.4698155155201675e-06
, O 0 2.2925263465367607e-08
SF O 0 0.020562846213579178
- O 0 8.960540071711875e-06
1 O 0 3.645433732657466e-09
participates O 0 8.825741026896594e-09
in O 0 1.885664513423535e-09
sexual O 0 2.6941400221858203e-08
development O 0 3.3618027805992767e-10
by O 0 8.046937005623533e-10
regulating O 0 2.5493500643847256e-08
expression O 0 9.065797890173144e-09
of O 0 1.389582060529193e-10
the O 0 2.1759753110472957e-08
polypeptide O 0 4.39141622337047e-05
hormone O 0 4.053174507134827e-06
Mullerian O 0 6.9850207182753365e-06
inhibiting O 0 7.791097118570178e-07
substance O 0 2.4027127437875606e-05
( O 0 6.322507317690906e-08
MIS O 0 6.557191227329895e-05
) O 0 1.531483384553667e-08
. O 0 1.1434418212274977e-07

Here O 0 9.337802566733444e-07
, O 0 6.5094933887621664e-09
we O 0 2.8869728829761243e-09
show O 0 7.931380707759672e-08
that O 0 4.28017763454136e-08
WT1 O 0 0.00019991319277323782
- O 0 0.00010628961172187701
KTS O 0 3.972948979935609e-05
isoforms O 0 4.8146834075168954e-08
associate O 0 9.018852331621474e-09
and O 0 3.0116862337337125e-09
synergize O 0 2.3372842861135723e-06
with O 0 2.8380753747114795e-07
SF O 1 0.9912422895431519
- O 0 8.949659968493506e-05
1 O 0 1.1261456656086466e-08
to O 0 3.0024862596178536e-09
promote O 0 1.4668508185877727e-07
MIS O 0 0.00032375144655816257
expression O 0 2.9242548862384865e-06
. O 0 2.788928838981519e-07

In O 0 5.235817752691219e-07
contrast O 0 5.53869313080213e-06
, O 0 8.245537941320435e-08
WT1 O 0 0.0002025372814387083
missense O 0 0.0004084994725417346
mutations O 0 3.671466765808873e-05
, O 0 3.736312592650393e-09
associated O 0 2.409016985893686e-08
with O 0 4.5973497009299535e-08
male B-Disease 0 0.02499501034617424
pseudohermaphroditism I-Disease 1 0.9999966621398926
in O 0 4.843627903028391e-05
Denys B-Disease 1 0.9994750618934631
- I-Disease 1 0.9999656677246094
Drash I-Disease 1 0.9999703168869019
syndrome I-Disease 1 0.9999823570251465
, O 0 1.0441323894383459e-07
fail O 0 2.6109369173354935e-06
to O 0 3.7220015958183694e-09
synergize O 0 1.9475544831948355e-05
with O 0 7.218945370368601e-07
SF O 1 0.9988002777099609
- O 0 0.0005906391888856888
1 O 0 3.299101365428214e-07
. O 0 3.0083523938628787e-07

Additionally O 0 2.4733062673476525e-06
, O 0 5.639743339003189e-09
the O 0 1.6495377286318558e-09
X O 0 0.00019850626995321363
- O 0 4.404417268233374e-05
linked O 0 1.346167209703708e-05
, O 0 5.543947079189593e-09
candidate O 0 4.138781832807581e-07
dosage O 0 2.7724032406695187e-05
- O 0 5.231233444646932e-06
sensitive O 0 2.6751104087452404e-06
sex O 0 2.840384922819794e-07
- O 0 5.192774210627249e-07
reversal O 0 6.244462724680488e-08
gene O 0 7.928730560990971e-09
, O 0 7.276543811940428e-10
Dax O 0 0.0006641776417382061
- O 0 5.814011274196673e-06
1 O 0 3.5966529754460907e-09
, O 0 3.2215830003679e-10
antagonizes O 0 4.348758153582821e-08
synergy O 0 4.596727265493428e-08
between O 0 4.6832429489995775e-08
SF O 0 0.27401310205459595
- O 0 1.4603545423597097e-05
1 O 0 1.2248233538514341e-08
and O 0 3.85452061379965e-08
WT1 O 0 1.1555740456969943e-05
, O 0 1.274134020512463e-09
most O 0 2.4104943041614035e-10
likely O 0 1.6699309712819854e-09
through O 0 2.548777335020791e-11
a O 0 9.174566106828763e-10
direct O 0 1.8570535109674324e-09
interaction O 0 1.017486805920953e-08
with O 0 3.3457314430052065e-07
SF O 1 0.9956973791122437
- O 0 0.0002752846048679203
1 O 0 8.853327670976796e-08
. O 0 1.4880376397741202e-07

We O 0 7.689262702115229e-07
propose O 0 6.299804340414994e-07
that O 0 1.977582009260459e-08
WT1 O 0 3.872778506774921e-06
and O 0 1.5099818284625144e-08
Dax O 0 0.03237653896212578
- O 0 2.0071593098691665e-05
1 O 0 8.380832028365148e-09
functionally O 0 4.264214226168406e-08
oppose O 0 5.88343995744367e-09
each O 0 3.3992902936930136e-10
other O 0 1.9522231053947792e-10
in O 0 2.246152153162484e-09
testis O 0 2.249807948828675e-06
development O 0 7.770359355951939e-10
by O 0 4.176999635063794e-09
modulating O 0 3.0845996661810204e-05
SF O 1 0.7669320106506348
- O 0 3.201659637852572e-05
1 O 0 2.5319291552250434e-08
- O 0 2.3333113858825527e-06
mediated O 0 3.031640289918869e-06
transactivation O 0 4.1756789869396016e-05
. O 0 7.085357367486722e-08
. O 0 1.5173141321156436e-07

A O 0 1.24278790281096e-06
mouse O 0 7.1148774622997735e-06
model O 0 4.929330316372216e-06
for O 0 1.1388789062038995e-05
Prader B-Disease 1 0.9999995231628418
- I-Disease 1 0.9999996423721313
Willi I-Disease 1 1.0
syndrome I-Disease 1 0.9999953508377075
imprinting O 1 0.6297386884689331
- O 0 0.15167514979839325
centre O 0 4.608109520631842e-05
mutations O 0 5.733081707148813e-05
. O 0 8.209411817006185e-07

Imprinting O 0 0.0001817640441004187
in O 0 6.207152836168461e-08
the O 0 4.221717198049646e-09
15q11 O 0 6.064613558010024e-07
- O 0 4.879811513092136e-06
q13 O 0 4.373071362806513e-07
region O 0 3.6483969179101905e-09
involves O 0 9.279526036465313e-10
an O 0 4.788266450006518e-10
imprinting O 0 2.4732169094932033e-06
centre O 0 9.453410854121103e-08
( O 0 1.1976895031295953e-09
IC O 0 5.822723210258118e-07
) O 0 2.4018617650334306e-10
, O 0 4.320567167925837e-11
mapping O 0 6.182691247857974e-09
in O 0 6.362434468165645e-10
part O 0 8.252925010054923e-10
to O 0 6.542911767937198e-10
the O 0 2.4158395284246126e-09
promoter O 0 3.74290948457201e-06
and O 0 1.2352023404105239e-08
first O 0 5.1914339493919215e-09
exon O 0 6.170300821395358e-07
of O 0 2.3814143546019295e-08
SNRPN O 0 0.002749229548498988
. O 0 9.18533089588891e-07

Deletion O 0 3.482180181890726e-05
of O 0 1.8101509624557366e-08
this O 0 1.3567311718531982e-08
IC O 0 8.682246516400483e-06
abolishes O 0 1.1683021057251608e-06
local O 0 4.850563950498099e-09
paternally O 0 1.8369186705058382e-07
derived O 0 3.859079722445813e-09
gene O 0 9.205368023401661e-09
expression O 0 3.997325848104083e-08
and O 0 1.5518283547066858e-08
results O 0 7.175292466854444e-07
in O 0 0.00034235542989335954
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 0.9999997615814209
( O 0 0.0012044641189277172
PWS B-Disease 1 0.9999877214431763
) O 0 9.58106511461665e-07
. O 0 7.949590781208826e-07

We O 0 1.8090485127686406e-06
have O 0 1.134636118393928e-08
created O 0 1.2297034501784765e-09
two O 0 6.34124475151765e-10
deletion O 0 1.8949588138639228e-06
mutations O 0 5.122324182593729e-06
in O 0 9.497345843101357e-08
mice O 0 6.43741586827673e-05
to O 0 6.505573537651799e-07
understand O 0 0.001054037711583078
PWS B-Disease 1 0.999990701675415
and O 0 1.2025664375414635e-07
the O 0 1.4922981739218244e-09
mechanism O 0 1.1597987459310843e-08
of O 0 3.190841202371786e-10
this O 0 1.9077768698139153e-08
IC O 0 0.00011191540397703648
. O 0 3.524097564877593e-07

Mice O 0 0.009703472256660461
harbouring O 0 0.0008539943373762071
an O 0 8.444875732038781e-08
intragenic O 0 2.3560502086183988e-05
deletion O 0 1.3526505426852964e-05
in O 0 1.3598094028566265e-07
Snrpn O 0 0.0001396928128087893
are O 0 1.9385518967851567e-08
phenotypically O 0 1.321629315498285e-05
normal O 0 1.165515044476706e-07
, O 0 6.624610304761802e-10
suggesting O 0 4.351330318286273e-08
that O 0 4.574892908948414e-09
mutations O 0 2.4837433443281043e-08
of O 0 9.0811969055693e-10
SNRPN O 0 0.00016398362640757114
are O 0 2.0985415627450266e-09
not O 0 2.6487754212212167e-09
sufficient O 0 1.5418354593066397e-08
to O 0 7.383037825547945e-08
induce O 0 7.898672629380599e-05
PWS B-Disease 1 0.9999390840530396
. O 0 4.610284577211132e-06

Mice O 0 0.00044830620754510164
with O 0 2.5130209024837313e-08
a O 0 2.010384214656824e-08
larger O 0 3.719363661502939e-08
deletion O 0 9.078829634745489e-07
involving O 0 9.824294266991274e-08
both O 0 2.8899988180342007e-08
Snrpn O 0 9.567283268552274e-05
and O 0 8.587685584870997e-08
the O 0 6.033990729292782e-08
putative O 0 0.012553086504340172
PWS O 1 0.9999866485595703
- O 0 0.008986957371234894
IC O 0 6.462584860855713e-05
lack O 0 1.9728075528746558e-07
expression O 0 5.718941054055904e-08
of O 0 3.8790173850777876e-10
the O 0 7.177275218595014e-09
imprinted O 0 8.152133523253724e-05
genes O 0 5.424353233252077e-08
Zfp127 O 0 2.4547846351197222e-06
( O 0 1.209104039112674e-09
mouse O 0 7.280965519385063e-08
homologue O 0 1.0638004965812797e-07
of O 0 1.9683576990559004e-09
ZNF127 O 0 0.0022714065853506327
) O 0 3.975675788581157e-09
, O 0 2.156711254031052e-09
Ndn O 0 1.87416844710242e-06
and O 0 3.1803150335463215e-08
Ipw O 0 7.147726137191057e-06
, O 0 5.62632385125994e-09
and O 0 2.2033725954884176e-08
manifest O 0 3.449843575253908e-07
several O 0 3.850638918834193e-09
phenotypes O 0 1.796375545382034e-05
common O 0 1.9401834379095817e-06
to O 0 4.2420317186042666e-05
PWS B-Disease 1 0.9999970197677612
infants O 0 0.1832897961139679
. O 0 1.8087724811266526e-06

These O 0 1.729961596197427e-08
data O 0 2.4531173536956885e-08
demonstrate O 0 1.8012650926380047e-08
that O 0 5.915099521303091e-10
both O 0 1.0252019372325449e-10
the O 0 5.290835547455686e-10
position O 0 2.212384409006063e-08
of O 0 2.0800898503647858e-10
the O 0 7.3475492357033545e-09
IC O 0 6.239592039491981e-06
and O 0 5.464819263778509e-09
its O 0 1.891149320476515e-10
role O 0 2.4648554308726034e-09
in O 0 4.1252723459450635e-10
the O 0 1.794511067521043e-10
coordinate O 0 1.3121401742921535e-08
expression O 0 8.023523179190306e-09
of O 0 2.727335302044054e-10
genes O 0 2.776040952667813e-09
is O 0 6.411393638217078e-10
conserved O 0 2.704868773406588e-09
between O 0 1.1239670305585037e-09
mouse O 0 2.341619392609573e-06
and O 0 2.1638368252752116e-07
human O 0 1.1266401855891672e-07
, O 0 6.051807943663334e-09
and O 0 3.859611652501371e-08
indicate O 0 2.586481286925846e-07
that O 0 6.067179647573084e-09
the O 0 1.7563056564640078e-09
mouse O 0 3.8609078956142184e-07
is O 0 1.2911021141093215e-09
a O 0 9.488502206167482e-10
suitable O 0 2.3666827075885521e-07
model O 0 1.0886981272051344e-06
system O 0 5.993673113380282e-08
in O 0 1.3677236010423144e-09
which O 0 4.162802991203307e-09
to O 0 8.685260843854792e-10
investigate O 0 2.6574300093784586e-08
the O 0 2.795882636519309e-09
molecular O 0 7.960074981383514e-07
mechanisms O 0 5.131049807260979e-09
of O 0 1.2429481055509228e-10
imprinting O 0 8.010313194972696e-07
in O 0 3.06328806765066e-09
this O 0 1.9036829890239915e-09
region O 0 1.543191130437549e-09
of O 0 2.286083405911299e-10
the O 0 7.910407440192557e-09
genome O 0 8.037970644636516e-08
. O 0 1.3863880710118792e-08
. O 0 3.321245856113819e-08

Mutations O 0 0.00012585680815391243
of O 0 1.81887234163014e-08
the O 0 1.1297081492500638e-08
ATM O 0 4.081475344719365e-05
gene O 0 1.7250347355002305e-06
detected O 0 0.00014678218576591462
in O 0 1.2757016065734206e-06
Japanese O 1 0.7355639338493347
ataxia B-Disease 1 0.9999996423721313
- I-Disease 1 0.999997615814209
telangiectasia I-Disease 1 0.9999995231628418
patients O 0 0.00020924786804243922
: O 0 2.1841085384721737e-08
possible O 0 2.421584355261075e-08
preponderance O 0 1.3144318700142321e-06
of O 0 1.1518199727333922e-09
the O 0 5.953553205984008e-09
two O 0 9.703575720720892e-09
founder O 0 1.0100502549903467e-06
mutations O 0 9.761018873177818e-07
4612del165 O 0 4.378420896955504e-07
and O 0 5.95819074078463e-08
7883del5 O 0 3.859251137328101e-06
. O 0 3.069003753353172e-07

The O 0 2.7007726544070465e-07
ATM O 0 0.0001076401531463489
( O 0 4.357663669907197e-07
A O 1 0.9968987703323364
- O 1 0.9999783039093018
T O 1 0.9999986886978149
, O 0 8.219080172011672e-08
mutated O 0 3.6879745834994537e-07
) O 0 2.441487012561083e-10
gene O 0 3.2793463500269127e-09
on O 0 8.09512812338653e-08
human O 0 7.941762873997504e-07
chromosome O 0 0.0003973208658862859
11q22 O 0 4.768855797010474e-05
. O 0 8.36602794151986e-07

3 O 0 6.011923119331186e-07
has O 0 1.3209270832703623e-07
recently O 0 1.610811608543372e-07
been O 0 1.759307188820003e-08
identified O 0 5.087336774067808e-08
as O 0 8.076120883160343e-10
the O 0 7.49659390120172e-10
gene O 0 1.2068236188156334e-08
responsible O 0 6.7354335442360025e-09
for O 0 2.123970999079461e-09
the O 0 8.93112499511517e-08
human O 0 0.0015160851180553436
recessive B-Disease 1 0.9999085664749146
disease I-Disease 1 0.9998642206192017
ataxia B-Disease 1 0.9999997615814209
- I-Disease 1 0.9999985694885254
telangiectasia I-Disease 1 0.9999996423721313
( O 0 0.0003992412821389735
A B-Disease 1 0.9999926090240479
- I-Disease 1 0.9999953508377075
T I-Disease 1 0.9999986886978149
) O 0 5.448886781778128e-07
. O 0 2.526264211155649e-07

In O 0 9.195842665121745e-08
order O 0 2.765766948797932e-09
to O 0 6.854742329309715e-10
define O 0 2.000805565671726e-08
the O 0 1.4267638182019482e-09
types O 0 1.1172907221634887e-07
of O 0 3.0259325711767815e-08
disease O 0 0.00043006669147871435
- O 0 0.0007252593641169369
causing O 0 2.255363142467104e-06
ATM O 0 0.00011101081327069551
mutations O 0 6.319631324913644e-07
in O 0 3.0355964408812497e-09
Japanese O 0 9.067771316040307e-06
A B-Disease 1 0.9999426603317261
- I-Disease 1 0.999994158744812
T I-Disease 1 0.9999996423721313
patients O 0 4.006069218576158e-07
as O 0 2.645957897229323e-09
well O 0 4.375388051869322e-09
as O 0 1.4124942326887435e-09
to O 0 6.7514566159943e-10
look O 0 6.138535724176108e-08
for O 0 3.867337838858731e-10
possible O 0 3.862233199924958e-08
mutational O 0 5.561759735428495e-06
hotspots O 0 4.624789937679452e-07
, O 0 1.217518419416308e-09
reverse O 0 5.786254675399505e-08
- O 0 2.7723129392143164e-07
transcribed O 0 1.9848526378041242e-08
RNA O 0 4.9920965139449436e-09
derived O 0 4.813759946209473e-10
from O 0 2.0229833086471416e-10
ten O 0 2.397418930044637e-09
patients O 0 9.258580568882735e-09
belonging O 0 5.50189760417652e-08
to O 0 4.133118736149299e-09
eight O 0 5.582890594268974e-09
unrelated O 0 5.096476343169343e-07
Japanese O 0 2.1149966414668597e-05
A B-Disease 1 0.9998136162757874
- I-Disease 1 0.9999490976333618
T I-Disease 1 0.9999964237213135
families O 0 4.875117909364235e-08
was O 0 1.422987452315283e-07
analyzed O 0 4.965698963133036e-08
for O 0 1.1947144384905073e-09
mutations O 0 1.0655667459502638e-08
by O 0 2.6115312690144776e-10
the O 0 1.2601741872231287e-09
restriction O 0 1.5675233555612067e-08
endonuclease O 0 3.537188604241237e-07
fingerprinting O 0 1.818473975845336e-07
method O 0 9.088881114394098e-08
. O 0 1.1942074706894346e-07

As O 0 1.809176382039368e-07
has O 0 4.602086889349266e-08
been O 0 3.2016107098797875e-08
reported O 0 3.043923868517595e-08
by O 0 3.735443065977506e-09
others O 0 7.90348835266741e-08
, O 0 6.0841447435677765e-09
mutations O 0 1.974830432516228e-08
that O 0 1.575189201297178e-09
lead O 0 8.417726071741072e-09
to O 0 2.3880311061930115e-09
exon O 0 1.7289576135226525e-06
skipping O 0 1.8708828974922653e-07
or O 0 8.935418804867368e-08
premature O 0 1.5343991321969952e-07
protein O 0 3.658131131345499e-09
truncation O 0 2.776677909821501e-08
were O 0 6.091067206170919e-08
also O 0 3.205906651260193e-08
predominant O 0 3.6992432228544203e-07
in O 0 1.5961733268454736e-08
our O 0 9.67936415463555e-08
mutants O 0 2.1111902697157348e-06
. O 0 1.4440928453041124e-07

Six O 0 1.4306769458016788e-07
different O 0 8.053036459898522e-09
mutations O 0 4.92631329507276e-07
were O 0 1.2263007498347633e-08
identified O 0 1.5088166094301414e-07
on O 0 9.683371615665237e-08
12 O 0 1.8455281747264962e-09
of O 0 9.327664335367913e-11
the O 0 1.3412189581174516e-08
16 O 0 9.264272904374593e-08
alleles O 0 1.903049167140125e-07
examined O 0 9.99150415736949e-06
. O 0 9.887002079267404e-07

Four O 0 2.896599937685096e-07
were O 0 1.2232708179737983e-08
deletions O 0 3.3497192930553865e-07
involving O 0 2.3303063301227667e-07
a O 0 6.269489176702336e-07
loss O 0 2.2053084194340045e-06
of O 0 5.717986084619042e-10
a O 0 7.705295956839109e-08
single O 0 1.7163799839181593e-06
exon O 0 9.50612775341142e-06
exon O 0 8.101096682366915e-06
7 O 0 1.6581502393364644e-08
, O 0 3.2658245552319443e-10
exon O 0 2.0698225000614912e-07
16 O 0 1.5188864610493624e-09
, O 0 2.0669950473450882e-10
exon O 0 2.443842959110043e-07
33 O 0 8.179869226410119e-09
or O 0 2.0568856839986438e-08
exon O 0 1.6450210750917904e-05
35 O 0 1.967049456652603e-07
. O 0 3.814216995579045e-07

The O 0 1.9164208708843944e-07
others O 0 2.315417013676324e-08
were O 0 2.543913524277741e-09
minute O 0 3.00048252910301e-09
deletions O 0 3.241093793349137e-07
, O 0 2.603336657358568e-09
4649delA O 0 3.108747392843725e-08
in O 0 7.297196735756017e-10
exon O 0 5.40208134225395e-07
33 O 0 6.242793393340662e-09
and O 0 4.374228090853194e-09
7883del5 O 0 2.7425085136201233e-07
in O 0 1.0482426482383289e-08
exon O 0 8.507135135005228e-06
55 O 0 1.5371848860468162e-07
. O 0 2.973849007048557e-07

The O 0 4.3953733097623626e-07
mutations O 0 3.968787495978177e-06
4612del165 O 0 8.105632787192008e-07
and O 0 1.7780333649852764e-08
7883del5 O 0 4.998692588742415e-07
were O 0 2.2461831505893315e-08
found O 0 9.337784767637913e-09
in O 0 5.648632672716758e-10
more O 0 5.817984982670055e-11
than O 0 2.710295321506351e-10
two O 0 6.253933482192053e-10
unrelated O 0 3.739587128848143e-08
families O 0 9.145929569243094e-10
; O 0 1.3985079760914232e-10
44 O 0 2.2816835920647094e-10
% O 0 1.52072063275277e-10
( O 0 7.130737667004894e-11
7 O 0 3.9828085274251634e-10
of O 0 3.3298944157600374e-10
16 O 0 7.84941711629017e-09
) O 0 4.631518085718156e-11
of O 0 1.3120982599035269e-11
the O 0 1.2048266828657006e-09
mutant O 0 4.058532852013741e-07
alleles O 0 5.488500320893763e-09
had O 0 4.929555785793127e-08
one O 0 6.602786650766745e-10
of O 0 1.5697777799861257e-10
the O 0 5.850953055386299e-09
two O 0 9.006548395973368e-08
mutations O 0 1.2034206520183943e-05
. O 0 3.4403876725264126e-07

The O 0 1.0879730893975648e-07
4612del165 O 0 3.4789879919117084e-06
mutations O 0 2.3780521587468684e-06
in O 0 2.977428081862854e-09
three O 0 6.462665402828804e-10
different O 0 4.17361312177178e-10
families O 0 1.4081392718523489e-09
were O 0 9.561630598398096e-09
all O 0 2.190456011019748e-10
ascribed O 0 1.7566515353450995e-08
to O 0 4.759420635380707e-10
the O 0 6.566353016879134e-10
same O 0 4.366161832081161e-08
T O 0 1.2454418538254686e-05
- O 0 6.882384013806586e-07
- O 0 8.651018106320407e-07
> O 0 2.2510198149916505e-09
A O 0 9.050573068769552e-10
substitution O 0 3.4946351368247974e-10
at O 0 1.996293963468787e-10
the O 0 6.843986488647147e-11
splice O 0 6.431952215280035e-08
donor O 0 4.0118994348858905e-08
site O 0 1.0940660644109812e-07
in O 0 1.1958618095775364e-08
intron O 0 3.229087815270759e-05
33 O 0 2.551676061557373e-07
. O 0 1.5309846901345736e-07

Microsatellite O 0 0.0007293405942618847
genotyping O 0 0.00021918400307185948
around O 0 9.163556313751542e-08
the O 0 1.007043426426435e-08
ATM O 0 2.006810791499447e-05
locus O 0 2.6888712454820052e-05
also O 0 3.358362050676078e-07
indicated O 0 1.6975682228803635e-06
that O 0 7.882754893273614e-09
a O 0 1.1396467414215294e-07
common O 0 3.4118381790904095e-06
haplotype O 0 0.0002008342562476173
was O 0 4.946414833284507e-07
shared O 0 8.590123279361705e-09
by O 0 1.6367978084019796e-09
the O 0 2.6314881385047784e-09
mutant O 0 3.4435583984304685e-07
alleles O 0 1.9447625732027518e-08
in O 0 5.755619092440156e-09
both O 0 6.63879617945895e-08
mutations O 0 1.0270465281791985e-05
. O 0 6.742865821252053e-07

This O 0 5.920670531622818e-08
suggests O 0 4.417586296767695e-08
that O 0 1.3617521554820655e-09
these O 0 1.7449552913717525e-10
two O 0 5.634256949882399e-10
founder O 0 8.851814641275269e-07
mutations O 0 4.190506842860486e-06
may O 0 1.3573558135249186e-06
be O 0 1.7941193419801493e-08
predominant O 0 3.0876159939907666e-07
among O 0 2.9026316905600424e-09
Japanese O 0 4.015980721305823e-07
ATM O 0 1.3019067409913987e-05
mutant O 0 3.1324657356890384e-06
alleles O 0 1.034109118336346e-06
. O 0 2.881100158447225e-07

W474C O 0 2.8122127332608216e-05
amino O 0 2.68077485543472e-07
acid O 0 5.005179914974178e-08
substitution O 0 1.5902141825563376e-08
affects O 0 1.2761096179758624e-08
early O 0 9.012520174600525e-10
processing O 0 5.328184005115588e-10
of O 0 2.403964353969723e-11
the O 0 7.602178608845378e-11
alpha O 0 2.5952689997055245e-10
- O 0 3.628445099934652e-09
subunit O 0 2.136830712373694e-10
of O 0 3.4990819269831164e-11
beta O 0 2.4705411050263137e-09
- O 0 8.975650871434482e-07
hexosaminidase O 0 1.6499026287419838e-06
A O 0 1.0343641321242103e-07
and O 0 3.435835793652586e-08
is O 0 2.2639600416596295e-08
associated O 0 3.1610895234734926e-08
with O 0 3.8712133232365886e-07
subacute O 1 0.9066002368927002
G B-Disease 0 0.2400052696466446
( I-Disease 0 3.808168713703708e-08
M2 I-Disease 0 0.0028874382842332125
) I-Disease 0 6.050262868484424e-08
gangliosidosis I-Disease 0 5.388473437051289e-05
. O 0 2.0524029764601437e-07

Mutations O 0 0.0005365381366573274
in O 0 1.8162936044063827e-07
the O 0 1.9890251223841915e-08
HEXA O 0 0.00015831812925171107
gene O 0 1.3159603895473992e-07
, O 0 3.652433078205064e-10
encoding O 0 1.2400100946052817e-09
the O 0 2.54171017566307e-10
alpha O 0 9.617778795600884e-10
- O 0 7.718840677739536e-09
subunit O 0 3.9048728139867706e-10
of O 0 1.286401540845361e-10
beta O 0 1.975011265642479e-08
- O 0 4.169021394773154e-06
hexosaminidase O 0 1.1126042409159709e-05
A O 0 3.9734837287142e-07
( O 0 1.4258469960282127e-09
Hex O 0 4.917301055229473e-08
A O 0 3.5066971548758374e-08
) O 0 1.446185671216682e-10
, O 0 4.972676784231744e-11
that O 0 4.945561182800873e-10
abolish O 0 4.860485347535359e-08
Hex O 0 1.0631573843511433e-07
A O 0 2.2399069266043625e-08
enzyme O 0 6.061791424372132e-08
activity O 0 4.758862814924214e-07
cause O 0 0.007833043113350868
Tay B-Disease 1 0.9999995231628418
- I-Disease 1 0.9999986886978149
Sachs I-Disease 1 0.9999995231628418
disease I-Disease 1 0.5663124918937683
( O 0 6.78368152762232e-08
TSD B-Disease 0 0.00011544764856807888
) O 0 2.7129343216358848e-09
, O 0 1.2445428021479188e-09
the O 0 3.449053309623196e-08
fatal O 0 0.06040657311677933
infantile B-Disease 0 0.02057572267949581
form I-Disease 0 3.2499210078640317e-07
of I-Disease 0 2.5739311126926623e-08
G I-Disease 0 0.004270932171493769
( I-Disease 0 7.060558804283801e-09
M2 I-Disease 0 0.0006258116918615997
) I-Disease 0 6.452864020900506e-09
gangliosidosis I-Disease 0 3.468251406957279e-06
, I-Disease 0 4.9303809923628705e-09
Type I-Disease 0 1.4659071894129738e-06
1 I-Disease 0 5.26830454816718e-08
. O 0 1.405462626280496e-07

Less O 0 2.1445928723551333e-05
severe O 0 0.006046261638402939
, O 0 6.733079089826788e-07
subacute O 0 0.35589417815208435
( O 0 1.8014836768998066e-06
juvenile O 0 0.2551111876964569
- O 1 0.6952067017555237
onset O 0 0.0030083104502409697
) O 0 2.1019239682118496e-07
and O 0 1.1337910109432414e-05
chronic O 1 0.6818403005599976
( O 0 1.77234056764064e-07
adult O 0 8.386733679799363e-05
- O 0 0.1537378579378128
onset O 0 0.00022479583276435733
) O 0 9.06320529736604e-09
variants O 0 1.0104243131081603e-07
are O 0 6.480097347605351e-09
characterized O 0 6.611614367102447e-08
by O 0 1.818593942104485e-09
a O 0 7.933619627920052e-08
broad O 0 5.066179653567815e-08
spectrum O 0 4.930679438075458e-07
of O 0 1.7099757165794927e-09
clinical O 0 5.776175839855568e-07
manifestations O 0 1.3822573237121105e-05
and O 0 1.9706958198639768e-07
are O 0 8.904722292868428e-09
associated O 0 1.9582218513392036e-08
with O 0 7.1961228087502604e-09
residual O 0 0.001516937161795795
levels O 0 2.2841707902898634e-07
of O 0 5.184267459767966e-10
Hex O 0 6.012771791574778e-07
A O 0 8.143570084939711e-08
enzyme O 0 1.0711831777143743e-07
activity O 0 1.0933756300346431e-07
. O 0 5.053295737411645e-08

We O 0 4.011043017726479e-07
identified O 0 1.34641609861319e-07
a O 0 1.8800561107923386e-08
1422 O 0 1.7359217963530682e-05
G O 0 6.735982606187463e-05
- O 0 4.928803537040949e-05
- O 0 0.0004710161010734737
> O 0 2.2104140953160822e-06
C O 0 5.52818960386503e-07
( O 0 1.9337897949611715e-10
amino O 0 6.966116017359525e-10
acid O 0 2.0618298179897465e-09
W474C O 0 1.0662818406004249e-09
) O 0 4.566325616239819e-12
substitution O 0 4.5579998109168685e-11
in O 0 2.6087021431919766e-11
the O 0 5.374427985982422e-11
first O 0 2.012973121523487e-09
position O 0 1.8566646886597482e-08
of O 0 1.45777848126194e-10
exon O 0 6.38803669517074e-07
13 O 0 1.6509227318550757e-09
of O 0 2.5730545472057997e-10
HEXA O 0 9.632117325963918e-06
of O 0 5.796920166112329e-10
a O 0 1.5106134299003315e-07
non O 0 8.262162509709015e-08
- O 0 2.278806277900003e-05
Jewish O 0 4.945806608702696e-07
proband O 0 5.729835174861364e-05
who O 0 1.2574166419199173e-07
manifested O 0 3.3810079003160354e-07
a O 0 1.5186721213922283e-07
subacute O 0 0.0003349973412696272
variant O 0 2.4324168407474644e-05
of O 0 3.436976570014849e-08
G B-Disease 0 0.023116596043109894
( I-Disease 0 2.9532674972188033e-08
M2 I-Disease 0 0.0024013593792915344
) I-Disease 0 1.0320918875095231e-07
gangliosidosis I-Disease 0 5.336904359865002e-05
. O 0 3.1260447030945215e-07

On O 0 1.890892065148364e-07
the O 0 8.047017274748214e-09
second O 0 9.026720704241598e-08
maternally O 0 0.00011046728468500078
inherited O 0 0.0012329637538641691
allele O 0 5.064573997515254e-06
, O 0 4.616230064868887e-09
we O 0 4.591730107250669e-09
identified O 0 2.6482716464215628e-08
the O 0 1.7307272059952084e-08
common O 0 4.3670606828527525e-05
infantile O 1 0.9988633394241333
disease O 0 0.13018587231636047
- O 0 0.001600101008079946
causing O 0 3.1490112633036915e-06
4 O 0 1.1791019005613634e-07
- O 0 3.476002166280523e-05
bp O 0 2.2877402443555184e-06
insertion O 0 4.439692347091295e-08
, O 0 4.637232819959536e-09
+ O 0 2.459540482391276e-08
TATC O 0 2.026130459853448e-06
1278 O 0 1.5358031077994383e-06
, O 0 2.4130257791910026e-09
in O 0 3.569800677283297e-09
exon O 0 7.17291004548315e-06
11 O 0 4.297774012229638e-07
. O 0 4.0614136764816067e-07

Pulse O 0 0.0007242567953653634
- O 0 9.098035661736503e-06
chase O 0 2.3792721037807496e-07
analysis O 0 7.182698436025703e-09
using O 0 8.363713277503848e-09
proband O 0 1.0223752724414226e-06
fibroblasts O 0 7.330950069217579e-08
revealed O 0 3.2040182418313634e-07
that O 0 7.509645683079214e-10
the O 0 1.8831622372594836e-10
W474C O 0 3.192134911955691e-08
- O 0 4.3434113194962265e-08
containing O 0 5.2722417542838684e-09
alpha O 0 3.0664388805945464e-09
- O 0 6.855739531630434e-09
subunit O 0 4.925030383517992e-10
precursor O 0 2.5785389379251455e-09
was O 0 1.6704477800999484e-08
normally O 0 1.726311982253037e-09
synthesized O 0 2.3346677480162725e-08
, O 0 3.012965987814198e-10
but O 0 6.138471952965574e-10
not O 0 4.3562420337650565e-10
phosphorylated O 0 4.312346923995847e-09
or O 0 1.5882279935652832e-09
secreted O 0 2.2801373233960476e-08
, O 0 5.010026837837245e-10
and O 0 1.0411285167322148e-09
the O 0 4.13136902466249e-09
mature O 0 8.341365287378721e-08
lysosomal O 0 1.2943953606736613e-06
alpha O 0 4.697088495930757e-09
- O 0 1.084120100358632e-07
subunit O 0 1.1630485019509251e-08
was O 0 1.270638136929847e-07
not O 0 4.267957720571758e-08
detected O 0 2.5983086743508466e-05
. O 0 2.2961634726925695e-07

When O 0 1.448688919936103e-07
the O 0 2.481682193078427e-09
W474C O 0 8.723703359692081e-08
- O 0 4.486528482061658e-08
containing O 0 7.548120350975296e-09
alpha O 0 4.369674844184601e-09
- O 0 6.675173125358924e-08
subunit O 0 1.3034124890509702e-08
was O 0 1.5255002949743357e-07
transiently O 0 1.094982053473359e-06
co O 0 1.0801134067150997e-06
- O 0 4.295937969800434e-07
expressed O 0 8.582862753847564e-10
with O 0 3.4603106491282176e-10
the O 0 4.751909976619118e-10
beta O 0 1.591676124235164e-09
- O 0 1.3217127836639975e-08
subunit O 0 9.911088616476604e-10
to O 0 3.0984792509514136e-10
produce O 0 3.805037618320739e-09
Hex O 0 1.2899882051442546e-07
A O 0 1.2328173681908083e-07
( O 0 9.416708524057071e-10
alphabeta O 0 5.222074719313241e-07
) O 0 1.7424243992092414e-10
in O 0 9.154481617201782e-10
COS O 0 8.090950359473936e-06
- O 0 2.7579828838497633e-06
7 O 0 7.20213755300847e-09
cells O 0 1.1467831129152728e-08
, O 0 1.1341935723940821e-10
the O 0 2.2852289505159717e-10
mature O 0 1.6790077106421109e-09
alpha O 0 1.66828106884509e-10
- O 0 7.503035526212898e-09
subunit O 0 8.355114933245034e-10
was O 0 2.0947474865806726e-08
present O 0 7.79807940443078e-10
, O 0 1.631585283545789e-10
but O 0 2.0878924977818514e-10
its O 0 1.6890314147310903e-10
level O 0 6.452224088349112e-09
was O 0 1.0093206270767041e-07
much O 0 3.3506144525574655e-09
lower O 0 1.1715647119103778e-08
than O 0 9.421415869681482e-10
that O 0 9.180868287828048e-10
from O 0 4.505020245737512e-10
normal O 0 1.454410369916559e-09
alpha O 0 4.603829817373395e-10
- O 0 9.982769277883108e-09
subunit O 0 1.5468039071819817e-09
transfections O 0 1.0777247183568761e-07
, O 0 1.1585549880566148e-10
although O 0 2.0784003684770624e-10
higher O 0 1.57067403527833e-09
than O 0 3.588223052020112e-10
in O 0 1.6284180670567139e-09
those O 0 2.994822390078866e-09
cells O 0 7.733444107316245e-09
transfected O 0 8.950855345801756e-08
with O 0 5.890960497190179e-10
an O 0 4.585539725709964e-10
alpha O 0 4.2367616082117365e-09
- O 0 7.487668653993751e-07
subunit O 0 1.6389760659762942e-08
associated O 0 5.361852828400515e-08
with O 0 3.60740045834973e-07
infantile O 1 0.98454350233078
TSD B-Disease 0 0.12399671226739883
. O 0 2.3938071080920054e-06

Furthermore O 0 1.0362720786361024e-05
, O 0 4.112625795471558e-09
the O 0 2.3361620971051877e-10
precursor O 0 3.0977660436803944e-09
level O 0 1.5897979599444056e-09
of O 0 2.410484312154182e-11
the O 0 4.324270941324926e-10
W474C O 0 1.6185287776693258e-08
alpha O 0 5.847916040302437e-10
- O 0 7.116288447406305e-09
subunit O 0 1.5103037709351952e-09
was O 0 1.7003886298994075e-08
found O 0 3.012001981161916e-09
to O 0 8.356580982749051e-10
accumulate O 0 1.3344671145887332e-08
in O 0 1.9535828510441888e-10
comparison O 0 5.42035838435595e-09
to O 0 5.855348983452302e-10
the O 0 1.090273649140272e-09
normal O 0 5.72927749686869e-09
alpha O 0 2.742924776200084e-09
- O 0 5.8489810328410385e-08
subunit O 0 1.0691212359859037e-08
precursor O 0 9.22016667459502e-08
levels O 0 3.4241460866724083e-07
. O 0 3.520227309650181e-08

We O 0 2.453174090533139e-07
conclude O 0 7.635146914708457e-08
that O 0 6.494768611808865e-10
the O 0 7.410951852193648e-10
1422 O 0 4.201783212920418e-06
G O 0 5.501771374838427e-05
- O 0 3.8155249058036134e-05
- O 0 0.0002432029286865145
> O 0 8.575750030104246e-07
C O 0 8.039041858864948e-07
mutation O 0 7.797373058338053e-08
is O 0 4.454191737668367e-10
the O 0 1.2267632465423617e-09
cause O 0 1.7329313095615362e-07
of O 0 2.8947420016578462e-09
Hex B-Disease 0 0.00027902889996767044
A I-Disease 0 0.016596127301454544
enzyme I-Disease 1 0.9999839067459106
deficiency I-Disease 1 0.999987006187439
in O 0 4.3085503165229966e-08
the O 0 7.776609578513671e-08
proband O 0 0.00104261445812881
. O 0 1.4279645483838976e-06

The O 0 1.6849924122652737e-07
resulting O 0 1.9283338303921482e-07
W474C O 0 1.7866160817447962e-07
substitution O 0 1.9075658386213945e-08
clearly O 0 3.011130544905427e-08
interferes O 0 3.576713325514902e-08
with O 0 1.6955871429136238e-10
alpha O 0 1.5007930453947438e-09
- O 0 1.527810233881155e-08
subunit O 0 1.0181016030230694e-09
processing O 0 1.5575208900386883e-09
, O 0 1.8957033165456494e-10
but O 0 3.953578298077076e-10
because O 0 2.309385321863644e-10
the O 0 2.5854603180608393e-11
base O 0 2.64428645646575e-10
substitution O 0 5.032389505110757e-10
falls O 0 1.688430728563617e-08
at O 0 5.069941688695678e-11
the O 0 2.9872944395936685e-11
first O 0 4.3928208293131377e-10
position O 0 3.5840186374258565e-09
of O 0 6.298281340910705e-11
exon O 0 9.107221217163897e-07
13 O 0 6.72785827049438e-09
, O 0 9.61352442097052e-10
aberrant O 0 7.093294840387898e-08
splicing O 0 3.514465447551629e-07
may O 0 1.6298969285344356e-06
also O 0 2.9701678894156203e-09
contribute O 0 1.071480681957837e-09
to O 0 1.0194856514544881e-08
Hex B-Disease 0 3.1592197046848014e-05
A I-Disease 0 0.0010306264739483595
deficiency I-Disease 0 0.011528692208230495
in O 0 4.340849901751653e-09
this O 0 1.021022999481147e-08
proband O 0 3.673190076369792e-05
. O 0 3.0450507892965106e-08
. O 0 1.238987579199602e-07

Two O 0 3.573546507595893e-07
frequent O 0 3.564612052286975e-05
missense O 0 0.03977908194065094
mutations O 0 0.16876257956027985
in O 0 0.0009295088821090758
Pendred B-Disease 1 0.9999985694885254
syndrome I-Disease 1 0.9999996423721313
. O 0 0.0001532305177533999

Pendred B-Disease 1 0.9999980926513672
syndrome I-Disease 1 0.9999998807907104
is O 0 0.0040964046493172646
an O 0 0.12867006659507751
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 1 0.9916119575500488
by O 0 2.7368636438040994e-05
early O 0 0.14414459466934204
childhood O 1 0.9999654293060303
deafness B-Disease 1 0.9999998807907104
and O 1 0.9748418927192688
goiter B-Disease 1 0.9999996423721313
. O 0 0.000247420568484813

A O 0 4.4581059910342447e-07
century O 0 3.4464029852188105e-08
after O 0 5.025150517923294e-09
its O 0 4.2609338279930853e-10
recognition O 0 5.121839397048689e-09
as O 0 1.9635290726682797e-08
a O 0 0.00026031621382571757
syndrome O 1 0.9921898245811462
by O 0 6.715899303344486e-08
Vaughan O 0 1.4480095842372975e-06
Pendred O 0 1.2093963960069232e-05
, O 0 3.0868958500462895e-09
the O 0 3.0707187903544764e-08
disease O 0 8.232216714532115e-06
gene O 0 1.746444695527316e-07
( O 0 1.40224356570684e-08
PDS O 0 2.979146120196674e-05
) O 0 1.4622487665150175e-09
was O 0 2.0796403532585828e-07
mapped O 0 1.76799494511215e-05
to O 0 6.295432086744768e-08
chromosome O 0 8.603977767052129e-05
7q22 O 0 4.15186514146626e-06
- O 0 8.401775266975164e-05
q31 O 0 1.8424114387016743e-05
. O 0 4.960185151503538e-07

1 O 0 8.092100642898004e-07
and O 0 6.569954535962097e-08
, O 0 1.029944041164299e-08
recently O 0 2.1103036829117627e-07
, O 0 9.334966133422995e-10
found O 0 2.1311048481464923e-09
to O 0 4.246087093040529e-10
encode O 0 3.19200097465e-08
a O 0 8.855470241542207e-07
putative O 0 0.0014542954741045833
sulfate O 0 0.0918489396572113
transporter O 0 0.0009887625928968191
. O 0 7.668772354918474e-07

We O 0 7.217100801426568e-07
performed O 0 1.1673170519088671e-07
mutation O 0 5.562316118812305e-08
analysis O 0 1.8373831345286362e-09
of O 0 1.3807287257971979e-10
the O 0 3.973818607505564e-09
PDS B-Disease 0 1.6317417248501442e-05
gene O 0 9.303477099820157e-08
in O 0 4.269895015340808e-08
patients O 0 4.798236830083624e-08
from O 0 3.898913636390944e-09
14 O 0 2.6269209030260754e-08
Pendred B-Disease 0 8.352257282240316e-06
families O 0 3.178518115376505e-09
originating O 0 1.4120579150400658e-09
from O 0 5.662763591374187e-10
seven O 0 7.482937047775806e-10
countries O 0 1.7405742125387036e-10
and O 0 9.80366188230164e-09
identified O 0 5.152678568265401e-07
all O 0 7.820694314375487e-09
mutations O 0 1.7623453913984122e-06
. O 0 2.7019009962714335e-07

The O 0 7.35134335627663e-07
mutations O 0 2.3289139789994806e-06
include O 0 4.2162127122935544e-09
three O 0 4.059242275644692e-09
single O 0 9.766394981625126e-08
base O 0 7.892928266528543e-08
deletions O 0 6.619399073315435e-07
, O 0 2.191811399043786e-09
one O 0 8.038055221426532e-10
splice O 0 1.2828949138565804e-06
site O 0 3.335852852615062e-06
mutation O 0 6.9147395151958335e-06
and O 0 4.025036659527359e-08
10 O 0 5.184549678460826e-08
missense O 0 0.0003416110994294286
mutations O 0 0.00014086480950936675
. O 0 1.768871811691497e-06

One O 0 1.8190634136772132e-06
missense O 0 0.0009728780132718384
mutation O 0 0.00037800639984197915
( O 0 2.7926171597414395e-08
L236P O 0 6.823044031989411e-07
) O 0 1.3265208931301231e-09
was O 0 1.611799547163173e-07
found O 0 6.220296455694552e-08
in O 0 3.752854027538888e-09
a O 0 1.0270411365809196e-07
homozygous O 0 1.3519128515326884e-05
state O 0 4.664219588335072e-08
in O 0 9.260665123633771e-09
two O 0 4.7062176378176446e-09
consanguineous O 0 3.805625965469517e-05
families O 0 2.0867718220074494e-08
and O 0 1.6303893346503173e-08
in O 0 2.3993860231996678e-09
a O 0 4.834209832438319e-08
heterozygous O 0 2.3642215296604263e-07
state O 0 6.633186000470914e-09
in O 0 4.862003688543837e-09
five O 0 1.8816264102383684e-09
additional O 0 4.3158028262269e-09
non O 0 1.5024124877527356e-07
- O 0 0.0002799674402922392
consanguineous O 0 0.00036432495107874274
families O 0 7.434687177010346e-07
. O 0 5.527277835426503e-07

Another O 0 2.700329332583351e-06
missense O 0 0.0010566918645054102
mutation O 0 0.00027512351516634226
( O 0 2.4017772659590264e-08
T416P O 0 3.288663208422804e-07
) O 0 1.6037774441812758e-09
was O 0 2.733025610268669e-07
found O 0 3.010958238292005e-08
in O 0 2.296604018070525e-09
a O 0 4.500584793731832e-08
homozygous O 0 7.188468771346379e-06
state O 0 2.3387235259519912e-08
in O 0 1.5913400375211495e-08
one O 0 3.253908786859938e-08
family O 0 3.297946093994142e-08
and O 0 2.4768743500658275e-08
in O 0 3.0948188456392245e-09
a O 0 1.596046246277183e-07
heterozygous O 0 1.2810695579901221e-06
state O 0 1.5491400162659374e-08
in O 0 1.7694469889306674e-08
four O 0 2.534257959041497e-08
families O 0 1.354229084427061e-07
. O 0 3.0102665959930164e-07

Pendred B-Disease 0 0.04346361756324768
patients O 0 8.216215974243823e-06
in O 0 2.0876637307765122e-08
three O 0 9.70248414944308e-09
non O 0 1.0637071312658009e-07
- O 0 5.3819516324438155e-05
consanguineous O 0 4.713214366347529e-05
families O 0 4.1632258529489263e-08
were O 0 4.348758153582821e-08
shown O 0 1.5040885159578465e-07
to O 0 2.6767033034502674e-09
be O 0 1.5177029411006515e-08
compound O 0 4.103241124653323e-08
heterozygotes O 0 2.2395444432277145e-07
for O 0 1.461777476841064e-09
L236P O 0 3.86241822525335e-07
and O 0 3.3510765717892355e-08
T416P O 0 1.3381063581618946e-06
. O 0 1.1433131419380516e-07

In O 0 7.0836819077158e-08
total O 0 6.575994859758794e-09
, O 0 1.1592319326680922e-09
one O 0 8.095059067514399e-10
or O 0 3.701993156468575e-09
both O 0 2.4479407390032293e-10
of O 0 1.7317690337304015e-10
these O 0 8.81396555740821e-09
mutations O 0 2.446865323690872e-07
were O 0 1.1593424176226108e-07
found O 0 1.9617552027284546e-07
in O 0 4.029505173974712e-09
nine O 0 6.950349185075311e-10
of O 0 2.1756660362193259e-10
the O 0 1.1922837828137745e-08
14 O 0 9.790581678714716e-09
families O 0 2.4139017895663528e-08
analyzed O 0 1.1870737353092409e-06
. O 0 9.160294212051667e-07

The O 0 4.247938178991717e-08
identification O 0 7.7399405995493e-08
of O 0 4.790861041215067e-10
two O 0 3.097369916105208e-09
frequent O 0 7.350449777732138e-06
PDS B-Disease 0 0.020760715007781982
mutations O 0 3.82509051632951e-06
will O 0 2.5594533159534194e-09
facilitate O 0 1.4108975099347276e-09
the O 0 1.047756814642753e-08
molecular O 0 0.0015251566655933857
diagnosis O 0 0.2171999216079712
of O 0 0.00017187003686558455
Pendred B-Disease 1 0.9999998807907104
syndrome I-Disease 1 0.9999998807907104
. O 0 9.584359941072762e-05

Insertional O 0 0.00031859189039096236
mutation O 0 1.1588738743739668e-05
by O 0 1.181785336257235e-08
transposable O 0 2.1729827494709753e-05
element O 0 1.685945449025894e-06
, O 0 1.3357096761978937e-08
L1 O 0 0.00011875898053403944
, O 0 3.1687665824620126e-09
in O 0 9.495145780746839e-10
the O 0 4.817631804598932e-08
DMD B-Disease 1 0.999984622001648
gene O 0 6.267898697842611e-07
results O 0 1.8804350077061827e-07
in O 0 1.6074477571237367e-07
X B-Disease 1 0.9962749481201172
- I-Disease 1 0.9994537234306335
linked I-Disease 1 0.9998167157173157
dilated I-Disease 1 0.9998815059661865
cardiomyopathy I-Disease 1 0.9999985694885254
. O 0 8.411394082941115e-05

X B-Disease 1 0.9956598877906799
- I-Disease 1 0.998794436454773
linked I-Disease 1 0.9981333613395691
dilated I-Disease 1 0.9999322891235352
cardiomyopathy I-Disease 1 0.9999997615814209
( O 0 1.2533869266917463e-05
XLDCM B-Disease 0 0.08403422683477402
) O 0 1.1284979173353804e-08
is O 0 2.7385023138037923e-09
a O 0 5.034285877059119e-08
clinical O 0 2.7502348984853597e-06
phenotype O 0 3.787017340073362e-05
of O 0 7.660875489534646e-09
dystrophinopathy B-Disease 0 0.005135531537234783
which O 0 1.0762103102024412e-06
is O 0 2.393737297268217e-08
characterized O 0 7.84741445158943e-08
by O 0 2.3312235697403594e-08
preferential O 0 1.3849067727278452e-05
myocardial B-Disease 1 0.993297278881073
involvement I-Disease 0 1.9658727978821844e-05
without O 0 6.114743911211917e-08
any O 0 5.668775227007927e-09
overt O 0 7.78267076384509e-06
clinical O 0 7.2072361945174634e-06
signs O 0 9.143564966507256e-05
of O 0 7.0173159656405915e-06
skeletal B-Disease 1 0.9999978542327881
myopathy I-Disease 1 0.9999998807907104
. O 0 0.0011659485753625631

To O 0 9.896305641632352e-08
date O 0 2.65476103322726e-07
, O 0 8.640795856607042e-10
several O 0 3.175771590147036e-10
mutations O 0 4.948698801854334e-07
in O 0 3.1980707859702306e-08
the O 0 3.713041678565787e-06
Duchenne B-Disease 1 0.9999454021453857
muscular I-Disease 1 0.9998815059661865
dystrophy I-Disease 1 0.9996747970581055
gene O 0 0.0007926539401523769
, O 0 2.032296151810442e-06
DMD O 1 0.9999940395355225
, O 0 8.125417139126512e-08
have O 0 3.65762353737864e-08
been O 0 1.5024011190689635e-07
identified O 0 2.67721611635352e-06
in O 0 1.2091072676412296e-07
patients O 0 8.852922661617413e-08
with O 0 5.3133728528109714e-08
XLDCM B-Disease 0 0.23582971096038818
, O 0 1.85991133605512e-08
but O 0 2.177576785555857e-09
a O 0 1.4830232153428824e-08
pathogenic O 0 3.4055950948186364e-08
correlation O 0 7.2593162592227145e-09
of O 0 1.5371269534991683e-10
these O 0 3.6442797668456706e-09
cardiospecific O 0 0.000262521265540272
mutations O 0 1.0131120689038653e-05
in O 0 3.8059033613535576e-07
DMD O 1 0.9999779462814331
with O 0 6.167570631987473e-08
the O 0 1.5489368365706468e-07
XLDCM B-Disease 0 0.17606212198734283
phenotype O 0 0.0004257536493241787
has O 0 1.0697009145133052e-07
remained O 0 4.064381187163235e-08
to O 0 3.1705438274798325e-09
be O 0 1.3442081581160892e-07
elucidated O 0 0.00010150846355827525
. O 0 4.67843989326866e-07

We O 0 3.014983576576924e-06
report O 0 3.062314135604538e-08
here O 0 2.0366548447725563e-09
the O 0 1.3167970880356705e-10
identification O 0 2.8939912688485947e-09
of O 0 1.7696374920994629e-10
a O 0 2.8138918750642006e-08
unique O 0 5.883443066068139e-08
de O 0 5.364389465967179e-08
novo O 0 8.64101892261715e-08
L1 O 0 8.775485866863164e-07
insertion O 0 6.9684054082586044e-09
in O 0 4.686186994007357e-10
the O 0 7.52837514550464e-10
muscle O 0 2.321400671689844e-07
exon O 0 2.7720641355699627e-06
1 O 0 3.8827518977768705e-08
in O 0 3.67732951644939e-07
DMD O 1 0.9999923706054688
in O 0 3.2534626370761544e-07
three O 0 6.312867384394849e-08
XLDCM B-Disease 0 0.30164024233818054
patients O 0 1.8514333532948513e-07
from O 0 1.72996084124577e-09
two O 0 4.328464697778145e-09
unrelated O 0 1.3655238717547036e-06
Japanese O 0 1.2080499800504185e-05
families O 0 1.4968749439958628e-07
. O 0 6.825133027632546e-07

The O 0 7.874147911479668e-08
insertion O 0 4.306098446704709e-07
was O 0 2.0871864592209022e-07
a O 0 6.2682312673700835e-09
5 O 0 2.708405277829229e-09
- O 0 1.413937695815548e-07
truncated O 0 8.946415164245991e-09
form O 0 1.6198991037441601e-09
of O 0 1.2199329046946872e-10
human O 0 6.069748703652067e-09
L1 O 0 3.8018004033801844e-06
inversely O 0 1.8965160109019052e-07
integrated O 0 7.49301278801795e-08
in O 0 1.403024030288691e-09
the O 0 1.8387118494445076e-09
5 O 0 1.2948513372634807e-08
- O 0 8.133811206789687e-06
untranslated O 0 3.018896677531302e-06
region O 0 7.776932875458442e-09
in O 0 6.641537875218262e-10
the O 0 7.013899461227879e-10
muscle O 0 7.173458982379088e-08
exon O 0 8.617529374532751e-07
1 O 0 1.1625805207415851e-08
, O 0 1.1281831024945177e-09
which O 0 3.533511483411189e-09
affected O 0 6.131158358790856e-10
the O 0 2.795273457145697e-10
transcription O 0 1.368250623912104e-09
or O 0 4.971401512676721e-09
the O 0 6.781928352239674e-10
stability O 0 1.1263540322659082e-08
of O 0 1.080773873174401e-10
the O 0 4.385539487117285e-09
muscle O 0 2.0976685277673823e-07
form O 0 3.6706699901856155e-09
of O 0 6.161474663812783e-10
dystrophin O 0 7.664181111977086e-07
transcripts O 0 7.650000810599522e-08
but O 0 1.626385959241361e-08
not O 0 1.1730800775211492e-09
that O 0 3.617511290521236e-10
of O 0 9.00073071630203e-11
the O 0 6.028147225833891e-08
brain O 0 0.002368335612118244
or O 0 3.382239697202749e-07
Purkinje O 0 0.00010001992632169276
cell O 0 3.361274866620079e-05
form O 0 2.2907174468400626e-07
, O 0 5.087782994905865e-08
probably O 0 4.629829390978557e-07
due O 0 1.1103603370088422e-08
to O 0 8.791043448752589e-10
its O 0 1.8668908641217286e-09
unique O 0 5.61874191618017e-09
site O 0 2.1337497102535963e-08
of O 0 7.674458291084818e-10
integration O 0 9.87366206572915e-08
. O 0 2.6936962171930645e-07

We O 0 5.573051566898357e-07
speculate O 0 2.1648297376941628e-07
that O 0 3.811849169643722e-10
this O 0 6.111353784143958e-11
insertion O 0 8.576905852208938e-10
of O 0 1.0896910457303122e-10
an O 0 1.7744310465417357e-09
L1 O 0 9.925422637024894e-05
sequence O 0 3.469163800673414e-07
in O 0 4.824901225219946e-07
DMD O 1 0.9999971389770508
is O 0 1.4063662945318356e-07
responsible O 0 1.6334864127998117e-08
for O 0 3.908889323334108e-10
some O 0 2.6177138581773285e-11
of O 0 5.7484930010565094e-11
the O 0 1.6057393192880909e-09
population O 0 1.2370213187118395e-10
of O 0 1.4191015029751952e-10
Japanese O 0 9.276238415623084e-06
patients O 0 2.4349462890427276e-08
with O 0 2.2533535926072545e-08
XLDCM B-Disease 0 0.0005905716679990292
. O 0 4.839468203954311e-08
. O 0 1.1421448675719148e-07

Severe O 0 0.004574163816869259
early O 0 3.901027230313048e-05
- O 1 0.9976881742477417
onset O 1 0.9993207454681396
obesity B-Disease 1 0.9999994039535522
, O 0 0.02151576243340969
adrenal B-Disease 1 0.9999990463256836
insufficiency I-Disease 1 0.9999991655349731
and O 0 0.0022306928876787424
red O 0 0.1259232759475708
hair O 1 0.9964967370033264
pigmentation O 0 0.05057269334793091
caused O 0 2.9490229280781932e-06
by O 0 2.1899784030665614e-07
POMC O 0 0.0166738573461771
mutations O 0 9.197803592542186e-06
in O 0 1.3883943950077082e-07
humans O 0 8.097272825580148e-07
. O 0 4.925716439174721e-07

Sequential O 0 2.680910483832122e-06
cleavage O 0 2.3959992176969536e-05
of O 0 4.293928768106525e-09
the O 0 1.4221993582808068e-09
precursor O 0 7.1370314103091914e-09
protein O 0 1.1765426854992711e-08
pre O 0 4.3392319639679044e-06
- O 0 0.005173500161617994
pro O 0 2.0582161596394144e-05
- O 0 0.005301780998706818
opiomelanocortin O 0 5.8292374887969345e-05
( O 0 6.467107294128027e-09
POMC O 0 2.198056108682067e-06
) O 0 2.936839660350188e-10
generates O 0 3.7163478960877683e-09
the O 0 2.278436328495559e-09
melanocortin O 0 9.353130735689774e-06
peptides O 0 3.066083081648685e-06
adrenocorticotrophin O 0 2.969929664686788e-05
( O 0 1.4598862563275361e-08
ACTH O 0 6.168515938043129e-06
) O 0 1.0092408020412336e-09
, O 0 8.992585009970355e-10
melanocyte O 0 1.1944348443648778e-05
- O 0 9.444577153772116e-05
stimulating O 0 5.235122443991713e-05
hormones O 0 1.1542017091414891e-05
( O 0 6.206795077901006e-09
MSH O 0 2.05203241421259e-06
) O 0 2.121577219460491e-10
alpha O 0 4.303372103109382e-10
, O 0 6.904720545319876e-11
beta O 0 1.9944480789124697e-10
and O 0 2.4369231632626054e-10
gamma O 0 7.602491081115659e-09
as O 0 1.0124543564637989e-10
well O 0 1.2904294299787011e-10
as O 0 9.063507583340069e-11
the O 0 2.509052965393721e-10
opioid O 0 1.1898829654910514e-07
- O 0 3.789121194586187e-07
receptor O 0 3.1091627050727766e-08
ligand O 0 1.9266367417003494e-06
beta O 0 7.102608492459694e-07
- O 0 0.00020382615912239999
endorphin O 0 0.002340644598007202
. O 0 2.8837087029387476e-07

While O 0 1.0765270275214789e-07
a O 0 1.5478670789548232e-08
few O 0 2.606079130273997e-09
cases O 0 2.816274324857204e-09
of O 0 5.969210015166482e-09
isolated O 0 0.005495558958500624
ACTH B-Disease 1 0.9999473094940186
deficiency I-Disease 1 0.9988780617713928
have O 0 1.2627176602109103e-06
been O 0 1.9515643998602172e-06
reported O 0 1.2559665265143849e-05
( O 0 3.014411831259167e-08
OMIM O 0 0.00021553719125222415
201400 O 0 1.9032756881642854e-06
) O 0 5.550631065887046e-10
, O 0 7.460406181714063e-10
an O 0 2.7970948224265157e-08
inherited O 1 0.6369692087173462
POMC O 1 0.8866903185844421
defect O 0 0.08376619964838028
has O 0 1.6124913599924184e-06
not O 0 4.570979328377689e-08
been O 0 4.8625256710010945e-08
described O 0 2.777385930130549e-07
so O 0 9.207777651454307e-08
far O 0 1.074086313224143e-07
. O 0 1.3873606974357244e-07

Recent O 0 3.2602879400656093e-06
studies O 0 2.9095764375597355e-07
in O 0 7.65325225415836e-09
animal O 0 5.6685404814516005e-08
models O 0 3.239984209812974e-07
elucidated O 0 3.487598405627068e-06
a O 0 1.7516496697567163e-08
central O 0 1.8101602439202225e-09
role O 0 9.68009450375007e-10
of O 0 2.470181836855545e-10
alpha O 0 3.1449481241452304e-08
- O 0 2.3581023924634792e-05
MSH O 0 5.2609116210078355e-06
in O 0 6.025544507792802e-10
the O 0 1.9539254936251638e-10
regulation O 0 1.1242564657010234e-09
of O 0 6.502884342118875e-11
food O 0 5.438833383664132e-09
intake O 0 6.8086056792537875e-09
by O 0 6.697558480039945e-11
activation O 0 1.1844519809400822e-09
of O 0 8.490732422705705e-11
the O 0 1.2757007894492745e-08
brain O 0 2.9323728085728362e-05
melanocortin O 0 4.105866992176743e-06
- O 0 2.946301947304164e-06
4 O 0 6.3599503441480465e-09
- O 0 7.72679698002321e-07
receptor O 0 7.705649096578782e-08
( O 0 3.2704516872428258e-09
MC4 O 0 5.333251829142682e-05
- O 0 9.869169844023418e-06
R O 0 2.1770187231595628e-05
; O 0 7.631048570821974e-10
refs O 0 7.499460963344973e-08
3 O 0 1.1922240972239706e-09
- O 0 4.848892558584339e-07
5 O 0 1.2543805993914248e-09
) O 0 4.481168214276465e-11
and O 0 1.2211412436791136e-10
the O 0 2.336322524332246e-10
linkage O 0 4.563844413496554e-07
of O 0 4.220251703657141e-09
human O 0 1.1051794899685774e-05
obesity B-Disease 1 0.9999098777770996
to O 0 5.09679658478035e-08
chromosome O 0 1.7285656213061884e-05
2 O 0 1.1084241080538959e-08
in O 0 2.3066837329110967e-09
close O 0 2.0076750928410547e-08
proximity O 0 3.485385491330817e-08
to O 0 1.6742884412224157e-08
the O 0 1.7655935380389565e-08
POMC O 0 2.0099900211789645e-05
locus O 0 7.74556610849686e-07
, O 0 6.58030796518716e-10
led O 0 6.09191030953582e-10
to O 0 1.9416730723254005e-10
the O 0 6.490211701404291e-10
proposal O 0 1.0748708589858325e-08
of O 0 1.7444229394314448e-10
an O 0 7.694498371790814e-09
association O 0 2.8894626691311487e-09
of O 0 1.1158819424039734e-09
POMC O 0 9.859871352091432e-05
with O 0 2.2406425159715582e-07
human O 0 0.00013037037570029497
obesity B-Disease 1 0.9999368190765381
. O 0 2.915939603553852e-06

The O 0 4.3961524198721236e-08
dual O 0 3.019810321802652e-07
role O 0 1.4488679589419462e-08
of O 0 8.099599879685115e-10
alpha O 0 1.372334281768417e-07
- O 0 7.141955575207248e-05
MSH O 0 7.299760181922466e-05
in O 0 4.130698894044826e-09
regulating O 0 6.839859878482457e-08
food O 0 2.3519287850604087e-08
intake O 0 6.563817578353337e-08
and O 0 2.880158334050975e-09
influencing O 0 1.451153082143719e-07
hair O 0 0.04953334107995033
pigmentation O 0 5.4364332754630595e-05
predicts O 0 1.3933939726484823e-06
that O 0 2.600810455888336e-09
the O 0 8.533098672103279e-09
phenotype O 0 2.0147863324382342e-05
associated O 0 6.029711130395299e-08
with O 0 1.8691864056563645e-08
a O 0 2.228937592008151e-05
defect O 0 0.02494896948337555
in O 0 5.099315103507251e-07
POMC O 0 0.00022458506282418966
function O 0 2.3595950437993451e-07
would O 0 8.525456252073127e-08
include O 0 4.7141216441559664e-07
obesity B-Disease 1 0.9999403953552246
, O 0 4.1443140474939355e-08
alteration O 0 5.5203317970153876e-06
in O 0 3.0572973628295586e-06
pigmentation O 1 0.8042113780975342
and O 0 0.02705780602991581
ACTH B-Disease 1 0.9998282194137573
deficiency I-Disease 1 0.9899889230728149
. O 0 1.2623033853742527e-06

The O 0 1.1062132188044416e-07
observation O 0 4.224393990170938e-07
of O 0 1.5267782593753054e-09
these O 0 1.4055264507817355e-08
symptoms O 0 8.732607739148079e-07
in O 0 1.1635293839518113e-09
two O 0 1.79999348759452e-09
probands O 0 8.525245903001633e-06
prompted O 0 1.8680959001926567e-08
us O 0 2.2590027626279152e-09
to O 0 1.1449001469099329e-10
search O 0 3.3422022926998807e-09
for O 0 4.152636012833e-09
mutations O 0 1.4386328928139847e-07
within O 0 2.0312314052972624e-09
their O 0 8.646509286336368e-08
POMC O 0 0.00022958901536185294
genes O 0 4.357368368346215e-07
. O 0 1.1912943165270917e-07

Patient O 0 0.0001317136484431103
1 O 0 4.4571365265255736e-08
was O 0 2.0915700815749005e-07
found O 0 3.010929461311207e-08
to O 0 1.6850905115717296e-09
be O 0 7.706997706691254e-09
a O 0 4.47965176064713e-09
compound O 0 3.1879125117484364e-08
heterozygote O 0 1.1137884570189271e-07
for O 0 2.565111456576119e-10
two O 0 1.4250151059158611e-09
mutations O 0 1.2162568907569948e-07
in O 0 5.44645306632674e-09
exon O 0 3.0977316782809794e-06
3 O 0 3.170080020709065e-08
( O 0 1.5782748441495187e-09
G7013T O 0 9.799403244414862e-08
, O 0 2.164731061071734e-09
C7133delta O 0 2.008733872571611e-06
) O 0 5.850325224265873e-10
which O 0 1.6433199245824426e-09
interfere O 0 3.0957578722734524e-09
with O 0 2.8642041516313554e-10
appropriate O 0 2.1965904650755874e-09
synthesis O 0 9.47756362279506e-09
of O 0 1.0851908260889331e-09
ACTH O 0 4.2678631871240214e-05
and O 0 4.166887990209034e-08
alpha O 0 1.1042590841725541e-07
- O 0 0.00011140846618218347
MSH O 0 0.0003285895800217986
. O 0 1.5855327717417822e-07

Patient O 0 0.000204835319891572
2 O 0 5.329978591817053e-08
was O 0 3.227718536891189e-08
homozygous O 0 2.392008298102155e-07
for O 0 5.520834900352156e-10
a O 0 5.92690767575732e-08
mutation O 0 1.0754480399555177e-06
in O 0 6.5312950603413356e-09
exon O 0 1.65490109793609e-05
2 O 0 2.0400466382852755e-07
( O 0 8.58951665350105e-09
C3804A O 0 1.0562473562458763e-06
) O 0 1.4605400222578169e-09
which O 0 5.376517719923868e-08
abolishes O 0 7.237474346766248e-05
POMC O 0 0.00020930235041305423
translation O 0 1.011320591715048e-06
. O 0 2.49406696184451e-07

These O 0 4.238323469962779e-08
findings O 0 3.19810773419249e-08
represent O 0 1.0843508313485017e-09
the O 0 2.4423116307126236e-10
first O 0 5.557961868518646e-10
examples O 0 3.945121118675843e-09
of O 0 1.7489948378468512e-09
a O 0 0.0002566770708654076
genetic B-Disease 1 0.9999945163726807
defect I-Disease 1 0.9999871253967285
within O 0 4.749160709138778e-08
the O 0 9.135059286791147e-08
POMC O 0 5.939329639659263e-05
gene O 0 3.078935506550806e-08
and O 0 3.393358261050139e-09
define O 0 4.572818923520572e-08
a O 0 2.1346052392345882e-07
new O 0 1.9717497252713656e-06
monogenic B-Disease 1 0.8767022490501404
endocrine I-Disease 1 0.7726976275444031
disorder I-Disease 0 0.0011040804674848914
resulting O 0 5.816756925014488e-07
in O 0 5.536426428420782e-08
early O 0 1.1865884516737424e-05
- O 1 0.9997149109840393
onset O 1 0.9997791647911072
obesity B-Disease 1 0.9999997615814209
, O 0 0.09733009338378906
adrenal B-Disease 1 0.9999992847442627
insufficiency I-Disease 1 0.9999988079071045
and O 0 0.00011637143325060606
red O 0 0.006376032251864672
hair O 1 0.7646841406822205
pigmentation O 0 0.0009870129870250821
. O 0 1.0469022981851595e-07
. O 0 3.284444289874955e-07

A O 0 5.15077499585459e-06
European O 0 9.7107874807989e-07
multicenter O 0 0.0008257043082267046
study O 0 2.386464984738268e-06
of O 0 5.9065087043563835e-06
phenylalanine B-Disease 1 0.9999967813491821
hydroxylase I-Disease 1 0.9999972581863403
deficiency I-Disease 1 0.9999994039535522
: O 0 1.8729805617567763e-07
classification O 0 1.2037482122195797e-07
of O 0 3.531811509915883e-10
105 O 0 1.739066135542089e-08
mutations O 0 1.964078137461911e-06
and O 0 1.0004289840992442e-08
a O 0 4.077091375620512e-08
general O 0 1.730618492956637e-08
system O 0 5.6279365168165896e-08
for O 0 4.9460253670474685e-09
genotype O 0 6.378776743076742e-05
- O 0 1.8648455807124265e-05
based O 0 6.778184058475745e-08
prediction O 0 1.1432186965976143e-06
of O 0 4.8388932860632394e-09
metabolic O 0 0.0077459909953176975
phenotype O 0 0.0009457595879212022
. O 0 1.4856159396003932e-06

Phenylketonuria B-Disease 1 0.98870849609375
( O 0 7.587624622829026e-06
PKU B-Disease 0 0.006747194565832615
) O 0 8.839609932920212e-08
and O 0 7.97213203895808e-07
mild B-Disease 1 0.613423764705658
hyperphenylalaninemia I-Disease 1 0.9999997615814209
( O 0 0.0019656771328300238
MHP B-Disease 1 0.9999982118606567
) O 0 2.1354480850277469e-07
are O 0 4.941200018038217e-07
allelic B-Disease 0 0.27328556776046753
disorders I-Disease 1 0.9969612956047058
caused O 0 0.00010141326492885128
by O 0 1.8840627546978794e-07
mutations O 0 1.155496920546284e-05
in O 0 2.0376116793840993e-08
the O 0 1.0367219971385566e-08
gene O 0 4.1540016582075623e-07
encoding O 0 1.917378540383652e-06
phenylalanine O 0 0.009074239060282707
hydroxylase O 0 0.12356527894735336
( O 0 1.4794896969760885e-06
PAH O 0 0.004043521825224161
) O 0 3.0816263318911297e-08
. O 0 1.5490151383801276e-07

Previous O 0 3.603302729970892e-06
studies O 0 2.65204306515443e-07
have O 0 1.1708922720288228e-08
suggested O 0 2.9621016750525087e-08
that O 0 2.262655174334327e-09
the O 0 2.4858275438077726e-09
highly O 0 1.0077459364765673e-06
variable O 0 0.0002483612624928355
metabolic O 0 0.1358957290649414
phenotypes O 0 0.0010313763050362468
of O 0 1.772082941897679e-05
PAH B-Disease 1 0.9999730587005615
deficiency I-Disease 1 0.990206778049469
correlate O 0 0.0003527715743985027
with O 0 3.2156069210032e-05
PAH O 1 0.9951404333114624
genotypes O 0 0.0014174727257341146
. O 0 8.614752005087212e-07

We O 0 8.850961989992356e-07
identified O 0 3.2947531281024567e-07
both O 0 4.181415658166543e-09
causative O 0 7.894229383964557e-06
mutations O 0 1.5536177215835778e-06
in O 0 2.4033855794414194e-08
686 O 0 9.088288607017603e-06
patients O 0 9.60761781243491e-07
from O 0 1.19809007159688e-08
seven O 0 5.4924715442439265e-08
European O 0 3.677077131669648e-07
centers O 0 1.5311263723560842e-07
. O 0 4.195062501821667e-07

On O 0 1.1297474600269197e-07
the O 0 1.4086872779373039e-09
basis O 0 6.985141909332526e-10
of O 0 1.3367304485534248e-10
the O 0 9.910691156633789e-10
phenotypic O 0 4.183045518857398e-07
characteristics O 0 4.1095941583080275e-07
of O 0 1.0983806086883874e-09
297 O 0 2.0773843800725444e-07
functionally O 0 4.584881025948562e-06
hemizygous O 0 8.846566925058141e-05
patients O 0 3.202026022108839e-08
, O 0 2.2475309113811903e-10
105 O 0 5.429520374966579e-11
of O 0 2.5256309196808324e-11
the O 0 6.0017582015348125e-09
mutations O 0 6.65918150843936e-07
were O 0 5.4318903153216525e-08
assigned O 0 1.9334043699359427e-08
to O 0 6.363077842408416e-10
one O 0 7.044413385948189e-10
of O 0 3.1247590626115596e-10
four O 0 3.412218951837076e-09
arbitrary O 0 4.863592835135933e-07
phenotype O 0 4.9539285100763664e-05
categories O 0 7.419473035952251e-07
. O 0 4.705089224898984e-07

We O 0 4.559154831440537e-07
proposed O 0 2.9285917690913266e-08
and O 0 1.4071814824490048e-08
tested O 0 5.388250770010927e-07
a O 0 9.96555282739564e-09
simple O 0 7.532518964126211e-08
model O 0 1.2451138786673255e-07
for O 0 1.6609087716279447e-10
correlation O 0 9.163818504021037e-08
between O 0 4.9814463665143194e-08
genotype O 0 8.399419311899692e-05
and O 0 2.0402444178557744e-08
phenotypic O 0 1.714557470222644e-06
outcome O 0 4.5171236706664786e-06
. O 0 9.89830368780531e-07

The O 0 2.15692253391353e-07
observed O 0 1.2363593668851536e-06
phenotype O 0 2.5479033865849487e-05
matched O 0 7.851649570511654e-07
the O 0 2.982401436923965e-09
predicted O 0 2.642487402226834e-07
phenotype O 0 1.082918856809556e-06
in O 0 7.374572619234243e-10
79 O 0 7.60079055250884e-10
% O 0 1.2229756096715505e-10
of O 0 8.119982464194209e-11
the O 0 1.2985686304034516e-08
cases O 0 7.110755717576467e-08
, O 0 5.264042535202407e-09
and O 0 1.364118507041212e-08
in O 0 3.856666097590278e-09
only O 0 1.1043845837832578e-09
5 O 0 3.5238512108293207e-10
of O 0 9.05017172314615e-11
184 O 0 2.686540412355498e-08
patients O 0 8.7265490833488e-08
was O 0 7.473016125914e-07
the O 0 6.032101929065448e-09
observed O 0 3.005049222792877e-07
phenotype O 0 1.0036976050287194e-07
more O 0 5.0197710571575627e-11
than O 0 2.759726613899005e-10
one O 0 2.3006507809952836e-09
category O 0 5.089743737585195e-08
away O 0 2.666201703860338e-09
from O 0 7.418234915235189e-10
that O 0 1.6620955278767724e-08
expected O 0 1.848430599693529e-07
. O 0 1.9009161178473732e-07

Among O 0 1.0187726928734264e-07
the O 0 2.548954824987959e-09
seven O 0 2.3951107763764412e-09
contributing O 0 5.4377751190770596e-09
centers O 0 7.793737322181471e-10
, O 0 1.0567169361763717e-10
the O 0 1.2477271993383e-10
proportion O 0 5.222648979952282e-09
of O 0 4.642239648244839e-10
patients O 0 1.3739523296862899e-08
for O 0 1.3632802664531596e-09
whom O 0 4.56925306480116e-08
the O 0 4.3643275660087966e-09
observed O 0 5.101368287796504e-07
phenotype O 0 2.6553127554507228e-06
did O 0 2.1032429131651043e-08
not O 0 5.262935642846855e-10
match O 0 1.904859825430094e-09
the O 0 7.08712144525947e-10
predicted O 0 1.0813094775130594e-07
phenotype O 0 1.4562174044385756e-07
was O 0 1.0198669464500654e-08
4 O 0 5.113803269729544e-10
% O 0 4.682041421233407e-10
- O 0 1.6216716858252767e-06
23 O 0 8.623694647269531e-09
% O 0 4.396584207810861e-10
( O 0 8.135924156604801e-10
P O 0 1.1100257324869744e-05
< O 0 1.4162142747409234e-07
. O 0 8.746920965307936e-10
0001 O 0 5.10409314813387e-08
) O 0 3.598817771566232e-11
, O 0 3.718095623050921e-11
suggesting O 0 1.658131232318283e-08
that O 0 3.7220015958183694e-09
differences O 0 1.9024353647978387e-08
in O 0 8.290474973193795e-10
methods O 0 2.9124083145148916e-09
used O 0 1.6695112847742166e-08
for O 0 2.169120438821892e-09
mutation O 0 5.1200453299316e-07
detection O 0 6.226163804967655e-06
or O 0 2.611499894555891e-06
phenotype O 0 0.0016568098217248917
classification O 0 1.3764353752776515e-05
may O 0 3.861865423004929e-07
account O 0 6.536828411896067e-09
for O 0 2.3137855520438677e-10
a O 0 4.5608659071660895e-09
considerable O 0 2.1048080611762998e-08
proportion O 0 2.1234764346900192e-07
of O 0 3.8208497699088184e-08
genotype O 0 0.4692026674747467
- O 0 0.38232287764549255
phenotype O 0 0.0023410790599882603
inconsistencies O 0 3.1626408599549904e-05
. O 0 1.344581505691167e-06

Our O 0 1.1458579365353216e-06
data O 0 3.0333094969137164e-07
indicate O 0 1.8248097433115618e-07
that O 0 7.328444073806395e-09
the O 0 7.12385528345294e-08
PAH O 0 0.05944615975022316
- O 0 0.00015876801626291126
mutation O 0 1.775193595676683e-05
genotype O 0 3.2100673706736416e-05
is O 0 8.232659554074928e-10
the O 0 1.315883235708526e-10
main O 0 2.099206142247567e-09
determinant O 0 1.0025764396459635e-07
of O 0 7.030015236608733e-09
metabolic O 0 0.08035192638635635
phenotype O 0 0.0015395758673548698
in O 0 1.5583633228288818e-07
most O 0 3.5704294987226604e-07
patients O 0 1.068324490915984e-05
with O 0 0.005211481358855963
PAH B-Disease 1 0.9999812841415405
deficiency I-Disease 1 0.9908285140991211
. O 0 2.1338003080018098e-06

In O 0 7.287996339755409e-08
the O 0 6.219428083653611e-09
present O 0 1.2949575634024768e-08
study O 0 4.79002260078687e-09
, O 0 3.807583692783112e-10
the O 0 3.859239594561359e-10
classification O 0 3.679118165678119e-08
of O 0 8.73413508184484e-10
105 O 0 1.4989949193022767e-07
PAH O 0 0.0011846944689750671
mutations O 0 7.822382031008601e-07
may O 0 2.5283000582021486e-08
allow O 0 3.294302886036604e-10
the O 0 8.619956415323315e-10
prediction O 0 3.974358975256109e-08
of O 0 5.637263919555657e-11
the O 0 3.972401962926142e-09
biochemical O 0 1.4166226719680708e-05
phenotype O 0 2.661864300534944e-06
in O 0 3.7517233764106095e-09
> O 0 4.140900955462712e-08
10 O 0 8.651763194755802e-10
, O 0 3.908091628090915e-10
000 O 0 4.681168785936052e-09
genotypes O 0 6.920273563082446e-07
, O 0 9.54242818096418e-09
which O 0 1.492407761816139e-07
may O 0 5.270656515676819e-07
be O 0 5.617799114787658e-09
useful O 0 5.249604750900971e-09
for O 0 6.052635614928192e-10
the O 0 7.462316986561746e-09
management O 0 8.675431040217063e-09
of O 0 3.64953844922411e-09
hyperphenylalaninemia B-Disease 1 0.9999780654907227
in O 0 1.898791379062459e-05
newborns O 0 0.000865644309669733
. O 0 7.148804570533684e-07

Somatic O 0 5.778815466328524e-05
instability O 0 2.9218324925750494e-05
of O 0 1.4274097459576751e-08
the O 0 1.6220889520468518e-08
CTG O 0 1.4115535122982692e-05
repeat O 0 2.2134581740829162e-06
in O 0 9.542974410692295e-09
mice O 0 5.104083697915485e-07
transgenic O 0 5.898893107314507e-08
for O 0 5.120618151721601e-09
the O 0 8.904214155336376e-06
myotonic B-Disease 1 0.9999997615814209
dystrophy I-Disease 1 0.9999997615814209
region O 0 4.115635601920076e-05
is O 0 1.791869550515912e-07
age O 0 1.0629465663214432e-07
dependent O 0 1.9884751623067132e-08
but O 0 6.389813123064414e-09
not O 0 1.1101585206674258e-09
correlated O 0 1.4003084025659973e-08
to O 0 1.8646835464597444e-10
the O 0 4.189788516129056e-10
relative O 0 1.5249796092575707e-07
intertissue O 0 1.6481884586028173e-06
transcription O 0 5.109440337491833e-08
levels O 0 1.3996948666772369e-07
and O 0 3.657826042058332e-08
proliferative O 0 0.001411485718563199
capacities O 0 9.64842638495611e-06
. O 0 3.511717920900992e-07

A O 0 1.2564697499328759e-05
( O 0 7.040954130843602e-08
CTG O 0 3.277974656157312e-06
) O 0 1.565102714096156e-09
nexpansion O 0 1.0623912061191731e-07
in O 0 7.925762268712333e-10
the O 0 5.972452532532202e-10
3 O 0 1.541188687781414e-08
- O 0 0.00035638880217447877
untranslated O 0 2.582651359261945e-05
region O 0 3.1540551503894676e-08
( O 0 9.52945500287683e-10
UTR O 0 8.649362115420445e-08
) O 0 1.4305472605113945e-11
of O 0 2.7819854059307758e-11
the O 0 3.006642756986366e-08
DM O 1 0.9999936819076538
protein O 0 6.675834924863011e-07
kinase O 0 4.546052878140472e-06
gene O 0 1.564674363407903e-07
( O 0 5.171569394946118e-09
DMPK O 0 4.2717234464362264e-05
) O 0 2.015039912706129e-09
is O 0 3.4914588997736473e-09
responsible O 0 1.5161583633016562e-07
for O 0 2.618584858282702e-06
causing O 1 0.9587722420692444
myotonic B-Disease 1 0.9999998807907104
dystrophy I-Disease 1 1.0
( O 0 0.020757827907800674
DM B-Disease 1 0.9999983310699463
) O 0 8.174895356205525e-07
. O 0 4.218524054522277e-07

Major O 0 5.5564801186847035e-06
instability O 0 7.146485586417839e-05
, O 0 7.659370915291674e-09
with O 0 7.427367054724243e-10
very O 0 1.3990903990901415e-09
large O 0 1.4727057351393569e-09
expansions O 0 7.997232387424447e-08
between O 0 4.0006415957805075e-09
generations O 0 2.996240766606206e-08
and O 0 3.352463906480807e-08
high O 0 2.647247185905144e-07
levels O 0 8.724165390106009e-09
of O 0 6.71877276037236e-11
somatic O 0 2.6091620952684025e-07
mosaicism O 0 2.2508922484121285e-05
, O 0 3.5112937002423905e-09
is O 0 2.91681123698595e-09
observed O 0 1.4265432923821209e-07
in O 0 1.421266375700725e-07
patients O 0 1.2983330179849872e-06
. O 0 1.9762489955610363e-06

There O 0 5.189338594391302e-07
is O 0 6.883583036909613e-09
a O 0 5.230853972193472e-09
good O 0 2.754523187320501e-08
correlation O 0 5.963567417666127e-08
between O 0 8.387804228959794e-09
repeat O 0 1.107872503780527e-05
size O 0 4.824482857657131e-06
( O 0 1.459729670472143e-09
at O 0 2.042813473934757e-09
least O 0 3.561515249383973e-10
in O 0 1.8863228756771377e-09
leucocytes O 0 9.004757885122672e-06
) O 0 1.1988071646484855e-09
, O 0 1.4662564495893093e-09
clinical O 0 2.2211393968518678e-07
severity O 0 8.862980757839978e-05
and O 0 5.699144480786345e-07
age O 0 6.364284672599752e-07
of O 0 9.354399033156824e-09
onset O 0 0.0001046121833496727
. O 0 5.184276687941747e-06

The O 0 1.9140843505738303e-06
trinucleotide O 0 0.00047218240797519684
repeat O 0 3.698582440847531e-05
instability O 0 2.4240905531769386e-06
mechanisms O 0 7.225585250125732e-07
involved O 0 2.1208414580087265e-07
in O 0 1.3281248811836122e-06
DM B-Disease 1 0.9999985694885254
and O 0 1.8399637156107929e-06
other O 0 2.0601372341388924e-07
human O 0 0.0017349164700135589
genetic B-Disease 1 0.9999990463256836
diseases I-Disease 1 0.9999985694885254
are O 0 1.3257622413220815e-06
unknown O 0 2.5987796107074246e-05
. O 0 4.0253058841699385e-07

We O 0 8.242571993832826e-07
studied O 0 5.4740752375437296e-08
somatic O 0 2.8962574560864596e-07
instability O 0 7.179796739364974e-07
by O 0 4.251048402181823e-09
measuring O 0 0.00016576226335018873
the O 0 1.0347962842160996e-07
CTG O 0 2.4076854970189743e-05
repeat O 0 1.0293940704286797e-06
length O 0 1.031960010777766e-07
at O 0 1.315013320457581e-09
several O 0 3.712838925196138e-10
ages O 0 7.108667432476068e-08
in O 0 8.826612218904017e-10
various O 0 2.06749173337073e-10
tissues O 0 4.5230020617736955e-08
of O 0 3.2986915976529474e-10
transgenic O 0 1.4005563571117818e-06
mice O 0 4.340432496974245e-06
carrying O 0 5.3570481384213053e-08
a O 0 1.238724109953182e-07
( O 0 8.283018715360413e-09
CTG O 0 1.1817468248409568e-06
) O 0 4.527244135132946e-10
55expansion O 0 7.360723941474134e-08
surrounded O 0 1.7992700662716743e-08
by O 0 1.0244244341706121e-09
45 O 0 2.6274293851713537e-10
kb O 0 6.899977478269648e-08
of O 0 5.8438792693849e-10
the O 0 7.742346497252584e-08
human O 0 4.548783181235194e-05
DM B-Disease 1 0.9999991655349731
region O 0 5.231734689914447e-07
, O 0 4.910229445265202e-10
using O 0 2.0306927250857143e-09
small O 0 2.1394063409729824e-08
- O 0 2.9024979085079394e-05
pool O 0 3.1426152418134734e-06
PCR O 0 3.004137943207752e-05
. O 0 3.0184799015842145e-07

These O 0 4.2991268855985254e-07
mice O 0 2.5186624043271877e-05
have O 0 3.4805029969220413e-08
been O 0 2.534808807297395e-08
shown O 0 8.504716220159025e-08
to O 0 4.418132082406601e-09
reproduce O 0 1.283105348193203e-06
the O 0 1.3642895702048463e-09
intergenerational O 0 6.240396714929375e-07
and O 0 1.070159694194217e-08
somatic O 0 1.2956374462191889e-07
instability O 0 1.5432793531999778e-07
of O 0 3.222923039558623e-10
the O 0 6.2451395166363e-09
55 O 0 7.755409647813849e-09
CTG O 0 1.2199898264952935e-06
repeat O 0 5.625199150927074e-07
suggesting O 0 2.817206166128017e-07
that O 0 2.8618138969704887e-09
surrounding O 0 7.31281968313624e-09
sequences O 0 6.514923711620213e-08
and O 0 3.0160722808147966e-09
the O 0 3.3336076121770475e-09
chromatin O 0 4.3330396692908835e-07
environment O 0 1.8114861859430675e-06
are O 0 2.378598873420401e-09
involved O 0 5.116498336121822e-09
in O 0 3.120140945611638e-08
instability O 0 1.3019335938224685e-06
mechanisms O 0 4.369612724985927e-06
. O 0 6.590952352780732e-07

As O 0 1.1755045647987572e-07
observed O 0 1.058130223441367e-07
in O 0 4.281242582671041e-10
some O 0 1.2135341342922601e-11
of O 0 4.282914994879761e-11
the O 0 5.675655945225344e-09
tissues O 0 1.0826857760548592e-05
of O 0 1.1154695584991714e-06
DM B-Disease 1 0.9999998807907104
patients O 0 6.245382246561348e-05
, O 0 1.884299294374614e-08
there O 0 1.7788744699487324e-08
is O 0 6.5301488660907125e-09
a O 0 7.434556970054018e-09
tendency O 0 4.520018137554871e-08
for O 0 2.80070766578433e-09
repeat O 0 2.4879977900127415e-06
length O 0 5.317828595252649e-07
and O 0 6.533724672408425e-09
somatic O 0 1.3991730440920946e-07
mosaicism O 0 2.617858399389661e-06
to O 0 1.7054742063038475e-09
increase O 0 4.836770983729366e-09
with O 0 1.0968587149662312e-09
the O 0 1.8058713635582535e-08
age O 0 4.300742162399729e-08
of O 0 2.2120996701069373e-10
the O 0 1.381504688424684e-08
mouse O 0 1.442438497178955e-05
. O 0 3.6821373328166374e-07

Furthermore O 0 2.421936187602114e-05
, O 0 2.9952925473253345e-08
we O 0 3.138385329393145e-09
observed O 0 1.2243445368653738e-08
no O 0 1.3912136997973334e-09
correlation O 0 1.604053601056421e-08
between O 0 6.866899271429361e-10
the O 0 1.5751231430272128e-09
somatic O 0 2.059975486190524e-06
mutation O 0 1.6942163711064495e-05
rate O 0 5.262688318907749e-06
and O 0 5.5612130012150374e-08
tissue O 0 0.0003644528042059392
proliferation O 0 3.2457443012390286e-05
capacity O 0 8.094331178654102e-07
. O 0 7.740117524690504e-08

The O 0 1.0796237148724686e-07
somatic O 0 6.429526820284082e-06
mutation O 0 0.0001188106180052273
rates O 0 3.1800593660591403e-06
in O 0 3.6803724512424196e-09
different O 0 1.7964710830042918e-09
tissues O 0 1.11310396277986e-06
were O 0 2.389609505826229e-07
also O 0 4.441470835558903e-08
not O 0 3.196099607194469e-09
correlated O 0 1.462146315134305e-08
to O 0 2.3106543067807905e-10
the O 0 2.9631386233575085e-10
relative O 0 3.154717020947828e-08
inter O 0 3.2217954526458925e-08
- O 0 5.320613126968965e-05
tissue O 0 3.4106455132132396e-05
difference O 0 1.814977679259755e-07
in O 0 7.102345378484642e-10
transcriptional O 0 2.7295603999277773e-08
levels O 0 1.0755393908823407e-08
of O 0 4.608237749725852e-11
the O 0 8.590823052934127e-10
three O 0 6.510474381826725e-09
genes O 0 1.4862997055331562e-08
( O 0 1.4317089735982336e-09
DMAHP O 0 1.4420203115150798e-05
, O 0 3.141457316502283e-09
DMPK O 0 7.4508234320092015e-06
and O 0 1.0991020538142493e-08
59 O 0 2.5094897271316086e-09
) O 0 1.0683210566186929e-10
surrounding O 0 4.379863582926191e-09
the O 0 2.6042123124625505e-08
repeat O 0 2.0534404029604048e-05
. O 0 3.549677884961966e-08
. O 0 1.2765482892973523e-07

A O 0 4.433558842720231e-06
novel O 0 9.019059916681726e-07
missense O 0 0.00041332849650643766
mutation O 0 9.301261889049783e-05
in O 0 8.490550840178912e-08
patients O 0 1.1661454379918723e-07
from O 0 5.566877181450991e-09
a O 0 2.763042857623077e-06
retinoblastoma B-Disease 0 0.004537750966846943
pedigree O 0 0.0015302320243790746
showing O 0 2.9253957109176554e-05
only O 0 1.678099259549981e-08
mild O 0 8.857058446665178e-07
expression O 0 4.0110347043764705e-08
of O 0 8.501983561615134e-10
the O 0 2.915901688993472e-07
tumor B-Disease 0 0.013220096938312054
phenotype O 0 0.0002978459815494716
. O 0 7.736109068900987e-07

We O 0 5.545873591472628e-07
have O 0 1.5175052325844263e-09
used O 0 1.9218955316091524e-09
single O 0 1.4483402033249604e-08
strand O 0 1.3941037195763784e-06
conformation O 0 2.744648554653395e-06
polymorphism O 0 1.6084612752820249e-06
analysis O 0 8.585880451050798e-09
to O 0 6.0129612400317e-10
study O 0 9.275740175951341e-10
the O 0 1.2213933198168547e-09
27 O 0 3.5220928396029194e-09
exons O 0 3.4775882173931905e-09
of O 0 2.0477042284028357e-10
the O 0 2.5875758424831474e-08
RB1 O 0 1.3387367289396934e-05
gene O 0 8.202413859237367e-09
in O 0 8.302232235024576e-10
individuals O 0 2.652899844246548e-10
from O 0 1.0349315848756646e-09
a O 0 3.7474057990039e-07
family O 0 6.581769298463769e-07
showing O 0 0.0003828902554232627
mild O 0 2.3655851691728458e-05
expression O 0 1.4315300234102324e-07
of O 0 1.782650582704548e-09
the O 0 2.574084021489398e-07
retinoblastoma B-Disease 0 0.0015318356454372406
phenotype O 0 0.0006226899567991495
. O 0 6.71144221087161e-07

In O 0 2.1350082590743114e-07
this O 0 1.2416887074095939e-08
family O 0 1.2707749874607543e-07
affected O 0 1.488029877094732e-08
individuals O 0 4.3302073038375966e-09
developed O 0 1.0999808637279784e-06
unilateral B-Disease 0 0.2686949670314789
tumors I-Disease 1 0.9999998807907104
and O 0 1.3815153579344042e-05
, O 0 4.901071548601976e-09
as O 0 9.153731106437135e-10
a O 0 2.258956399714407e-08
result O 0 2.3230166235066463e-08
of O 0 4.00244060116961e-10
linkage O 0 4.979013738193316e-06
analysis O 0 1.0398395744459776e-07
, O 0 6.009742037349497e-09
unaffected O 0 9.107967571253539e-07
mutation O 0 8.93807623469911e-07
carriers O 0 4.982918966334182e-08
were O 0 2.640665286435251e-08
also O 0 3.294652017871158e-08
identified O 0 1.6723421936148952e-07
within O 0 8.229754655530996e-10
the O 0 2.853389169388265e-08
pedigree O 0 0.00015673079178668559
. O 0 2.7231311605646624e-07

A O 0 1.4855762628940283e-06
single O 0 1.5277089460141724e-07
band O 0 3.1095421348936725e-08
shift O 0 3.3265317167519015e-09
using O 0 2.297261270101103e-09
SSCP O 0 1.557254836370703e-05
was O 0 1.1514388376099305e-07
identified O 0 5.80615449052857e-08
in O 0 1.6957497628311557e-09
exon O 0 2.0576487713697134e-06
21 O 0 2.051545244796671e-08
which O 0 4.039662826471613e-09
resulted O 0 5.572783567941997e-09
in O 0 3.809728532644385e-09
a O 0 1.064839807440876e-07
missense O 0 1.7838774510892108e-05
mutation O 0 2.6050275891975616e-07
converting O 0 3.758606315074076e-09
a O 0 3.936020931405437e-08
cys O 0 0.00019564446120057255
- O 0 4.211672057863325e-05
- O 0 2.056185621768236e-05
> O 0 1.4592313846151228e-07
arg O 0 4.314997781307284e-08
at O 0 1.482946099251592e-09
nucleotide O 0 4.988386947957224e-08
position O 0 1.7710608091192626e-08
28 O 0 1.4873594578190819e-09
in O 0 8.584140065437396e-10
the O 0 1.4477575582816371e-08
exon O 0 8.184810576494783e-05
. O 0 9.329507406619086e-07

The O 0 4.984954102837946e-07
mutation O 0 7.548650955868652e-06
destroyed O 0 8.562111020182783e-07
an O 0 6.723022583088323e-09
NdeI O 0 6.156397375889355e-06
restriction O 0 9.577075843480998e-08
enzyme O 0 9.135076339816806e-08
site O 0 8.330408718393301e-07
. O 0 2.470708011514944e-07

Analysis O 0 4.580811037158128e-07
of O 0 1.565831242444915e-09
all O 0 3.224017441905147e-10
family O 0 4.1450869403547586e-09
members O 0 4.395586672423235e-10
demonstrated O 0 5.541751235682568e-08
that O 0 4.913932816208444e-09
the O 0 8.155675246257488e-09
missense O 0 8.06147072580643e-05
mutation O 0 2.310011950612534e-05
co O 0 7.128733159333933e-06
- O 0 6.8367039602890145e-06
segregated O 0 2.9149441971298984e-08
with O 0 1.0486208879001424e-07
patients O 0 8.935093092077295e-07
with O 0 3.7585297832265496e-05
tumors B-Disease 1 0.9999998807907104
or O 0 6.379993283189833e-05
who O 0 2.1395178464445053e-06
, O 0 1.530445992159457e-09
as O 0 4.2491737906047433e-10
a O 0 7.286477643475564e-09
result O 0 7.785599720477876e-09
of O 0 1.0048896437186983e-10
linkage O 0 8.127817068270815e-07
analysis O 0 6.798304497124263e-08
had O 0 5.427373821476067e-07
been O 0 1.574804855408729e-07
predicted O 0 1.0314503384734053e-07
to O 0 4.354298033248938e-10
carry O 0 4.662458508164491e-08
the O 0 1.1505404629019722e-08
predisposing O 0 2.461404619680252e-06
mutation O 0 1.0976169505738653e-05
. O 0 3.620600921294681e-07

These O 0 1.572818320028091e-08
observations O 0 9.343327889155262e-08
point O 0 8.316690447429664e-09
to O 0 3.294862160885259e-10
another O 0 1.0053233800988437e-09
region O 0 1.4452929963937322e-09
of O 0 1.8292801995389851e-10
the O 0 6.28602521146604e-08
RB1 O 0 2.7662841603159904e-05
gene O 0 1.2913343283571521e-08
where O 0 4.469836500931024e-09
mutations O 0 1.3331720616349685e-08
only O 0 3.742137710815996e-10
modify O 0 6.656620588074702e-09
the O 0 3.3012470534998783e-10
function O 0 5.382206902382336e-10
of O 0 2.0825141958114024e-11
the O 0 3.892298428009866e-10
gene O 0 7.46594697176306e-09
and O 0 4.857573010497163e-09
raise O 0 8.034043652571654e-09
important O 0 3.6881567244684277e-10
questions O 0 3.075189436430037e-09
for O 0 8.816785079801548e-10
genetic O 0 4.1801303041211213e-07
counseling O 0 7.492583620205551e-08
in O 0 1.225176227137581e-08
families O 0 2.7960906923141238e-09
with O 0 1.4206140264150235e-08
these O 0 1.7384426342914594e-08
distinctive O 0 3.546850348357111e-05
phenotypes O 0 1.6540301658096723e-05
. O 0 3.47450708204633e-08
. O 0 1.1771368235713453e-07

Maternal B-Disease 0 0.01252678781747818
disomy I-Disease 0 0.030198877677321434
and O 0 0.0012394777731969953
Prader B-Disease 1 0.9999995231628418
- I-Disease 1 0.9999997615814209
Willi I-Disease 1 1.0
syndrome I-Disease 1 0.9999986886978149
consistent O 0 0.0002599808794911951
with O 0 7.497072829210083e-08
gamete O 0 3.4544398658908904e-05
complementation O 0 7.386786455754191e-05
in O 0 2.5351425847475184e-08
a O 0 5.119244050888483e-08
case O 0 8.296144926589477e-08
of O 0 1.4351839716653103e-09
familial O 0 0.0003140781191177666
translocation O 0 0.00259982468560338
( O 0 1.4233425105203423e-08
3 O 0 8.831954723120816e-09
; O 0 1.3436923573806325e-08
15 O 0 4.891368199366752e-09
) O 0 4.5213330301940857e-10
( O 0 3.309815477248179e-10
p25 O 0 2.069482007982515e-08
; O 0 1.1544835087917704e-09
q11 O 0 1.7280225250715375e-08
. O 0 6.702596810903572e-10
2 O 0 1.9672881101939765e-09
) O 0 4.566071076794742e-09
. O 0 8.709289289754452e-08

Maternal B-Disease 0 0.3674769103527069
uniparental I-Disease 1 0.9666842818260193
disomy I-Disease 1 0.7555035352706909
( I-Disease 0 5.747729574068217e-06
UPD I-Disease 1 0.9996589422225952
) I-Disease 0 8.545232077494802e-09
for I-Disease 0 2.408326649216974e-09
chromosome I-Disease 0 1.6076292013167404e-05
15 I-Disease 0 6.92159218829147e-09
is O 0 1.1063732152649663e-08
responsible O 0 6.483027448211942e-09
for O 0 3.064472842151389e-10
an O 0 1.4065582032429802e-09
estimated O 0 2.0073343875992578e-08
30 O 0 1.1386201981267163e-09
% O 0 1.541516359004902e-10
of O 0 3.2555688700419694e-10
cases O 0 2.915345476139919e-07
of O 0 0.00010946160909952596
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 0.9999995231628418
( O 0 0.0005318484618328512
PWS B-Disease 1 0.9999822378158569
) O 0 1.2215009519422892e-06
. O 0 4.5637048629032506e-07

We O 0 2.465013039909536e-06
report O 0 1.7732849855178756e-08
on O 0 1.494018464498481e-09
an O 0 2.8464608448075523e-10
unusual O 0 2.3312058061719654e-08
case O 0 1.9598623168803897e-08
of O 0 8.620417157878535e-10
maternal B-Disease 0 3.406452378840186e-05
disomy I-Disease 0 0.00011118750990135595
15 I-Disease 0 1.560947637813115e-08
in O 0 1.1674318045606924e-07
PWS B-Disease 1 0.9999845027923584
that O 0 2.0063473016307398e-07
is O 0 6.804555141570745e-09
most O 0 3.3760100270896487e-10
consistent O 0 4.0966256165120285e-08
with O 0 1.121895798483763e-09
adjacent O 0 1.407067884429125e-07
- O 0 4.6430406655417755e-05
1 O 0 3.684945015791641e-09
segregation O 0 2.8535074303448482e-09
of O 0 6.660728218976786e-11
a O 0 1.886615486057508e-08
paternal O 0 2.0355106244096532e-05
t O 0 6.794150067435112e-06
( O 0 2.62070254386515e-10
3 O 0 6.020213771940064e-10
; O 0 5.007791403777162e-10
15 O 0 8.669785445114542e-10
) O 0 1.1769814289852576e-10
( O 0 7.241787031153635e-11
p25 O 0 6.115849604526602e-09
; O 0 3.6546074499987924e-10
q11 O 0 7.212928920807826e-09
. O 0 5.073184650150608e-10
2 O 0 3.2015462503309777e-10
) O 0 1.4791874322628296e-11
with O 0 1.5027629141073362e-10
simultaneous O 0 1.7668553482508287e-06
maternal O 0 7.66086668591015e-05
meiotic O 0 5.2129234973108396e-05
nondisjunction O 0 4.853642894886434e-05
for O 0 1.1542859112978476e-08
chromosome O 0 3.9558646676596254e-05
15 O 0 1.0398673566669459e-07
. O 0 2.1563486996001302e-07

The O 0 5.771076985183754e-07
patient O 0 5.6715689424891025e-06
( O 0 1.3299898071750249e-08
J O 0 8.286203956231475e-05
. O 0 8.952594221511845e-09
B O 0 5.961918958519163e-08
. O 0 3.887668520441423e-10
) O 0 4.423962585153873e-11
, O 0 2.6557742116573024e-11
a O 0 1.104616287328497e-09
17 O 0 4.049027779728931e-09
- O 0 1.8645843056219746e-06
year O 0 7.300169357904451e-08
- O 0 2.1380663383752108e-05
old O 0 1.271367545996327e-05
white O 0 4.3785562411358114e-06
male O 0 1.78714731191576e-06
with O 0 4.549864343061927e-07
PWS B-Disease 1 0.9999836683273315
, O 0 6.981045430620725e-08
was O 0 4.889813567388046e-07
found O 0 6.468118929348066e-09
to O 0 5.32652810747436e-10
have O 0 1.0851954890256366e-08
47 O 0 1.5474058701059334e-09
chromosomes O 0 1.503641833267011e-08
with O 0 1.4984818941243816e-09
a O 0 1.2099262391984666e-07
supernumerary O 0 4.047578477184288e-05
, O 0 2.0884241891394595e-08
paternal O 0 7.372803338512313e-06
der O 0 0.004644935950636864
( O 0 2.36497732508667e-09
15 O 0 3.509363355469475e-10
) O 0 2.0430684921635134e-11
consisting O 0 8.616417995765957e-11
of O 0 1.492405643510608e-10
the O 0 1.00086792187426e-08
short O 0 3.4227616652060533e-07
arm O 0 5.294535867506056e-07
and O 0 1.5325697377832626e-09
the O 0 1.128236948311212e-09
proximal O 0 8.326643978762149e-07
long O 0 2.385998641329934e-06
arm O 0 3.0023504677956225e-06
of O 0 2.7927806733885063e-09
chromosome O 0 4.811782491742633e-05
15 O 0 1.9493786140856173e-08
, O 0 3.195496312002888e-09
and O 0 8.950173224775426e-08
distal O 0 0.000198002700926736
chromosome O 1 0.7468999624252319
arm O 0 0.03956904262304306
3p O 0 0.05584103614091873
. O 0 1.925167453009635e-06

The O 0 5.042724069426185e-07
t O 0 5.405923729995266e-06
( O 0 1.5776758788277334e-09
3 O 0 5.485316090236836e-10
; O 0 4.4129080944976806e-10
15 O 0 4.1798109418067497e-10
) O 0 1.5515780327213236e-10
was O 0 7.142195102005644e-08
present O 0 3.901948986140269e-09
in O 0 3.7602414515447435e-09
the O 0 1.5332567437909006e-09
balanced O 0 2.7097456722913194e-07
state O 0 5.020226456764476e-09
in O 0 2.705291990423575e-09
the O 0 3.0441562159921887e-08
patients O 0 2.20553019403269e-07
father O 0 1.2358183312244364e-06
and O 0 3.643238954964545e-08
a O 0 6.207531555446621e-07
sister O 0 0.0002453456399962306
. O 0 1.1287689858363592e-06

Fluorescent O 0 9.153404243988916e-05
in O 0 5.6856922725501136e-08
situ O 0 7.349219117713801e-07
hybridization O 0 1.7796897111566068e-07
analysis O 0 5.1201816120283183e-08
demonstrated O 0 2.5120775148934626e-07
that O 0 1.1966101887139757e-08
the O 0 8.502299664314705e-08
PWS B-Disease 1 0.9999643564224243
critical O 0 4.617157287611917e-07
region O 0 1.9028236764029316e-08
resided O 0 2.7652673040279296e-08
on O 0 2.9463567141618796e-09
the O 0 2.2986715308981331e-10
derivative O 0 6.17293736127067e-08
chromosome O 0 7.867224667279515e-07
3 O 0 2.3247042069129975e-09
and O 0 1.02549240210692e-08
that O 0 5.839116568040481e-08
there O 0 4.9092601983602435e-08
was O 0 9.447747402191453e-07
no O 0 6.145354092268462e-08
deletion O 0 7.86802232255468e-08
of O 0 2.20047779997401e-09
the O 0 1.835074499467737e-06
PWS B-Disease 1 0.9999939203262329
region O 0 1.0280955820007875e-07
on O 0 5.3435265101597906e-08
the O 0 5.049256124323165e-09
normal O 0 1.0713708142873202e-08
pair O 0 3.491247468900838e-08
of O 0 8.866822276409891e-10
15s O 0 1.5215918836020137e-07
present O 0 2.9735931050822728e-08
in O 0 1.232190811606415e-07
J O 0 0.005708837881684303
. O 0 6.803791166021256e-07

B O 0 0.0004534002800937742
. O 0 2.7926148504775483e-06

Methylation O 0 1.7357115211780183e-05
analysis O 0 2.9532066037063487e-07
at O 0 1.2713091024352252e-08
exon O 0 4.194118332634389e-07
alpha O 0 1.1383753495408655e-08
of O 0 2.4058646741487166e-10
the O 0 1.462630794257791e-09
small O 0 1.0729355892635795e-07
nuclear O 0 0.0031884582713246346
ribonucleoprotein O 0 0.0013498013140633702
- O 0 0.00013096733891870826
associated O 0 4.083683791122894e-07
polypeptide O 0 2.1801790353492834e-05
N O 0 1.2873136256530415e-05
( O 0 1.981761199587595e-09
SNRPN O 0 3.1207830488710897e-06
) O 0 4.358818028737943e-10
gene O 0 3.939023329735392e-09
showed O 0 9.46156433201395e-08
a O 0 3.072037202400679e-08
pattern O 0 5.11697010097123e-07
characteristic O 0 8.787933580833851e-08
of O 0 3.203440013255232e-10
only O 0 2.4649025043288475e-09
the O 0 1.2598287746357073e-08
maternal O 0 9.491028322372586e-05
chromosome O 0 6.007731644785963e-05
15 O 0 3.675042847817167e-08
in O 0 1.8581107497084304e-07
J O 0 0.16040827333927155
. O 0 2.751971578618395e-06

B O 0 0.0006605145172215998
. O 0 3.954814928874839e-06

Maternal B-Disease 0 0.013150842860341072
disomy I-Disease 0 0.0017419394571334124
was O 0 1.193612320093962e-06
confirmed O 0 1.1185828441284684e-07
by O 0 1.148292794184158e-09
polymerase O 0 5.9364111848481116e-08
chain O 0 2.1488474999387108e-07
reaction O 0 8.417148755768267e-09
analysis O 0 1.0473028000390627e-09
of O 0 1.4470906417596296e-10
microsatellite O 0 1.5858609003771562e-06
repeats O 0 3.472798368875374e-07
at O 0 1.170719743370796e-09
the O 0 3.354116984155553e-10
gamma O 0 2.6013134402091964e-07
- O 0 2.3616780708834995e-06
aminobutyric O 0 3.36011885337939e-06
acid O 0 4.501666595047027e-08
receptor O 0 4.033744005482731e-08
beta3 O 0 8.046819743867673e-07
subunit O 0 5.825833682138182e-08
( O 0 1.0806039618671548e-08
GABRB3 O 0 1.8313423424842767e-05
) O 0 1.3045341695772095e-08
locus O 0 8.680913197167683e-06
. O 0 1.1612927437454346e-06

A O 0 1.0362542525399476e-05
niece O 0 0.0005129344062879682
( O 0 3.571940965230169e-08
B O 0 4.886018700744899e-07
. O 0 1.875413602192566e-09
B O 0 4.4688157174732623e-08
. O 0 1.3548369370841584e-10
) O 0 5.556102019438347e-12
with O 0 4.2442386410934674e-11
45 O 0 1.4207290899292957e-10
chromosomes O 0 7.436570914620688e-09
and O 0 6.639410132791568e-10
the O 0 1.7433120225174292e-10
derivative O 0 3.20862874048089e-08
3 O 0 1.423146378520812e-09
but O 0 3.5333831416295425e-09
without O 0 2.5565356498447045e-09
the O 0 6.2419478474851076e-09
der O 0 0.0018266931874677539
( O 0 1.3618612904053862e-09
15 O 0 4.835984945827931e-10
) O 0 1.0105058456666427e-10
demonstrated O 0 1.5135110942310348e-08
a O 0 1.2955065642472618e-07
phenotype O 0 4.1367497033206746e-05
consistent O 0 1.347420948150102e-06
with O 0 1.0564559893566638e-08
that O 0 1.1997805415830953e-07
reported O 0 1.4549458171586593e-07
for O 0 1.3431690204512847e-09
haploinsufficiency O 0 1.1753201079045539e-06
of O 0 6.112312878059356e-10
distal O 0 2.268815933348378e-06
3 O 0 9.507248250884004e-07
p O 0 9.396248060511425e-05
. O 0 5.166416485735681e-07

Uniparental B-Disease 1 0.9997063279151917
disomy I-Disease 1 0.9994810223579407
associated O 0 2.390446388744749e-05
with O 0 6.420185627575847e-08
unbalanced O 0 5.558796146942768e-06
segregation O 0 2.5246720269933576e-07
of O 0 1.3332757120565475e-09
non O 0 6.271211105968177e-08
- O 0 2.0533854694804177e-05
Robertsonian O 0 9.92737477645278e-06
translocations O 0 3.8374044379452243e-05
has O 0 2.9425009984151984e-07
been O 0 5.919270762433371e-08
reported O 0 2.2863174820031418e-07
previously O 0 1.6281634884762752e-07
but O 0 2.384487629569776e-07
has O 0 5.028105931614846e-08
not O 0 4.597198177691553e-09
, O 0 1.4162405970186143e-10
to O 0 1.5292779542708246e-10
our O 0 1.795131709947384e-09
knowledge O 0 3.1420568369355806e-09
, O 0 6.529024543233675e-10
been O 0 6.257909745954748e-09
observed O 0 2.8295211507156637e-08
in O 0 1.3176771895828665e-09
a O 0 5.288076820875176e-08
case O 0 7.931801633276336e-07
of O 0 5.267958158583497e-07
PWS B-Disease 1 0.9999604225158691
. O 0 5.600305485131685e-06

Furthermore O 0 1.6140473235282116e-05
, O 0 2.602027571185772e-08
our O 0 1.2161914142438945e-08
findings O 0 1.2976006047438204e-08
are O 0 5.578970618813628e-10
best O 0 1.7181031042312611e-09
interpreted O 0 8.743822554890812e-09
as O 0 3.2498197466424017e-09
true O 0 9.624026375831818e-08
gamete O 0 1.3053252132522175e-06
complementation O 0 2.7425476218922995e-06
resulting O 0 1.7296358123530808e-07
in O 0 4.050945960898389e-07
maternal B-Disease 0 0.2970804274082184
UPD I-Disease 1 0.9999760389328003
15 I-Disease 0 8.72198143042624e-06
and O 0 0.00011686897050822154
PWS B-Disease 1 0.9998766183853149

Schwartz B-Disease 0 0.3826529085636139
- I-Disease 1 0.9611252546310425
Jampel I-Disease 1 0.9953248500823975
syndrome I-Disease 1 0.9997857213020325
type I-Disease 0 3.491084498818964e-05
2 I-Disease 0 5.4247255576456155e-08
and O 0 5.685963060386712e-07
Stuve B-Disease 1 0.943155825138092
- I-Disease 1 0.9999790191650391
Wiedemann I-Disease 1 0.9999923706054688
syndrome I-Disease 1 0.9999668598175049
: O 0 1.4656951208280589e-08
a O 0 8.134504270174148e-08
case O 0 3.9956111663741467e-07
for O 0 1.2206999855379763e-08
" O 0 1.1363453467083673e-07
lumping O 0 2.8390734314598376e-06
" O 0 2.7417451065048226e-07
. O 0 7.235846766207032e-08

Recent O 0 2.7559269710764056e-06
studies O 0 2.869175546038605e-07
demonstrated O 0 2.395638034613512e-07
the O 0 1.4399493819539089e-09
existence O 0 1.4383799928907592e-08
of O 0 1.8949368463250238e-10
a O 0 3.9059639078686814e-08
genetically O 0 3.3166628554681665e-08
distinct O 0 5.31290389460537e-09
, O 0 3.4613754085199844e-09
usually O 0 3.96192190166289e-09
lethal O 0 1.5381257156832362e-08
form O 0 9.087642305338761e-10
of O 0 2.288797207317117e-10
the O 0 2.1682947703993705e-07
Schwartz B-Disease 0 0.016736768186092377
- I-Disease 1 0.9980252981185913
Jampel I-Disease 1 0.999153733253479
syndrome I-Disease 1 0.9998986721038818
( O 0 3.357314994900662e-07
SJS B-Disease 0 0.05444527417421341
) O 0 8.603514567440129e-10
of O 0 8.18383316669724e-09
myotonia B-Disease 1 0.7983458638191223
and O 0 0.00043029282824136317
skeletal B-Disease 1 0.9988246560096741
dysplasia I-Disease 1 0.9991198182106018
, O 0 3.242466277697531e-07
which O 0 1.2807822713511996e-07
we O 0 6.868935997772496e-08
called O 0 1.9480130504234694e-06
SJS B-Disease 0 0.05984706059098244
type I-Disease 0 1.710785181785468e-05
2 I-Disease 0 1.756448000378441e-07
. O 0 4.4218523953531985e-07

This O 0 1.463125863665482e-05
disorder O 0 0.0011807347182184458
is O 0 3.153742511585733e-08
reminiscent O 0 7.948733582452405e-07
of O 0 1.3070090565392434e-09
another O 0 2.0084110019524815e-07
rare O 0 7.322376040974632e-05
condition O 0 0.00010823001503013074
, O 0 3.4728555586838183e-09
the O 0 2.5827832317304456e-08
Stuve B-Disease 1 0.8033239841461182
- I-Disease 1 0.9999706745147705
Wiedemann I-Disease 1 0.9999792575836182
syndrome I-Disease 1 0.9999794960021973
( O 0 4.517570744155819e-07
SWS B-Disease 0 0.03296472877264023
) O 0 3.8763570131550296e-09
, O 0 5.765383725986339e-10
which O 0 4.033641864964466e-09
comprises O 0 1.0224100455147322e-09
campomelia B-Disease 0 7.057806669763522e-06
at O 0 1.4776450996123458e-07
birth O 0 1.2972306649317034e-05
with O 0 1.6928216837186483e-06
skeletal B-Disease 1 0.9988419413566589
dysplasia I-Disease 1 0.9991663694381714
, O 0 1.4878149841024424e-06
contractures B-Disease 0 0.2699548900127411
, O 0 5.039973771658879e-08
and O 0 5.9054450218809507e-08
early B-Disease 0 6.634219289480825e-07
death I-Disease 0 0.00011422907846281305
. O 0 7.173848644015379e-07

To O 0 8.3672908601784e-08
test O 0 3.351344801671985e-08
for O 0 4.1639680592453487e-10
possible O 0 3.4797594139490684e-08
nosologic O 0 9.499557927483693e-05
identity O 0 1.0555863809713628e-05
between O 0 7.970795934397756e-08
these O 0 7.305252438527532e-07
disorders O 0 0.002712428802624345
, O 0 1.2079751421367746e-08
we O 0 5.193860452834542e-09
reviewed O 0 1.1028921109712542e-09
the O 0 1.4618994903514704e-10
literature O 0 6.436389199393489e-10
and O 0 3.2961380846963095e-10
obtained O 0 1.1992074000488628e-09
a O 0 8.93696172621361e-10
follow O 0 3.0504651582496933e-10
- O 0 1.8762658982041103e-08
up O 0 3.569526618729668e-10
of O 0 1.3938790226208919e-11
the O 0 2.230087225996158e-10
only O 0 1.980184488603598e-10
two O 0 6.306675182088384e-10
surviving O 0 3.4632771530596074e-06
patients O 0 6.876433644720237e-08
, O 0 6.216767656219702e-10
one O 0 7.544503910494882e-10
with O 0 2.3295701367942456e-08
SJS B-Disease 0 0.0005547130713239312
type I-Disease 0 4.93676338919613e-07
2 I-Disease 0 3.1984597193002173e-09
at O 0 3.546321281078235e-08
age O 0 1.1696884172351929e-07
10 O 0 4.812171772172746e-10
years O 0 2.7325752771645284e-09
and O 0 2.7931537083247804e-09
another O 0 1.197071330949484e-08
with O 0 3.3724546710800496e-07
SWS B-Disease 0 0.006595687009394169
at O 0 1.1239080066616225e-07
age O 0 9.777783560593889e-08
7 O 0 2.7559314830227777e-08
years O 0 1.1758902473957278e-07
. O 0 2.3826711981200788e-07

Patients O 0 0.00025728618493303657
reported O 0 5.06337664774037e-06
as O 0 1.572308505615183e-08
having O 0 8.236741564360273e-07
either O 0 0.00010371803364250809
neonatal O 1 0.9999744892120361
SJS B-Disease 1 0.9987651109695435
or O 0 1.1612048183451407e-05
SWS B-Disease 0 0.008901678025722504
presented O 0 2.0130093503212265e-07
a O 0 1.384691472594568e-08
combination O 0 4.772324757595925e-08
of O 0 1.1271550359737148e-09
a O 0 5.906970727664884e-06
severe O 0 0.05573129653930664
, O 0 7.565356554550817e-06
prenatal O 1 0.9986158609390259
- O 1 0.9999250173568726
onset O 1 0.9989916682243347
neuromuscular B-Disease 1 0.9999916553497314
disorder I-Disease 1 0.9998860359191895
( O 0 2.8409695005393587e-06
with O 0 0.004416417330503464
congenital B-Disease 1 0.9999980926513672
joint I-Disease 1 0.9961007833480835
contractures I-Disease 1 0.9999969005584717
, O 0 0.26120424270629883
respiratory O 1 0.9991649389266968
and O 0 2.7901737666979898e-06
feeding O 0 2.9951101168990135e-05
difficulties O 0 5.339561084838351e-06
, O 0 2.532107856723087e-08
tendency O 0 5.969997829424756e-08
to O 0 2.484330963170578e-08
hyperthermia B-Disease 0 0.1569509506225586
, O 0 5.5174719904016456e-08
and O 0 1.6615029352351485e-08
frequent O 0 1.3392655091593042e-06
death O 0 0.00015372675261460245
in O 0 3.48879837019922e-07
infancy O 0 0.0001409911346854642
) O 0 3.345383137176583e-10
with O 0 1.3621391792284498e-09
a O 0 2.8978018917769077e-07
distinct O 0 6.668313403679349e-07
campomelic B-Disease 0 0.023937523365020752
- I-Disease 0 0.29599934816360474
metaphyseal I-Disease 0 0.19776348769664764
skeletal I-Disease 1 0.9275155067443848
dysplasia I-Disease 1 0.9199114441871643
. O 0 6.1463074416678865e-06

The O 0 5.307720485348e-08
similarity O 0 1.3606590698600485e-07
of O 0 2.0873758277417664e-09
the O 0 1.1204209116044694e-08
clinical O 0 1.0618355190672446e-06
and O 0 4.582768724503694e-07
radiographic O 0 0.046656589955091476
findings O 0 3.848023879982065e-06
is O 0 3.5853606306091024e-08
so O 0 1.759648760035759e-09
extensive O 0 3.934632530899762e-08
that O 0 6.544091206706071e-07
these O 0 4.5190745368017815e-07
disorders O 0 0.0005094310035929084
appear O 0 1.748554581126882e-07
to O 0 8.658519234927553e-09
be O 0 5.771353173145144e-08
a O 0 8.791839434252324e-08
single O 0 4.022184384666616e-06
entity O 0 4.376752713142196e-06
. O 0 8.010816827663803e-07

The O 0 7.238497090611418e-08
follow O 0 1.866083820800668e-08
- O 0 3.546805658061203e-07
up O 0 5.88729065498228e-09
observation O 0 1.0442877851346566e-07
of O 0 5.192282714894247e-10
an O 0 7.060451334695017e-09
identical O 0 1.2116774087189697e-05
and O 0 7.396865697728572e-08
unique O 0 4.418858878807441e-08
pattern O 0 5.865275056748942e-07
of O 0 2.64900279489666e-09
progressive O 0 0.0007894554873928428
bone B-Disease 1 0.9903021454811096
dysplasia I-Disease 1 0.8922109007835388
in O 0 1.0318576926238165e-07
the O 0 1.8117189526378752e-08
two O 0 1.5663674446386722e-07
patients O 0 5.899950679122412e-07
( O 0 2.964547496375758e-09
one O 0 1.5635192696095146e-08
with O 0 9.85791871244146e-07
SJS B-Disease 0 0.2643090486526489
type I-Disease 0 7.375326822511852e-05
2 I-Disease 0 3.119516023275537e-08
, O 0 1.2052772113690935e-09
one O 0 4.151226473680936e-09
with O 0 2.529043570120848e-07
SWS B-Disease 0 0.16530035436153412
) O 0 2.0892558794116667e-09
surviving O 0 1.6386547940783203e-07
beyond O 0 4.189297087009436e-08
infancy O 0 1.0433266197651392e-06
adds O 0 7.757732234381365e-09
to O 0 8.456017136504457e-11
the O 0 2.182952846263575e-10
evidence O 0 1.7195432633343444e-08
in O 0 3.7332208435714165e-09
favor O 0 1.5254916219120673e-09
of O 0 1.4000459680474364e-09
identity O 0 1.0643525456544012e-05
. O 0 5.43526255114557e-07

The O 0 1.7129349316746811e-07
hypothesis O 0 2.097895730912569e-06
that O 0 1.7137944041678566e-07
SWS B-Disease 0 0.0010193635243922472
and O 0 5.474137196870288e-07
SJS B-Disease 0 0.022777333855628967
type I-Disease 0 2.7050593416788615e-05
2 I-Disease 0 1.5076421888693403e-08
are O 0 1.4716471374853768e-09
the O 0 1.4735297426682337e-08
same O 0 3.439663487370126e-05
disorder O 0 0.0003689441364258528
should O 0 4.66560763356938e-08
be O 0 3.735991960240881e-09
testable O 0 3.908252210749197e-08
by O 0 1.3333494308653826e-09
molecular O 0 7.726679314146168e-07
methods O 0 1.0212493606331918e-07
. O 0 3.0496423164549924e-08
. O 0 1.044363457936015e-07

A O 0 1.6425301510025747e-06
mouse O 0 2.988489768540603e-06
model O 0 1.7624025758777861e-06
of O 0 8.535875508641766e-07
severe O 1 0.9982842803001404
von B-Disease 1 1.0
Willebrand I-Disease 1 0.9999996423721313
disease I-Disease 1 1.0
: O 0 0.10014963150024414
defects O 1 0.9998414516448975
in O 0 1.9302196960779838e-05
hemostasis O 1 0.9938029050827026
and O 0 0.00444658100605011
thrombosis B-Disease 1 0.9991533756256104
. O 0 7.596985960844904e-05

von B-Disease 1 0.9640288352966309
Willebrand I-Disease 1 0.9776145219802856
factor I-Disease 0 0.0002282153582200408
( I-Disease 0 3.794512622334878e-06
vWf I-Disease 0 0.0016745253233239055
) I-Disease 0 7.17102739145048e-05
deficiency I-Disease 1 0.9991225600242615
causes O 0 0.19422990083694458
severe O 1 0.9998661279678345
von B-Disease 1 1.0
Willebrand I-Disease 1 0.9999997615814209
disease I-Disease 1 0.9999997615814209
in O 0 0.0009294539922848344
humans O 0 4.287063347874209e-05
. O 0 2.3703132683294825e-06

We O 0 2.596059403003892e-07
generated O 0 2.3921124636672175e-08
a O 0 4.830133182309737e-09
mouse O 0 1.8755008568405174e-07
model O 0 2.036982778008678e-07
for O 0 2.770624396575272e-09
this O 0 1.0703070074669085e-07
disease O 0 3.4322604847147886e-07
by O 0 1.145556094428457e-09
using O 0 9.971907388717227e-08
gene O 0 2.151117257653823e-07
targeting O 0 1.3347797676033224e-06
. O 0 2.854581850897375e-07

vWf B-Disease 0 0.005644498858600855
- I-Disease 1 0.8630921840667725
deficient I-Disease 0 0.39578402042388916
mice O 0 0.00019367651839274913
appeared O 0 4.984872816748975e-07
normal O 0 6.649833750316247e-08
at O 0 2.0833557101695988e-08
birth O 0 4.201735464448575e-06
; O 0 7.3885706441956245e-09
they O 0 5.4095550261479275e-09
were O 0 2.648685892836511e-08
viable O 0 2.769416482806264e-07
and O 0 2.1012164097555797e-07
fertile O 0 6.197397397045279e-06
. O 0 4.962195703228645e-07

Neither O 0 0.0001945397089002654
vWf O 0 0.0003845935862045735
nor O 0 2.178127942897845e-05
vWf O 0 5.307740866555832e-05
propolypeptide O 0 7.08044390194118e-05
( O 0 9.402754130860558e-08
von B-Disease 0 0.004698673728853464
Willebrand I-Disease 0 0.10375721752643585
antigen O 0 0.007264435291290283
II O 0 0.005606252700090408
) O 0 3.6935439151619676e-09
were O 0 1.0092009006257285e-08
detectable O 0 5.507700734597165e-06
in O 0 3.5115077512415382e-09
plasma O 0 5.108975528855808e-06
, O 0 8.824966535314616e-09
platelets O 0 2.7437931748863775e-07
, O 0 1.0816570972238537e-09
or O 0 2.1485815349109316e-09
endothelial O 0 3.1786775878117624e-08
cells O 0 4.169668610387589e-09
of O 0 9.447845977783587e-11
the O 0 3.457937269857325e-09
homozygous O 0 1.7232589016202837e-05
mutant O 0 4.736793925985694e-05
mice O 0 6.528552330564708e-05
. O 0 2.3553951677968143e-07

The O 0 6.171831046231091e-07
mutant O 0 7.770768570480868e-05
mice O 0 0.005371821578592062
exhibited O 0 0.013738133013248444
defects O 1 0.9969244599342346
in O 0 6.093194429013238e-07
hemostasis O 0 0.0019348502391949296
with O 0 8.59835509459117e-08
a O 0 3.7318352497095475e-06
highly O 0 1.071884162229253e-05
prolonged O 0 0.0021172682754695415
bleeding O 0 0.2691607177257538
time O 0 1.873670214536105e-07
and O 0 3.123457403830798e-08
spontaneous O 0 1.5387910252684378e-06
bleeding O 0 8.412003808189183e-05
events O 0 7.320271944166734e-09
in O 0 9.260783806475104e-10
approximately O 0 4.370256656560656e-10
10 O 0 5.536600622413346e-10
% O 0 1.5411261156117462e-09
of O 0 2.417011657485091e-08
neonates O 0 0.26023873686790466
. O 0 7.2674279181228485e-06

As O 0 4.463781166919034e-08
in O 0 2.7466000585008032e-09
the O 0 5.928984858627473e-09
human O 0 8.203127208616934e-07
disease O 0 1.0524222489038948e-05
, O 0 6.928443374576432e-10
the O 0 8.015029751007319e-10
factor O 0 1.2356547784975191e-08
VIII O 0 4.1623919969424605e-05
level O 0 1.073793356454189e-07
in O 0 3.6787792812020825e-09
these O 0 4.9063841878194125e-09
mice O 0 3.72441877516394e-06
was O 0 5.994107254991832e-07
reduced O 0 2.3576598451313657e-08
strongly O 0 1.2672999538665408e-08
as O 0 4.093981265107516e-10
a O 0 2.4698392220301457e-09
result O 0 7.918015576535709e-09
of O 0 1.172238556224059e-10
the O 0 3.7717984291418816e-09
lack O 0 2.952569033709551e-08
of O 0 7.074534291717782e-10
protection O 0 1.8914657573532168e-07
provided O 0 1.575427432953802e-08
by O 0 3.3946157884656714e-08
vWf O 0 5.724796665163012e-06
. O 0 2.930422908775654e-07

Defective O 1 0.9051027297973633
thrombosis B-Disease 1 0.9872933626174927
in O 0 1.0068256415252108e-06
mutant O 0 0.00011813123273896053
mice O 0 0.0024794810451567173
was O 0 5.579828666668618e-06
also O 0 1.6960061799409232e-08
evident O 0 1.3473126614371722e-07
in O 0 1.1827542278908254e-09
an O 0 5.96573568323322e-10
in O 0 1.4510998624928106e-08
vivo O 0 1.5619804116795422e-06
model O 0 1.7541832164624793e-07
of O 0 3.537862980351747e-08
vascular B-Disease 1 0.9069076180458069
injury I-Disease 0 0.39442503452301025
. O 0 1.8020980860455893e-05

In O 0 1.219596157397973e-07
this O 0 3.0203726186783797e-09
model O 0 7.974308857683354e-08
, O 0 4.858182189870774e-10
the O 0 1.2726621978487174e-09
exteriorized O 0 2.084813968394883e-05
mesentery O 0 3.6545388866215944e-05
was O 0 4.2596502680680715e-07
superfused O 0 1.2557956097225542e-06
with O 0 8.818707541990989e-09
ferric O 0 3.690602852657321e-06
chloride O 0 2.7631378998194123e-06
and O 0 1.3862876180326111e-08
the O 0 1.2370618973633896e-09
accumulation O 0 3.5640056239572004e-08
of O 0 5.149872195353566e-10
fluorescently O 0 7.712314982200041e-05
labeled O 0 3.3449796319473535e-05
platelets O 0 3.5298396596772363e-06
was O 0 2.278540165434606e-07
observed O 0 3.412194615748376e-08
by O 0 9.669820499880188e-09
intravital O 0 3.086382639594376e-05
microscopy O 0 1.771310780895874e-05
. O 0 2.94066069272958e-07

We O 0 1.0267742709402228e-06
conclude O 0 1.9507666593199247e-07
that O 0 2.9251738808966365e-09
these O 0 8.024376163540126e-10
mice O 0 8.323452220793115e-07
very O 0 1.370643865072907e-08
closely O 0 1.3056364878138993e-06
mimic O 0 0.006214203778654337
severe O 0 0.05908564105629921
human O 0 0.032363153994083405
von B-Disease 1 1.0
Willebrand I-Disease 1 0.999998927116394
disease I-Disease 1 0.9999997615814209
and O 0 0.00010442799975862727
will O 0 2.013642188103404e-06
be O 0 6.284346909524174e-08
very O 0 1.1930453291952858e-09
useful O 0 1.0407512629484472e-09
for O 0 2.2828024193177754e-10
investigating O 0 3.4212661148558254e-08
the O 0 4.771619210863776e-10
role O 0 2.1157711138641844e-09
of O 0 2.586235947621418e-10
vWf O 0 7.395031786927575e-08
in O 0 1.4897962863358316e-08
normal O 0 2.50475011398521e-07
physiology O 0 8.596778684477613e-07
and O 0 3.15660706462495e-08
in O 0 8.506831363774836e-07
disease O 0 7.2228408498631325e-06
models O 0 1.0099307701239013e-06
. O 0 7.492998577163235e-08
. O 0 1.9288120256533148e-07

Oral O 0 0.0012059399159625173
contraceptives O 0 0.01184155885130167
and O 0 6.767926663542312e-08
the O 0 2.1312850151389284e-08
risk O 0 2.5249998998333467e-06
of O 0 1.1506082273626816e-06
hereditary B-Disease 1 0.9999961853027344
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999994039535522
. O 0 0.0007919042254798114

Hereditary B-Disease 1 0.9998593330383301
Ovarian I-Disease 1 0.9999922513961792
Cancer I-Disease 1 0.9997581839561462
Clinical O 0 0.012409716844558716
Study O 0 7.697870387346484e-06
Group O 0 2.860494987544371e-06
. O 0 6.492434181382123e-07

BACKGROUND O 0 0.0008162253070622683
Women O 0 1.9517807459124015e-07
with O 0 1.0303605968431384e-08
mutations O 0 1.6252466821242706e-06
in O 0 7.337115803807137e-09
either O 0 2.95170199393624e-08
the O 0 4.679957044118055e-08
BRCA1 O 0 3.471974196145311e-05
or O 0 8.732993705962144e-08
the O 0 1.9785819205253574e-08
BRCA2 O 0 5.323574441717938e-06
gene O 0 2.5715461760000835e-08
have O 0 6.86487311440942e-09
a O 0 6.64557333607263e-08
high O 0 1.1895217539859004e-05
lifetime O 0 0.00017541878332849592
risk O 0 3.71995811292436e-05
of O 0 8.911482291296124e-05
ovarian B-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999988079071045
. O 0 0.00017998457769863307

Oral O 0 0.005002917721867561
contraceptives O 1 0.8332434296607971
protect O 0 0.0007514863391406834
against O 0 0.4717009365558624
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999995231628418
in O 0 6.7367210476732e-07
general O 0 1.7122808060321404e-08
, O 0 5.896314547726433e-09
but O 0 1.2136771587734074e-08
it O 0 2.3634036949715664e-09
is O 0 2.0859509675119625e-09
not O 0 1.653103098853137e-09
known O 0 1.9483741287018574e-09
whether O 0 9.418492652457644e-09
they O 0 1.1579994740884558e-08
also O 0 9.639895992563652e-09
protect O 0 3.1266463196288896e-08
against O 0 4.178057793069456e-07
hereditary B-Disease 0 0.021429652348160744
forms I-Disease 0 3.650585495051928e-05
of I-Disease 0 0.006525840610265732
ovarian I-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999982118606567
. O 0 7.635726069565862e-05

METHODS O 0 1.4377924344444182e-06
We O 0 2.5281169158120065e-08
enrolled O 0 7.501017584843339e-09
207 O 0 2.0582866966378788e-08
women O 0 1.5299936251267354e-07
with O 0 3.219927384634502e-05
hereditary B-Disease 1 0.9999992847442627
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
and O 0 2.4281903279188555e-06
161 O 0 1.5636652861417133e-08
of O 0 7.183721950632105e-10
their O 0 1.3884394434171554e-07
sisters O 0 6.866525268378609e-07
as O 0 4.989926249976406e-09
controls O 0 7.96813566239507e-08
in O 0 1.7499324211911471e-09
a O 0 7.674904622945178e-08
case O 0 3.539419594744686e-06
- O 0 0.0013618484372273088
control O 0 2.349421492908732e-06
study O 0 1.4250774427182478e-07
. O 0 4.433760523170349e-07

All O 0 3.306726625851297e-08
the O 0 1.785016046085275e-08
patients O 0 5.741707553852393e-08
carried O 0 1.2493482870468142e-07
a O 0 1.600438963578199e-07
pathogenic O 0 4.885286671196809e-06
mutation O 0 8.098632520159299e-07
in O 0 3.1724072258043634e-09
either O 0 2.1599463195798307e-07
BRCA1 O 0 3.284722697571851e-05
( O 0 3.1895528440628595e-09
179 O 0 2.0852439774898812e-08
women O 0 1.304686350067641e-07
) O 0 4.061449843106857e-09
or O 0 3.454228476584831e-07
BRCA2 O 0 3.895432018907741e-05
( O 0 1.8446774774361074e-08
28 O 0 1.1129070998094903e-07
women O 0 3.3116756981144135e-07
) O 0 3.652618119076578e-08
. O 0 5.146068247086077e-07

The O 0 3.5871187265001936e-07
control O 0 1.4762972568860278e-06
women O 0 7.079224673134377e-08
were O 0 2.00698959673673e-08
enrolled O 0 1.1611821726376093e-08
regardless O 0 8.740271617568851e-09
of O 0 8.251000577219614e-11
whether O 0 7.79882736168247e-09
or O 0 6.08682881875211e-08
not O 0 2.3091807577202417e-08
they O 0 1.284975681414835e-08
had O 0 1.5624839022621018e-07
either O 0 2.56680579013846e-07
mutation O 0 1.5571937183267437e-05
. O 0 4.6664263209095225e-07

Lifetime O 0 4.6812445361865684e-05
histories O 0 1.3869773738406366e-06
of O 0 8.315056199137416e-09
oral O 0 5.988067641737871e-06
- O 0 0.00016554491594433784
contraceptive O 0 0.00016231271729338914
use O 0 5.7740173531328765e-08
were O 0 4.3189999132664525e-08
obtained O 0 7.751992825433263e-09
by O 0 1.1162650803697716e-09
interview O 0 3.5990954074804904e-06
or O 0 9.296094560795609e-09
by O 0 3.453400898578707e-10
written O 0 1.1350256734488084e-08
questionnaire O 0 6.629065296692715e-08
and O 0 2.4471202841880313e-09
were O 0 1.9866821077130226e-08
compared O 0 1.712399182451918e-07
between O 0 3.386170277508427e-08
patients O 0 1.1285112577752443e-07
and O 0 3.178138570092415e-07
control O 0 1.659932422626298e-05
women O 0 3.5324964642313716e-07
, O 0 1.4909837808829707e-09
after O 0 2.4734503334400415e-09
adjustment O 0 2.986381986147535e-08
for O 0 3.039871132592964e-10
year O 0 2.8868516466218352e-09
of O 0 5.581471951288108e-10
birth O 0 9.08665060705971e-06
and O 0 1.4720920660238335e-07
parity O 0 7.039475804049289e-06
. O 0 1.5632410566013277e-07

RESULTS O 0 5.008497737435391e-06
The O 0 2.777302832157602e-08
adjusted O 0 2.155188485630788e-05
odds O 0 0.0001789822126738727
ratio O 0 1.72347754414659e-05
for O 0 0.0003011027874890715
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
associated O 0 5.054638677393086e-05
with O 0 1.509411795552751e-08
any O 0 4.551984122969088e-09
past O 0 6.526239104687193e-09
use O 0 4.827094279846733e-09
of O 0 3.128416414810431e-09
oral O 0 0.0001318210706813261
contraceptives O 1 0.5446732640266418
was O 0 2.1391251721070148e-05
0 O 0 1.3106874519053235e-07
. O 0 6.814493502815822e-08

5 O 0 1.321118503483376e-07
( O 0 2.0147283841254193e-09
95 O 0 2.111497865442402e-09
percent O 0 1.3648367769292236e-08
confidence O 0 4.4886000694077666e-08
interval O 0 2.4585929736531398e-08
, O 0 6.143938829916706e-11
0 O 0 5.027599517259951e-11
. O 0 1.1338512594105676e-11
3 O 0 2.5646014825686514e-11
to O 0 1.38305880637013e-10
0 O 0 3.663444658741355e-09
. O 0 6.192070745036915e-10
8 O 0 5.355972998444258e-09
) O 0 2.592247527744007e-09
. O 0 4.473898584933522e-08

The O 0 2.4013204438233515e-06
risk O 0 1.2752351722156163e-05
decreased O 0 3.866560405185737e-07
with O 0 1.8398904622074497e-09
increasing O 0 1.1187082371577617e-08
duration O 0 6.063525859190122e-08
of O 0 1.3978039559159328e-10
use O 0 2.9628475672893728e-08
( O 0 3.950738403091236e-09
P O 0 6.592460977117298e-07
for O 0 2.934420761935286e-10
trend O 0 8.3769480241358e-09
, O 0 1.7200760260571712e-10
< O 0 5.4609015087692114e-09
0 O 0 1.5991885593535926e-10
. O 0 6.231437588155586e-11
001 O 0 2.329355819341572e-09
) O 0 1.3286338175488854e-11
; O 0 9.95330380615389e-12
use O 0 1.2258645487595032e-10
for O 0 1.6735843266779682e-10
six O 0 1.1009982925358486e-09
or O 0 2.839673163279599e-09
more O 0 2.727855719086847e-10
years O 0 4.2025021684821695e-08
was O 0 4.2344211692579847e-07
associated O 0 4.0790024691261806e-09
with O 0 4.683676224637168e-10
a O 0 7.903232557282536e-08
60 O 0 8.763306524883774e-09
percent O 0 1.4535991965658468e-07
reduction O 0 3.491934137400676e-07
in O 0 4.792831305167056e-07
risk O 0 1.1623691534623504e-05
. O 0 6.363229090311506e-07

Oral O 0 0.000249629927566275
- O 0 0.0002503146533854306
contraceptive O 0 0.0001960427762242034
use O 0 3.8250760781011195e-07
protected O 0 0.0006326877046376467
against O 1 0.6765134334564209
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999992847442627
both O 0 3.9870382551043804e-08
for O 0 1.698268081717913e-09
carriers O 0 1.2303538632352229e-08
of O 0 7.246014899209285e-11
the O 0 3.627872402489629e-08
BRCA1 O 0 0.0032793493010103703
mutation O 0 3.5143755212629912e-06
( O 0 1.8726469264152e-09
odds O 0 5.70719976167311e-06
ratio O 0 1.1032044255898654e-07
, O 0 8.594128880767826e-11
0 O 0 1.8892422348759652e-10
. O 0 4.451488830325978e-11
5 O 0 4.3391238518930564e-11
; O 0 5.157497692809265e-11
95 O 0 1.7196398471863716e-10
percent O 0 1.2456620623879644e-08
confidence O 0 6.052029277725524e-08
interval O 0 6.33571106689601e-09
, O 0 8.42631173170183e-11
0 O 0 3.711208770851293e-11
. O 0 1.720869280408266e-11
3 O 0 3.477299351239971e-11
to O 0 7.504745436204274e-11
0 O 0 5.562405536174708e-10
. O 0 1.8405775514818146e-10
9 O 0 1.2534573379241465e-09
) O 0 5.102225933417692e-11
and O 0 3.949252036505868e-10
for O 0 6.544871311575662e-10
carriers O 0 6.01073946171482e-09
of O 0 1.5876275294424147e-10
the O 0 3.743662091437727e-08
BRCA2 O 0 4.9852922529680654e-05
mutation O 0 1.1606704219957464e-06
( O 0 5.835993355240987e-10
odds O 0 6.071604161661526e-07
ratio O 0 3.247064128686361e-08
, O 0 4.6571187878319265e-11
0 O 0 5.6241296342296465e-11
. O 0 1.77160543179955e-11
4 O 0 6.252928036465377e-11
; O 0 6.454432821545453e-11
95 O 0 2.1520667192742593e-10
percent O 0 1.2227273415987838e-08
confidence O 0 4.307810996806438e-08
interval O 0 6.226917648177732e-09
, O 0 5.4806909011162475e-11
0 O 0 4.172544601499517e-11
. O 0 8.925709997498199e-12
2 O 0 2.4955685087868495e-11
to O 0 6.411781522386306e-11
1 O 0 1.0964925634127098e-09
. O 0 1.5629072480649597e-09
1 O 0 4.913801365802328e-09
) O 0 6.003635810714059e-09
. O 0 6.996268098191649e-08

CONCLUSIONS O 0 4.564879054669291e-05
Oral O 0 4.9864480388350785e-05
- O 0 7.056050526443869e-05
contraceptive O 0 5.9451485867612064e-05
use O 0 2.2609269478834904e-07
may O 0 3.0955234819884936e-07
reduce O 0 2.554611810978713e-08
the O 0 2.1085769574824553e-08
risk O 0 4.07655807066476e-06
of O 0 5.016778231947683e-05
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
in O 0 1.480565970268799e-05
women O 0 7.2302174203287e-07
with O 0 1.5442141432231438e-07
pathogenic O 0 1.786894426913932e-05
mutations O 0 4.7347390363938757e-07
in O 0 1.1406944722125445e-08
the O 0 1.4588695762540738e-07
BRCA1 O 0 0.0013785213232040405
or O 0 4.905657624476589e-05
BRCA2 O 0 0.0025576793123036623
gene O 0 0.00012597712338902056

A O 0 4.1819071157078724e-06
Japanese O 0 4.212921794533031e-06
family O 0 1.8951526215005288e-07
with O 0 2.2281386691247462e-07
adrenoleukodystrophy B-Disease 1 0.9999872446060181
with O 0 5.490031540489326e-08
a O 0 1.2561102380459488e-07
codon O 0 6.218884607278596e-08
291 O 0 8.340979462673204e-09
deletion O 0 3.627264106853545e-07
: O 0 3.39569550256158e-09
a O 0 7.153170145102195e-08
clinical O 0 1.3918680679125828e-06
, O 0 8.708243370847413e-08
biochemical O 0 0.0003724853158928454
, O 0 3.736471398951835e-08
pathological O 0 3.148149335174821e-05
, O 0 4.5701508355477927e-08
and O 0 3.2274667205456353e-07
genetic O 0 3.14148492179811e-05
report O 0 2.0659701931435848e-06
. O 0 4.571493832372653e-07

We O 0 1.2221022416269989e-06
report O 0 2.1930334881403724e-08
a O 0 4.313613466422339e-09
Japanese O 0 3.585990100418712e-07
family O 0 4.442949546046293e-07
with O 0 2.0828962078667246e-05
adrenoleukodystrophy B-Disease 1 0.9999997615814209
( O 0 0.0019019081955775619
ALD B-Disease 1 0.9999994039535522
) O 0 9.237097309267028e-09
with O 0 1.5565407851525492e-09
a O 0 5.755589427280938e-08
three O 0 1.3960361755493977e-08
base O 0 8.844281040865098e-08
pair O 0 1.0324368986402988e-06
deletion O 0 1.0752480648079654e-06
( O 0 2.7828372939353585e-09
delGAG O 0 1.8285813041529764e-07
291 O 0 9.260983091508024e-09
) O 0 7.368667342966262e-10
in O 0 8.619483793381733e-09
the O 0 1.8149929701394285e-06
ALD B-Disease 1 0.9999926090240479
gene O 0 2.404406768619083e-05
. O 0 8.147863468366268e-07

A O 0 1.1785931519625592e-06
variety O 0 6.872409130664892e-08
of O 0 7.1637082932340945e-09
phenotypes O 0 5.329855048330501e-05
were O 0 2.909501404246839e-07
observed O 0 1.097606286748487e-06
within O 0 2.411949084901721e-09
this O 0 1.1726444704152073e-08
family O 0 2.6961095045408e-07
. O 0 3.629104980973352e-07

While O 0 2.3543844918094692e-07
the O 0 1.0152438889576842e-08
proband O 0 3.1505096558248624e-05
( O 0 9.63504298567841e-09
patient O 0 1.9794921968241397e-07
1 O 0 1.293271623126202e-08
) O 0 1.366790014500907e-09
was O 0 1.5298622884074575e-06
classified O 0 4.466455720830709e-07
as O 0 1.9823668040430675e-08
having O 0 4.6245517637544253e-08
a O 0 5.511182621376065e-08
rare O 0 2.0448811710593873e-07
intermediate O 0 4.845656675911414e-08
type O 0 2.574535642452247e-07
of O 0 2.0309174342258984e-09
adult O 0 6.266763375606388e-05
cerebral O 0 0.18385592103004456
and O 0 1.177634771920566e-06
cerebello O 0 0.044667799025774
- O 1 0.5546995997428894
brain O 0 0.009407958015799522
stem O 0 2.2537676613865187e-06
forms O 0 1.1011336908950398e-07
, O 0 2.7565503213367037e-09
his O 0 6.441860023187473e-08
younger O 0 6.792173508074484e-07
brother O 0 8.958163562056143e-06
( O 0 5.756255916367081e-09
patient O 0 2.930378002474754e-07
2 O 0 2.5981989892898127e-08
) O 0 1.7254329076621389e-09
and O 0 8.996915568104669e-08
nephew O 0 0.00021610903786495328
( O 0 1.734871979408581e-08
patient O 0 1.2519237770902691e-06
3 O 0 4.7579369777395186e-08
) O 0 2.7211637387836163e-09
had O 0 1.0176186151511502e-06
a O 0 9.336522634839639e-05
childhood O 1 0.9951877593994141
ALD B-Disease 1 0.9999982118606567
type O 0 0.2583194375038147
. O 0 2.9448410714394413e-06

Another O 0 1.6389407164751901e-06
nephew O 0 4.495422399486415e-05
( O 0 1.3564258161125053e-08
patient O 0 2.6235591121803736e-07
4 O 0 7.2223587110897824e-09
) O 0 1.8459883621702033e-10
of O 0 3.9976572052680126e-10
patient O 0 6.815546839789022e-06
1 O 0 1.1701794022656031e-07
was O 0 1.0834708518814296e-05
classified O 0 2.4849100555002224e-06
as O 0 2.4078133264993085e-08
having O 0 1.3626549844047986e-07
an O 0 2.541189125793153e-08
adolescent O 0 0.00012382336717564613
form O 0 1.4776663874727092e-06
. O 0 1.7753750398696866e-06

The O 0 1.213639535535549e-07
tau O 0 2.6795993335326784e-07
level O 0 5.014391391000572e-08
in O 0 3.863985131857817e-09
the O 0 1.0155171992209944e-07
cerebrospinal O 1 0.7146610021591187
fluid O 0 0.1075655147433281
( O 0 2.096598734624422e-07
CSF O 0 0.00030969237559475005
) O 0 1.3154572986451285e-09
in O 0 3.9175267474433895e-09
patient O 0 8.08464903911954e-07
1 O 0 3.6938136105391095e-08
was O 0 2.5030765300471103e-06
as O 0 2.2018390666289633e-08
high O 0 6.042628797331417e-08
as O 0 7.026190740333504e-10
that O 0 1.2244747438217018e-09
of O 0 1.3929023490177883e-09
patients O 0 1.6575943391217152e-06
with O 0 0.001165636582300067
Alzheimers B-Disease 1 0.9999872446060181
disease I-Disease 0 0.27968406677246094
( O 0 5.674782244113885e-08
AD B-Disease 0 9.829926057136618e-06
) O 0 5.085929899451003e-08
. O 0 1.3222377504007454e-07

His O 0 9.614203008823097e-06
brain O 0 0.00014052781625650823
magnetic O 0 3.1878527806838974e-05
resonance O 0 0.0012200006749480963
image O 0 0.026033304631710052
( O 0 1.4590908392619895e-07
MRI O 0 0.40154293179512024
) O 0 2.5383488377883623e-07
showed O 0 0.010791100561618805
abnormalities B-Disease 1 0.6181934475898743
in I-Disease 0 5.4232771162787685e-08
the I-Disease 0 8.178047039564262e-08
bilateral I-Disease 0 0.00017890799790620804
cerebellar I-Disease 1 0.9981346130371094
hemispheres I-Disease 0 0.43218404054641724
and O 0 1.8797616576193832e-05
brain O 0 0.02980438433587551
stem O 0 6.243383722903673e-06
, O 0 7.092791243223928e-09
but O 0 1.0712604137097514e-08
not O 0 2.4015560651236e-09
in O 0 2.613246730120977e-09
the O 0 1.0834710195695152e-07
cerebral O 0 0.3077160716056824
white O 0 9.545500688545872e-06
matter O 0 9.26367178522014e-08
, O 0 2.022273459800772e-10
where O 0 3.019293981498805e-10
marked O 0 3.4496372425252275e-09
reductions O 0 4.7091653243569453e-08
of O 0 8.234948140062315e-11
the O 0 1.5436539158031337e-08
cerebral O 0 0.0073546008206903934
blood O 0 7.670162176509621e-07
flow O 0 7.500577225982852e-08
and O 0 5.006803149854022e-08
oxygen O 0 6.68030133965658e-06
metabolism O 0 2.0912688114549383e-07
were O 0 8.528753703274106e-09
clearly O 0 1.7568090981967543e-08
demonstrated O 0 9.125111333219138e-09
by O 0 4.376289108876108e-09
positron O 0 0.06950047612190247
emission O 0 0.0024287388660013676
tomography O 0 0.002998468466103077
( O 0 8.854003397118504e-08
PET O 0 9.014034003484994e-05
) O 0 3.8084664311099914e-08
. O 0 1.421655468902827e-07

In O 0 2.528780669308617e-07
patients O 0 9.731974870419435e-08
2 O 0 5.521827883825381e-09
and O 0 6.765613846937413e-09
3 O 0 8.264586348616376e-09
, O 0 5.622770027358115e-10
the O 0 2.5388335878062662e-09
autopsy O 0 0.0017197936540469527
findings O 0 4.939235623169225e-06
showed O 0 0.0002543716982472688
massive O 0 0.0007971969316713512
demyelination B-Disease 1 0.9999854564666748
of I-Disease 0 5.729007312993417e-08
the I-Disease 0 1.991543740587076e-06
cerebral I-Disease 1 0.8042277097702026
white I-Disease 0 9.702405805001035e-06
matter I-Disease 0 9.918752041926382e-09
with O 0 1.3527452769057646e-10
sparing O 0 1.0029064245742347e-09
of O 0 7.410637381521923e-11
the O 0 4.274807174908801e-09
U O 0 7.803093467373401e-06
- O 0 3.7462847103597596e-05
fibers O 0 7.4670851972769015e-06
, O 0 1.0272263040178586e-09
compatible O 0 1.9527863770463227e-09
with O 0 8.488404978912456e-10
the O 0 3.73862940605818e-09
findings O 0 5.7630586525192484e-08
of O 0 5.700851701817555e-08
childhood O 1 0.8030551671981812
ALD B-Disease 1 0.9999934434890747
. O 0 1.8695536709856242e-05

Oleic O 0 0.01120420265942812
and O 0 9.584894087311113e-07
erucic O 0 0.0023584237787872553
acids O 0 5.550276682697586e-07
( O 0 1.1246038544854287e-09
Lorenzos O 0 4.12582835451758e-07
Oil O 0 4.012152032828453e-08
) O 0 4.6628426814132595e-11
were O 0 2.741636639935763e-10
administered O 0 1.378030134446817e-09
to O 0 6.689764742162652e-09
patients O 0 8.17189960145015e-09
1 O 0 2.4389981145844786e-09
and O 0 1.0512740011847654e-08
4 O 0 7.750824870811357e-09
, O 0 3.97130855978034e-10
but O 0 1.585909403800656e-09
sufficient O 0 1.3180548208424625e-08
effectiveness O 0 8.53985966386972e-08
was O 0 4.1422842400606896e-07
not O 0 1.9544494023193693e-08
obtained O 0 9.45885787473344e-08
. O 0 1.3294170742028655e-07

The O 0 1.3993077629947948e-07
findings O 0 2.8740856805598014e-07
in O 0 3.615705734816288e-09
this O 0 1.9127019967868364e-09
family O 0 1.2388145620434443e-08
suggest O 0 3.3818263744933574e-08
that O 0 4.648816442909265e-09
delGAG291 O 0 2.7591249818215147e-07
is O 0 1.1781994269099982e-09
part O 0 4.365241501602668e-10
of O 0 1.4869559750163575e-10
the O 0 1.5673469633270543e-08
cause O 0 1.066105369318393e-06
of O 0 1.7830117826633796e-08
Japanese O 0 0.01658477820456028
ALD B-Disease 1 0.9999781847000122
with O 0 4.136449049951807e-08
phenotypic O 0 7.290203029697295e-06
variations O 0 1.0719660167524125e-05
. O 0 1.4131329635347356e-06

Moreover O 0 6.642330845352262e-06
, O 0 4.242980189417267e-09
although O 0 1.7248308337158846e-09
the O 0 2.7684254888526993e-10
scale O 0 2.446006988066074e-07
of O 0 1.818825368093968e-10
the O 0 6.3010276996067205e-09
study O 0 5.0124002726192884e-09
is O 0 2.385008857075377e-09
limited O 0 1.1963927626368331e-09
, O 0 1.5482146675793729e-09
there O 0 3.1356088836531626e-09
is O 0 1.175808561626468e-09
a O 0 5.8289209015072174e-09
possibility O 0 2.073951144154762e-08
that O 0 4.917000850923614e-08
PET O 0 2.2159179934533313e-05
can O 0 1.6022455895381427e-07
detect O 0 4.135526978643611e-05
an O 0 2.8895248860294487e-08
insidious B-Disease 0 0.007808911148458719
lesion I-Disease 1 0.6637093424797058
which O 0 6.855728429400187e-07
is O 0 2.1596182619987303e-08
undetectable O 0 1.77752198737835e-07
by O 0 7.048055472580472e-10
computed O 0 4.120246558159124e-06
tomogram O 0 5.370999133447185e-05
( O 0 3.197264231147301e-09
CT O 0 0.0017188346246257424
) O 0 3.2984714959383155e-10
or O 0 3.0681472917848396e-09
MRI O 0 7.677124085603282e-05
analysis O 0 4.797449548732402e-08
, O 0 9.470511042053431e-10
and O 0 8.919932570350397e-10
that O 0 1.257686510491851e-09
the O 0 1.6566984450960831e-09
higher O 0 3.347307497847396e-08
level O 0 2.1305115449621326e-09
of O 0 4.6069457276809445e-11
tau O 0 2.7729716300939344e-09
reflects O 0 1.1570980840147627e-09
the O 0 6.371016214590242e-11
process O 0 1.274607364099012e-10
of O 0 4.4756012784752386e-10
neuronal B-Disease 0 6.428594497265294e-05
degeneration I-Disease 0 0.004512143786996603
in O 0 6.073897020542063e-05
ALD B-Disease 1 0.9999908208847046
. O 0 1.912585321406368e-05

Lorenzos O 0 0.0008919358369894326
Oil O 0 3.6842134250036906e-06
should O 0 3.2516567216589465e-08
be O 0 1.2858968334583665e-09
given O 0 2.849562807938355e-10
in O 0 1.9896263803165226e-10
the O 0 5.266711511353606e-10
early O 0 1.1283343148704716e-08
stage O 0 6.384857442753855e-07
. O 0 3.347997079572451e-08
. O 0 1.3355179362406489e-07

Nonsense O 0 0.0001966624695342034
mutation O 0 1.6646497897454537e-05
in O 0 2.1517815085303482e-08
exon O 0 1.649861701480404e-06
4 O 0 7.692604775400014e-09
of O 0 7.852228312010823e-10
human O 0 4.384864382700471e-08
complement O 0 1.1292148656139034e-06
C9 O 0 0.00038755149580538273
gene O 0 1.9612127744039753e-07
is O 0 9.915814835892434e-10
the O 0 4.576478918050242e-10
major O 0 1.4281694937778866e-08
cause O 0 5.048093498771777e-07
of O 0 1.257859860714916e-08
Japanese O 0 0.00030595564749091864
complement B-Disease 0 0.0004065178509335965
C9 I-Disease 1 0.9972915053367615
deficiency I-Disease 1 0.8762568831443787
. O 0 7.288189749488083e-07

Deficiency B-Disease 1 0.9634256958961487
of I-Disease 0 8.232020398679651e-09
the I-Disease 0 6.7269598780228534e-09
ninth I-Disease 0 4.561181299322925e-08
component I-Disease 0 1.905660163004086e-08
of I-Disease 0 4.1689510177356226e-10
human I-Disease 0 2.3969766616005472e-08
complement I-Disease 0 3.501498042624007e-07
( O 0 3.078794463817758e-08
C9 O 0 1.9504517695168033e-05
) O 0 8.1429257781096e-10
is O 0 3.8170802629799994e-10
the O 0 2.445439406528749e-10
most O 0 7.4367978442069216e-09
common O 0 1.2521873031801078e-05
complement B-Disease 1 0.9999947547912598
deficiency I-Disease 1 0.9999992847442627
in O 0 4.1295990627077117e-07
Japan O 0 6.1369310060399584e-06
but O 0 1.827835092171881e-07
is O 0 1.3000135190566198e-08
rare O 0 4.499554862036348e-08
in O 0 3.683504612439492e-09
other O 0 1.996374843216131e-09
countries O 0 5.5367506135439726e-09
. O 0 2.682675415144331e-07

We O 0 7.009625164755562e-07
studied O 0 4.942661391282854e-08
the O 0 1.0648855131023538e-09
molecular O 0 9.704172043711878e-08
basis O 0 4.974863632156712e-09
of O 0 3.230157474831685e-08
C9 B-Disease 1 0.9994244575500488
deficiency I-Disease 1 0.8718627095222473
in O 0 5.542287073723173e-09
four O 0 8.370527382339787e-09
Japanese O 0 1.2447008884919342e-05
C9 B-Disease 0 0.038822632282972336
- I-Disease 1 0.8567395210266113
deficient I-Disease 0 0.257086843252182
patients O 0 2.491302666385309e-06
who O 0 1.4096065115154488e-06
had O 0 5.5682456149952486e-05
suffered O 1 0.8393783569335938
from O 0 0.0034743817523121834
meningococcal B-Disease 1 0.9999984502792358
meningitis I-Disease 1 0.9999879598617554
. O 0 4.505550350586418e-06

Direct O 0 1.1512027242588374e-07
sequencing O 0 2.4660423036948487e-07
of O 0 9.018818580841526e-09
amplified O 0 2.952720933535602e-06
C9 O 0 9.18580190045759e-06
cDNA O 0 1.6248982603883633e-07
and O 0 1.5962099197963653e-08
DNA O 0 8.091367931228888e-07
revealed O 0 1.2513759202192887e-06
a O 0 4.090051675120776e-08
nonsense O 0 1.2560351478896337e-06
substitution O 0 1.9767977477158638e-08
( O 0 5.931493074484706e-10
CGA O 0 1.449468385317232e-07
- O 0 2.3027366751193767e-06
- O 0 5.3083504099049605e-06
> O 0 8.380515481576367e-08
TGA O 0 5.666691436090332e-07
) O 0 6.305541505602363e-11
at O 0 1.1094763996410961e-10
codon O 0 1.0226127722390288e-09
95 O 0 4.8378641370749875e-11
in O 0 1.6918785816777415e-10
exon O 0 2.512978767299501e-07
4 O 0 6.160819854272859e-09
in O 0 1.7553478670606637e-09
the O 0 5.8973714800458765e-09
four O 0 3.7054468293717946e-07
C9 B-Disease 0 0.13912926614284515
- I-Disease 0 0.19483759999275208
deficient I-Disease 0 0.0007104946416802704
individuals O 0 7.071329832797346e-08
. O 0 3.1215313356369734e-07

An O 0 1.830521512147243e-07
allele O 0 4.1402918213861994e-06
- O 0 4.231877710481058e-07
specific O 0 8.176468391241087e-09
polymerase O 0 2.2094586427101603e-07
chain O 0 1.8560896251074155e-06
reaction O 0 1.2239142677117343e-07
system O 0 4.601560377182068e-08
designed O 0 8.376670166398981e-07
to O 0 6.340014735428667e-09
detect O 0 1.0051907338493038e-05
exclusively O 0 3.855540775532518e-09
only O 0 3.4709002338928485e-10
one O 0 2.5474469755870643e-10
of O 0 4.744834386505303e-11
the O 0 2.1732533550533617e-09
normal O 0 8.088179903609216e-09
and O 0 1.7529490081713561e-09
mutant O 0 3.5358119987449754e-08
alleles O 0 2.7200222074696967e-09
indicated O 0 2.849266778071069e-08
that O 0 4.210866655363077e-10
all O 0 1.6982661804609833e-11
the O 0 3.599623099592719e-10
four O 0 1.1292945245600094e-08
patients O 0 2.9975439019835903e-08
were O 0 1.781968173020232e-08
homozygous O 0 1.8558544923052978e-07
for O 0 8.814733942763553e-10
the O 0 1.8140452473502933e-09
mutation O 0 7.45903321330843e-08
in O 0 8.60440052541378e-10
exon O 0 4.2175665271315665e-07
4 O 0 1.221710910215279e-08
and O 0 3.233054357565379e-08
that O 0 1.7668636331791276e-08
the O 0 2.8900524196018296e-09
parents O 0 2.265661969147459e-08
of O 0 1.04209807449962e-09
patient O 0 7.227473588500288e-07
2 O 0 2.653874275893031e-08
were O 0 5.279400170365989e-07
heterozygous O 0 1.7041900719050318e-05
. O 0 1.0875202178795007e-06

The O 0 2.700726327020675e-07
common O 0 2.1091408086704178e-07
mutation O 0 1.7296638077368698e-07
at O 0 2.2086603657101023e-09
codon O 0 4.179701473816522e-09
95 O 0 3.6921826707114747e-10
in O 0 7.022010750645791e-10
exon O 0 2.631726147228619e-06
4 O 0 6.353284476290355e-08
might O 0 8.440058536507422e-07
be O 0 1.4058915098758007e-07
responsible O 0 5.198392827310272e-08
for O 0 3.0171714016091755e-09
most O 0 7.784949218603288e-08
Japanese O 0 0.004890657030045986
C9 B-Disease 1 0.9966903924942017
deficiency I-Disease 0 0.159915491938591
. O 0 3.425628136710657e-08
. O 0 2.0918292875649058e-07

BRCA1 O 0 0.002277340507134795
required O 0 2.3400916404625605e-07
for O 0 4.416143450924892e-09
transcription O 0 1.7065562474272156e-07
- O 0 3.4997512557310984e-05
coupled O 0 2.7396814402891323e-05
repair O 0 0.00011973002983722836
of O 0 1.6300223393272972e-08
oxidative O 0 0.06911405920982361
DNA O 0 0.16676202416419983
damage O 0 0.47343286871910095
. O 0 7.600435765198199e-06

The O 0 1.8549624655861408e-05
breast B-Disease 1 0.9995575547218323
and I-Disease 1 0.9871795773506165
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999995231628418
susceptibility O 1 0.998879611492157
gene O 0 0.00033732946030795574
BRCA1 O 0 0.00017832010053098202
encodes O 0 5.860969167770236e-07
a O 0 6.850016802673053e-07
zinc O 0 0.0764021947979927
finger O 0 1.210166828968795e-05
protein O 0 3.863883790700129e-08
of O 0 1.6257120094564925e-09
unknown O 0 1.730062535898469e-06
function O 0 2.751551733126689e-07
. O 0 1.5286008192560985e-07

Association O 0 2.7109192046737007e-07
of O 0 1.0854661613990402e-09
the O 0 3.071250365138667e-09
BRCA1 O 0 5.240771315584425e-06
protein O 0 1.374002156495635e-08
with O 0 6.092525928202974e-10
the O 0 1.5996622915182002e-09
DNA O 0 8.807985068415292e-06
repair O 0 0.00026862724917009473
protein O 0 1.6891801806195872e-06
Rad51 O 0 7.794533303240314e-06
and O 0 2.5159261340945704e-09
changes O 0 5.680245163119935e-10
in O 0 8.036809412415025e-11
the O 0 2.8501319360163535e-11
phosphorylation O 0 7.14980796789888e-10
and O 0 5.0331121492774855e-09
cellular O 0 2.065458630795547e-07
localization O 0 6.456188028636234e-09
of O 0 8.870585689602084e-12
the O 0 1.2577459906903954e-10
protein O 0 5.260670121742805e-09
after O 0 1.3677921018029338e-08
exposure O 0 3.41383656632388e-06
to O 0 3.105912638190489e-09
DNA O 0 1.4035878848517314e-05
- O 0 0.001808593631722033
damaging O 0 9.071663953363895e-06
agents O 0 4.11335832950499e-07
are O 0 1.8492526399072062e-09
consistent O 0 4.636802231061665e-08
with O 0 5.887669241033677e-10
a O 0 7.752613662148633e-09
role O 0 1.4824548699721163e-08
for O 0 5.928566526591794e-09
BRCA1 O 0 3.87732325179968e-06
in O 0 4.02198985227642e-08
DNA O 0 6.758515519322827e-05
repair O 0 0.006152262911200523
. O 0 3.0299493118945975e-06

Here O 0 1.3157524563212064e-06
, O 0 4.770392969533077e-09
it O 0 6.982397993127165e-10
is O 0 6.942704189327742e-10
shown O 0 1.2741614874300922e-08
that O 0 2.4788107122475367e-09
mouse O 0 6.494738045148551e-07
embryonic O 0 1.1087264510933892e-06
stem O 0 3.6908036236127373e-06
cells O 0 3.357745072207763e-06
deficient B-Disease 0 1.671311656537e-05
in I-Disease 0 2.6399199271054385e-08
BRCA1 I-Disease 0 8.942663043853827e-06
are O 0 1.4595270769746094e-08
defective O 0 3.278246140325791e-06
in O 0 8.367494253036512e-09
the O 0 3.3707290292284142e-09
ability O 0 9.017545821166095e-09
to O 0 1.0008770479075224e-09
carry O 0 2.982425684194823e-08
out O 0 2.3011466065980812e-09
transcription O 0 6.790539242018667e-09
- O 0 4.034662651974941e-06
coupled O 0 1.285080770685454e-06
repair O 0 4.803099272976397e-06
of O 0 1.7787989969875184e-09
oxidative O 0 0.005936649162322283
DNA O 0 0.06698353588581085
damage O 0 0.30836862325668335
, O 0 2.556815204002305e-08
and O 0 4.3541032113125766e-08
are O 0 1.4501092771013191e-08
hypersensitive O 0 0.006818469613790512
to O 0 2.169718982258928e-06
ionizing O 1 0.9998210072517395
radiation O 1 0.9999223947525024
and O 0 2.474587518008775e-06
hydrogen O 0 0.0004827486991416663
peroxide O 0 0.05287264660000801
. O 0 7.099039294189424e-07

These O 0 6.268138008636015e-08
results O 0 4.7845283290826046e-08
suggest O 0 7.959508252497471e-08
that O 0 2.2476017491612765e-08
BRCA1 O 0 8.054796126089059e-06
participates O 0 5.3627935869826615e-08
, O 0 1.9109953619533826e-09
directly O 0 3.4159044481896217e-09
or O 0 2.844054236561533e-08
indirectly O 0 1.1723329862434184e-07
, O 0 6.380481143430927e-10
in O 0 5.768001631878406e-10
transcription O 0 5.410906833702711e-09
- O 0 1.413215522916289e-05
coupled O 0 3.7736972444690764e-06
repair O 0 8.2724791354849e-06
of O 0 1.6499783761503295e-09
oxidative O 0 0.008115622214972973
DNA O 0 0.014827177859842777
damage O 0 0.05425183102488518
. O 0 1.836393010989923e-07
. O 0 2.8102829219278647e-07

Truncation O 0 0.00014768743130844086
mutations O 0 0.00034429540392011404
in O 0 8.453207556158304e-08
the O 0 1.4494346167737149e-08
transactivation O 0 1.3553426470025443e-05
region O 0 5.651644841009329e-08
of O 0 2.5562774119691767e-09
PAX6 O 0 0.0001423737412551418
result O 0 4.694543065397738e-07
in O 0 1.4949998572433287e-08
dominant O 0 1.8454272776580183e-06
- O 0 5.350454375729896e-05
negative O 0 5.982605216559023e-06
mutants O 0 1.3082403711450752e-05
. O 0 3.7194632795944926e-07

PAX6 O 0 0.0054229372180998325
is O 0 9.864720595942345e-08
a O 0 8.515359972705028e-09
transcription O 0 1.0967860397670393e-08
factor O 0 2.6107556116983233e-09
with O 0 2.0055489213799405e-10
two O 0 4.932362851484129e-10
DNA O 0 1.0098815437231679e-05
- O 0 0.0005931950872763991
binding O 0 1.923365289258072e-06
domains O 0 2.726951322529203e-07
( O 0 1.0656475701864565e-09
paired O 0 3.1885031148704e-07
box O 0 1.560378041176591e-05
and O 0 9.744977802483845e-08
homeobox O 0 2.714618574373162e-07
) O 0 7.816485236844528e-10
and O 0 1.045386888165467e-09
a O 0 1.057359497735888e-07
proline O 0 1.4494323295366485e-05
- O 0 5.886400231247535e-06
serine O 0 1.8314171938982327e-06
- O 0 4.2367442802060395e-05
threonine O 0 2.740322543104412e-06
( O 0 1.0149766360711965e-08
PST O 0 2.44209986703936e-05
) O 0 1.7174149880005984e-09
- O 0 1.234220121659746e-06
rich O 0 2.6232513050672424e-07
transactivation O 0 1.189389149658382e-05
domain O 0 1.5734145790702314e-06
. O 0 1.9976600640347897e-07

PAX6 O 0 0.01418623048812151
regulates O 0 9.253753523807973e-05
eye O 0 0.0002623516193125397
development O 0 5.80446020137515e-08
in O 0 3.726151476257655e-08
animals O 0 5.756994170269536e-08
ranging O 0 6.983549383221543e-08
from O 0 8.789236893846919e-09
jellyfish O 0 2.9482595209628926e-07
to O 0 1.0999152699753267e-09
Drosophila O 0 5.122816393310359e-09
to O 0 5.383338663733639e-09
humans O 0 1.859227438671951e-07
. O 0 1.5768019068218564e-07

Heterozygous O 0 0.0007431824924424291
mutations O 0 0.00035008060513064265
in O 0 6.067077151783451e-08
the O 0 1.215224454398367e-08
human O 0 4.875247938684879e-08
PAX6 O 0 3.9293765439651906e-05
gene O 0 3.536177075602609e-07
result O 0 5.4740752375437296e-08
in O 0 2.5399666814251987e-09
various O 0 2.355532657816184e-09
phenotypes O 0 3.36945267918054e-05
, O 0 1.0569396913240325e-08
including O 0 4.32859991406076e-07
aniridia B-Disease 1 0.9999996423721313
, O 0 0.0017567971954122186
Peters B-Disease 1 0.9999938011169434
anomaly I-Disease 1 0.9999977350234985
, O 0 4.71849853056483e-06
autosomal B-Disease 0 0.24760271608829498
dominant I-Disease 0 0.0012136503355577588
keratitis I-Disease 1 0.873078465461731
, O 0 6.227917310752673e-07
and O 0 4.1579751268727705e-06
familial B-Disease 1 0.9912683963775635
foveal I-Disease 1 0.9996421337127686
dysplasia I-Disease 1 0.9995693564414978
. O 0 5.002599209547043e-05

It O 0 3.7376480577222537e-07
is O 0 1.2404981042379859e-08
believed O 0 5.418448623117911e-08
that O 0 7.637135368554482e-10
the O 0 5.344601983203745e-10
mutated O 0 8.278693996999209e-08
allele O 0 1.4533712011655098e-08
of O 0 3.5166267120523287e-10
PAX6 O 0 9.169164513878059e-06
produces O 0 1.0564177088667748e-08
an O 0 1.4367094181011453e-09
inactive O 0 8.852720156937721e-08
protein O 0 6.371438843189026e-08
and O 0 4.204057404422201e-07
aniridia B-Disease 1 0.9999953508377075
is O 0 2.274600319651654e-06
caused O 0 2.5425767944398103e-06
due O 0 1.241004952134972e-07
to O 0 8.695214859244516e-08
genetic O 0 6.76575000397861e-05
haploinsufficiency O 0 0.006217906251549721
. O 0 1.5279930494216387e-06

However O 0 4.851048061027541e-07
, O 0 9.06534458611219e-10
several O 0 9.006517753817889e-11
truncation O 0 1.0870687106034893e-07
mutations O 0 1.8346809156355448e-06
have O 0 7.473088459164501e-08
been O 0 4.7794937785283764e-08
found O 0 3.2152023266007745e-08
to O 0 1.4032763395732673e-08
occur O 0 1.6458020724030575e-08
in O 0 9.175038506725741e-10
the O 0 1.4289788019539174e-08
C O 0 9.661961485107895e-06
- O 0 1.3208707969170064e-05
terminal O 0 1.1988676362761908e-07
half O 0 4.22658158472089e-10
of O 0 2.765533357873551e-10
PAX6 O 0 9.627065992390271e-06
in O 0 7.986850647512256e-08
patients O 0 6.551484688088749e-08
with O 0 7.97029429122631e-08
Aniridia B-Disease 1 0.9999887943267822
resulting O 0 1.216314217344916e-06
in O 0 6.830079612996087e-09
mutant O 0 5.729739527282618e-08
proteins O 0 7.164742688026138e-10
that O 0 3.912574153552839e-10
retain O 0 7.74897745969838e-09
the O 0 5.81060255466781e-10
DNA O 0 4.3162003748875577e-07
- O 0 2.2048184291634243e-06
binding O 0 6.053818424334168e-08
domains O 0 1.823673123624303e-08
but O 0 1.9620690849819766e-08
have O 0 3.050526586889646e-08
lost O 0 3.7231967553452705e-07
most O 0 1.70857300529903e-10
of O 0 1.2820708383820545e-10
the O 0 7.465762230651762e-09
transactivation O 0 1.12329453259008e-05
domain O 0 5.583377742368612e-07
. O 0 2.381769235171305e-07

It O 0 5.030840384279145e-07
is O 0 3.4191003805972287e-08
not O 0 1.6607734076856673e-09
clear O 0 3.0070599343900994e-09
whether O 0 2.068462956472672e-09
such O 0 1.9436230402902765e-09
mutants O 0 1.5448727026523557e-06
really O 0 1.7968611700780457e-06
behave O 0 3.231839684758597e-08
as O 0 9.142057666444714e-10
loss O 0 2.2965044976785975e-08
- O 0 1.6848734674113075e-07
of O 0 9.099923037325652e-10
- O 0 4.2250034312019125e-05
function O 0 5.8007746162047624e-08
mutants O 0 9.944537282535748e-08
as O 0 2.4247721608361417e-09
predicted O 0 8.087195624284504e-08
by O 0 1.196324905805568e-08
haploinsufficiency O 0 0.00022189589799381793
. O 0 7.184529522419325e-07

Contrary O 0 2.0783525087608723e-06
to O 0 4.222723948288376e-09
this O 0 9.120965649422885e-10
theory O 0 1.1298418201022287e-08
, O 0 1.583532749371841e-10
our O 0 4.439831557956353e-10
data O 0 5.524197987938351e-09
showed O 0 1.689623587708411e-07
that O 0 8.892515057645767e-10
these O 0 2.2185771275662347e-10
mutants O 0 8.75191563665112e-09
are O 0 3.2318303588851904e-10
dominant O 0 2.1596019195158078e-08
- O 0 1.0610248182274518e-06
negative O 0 3.846016838338073e-08
in O 0 3.83074283405449e-09
transient O 0 1.4194161224168056e-07
transfection O 0 7.092089163052151e-06
assays O 0 7.55232304072706e-06
when O 0 7.224469555922042e-08
they O 0 6.346245307042864e-09
are O 0 4.0677039514491753e-10
coexpressed O 0 3.4092354894710297e-07
with O 0 7.726367101668075e-09
wild O 0 2.6024874841823475e-06
- O 0 0.0008623903850093484
type O 0 0.00030039544799365103
PAX6 O 0 0.0005117864347994328
. O 0 1.045010435518634e-06

We O 0 4.1272684825344186e-07
found O 0 1.3294013889719736e-08
that O 0 7.582560135332983e-10
the O 0 8.116456395867999e-10
dominant O 0 1.631348141017952e-07
- O 0 8.59717601997545e-06
negative O 0 1.680584063024071e-07
effects O 0 7.399080459435936e-07
result O 0 1.9858182653820222e-08
from O 0 2.2217870598861822e-10
the O 0 2.3793234049662715e-10
enhanced O 0 4.85346340894921e-08
DNA O 0 2.5806713210840826e-07
binding O 0 9.55922772050144e-08
ability O 0 4.434256961616256e-09
of O 0 1.2036063812281839e-10
these O 0 6.27010843246012e-09
mutants O 0 2.313705635970109e-06
. O 0 1.231500021958709e-07

Kinetic O 0 2.6019339202321135e-05
studies O 0 6.896635795783368e-08
of O 0 9.839062897754047e-10
binding O 0 5.370172857510624e-07
and O 0 9.542031165210574e-08
dissociation O 0 0.00017057746299542487
revealed O 0 7.722900591033977e-06
that O 0 1.040973751642582e-09
various O 0 6.341024233469383e-11
truncation O 0 6.608613745129333e-08
mutants O 0 9.10930779696173e-08
have O 0 2.5737234565781364e-09
3 O 0 5.188838247960348e-10
- O 0 2.645225549713359e-07
5 O 0 2.0007473455763147e-09
- O 0 6.386270001712546e-07
fold O 0 3.2431032082058664e-08
higher O 0 7.475761676367654e-10
affinity O 0 6.833568710895577e-10
to O 0 4.967168690250823e-11
various O 0 4.451369481350831e-11
DNA O 0 9.812701051714612e-08
- O 0 3.3806080068643496e-07
binding O 0 5.09535569293007e-09
sites O 0 1.1259173593458627e-09
when O 0 2.554892963857469e-09
compared O 0 4.039901746466512e-09
with O 0 5.686250914571644e-10
the O 0 5.291968641074618e-09
wild O 0 7.952555165502417e-07
- O 0 0.0004823621129617095
type O 0 0.00023621214495506138
PAX6 O 0 0.0006405870663002133
. O 0 7.466618967555405e-07

These O 0 1.1119862364239452e-07
results O 0 4.058191649392029e-08
provide O 0 1.2056312614916465e-09
a O 0 2.4576261026254542e-09
new O 0 1.6451828788177636e-09
insight O 0 6.769860672051209e-09
into O 0 1.0705566294566538e-10
the O 0 2.761827710973108e-10
role O 0 1.411155858832558e-09
of O 0 2.9297175796472175e-10
mutant O 0 3.181318106726394e-06
PAX6 O 0 4.575670027406886e-05
in O 0 1.9994975275494653e-07
causing O 0 5.127539225213695e-06
aniridia B-Disease 1 0.9997597336769104
. O 0 3.2139703876055137e-07
. O 0 2.541568164815544e-07

Reversal O 0 0.00021405074221547693
of O 0 2.252448439321597e-06
severe O 1 0.9946653842926025
hypertrophic B-Disease 1 0.9999903440475464
cardiomyopathy I-Disease 1 0.9999998807907104
and O 0 2.5370120056322776e-05
excellent O 0 7.4756922003871296e-06
neuropsychologic O 0 4.475190507946536e-05
outcome O 0 1.690155500000401e-07
in O 0 1.28749029215669e-08
very B-Disease 0 6.636301463913696e-08
- I-Disease 0 0.00019551487639546394
long I-Disease 0 1.0463932994753122e-05
- I-Disease 0 0.00018352101324126124
chain I-Disease 0 2.998304807988461e-05
acyl I-Disease 0 8.713717761565931e-06
- I-Disease 0 1.3982214113639202e-05
coenzyme I-Disease 0 1.5506840327361715e-06
A I-Disease 0 4.669779627874959e-06
dehydrogenase I-Disease 0 0.0034558067563921213
deficiency I-Disease 0 0.3152492046356201
. O 0 1.240043616235198e-06

Very B-Disease 0 2.5630754407757195e-06
- I-Disease 0 2.2966041797189973e-05
long I-Disease 0 1.4726186918778694e-06
- I-Disease 0 4.024066583951935e-05
chain I-Disease 0 5.281714038574137e-06
acyl I-Disease 0 1.930995949805947e-06
- I-Disease 0 2.4174833015422337e-06
coenzyme I-Disease 0 1.534258728952409e-07
A I-Disease 0 5.043676054583557e-08
dehydrogenase I-Disease 0 5.600041959041846e-07
( I-Disease 0 3.706799489577861e-08
VLCAD I-Disease 0 0.062458522617816925
) I-Disease 0 1.5257054428730044e-06
deficiency I-Disease 0 0.015231968834996223
is O 0 3.3140004518372734e-08
a O 0 2.277111434523249e-06
disorder O 0 0.0003134559083264321
of O 0 2.827082568046535e-08
fatty O 0 8.285240619443357e-05
acid O 0 5.55594340312382e-07
beta O 0 3.263285863752685e-09
oxidation O 0 5.105563261054158e-08
that O 0 2.5471724285353048e-08
reportedly O 0 3.5965290408057626e-06
has O 0 4.4576552227226784e-08
high O 0 2.5464930786256446e-07
rates O 0 2.21151395862762e-07
of O 0 5.575803374568977e-09
morbidity O 0 0.17016717791557312
and O 0 6.8638278207799885e-06
mortality O 0 0.00023654794495087117
. O 0 5.029900194131187e-07

We O 0 1.9666141781726765e-07
describe O 0 1.976725982899552e-08
the O 0 2.1295029628554119e-10
outcome O 0 8.91380969036959e-10
of O 0 2.8148429767616e-11
a O 0 3.559866623703556e-09
5 O 0 2.6264237451556482e-09
- O 0 3.4740412502287654e-06
year O 0 7.656321088234108e-08
- O 0 0.0001647324243094772
old O 0 0.0012933574616909027
girl O 0 0.04496089369058609
with O 0 9.688489808468148e-05
VLCAD B-Disease 1 0.9999998807907104
deficiency I-Disease 1 0.9999992847442627
who O 0 1.138802986133669e-06
was O 0 6.072588121242006e-08
first O 0 2.145956301546903e-09
seen O 0 1.7560762444190914e-07
at O 0 1.5862904323427074e-09
5 O 0 1.0038346820451238e-09
months O 0 4.661353525392542e-09
of O 0 1.2942703575546943e-09
age O 0 6.136328465800034e-06
with O 0 3.0840292311040685e-05
severe O 1 0.9998842477798462
hypertrophic B-Disease 1 0.9999974966049194
cardiomyopathy I-Disease 1 1.0
, O 1 0.8775633573532104
hepatomegaly B-Disease 1 0.9999992847442627
, O 0 0.013549160212278366
encephalopathy B-Disease 1 0.9855120778083801
, O 0 6.529441520797263e-07
and O 0 3.056125478906324e-06
hypotonia B-Disease 0 0.023713702335953712
. O 0 6.25677648713463e-06

Biochemical O 0 0.021870162338018417
studies O 0 0.0006282678805291653
indicated O 1 0.9789292216300964
VLCAD B-Disease 1 0.9999994039535522
deficiency I-Disease 1 0.9999997615814209
caused O 0 0.00034120198688469827
by O 0 2.727879255814969e-08
a O 0 3.0158723802742315e-06
stable O 0 0.0002008957089856267
yet O 0 3.6781050312129082e-06
inactive O 0 6.118034434621222e-07
enzyme O 0 1.890259255787896e-07
. O 0 7.025379744618476e-08

Molecular O 0 0.00012285496632102877
genetic O 0 8.245958269981202e-06
analysis O 0 8.107536331181109e-08
of O 0 2.6692039689635294e-09
her O 0 5.217054876993643e-06
VLCAD O 0 0.04799415543675423
gene O 0 1.4988535212978604e-06
revealed O 0 5.958536348771304e-06
a O 0 1.7006391317408998e-07
T1372C O 0 5.704946943296818e-06
( O 0 5.631724420140927e-09
F458L O 0 4.146829724049894e-07
) O 0 1.6199331875910161e-09
missense O 0 7.023669695627177e-06
mutation O 0 5.28973896507523e-06
and O 0 4.025766031645617e-08
a O 0 4.007107236247975e-06
1668 O 0 0.10326972603797913
ACAG O 0 0.030707964673638344
1669 O 0 3.1697971280664206e-05
splice O 0 2.1082441890030168e-05
site O 0 1.895148125186097e-05
mutation O 0 5.456002691062167e-05
. O 0 1.0587807537376648e-06

After O 0 3.3362206863785104e-07
initial O 0 2.615662140215136e-07
treatment O 0 1.937794706918794e-07
with O 0 8.3953111129631e-09
intravenous O 0 1.578734918439295e-05
glucose O 0 0.0001360114401904866
and O 0 7.111731861186854e-07
carnitine O 0 8.069215255090967e-05
, O 0 2.2549948575090184e-09
the O 0 1.4412958604381743e-09
patient O 0 6.494390731859312e-07
has O 0 1.315929765155488e-08
thrived O 0 3.152635841274787e-08
on O 0 6.301520194540444e-09
a O 0 3.0470026501916436e-08
low O 0 1.0707925639508176e-06
- O 0 5.9325957408873364e-06
fat O 0 5.268294671623153e-07
diet O 0 3.409506232898707e-09
supplemented O 0 1.3599923409657322e-09
with O 0 5.961913740470948e-10
medium O 0 5.5792742870153234e-08
- O 0 4.308158167987131e-06
chain O 0 2.2694541712553473e-06
triglyceride O 0 2.835220584529452e-06
oil O 0 2.221332238150353e-07
and O 0 1.0967232455527665e-08
carnitine O 0 6.419735200324794e-06
and O 0 2.3986642005979775e-08
avoidance O 0 2.5620495307521196e-06
of O 0 1.1021670687227925e-08
fasting O 0 2.614904133224627e-06
. O 0 3.0220169833228283e-07

Her O 0 6.858396955067292e-05
ventricular O 0 0.0014236938441172242
hypertrophy O 0 0.0023622324224561453
resolved O 0 4.268024895281997e-06
significantly O 0 1.404058593834634e-07
over O 0 3.654665237107224e-09
1 O 0 8.973998433248198e-09
year O 0 3.821826410899121e-08
, O 0 3.105533608049882e-09
and O 0 4.5393232994683785e-07
cognitively O 0 0.002811683341860771
, O 0 7.53593631941385e-09
she O 0 8.136286169246887e-07
is O 0 1.4885458421431963e-09
in O 0 3.9123276840413723e-10
the O 0 1.006242311696326e-09
superior O 0 1.202892150331536e-07
range O 0 3.058158171143077e-08
for O 0 1.4737405962250705e-08
age O 0 7.496399803130771e-07
. O 0 1.223973811192991e-07

Clinical O 0 2.6807960239239037e-05
recognition O 0 5.543765837501269e-06
of O 0 2.0583300283760764e-05
VLCAD B-Disease 1 0.9999998807907104
deficiency I-Disease 1 0.9999998807907104
is O 0 5.231645445746835e-07
important O 0 1.0636275860065325e-08
because O 0 2.8901421700311403e-08
it O 0 2.0615937845747112e-09
is O 0 4.660702379588599e-10
one O 0 8.505693371851919e-11
of O 0 2.7063110433211968e-11
the O 0 1.2714272967784268e-09
few O 0 2.87750214766902e-08
directly O 0 1.5976322174537927e-05
treatable O 1 0.9900118708610535
causes O 0 6.762804332538508e-06
of O 0 1.4482734513876494e-06
cardiomyopathy B-Disease 1 0.9999991655349731
in O 0 8.581497240811586e-06
children O 0 2.9225013804534683e-06
. O 0 2.9548516522481805e-07
. O 0 7.48361401292641e-07

Cloning O 0 2.3362506453850074e-06
of O 0 5.982717432573281e-09
a O 0 2.0917569898415422e-08
novel O 0 1.6112011280711158e-08
member O 0 6.987753708997957e-10
of O 0 8.386612238009405e-11
the O 0 1.019089079790092e-08
low O 0 1.3579600818047766e-05
- O 0 0.00022987397096585482
density O 0 1.7150138091892586e-06
lipoprotein O 0 0.005028568673878908
receptor O 0 1.6069823686848395e-05
family O 0 2.2669298687105766e-06
. O 0 2.9689411462641146e-07

A O 0 4.0733218042987573e-07
gene O 0 8.511564431046281e-08
encoding O 0 5.918796119885883e-08
a O 0 1.521557813077834e-08
novel O 0 7.14105112820107e-08
transmembrane O 0 3.4654574847081676e-05
protein O 0 1.4651172364210652e-07
was O 0 1.433654546190155e-07
identified O 0 2.671329113468346e-08
by O 0 1.6871189167932954e-10
DNA O 0 1.7496461168775568e-08
sequence O 0 1.5401946384940857e-09
analysis O 0 7.094286269548888e-11
within O 0 5.456949475624029e-11
the O 0 7.597360074385051e-09
insulin B-Disease 0 0.025708135217428207
- I-Disease 1 0.9988213181495667
dependent I-Disease 1 0.9727569222450256
diabetes I-Disease 1 0.9999994039535522
mellitus I-Disease 1 0.9999979734420776
( O 0 1.8031510080618318e-06
IDDM B-Disease 0 0.004265468567609787
) O 0 4.25757251676373e-09
locus O 0 1.377312855765922e-06
IDDM4 O 0 0.00012253042950760573
on O 0 1.0013014843934798e-06
chromosome O 0 0.00017724739154800773
11q13 O 0 2.9595084924949333e-05
. O 0 3.943284241358924e-07

Based O 0 5.244293674877554e-07
on O 0 2.7116062284449072e-08
its O 0 6.464702551056689e-09
chromosomal O 0 0.00023746768420096487
position O 0 5.655360837408807e-06
, O 0 3.338303189437397e-09
this O 0 8.694410191800728e-10
gene O 0 9.429474090438816e-09
is O 0 7.172727967130754e-10
a O 0 5.486270548971106e-09
candidate O 0 2.0361399322155194e-07
for O 0 5.820565807113098e-09
conferring O 0 1.632132443774026e-05
susceptibility O 0 0.025192877277731895
to O 0 2.154206231352873e-05
diabetes B-Disease 1 0.5176048278808594
. O 0 1.0496587492525578e-05

The O 0 9.603233053212534e-08
gene O 0 2.2320858761304407e-07
, O 0 2.460890824451667e-09
termed O 0 1.6541945058179408e-07
low O 0 1.0727079597927514e-06
- O 0 5.892803073948016e-06
density O 0 1.907748270468801e-07
lipoprotein O 0 5.2208881243132055e-05
receptor O 0 4.7105669409575057e-07
related O 0 7.297649773363446e-08
protein O 0 1.5870698177877784e-07
5 O 0 1.829365636751845e-08
( O 0 3.67415120550163e-09
LRP5 O 0 4.0272610931424424e-05
) O 0 2.6927965413037214e-10
, O 0 3.3332350768411345e-11
encodes O 0 1.9065417300456744e-10
a O 0 1.6464823948680873e-09
protein O 0 1.5718818469068196e-09
of O 0 2.617175920427428e-10
1615 O 0 1.4551343156199437e-05
amino O 0 1.4404061943196211e-08
acids O 0 1.2405920735147902e-09
that O 0 2.575509527869002e-10
contains O 0 5.225366805916565e-10
conserved O 0 2.908047136429559e-08
modules O 0 1.5667379216210975e-07
which O 0 2.4308256740823708e-08
are O 0 2.095812412505893e-10
characteristic O 0 1.293760210074879e-08
of O 0 2.1070352407281945e-10
the O 0 2.613911220805676e-08
low O 0 4.019564585178159e-05
- O 0 0.001807152177207172
density O 0 1.0549906619417015e-05
lipoprotein O 0 0.49772998690605164
( O 0 2.1680611439478525e-07
LDL O 0 0.0007383788470178843
) O 0 5.181867823722541e-09
receptor O 0 3.6818141779804137e-07
family O 0 5.397395170803065e-07
. O 0 3.0529514560839743e-07

These O 0 1.1675553679424411e-07
modules O 0 1.9737315426482382e-07
include O 0 3.4111127256153395e-09
a O 0 9.83458292580508e-09
putative O 0 4.3904213953283033e-07
signal O 0 2.424783360766014e-07
peptide O 0 2.665420062442081e-08
for O 0 7.989566647159663e-11
protein O 0 6.670305419120837e-10
export O 0 9.547629353789944e-10
, O 0 1.3212400618023423e-10
four O 0 5.915822276492122e-10
epidermal O 0 3.4927243177662604e-06
growth O 0 8.050534461290226e-07
factor O 0 2.980236502025946e-08
( O 0 4.108987816664467e-09
EGF O 0 1.0280195965606254e-06
) O 0 3.739319409667985e-10
repeats O 0 2.0065035855054703e-08
with O 0 1.1622827145174597e-09
associated O 0 1.8390739597862193e-08
spacer O 0 8.93846845428925e-07
domains O 0 3.975557376634242e-07
, O 0 4.851878010470045e-09
three O 0 1.1495270513250944e-08
LDL O 0 0.0014960372354835272
- O 0 4.2315354221500456e-05
receptor O 0 1.8572723092802335e-06
( O 0 1.0923391080552847e-08
LDLR O 0 2.107530781358946e-05
) O 0 7.355061004687968e-10
repeats O 0 2.7949029757223798e-08
, O 0 1.5856060908703284e-10
a O 0 4.131195829870649e-09
single O 0 1.096491018870438e-06
transmembrane O 0 9.738482731336262e-06
spanning O 0 1.0323360299935302e-07
domain O 0 7.974338700478256e-08
, O 0 1.2915478686537085e-09
and O 0 3.020217187454932e-09
a O 0 5.563695637533783e-08
cytoplasmic O 0 1.93174378182448e-06
domain O 0 1.1587039807636756e-06
. O 0 3.643746708803519e-07

The O 0 5.190763729956416e-08
encoded O 0 8.243776505878486e-08
protein O 0 8.710585319704478e-08
has O 0 9.354791608018331e-09
a O 0 5.844785100350691e-09
unique O 0 2.7139915204088538e-08
organization O 0 1.4698630090848042e-09
of O 0 2.431287116078096e-10
EGF O 0 3.2170908070838777e-06
and O 0 6.222740722705566e-08
LDLR O 0 0.00025296310195699334
repeats O 0 1.9389090084587224e-06
; O 0 3.5968521494567085e-09
therefore O 0 3.93177224111696e-09
, O 0 1.0719098941791572e-09
LRP5 O 0 3.066337512791506e-06
likely O 0 1.1956702294924071e-08
represents O 0 6.407017694165518e-10
a O 0 3.479392773897416e-09
new O 0 2.395097009610936e-09
category O 0 1.2968855322981199e-08
of O 0 1.5182687052028854e-10
the O 0 3.356820954536488e-08
LDLR O 0 0.0021937526762485504
family O 0 4.5403928083942446e-07
. O 0 1.9353237235009146e-07

Both O 0 2.5496302669125726e-07
human O 0 7.149719039034608e-08
and O 0 8.761802838819222e-09
mouse O 0 2.2272004116530297e-06
LRP5 O 0 0.00017835172184277326
cDNAs O 0 4.810502559848828e-06
have O 0 5.571277483795711e-08
been O 0 4.3183245423961125e-08
isolated O 0 2.8060455292688857e-08
and O 0 2.556530764863396e-09
the O 0 4.960742927551109e-10
encoded O 0 2.0546153223222063e-08
mature O 0 5.4811040151037105e-09
proteins O 0 1.9622203861757725e-10
are O 0 5.198464228528543e-11
95 O 0 3.683228722017873e-10
% O 0 1.0448805154439356e-09
identical O 0 2.597721504571382e-06
, O 0 3.2985423281672865e-09
indicating O 0 2.7682364134307136e-07
a O 0 1.7134054530743015e-07
high O 0 5.482820597535465e-07
degree O 0 8.219958402833072e-08
of O 0 6.783635875251548e-10
evolutionary O 0 5.294445486470067e-07
conservation O 0 3.571681972402985e-08
. O 0 5.047859907847396e-09
. O 0 5.9590547607513145e-08

The O 0 2.4063174919319863e-07
APC B-Disease 0 1.369558958685957e-06
variants O 0 1.3380268626406178e-07
I1307K O 0 8.246542506640253e-07
and O 0 1.3246024721524918e-08
E1317Q O 0 6.445264943977236e-07
are O 0 7.546579361417116e-09
associated O 0 5.474870704347268e-06
with O 1 0.9968294501304626
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 0.0026344461366534233
but O 0 1.7979376707444317e-06
not O 0 5.937452840498736e-08
always O 0 5.4677933292168746e-08
with O 0 9.396847744369552e-10
a O 0 1.5842843481550517e-07
family O 0 1.1913402886420954e-06
history O 0 3.1240179509950394e-07
. O 0 2.410157264876034e-07

Classical O 1 0.7289026975631714
familial B-Disease 1 0.999987006187439
adenomatous I-Disease 1 0.9999121427536011
polyposis I-Disease 1 0.9999940395355225
( O 0 0.00013743613089900464
FAP B-Disease 0 0.0007539140642620623
) O 0 2.143441690805048e-08
is O 0 7.819918934615089e-09
a O 0 1.1617984796430392e-07
high O 0 9.851805953076109e-05
- O 1 0.9879823923110962
penetrance O 1 0.9602225422859192
autosomal B-Disease 1 0.9949377775192261
dominant I-Disease 1 0.8847704529762268
disease I-Disease 0 0.03956509754061699
that O 0 6.494291682201947e-08
predisposes O 0 3.1728313842904754e-06
to O 0 3.5777283358129353e-09
hundreds O 0 2.9655826683239184e-09
or O 0 3.9505216875568294e-08
thousands O 0 1.68080926954417e-08
of O 0 3.5732566175283864e-05
colorectal B-Disease 1 1.0
adenomas I-Disease 1 0.9999997615814209
and I-Disease 1 0.9983426332473755
carcinoma I-Disease 1 1.0
and O 0 1.3996408597449772e-05
that O 0 2.1546898665292247e-07
results O 0 4.451427315643741e-08
from O 0 2.5884432375278266e-09
truncating O 0 2.1456316972034983e-06
mutations O 0 7.556945433861983e-07
in O 0 4.755611904272428e-09
the O 0 2.0807028988656384e-08
APC B-Disease 0 2.8116926387156127e-06
gene O 0 6.619816304009873e-07
. O 0 3.903603840171854e-07

A O 0 3.6044953048985917e-06
variant O 0 1.749588227539789e-05
of O 0 5.820235671194496e-08
FAP B-Disease 0 0.0032498594373464584
is O 0 2.8874350391561165e-05
attenuated B-Disease 1 0.9953936338424683
adenomatous I-Disease 1 0.9999885559082031
polyposis I-Disease 1 0.9998369216918945
coli I-Disease 1 0.9998968839645386
, O 0 2.4174914869945496e-07
which O 0 1.9186110478131013e-08
results O 0 1.5934539021600358e-08
from O 0 3.637016243729363e-09
germ O 0 0.013235707767307758
- O 0 0.0005288961692713201
line O 0 6.9774109761056025e-06
mutations O 0 6.066417768124666e-08
in O 0 3.4384611824478384e-10
the O 0 3.5069278037092033e-10
5 O 0 1.1737806282496877e-09
and O 0 4.778379025793811e-09
3 O 0 1.7239591976192514e-09
regions O 0 4.701693478992297e-10
of O 0 4.40560837811077e-10
the O 0 7.548397462642242e-08
APC B-Disease 0 6.588792984985048e-06
gene O 0 5.747108957621094e-07
. O 0 2.676322594652447e-07

Attenuated B-Disease 1 0.9987848401069641
adenomatous I-Disease 1 0.9999454021453857
polyposis I-Disease 1 0.9999308586120605
coli I-Disease 1 0.9999791383743286
patients O 0 0.07833432406187057
have O 0 4.240986527292989e-06
" O 0 5.065957111582975e-07
multiple O 0 5.830416193930432e-05
" O 1 0.8432285785675049
colorectal B-Disease 1 1.0
adenomas I-Disease 1 0.999996542930603
( O 0 2.407823274097609e-07
typically O 0 7.395511403274213e-08
fewer O 0 1.8415968749962985e-09
than O 0 1.4891649025017273e-09
100 O 0 1.6153112181171991e-09
) O 0 2.670658971748452e-10
without O 0 1.0471770117703727e-09
the O 0 2.3053070563605615e-09
florid O 0 0.00010625931463437155
phenotype O 0 5.222390882408945e-06
of O 0 8.95124507849232e-09
classical O 0 9.368653991259634e-06
FAP B-Disease 0 0.00011502382403705269
. O 0 7.636419923073845e-07

Another O 0 7.36176900772989e-07
group O 0 1.1492491580611386e-07
of O 0 4.214010029812698e-09
patients O 0 1.2712490615740535e-07
with O 0 2.261983134133061e-08
multiple O 0 3.089551682933234e-05
adenomas B-Disease 0 0.2511869966983795
has O 0 6.714849405398127e-06
no O 0 4.377702964575292e-07
mutations O 0 1.3716095281779417e-07
in O 0 8.894703307227303e-10
the O 0 2.1743313816102727e-09
APC B-Disease 0 3.9616523395125114e-07
gene O 0 3.1387457966047805e-08
, O 0 1.1738007232864334e-09
and O 0 2.061955717280739e-09
their O 0 1.3843111545952524e-08
phenotype O 0 1.3031190064793918e-05
probably O 0 2.563974987879192e-07
results O 0 5.000997393977968e-09
from O 0 2.337062487978159e-10
variation O 0 4.651754537121633e-08
at O 0 2.6323327517729922e-08
a O 0 1.6736473185119394e-07
locus O 0 2.0285149730625562e-05
, O 0 2.423589862132758e-08
or O 0 1.1755759032894275e-08
loci O 0 1.4426717598325922e-08
, O 0 3.112887059231184e-09
elsewhere O 0 7.202370699843641e-09
in O 0 2.128504927867425e-09
the O 0 9.74205693893282e-09
genome O 0 6.706125645905558e-07
. O 0 2.1076890277527127e-07

Recently O 0 3.327842932776548e-05
, O 0 1.0158462515619249e-08
however O 0 4.8739998703695164e-09
, O 0 3.0752056456861965e-10
a O 0 1.3588106639872422e-08
missense O 0 2.289401163579896e-05
variant O 0 5.55786846234696e-06
of O 0 8.013780750104615e-09
APC B-Disease 0 4.554427960101748e-06
( O 0 3.5389271513253107e-09
I1307K O 0 3.971676960645709e-07
) O 0 1.1717293801893902e-09
was O 0 8.508870052992279e-08
described O 0 3.27969274849238e-07
that O 0 6.794400153609104e-09
confers O 0 8.587571187490539e-08
an O 0 1.3943403098792828e-09
increased O 0 1.5182811239355942e-06
risk O 0 7.194795762188733e-05
of O 0 0.357808381319046
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 2.6534433345659636e-05
including O 0 1.0552560780752174e-07
multiple O 0 3.463699613348581e-05
adenomas B-Disease 0 0.03645933419466019
, O 0 1.3844068291746225e-07
in O 0 2.2247496644922649e-07
Ashkenazim O 0 6.818070687586442e-05
. O 0 7.418000791403756e-07

We O 0 3.733248377102427e-07
have O 0 7.658596423709696e-09
studied O 0 2.377387620100535e-09
a O 0 5.57063450923323e-10
set O 0 4.5058734521319366e-09
of O 0 3.134369708224227e-10
164 O 0 4.3183575826333254e-07
patients O 0 2.2353474093961267e-07
with O 0 2.636569661262911e-06
multiple O 1 0.9999479055404663
colorectal B-Disease 1 1.0
adenomas I-Disease 1 0.9999995231628418
and I-Disease 0 0.2888568639755249
/ I-Disease 0 0.20288489758968353
or I-Disease 0 0.04336124658584595
carcinoma I-Disease 1 0.9999998807907104
and O 0 6.091083832870936e-06
analyzed O 0 1.5456445908057503e-05
codons O 0 7.066947205203178e-07
1263 O 0 1.2369795513222925e-05
- O 0 2.8240159736014903e-05
1377 O 0 3.7332742067519575e-05
( O 0 7.934676027332443e-09
exon O 0 1.155268137154053e-06
15G O 0 4.248400671258423e-07
) O 0 7.245504196617958e-11
of O 0 2.07561034332171e-11
the O 0 1.1828625856580288e-09
APC B-Disease 0 7.367662391288832e-08
gene O 0 8.284661845436858e-09
for O 0 3.1661988586506595e-09
germ O 0 0.007318866439163685
- O 0 0.00044439747580327094
line O 0 9.815369594434742e-06
variants O 0 1.1157375183756812e-06
. O 0 3.6940534187124285e-07

Three O 0 3.089315612214705e-07
patients O 0 9.727150285243624e-08
with O 0 1.5053628343864034e-09
the O 0 3.3115663544691643e-09
I1307K O 0 1.4889916428728611e-06
allele O 0 5.620341312351229e-07
were O 0 3.744261789506709e-08
detected O 0 3.7360762235039147e-06
, O 0 2.1089369139914993e-10
each O 0 1.8796669776222075e-10
of O 0 2.4962421019125713e-09
Ashkenazi O 0 1.1804034329543356e-05
descent O 0 3.1110459531191736e-05
. O 0 1.1123486274300376e-06

Four O 0 1.125909193433472e-06
patients O 0 6.683810624963371e-07
had O 0 6.650531503282764e-08
a O 0 1.3585818692263274e-07
germ O 0 0.053982172161340714
- O 0 0.0003468955692369491
line O 0 4.64161666968721e-06
E1317Q O 0 3.8351683429027617e-07
missense O 0 9.578899380358052e-07
variant O 0 1.1172672742532086e-07
of O 0 4.029818145845354e-10
APC O 0 1.3054705050308257e-07
that O 0 3.013865423895368e-08
was O 0 6.371232075252919e-07
not O 0 1.0837434061272688e-08
present O 0 2.779983132583652e-09
in O 0 9.315511917407093e-09
controls O 0 2.319486327451159e-07
; O 0 2.3193762466178214e-09
one O 0 5.027123162193448e-10
of O 0 9.533249190063486e-11
these O 0 2.1328780963614236e-09
individuals O 0 1.7794845597052245e-09
had O 0 1.958711806082647e-07
an O 0 1.155710749323191e-09
unusually O 0 2.2396727672457928e-07
large O 0 3.0037579090702593e-09
number O 0 8.467173628901037e-10
of O 0 3.50131368342943e-10
metaplastic B-Disease 0 2.2396978238248266e-05
polyps I-Disease 0 1.5102058341653901e-06
of I-Disease 0 1.3230893047833092e-09
the I-Disease 0 8.120134253886135e-08
colorectum I-Disease 0 0.00033248504041694105
. O 0 6.980153557378799e-07

There O 0 4.99442307955178e-07
is O 0 3.881809540473569e-09
increasing O 0 1.257295711987183e-09
evidence O 0 1.9953633412228555e-08
that O 0 2.6047386469940648e-08
there O 0 1.0125866367616254e-08
exist O 0 5.140064729403093e-08
germ O 0 0.00014648630167357624
- O 0 3.9537517295684665e-06
line O 0 1.2445985930753523e-07
variants O 0 1.6647535572289485e-09
of O 0 5.5296527773363024e-11
the O 0 1.3258100173274556e-09
APC B-Disease 0 3.3719782521757224e-08
gene O 0 3.519245339589361e-09
that O 0 9.309326642892302e-10
predispose O 0 6.136777752629996e-09
to O 0 7.305440696825372e-10
the O 0 1.44257472634024e-09
development O 0 1.8008313729112047e-09
of O 0 3.539631165949686e-08
multiple O 1 0.9995625615119934
colorectal B-Disease 1 1.0
adenomas I-Disease 1 0.9999998807907104
and I-Disease 1 0.9996826648712158
carcinoma I-Disease 1 1.0
, O 0 4.529081252258038e-06
but O 0 7.772635512992565e-08
without O 0 6.906347493895737e-09
the O 0 4.212282522786381e-09
florid O 0 0.00020090528414584696
phenotype O 0 3.8950979615037795e-06
of O 0 9.042635529254994e-10
classical O 0 1.0016968872150755e-06
FAP B-Disease 0 4.728886324301129e-06
, O 0 1.7748779113091473e-09
and O 0 2.386797204323443e-09
possibly O 0 6.267406593707392e-09
with O 0 1.5439859391008781e-09
importance O 0 2.4052765184023883e-06
for O 1 0.6402363181114197
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
risk O 0 0.00905216671526432
in O 0 9.436149639441282e-09
the O 0 1.1816133627107206e-09
general O 0 2.7563191729029768e-09
population O 0 2.558267375718515e-09
. O 0 8.162943210265894e-09
. O 0 1.0346818157813686e-07

Genomic O 0 4.102085586055182e-05
structure O 0 2.9639018066518474e-06
of O 0 9.427784775084547e-09
the O 0 4.447362584869552e-07
human O 0 0.0016026345547288656
congenital B-Disease 1 0.9999984502792358
chloride I-Disease 1 0.9999967813491821
diarrhea I-Disease 1 0.9999997615814209
( O 0 0.00021538844157475978
CLD B-Disease 1 0.5956414341926575
) O 0 1.4872304632262967e-07
gene O 0 1.8757204998109955e-06
. O 0 6.031689849805844e-07

Congenital B-Disease 1 0.9999934434890747
chloride I-Disease 1 0.9999510049819946
diarrhea I-Disease 1 0.9999992847442627
( O 0 0.00012695850455202162
CLD B-Disease 1 0.822317361831665
) O 0 1.663872666313182e-07
is O 0 9.52232213080606e-08
caused O 0 2.911161232077575e-07
by O 0 3.091959044354553e-08
mutations O 0 1.2147388588346075e-05
in O 0 9.186039484632147e-09
a O 0 6.230460058986864e-08
gene O 0 7.643816957170202e-08
which O 0 8.948121354990235e-09
encodes O 0 4.5803609793892974e-08
an O 0 3.680385134430253e-07
intestinal O 1 0.9996349811553955
anion O 1 0.9048818945884705
transporter O 0 0.3507533073425293
. O 0 2.214182359239203e-06

We O 0 7.197031095529383e-07
report O 0 2.174552271583252e-08
here O 0 7.307671134881843e-10
the O 0 1.2119225067941386e-10
complete O 0 1.8268297985457593e-09
genomic O 0 2.0985305937415433e-08
organization O 0 4.4300951795861465e-10
of O 0 4.000316744523502e-11
the O 0 4.656359742227778e-09
human O 0 4.462674496608088e-08
CLD B-Disease 0 2.475923793099355e-05
gene O 0 2.2179785119647022e-08
which O 0 4.547402010501855e-09
spans O 0 1.2362582069158634e-08
approximately O 0 8.200954915160708e-10
39kb O 0 1.9013979226656375e-06
, O 0 1.5897010374743559e-09
and O 0 2.737771120919774e-09
comprises O 0 3.992591590673555e-09
21 O 0 2.209537974806608e-08
exons O 0 1.454632524655608e-06
. O 0 5.655634822687716e-07

All O 0 3.187116703884385e-07
exon O 0 2.3794316803105175e-05
/ O 0 3.7859024359931936e-06
intron O 0 7.239446404128103e-06
boundaries O 0 6.111012851306441e-08
conform O 0 2.894095416650089e-07
to O 0 2.686354694247939e-09
the O 0 1.4702394857124546e-08
GT O 0 1.7644626495894045e-05
/ O 0 3.23503372783307e-05
AG O 0 0.15534627437591553
rule O 0 7.465650355698017e-07
. O 0 4.089646949978487e-07

An O 0 1.802093230196533e-08
analysis O 0 6.271986485728576e-09
of O 0 2.1029761265722868e-10
the O 0 3.4286919969872542e-09
putative O 0 9.54923416429665e-06
promoter O 0 4.5514298108173534e-05
region O 0 2.1004845862648835e-08
sequence O 0 9.154206281891675e-09
shows O 0 1.202251720400227e-08
a O 0 1.9685201024799426e-08
putative O 0 8.835554581310134e-06
TATA O 0 0.00012696164776571095
box O 0 1.828103995649144e-05
and O 0 9.251647270502872e-08
predicts O 0 7.422190719807986e-07
multiple O 0 3.6591309537925554e-08
transcription O 0 2.895444417561066e-08
factor O 0 1.2272624694276146e-08
binding O 0 1.1625465390352474e-07
sites O 0 3.7947697251183854e-07
. O 0 2.998722266056575e-07

The O 0 1.3580753943642776e-07
genomic O 0 1.5366308616648894e-06
structure O 0 1.8553180325397989e-06
was O 0 1.2174673713616357e-07
determined O 0 3.53134339547978e-08
using O 0 2.9334485951437728e-09
DNA O 0 9.927916266860848e-08
from O 0 6.445430855706036e-10
several O 0 2.4241419982473644e-10
sources O 0 1.7562621357214425e-09
including O 0 1.2395720561109158e-10
multiple O 0 8.984274657564129e-09
large O 0 1.0505808489824631e-07
- O 0 0.0001058573107002303
insert O 0 3.864234258799115e-06
libaries O 0 2.109847855535918e-06
and O 0 9.56645984651061e-10
genomic O 0 1.9629224468076245e-08
DNA O 0 4.0576426840743807e-07
from O 0 2.1092850133186403e-08
Finnish O 0 0.2113574892282486
CLD B-Disease 1 0.6864784955978394
patients O 0 2.7727940050681354e-06
and O 0 1.0926186888582379e-07
controls O 0 1.016354053717805e-05
. O 0 1.0369474239269039e-06

Exon O 0 0.00012517627328634262
- O 0 6.216279416548787e-06
specific O 0 3.18050297209993e-08
primers O 0 7.597182502649957e-06
developed O 0 5.364434514376626e-07
in O 0 7.84200970826987e-09
this O 0 2.4209965143739964e-09
study O 0 2.2518014120009866e-09
will O 0 1.2009286898262417e-09
facilitate O 0 1.6819373671594917e-09
mutation O 0 1.0257901550403403e-07
screening O 0 4.1329787592303546e-08
studies O 0 3.3395131104896336e-09
of O 0 6.734659496743234e-10
patients O 0 4.267420194992155e-08
with O 0 5.4640821645079996e-08
the O 0 1.7705051504890434e-05
disease O 0 0.008400822058320045
. O 0 2.6645566322258674e-06

Genomic O 0 7.898755939095281e-06
sequencing O 0 1.2975320942132385e-06
of O 0 1.6956697379555408e-08
a O 0 6.866970352348289e-07
BAC O 0 0.00010585306881694123
clone O 0 0.00037859531585127115
H O 1 0.999996542930603
_ O 0 2.1431436891816702e-07
RG364P16 O 0 1.4571287465514615e-07
revealed O 0 9.501530939814984e-08
the O 0 2.493224238175884e-10
presence O 0 1.3890739669619734e-09
of O 0 8.647139948525506e-11
another O 0 7.554557868161282e-09
, O 0 1.7201687851908787e-09
highly O 0 2.2161676938026176e-09
homologous O 0 1.0110408510399793e-08
gene O 0 9.925318344983225e-09
3 O 0 2.876412719121646e-10
of O 0 8.15807837950544e-11
the O 0 5.422263527066207e-08
CLD B-Disease 0 0.0015272974269464612
gene O 0 2.530626375119027e-07
, O 0 6.108478167732301e-10
with O 0 2.209889771176421e-10
a O 0 3.3899894447131373e-08
similar O 0 6.23605984628739e-08
genomic O 0 6.101835765548458e-07
structure O 0 7.81830294727115e-06
, O 0 9.072112838737212e-09
recently O 0 2.3678634875068383e-07
identified O 0 3.3344298344673007e-07
as O 0 5.452005780171021e-08
the O 0 8.82856547832489e-05
Pendred B-Disease 1 0.9999998807907104
syndrome I-Disease 1 0.9999998807907104
gene O 0 3.8582980778301135e-05
( O 0 1.1522912757300219e-07
PDS B-Disease 0 8.729364344617352e-05
) O 0 9.099701436809937e-09
. O 0 1.4755266342092455e-08
. O 0 2.724666501308093e-07

The O 0 5.137124503562518e-07
APCI1307K O 0 0.0007673377403989434
allele O 0 0.00013126390695106238
and O 0 3.781179430006887e-06
cancer B-Disease 0 0.006146000698208809
risk O 0 4.985779924027156e-06
in O 0 1.310494557316133e-08
a O 0 1.3996414338635077e-07
community O 0 1.0756440183001814e-08
- O 0 2.146733459085226e-05
based O 0 2.0615713580696138e-08
study O 0 2.1289923157752355e-09
of O 0 2.0550297019639174e-09
Ashkenazi O 0 4.491568688536063e-06
Jews O 0 1.0245050816592993e-06
. O 0 5.030226475355448e-07

Mutations O 0 0.0011147859040647745
in O 0 5.242473548605631e-07
APC O 0 1.5280691513908096e-05
are O 0 1.69226822777091e-07
classically O 1 0.6763579845428467
associated O 0 6.208044214872643e-05
with O 0 0.002659608144313097
familial B-Disease 1 0.9999998807907104
adenomatous I-Disease 1 0.9999984502792358
polyposis I-Disease 1 0.9999995231628418
( O 0 3.853180169244297e-05
FAP B-Disease 0 7.694817031733692e-05
) O 0 9.31057364539356e-09
, O 0 1.270009430953678e-09
a O 0 5.092744572721131e-07
highly O 0 0.042397499084472656
penetrant O 1 0.9999792575836182
autosomal B-Disease 1 0.9999998807907104
dominant I-Disease 1 0.9999933242797852
disorder I-Disease 1 0.9999996423721313
characterized O 0 0.008046829141676426
by O 0 4.147259005549131e-06
multiple O 0 0.31644463539123535
intestinal O 1 0.9999657869338989
polyps B-Disease 0 0.1800045520067215
and O 0 9.584126701156492e-07
, O 0 3.890853417232165e-09
without O 0 7.042361804820985e-09
surgical O 0 8.198121577152051e-07
intervention O 0 3.080562649415697e-08
, O 0 4.476420900623168e-10
the O 0 7.831348347586697e-10
development O 0 2.074303395716015e-08
of O 0 0.0038820363115519285
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 4.581180473905988e-05
CRC B-Disease 0 0.006173642352223396
) O 0 5.5650751562552614e-08
. O 0 2.9270097456901567e-07

APC B-Disease 0 0.0001038081682054326
is O 0 4.4312957925285446e-07
a O 0 1.4554775589203928e-06
tumour O 1 0.999983549118042
- O 0 0.007636910304427147
suppressor O 0 0.00012106636131647974
gene O 0 2.651719626101112e-07
, O 0 1.105741831430862e-09
and O 0 2.496942430596505e-09
somatic O 0 2.802531753332005e-06
loss O 0 0.00011509546311572194
occurs O 0 1.1388681286916835e-06
in O 0 2.357883658987703e-06
tumours B-Disease 1 0.9999874830245972
. O 0 5.513032010640018e-05

The O 0 1.936252260748006e-07
germline O 0 2.8278025638428517e-05
T O 0 5.564360253629275e-05
- O 0 2.4924290755734546e-06
to O 0 5.883574516474255e-09
- O 0 9.051994311448652e-06
A O 0 4.6241899553933763e-07
transversion O 0 1.25203450807021e-05
responsible O 0 1.395019388894525e-08
for O 0 1.2905400359475294e-10
the O 0 7.585742589633071e-10
APC O 0 3.5401981790528225e-08
I1307K O 0 1.2080557887372834e-08
allele O 0 4.741645742711853e-09
converts O 0 5.542675207692582e-10
the O 0 1.0896287344630551e-10
wild O 0 5.529015467686804e-09
- O 0 2.852992508906027e-07
type O 0 1.4258782243814494e-07
sequence O 0 3.0661815308974383e-09
to O 0 9.14190056988673e-10
a O 0 7.406450777125428e-07
homopolymer O 0 0.03852933272719383
tract O 0 0.010960032232105732
( O 0 5.78101513326601e-08
A8 O 0 0.00010222612036159262
) O 0 6.587543843750154e-09
that O 0 2.811343691178081e-08
is O 0 5.391140689425811e-08
genetically O 0 2.2854410985928553e-07
unstable O 0 9.315737406723201e-05
and O 0 3.3585554319870425e-06
prone O 0 0.00023656644043512642
to O 0 4.782448215223667e-08
somatic O 0 5.58242027182132e-05
mutation O 0 8.269824320450425e-05
. O 0 1.7866207144834334e-06

The O 0 2.0084645768747578e-07
I1307K O 0 3.4400638924125815e-06
allele O 0 3.01029785987339e-06
was O 0 1.4820709282048483e-07
found O 0 4.3587146336676597e-08
in O 0 1.6125078161621786e-08
6 O 0 5.090647050565167e-07
. O 0 3.9857312117419497e-07

1 O 0 3.276853988154471e-07
% O 0 1.6409559933094897e-08
of O 0 3.59412277717297e-09
unselected O 0 0.00019168903236277401
Ashkenazi O 0 3.162785651511513e-05
Jews O 0 4.304862386561581e-07
and O 0 2.6328851987500457e-08
higher O 0 5.4583008335384875e-08
proportions O 0 2.628686104344524e-07
of O 0 5.591818674766103e-10
Ashkenazim O 0 7.261797918545199e-07
with O 0 1.3315583302642153e-08
family O 0 9.905936337872845e-08
or O 0 4.289134380996984e-08
personal O 0 4.158197043580003e-06
histories O 0 5.720009994547581e-07
of O 0 1.6589030593650023e-08
CRC B-Disease 0 0.0004003640788141638
( O 0 1.2573705632235033e-08
ref O 0 3.3015683584380895e-05
. O 0 1.183950493199859e-09
2 O 0 3.3773448482321555e-09
) O 0 4.197869607480698e-09
. O 0 1.128743747358385e-07

To O 0 1.9552031460534636e-07
evaluate O 0 1.5802554287347448e-07
the O 0 1.6611567676960703e-09
role O 0 2.615021754692748e-09
of O 0 2.8697164089486193e-10
I1307K O 0 5.204404942560359e-07
in O 0 2.4810972831801337e-07
cancer B-Disease 0 2.601313462946564e-05
, O 0 4.355737104333457e-09
we O 0 8.942559581726073e-09
genotyped O 0 1.1321262718411162e-06
5 O 0 1.8852905903088413e-09
, O 0 8.82329542761795e-10
081 O 0 2.879973806102498e-07
Ashkenazi O 0 1.6029808591611072e-07
volunteers O 0 6.658944506909847e-09
in O 0 1.8322071637655313e-09
a O 0 2.328668280426882e-08
community O 0 7.261532264379866e-09
survey O 0 1.1583107379919966e-06
. O 0 2.0959149082955264e-07

Risk O 0 6.854996172478423e-05
of O 0 3.674587389923545e-08
developing O 0 2.190150371461641e-05
colorectal B-Disease 1 0.9999990463256836
, I-Disease 0 2.111445428454317e-05
breast I-Disease 0 0.43148311972618103
and I-Disease 0 1.4987191434556735e-06
other I-Disease 0 2.384960566814698e-07
cancers I-Disease 0 0.2619992196559906
were O 0 1.3636602034239331e-06
compared O 0 2.7112007501273183e-06
between O 0 2.5669201875189174e-08
genotyped O 0 5.6562079407740384e-05
I1307K O 0 7.744162644485186e-07
carriers O 0 1.090785950452755e-08
and O 0 7.493219933429884e-10
non O 0 2.6261182117792714e-09
- O 0 1.3064621953162714e-06
carriers O 0 2.6116833140577e-08
and O 0 1.1210423700447336e-09
their O 0 4.0247791210923367e-10
first O 0 9.852682225641729e-09
- O 0 2.3102124032448046e-05
degree O 0 1.1790045846282737e-06
relatives O 0 1.603804889782623e-06
. O 0 2.8754402592312545e-07

Sperm O 0 3.0972863896749914e-05
DNA O 0 6.999738161539426e-06
analysis O 0 4.4807308086092235e-07
in O 0 4.490030036663484e-08
a O 0 2.7505784601089545e-06
Friedreich B-Disease 1 0.643111526966095
ataxia I-Disease 1 0.991374671459198
premutation O 0 0.4687909185886383
carrier O 0 0.00019950185378547758
suggests O 0 8.356525427188899e-08
both O 0 1.4809731219145306e-09
meiotic O 0 1.7485588159615872e-06
and O 0 1.217978873313541e-08
mitotic O 0 8.989966318040388e-07
expansion O 0 1.2687856099091732e-07
in O 0 3.8917140621208546e-09
the O 0 1.2446242259045448e-08
FRDA B-Disease 0 0.00015683482342865318
gene O 0 1.1346434121151106e-06
. O 0 3.399845809326507e-07

Friedreich B-Disease 1 0.9894559979438782
ataxia I-Disease 1 0.9985789060592651
is O 0 6.532936822623014e-05
usually O 0 3.027173761438462e-06
caused O 0 8.477829283037863e-07
by O 0 2.355150741095713e-09
an O 0 3.985189067634565e-09
expansion O 0 7.36186080985135e-08
of O 0 1.2672436433547318e-09
a O 0 1.112662516788987e-06
GAA O 0 5.9946316468995064e-05
trinucleotide O 0 4.050091320095817e-06
repeat O 0 1.8037856364117033e-07
in O 0 1.5160760424848263e-09
intron O 0 5.224405867920723e-07
1 O 0 1.2078639199941676e-09
of O 0 1.599682886155307e-10
the O 0 1.8380289290576002e-08
FRDA B-Disease 0 0.00037156889447942376
gene O 0 8.296032660837227e-07
. O 0 2.0170833181509806e-07

Occasionally O 0 8.8915039668791e-06
, O 0 5.097571698087222e-09
a O 0 7.077034513969238e-09
fully O 0 5.662920798954474e-08
expanded O 0 2.2020868684080597e-08
allele O 0 5.761046963925764e-07
has O 0 1.6330689689425526e-08
been O 0 2.1484760637235922e-08
found O 0 2.9351962638202167e-08
to O 0 4.918546014920366e-09
arise O 0 2.3567158891069084e-08
from O 0 1.4543846682535388e-10
a O 0 6.1065832390738706e-09
premutation O 0 5.878563342776033e-07
of O 0 3.14208520313386e-10
100 O 0 1.4156363858930376e-09
or O 0 1.5268371456045315e-08
less O 0 4.881203352624652e-08
triplet O 0 0.001856894581578672
repeats O 0 1.941640402947087e-05
. O 0 2.157844249950358e-07

We O 0 1.3599706107925158e-06
have O 0 8.597744738381152e-09
examined O 0 2.3504847845856602e-08
the O 0 3.056767339248978e-10
sperm O 0 5.718581519431609e-08
DNA O 0 3.484734278913493e-08
of O 0 3.703220230466542e-10
a O 0 1.4544409054906282e-07
premutation O 0 0.000444225559476763
carrier O 0 8.76469784998335e-05
. O 0 3.2955196616057947e-07

This O 0 4.876159565014859e-08
mans O 0 4.216319950955949e-07
leucocyte O 0 5.2166165005473886e-06
DNA O 0 2.8753929655067623e-06
showed O 0 3.1971158023225144e-06
one O 0 5.241870049133013e-09
normal O 0 6.274068375944353e-09
allele O 0 1.565348384247045e-08
and O 0 4.4648582053774533e-10
one O 0 3.7694666832344126e-10
allele O 0 7.043436500708822e-09
of O 0 1.4499364209275e-10
approximately O 0 1.665916182780336e-09
100 O 0 1.4978025930645344e-08
repeats O 0 1.3843291526427492e-06
. O 0 3.363416567481181e-07

His O 0 7.029694870652747e-07
sperm O 0 7.835343240003567e-06
showed O 0 1.1943981235162937e-06
an O 0 6.719800826893163e-10
expanded O 0 9.952160873183402e-09
allele O 0 6.53083631618756e-08
in O 0 2.0748642803880557e-09
a O 0 5.291062876722208e-08
tight O 0 2.5089343580475543e-06
range O 0 1.7473784197363784e-08
centering O 0 2.0474056228181325e-08
on O 0 2.0219051322101222e-08
a O 0 1.0313752518698038e-08
size O 0 8.922663141675002e-08
of O 0 6.758478221513542e-10
approximately O 0 9.682979751346465e-09
320 O 0 5.8892474896765634e-08
trinucleotide O 0 2.236082400486339e-05
repeats O 0 4.1344401324749924e-06
. O 0 1.8037512461432925e-07

His O 0 6.735802344337571e-06
affected O 0 8.745025183998223e-07
son O 0 1.4983909750299063e-05
has O 0 4.582974000300055e-08
repeat O 0 5.457982865664235e-07
sizes O 0 1.7355891657189204e-07
of O 0 1.6959406101690888e-09
1040 O 0 4.012858880741987e-06
and O 0 1.1008775402387982e-07
540 O 0 5.492408376994717e-07
. O 0 2.302746793247934e-07

These O 0 8.145154595240456e-08
data O 0 8.208301949252927e-08
suggest O 0 3.6290142446659956e-08
that O 0 7.504719623518952e-10
expansion O 0 5.53184253959671e-09
occurs O 0 8.762635061998481e-10
in O 0 5.636253269658553e-11
two O 0 2.0252301224932268e-10
stages O 0 7.636676002675813e-08
, O 0 5.564538829716525e-10
the O 0 7.086144865331434e-11
first O 0 7.636901666607798e-10
during O 0 9.345946239136538e-09
meiosis O 0 1.8414924696230628e-08
followed O 0 1.9065644618621036e-09
by O 0 1.6344042785831903e-10
a O 0 7.042657124145535e-09
second O 0 1.6979189609855894e-08
mitotic O 0 7.179617114161374e-06
expansion O 0 1.230878297064919e-06
. O 0 1.3939228438175633e-07

We O 0 5.655753056998947e-07
also O 0 6.199128321782155e-09
show O 0 2.2615690653537968e-08
that O 0 1.4031336093012214e-09
in O 0 3.2677624495214275e-10
all O 0 1.7037339594683232e-10
informative O 0 1.646232874463749e-07
carrier O 0 8.232703294197563e-06
father O 0 2.584912976999476e-07
to O 0 3.4890821343225298e-09
affected O 0 2.2084087447638012e-08
child O 0 4.421963694767328e-06
transmissions O 0 1.0935576938209124e-05
, O 0 4.103495321317041e-10
with O 0 1.2383478964483885e-10
the O 0 3.3039179725413703e-10
notable O 0 4.310734880164091e-09
exception O 0 1.991069975559867e-09
of O 0 1.1198258292877128e-10
the O 0 4.049212964929438e-09
premutation O 0 1.3693952496396378e-05
carrier O 0 5.430977694231842e-07
, O 0 9.048790189369882e-11
the O 0 4.514195614535588e-11
expansion O 0 2.5665907177341296e-09
size O 0 9.173086823466292e-08
decreases O 0 2.3693407058544835e-07
. O 0 8.799267092740592e-09
. O 0 9.964777092363875e-08

The O 0 2.3336200172252575e-07
R496H O 0 1.4842931932435022e-06
mutation O 0 5.003772116651817e-07
of O 0 2.3236224055978028e-09
arylsulfatase O 0 9.58185555646196e-05
A O 0 9.655329449742567e-06
does O 0 2.646590928634396e-06
not O 0 5.688870032827253e-07
cause O 0 0.00013065924576949328
metachromatic B-Disease 1 0.9999735355377197
leukodystrophy I-Disease 1 0.9999649524688721
. O 0 1.8190885384683497e-05

Deficiency B-Disease 1 0.9943441152572632
of I-Disease 0 1.3696070766400226e-07
arylsulfatase I-Disease 0 0.00040613714372739196
A I-Disease 0 9.975470675271936e-06
( O 0 1.0253793902847974e-07
ARSA O 0 0.0011540178675204515
) O 0 1.08004964971542e-08
enzyme O 0 1.0911276859815189e-07
activity O 0 1.2741028285745415e-06
causes O 0 0.00030239857733249664
metachromatic B-Disease 1 0.9999934434890747
leukodystrophy I-Disease 1 0.9999959468841553
( O 0 0.00041987752774730325
MLD B-Disease 1 0.9999639987945557
) O 0 3.8777940858381044e-07
. O 0 3.166019837408385e-07

A O 0 4.3823979467561003e-07
number O 0 1.0345313938842082e-08
of O 0 2.9360740505524063e-09
ARSA O 0 0.010394389741122723
gene O 0 1.1332019312249031e-05
mutations O 0 2.766038778645452e-05
responsible O 0 1.0229458666799474e-06
for O 0 1.6734252312744502e-06
MLD B-Disease 1 0.9999966621398926
have O 0 8.839288057060912e-06
been O 0 2.6971531497110846e-06
identified O 0 1.1174882274644915e-05
. O 0 6.902702125444193e-07

Recently O 0 1.5208666809485294e-05
, O 0 7.033595927907754e-09
the O 0 7.392303436049019e-10
R496H O 0 1.0937739602923102e-07
mutation O 0 2.805360388435929e-08
of O 0 8.185671029892205e-10
ARSA O 0 0.0007414667052216828
was O 0 6.49272521968669e-07
proposed O 0 6.513157568832639e-09
to O 0 1.7811720987026547e-09
be O 0 4.925439611724869e-08
a O 0 4.3551335693337023e-07
cause O 0 8.638291546958499e-06
of O 0 5.585592930401617e-07
MLD B-Disease 1 0.999997615814209
( O 0 1.316819151497839e-07
Draghia O 0 1.8807964806910604e-05
et O 0 1.883895265564206e-06
al O 0 8.513332545589947e-07
. O 0 2.042010782687953e-09
, O 0 9.641655251968473e-10
1997 O 0 2.081512562313037e-08
) O 0 9.88724568884436e-09
. O 0 1.4257341263146373e-07

We O 0 1.0898002074100077e-06
have O 0 9.475539464176563e-09
investigated O 0 6.913941774655541e-08
the O 0 1.499622648282184e-09
R496H O 0 4.261088690782344e-07
mutation O 0 5.419383342086803e-07
and O 0 4.2932408739204675e-09
found O 0 8.120563776969902e-09
this O 0 4.252727059395056e-09
mutation O 0 1.5667050945467054e-07
at O 0 6.247653505653261e-09
a O 0 2.479114513675995e-08
relatively O 0 5.207880349189509e-08
high O 0 7.906820087555388e-08
frequency O 0 1.7885507475057238e-07
in O 0 2.6063112779084463e-10
an O 0 2.1495150104300365e-10
African O 0 1.389759557435255e-10
American O 0 2.801797682749907e-09
population O 0 2.0410909074008998e-10
( O 0 1.0511566617132928e-10
f O 0 6.472194513662544e-08
= O 0 7.556749004322683e-09
0 O 0 2.786160746559574e-10
. O 0 1.6081599940598323e-10
09 O 0 1.296088569802123e-09
, O 0 1.1879809636017313e-10
n O 0 9.670230127767354e-08
= O 0 2.392722251443047e-07
61 O 0 5.042307460456641e-09
subjects O 0 3.2460243915011233e-07
) O 0 1.1826940315984302e-08
. O 0 1.3662399567238026e-07

The O 0 6.225482707122865e-07
ARSA O 0 0.0002606614143587649
enzyme O 0 4.373763715648238e-07
activity O 0 7.854003314378133e-08
in O 0 4.5341681520483235e-09
subjects O 0 1.6251833301339502e-07
with O 0 1.2644629343583347e-08
and O 0 4.600419956091173e-08
without O 0 5.6083884203417256e-09
the O 0 4.2825573642879533e-10
R496H O 0 1.109674769850244e-07
mutation O 0 1.397003615011272e-07
was O 0 6.090881754516886e-08
determined O 0 1.552720192421475e-07
and O 0 1.192524923254723e-08
found O 0 4.004781573030414e-08
to O 0 2.8219149239561148e-09
be O 0 8.554058439358414e-08
normal O 0 8.077129365346991e-08
. O 0 1.8907982735072437e-07

It O 0 1.041364384946064e-06
is O 0 2.4612111459987318e-08
therefore O 0 9.37837363323979e-09
concluded O 0 7.297729531785535e-09
that O 0 7.215484876255118e-10
the O 0 5.572132200093449e-10
R496H O 0 2.366617195548315e-07
mutation O 0 3.555444294534027e-08
of O 0 1.0591874044507676e-09
ARSA O 0 0.00034750261693261564
does O 0 3.649407886996414e-08
not O 0 5.846086947869367e-10
negatively O 0 1.242894231978653e-09
influence O 0 4.918449536539526e-10
the O 0 3.406572524067286e-10
activity O 0 3.961113659300963e-09
of O 0 2.633590567846511e-10
ARSA O 0 0.00017363402002956718
and O 0 3.9437388466012635e-08
is O 0 6.763859250469295e-09
not O 0 2.194237236352592e-09
a O 0 9.961698310689826e-08
cause O 0 1.3509849850379396e-05
of O 0 4.61477202406968e-06
MLD B-Disease 1 0.9999581575393677

Down O 0 9.453693564864807e-06
- O 0 6.1752375586365815e-06
regulation O 0 6.347349312818551e-08
of O 0 3.124397185416683e-09
transmembrane O 0 0.00012915505794808269
carbonic O 0 1.887666257971432e-05
anhydrases O 0 0.00010406100045656785
in O 0 2.454775312799029e-06
renal B-Disease 1 0.9876692891120911
cell I-Disease 1 0.9998631477355957
carcinoma I-Disease 1 1.0
cell O 1 0.6631011366844177
lines O 0 1.0035940249508712e-05
by O 0 1.2398143844905007e-08
wild O 0 1.933115072461078e-06
- O 0 0.01365579478442669
type O 0 0.14137643575668335
von B-Disease 1 0.9995900988578796
Hippel I-Disease 1 0.9991186261177063
- I-Disease 1 0.9210866689682007
Lindau I-Disease 1 0.8374006152153015
transgenes O 0 0.0023754779249429703
. O 0 3.894879228028003e-06

To O 0 2.924055308994866e-07
discover O 0 1.3689452771359356e-06
genes O 0 8.075573987298412e-08
involved O 0 4.2733905303293795e-08
in O 0 2.0508494458226778e-07
von B-Disease 1 0.9987414479255676
Hippel I-Disease 1 0.9998094439506531
- I-Disease 1 0.9994686245918274
Lindau I-Disease 1 0.9994747042655945
( O 0 7.64801598052145e-07
VHL B-Disease 0 0.0001522121747257188
) O 0 1.8117181088683765e-09
- O 0 1.2969815088581527e-06
mediated O 0 9.813478754949756e-06
carcinogenesis O 0 0.02508002519607544
, O 0 7.632831966475351e-08
we O 0 5.294758054219528e-08
used O 0 3.0568509828299284e-05
renal B-Disease 1 0.9862944483757019
cell I-Disease 1 0.999825656414032
carcinoma I-Disease 1 1.0
cell O 1 0.8647081255912781
lines O 0 0.0003094447311013937
stably O 0 7.144919800339267e-05
transfected O 0 6.424010734917829e-06
with O 0 1.6643289413309503e-08
wild O 0 1.666265575295256e-06
- O 0 0.011755509302020073
type O 0 0.04727453738451004
VHL O 0 0.02099039778113365
- O 0 0.00016471388516947627
expressing O 0 3.946228844142752e-06
transgenes O 0 0.0001288334169657901
. O 0 9.502797411187203e-07

Large O 0 8.886433988664066e-07
- O 0 2.7154833333042916e-06
scale O 0 3.976046173193026e-06
RNA O 0 1.5746306303299207e-07
differential O 0 3.645696722287539e-07
display O 0 6.060670330043649e-07
technology O 0 6.094704474435275e-08
applied O 0 3.623610744796224e-09
to O 0 5.881237719052024e-10
these O 0 9.185351923512997e-10
cell O 0 4.6384170673263725e-06
lines O 0 3.385250693099806e-07
identified O 0 3.6664875580072476e-08
several O 0 1.404027033524713e-10
differentially O 0 1.2435035046109988e-07
expressed O 0 6.095132398797887e-09
genes O 0 1.2116718295374085e-08
, O 0 1.7098771010193303e-10
including O 0 2.1133220173830125e-10
an O 0 3.6141543091616768e-09
alpha O 0 4.799308044312056e-07
carbonic O 0 1.7275996242460678e-06
anhydrase O 0 1.657456778048072e-06
gene O 0 4.118680152487286e-08
, O 0 3.544784243914023e-09
termed O 0 6.621394277317449e-07
CA12 O 0 0.0005853351322002709
. O 0 5.508333629222761e-07

The O 0 3.171374274302252e-08
deduced O 0 4.611885060512577e-07
protein O 0 5.630954191815363e-08
sequence O 0 3.233091305787639e-08
was O 0 7.01422635529525e-08
classified O 0 2.6235559502651995e-08
as O 0 6.562359544659557e-10
a O 0 1.845247510345871e-08
one O 0 1.934845528239748e-07
- O 0 0.005771068390458822
pass O 0 3.903084871126339e-05
transmembrane O 0 0.0346381738781929
CA O 0 4.2994644900318235e-05
possessing O 0 5.7704063749497436e-08
an O 0 1.762782919634276e-09
apparently O 0 3.533837116265204e-07
intact O 0 6.836052079961519e-08
catalytic O 0 3.7505447636476674e-08
domain O 0 5.56368195958612e-09
in O 0 1.2028933404906184e-09
the O 0 8.375829807505397e-09
extracellular O 0 7.016406016191468e-06
CA O 0 0.00013363927428144962
module O 0 0.00012293960025999695
. O 0 2.3543981342299958e-07

Reintroduced O 0 4.284689202904701e-05
wild O 0 3.97073335989262e-06
- O 0 0.00037185061955824494
type O 0 0.00014897790970280766
VHL B-Disease 0 0.0002453839988447726
strongly O 0 6.462930457473703e-08
inhibited O 0 5.164632810306102e-08
the O 0 4.577387080484385e-10
overexpression O 0 9.598431383039951e-09
of O 0 1.0857513499384908e-10
the O 0 2.795162767910142e-09
CA12 O 0 1.5872585208853707e-05
gene O 0 2.944818788819248e-08
in O 0 4.132622244412687e-09
the O 0 7.897942566614802e-08
parental O 0 0.3040761649608612
renal B-Disease 1 0.9994791150093079
cell I-Disease 1 0.9999552965164185
carcinoma I-Disease 1 0.9999998807907104
cell O 1 0.9874792695045471
lines O 0 0.003069557948037982
. O 0 2.18043896893505e-06

Similar O 0 1.6307117221003864e-06
results O 0 5.471600843520719e-07
were O 0 1.716381170524528e-08
obtained O 0 1.577045622980222e-07
with O 0 8.759317893236584e-08
CA9 O 0 0.002254405990242958
, O 0 2.642951635323243e-09
encoding O 0 2.4988813240867103e-09
another O 0 1.5679876241847523e-07
transmembrane O 0 0.03262389078736305
CA O 0 9.454192331759259e-05
with O 0 1.9290531394489108e-09
an O 0 8.202334811358014e-09
intact O 0 2.046150484602549e-06
catalytic O 0 1.358841359433427e-06
domain O 0 4.6208043613660266e-07
. O 0 1.2134854898704361e-07

Although O 0 1.9575875853661273e-07
both O 0 1.2877843236225317e-09
domains O 0 1.640671243308134e-08
of O 0 4.4223114059604995e-10
the O 0 1.2588872166929832e-08
VHL B-Disease 0 3.657146589830518e-05
protein O 0 1.514233005650567e-08
contribute O 0 4.73756589514096e-10
to O 0 3.809741133675715e-10
regulation O 0 5.812422987361288e-09
of O 0 3.6251435187040215e-10
CA12 O 0 4.702067235484719e-05
expression O 0 6.862035206722794e-08
, O 0 1.9129635375758625e-10
the O 0 1.1303665642392602e-10
elongin O 0 1.9309284482460498e-07
binding O 0 3.074569576710928e-08
domain O 0 2.2342279137888e-08
alone O 0 1.9526949301962304e-07
could O 0 4.781189488767268e-08
effectively O 0 1.2855142017542676e-07
regulate O 0 2.725133981584804e-06
CA9 O 0 0.0005655941786244512
expression O 0 4.117119715374429e-06
. O 0 3.743776630926732e-07

We O 0 1.7828643876782735e-06
mapped O 0 2.5721019483171403e-05
CA12 O 0 0.00033979900763370097
and O 0 2.0608879935934965e-07
CA9 O 0 0.0002640064340084791
loci O 0 5.082933967059944e-07
to O 0 3.14863335404425e-08
chromosome O 0 3.248549546697177e-05
bands O 0 3.252793931096676e-06
15q22 O 0 3.2360517252527643e-06
and O 0 1.4048957552859065e-07
17q21 O 0 1.6854175555636175e-05
. O 0 7.914030675237882e-07

2 O 0 1.9125502603856148e-07
respectively O 0 1.875096700132417e-07
, O 0 4.9146358094276366e-09
regions O 0 2.527345444036655e-08
prone O 0 1.2263904864084907e-05
to O 0 3.2509108738310033e-09
amplification O 0 1.7165044710054644e-06
in O 0 7.885070374413772e-09
some O 0 1.7152937958897496e-09
human O 0 3.665984422696056e-06
cancers B-Disease 0 0.41633540391921997
. O 0 2.4286860025313217e-06

Additional O 0 1.3570267753948428e-07
experiments O 0 1.8768101881505572e-06
are O 0 2.0638915021464754e-09
needed O 0 2.236285823187245e-09
to O 0 3.3288022338595624e-10
define O 0 1.2820135175672931e-08
the O 0 7.33291538601577e-10
role O 0 2.8497831650042826e-08
of O 0 2.5489852006899127e-08
CA O 0 0.0014918781816959381
IX O 0 3.505623681121506e-05
and O 0 4.79774257655663e-07
CA O 0 3.725705755641684e-05
XII O 0 2.1238968201942043e-06
enzymes O 0 1.05938182670684e-08
in O 0 4.454395741149142e-10
the O 0 1.8664911283217123e-10
regulation O 0 4.505959161349438e-09
of O 0 4.833743405541213e-10
pH O 0 2.3719419914414175e-05
in O 0 1.8721864059045856e-09
the O 0 6.248543904519011e-10
extracellular O 0 2.906394591661865e-08
microenvironment O 0 5.097321604807803e-07
and O 0 2.3539381555082173e-09
its O 0 9.920827492848616e-10
potential O 0 2.776725516184797e-08
impact O 0 2.4296699052683834e-07
on O 0 2.9350194381549954e-05
cancer B-Disease 0 0.005125226452946663
cell O 0 0.00030183224589563906
growth O 0 5.642571068165125e-06
. O 0 3.67344597407282e-07

A O 0 5.198750159252086e-07
gene O 0 6.578280675739734e-08
encoding O 0 4.6993939406547725e-08
a O 0 3.0626413405343555e-08
transmembrane O 0 2.3359039914794266e-05
protein O 0 1.1273419886492775e-07
is O 0 7.703808257986111e-09
mutated O 0 6.366579441419162e-07
in O 0 2.79734109653873e-07
patients O 0 1.1572481525945477e-05
with O 0 0.4380311965942383
diabetes B-Disease 1 0.9999997615814209
mellitus I-Disease 1 0.9999996423721313
and O 1 0.9983348250389099
optic B-Disease 1 0.9999994039535522
atrophy I-Disease 1 0.9999905824661255
( O 1 0.5003216862678528
Wolfram B-Disease 1 0.9999961853027344
syndrome I-Disease 1 0.9999997615814209
) O 0 4.687479759013513e-06
. O 0 1.8282760265719844e-06

Wolfram B-Disease 1 0.9999793767929077
syndrome I-Disease 1 0.9999996423721313
( O 0 0.00017316726734861732
WFS B-Disease 1 0.8148080706596375
; O 0 7.209546311059967e-06
OMIM O 0 0.04778942093253136
222300 O 0 4.805486969416961e-05
) O 0 1.2281218708665165e-08
is O 0 1.2922509284862826e-08
an O 0 3.4913080071419245e-07
autosomal B-Disease 1 0.9999234676361084
recessive I-Disease 1 0.9999866485595703
neurodegenerative I-Disease 1 0.9999817609786987
disorder I-Disease 1 0.9966186285018921
defined O 0 1.805369720386807e-05
by O 0 1.4931522684946685e-07
young O 0 1.8673496242627152e-06
- O 0 0.00032761177862994373
onset O 0 4.541173893812811e-06
non O 0 7.305154667847091e-07
- O 0 0.024158576503396034
immune O 0 0.005763043649494648
insulin B-Disease 0 0.12052085995674133
- I-Disease 1 0.9829304814338684
dependent I-Disease 0 0.39640846848487854
diabetes I-Disease 1 0.9999977350234985
mellitus I-Disease 1 0.9999947547912598
and O 0 0.0006489125662483275
progressive O 1 0.897335946559906
optic B-Disease 1 0.9999845027923584
atrophy I-Disease 1 0.998437225818634
. O 0 1.5961717508616857e-05

Linkage O 0 0.00017482865951023996
to O 0 1.018354964799073e-07
markers O 0 4.055417321069399e-06
on O 0 3.0753606097277952e-06
chromosome O 0 0.07280972599983215
4p O 1 0.5316112637519836
was O 0 1.7935564756044187e-05
confirmed O 0 1.0035710147349164e-06
in O 0 9.217807850347981e-09
five O 0 1.5696894450911714e-08
families O 0 2.854282570297073e-07
. O 0 8.299926435029192e-07

On O 0 9.159921887658129e-08
the O 0 1.5850172285780673e-09
basis O 0 2.105316809775104e-09
of O 0 4.987668056344319e-10
meiotic O 0 0.00015076609270181507
recombinants O 0 0.11211907863616943
and O 0 4.524970063357614e-05
disease O 0 0.0011476508807390928
- O 0 0.0011470337631180882
associated O 0 1.2158827757957624e-06
haplotypes O 0 1.843912832555361e-05
, O 0 1.5088359006654173e-08
the O 0 7.31521954122627e-09
WFS B-Disease 0 1.7928758097696118e-05
gene O 0 4.9205567620447255e-08
was O 0 4.548913778990027e-08
localized O 0 1.1005877809111553e-07
to O 0 1.0212566792233702e-08
a O 0 2.7576988941291347e-06
BAC O 0 6.590391421923414e-05
/ O 0 1.1116698033220018e-06
P1 O 0 5.1000548410229385e-05
contig O 0 3.795855718635721e-07
of O 0 2.152629047236232e-10
less O 0 3.896571953987404e-09
than O 0 3.245743895874398e-09
250 O 0 1.0420588836268507e-08
kb O 0 4.302672459743917e-05
. O 0 1.5609469983246527e-06

Mutations O 0 0.0006709292065352201
in O 0 7.849839533946579e-08
a O 0 5.2020133978203376e-08
novel O 0 1.1267175636930915e-07
gene O 0 3.311587306598085e-07
( O 0 4.2008170275664725e-09
WFS1 O 0 1.183744734589709e-05
) O 0 1.6673012970258583e-10
encoding O 0 1.019071049768172e-09
a O 0 7.271330648705998e-09
putative O 0 6.701816346321721e-07
transmembrane O 0 1.0908838703471702e-05
protein O 0 5.6835126827081695e-08
were O 0 2.613567140485884e-08
found O 0 8.678016172325442e-08
in O 0 7.535303048200603e-09
all O 0 3.4432541262674476e-09
affected O 0 7.388261114016359e-09
individuals O 0 9.492647778941432e-10
in O 0 1.2905980284472207e-08
six O 0 1.415173329633035e-07
WFS B-Disease 0 4.7715580876683816e-05
families O 0 1.1993292581280457e-08
, O 0 1.0829390717503884e-09
and O 0 4.633554873123558e-09
these O 0 1.5447459977835365e-09
mutations O 0 1.1341474959181141e-07
were O 0 2.2729379267616423e-08
associated O 0 3.9099294468769585e-08
with O 0 3.8704484950358164e-08
the O 0 1.2796392184100114e-05
disease O 0 0.009087547659873962
phenotype O 0 0.001114075188525021
. O 0 2.145292000932386e-06

WFS1 O 0 0.0017734852153807878
appears O 0 1.1020661077054683e-06
to O 0 2.2303818791868935e-09
function O 0 1.1512999442686578e-08
in O 0 9.507292730859263e-09
survival O 0 6.62718093735748e-07
of O 0 1.4094235778472353e-09
islet O 0 1.6416579455835745e-05
beta O 0 8.195738843141953e-08
- O 0 8.12353209767025e-06
cells O 0 2.1107102554651647e-07
and O 0 3.000575787837079e-08
neurons O 0 1.5825160062377108e-06
. O 0 1.337290278513592e-08
. O 0 1.155299571564683e-07

Stable O 0 3.2970001484500244e-05
interaction O 0 9.543742152118284e-08
between O 0 7.326347972735903e-09
the O 0 1.6129653168661662e-09
products O 0 5.286823423489295e-09
of O 0 4.660177799209464e-10
the O 0 7.321378348024155e-08
BRCA1 O 0 0.0006785308360122144
and O 0 2.0831250822084257e-06
BRCA2 O 0 0.000172308151377365
tumor B-Disease 0 5.532729483093135e-05
suppressor O 0 1.0710768947319593e-05
genes O 0 7.206825358707647e-08
in O 0 4.2021555124449606e-09
mitotic O 0 7.0023152147769e-06
and O 0 4.172359808762849e-07
meiotic O 0 0.0008210481610149145
cells O 0 9.77598610916175e-05
. O 0 8.675597769070009e-07

BRCA1 O 0 0.12627670168876648
and O 0 1.2895543477497995e-06
BRCA2 O 0 6.956301513127983e-05
account O 0 1.5584019763537071e-07
for O 0 3.7082827919476813e-09
most O 0 2.7831239535203167e-09
cases O 0 3.66048324984547e-09
of O 0 1.6834104110685644e-09
familial O 0 0.00489443214610219
, O 0 1.0067211775321994e-07
early O 0 1.8150379901271663e-06
onset O 0 0.0007682833820581436
breast B-Disease 1 0.8724669218063354
and I-Disease 0 0.00013436697190627456
/ I-Disease 0 0.39537912607192993
or I-Disease 1 0.9955379962921143
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
and O 0 6.699087862216402e-07
encode O 0 1.1292767254644787e-07
products O 0 3.531835091052926e-08
that O 0 1.3235512685838557e-09
each O 0 1.1791008169836914e-09
interact O 0 7.721151717987595e-09
with O 0 3.118909219779198e-08
hRAD51 O 0 3.9131398807512596e-05
. O 0 7.069272669468774e-07

Results O 0 2.9100835945428116e-06
presented O 0 2.6912235284726194e-07
here O 0 1.4486690069759334e-08
show O 0 1.0441702613661619e-07
that O 0 7.383249567283201e-08
BRCA1 O 0 0.00011409670696593821
and O 0 9.380404435432865e-07
BRCA2 O 0 0.00013654054782819003
coexist O 0 5.5010341384331696e-06
in O 0 9.812174184276046e-09
a O 0 1.8494198172902543e-07
biochemical O 0 7.932791049825028e-05
complex O 0 1.1288013865851099e-06
and O 0 5.527932245286138e-08
colocalize O 0 1.181768675451167e-05
in O 0 1.0189997290410702e-08
subnuclear O 0 3.308157374704024e-06
foci O 0 1.0463028274898534e-06
in O 0 2.114246333562164e-09
somatic O 0 1.340851127906717e-07
cells O 0 9.916428922451814e-08
and O 0 3.0883327006847594e-09
on O 0 8.220707670147931e-09
the O 0 1.341284749933891e-09
axial O 0 3.6361376487548114e-07
elements O 0 2.236670937350027e-08
of O 0 1.9340231638409477e-09
developing O 0 1.5454075708021264e-07
synaptonemal O 0 5.0438142352504656e-05
complexes O 0 9.824152584769763e-06
. O 0 4.7403821668012824e-07

Like O 0 1.5646877727704123e-05
BRCA1 O 0 0.001736433245241642
and O 0 9.337660458186292e-07
RAD51 O 0 0.008193867281079292
, O 0 6.734382651529813e-08
BRCA2 O 0 8.927529052016325e-06
relocates O 0 1.1212234767299378e-06
to O 0 1.4051511065815703e-08
PCNA O 0 1.8738768631010316e-05
+ O 0 2.114166619548996e-08
replication O 0 6.521187145835938e-09
sites O 0 3.844562446175814e-09
following O 0 1.5500704053650338e-09
exposure O 0 5.688235660272767e-07
of O 0 7.39900307689112e-10
S O 0 1.4939051652618218e-05
phase O 0 7.798741563647127e-08
cells O 0 5.4324704734654006e-08
to O 0 2.5896282895843115e-09
hydroxyurea O 0 3.6557064504449954e-06
or O 0 5.618653062811063e-07
UV O 0 0.22328780591487885
irradiation O 0 9.621115896152332e-05
. O 0 4.055515319123515e-07

Thus O 0 3.637327381511568e-06
, O 0 2.9136488777226077e-08
BRCA1 O 0 1.240704568772344e-05
and O 0 8.337992341012068e-08
BRCA2 O 0 1.4553133951267228e-05
participate O 0 4.6057464508919566e-09
, O 0 1.685412032159661e-09
together O 0 1.7033155996770688e-09
, O 0 9.870471107120693e-10
in O 0 9.879191908979124e-10
a O 0 1.434479059980731e-07
pathway O 0 4.985400892110192e-07
( O 0 1.3611789917433725e-08
s O 0 2.5855419153231196e-05
) O 0 3.4846661112197808e-09
associated O 0 6.350858949843996e-09
with O 0 3.815435190013261e-10
the O 0 1.215265665877041e-09
activation O 0 6.0992260131342846e-09
of O 0 6.543448560769605e-10
double O 0 5.3906576795270666e-05
- O 0 0.0007452621939592063
strand O 0 2.5342022127006203e-05
break O 0 9.531309842714109e-06
repair O 0 0.0002773846499621868
and O 0 3.514998354603449e-07
/ O 0 6.254576874198392e-07
or O 0 1.6187694740210645e-08
homologous O 0 5.499815074472281e-07
recombination O 0 1.1584870662773028e-05
. O 0 1.437485366295732e-06

Dysfunction O 0 0.0004288561176508665
of O 0 3.764448308629653e-08
this O 0 2.2114312159260407e-08
pathway O 0 4.115932483728102e-07
may O 0 7.164844078033639e-07
be O 0 1.3013771171799249e-09
a O 0 4.22958335022372e-09
general O 0 2.419703992728728e-09
phenomenon O 0 3.5104914530847964e-08
in O 0 3.632265599406992e-10
the O 0 2.1299050023682042e-10
majority O 0 4.838116018923699e-10
of O 0 1.9992280053671152e-10
cases O 0 1.946917960182759e-09
of O 0 2.6381667961317135e-09
hereditary B-Disease 1 0.9232631921768188
breast I-Disease 1 0.9995920062065125
and I-Disease 0 0.13159045577049255
/ I-Disease 1 0.990980327129364
or I-Disease 1 0.9997771382331848
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999995231628418
. O 0 4.777005869982531e-06
. O 0 1.4541873269990901e-06

A O 0 1.8661088461158215e-06
novel O 0 4.822661026082642e-07
Arg362Ser O 0 2.0748411770910025e-05
mutation O 0 9.502470561528753e-07
in O 0 2.793116182786548e-09
the O 0 5.630832689007548e-09
sterol O 0 0.00028622354147955775
27 O 0 3.949174072204187e-07
- O 0 0.00019581374363042414
hydroxylase O 0 0.0002212977415183559
gene O 0 3.335441363105929e-07
( O 0 3.2601754629268953e-09
CYP27 O 0 8.73322642291896e-06
) O 0 4.6127687780561644e-10
: O 0 9.874590034542052e-11
its O 0 1.8554628666844764e-10
effects O 0 5.180240236768441e-08
on O 0 5.7174904810608496e-08
pre O 0 7.396522960334551e-06
- O 0 2.069614538413589e-06
mRNA O 0 4.100187744882078e-09
splicing O 0 1.0200711386687544e-08
and O 0 2.5489355071073305e-09
enzyme O 0 3.677279991620708e-08
activity O 0 1.0598187571986273e-07
. O 0 1.238773705836138e-07

A O 0 1.5373623227787903e-06
novel O 0 6.243689085749793e-07
C O 0 7.169013542807079e-07
to O 0 1.0899618985149573e-09
A O 0 1.6643168976315792e-07
mutation O 0 3.6338289532977797e-07
in O 0 2.6552704479598788e-09
the O 0 5.200184727272017e-09
sterol O 0 0.00015378103125840425
27 O 0 1.3115865726831544e-07
- O 0 4.295280814403668e-05
hydroxylase O 0 3.0113833417999558e-05
gene O 0 1.5409263198762346e-07
( O 0 2.5870512398995515e-09
CYP27 O 0 1.4256664144340903e-05
) O 0 6.21963813784987e-10
was O 0 4.3821639650332145e-08
identified O 0 1.8372753984863266e-08
by O 0 8.752144564638797e-10
sequencing O 0 2.0910508879978806e-08
amplified O 0 1.5294567674573045e-06
CYP27 O 0 1.3127806823831634e-06
gene O 0 2.6057906943321996e-09
products O 0 1.9725068245435295e-09
from O 0 2.886013650282848e-10
a O 0 2.519827546620945e-07
patient O 0 2.6880254154093564e-05
with O 0 8.953449651016854e-06
cerebrotendinous B-Disease 1 0.9999963045120239
xanthomatosis I-Disease 1 0.9999945163726807
( O 0 2.274891130582546e-06
CTX B-Disease 0 0.0514972023665905
) O 0 3.3125218124041567e-08
. O 0 1.0297264196879041e-07

The O 0 2.738692614911997e-07
mutation O 0 4.963766059518093e-06
changed O 0 3.864694519961631e-08
the O 0 8.499145831564192e-10
adrenodoxin O 0 4.5167132611823035e-07
cofactor O 0 2.83418231106225e-08
binding O 0 5.1388585831091405e-08
residue O 0 6.628154665122565e-07
362Arg O 0 2.3599190512868518e-07
to O 0 4.134908859754205e-09
362Ser O 0 1.5092525700310944e-06
( O 0 1.8232931831008159e-09
CGT O 0 4.6171129497452057e-07
362Arg O 0 1.0034927555579998e-07
to O 0 2.405590393550483e-09
AGT O 0 9.186091119772755e-06
362Ser O 0 4.832743911720172e-07
) O 0 2.1087277757292355e-10
, O 0 2.8700009035986795e-10
and O 0 4.546075071942823e-09
was O 0 2.159838231818867e-06
responsible O 0 8.62331660300697e-07
for O 0 2.019758085225476e-06
deficiency O 0 0.005596464965492487
in O 0 3.5341178872272394e-09
the O 0 1.2262726833967008e-08
sterol O 0 0.0003876849077641964
27 O 0 1.780711755827724e-07
- O 0 8.104974767775275e-06
hydroxylase O 0 3.5668463169713505e-06
activity O 0 2.478878258216355e-08
, O 0 1.336567245768805e-10
as O 0 2.78027878497511e-10
confirmed O 0 2.0905155384554064e-09
by O 0 2.1141162431792537e-10
expression O 0 6.181205769451026e-09
of O 0 6.127531121391527e-11
mutant O 0 1.1147805345501638e-08
cDNA O 0 3.3582923109065632e-09
into O 0 1.9272179407892054e-09
COS O 0 2.1056971490907017e-06
- O 0 9.252173640561523e-07
1 O 0 8.774144966139374e-09
cells O 0 9.622007013376788e-08
. O 0 1.2077208566552144e-07

Quantitative O 0 4.509032351052156e-06
analysis O 0 1.1967628097409033e-06
showed O 0 1.7667239262664225e-06
that O 0 1.6059261698231353e-09
the O 0 5.776269462742789e-10
expression O 0 9.9869978953393e-09
of O 0 2.6405619357738885e-10
CYP27 O 0 1.0872817028939608e-06
gene O 0 2.815543798107001e-09
mRNA O 0 2.085935202345013e-09
in O 0 2.712291502504627e-10
the O 0 7.475233765319445e-10
patient O 0 2.475448468430841e-07
represented O 0 8.336657231211575e-08
52 O 0 1.0526869687055296e-07
. O 0 2.132322265424591e-07

5 O 0 1.781678236056905e-07
% O 0 8.083245184309362e-09
of O 0 3.7821129561521616e-10
the O 0 9.689944846513754e-09
normal O 0 1.3856535474587872e-07
level O 0 6.612345941903186e-07
. O 0 3.7410569575513364e-07

As O 0 4.235365835825178e-08
the O 0 7.85827047877774e-09
mutation O 0 2.9773281084999326e-07
occurred O 0 7.499318144255085e-08
at O 0 8.803241469124146e-10
the O 0 1.424503431879387e-10
penultimate O 0 1.3496231687781801e-08
nucleotide O 0 1.2014035100094134e-08
of O 0 3.87612372754198e-11
exon O 0 4.0859549699234776e-07
6 O 0 1.4031799722147298e-08
( O 0 1.8043855298799372e-10
- O 0 6.054846579672812e-08
2 O 0 5.130020297450244e-10
position O 0 3.792126612722768e-09
of O 0 9.89259368866513e-11
exon O 0 6.681459012725099e-07
6 O 0 1.9964824460316777e-08
- O 0 7.337314400501782e-07
intron O 0 1.935199406943866e-06
6 O 0 4.226623939729279e-09
splice O 0 1.0032822927996676e-07
site O 0 5.003079905918639e-08
) O 0 2.4913784577029752e-11
of O 0 8.801604410579866e-12
the O 0 9.151949753594124e-10
gene O 0 3.54223814724719e-08
, O 0 2.956867417580611e-09
we O 0 2.378063523877927e-09
hypothesized O 0 1.3693242983947584e-08
that O 0 1.5768847339003855e-09
the O 0 1.3452822855697377e-08
mutation O 0 1.6220759789575823e-05
may O 0 2.643503421495552e-06
partially O 0 6.177136810947559e-07
affect O 0 7.672721125118187e-09
the O 0 5.537234004648894e-10
normal O 0 2.225626571927819e-09
splicing O 0 3.969970574502213e-09
efficiency O 0 1.0147907403279532e-08
in O 0 6.831274990126701e-10
exon O 0 7.57632051318069e-07
6 O 0 5.5899899820133214e-08
and O 0 2.4629299488765355e-08
cause O 0 1.1260236476573482e-07
alternative O 0 6.0878826424470844e-09
splicing O 0 4.643067796905598e-08
elsewhere O 0 1.7930316786873846e-08
, O 0 2.2608377669985913e-10
which O 0 3.356132871612516e-10
resulted O 0 2.401867815748915e-09
in O 0 7.626469233912303e-09
decreased O 0 1.1054683000111254e-06
transcript O 0 6.567198056472989e-07
in O 0 1.127779203358159e-08
the O 0 3.116661417834621e-08
patient O 0 1.2352031262707897e-05
. O 0 2.020425569071449e-07

Transfection O 0 0.0002625185006763786
of O 0 8.342892954260606e-08
constructed O 0 1.9276643797638826e-05
minigenes O 0 0.0002108257613144815
, O 0 3.735820985895089e-09
with O 0 1.5432941591342342e-09
or O 0 6.050644429933527e-08
without O 0 6.227653948087664e-09
the O 0 1.4906994527663642e-09
mutation O 0 1.2611768340775598e-07
, O 0 1.453624720593183e-10
into O 0 6.577020039699732e-10
COS O 0 3.1868842143012444e-06
- O 0 1.2293613735891995e-06
1 O 0 2.5645943146912487e-09
cells O 0 2.2503300556309114e-08
confirmed O 0 1.8521657096925992e-08
that O 0 2.938901899618429e-10
the O 0 2.681653787917071e-10
mutant O 0 2.05970124511623e-07
minigene O 0 5.168947609490715e-06
was O 0 6.32256103472173e-07
responsible O 0 9.605354733821514e-09
for O 0 3.3963867829278627e-10
a O 0 9.600372052886996e-09
mRNA O 0 1.419549544579013e-08
species O 0 2.900565621022366e-10
alternatively O 0 4.40581215954694e-09
spliced O 0 2.0594811189766915e-07
at O 0 4.96931811255763e-08
an O 0 1.865183385518776e-08
activated O 0 8.250125392805785e-05
cryptic O 0 2.7440989924798487e-06
5 O 0 1.5612775516871125e-09
splice O 0 7.684616321057547e-08
site O 0 1.1176146585967217e-07
88 O 0 2.766014972621633e-09
bp O 0 5.6296222794571804e-08
upstream O 0 5.803712510576986e-10
from O 0 4.732479338964701e-11
the O 0 1.510400832183123e-10
3 O 0 9.079776375209292e-10
end O 0 3.1004376843668524e-09
of O 0 1.42337441833007e-09
exon O 0 2.1994581402395852e-05
6 O 0 3.9766038639754697e-07
. O 0 2.1285107720814267e-07

Our O 0 3.87054512884788e-07
data O 0 4.7556596882714075e-08
suggest O 0 3.0429834652068166e-08
that O 0 1.2989321840350954e-09
the O 0 7.097118448484707e-10
C O 0 1.0543990214273435e-07
to O 0 4.478846182820462e-10
A O 0 5.269254188533523e-07
mutation O 0 4.0530676415073685e-07
at O 0 1.5880917692001617e-09
the O 0 2.3099580581664725e-10
penultimate O 0 1.2557912043575925e-08
nucleotide O 0 7.592115380816722e-09
of O 0 3.38020895995772e-11
exon O 0 7.617357056233232e-08
6 O 0 7.924719214180698e-10
of O 0 6.705943439433426e-11
the O 0 4.398683639550427e-09
CYP27 O 0 8.393126336159185e-05
gene O 0 2.012747657431646e-08
not O 0 3.5648881624439355e-09
only O 0 1.2280884087445543e-09
causes O 0 9.814535673058344e-08
the O 0 3.322095381008694e-07
deficiency B-Disease 0 0.0010247353930026293
in I-Disease 0 2.8860478451520066e-09
the I-Disease 0 1.508404423589127e-08
sterol I-Disease 0 0.00030709680868312716
27 I-Disease 0 2.430047345569619e-07
- I-Disease 0 6.0883139667566866e-06
hydroxylase I-Disease 0 5.035586582380347e-06
activity I-Disease 0 3.783270940971306e-08
, O 0 5.611798248317257e-10
but O 0 2.88919266289156e-09
also O 0 4.33031477342638e-09
partially O 0 2.3852061303841765e-07
leads O 0 2.044341362861246e-09
to O 0 2.2087982831653363e-10
alternative O 0 2.3323165621036424e-09
pre O 0 1.2917547564939014e-07
- O 0 7.216537056820016e-08
mRNA O 0 9.784453247618785e-10
splicing O 0 9.489533603357359e-10
of O 0 5.943608105685172e-11
the O 0 1.3554837252627294e-09
gene O 0 1.1514915598809239e-07
. O 0 1.5335844238961727e-07

To O 0 1.0831816865675137e-07
our O 0 1.838607488480193e-08
knowledge O 0 9.001769996075382e-09
, O 0 2.827166278862592e-10
this O 0 1.0775813574781523e-10
is O 0 2.585723024584041e-10
the O 0 9.089197450240505e-11
first O 0 9.820262825144255e-09
report O 0 5.683716164384123e-09
regarding O 0 2.12188577819461e-09
effects O 0 7.834642445914142e-08
on O 0 1.9325637978795385e-08
pre O 0 6.704731845275091e-07
- O 0 1.7897571069624973e-07
mRNA O 0 4.609312653780506e-10
splicing O 0 2.5378008028376087e-10
of O 0 9.637711635701596e-12
a O 0 3.2120928139534044e-09
mutation O 0 5.693332383316374e-08
at O 0 1.4433040318451162e-09
the O 0 7.932038914582051e-10
- O 0 1.444896270186291e-06
2 O 0 2.6288140553276662e-09
position O 0 1.1033995939158103e-08
of O 0 1.4440358631073735e-10
a O 0 4.062149017158845e-08
5 O 0 1.4097065736962122e-08
splice O 0 2.7209323434362886e-06
site O 0 3.608563929446973e-06
. O 0 2.721306202602136e-07

ATM O 0 0.0006791524938307703
germline O 0 0.004281546920537949
mutations O 0 0.0007464747759513557
in O 0 1.3107653558108723e-06
classical O 0 0.009354077279567719
ataxia B-Disease 1 0.9999995231628418
- I-Disease 1 0.9999979734420776
telangiectasia I-Disease 1 0.9999997615814209
patients O 0 0.003926816862076521
in O 0 1.5301584710414318e-07
the O 0 1.1785521536467058e-07
Dutch O 0 0.0005655562272295356
population O 0 1.9795903938302217e-07
. O 0 4.2158939095315873e-07

Germline O 0 0.0023318224120885134
mutations O 0 0.00014894410560373217
in O 0 3.21402495728762e-08
the O 0 3.7700007560204085e-09
ATM O 0 2.0389999917824753e-05
gene O 0 2.924928139691474e-07
are O 0 4.40113412381038e-09
responsible O 0 6.41699102743587e-08
for O 0 4.4089082962273096e-07
the O 1 0.9534033536911011
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
telangiectasia I-Disease 1 0.9999998807907104
( O 0 0.00350906141102314
A B-Disease 1 0.9999970197677612
- I-Disease 1 0.9999985694885254
T I-Disease 1 0.9999995231628418
) O 0 8.665063546686724e-07
. O 0 4.262287802703213e-07

In O 0 2.214056706861811e-07
our O 0 3.955528171672995e-08
study O 0 7.755956765720384e-09
, O 0 2.102126916980751e-09
we O 0 4.052203017579359e-09
have O 0 2.0269395051286665e-09
determined O 0 9.333938955080612e-09
the O 0 6.165777333144717e-10
ATM O 0 2.1548553377215285e-06
mutation O 0 1.044401329863831e-07
spectrum O 0 2.4485503402615905e-08
in O 0 2.542865473742495e-09
19 O 0 5.682263548578703e-09
classical O 0 1.9691394754772773e-06
A B-Disease 1 0.9999833106994629
- I-Disease 1 0.999997615814209
T I-Disease 1 0.9999998807907104
patients O 0 1.765635829542589e-06
, O 0 3.616897337188618e-10
including O 0 6.741608660210119e-11
some O 0 1.069479158011255e-10
immigrant O 0 1.8117852107479848e-07
populations O 0 3.768799938796974e-09
, O 0 3.042980589729183e-10
as O 0 4.401215780713841e-10
well O 0 9.898657449269876e-10
as O 0 5.1776866127895e-10
12 O 0 1.7627416193377599e-10
of O 0 1.5455761670502e-10
Dutch O 0 8.28062547952868e-06
ethnic O 0 2.786152997202862e-08
origin O 0 6.829931749052776e-07
. O 0 2.5580547458048386e-07

Both O 0 6.679859865243998e-08
the O 0 4.310520829164943e-09
protein O 0 1.5059034907949354e-08
truncation O 0 3.2264759397548914e-07
test O 0 1.3566618406457565e-07
( O 0 2.174878943606018e-09
PTT O 0 1.0164334298679023e-06
) O 0 2.468476811845477e-10
and O 0 2.5980870232977793e-10
the O 0 3.1274366429911993e-10
restriction O 0 4.591335756032322e-09
endonuclease O 0 5.277436230244348e-07
fingerprinting O 0 3.542036211001687e-07
( O 0 1.8458731210202473e-09
REF O 0 5.695358140656026e-06
) O 0 1.96440277239196e-11
method O 0 2.3254170811171093e-10
were O 0 6.778139716168141e-10
used O 0 2.2421469125788462e-08
and O 0 4.261943686856284e-09
compared O 0 3.542035642567498e-08
for O 0 2.792049647037942e-10
their O 0 2.4325359504473454e-09
detection O 0 4.030084141959378e-07
efficiency O 0 5.976925621098417e-08
, O 0 1.4614980059501903e-10
identifying O 0 1.1362922824886823e-09
76 O 0 6.661405871355441e-10
% O 0 1.1088586299168313e-10
and O 0 6.691254217372489e-10
60 O 0 3.703827800016768e-10
% O 0 1.2089142187310387e-10
of O 0 1.4594561670300266e-10
the O 0 7.673558144460912e-08
mutations O 0 5.780050287285121e-06
, O 0 1.5178533985249487e-08
respectively O 0 7.075639700815373e-07
. O 0 3.584916612453526e-07

Most O 0 1.6864164535945747e-06
patients O 0 1.1396775789762614e-06
were O 0 9.968237435487026e-08
found O 0 1.0185841858856293e-07
to O 0 1.0154257878980388e-08
be O 0 1.8992525951944117e-07
compound O 0 8.091189556580503e-06
heterozygote O 0 9.976749424822628e-05
. O 0 8.757151590543799e-07

Seventeen O 0 3.995091446995502e-06
mutations O 0 1.4080282198847272e-05
were O 0 1.1795986409879333e-08
distinct O 0 7.187933803720625e-09
, O 0 6.433786836623767e-10
of O 0 1.3581744062740597e-10
which O 0 7.191459872046835e-08
10 O 0 4.518446949930421e-09
were O 0 3.622970439209894e-07
not O 0 1.5789822782608098e-06
reported O 0 5.740530923503684e-06
previously O 0 1.4304001751952455e-06
. O 0 3.089925542099081e-07

Mutations O 0 0.0007770860102027655
are O 0 2.2308254798986127e-08
small O 0 1.2467340937405424e-08
deletions O 0 1.685279812591034e-06
or O 0 2.5318792040707194e-07
point O 0 6.914851269357314e-07
mutations O 0 7.1273939283855725e-06
frequently O 0 3.60219559070174e-07
affecting O 0 5.800929869792526e-08
splice O 0 3.0732378490938572e-06
sites O 0 3.5084817682218272e-06
. O 0 9.296910548073356e-07

Moreover O 0 2.6091496692970395e-05
, O 0 4.847080248282509e-08
a O 0 4.496225969319312e-08
16 O 0 7.59814540174375e-08
. O 0 4.191211360193847e-07

7 O 0 1.3350827430258505e-06
- O 0 2.254047331007314e-06
kb O 0 1.655741129980015e-06
genomic O 0 2.9044005600553646e-07
deletion O 0 9.604027582099661e-07
of O 0 7.508528243604928e-10
the O 0 2.802011289659845e-09
3 O 0 1.9130301787129156e-09
end O 0 2.8329756318612453e-09
of O 0 7.087969794428162e-11
the O 0 3.915682000865672e-09
gene O 0 2.2001557908879477e-08
, O 0 4.206684167673558e-10
most O 0 3.219206012872178e-10
likely O 0 6.148247244652794e-09
a O 0 7.094848264443954e-09
result O 0 6.170321587006811e-09
of O 0 4.692087690605362e-11
recombination O 0 1.8532929857428826e-08
between O 0 1.053256948324588e-08
two O 0 1.1464572402530848e-08
LINE O 0 1.7037578800227493e-05
elements O 0 5.386139037000248e-07
, O 0 1.666311000292353e-08
was O 0 1.360323381049966e-06
identified O 0 2.7868816232512472e-06
. O 0 4.296511804113834e-07

The O 0 2.838403077021212e-07
most O 0 1.0728983923513624e-08
frequently O 0 8.732576617376253e-08
found O 0 7.011470870565972e-08
mutation O 0 1.8317908825338236e-06
, O 0 4.121876617801945e-09
identified O 0 1.6632016297535301e-07
in O 0 3.5215215188344473e-09
three O 0 6.742451486019263e-09
unrelated O 0 3.748832341443631e-06
Turkish O 0 7.851241389289498e-05
A B-Disease 1 0.9999794960021973
- I-Disease 1 0.9999805688858032
T I-Disease 1 0.999997615814209
individuals O 0 9.896475461346199e-08
, O 0 1.2502202828557074e-08
was O 0 1.0601135045362753e-06
previously O 0 2.766180386970518e-07
described O 0 6.38650135442731e-07
to O 0 3.6910507983378693e-09
be O 0 3.844755269710731e-08
a O 0 1.7304542154761293e-07
Turkish O 0 7.401410402962938e-05
A B-Disease 1 0.9999526739120483
- I-Disease 1 0.9999653100967407
T I-Disease 1 0.9999889135360718
founder O 0 2.514913103368599e-05
mutation O 0 1.34051506393007e-05
. O 0 1.4616394139466138e-07

The O 0 9.217512086934221e-08
presence O 0 1.9216324531612372e-08
of O 0 4.253966345846294e-10
a O 0 8.384465388644458e-08
founder O 0 3.567377007129835e-06
mutation O 0 1.4490802868749597e-06
among O 0 8.997525502429937e-10
relatively O 0 1.3382744912249223e-09
small O 0 6.96191881921493e-10
ethnic O 0 1.597512677697921e-09
population O 0 6.024670762272422e-10
groups O 0 1.032763874420084e-10
in O 0 1.0913764336706322e-09
Western O 0 2.0387573851365914e-09
Europe O 0 2.579829150306523e-08
could O 0 8.651012706195615e-08
indicate O 0 3.0801572847849457e-08
a O 0 2.5763672084622158e-08
high O 0 3.768780914015224e-07
carrier O 0 1.4527705616274034e-06
frequency O 0 3.3242505992348015e-07
in O 0 9.40326594367491e-10
such O 0 3.4275413618445327e-09
communities O 0 6.603674762573064e-08
. O 0 4.2443710412953806e-07

In O 0 6.137786954241164e-07
patients O 0 8.617449509529251e-08
of O 0 9.003414125352549e-10
Dutch O 0 4.210239239910152e-06
ethnic O 0 1.7230199489404185e-08
origin O 0 2.2909053143393976e-07
, O 0 3.0063487255205246e-09
however O 0 3.3830311885196807e-09
, O 0 1.0516525428272416e-09
no O 0 3.222045741324564e-09
significant O 0 2.143326183201566e-09
founder O 0 1.2962998141574644e-07
effect O 0 1.3984445956793934e-07
could O 0 1.9994479316665092e-07
be O 0 1.640581217543513e-07
identified O 0 1.970792709471425e-06
. O 0 5.061543220108433e-07

The O 0 2.0224842955940403e-07
observed O 0 4.6030353928472323e-07
genetic O 0 2.7635965693662e-07
heterogeneity O 0 7.643174058102886e-07
including O 0 4.8206629799096845e-09
the O 0 5.4889293110704784e-09
relative O 0 2.5855388230411336e-06
high O 0 5.379932872529025e-07
percentage O 0 7.951222613655773e-08
of O 0 4.282867671623336e-10
splice O 0 1.1115617780887987e-05
- O 0 0.0004784516349900514
site O 0 1.1268995876889676e-05
mutations O 0 2.9527377591875847e-06
had O 0 2.83752598306819e-07
no O 0 1.2823318229493452e-07
reflection O 0 2.140627088920155e-07
on O 0 1.164197485081786e-07
the O 0 1.3726524628054904e-07
phenotype O 0 0.00018712211749516428
. O 0 2.7524811230250634e-07

All O 0 2.4256576125480933e-07
patients O 0 9.60931288318534e-07
manifested O 0 4.504806838667719e-06
classical O 0 1.9933142539230175e-05
A B-Disease 1 0.9994673132896423
- I-Disease 1 0.9999253749847412
T I-Disease 1 0.9999902248382568
and O 0 2.441057063151675e-07
increased O 0 1.3883943950077082e-07
cellular O 0 1.995699904000503e-06
radioresistant O 0 2.2373678802978247e-06
DNA O 0 6.161645274005423e-07
synthesis O 0 7.635997576471709e-07
. O 0 1.255949655387667e-07

Determination O 0 4.289832304493757e-06
of O 0 2.3011466065980812e-09
the O 0 1.599726351386721e-09
genomic O 0 9.420219981848277e-08
structure O 0 1.2468414922750526e-07
of O 0 3.280790084048135e-10
the O 0 4.4705865676064604e-09
COL4A4 O 0 5.2611871069530025e-05
gene O 0 1.538342786489011e-08
and O 0 7.921274747246798e-10
of O 0 1.304498620235961e-09
novel O 0 5.864156264578924e-06
mutations O 0 0.0006229947903193533
causing O 0 0.006238069385290146
autosomal B-Disease 1 0.9998385906219482
recessive I-Disease 1 0.9999682903289795
Alport I-Disease 1 0.9999948740005493
syndrome I-Disease 1 0.9999879598617554
. O 0 6.547968951053917e-05

Autosomal B-Disease 1 0.9999209642410278
recessive I-Disease 1 0.999970555305481
Alport I-Disease 1 0.9999942779541016
syndrome I-Disease 1 0.9999971389770508
is O 0 2.3042235625325702e-05
a O 0 7.202412689366611e-06
progressive O 0 0.03087870590388775
hematuric B-Disease 1 0.9996342658996582
glomerulonephritis I-Disease 1 0.999996542930603
characterized O 0 0.002153032924979925
by O 0 2.9007733246544376e-06
glomerular B-Disease 1 0.9995038509368896
basement I-Disease 1 0.9998681545257568
membrane I-Disease 1 0.9773290753364563
abnormalities I-Disease 1 0.996896505355835
and O 0 7.523365184169961e-07
associated O 0 3.1142315037868684e-07
with O 0 1.3918466379436722e-07
mutations O 0 5.4843239922774956e-06
in O 0 2.0011183821111445e-08
either O 0 2.7633163313112163e-08
the O 0 1.5281132803579567e-08
COL4A3 O 0 7.045386882964522e-05
or O 0 1.6839859284800696e-08
the O 0 2.255941211615209e-09
COL4A4 O 0 1.6601159586571157e-05
gene O 0 8.141546992135318e-09
, O 0 1.3865029957482733e-10
which O 0 9.841984865976983e-11
encode O 0 8.547135221803615e-10
the O 0 1.1096864538373552e-09
alpha3 O 0 3.915373326890403e-06
and O 0 2.158037304411664e-08
alpha4 O 0 2.319417762919329e-05
type O 0 8.500001422362402e-05
IV O 0 0.00048820135998539627
collagen O 0 5.056571899331175e-05
chains O 0 1.9895576770068146e-05
, O 0 2.9185713401602698e-08
respectively O 0 6.144422854958975e-07
. O 0 2.262790701479389e-07

To O 0 1.1184270931607898e-07
date O 0 2.7588566808844917e-07
, O 0 2.123298648015748e-09
mutation O 0 1.7220934012129874e-08
screening O 0 1.3960121947320658e-08
in O 0 2.948481903075617e-09
the O 0 1.4637080436585848e-09
two O 0 1.0528090399475332e-08
genes O 0 5.6473453469152446e-08
has O 0 1.379119964894926e-07
been O 0 1.847845396696357e-07
hampered O 0 1.7658211390880751e-06
by O 0 4.572589862306131e-09
the O 0 6.118510142982814e-09
lack O 0 1.3532911680158577e-08
of O 0 2.8013794062253794e-10
genomic O 0 3.2214796874541207e-07
structure O 0 1.3334590676095104e-06
information O 0 6.672143371133643e-08
. O 0 1.8549981462001597e-07

We O 0 5.517355816664349e-07
report O 0 2.1571647579321507e-08
here O 0 3.448201169042875e-10
the O 0 4.947785237074953e-11
complete O 0 9.770430020594745e-10
characterization O 0 4.986313228982908e-08
of O 0 6.570722438370424e-11
the O 0 1.4122490954449063e-09
48 O 0 1.4191130492946513e-09
exons O 0 3.3391691633966047e-09
of O 0 5.24326519701912e-11
the O 0 2.31311614307117e-09
COL4A4 O 0 2.049959402938839e-05
gene O 0 1.6144465320167e-08
, O 0 1.2837005070043261e-10
a O 0 7.40767336360193e-10
comprehensive O 0 8.793982431143377e-09
gene O 0 1.800509430438524e-08
screen O 0 1.3393112567428034e-05
, O 0 5.410823789020469e-09
and O 0 6.969611554552557e-10
the O 0 1.7388322726130667e-10
subsequent O 0 3.911934332023748e-09
detection O 0 1.759828194280999e-07
of O 0 1.803243249165476e-10
10 O 0 7.924175204898631e-10
novel O 0 1.7166234655974222e-08
mutations O 0 1.3278420851747796e-07
in O 0 2.1800838467811445e-08
eight O 0 1.3281717201607535e-06
patients O 0 0.00015695631736889482
diagnosed O 1 0.9524546265602112
with O 0 0.00245186616666615
autosomal B-Disease 1 0.9999555349349976
recessive I-Disease 1 0.9999806880950928
Alport I-Disease 1 0.9999960660934448
syndrome I-Disease 1 0.99998939037323
. O 0 3.512449984555133e-05

Furthermore O 0 1.81436917046085e-05
, O 0 3.510036350462542e-08
we O 0 3.4098637247126362e-09
identified O 0 9.238260822996835e-09
a O 0 4.6971693201669495e-09
glycine O 0 5.374450893214089e-07
to O 0 5.461731622524724e-10
alanine O 0 1.0653716131514557e-08
substitution O 0 1.5564221023112168e-09
in O 0 7.673491841941882e-10
the O 0 1.1053560289298048e-09
collagenous O 0 1.9400706150918268e-05
domain O 0 5.472749720070169e-08
that O 0 1.9668913608938965e-08
is O 0 2.236564178303979e-08
apparently O 0 4.824661914426542e-07
silent O 0 1.6066339867393253e-06
in O 0 1.8849670713194655e-09
the O 0 1.0183268672747658e-09
heterozygous O 0 1.418761144122982e-07
carriers O 0 2.670478416177957e-08
, O 0 8.877025781117709e-10
in O 0 7.512973354550923e-09
11 O 0 3.317700603133744e-08
. O 0 2.0498973185567593e-07

5 O 0 2.651952115684253e-07
% O 0 4.922065421908428e-09
of O 0 2.0023151192649635e-10
all O 0 1.0100245084743165e-09
control O 0 3.5190868175050127e-07
individuals O 0 1.8836848525438654e-08
, O 0 6.729603541089091e-09
and O 0 1.7534080853920386e-08
in O 0 5.179792594844912e-09
one O 0 1.902979640533431e-08
control O 0 9.999161676432777e-08
individual O 0 5.4733941823315035e-09
homozygous O 0 3.0663883876513864e-07
for O 0 9.4024044106078e-10
this O 0 7.706082438829753e-10
glycine O 0 6.547811608470511e-07
substitution O 0 2.8389064254952245e-07
. O 0 8.763662151523022e-08

There O 0 8.20002924228902e-07
has O 0 5.084601184535131e-08
been O 0 5.71120928327673e-09
no O 0 2.5723934093946355e-09
previous O 0 1.309209629596353e-09
finding O 0 4.0720199434574056e-10
of O 0 2.2921994163871418e-11
a O 0 1.9147787799767002e-09
glycine O 0 8.425279673929253e-08
substitution O 0 4.942677378494409e-09
that O 0 9.324329752757876e-09
is O 0 5.51066481335738e-09
not O 0 6.576070354924468e-09
associated O 0 3.889450983507459e-09
with O 0 1.3089549444345039e-09
any O 0 4.6704776934802794e-08
obvious O 0 4.927426289214054e-06
phenotype O 0 2.865369970095344e-05
in O 0 3.054071839869721e-08
homozygous O 0 1.4358946827996988e-05
individuals O 0 2.764455757642281e-07
. O 0 1.5370704886663589e-06

Founder O 0 9.855019743554294e-05
BRCA1 O 0 0.001203919411636889
and O 0 7.941444550851884e-07
BRCA2 O 0 0.00017745589138939977
mutations O 0 1.5949908629409038e-05
in O 0 1.2759566914155585e-07
French O 0 0.000272021017735824
Canadian O 0 0.4836626648902893
breast B-Disease 1 0.9999266862869263
and I-Disease 1 0.9998167157173157
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999994039535522
families O 0 0.00011256711150053889
. O 0 6.039816071279347e-06

We O 0 9.187907039631682e-07
have O 0 9.820168678231767e-09
identified O 0 6.758793347216852e-08
four O 0 2.072633398242374e-09
mutations O 0 5.279540360447754e-08
in O 0 3.9976266741348354e-10
each O 0 4.3108641656353086e-10
of O 0 7.977251637036886e-10
the O 0 2.4851995021890616e-06
breast B-Disease 1 0.9995443224906921
cancer I-Disease 1 0.5419451594352722
- O 0 0.01764243096113205
susceptibility O 0 0.005229330621659756
genes O 0 2.50640624699372e-07
, O 0 7.297729531785535e-09
BRCA1 O 0 7.459369498974411e-06
and O 0 8.789793781716071e-08
BRCA2 O 0 6.715361450915225e-06
, O 0 1.8879606766830648e-09
in O 0 4.909642026262873e-09
French O 0 2.7073740056948736e-05
Canadian O 0 0.24261713027954102
breast B-Disease 1 0.9998273253440857
cancer I-Disease 1 0.9564136862754822
and O 0 0.0509466752409935
breast B-Disease 1 0.9999947547912598
/ I-Disease 1 0.9999972581863403
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
families O 0 1.4439525330089964e-05
from O 0 7.410280318254081e-07
Quebec O 0 0.00015594519209116697
. O 0 2.086419044644572e-06

To O 0 2.285794238332528e-07
identify O 0 8.18194621388102e-07
founder O 0 1.0668060212992714e-06
effects O 0 4.625814199243905e-06
, O 0 8.077542190676468e-09
we O 0 1.1038038039146159e-08
examined O 0 2.0083707852336374e-07
independently O 0 7.801865820056264e-08
ascertained O 0 2.0420138753252104e-06
French O 0 4.902719410893042e-06
Canadian O 0 0.00011146988981636241
cancer B-Disease 0 2.0736761143780313e-05
families O 0 1.3669828602402845e-09
for O 0 1.595742427085156e-10
the O 0 2.891319406117532e-10
distribution O 0 4.681112719673308e-10
of O 0 7.513095007238846e-11
these O 0 1.0422331886417169e-09
eight O 0 3.01645926015226e-08
mutations O 0 2.2220451683097053e-06
. O 0 5.205616275816283e-07

Mutations O 0 0.0004906674730591476
were O 0 1.1886693584983732e-07
found O 0 2.019080369564108e-08
in O 0 2.108740959627653e-09
41 O 0 1.1632630414482037e-09
of O 0 4.4120834763461403e-10
97 O 0 5.6104024537262376e-08
families O 0 1.3512514840385847e-07
. O 0 3.971730109242344e-07

Six O 0 1.1533730770452166e-07
of O 0 1.9629438074986183e-09
eight O 0 1.3630521600305201e-08
mutations O 0 8.382904184145445e-07
were O 0 6.993199974658637e-08
observed O 0 5.763245098933112e-07
at O 0 3.1687076074149445e-08
least O 0 1.564990093072538e-08
twice O 0 4.3426680349512026e-06
. O 0 5.185237341720494e-07

The O 0 7.168453066697111e-07
BRCA1 O 0 0.00019958613847848028
C4446T O 0 1.8567710867500864e-05
mutation O 0 1.41370337587432e-05
was O 0 8.937873730019419e-08
the O 0 1.5006241804726983e-09
most O 0 3.905865408881937e-09
common O 0 1.8684828262394149e-07
mutation O 0 6.04072056376026e-06
found O 0 1.9642450865831051e-07
, O 0 1.0041927289705654e-09
followed O 0 4.150482624254437e-09
by O 0 3.5760159278197534e-09
the O 0 1.138165188763196e-07
BRCA2 O 0 0.00012645636161323637
8765delAG O 0 1.952696402440779e-05
mutation O 0 7.882365935074631e-06
. O 0 1.7355147008402128e-07

Together O 0 2.420047451323626e-07
, O 0 5.989133189387985e-09
these O 0 4.1807199369081616e-10
mutations O 0 3.99024919772728e-08
were O 0 1.3656804576100967e-08
found O 0 2.2113466613404853e-08
in O 0 5.764440924593828e-09
28 O 0 1.8263036638543895e-09
of O 0 1.4989155749933758e-10
41 O 0 1.097112356518437e-08
families O 0 3.2796718674177328e-09
identified O 0 3.611028489558521e-07
to O 0 1.9929936811990956e-08
have O 0 2.253450901434917e-07
a O 0 2.052970103250118e-06
mutation O 0 6.829992344137281e-05
. O 0 7.073703613968974e-07

The O 0 8.380595062362772e-08
odds O 0 2.2260410332819447e-06
of O 0 6.184823209132162e-10
detection O 0 4.817053422812023e-07
of O 0 1.502757224214335e-10
any O 0 2.7214390740937233e-09
of O 0 1.6141647740663956e-10
the O 0 5.258443458444617e-09
four O 0 1.2900619594802265e-07
BRCA1 O 0 7.732994708931074e-05
mutations O 0 1.0606586329231504e-06
was O 0 2.148637577192858e-06
18 O 0 2.134934931063981e-07
. O 0 2.3874000021351094e-07

7x O 0 0.001075450680218637
greater O 0 2.897600097639952e-07
if O 0 2.765272455462764e-08
one O 0 9.924632227154007e-10
or O 0 5.186225893183405e-10
more O 0 1.2719020281437565e-10
cases O 0 1.4888702715154523e-08
of O 0 0.0003216391778551042
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
were O 0 0.00030599150341004133
also O 0 1.7253654505111626e-07
present O 0 1.085845635628857e-08
in O 0 7.753885533645644e-09
the O 0 3.5263898467974286e-08
family O 0 1.0578754654488876e-06
. O 0 3.221009592380142e-07

The O 0 1.193358087903107e-07
odds O 0 1.7252945099244243e-06
of O 0 7.686705161269458e-10
detection O 0 5.029804128753312e-07
of O 0 1.754851541857505e-10
any O 0 2.6204940439811253e-09
of O 0 3.583709162757742e-10
the O 0 7.308622596013947e-09
four O 0 2.0086407914732263e-07
BRCA2 O 0 4.47497695859056e-05
mutations O 0 1.0761056046248996e-06
was O 0 1.0366171636633226e-06
5 O 0 9.240572040880579e-08
. O 0 1.2365605073227925e-07

3x O 0 0.0003719409869518131
greater O 0 4.1803176031862677e-07
if O 0 7.360456777405489e-08
there O 0 1.999736154445486e-09
were O 0 2.212484861985331e-09
at O 0 2.1158357288442176e-09
least O 0 5.078131803948338e-10
five O 0 3.4682134941732556e-10
cases O 0 4.391231378519933e-09
of O 0 5.8866646668320755e-08
breast B-Disease 1 0.9998170733451843
cancer I-Disease 1 0.6164278984069824
in O 0 1.4305446427442803e-07
the O 0 1.0822999030324354e-07
family O 0 3.1278684673452517e-06
. O 0 6.139532047200191e-07

Interestingly O 0 2.1804449716000818e-05
, O 0 6.277132591492318e-09
the O 0 4.2727424376387546e-10
presence O 0 1.6065849761659479e-09
of O 0 2.2130405841203071e-10
a O 0 5.7774932429310866e-06
breast B-Disease 1 0.9973758459091187
cancer I-Disease 0 0.004420047625899315
case O 0 4.373955562186893e-07
< O 0 3.8196736795725883e-07
36 O 0 5.989861384669837e-10
years O 0 1.0699978680861477e-09
of O 0 2.370300622445143e-10
age O 0 3.460216078110534e-07
was O 0 1.2258931292308262e-07
strongly O 0 2.2363979113038113e-08
predictive O 0 2.7082929676680578e-08
of O 0 4.428918690124739e-11
the O 0 1.6394714752454576e-10
presence O 0 9.137699485961548e-10
of O 0 1.8295722575834006e-11
any O 0 2.62806582052022e-10
of O 0 8.055425770869817e-11
the O 0 2.48339149244714e-09
eight O 0 2.6740256231505555e-08
mutations O 0 1.0048246394944726e-06
screened O 0 2.3753327695885673e-05
. O 0 1.7917516288434854e-06

Carriers O 0 9.943832992576063e-07
of O 0 1.016022044275644e-09
the O 0 1.7193749757282717e-09
same O 0 1.060202503566643e-08
mutation O 0 3.894991209563159e-07
, O 0 5.201223340911554e-10
from O 0 1.6657436541223092e-10
different O 0 5.831786720200682e-10
families O 0 6.707280508777558e-09
, O 0 9.102023579288243e-10
shared O 0 2.870319981695957e-09
similar O 0 2.048440705948451e-08
haplotypes O 0 1.226459630743193e-06
, O 0 5.60784219061361e-09
indicating O 0 1.495365324899467e-07
that O 0 1.2998639942196633e-09
the O 0 4.163753786201596e-10
mutant O 0 1.1425621693206267e-07
alleles O 0 1.0638588676670224e-08
were O 0 6.0459029782578e-08
likely O 0 3.0538213735553654e-08
to O 0 1.8373376153846266e-09
be O 0 1.1220424056546108e-07
identical O 0 1.742090944389929e-06
by O 0 9.883191154358428e-09
descent O 0 1.3230302329247934e-06
for O 0 9.98569671395444e-10
a O 0 1.9001330997525656e-07
mutation O 0 5.527066946342529e-07
in O 0 3.1962399393847818e-09
the O 0 8.211570978744476e-09
founder O 0 8.720930964045692e-07
population O 0 3.0721427179969396e-08
. O 0 1.4259978797781514e-07

The O 0 3.096804590541069e-08
identification O 0 1.4512927748455695e-07
of O 0 3.2855822507116272e-09
common O 0 2.3520778995589353e-06
BRCA1 O 0 0.0007448497344739735
and O 0 3.854091119137593e-06
BRCA2 O 0 0.00133035599719733
mutations O 0 1.1563765838218387e-05
will O 0 2.098134466166357e-08
facilitate O 0 1.3134672904868694e-08
carrier O 0 3.0408016300498275e-06
detection O 0 1.8420566902932478e-06
in O 0 2.324696524169667e-08
French O 0 6.157621101010591e-05
Canadian O 0 0.05068480223417282
breast B-Disease 1 0.9998465776443481
cancer I-Disease 1 0.964996337890625
and O 0 0.08729716390371323
breast B-Disease 1 0.9999972581863403
/ I-Disease 1 0.9999960660934448
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999992847442627
families O 0 0.0001522349484730512
. O 0 4.9353793656337075e-06

Are O 0 3.227885372325545e-07
Dp71 O 0 3.2208427001023665e-05
and O 0 9.735762773743772e-08
Dp140 O 0 1.4043537703400943e-05
brain O 0 0.00022849382366985083
dystrophin O 0 2.354004573135171e-05
isoforms O 0 6.781907586628222e-07
related O 0 2.808134240694926e-07
to O 0 3.096851841632997e-08
cognitive B-Disease 0 0.00011825160618172958
impairment I-Disease 1 0.5137825012207031
in O 0 0.002450557891279459
Duchenne B-Disease 1 0.9999624490737915
muscular I-Disease 1 0.9999692440032959
dystrophy I-Disease 1 0.9999607801437378
? O 0 0.1355055421590805

Molecular O 0 0.0005626938072964549
study O 0 7.343446668528486e-07
and O 0 5.4697338214282354e-08
neuropsychological O 0 4.9512841542309616e-06
analysis O 0 5.314457496297109e-08
were O 0 6.571480692940668e-09
performed O 0 2.324359549277233e-08
concurrently O 0 5.698109095675363e-09
on O 0 6.969923305177872e-08
49 O 0 5.389413360035178e-08
patients O 0 1.4082748123200872e-07
with O 0 2.16784501390066e-05
Duchenne B-Disease 1 0.9999871253967285
muscular I-Disease 1 0.9999911785125732
dystrophy I-Disease 1 0.9999868869781494
( O 0 0.00016832631081342697
DMD B-Disease 1 0.9999973773956299
) O 0 2.4231738393609703e-08
in O 0 3.128840075916628e-09
order O 0 1.8175744243009717e-09
to O 0 1.001530081090607e-09
find O 0 2.0425805047352696e-08
a O 0 5.350869969333871e-08
molecular O 0 1.959800783879473e-06
explanation O 0 1.3442306823208128e-08
for O 0 6.73555877739318e-10
the O 0 1.178530339984718e-08
cognitive B-Disease 0 3.032496124433237e-06
impairment I-Disease 0 4.172900298726745e-05
observed O 0 3.787834430113435e-06
in O 0 3.738553289167612e-07
most O 0 8.790648280410096e-06
DMD B-Disease 1 0.9999957084655762
patients O 0 8.626635826658458e-05
. O 0 1.626924586162204e-06

Complete O 0 4.816492946702056e-07
analysis O 0 2.6757552618050795e-08
of O 0 5.354713894512031e-10
the O 0 3.3825731104997203e-09
dystrophin O 0 7.405846645269776e-06
gene O 0 2.992608756358095e-07
was O 0 1.5023209698483697e-07
performed O 0 2.9461729056379227e-08
to O 0 1.0316757448336489e-09
define O 0 3.168308992940183e-08
the O 0 6.992793566418243e-10
localization O 0 3.308764462417457e-08
of O 0 1.0962891705545985e-10
deletions O 0 2.334517006374881e-07
and O 0 5.3928477683484743e-08
duplications O 0 1.4815086615271866e-06
in O 0 1.412325278948856e-08
relation O 0 1.9245638327447523e-07
to O 0 4.652240370717209e-09
the O 0 2.2960664480820014e-08
different O 0 4.833232196688186e-07
DMD B-Disease 1 0.999969482421875
promoters O 0 0.00021687608386855572
. O 0 8.9652911583471e-07

Qualitative O 0 1.7856141312222462e-06
analysis O 0 1.4000339376707416e-07
of O 0 1.3185293967765688e-09
the O 0 2.513101282630714e-09
Dp71 O 0 5.581739515037043e-06
transcript O 0 2.6885991246672347e-06
and O 0 1.4002123016609858e-08
testing O 0 2.773405505251958e-09
for O 0 1.2155733364327403e-10
the O 0 1.6067833175092971e-10
specific O 0 5.123458879374709e-10
first O 0 9.569580683432832e-10
exon O 0 4.484680360405946e-08
of O 0 2.552329736449366e-10
Dp140 O 0 2.392204407897225e-07
were O 0 3.584731445016587e-08
also O 0 1.3883991734076062e-08
carried O 0 1.886011489204975e-07
out O 0 4.4414537825332445e-08
. O 0 1.775643170276453e-07

Neuropsychological O 0 0.0006629140698350966
analysis O 0 3.024732450285228e-06
assessed O 0 4.1064386095968075e-06
verbal O 0 1.3620533536595758e-05
and O 0 5.272124212751805e-07
visuospatial O 0 0.0008637711871415377
intelligence O 0 1.1706359146046452e-05
, O 0 7.698623960550321e-09
verbal O 0 1.4688781675431528e-06
memory O 0 0.0019155180780217052
, O 0 3.8165815396951075e-08
and O 0 2.953132316463325e-08
reading O 0 1.2713875321423984e-06
skills O 0 1.148366436609649e-06
. O 0 1.1858658410801581e-07

Comparison O 0 1.4894575315338443e-06
of O 0 1.6780417055883845e-08
molecular O 0 1.3254588338895701e-05
and O 0 1.0622594004416896e-07
psychometric O 0 0.000756887486204505
findings O 0 2.974069502670318e-06
demonstrated O 0 1.5314095662688487e-06
that O 0 3.319357011477564e-09
deletions O 0 4.453920325886429e-07
and O 0 1.8593048878301488e-08
duplications O 0 2.012300228670938e-06
that O 0 1.358386185756899e-07
were O 0 4.867861136403917e-08
localized O 0 5.955798769718967e-07
in O 0 1.0845416120730533e-08
the O 0 1.1954597312069382e-09
distal O 0 4.038871281863976e-08
part O 0 3.0299278641621186e-09
of O 0 2.54485349460154e-10
the O 0 1.8290856607094952e-09
gene O 0 1.630905543947847e-08
seemed O 0 1.8332567464085514e-08
to O 0 2.810627564020507e-10
be O 0 8.60483151399194e-09
preferentially O 0 2.4167283640963433e-07
associated O 0 3.089323996618987e-08
with O 0 1.8372443832959107e-07
cognitive B-Disease 0 0.0002553740341681987
impairment I-Disease 0 0.010249225422739983
. O 0 4.375926437205635e-06

Two O 0 1.0511460857287602e-07
altered O 0 1.66909160270734e-06
Dp71 O 0 5.407088792708237e-06
transcripts O 0 2.3966984485923604e-07
and O 0 2.8329540935345676e-09
two O 0 2.0970239433815152e-10
deleted O 0 2.8150836328677542e-08
Dp140 O 0 1.7754034686845444e-08
DNA O 0 1.62066644548986e-08
sequences O 0 9.865827266253291e-09
were O 0 5.0571591359016566e-09
found O 0 2.636900475749826e-08
in O 0 1.0618013135399451e-08
four O 0 8.125603301323281e-08
patients O 0 7.555555043836648e-07
with O 0 1.8271157387061976e-05
severe O 1 0.9995354413986206
cerebral B-Disease 1 0.9999749660491943
dysfunction I-Disease 1 0.9954220652580261
. O 0 3.388554978300817e-05

These O 0 3.559223316074167e-08
findings O 0 6.315396205991419e-08
suggest O 0 1.7833146515044973e-08
that O 0 3.806291115626692e-10
some O 0 3.280569565999869e-11
sequences O 0 2.3889787925668315e-09
located O 0 1.4893325461784457e-09
in O 0 5.647760037419403e-10
the O 0 2.871928250769429e-10
distal O 0 1.4215464361200247e-08
part O 0 1.2662603188218213e-09
of O 0 9.118560767573669e-11
the O 0 1.7873523772138356e-09
gene O 0 6.82796974516009e-09
and O 0 1.2186528230984095e-08
, O 0 1.236580726704517e-09
in O 0 1.0256717697387785e-09
particular O 0 5.124165092240673e-09
, O 0 1.8980523819323025e-09
some O 0 1.7204018210037475e-09
DMD B-Disease 1 0.999711811542511
isoforms O 0 2.8840407395591683e-08
expressed O 0 5.554478654801187e-09
in O 0 1.0468021116594173e-08
the O 0 1.5080455284532945e-07
brain O 1 0.6506222486495972
may O 0 3.3426167647121474e-05
be O 0 4.133680420181918e-08
related O 0 1.9493267444659068e-08
to O 0 2.933605136590245e-09
the O 0 2.392414160112821e-07
cognitive B-Disease 0 0.0002322397631360218
impairment I-Disease 0 0.006028603296726942
associated O 0 7.363176791841397e-06
with O 0 5.2293842600192875e-05
DMD B-Disease 1 0.9999988079071045
. O 0 2.2785691271565156e-06
. O 0 7.460447477569687e-07

I1307K O 0 0.00010097229824168608
APC O 0 1.5894396710791625e-05
and O 0 8.0551139092222e-08
hMLH1 O 0 2.6001976038969588e-06
mutations O 0 1.06903553387383e-06
in O 0 3.6385288115781123e-09
a O 0 6.590487089397357e-08
non O 0 1.075783941928421e-07
- O 0 3.794689473579638e-05
Jewish O 0 3.260152823258977e-07
family O 0 7.869898155377086e-08
with O 0 9.777261311683105e-08
hereditary B-Disease 1 0.9501392841339111
non I-Disease 1 0.824455201625824
- I-Disease 1 0.9999977350234985
polyposis I-Disease 1 0.999996542930603
colorectal I-Disease 1 1.0
cancer I-Disease 1 0.9999991655349731
. O 0 0.0003070344391744584

We O 0 3.116658717772225e-07
describe O 0 2.0346956830508134e-07
a O 0 2.8989646239097056e-08
French O 0 2.769429556792602e-06
Canadian O 0 3.3452921343268827e-05
hereditary B-Disease 1 0.882426917552948
non I-Disease 0 0.4836212694644928
- I-Disease 1 0.9999980926513672
polyposis I-Disease 1 0.9999986886978149
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 0.0008896191720850766
HNPCC B-Disease 1 0.9870157241821289
) O 0 1.088919745484418e-07
kindred O 0 1.2912173588119913e-05
which O 0 3.1321555127306056e-08
carries O 0 3.027266259891803e-08
a O 0 7.46814077245972e-09
novel O 0 6.299467969483885e-08
truncating O 0 8.481293662043754e-06
mutation O 0 4.747132152260747e-06
in O 0 4.961703226058489e-08
hMLH1 O 0 8.916969818528742e-06
. O 0 7.819458005542401e-07

Interestingly O 0 4.592343248077668e-05
, O 0 1.6500200317182134e-08
the O 0 2.3241588653633016e-09
I1307K O 0 4.033067853015382e-07
APC O 0 5.953407935521682e-07
polymorphism O 0 1.558508665766567e-05
, O 0 2.915798935632097e-09
associated O 0 4.971287825838999e-09
with O 0 6.592166257313181e-10
an O 0 5.579367190478024e-09
increased O 0 3.4964687074534595e-05
risk O 0 0.0015097922878339887
of O 0 0.0340801365673542
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 2.104262966895476e-05
is O 0 5.483270726358569e-08
also O 0 9.531404998597282e-09
present O 0 8.920719274385647e-09
in O 0 1.439455843410542e-08
this O 0 2.2087375484147742e-08
family O 0 5.147535944161064e-07
. O 0 1.0843243671843084e-06

The O 0 9.455322924623033e-08
I1307K O 0 1.2064344900863944e-06
polymorphism O 0 2.985360515594948e-05
has O 0 6.656534168314465e-08
previously O 0 2.320585323900559e-08
only O 0 7.936579171641256e-10
been O 0 7.24710389476968e-08
identified O 0 7.597897138111875e-07
in O 0 5.826553017840297e-09
individuals O 0 8.766078418709355e-10
of O 0 3.999451436698109e-09
self O 0 0.04641088470816612
- O 0 0.2744728624820709
reported O 0 3.845991886919364e-05
Ashkenazi O 0 2.2057076876080828e-06
Jewish O 0 3.3905851637427986e-07
origins O 0 1.5130196970858378e-06
. O 0 1.7201475088768348e-07

In O 0 1.0132284700148375e-07
addition O 0 1.3294876310965265e-08
, O 0 8.906671511432762e-10
in O 0 3.8020897541457543e-10
this O 0 2.34054309267151e-09
family O 0 4.5671271209357656e-08
, O 0 2.2565695978471467e-09
there O 0 2.1558022034184887e-09
appears O 0 6.899990978581627e-08
to O 0 1.3525731645813721e-09
be O 0 2.5791402791242035e-08
no O 0 2.518424047082135e-08
relationship O 0 2.294403067537587e-08
between O 0 1.1760821205797356e-09
the O 0 3.165353756884315e-09
I1307K O 0 2.3154925088419986e-07
polymorphism O 0 2.893082182708895e-06
and O 0 1.994890475032207e-09
the O 0 7.693892745130881e-10
presence O 0 5.835461891479099e-09
or O 0 1.1386619647169027e-08
absence O 0 1.500999857739771e-08
of O 0 1.726451159811404e-08
cancer B-Disease 0 0.0008751924615353346
. O 0 8.180590072015548e-08
. O 0 3.202539744506794e-07

Identification O 0 1.4226335451894556e-06
of O 0 3.1270444011965992e-09
a O 0 2.55903991330797e-08
novel O 0 3.527378567014239e-08
mutation O 0 6.70732163143839e-08
of O 0 1.2752031375296013e-10
the O 0 8.299592124672017e-09
CPO O 0 1.5610718037351035e-05
gene O 0 1.5905024852713723e-08
in O 0 1.4765731970456386e-09
a O 0 8.637987036763661e-08
Japanese O 0 6.181542994454503e-05
hereditary B-Disease 0 0.1973203867673874
coproporphyria I-Disease 0 0.05479301139712334
family O 0 4.7308035391324665e-06
. O 0 6.133661258900247e-07

Hereditary B-Disease 1 0.9919661283493042
coproporphyria I-Disease 1 0.7573566436767578
( O 0 3.4255215268785832e-06
HCP B-Disease 0 0.09460499882698059
) O 0 1.8798408163434033e-08
is O 0 1.5055331203939204e-08
an O 0 1.3909561857872177e-07
autosomal B-Disease 1 0.9996887445449829
dominant I-Disease 1 0.9998685121536255
disease I-Disease 1 0.9893859624862671
characterized O 0 0.00021627949899993837
by O 0 7.238027137645986e-07
a O 0 0.021936608478426933
deficiency B-Disease 0 0.48752376437187195
of I-Disease 0 1.419330253327189e-08
coproporphyrinogen I-Disease 0 0.005281759425997734
oxidase I-Disease 0 2.928167123172898e-05
( O 0 3.074862675589429e-08
CPO O 0 4.185103171039373e-05
) O 0 2.699930945482265e-09
caused O 0 2.319700520558854e-08
by O 0 3.380618895931775e-09
a O 0 1.1381287094991421e-06
mutation O 0 4.26683664045413e-06
in O 0 1.422099682457656e-08
the O 0 4.8070948110989775e-08
CPO O 0 0.00012627201795112342
gene O 0 5.884003826395201e-07
. O 0 1.5697501964950789e-07

Only O 0 1.664743933815771e-07
11 O 0 8.748527235979964e-09
mutations O 0 4.677083609294641e-08
of O 0 2.1000499950130092e-10
the O 0 3.093709510793019e-09
gene O 0 3.8146279734974087e-07
have O 0 6.708064006488712e-07
been O 0 1.2424619626472122e-06
reported O 0 1.5753525076434016e-05
in O 0 1.3607022992800921e-06
HCP B-Disease 1 0.9306872487068176
patients O 0 9.901996236294508e-06
. O 0 9.58823989094526e-07

We O 0 1.241828272213752e-06
report O 0 3.7441616029809666e-08
another O 0 4.509518536366386e-09
mutation O 0 2.0174064729872043e-07
in O 0 3.814971449855875e-09
a O 0 1.2479621602778934e-07
Japanese O 0 2.0692925318144262e-05
family O 0 1.0588262284727534e-06
. O 0 2.610414071568812e-07

Polymerase O 0 3.4414617402944714e-05
chain O 0 2.3554683139082044e-05
reaction O 0 1.7500303783890558e-06
- O 0 4.362841991678579e-06
single O 0 2.2138246436043119e-07
strand O 0 2.27246687245497e-06
conformational O 0 6.341686002997449e-07
polymorphism O 0 1.4842796190350782e-05
and O 0 1.0956187068700274e-09
direct O 0 1.5362661143214495e-09
sequence O 0 8.781663396462136e-09
analyses O 0 6.487420733947147e-08
demonstrated O 0 6.208372127503026e-08
a O 0 2.9762031061864036e-08
C O 0 1.3813853172450763e-07
to O 0 5.524543045254404e-10
T O 0 8.316994382084886e-08
substitution O 0 3.483222321687407e-10
in O 0 1.1612828060281188e-10
exon O 0 1.3265341713974976e-08
1 O 0 1.495055190758876e-10
of O 0 2.222892182823788e-11
the O 0 2.1876096489847896e-09
CPO O 0 9.500459441369458e-07
gene O 0 7.636144494505004e-10
at O 0 1.7436611876586738e-10
nucleotide O 0 1.0984755327569928e-08
position O 0 1.161724849652046e-08
85 O 0 2.383675201667046e-10
, O 0 2.43623538009885e-10
which O 0 4.003679610065092e-09
lies O 0 2.5015816973450455e-08
in O 0 2.7530406843112587e-09
the O 0 2.219839645434263e-09
putative O 0 1.7963284335564822e-06
presequence O 0 1.3122649988872581e-06
for O 0 1.0733951505415007e-09
targeting O 0 3.650306013014415e-08
to O 0 2.009655730716986e-08
mitochondria O 0 2.1225816453807056e-05
. O 0 6.20377932136762e-07

This O 0 4.077686810433079e-07
mutation O 0 3.131527819277835e-06
changes O 0 1.07720028452718e-08
the O 0 8.243752902536983e-10
codon O 0 9.6298622409563e-09
for O 0 1.6195027263687933e-10
glutamine O 0 1.024405449356891e-08
to O 0 1.8349587127541866e-10
a O 0 5.520627066601946e-09
termination O 0 1.0492131252703985e-07
codon O 0 7.989529038354704e-09
at O 0 1.3231221673848381e-09
amino O 0 6.8388397167495896e-09
acid O 0 5.0677449792146945e-08
position O 0 1.7826675957621774e-07
29 O 0 1.7917945172030159e-07
. O 0 1.64425586035577e-07

MaeI O 0 7.977229688549414e-05
restriction O 0 4.1423712104915467e-07
analysis O 0 6.10082224739017e-08
showed O 0 9.884628582312871e-08
two O 0 4.1732631239632667e-10
other O 0 9.585144900015052e-10
carriers O 0 2.8598563517334696e-08
in O 0 4.132267417134017e-09
the O 0 1.3773266083205726e-08
family O 0 1.0626379207678838e-06
. O 0 5.514504550774291e-07

The O 0 1.198809741254081e-06
C O 0 9.124871576204896e-05
- O 0 0.005629509687423706
T O 0 0.017995581030845642
mutation O 0 2.6604179765854497e-06
is O 0 4.9394919265921544e-09
located O 0 1.7741771385360039e-09
within O 0 2.502929807857157e-10
a O 0 2.5017534710514155e-08
recently O 0 5.844731845172646e-07
proposed O 0 6.441157385239649e-09
putative O 0 9.520379506966492e-08
alternative O 0 3.0303728415503883e-09
translation O 0 4.498247996309601e-09
initiation O 0 1.3305371249217046e-09
codon O 0 1.3720510949610798e-08
( O 0 2.222431405574099e-10
TIC O 0 1.043586394189333e-06
- O 0 1.4335042806123965e-06
1 O 0 9.65168833744201e-09
) O 0 1.4978410178834167e-10
, O 0 1.046491573952757e-10
supporting O 0 7.230380294487304e-09
that O 0 1.3730124237554264e-07
TIC O 0 4.584484486258589e-05
- O 0 3.1065003440744476e-06
1 O 0 4.2661403298893674e-09
is O 0 1.5648520257371956e-09
the O 0 7.235053667287161e-10
real O 0 2.991358314829995e-06
TIC O 0 3.0514333047904074e-05
rather O 0 3.085347755060752e-09
than O 0 1.154038864470408e-09
TIC O 0 2.5607450879761018e-06
- O 0 5.582019753092027e-07
2 O 0 2.7682049985600088e-09
. O 0 5.5842646062842505e-09
. O 0 7.881284602717642e-08

Human B-Disease 0 3.3421006264688913e-06
complement I-Disease 0 1.2395574231049977e-05
factor I-Disease 0 0.00035633175866678357
H I-Disease 1 0.9999995231628418
deficiency I-Disease 1 0.9997797608375549
associated O 0 0.000202561030164361
with O 0 0.021411867812275887
hemolytic B-Disease 1 0.9999929666519165
uremic I-Disease 1 0.9999991655349731
syndrome I-Disease 1 0.9999960660934448
. O 0 0.0002432247274555266

This O 0 1.1500527818952833e-07
study O 0 1.955016060151138e-08
reports O 0 8.38698888117051e-09
on O 0 4.935160280439277e-09
six O 0 5.750999232390086e-09
cases O 0 2.2908391628106983e-08
of O 0 1.383424859113802e-07
deficiency B-Disease 0 0.14047466218471527
in I-Disease 0 3.1450066995120096e-09
the I-Disease 0 6.240123417988741e-10
human I-Disease 0 1.7065838742169603e-09
complement I-Disease 0 3.4619167532667916e-09
regulatory I-Disease 0 2.33105001967715e-08
protein I-Disease 0 4.63733265121391e-08
Factor I-Disease 0 6.503378102706847e-08
H I-Disease 1 0.9999822378158569
( O 0 4.9672710389359054e-08
FH O 0 2.616410711198114e-05
) O 0 2.304540863695692e-10
in O 0 2.1504090175206159e-10
the O 0 4.0930911437975226e-10
context O 0 3.406574355935277e-09
of O 0 3.732957498669975e-09
an O 0 0.00011647435167105868
acute B-Disease 1 0.9999812841415405
renal I-Disease 1 1.0
disease I-Disease 1 0.9999994039535522
. O 0 0.0012787841260433197

Five O 0 6.547337250140117e-08
of O 0 9.280960444613129e-10
the O 0 4.136667453025211e-09
cases O 0 2.776503116308504e-08
were O 0 8.137343598946245e-08
observed O 0 1.1221337672395748e-06
in O 0 6.793210616251599e-08
children O 0 2.0406224621183355e-07
presenting O 0 1.3049048902757932e-05
with O 0 0.05516001954674721
idiopathic O 1 0.9999974966049194
hemolytic B-Disease 1 0.9999992847442627
uremic I-Disease 1 0.9999997615814209
syndrome I-Disease 1 0.9999994039535522
( O 0 0.0008924582507461309
HUS B-Disease 1 0.9998855590820312
) O 0 2.4449134343740297e-06
. O 0 2.611928266560426e-06

Two O 0 1.2109047986541555e-08
of O 0 7.582907080028178e-10
the O 0 5.999262864264665e-09
children O 0 2.591023928744107e-07
exhibited O 0 9.347658487968147e-05
a O 0 3.328243110445328e-05
homozygous O 1 0.9995858073234558
deficiency O 1 0.9940028786659241
characterized O 0 1.5122031982173212e-06
by O 0 4.786050222804761e-09
the O 0 6.9683787629060134e-09
absence O 0 1.207793154378578e-08
of O 0 4.790730659398612e-11
the O 0 2.464097537124843e-10
150 O 0 2.5430485495192556e-10
- O 0 7.330278322115191e-07
kD O 0 1.7314411593361e-07
form O 0 5.103114597559966e-10
of O 0 2.7097268873177427e-10
Factor O 0 4.754163285269897e-08
H O 1 0.9999579191207886
and O 0 1.7290116005597156e-08
the O 0 6.16857676050131e-10
presence O 0 2.932307507919063e-09
, O 0 1.5046960899489648e-10
upon O 0 1.3433219814285025e-10
immunoblotting O 0 5.009353287732665e-08
, O 0 1.9735510101148712e-11
of O 0 6.356630066067792e-12
the O 0 1.920655856579856e-10
42 O 0 7.384904354701405e-10
- O 0 4.296659597002872e-07
kD O 0 8.443327601526107e-07
Factor O 0 6.910445549124233e-09
H O 1 0.9948911666870117
- O 0 3.154386547521426e-07
like O 0 7.065031226716201e-09
protein O 0 1.3526899600435627e-08
1 O 0 1.908897040436841e-09
( O 0 6.117526485382996e-10
FHL O 0 1.794318507108983e-07
- O 0 8.566075848648325e-08
1 O 0 7.44164618815546e-10
) O 0 8.134182216679164e-11
and O 0 2.902258988690676e-10
other O 0 2.1834367647244335e-09
FH O 0 0.00012689459254033864
- O 0 1.1099399671365973e-05
related O 0 9.578847937063983e-08
protein O 0 9.984830029452496e-08
( O 0 3.868645404025983e-09
FHR O 0 4.375347634777427e-05
) O 0 3.5311193968823318e-09
bands O 0 6.86235523517098e-07
. O 0 2.81377452893139e-07

Southern O 0 2.7425553525972646e-06
blot O 0 1.4847977581666782e-05
and O 0 4.059660163591161e-09
PCR O 0 9.487840202382358e-08
analysis O 0 1.5151307986016604e-09
of O 0 4.45952788585835e-11
DNA O 0 4.343361581504723e-08
of O 0 4.773056949680665e-10
one O 0 1.6432086624718067e-07
patient O 0 8.46144394017756e-06
with O 0 2.357056246182765e-06
homozygous O 1 0.9989084005355835
deficiency O 1 0.9957175850868225
ruled O 0 3.3193401804965106e-07
out O 0 4.110022544523417e-09
the O 0 7.461188888946424e-10
presence O 0 2.8757944914303835e-09
of O 0 9.134837331004064e-11
a O 0 2.8502491478121783e-09
large O 0 6.109553751798558e-09
deletion O 0 6.194485990818066e-08
of O 0 9.257870581258487e-10
the O 0 7.76162778493017e-08
FH O 0 0.00014272090629674494
gene O 0 2.143429433942856e-08
as O 0 3.763448663818281e-09
the O 0 1.4258532132771506e-08
underlying O 0 0.0008379063219763339
defect O 0 0.00013496444444172084
for O 0 9.392232414029422e-08
the O 0 4.264177186996676e-05
deficiency O 1 0.9055883288383484
. O 0 9.155054954135267e-07

The O 0 3.793343594793441e-08
other O 0 5.529761648581655e-10
four O 0 1.4898126066142936e-09
children O 0 1.1583794368164035e-08
presented O 0 7.90980493547977e-07
with O 0 1.0528498023631983e-05
heterozygous O 1 0.9667730927467346
deficiency O 1 0.9631738066673279
and O 0 8.620524027946885e-08
exhibited O 0 1.0196576113230549e-05
a O 0 6.559705525432946e-07
normal O 0 4.6390667307605327e-07
immunoblotting O 0 2.2615940906689502e-06
pattern O 0 3.719306818084078e-08
of O 0 8.765638909169482e-11
proteins O 0 1.1448614278819491e-09
of O 0 3.0955021879108813e-10
the O 0 3.932449885724054e-07
FH O 0 0.0793977901339531
family O 0 1.1563836324057775e-06
. O 0 6.249669581848138e-07

Factor B-Disease 0 0.01509650144726038
H I-Disease 1 0.9999988079071045
deficiency I-Disease 1 0.99759441614151
is O 0 1.8122511491469595e-08
the O 0 4.050819679690676e-09
only O 0 7.418644827339449e-07
complement B-Disease 1 0.9999886751174927
deficiency I-Disease 1 0.9999992847442627
associated O 0 2.4102724637486972e-05
with O 0 1.784346932254266e-05
HUS B-Disease 1 0.9997643828392029
. O 0 3.593836663640104e-05

These O 0 9.191160899035822e-08
observations O 0 2.9849101679246814e-07
suggest O 0 4.2100758435026364e-08
a O 0 4.204071313296254e-09
role O 0 1.403463745219824e-08
for O 0 1.6543625136478113e-08
FH O 0 0.0006201027426868677
and O 0 1.385352419447372e-07
/ O 0 2.8685483357548947e-06
or O 0 5.041281383455498e-07
FH O 0 6.5026426455006e-05
receptors O 0 1.5186590474058903e-07
in O 0 6.217435455369014e-09
the O 0 1.5001900166566884e-08
pathogenesis O 0 2.856577339116484e-06
of O 0 8.919192140410814e-08
idiopathic O 1 0.9993614554405212
HUS B-Disease 1 0.9999516010284424
. O 0 4.099348643649137e-06
. O 0 1.5651759213142213e-06

Further O 0 8.145868690689895e-08
evidence O 0 3.42609851600173e-08
for O 0 6.199764035486055e-10
a O 0 7.1427921355393664e-09
major O 0 1.4132683467948937e-08
ancient O 0 1.3045337254879996e-06
mutation O 0 0.1743888556957245
underlying O 1 0.9962531328201294
myotonic B-Disease 1 0.9999996423721313
dystrophy I-Disease 1 0.9999995231628418
from O 0 1.443221549379814e-06
linkage O 0 0.0009931145468726754
disequilibrium O 0 0.005346290301531553
studies O 0 1.1136481958828881e-07
in O 0 3.3632796547777843e-09
the O 0 4.015824561776071e-09
Japanese O 0 5.000398687116103e-06
population O 0 2.6039836953373197e-08
. O 0 2.4234842044279503e-07

The O 0 0.0002570478536654264
myotonic B-Disease 1 0.9999909400939941
dystrophy I-Disease 1 0.9999986886978149
( O 0 0.008626976050436497
DM B-Disease 1 0.9999980926513672
) O 0 6.571890480699949e-07
mutation O 0 1.4186059161147568e-05
is O 0 3.125072112197813e-08
an O 0 1.1965444457473495e-07
unstable O 0 0.024185920134186745
( O 0 5.4312891961671994e-08
CTG O 0 7.441095931426389e-06
) O 0 7.344588826008192e-10
n O 0 1.2602018273355498e-07
repeat O 0 7.399489163617545e-07
, O 0 4.985661328227309e-10
present O 0 6.271468899754495e-10
at O 0 5.240138323259202e-10
a O 0 2.0672876743788038e-09
copy O 0 2.2916825770380456e-08
number O 0 6.605731239783807e-11
of O 0 1.844956132313058e-11
5 O 0 1.3505365714649997e-09
- O 0 1.2567277281050337e-06
37 O 0 9.857207272645496e-10
repeats O 0 1.3047431579593649e-08
on O 0 9.825058100432216e-09
normal O 0 3.968880335492031e-09
chromosomes O 0 6.169639021891271e-09
but O 0 3.6468361663821725e-10
amplified O 0 1.126618265345769e-08
to O 0 2.476578941923435e-10
50 O 0 2.4875621007502957e-10
- O 0 4.12777936276143e-08
3000 O 0 9.679748558255596e-09
copies O 0 2.767493789690434e-08
on O 0 2.1270466277201194e-06
DM B-Disease 1 0.999969482421875
chromosomes O 0 5.339653216651641e-05
. O 0 8.375560014428629e-07

Previous O 0 2.2976757918513613e-06
findings O 0 1.0298732604496763e-06
in O 0 2.1075075906651364e-08
Caucasian O 0 2.319033910680446e-06
populations O 0 1.576217911747335e-08
of O 0 9.1048529826665e-10
a O 0 2.911390947701875e-05
DM B-Disease 1 0.9999991655349731
founder O 0 1.4586955330742057e-05
chromosome O 0 1.0982232197420672e-05
raise O 0 6.60619434711407e-08
a O 0 1.9173196363908573e-08
question O 0 1.6493183707666503e-08
about O 0 3.879305765508434e-10
the O 0 5.269504832483562e-10
molecular O 0 2.654872446328227e-07
events O 0 7.336220519960079e-09
involved O 0 4.200921388530787e-09
in O 0 2.3284807415535624e-09
the O 0 3.776679413647344e-09
expansion O 0 9.332995318800386e-07
mutation O 0 4.621748303179629e-06
. O 0 2.051336593922315e-07

To O 0 8.002404427998044e-08
investigate O 0 2.2753219752758014e-07
whether O 0 3.9870382551043804e-08
a O 0 2.8688218023376066e-08
founder O 0 4.206913217785768e-07
chromosome O 0 4.618390903488034e-06
for O 0 4.675671849696528e-09
the O 0 9.933586397892213e-07
DM B-Disease 1 0.9999995231628418
mutation O 0 7.245222514029592e-05
exists O 0 2.5254950131170517e-08
in O 0 5.168165340130315e-10
the O 0 5.44771727728488e-10
Japanese O 0 1.1831547652718655e-07
population O 0 3.6646591317079924e-10
, O 0 3.9770317594722826e-10
we O 0 2.0560884106402e-09
genotyped O 0 2.1240740011307935e-07
families O 0 2.424220824082113e-10
using O 0 2.2317392378568e-09
polymorphic O 0 1.3807347443162143e-07
markers O 0 8.298707143694628e-07
near O 0 1.4414331417356152e-07
the O 0 2.021997680401455e-08
( O 0 1.2247252989538993e-08
CTG O 0 1.961677980943932e-06
) O 0 6.597839496969016e-10
n O 0 1.1166195434952897e-07
repeat O 0 9.691276545709115e-07
region O 0 1.399245785904668e-08
and O 0 2.9037513726848374e-08
constructed O 0 7.025742525001988e-05
haplotypes O 0 0.00018744339467957616
. O 0 1.2947076584168826e-06

Six O 0 1.2342383115537814e-07
different O 0 6.761176063463381e-09
haplotypes O 0 1.937474507940351e-06
were O 0 1.750142644141306e-07
found O 0 8.422642281402659e-07
and O 0 1.024019638862228e-05
DM B-Disease 1 0.9999986886978149
alleles O 0 5.6613994274812285e-06
were O 0 1.1941543789362186e-06
always O 0 5.171324119146448e-06
haplotype O 0 1.4050906429474708e-05
A O 0 1.4167088693284313e-06
. O 0 4.693298478741781e-07

To O 0 5.760355747952417e-08
find O 0 2.9428536052478194e-08
an O 0 4.116068597070921e-10
origin O 0 3.787579583303113e-09
of O 0 4.4271894483749463e-10
the O 0 1.3928658226802781e-08
( O 0 9.328457117874223e-09
CTG O 0 1.4443520512941177e-06
) O 0 4.0580946936152884e-10
n O 0 1.0129328131824877e-07
repeat O 0 4.2077437001353246e-07
mutation O 0 1.4365818401529395e-07
and O 0 1.9610653101409525e-09
to O 0 1.3201777449012297e-09
investigate O 0 1.2553289963079806e-08
the O 0 3.8348860198489376e-10
mechanism O 0 1.4293297656564619e-09
of O 0 2.686505531923622e-11
the O 0 2.7589580620102083e-10
expansion O 0 5.476359810074882e-09
mutation O 0 1.2141656569042425e-08
in O 0 1.405691119060748e-10
the O 0 8.448472477162738e-11
Japanese O 0 1.0798502358966289e-07
population O 0 2.940853116584208e-10
we O 0 1.0686701523709985e-09
have O 0 4.3752693135168386e-10
studied O 0 1.79104142628006e-09
90 O 0 1.8891521680330925e-10
Japanese O 0 2.6898430860455846e-06
DM B-Disease 1 0.9999582767486572
families O 0 5.823331150622835e-09
comprising O 0 4.255832908306445e-10
190 O 0 1.936370619404215e-09
affected O 0 1.6853733963984041e-09
and O 0 4.948526033388134e-09
130 O 0 7.073930774481596e-09
unaffected O 0 8.890164053809713e-07
members O 0 2.2584739411968258e-08
. O 0 1.6526712443010183e-07

The O 0 6.448708234074729e-08
results O 0 1.3601946591279557e-07
suggest O 0 4.549434251543971e-08
that O 0 2.2462076643137152e-09
a O 0 6.8242589357225825e-09
few O 0 5.451951334833893e-09
common O 0 9.68334923356906e-09
ancestral O 0 5.696823563994258e-07
mutations O 0 1.4752514232441172e-07
in O 0 2.2049522208078542e-09
both O 0 8.19980083832661e-09
Caucasian O 0 1.2904991990581038e-06
and O 0 9.849341608969553e-08
Japanese O 0 1.742406652738282e-06
populations O 0 3.1365003927419366e-09
have O 0 1.4811624149402292e-09
originated O 0 2.3760038381226423e-10
by O 0 1.9550281532554337e-11
expansion O 0 1.9272169970996345e-10
of O 0 1.2157489424902135e-11
an O 0 2.929924358685554e-10
ancestral O 0 1.523922747992401e-07
n O 0 3.830208470390062e-07
= O 0 2.872019067012843e-08
5 O 0 1.227425105998492e-10
repeat O 0 5.909701172868154e-09
to O 0 7.24082405145765e-10
n O 0 3.825619501185429e-07
= O 0 9.316102023149142e-08
19 O 0 9.35692856529613e-10
- O 0 9.569808412379643e-08
37 O 0 3.345557164635693e-09
copies O 0 8.532890660717385e-08
. O 0 3.815118887473545e-08

These O 0 3.8010789182862936e-08
data O 0 1.6931876345438468e-08
support O 0 3.033258311191389e-09
multistep O 0 7.031358251197162e-08
models O 0 4.2652963827549684e-08
of O 0 1.1744928363199847e-09
triplet O 0 0.0001448301918571815
repeat O 0 1.8461366835254012e-06
expansion O 0 4.160265021369014e-08
that O 0 5.911956257875772e-09
have O 0 2.239624041777688e-09
been O 0 1.577453279111296e-09
proposed O 0 9.996292682501462e-10
for O 0 3.286346750286384e-09
both O 0 1.6380031411245e-06
DM B-Disease 1 0.9999988079071045
and O 0 0.0001310240477323532
Friedreichs B-Disease 0 0.004099288489669561
ataxia I-Disease 0 0.013458490371704102
. O 0 1.900299793078375e-07
. O 0 2.3174013108473446e-07

The O 0 8.057511280412655e-08
molecular O 0 1.7316555158686242e-06
basis O 0 6.656775752844624e-08
of O 0 9.108644917432684e-06
C6 B-Disease 1 1.0
deficiency I-Disease 1 0.9999995231628418
in O 0 4.010308174429156e-08
the O 0 4.658518015787649e-09
western O 0 2.086612660434639e-08
Cape O 0 2.536531553687382e-07
, O 0 3.177651475283483e-09
South O 0 6.800415786045733e-09
Africa O 0 2.4164261702708245e-08
. O 0 7.152242176289292e-08

Deficiency B-Disease 1 0.9865092635154724
of I-Disease 0 2.141635313535062e-08
the I-Disease 0 1.3986054092640643e-08
sixth I-Disease 0 1.4201756926013331e-07
component I-Disease 0 2.8618917014000544e-08
of I-Disease 0 4.674706177709709e-10
human I-Disease 0 9.868009520630494e-09
complement I-Disease 0 2.0037772685554955e-07
( O 0 1.5206323311645065e-08
C6 O 0 0.00016888818936422467
) O 0 4.429309696796224e-10
has O 0 6.484684345053893e-09
been O 0 5.993226892542225e-08
reported O 0 3.0969940212344227e-07
in O 0 1.3872285542504414e-09
a O 0 8.95450646964946e-09
number O 0 1.2453502673537287e-09
of O 0 2.574596091875492e-10
families O 0 1.9244776883198256e-09
from O 0 6.884354197822518e-10
the O 0 2.9655031763553552e-09
western O 0 1.5566723021720463e-08
Cape O 0 1.196685985860313e-07
, O 0 2.8200262125466224e-09
South O 0 3.995334285633589e-09
Africa O 0 6.2672507183947346e-09
. O 0 5.6254574332115226e-08

Meningococcal B-Disease 1 0.9992306232452393
disease I-Disease 1 0.9330323934555054
is O 0 1.0909087677646312e-06
endemic O 0 1.6045239590312121e-06
in O 0 4.915638562863478e-09
the O 0 1.0200205124988315e-08
Cape O 0 5.387146302382462e-07
and O 0 4.5135979398480686e-09
almost O 0 3.863098729794956e-10
all O 0 1.4213552557151843e-10
pedigrees O 0 1.193039480540392e-07
of O 0 6.34507113517202e-09
total O 0 0.0018346020951867104
C6 B-Disease 1 0.9999998807907104
deficiency I-Disease 1 0.9999988079071045
( O 0 8.909823634439817e-08
C6Q0 O 0 0.00019476839224807918
) O 0 2.996742187733048e-09
have O 0 7.272634494626118e-09
been O 0 6.67563142542349e-08
ascertained O 0 4.424190592544619e-06
because O 0 7.407143698401342e-08
of O 0 3.294846706580756e-08
recurrent O 1 0.9960378408432007
disease O 1 0.5892655253410339
. O 0 6.397031484084437e-06

We O 0 5.145263344275008e-07
have O 0 4.564869371392888e-09
sequenced O 0 1.5644230799694014e-08
the O 0 3.696051242840781e-10
expressed O 0 1.3331180603870507e-09
exons O 0 9.743096995862288e-09
of O 0 2.452371083982996e-10
the O 0 5.6337330356370785e-09
C6 O 0 1.41085629365989e-05
gene O 0 1.6265743196797189e-09
from O 0 7.648866262588427e-11
selected O 0 8.243171145672079e-10
cases O 0 1.1473447747434307e-09
and O 0 1.9076749069313337e-08
have O 0 1.254952337603754e-07
found O 0 1.610670210538956e-07
three O 0 1.646203706684446e-08
molecular O 0 0.004984359722584486
defects O 0 0.1129351332783699
leading O 0 1.305936194739843e-07
to O 0 1.304186270090213e-07
total O 0 1.8983679183293134e-05
deficiency O 1 0.5683271288871765
879delG O 0 8.422767677984666e-06
, O 0 1.2740667187927102e-08
which O 0 2.1757262658184118e-08
is O 0 6.041866118522421e-09
the O 0 6.994064438714531e-09
common O 0 1.3539569181375555e-06
defect O 0 4.487592741497792e-05
in O 0 1.555710582579195e-08
the O 0 1.4025618888524605e-08
Cape O 0 2.484523520251969e-07
and O 0 1.1088703288919532e-08
hitherto O 0 1.5927390961678611e-07
unreported O 0 6.320457401898238e-08
, O 0 1.2885189581979262e-09
and O 0 1.3039215263077608e-09
1195delC O 0 1.0837499786475746e-07
and O 0 6.0069802465534394e-09
1936delG O 0 1.6965456950401858e-07
, O 0 9.276500123611697e-10
which O 0 2.2379884612178103e-09
have O 0 9.363430919506754e-09
been O 0 6.6594040504242e-08
previously O 0 1.465059966676563e-07
reported O 0 1.8061405171465594e-07
in O 0 3.750757482379186e-09
African O 0 2.923522757214414e-09
- O 0 4.9714821216184646e-05
Americans O 0 1.0886783456953708e-06
. O 0 1.8634094089975406e-07

We O 0 7.641169759153854e-07
also O 0 5.979111872278509e-09
show O 0 1.3906811702213417e-08
that O 0 3.556505367985352e-10
the O 0 9.421901037143243e-10
879delG O 0 2.0036216028529452e-06
and O 0 3.998123077053606e-07
1195delC O 0 0.0002526297466829419
defects O 0 0.43699318170547485
are O 0 1.7636379467944607e-08
associated O 0 6.911529482067635e-08
with O 0 2.3344857424945076e-07
characteristic O 0 0.09374643117189407
C6 O 1 0.9942008852958679
/ O 0 0.0002966848260257393
C7 O 0 0.0003895951376762241
region O 0 6.831124466089022e-08
DNA O 0 9.56157691689441e-07
marker O 0 5.591425178863574e-06
haplotypes O 0 7.1021327130438294e-06
, O 0 1.092018386827931e-08
although O 0 2.478791838456118e-09
small O 0 2.507628549253127e-09
variations O 0 1.650642502681876e-07
were O 0 7.033243036858039e-07
observed O 0 4.404043465910945e-06
. O 0 7.131202437449247e-07

The O 0 4.6179764012777014e-07
1936delG O 0 2.986758408951573e-05
defect O 0 0.00013210182078182697
was O 0 3.236321788335772e-07
observed O 0 7.732105444802073e-08
only O 0 5.616189180379649e-10
once O 0 1.9820115326751875e-08
in O 0 1.0551666207447852e-09
the O 0 2.3386064196273537e-09
Cape O 0 1.35184450300585e-07
, O 0 1.2059072629355683e-09
but O 0 1.3083883976250377e-09
its O 0 9.794517419337012e-10
associated O 0 3.62426924027659e-08
haplotype O 0 1.438347908333526e-06
could O 0 1.9482901336687064e-07
be O 0 7.467573936992267e-08
deduced O 0 2.0654067611758364e-06
. O 0 4.847477725888893e-07

The O 0 1.2562408358007815e-07
data O 0 5.2361276203782836e-08
from O 0 7.241183208606117e-10
the O 0 1.3317356106767875e-09
haplotypes O 0 7.353804107879114e-07
indicate O 0 5.575592467721435e-07
that O 0 3.7700007560204085e-09
these O 0 4.720707158512027e-10
three O 0 6.7524639213445425e-09
molecular O 0 0.0024078451097011566
defects O 0 0.04670647904276848
account O 0 1.1545352407438259e-07
for O 0 4.71739758367562e-09
the O 0 2.2678156597066845e-07
defects O 1 0.6991016268730164
in O 0 1.8113597732849485e-08
all O 0 8.579000287944893e-10
the O 0 2.6507160910682614e-09
38 O 0 4.382696427995825e-09
unrelated O 0 1.8257236433782964e-07
C6Q0 O 0 7.580218516523018e-05
individuals O 0 6.18252604667191e-09
we O 0 1.8650517574769765e-08
have O 0 2.158493161985575e-09
studied O 0 9.789909327651003e-09
from O 0 9.106277398807094e-10
the O 0 1.218313450124242e-08
Cape O 0 1.1289660051261308e-06
. O 0 1.0851958620605728e-07

We O 0 2.324649130969192e-06
have O 0 1.0224514568335508e-08
also O 0 1.431829099729498e-09
observed O 0 6.232014904128391e-09
the O 0 8.035433984865392e-10
879delG O 0 8.713142278793384e-07
defect O 0 2.4270698304462712e-06
in O 0 5.378545608891727e-09
two O 0 2.4755098593232105e-07
Dutch O 1 0.997383177280426
C6 B-Disease 1 0.9999995231628418
- I-Disease 1 0.9999470710754395
deficient I-Disease 1 0.9999692440032959
kindreds O 0 3.427623596508056e-05
, O 0 1.0678434136934811e-08
but O 0 1.9833266140523165e-09
the O 0 4.1111022919260165e-10
879delG O 0 6.895010642438137e-07
defect O 0 1.1519784948177403e-06
in O 0 1.1223453277864337e-09
the O 0 2.8251352368613425e-09
Cape O 0 2.351469703398834e-07
probably O 0 3.4334982501604827e-07
did O 0 1.717003250689686e-08
not O 0 2.59511551137237e-10
come O 0 1.790538411983178e-10
from O 0 8.908128401596827e-11
The O 0 6.803240748531891e-10
Netherlands O 0 1.4554151448464836e-06
. O 0 2.0107984610717722e-08
. O 0 7.460398876446561e-08

Complement B-Disease 1 0.9852151870727539
C7 I-Disease 1 0.9999949932098389
deficiency I-Disease 1 0.9999971389770508
: O 0 1.9730126155081962e-07
seven O 0 5.308517625479681e-09
further O 0 9.045555415809758e-09
molecular O 0 0.20626036822795868
defects O 1 0.9989646673202515
and O 0 5.178615651857399e-07
their O 0 1.6541976322059782e-07
associated O 0 8.127972250804305e-07
marker O 0 3.629594357335009e-05
haplotypes O 0 0.00022949771664571017
. O 0 9.909638265526155e-07

Seven O 0 1.7134446750333154e-07
further O 0 6.259246898565607e-09
molecular O 0 1.9618819351308048e-06
bases O 0 2.2955730401008623e-06
of O 0 5.440489258035086e-05
C7 B-Disease 1 0.9999998807907104
deficiency I-Disease 1 0.9999997615814209
are O 0 2.730086862356984e-06
described O 0 8.582844020565972e-05
. O 0 2.4333319288416533e-06

All O 0 2.4399161802080016e-08
these O 0 2.1908415082094734e-09
new O 0 8.972116383176854e-09
molecular O 0 0.00014649861259385943
defects O 0 0.023246781900525093
involve O 0 4.866125280500455e-08
single O 0 1.1716706467268523e-06
- O 0 1.3945605132903438e-05
nucleotide O 0 4.507663788899663e-07
events O 0 5.726939367178829e-09
, O 0 2.761380013538428e-10
deletions O 0 2.6276524067725404e-08
and O 0 9.692070257472096e-09
substitutions O 0 3.0861201594234444e-08
, O 0 3.0388971894446115e-10
some O 0 1.810652322520312e-11
of O 0 1.3466877613055317e-10
which O 0 4.470179604254554e-08
alter O 0 3.7082642734276305e-07
splice O 0 2.5666025749160326e-07
sites O 0 5.7922616036876207e-08
, O 0 4.709198808683368e-09
and O 0 1.4797766567653525e-08
others O 0 3.807348036843905e-08
codons O 0 6.439551043513347e-07
. O 0 1.0297952002247257e-07

They O 0 2.5176657914016687e-07
are O 0 5.725985796622979e-10
distributed O 0 2.870635951168765e-10
along O 0 5.131399749558341e-10
the O 0 3.001936699220664e-09
C7 O 0 5.109654739499092e-05
gene O 0 4.69648178125226e-08
, O 0 4.675464460035528e-10
but O 0 2.7203372887640853e-10
predominantly O 0 6.188336648671466e-11
towards O 0 1.5249788931637198e-10
the O 0 7.006478175419772e-10
3 O 0 9.042312676399433e-09
end O 0 4.944113740634748e-08
. O 0 1.0751747225867803e-07

All O 0 7.377815336440108e-08
were O 0 3.672079174066312e-08
found O 0 2.5387281610278478e-08
in O 0 1.0509652703660777e-08
compound O 0 1.7706963717500912e-06
heterozygous O 0 9.934790796251036e-06
individuals O 0 2.8750261549248535e-07
. O 0 7.453243711097457e-07

The O 0 2.114361268468201e-05
C6 O 1 0.6985874772071838
/ O 0 0.00041569338645786047
C7 O 0 0.001272381516173482
marker O 0 4.5683718781219795e-05
haplotypes O 0 0.00016105348186101764
associated O 0 8.449981123703765e-07
with O 0 7.237392907200046e-08
most O 0 9.973644409910776e-06
C7 B-Disease 1 0.999755322933197
defects I-Disease 1 0.999523401260376
are O 0 2.46854114038797e-07
tabulated O 0 0.0001443318324163556
. O 0 5.3616684425605854e-08
. O 0 9.185727378735464e-08

A O 0 3.7046909255877836e-06
genome O 0 1.1523037528604618e-06
- O 0 1.9882340893673245e-06
wide O 0 8.937720252788495e-08
search O 0 5.1170864878713473e-08
for O 0 4.785840168608502e-09
chromosomal O 0 0.0004300947766751051
loci O 0 4.5172441787144635e-06
linked O 0 0.004099884536117315
to O 0 7.985608135641087e-06
mental O 1 0.9778326153755188
health O 0 0.0006030750228092074
wellness O 0 5.8130834077019244e-05
in O 0 2.6006489406427136e-07
relatives O 0 1.2623166867342661e-06
at O 0 1.1848568419736694e-06
high O 0 5.0696806283667684e-05
risk O 0 2.9649971111211926e-05
for O 0 2.7661119474942097e-06
bipolar B-Disease 1 0.9999485015869141
affective I-Disease 1 0.9998576641082764
disorder I-Disease 1 0.9803603291511536
among O 0 5.8440409844706664e-08
the O 0 6.625261050885456e-08
Old O 0 1.188824353448581e-05
Order O 0 2.645575669646405e-08
Amish O 0 7.018668384262128e-06
. O 0 1.7171285549011372e-07

Bipolar B-Disease 1 0.9996448755264282
affective I-Disease 1 0.9994614720344543
disorder I-Disease 1 0.9997826218605042
( O 0 0.0002133254165528342
BPAD B-Disease 1 0.9999947547912598
; O 0 0.0001141665707109496
manic B-Disease 1 0.9999287128448486
- I-Disease 1 0.9999946355819702
depressive I-Disease 1 0.9999985694885254
illness I-Disease 1 0.9997923970222473
) O 0 1.3627602868382382e-07
is O 0 3.949738314190654e-08
characterized O 0 1.0506830250278654e-07
by O 0 4.314288037932101e-09
episodes O 0 1.1862289284181315e-07
of O 0 1.591752862850626e-08
mania B-Disease 0 0.019592933356761932
and O 0 4.252577582519734e-06
/ O 0 6.289825978456065e-05
or O 0 4.6049331103859e-06
hypomania B-Disease 0 0.0002934285148512572
interspersed O 0 7.951842349029903e-07
with O 0 1.3949237320787233e-08
periods O 0 3.906002348230686e-07
of O 0 3.764483835766441e-08
depression B-Disease 0 0.00016989394498523325
. O 0 1.0962046417262172e-06

Compelling O 0 4.844649083679542e-06
evidence O 0 4.4981732116866624e-07
supports O 0 1.1535468757983836e-07
a O 0 9.480907614545231e-09
significant O 0 5.119885848614558e-09
genetic O 0 9.45308613609086e-08
component O 0 5.1176137105812813e-08
in O 0 3.746674526183824e-09
the O 0 6.8969749911218514e-09
susceptibility O 0 6.142819620436057e-05
to O 0 1.2610577471150464e-07
develop O 0 2.167404818465002e-05
BPAD B-Disease 1 0.9999808073043823
. O 0 7.564418865513289e-06

To O 0 1.1640054964345836e-07
date O 0 3.458638957454241e-07
, O 0 1.8810952795433877e-09
however O 0 1.0164717956229197e-09
, O 0 3.9532768725258904e-10
linkage O 0 3.8264661839093606e-07
studies O 0 7.144686176019377e-09
have O 0 1.939238769566032e-09
attempted O 0 1.2019941664220823e-07
only O 0 3.6094285338350574e-09
to O 0 3.5258298503038077e-09
identify O 0 4.2639626940399467e-07
chromosomal O 0 0.00016684309230186045
loci O 0 2.559582412686723e-07
that O 0 4.4186739955875964e-07
cause O 0 2.495766239007935e-06
or O 0 9.659262190098161e-08
increase O 0 1.5043495693589648e-07
the O 0 1.303199184121695e-07
risk O 0 3.4240715649502818e-06
of O 0 2.23516973818505e-08
developing O 0 7.33160368326935e-06
BPAD B-Disease 1 0.9999740123748779
. O 0 3.183542958140606e-06

To O 0 1.0349127421704907e-07
determine O 0 4.597003737671912e-07
whether O 0 3.457688535490888e-08
there O 0 1.186752385251566e-08
could O 0 1.3759238015609299e-07
be O 0 6.212174241682078e-08
protective O 0 6.91657942297752e-06
alleles O 0 2.8567326282313843e-08
that O 0 1.196363719202509e-08
prevent O 0 6.982297406921134e-08
or O 0 5.868704988643003e-08
reduce O 0 7.479804509102905e-08
the O 0 1.3249359831490892e-08
risk O 0 9.24783662981099e-08
of O 0 7.627788956021675e-10
developing O 0 4.575471450607438e-07
BPAD B-Disease 1 0.9999949932098389
, O 0 4.198566383450952e-09
similar O 0 1.4772323364553586e-09
to O 0 8.986412725064952e-10
what O 0 6.476921665665714e-09
is O 0 1.679353656136584e-09
observed O 0 1.539317295851106e-08
in O 0 5.758199694838595e-09
other O 0 7.711117291364644e-07
genetic B-Disease 1 0.999998927116394
disorders I-Disease 1 0.9999994039535522
, O 0 2.9275754513946595e-06
we O 0 1.6439890941910562e-06
used O 0 0.011067541316151619
mental O 1 0.6137233972549438
health O 0 4.400118632474914e-05
wellness O 0 1.8828763131750748e-05
( O 0 1.266096827379215e-08
absence O 0 3.1093641439383646e-08
of O 0 2.0431756286853897e-09
any O 0 2.1360161554184742e-05
psychiatric B-Disease 1 0.9922204613685608
disorder I-Disease 0 0.2592358887195587
) O 0 1.1295143487188852e-08
as O 0 5.719647422353091e-09
the O 0 2.9628250075575124e-08
phenotype O 0 1.755278935888782e-05
in O 0 1.596355936328564e-08
our O 0 2.7262981205922188e-08
genome O 0 4.5360042832953695e-08
- O 0 5.070921247352089e-07
wide O 0 5.033536965015628e-08
linkage O 0 4.365872428024886e-06
scan O 0 7.291357178473845e-06
of O 0 2.0887767904209653e-10
several O 0 1.850532505009994e-10
large O 0 1.238273572568005e-08
multigeneration O 0 1.182031337521039e-05
Old O 0 1.2978563290744205e-06
Order O 0 3.4158131878569975e-09
Amish O 0 8.250318046520988e-07
pedigrees O 0 3.4252473142259987e-06
exhibiting O 0 1.1790558573920862e-07
an O 0 5.3857420745373474e-09
extremely O 0 1.965494448086247e-06
high O 0 5.3671806199417915e-06
incidence O 0 0.000440650328528136
of O 0 1.8045099636765372e-07
BPAD B-Disease 1 0.999993085861206
. O 0 7.948090569698252e-06

We O 0 2.3066861558618257e-06
have O 0 1.620820988534888e-08
found O 0 1.0248510484700546e-08
strong O 0 9.793271082969568e-09
evidence O 0 1.6706900751728426e-08
for O 0 1.3014790356535855e-09
a O 0 4.828790878264044e-08
locus O 0 1.491916918894276e-06
on O 0 1.0703311090765055e-06
chromosome O 0 0.0001982628455152735
4p O 0 0.00011332899157423526
at O 0 3.765144640510698e-08
D4S2949 O 0 3.1488622198594385e-07
( O 0 9.907913378626176e-10
maximum O 0 7.960206716006724e-08
GENEHUNTER O 0 1.9529274140950292e-05
- O 0 9.360048238704621e-07
PLUS O 0 1.2020820783220643e-08
nonparametric O 0 3.2926038784353295e-08
linkage O 0 8.711316468179575e-08
score O 0 4.76392791881608e-09
= O 0 7.3040933301626865e-09
4 O 0 8.00298854963799e-11
. O 0 6.144688924347719e-11
05 O 0 3.595920716747969e-08
, O 0 3.190573638622851e-10
P O 0 8.248760536844202e-07
= O 0 8.845256083134245e-09
5 O 0 7.234056409455292e-11
. O 0 3.1463595617786666e-11
22 O 0 2.0167267855697446e-10
x O 0 5.098556812299648e-07
10 O 0 9.384131249845495e-10
( O 0 1.6658867341146077e-10
- O 0 8.712194699000975e-07
4 O 0 2.469660254078576e-09
) O 0 1.1291641927035911e-10
; O 0 1.2907468149858659e-10
SIBPAL O 0 9.58924886163004e-08
Pempirical O 0 1.5816690179804027e-08
value O 0 6.673206986995694e-10
< O 0 4.3042116537606034e-09
3 O 0 1.822009348950715e-10
x O 0 4.812507654605724e-07
10 O 0 1.110639358259391e-09
( O 0 2.1823574891666198e-10
- O 0 7.40755297101714e-07
5 O 0 2.12201922700217e-09
) O 0 3.4884214961117266e-10
) O 0 1.2120773829060738e-10
and O 0 2.8199669266371075e-09
suggestive O 0 2.5736667339515407e-06
evidence O 0 8.131463147265094e-08
for O 0 1.7321465373143496e-09
a O 0 1.1082723005984008e-07
locus O 0 6.381164894264657e-06
on O 0 8.207413884520065e-06
chromosome O 0 0.0020840910729020834
4q O 0 0.017568476498126984
at O 0 3.0710118892329774e-08
D4S397 O 0 2.822029898652545e-07
( O 0 5.612312281577658e-10
maximum O 0 5.6150380345343365e-08
GENEHUNTER O 0 2.102880898746662e-05
- O 0 1.0567118806648068e-06
PLUS O 0 1.3414260813249257e-08
nonparametric O 0 3.3999938864326396e-08
linkage O 0 6.78867735359745e-08
score O 0 5.838534100632842e-09
= O 0 1.1782202768984007e-08
3 O 0 7.23412510450494e-11
. O 0 5.694104909803599e-11
29 O 0 6.630185289679957e-10
, O 0 1.4045976881593703e-10
P O 0 4.757633291774255e-07
= O 0 3.843088958177532e-09
2 O 0 3.166026468770511e-11
. O 0 3.677660259659987e-11
57 O 0 2.1919856207919253e-10
x O 0 2.6907974870482576e-07
10 O 0 6.745869973734386e-10
( O 0 2.0164421521418063e-10
- O 0 1.3715259683522163e-06
3 O 0 3.859697894625924e-09
) O 0 2.3266193138749003e-10
; O 0 2.240144181264725e-10
SIBPAL O 0 9.33274861836253e-08
Pempirical O 0 1.601497956471576e-08
value O 0 7.039148153253905e-10
< O 0 3.2543105987770105e-09
1 O 0 3.4577907204180747e-10
x O 0 2.9004451107539353e-07
10 O 0 4.998992331195495e-10
( O 0 2.341461746713236e-10
- O 0 1.7203064999193884e-06
3 O 0 4.437962886072455e-09
) O 0 4.6331727343584816e-10
) O 0 1.241538261087527e-10
that O 0 3.033975737309902e-09
are O 0 2.8545320773787353e-08
linked O 0 0.0003470844530966133
to O 0 1.4216233466868289e-05
mental O 1 0.9807742238044739
health O 0 0.003580969525501132
wellness O 0 0.0007620857795700431
. O 0 2.137874162144726e-06

These O 0 2.3142740701587172e-07
findings O 0 1.7524860140838427e-07
are O 0 1.1287858425745867e-09
consistent O 0 2.5508334999813087e-08
with O 0 2.4071327153762923e-09
the O 0 5.2460413790811344e-09
hypothesis O 0 3.502657079934579e-07
that O 0 2.906537011071464e-09
certain O 0 7.109827171447591e-10
alleles O 0 1.1249669640278626e-08
could O 0 1.7353956138776994e-07
prevent O 0 1.5908885586668475e-07
or O 0 8.523862504716817e-08
modify O 0 5.3767227115031346e-08
the O 0 4.8069823677110435e-09
clinical O 0 1.550506425473941e-07
manifestations O 0 2.0822312762902584e-06
of O 0 4.435933931290492e-08
BPAD B-Disease 1 0.9999984502792358
and O 0 1.443885139451595e-06
perhaps O 0 1.174530765979398e-07
other O 0 2.856943570606063e-09
related O 0 6.781132924515987e-06
affective B-Disease 1 0.6806560754776001
disorders I-Disease 1 0.9835103750228882
. O 0 1.708823583612684e-05

Segregation O 0 0.0012581802438944578
distortion O 0 0.0930248498916626
in O 0 0.0011492354096844792
myotonic B-Disease 1 0.9999878406524658
dystrophy I-Disease 1 0.9999957084655762
. O 0 0.0006019971333444118

Myotonic B-Disease 1 0.9999663829803467
dystrophy I-Disease 1 0.9999933242797852
( O 0 0.020793264731764793
DM B-Disease 1 0.9999947547912598
) O 0 4.863230174123601e-07
is O 0 2.0163518854587892e-08
an O 0 8.697752207353915e-08
autosomal B-Disease 1 0.9863813519477844
dominant I-Disease 1 0.9990687966346741
disease I-Disease 1 0.9263649582862854
which O 0 1.2691306210399489e-06
, O 0 8.604930989974946e-09
in O 0 1.9043728816114935e-09
the O 0 4.425646960015683e-09
typical O 0 6.953285264899023e-06
pedigree O 0 5.49400137970224e-05
, O 0 2.8209715119409395e-10
shows O 0 1.7044726741133331e-09
a O 0 2.550559541347752e-09
three O 0 4.37009184395265e-09
generation O 0 4.2711334913292376e-07
anticipation O 0 5.911192033636326e-07
cascade O 0 6.902201675984543e-06
. O 0 3.64907776884138e-07

This O 0 1.7586471301456186e-07
results O 0 3.8035233274058555e-07
in O 0 8.399684929827345e-07
infertility B-Disease 1 0.9987013339996338
and O 1 0.9930853843688965
congenital B-Disease 1 0.9999998807907104
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 5.3540527005679905e-05
CDM B-Disease 0 0.000622689665760845
) O 0 2.9862208261732803e-09
with O 0 5.841773176307186e-10
the O 0 7.169859372879728e-09
disappearance O 0 4.81144752484397e-06
of O 0 7.870109186569607e-08
DM B-Disease 1 0.9999991655349731
in O 0 8.789238563622348e-07
that O 0 7.062945428515377e-07
pedigree O 0 0.000405847211368382
. O 0 3.696795545238274e-07

The O 0 2.5759446131701225e-08
concept O 0 2.543691479672816e-08
of O 0 6.886875514311441e-10
segregation O 0 5.59957271661915e-08
distortion O 0 4.4109408918302506e-05
, O 0 6.654932160898852e-09
where O 0 4.478677428920719e-09
there O 0 7.507253707572659e-10
is O 0 4.5828818517890113e-10
preferential O 0 4.178984269742614e-09
transmission O 0 9.451121485426484e-08
of O 0 3.03338257290342e-11
the O 0 2.748076211034345e-10
larger O 0 6.6516583352438374e-09
allele O 0 1.730558985002517e-08
at O 0 1.150913031544576e-09
the O 0 1.5789440865887627e-08
DM B-Disease 1 0.9999940395355225
locus O 0 2.7283451345283538e-05
, O 0 4.799445108005784e-08
has O 0 2.0655585686313316e-08
been O 0 5.678861381142042e-09
put O 0 1.057758591826996e-08
forward O 0 4.354773874837292e-09
to O 0 2.602234649984325e-09
explain O 0 1.591853759919104e-07
partially O 0 6.212470680111437e-07
the O 0 3.0484308410905214e-09
maintenance O 0 1.9723560740203538e-07
of O 0 8.115485172766057e-09
DM B-Disease 1 0.999990701675415
in O 0 8.289880781831016e-08
the O 0 2.9239203058750718e-08
population O 0 3.735787146297298e-08
. O 0 1.8522122502417915e-07

In O 0 1.35698400072215e-07
a O 0 8.42675831336237e-08
survey O 0 3.3609731531214493e-07
of O 0 1.7407851160555765e-08
DM B-Disease 1 0.999998927116394
in O 0 5.366599111766845e-07
Northern O 0 1.0243257975162123e-07
Ireland O 0 5.696970220014919e-07
, O 0 6.513045658351757e-09
59 O 0 9.792897159854874e-09
pedigrees O 0 3.1863251024333294e-06
were O 0 4.368377517494082e-07
ascertained O 0 5.571039582719095e-05
. O 0 3.909892996034614e-07

Sibships O 0 7.00787641108036e-05
where O 0 3.36913643650405e-08
the O 0 9.352182361865857e-10
status O 0 1.4733351205720169e-09
of O 0 3.661932215792696e-11
all O 0 4.9311849742439406e-11
the O 0 2.9994740025074407e-10
members O 0 5.382524981278891e-10
had O 0 2.7235390120949887e-07
been O 0 4.0783277199807344e-08
identified O 0 1.1223591656062126e-07
were O 0 1.5626158145209956e-08
examined O 0 1.3629954764837748e-07
to O 0 2.150508437992471e-09
determine O 0 6.921899142753318e-08
the O 0 4.432058275938289e-09
transmission O 0 2.408424961686251e-07
of O 0 1.6352086351645312e-10
the O 0 1.263848616872565e-07
DM B-Disease 1 0.9999784231185913
expansion O 0 7.148560143832583e-08
from O 0 2.238889296179991e-09
affected O 0 5.739077213462451e-09
parents O 0 5.410545345085893e-09
to O 0 1.4714338636423463e-09
their O 0 2.9116266730966345e-08
offspring O 0 3.4499266803322826e-06
. O 0 2.49127367624169e-07

Where O 0 6.199231279424566e-07
the O 0 6.309328171028028e-08
transmitting O 0 0.00011658424773486331
parent O 0 8.969276450443431e-07
was O 0 7.90912679349276e-07
male O 0 6.150619356048992e-07
, O 0 1.6316056061782547e-08
58 O 0 3.561192585266326e-08
. O 0 1.3403933962763404e-07

3 O 0 1.3811798282858945e-07
% O 0 3.821919669633189e-09
of O 0 1.9871954082262278e-10
the O 0 7.981974192716734e-09
offspring O 0 1.8950636331283022e-06
were O 0 8.824177371025144e-07
affected O 0 6.067679692023376e-08
, O 0 1.539936178573953e-09
and O 0 3.4013676319943897e-09
in O 0 9.57283030622591e-10
the O 0 1.7524308670857636e-09
case O 0 1.327655496652369e-08
of O 0 3.01083491471843e-10
a O 0 1.1067277227994055e-06
female O 0 0.0005791026051156223
transmitting O 0 0.0031937030144035816
parent O 0 3.1482377949032525e-07
, O 0 5.8274753911291555e-09
68 O 0 5.2481855306041325e-08
. O 0 2.3882469690761354e-07

7 O 0 1.9197661913494812e-06
% O 0 1.6541913794299035e-07
were O 0 1.9388853900181857e-07
affected O 0 6.209887715158402e-07
. O 0 6.509359877782117e-07

Studies O 0 8.41466203382879e-07
on O 0 2.6983723699913753e-08
meiotic O 0 2.1995197130308952e-06
drive O 0 7.219937288027722e-07
in O 0 5.003901151212631e-07
DM B-Disease 1 0.9999971389770508
have O 0 6.307974445007858e-07
shown O 0 2.5079174292841344e-07
increased O 0 4.6307917500598705e-08
transmission O 0 1.508908695768696e-07
of O 0 4.381054199975587e-11
the O 0 3.975386131394032e-10
larger O 0 6.742863156716794e-09
allele O 0 2.818457467412827e-08
at O 0 1.6859940110691696e-09
the O 0 2.3100573898204857e-08
DM B-Disease 1 0.9999668598175049
locus O 0 5.068854989076499e-06
in O 0 6.299263333175986e-08
non O 0 1.1127771131214104e-06
- O 1 0.7338417172431946
DM O 1 0.9999898672103882
heterozygotes O 0 5.774530291091651e-05
for O 0 8.262902895239677e-08
CTGn O 0 0.00013477873289957643
. O 0 5.609663844552415e-07

This O 0 7.97926844597896e-08
study O 0 4.7423962534765e-09
provides O 0 5.731394803198953e-10
further O 0 1.2978071395330915e-10
evidence O 0 3.1514135745425165e-09
that O 0 6.384440975892858e-09
the O 0 2.0242474363385554e-08
DM B-Disease 1 0.9999784231185913
expansion O 0 1.1848563730154638e-07
tends O 0 2.603218973717958e-08
to O 0 3.787382629738545e-10
be O 0 1.1935511246008446e-08
transmitted O 0 4.017377250420395e-06
preferentially O 0 1.4715769793838263e-06
. O 0 1.2499786805619806e-07

Diagnosis O 1 0.8653164505958557
of O 0 4.388310117064975e-05
hemochromatosis B-Disease 1 0.9999768733978271
. O 0 0.00021685562387574464

If O 0 0.00019430520478636026
untreated O 0 0.2104288935661316
, O 0 1.3676672097062692e-05
hemochromatosis B-Disease 1 0.9999994039535522
can O 0 0.017452390864491463
cause O 0 0.051702722907066345
serious O 1 0.5243909358978271
illness O 1 0.5290624499320984
and O 0 1.9211896074011747e-07
early B-Disease 0 6.85909640196769e-07
death I-Disease 0 7.544558320660144e-05
, O 0 6.796539331332951e-09
but O 0 4.788691754242791e-08
the O 0 1.7374141236814467e-07
disease O 0 1.3908787877880968e-05
is O 0 2.5374790268983816e-08
still O 0 4.444029855221743e-08
substantially O 0 2.869057880161563e-07
under O 0 5.229979365140025e-07
- O 1 0.9841593503952026
diagnosed O 1 0.9338474869728088
. O 0 5.383359166444279e-06

The O 0 6.929401763500209e-08
cornerstone O 0 3.2593817422821303e-07
of O 0 1.1852971937287293e-09
screening O 0 8.120087358065575e-08
and O 0 1.57795660982174e-08
case O 0 4.439150558255278e-08
detection O 0 5.105987384013133e-07
is O 0 7.313081251680842e-10
the O 0 1.1012035033841627e-10
measurement O 0 1.2023839701669203e-07
of O 0 6.189023737945831e-10
serum O 0 1.5856061509111896e-05
transferrin O 0 1.7536840459797531e-06
saturation O 0 2.8856538847321644e-07
and O 0 1.5620250648495926e-09
the O 0 1.3609037452511075e-08
serum O 0 7.740129512967542e-05
ferritin O 0 0.000295546546112746
level O 0 1.3821974107486312e-06
. O 0 2.2420405798584397e-07

Once O 0 2.976623136419221e-06
the O 0 7.424173276149304e-08
diagnosis O 0 0.0008101696148514748
is O 0 7.366622156723679e-08
suspected O 0 3.914611625077669e-06
, O 0 2.4679286170226078e-08
physicians O 0 1.9314731147801467e-08
must O 0 1.6761223520234125e-08
use O 0 8.1512773419945e-08
serum O 0 0.0023881839588284492
ferritin O 0 0.20610739290714264
levels O 0 3.236431211917079e-06
and O 0 4.6715378232420335e-08
hepatic O 0 5.912452979828231e-05
iron O 0 0.0009740322129800916
stores O 0 1.5897147420673718e-07
on O 0 1.3755172858509468e-06
liver O 0 1.9108352717012167e-05
biopsy O 0 0.016085710376501083
specimens O 0 3.096636646660045e-05
to O 0 1.893735657176876e-08
assess O 0 1.9506303488014964e-06
patients O 0 2.2010329558952435e-08
for O 0 5.775311340272538e-10
the O 0 1.9548995755513943e-09
presence O 0 4.022657407176666e-08
of O 0 1.6756333209855256e-08
iron B-Disease 1 0.7296249866485596
overload I-Disease 0 0.013405444100499153
. O 0 7.094877219060436e-07

Liver O 0 0.20344336330890656
biopsy O 1 0.605252742767334
is O 0 4.706440108748211e-07
also O 0 6.780612515910889e-09
used O 0 9.104232923107247e-09
to O 0 9.575131798555958e-10
establish O 0 4.56403359549995e-09
the O 0 1.5585669421724901e-09
presence O 0 5.453136608934983e-09
or O 0 1.3634031681419856e-08
absence O 0 8.535573137180563e-09
of O 0 2.890830019808277e-09
cirrhosis B-Disease 0 9.874879469862208e-05
, O 0 1.2879594279979756e-08
which O 0 4.403209885595061e-08
can O 0 7.308694875973742e-07
affect O 0 1.126863139688794e-06
prognosis O 0 0.006047977600246668
and O 0 7.488897040275333e-07
management O 0 1.013106498248817e-06
. O 0 1.9831901454381295e-07

A O 0 7.97599511770386e-07
DNA O 0 8.327633622684516e-06
- O 0 1.5300785889849067e-05
based O 0 3.053623487403456e-08
test O 0 2.9581592730920647e-09
for O 0 3.0394070593686706e-10
the O 0 2.672010612769782e-09
HFE O 0 3.25132641592063e-05
gene O 0 2.3195411813503597e-08
is O 0 6.115087880509407e-10
commercially O 0 6.040056899081492e-09
available O 0 1.8539142443430023e-09
, O 0 3.046383423299659e-10
but O 0 1.9345680613014338e-10
its O 0 9.667339845309542e-11
place O 0 2.4244115603977434e-09
in O 0 2.2694668366796122e-09
the O 0 2.7413621594973847e-08
diagnosis O 0 0.0010693860240280628
of O 0 5.704821433027973e-07
hemochromatosis B-Disease 1 0.9999997615814209
is O 0 1.348001660517184e-05
still O 0 3.7098487837283756e-07
being O 0 2.5658488311819383e-07
evaluated O 0 1.6480909152960521e-06
. O 0 6.483010679403378e-07

Currently O 0 5.24285781011713e-07
, O 0 2.143747179772504e-09
the O 0 4.75069594774169e-10
most O 0 2.860873760113236e-10
useful O 0 8.52092896241885e-10
role O 0 1.0773415493048333e-09
for O 0 2.3013912997527086e-10
this O 0 1.1919535358728695e-09
test O 0 1.085212009144243e-08
is O 0 1.0289263885354671e-09
in O 0 1.7268610152942898e-10
the O 0 1.0456382426582422e-09
detection O 0 4.935624019708484e-06
of O 0 1.0786542503637975e-07
hemochromatosis B-Disease 1 0.9999994039535522
in O 0 2.132783976094288e-07
the O 0 9.320168636861581e-09
family O 0 1.7072194324896373e-08
members O 0 1.5477975845445968e-10
of O 0 1.1459165838445529e-09
patients O 0 3.018807603893947e-08
with O 0 4.701193656586611e-09
a O 0 6.8362996898940764e-06
proven O 0 0.0010735818650573492
case O 0 1.070958504101327e-07
of O 0 2.9484650276856428e-09
the O 0 3.161124823236605e-06
disease O 0 0.00039273849688470364
. O 0 8.472147214888537e-07

It O 0 1.3315766977939347e-07
is O 0 4.755675409029436e-09
crucial O 0 1.4159503791688621e-08
to O 0 9.703474006528268e-07
diagnose O 1 0.9998311996459961
hemochromatosis B-Disease 1 0.9999997615814209
before O 0 0.21618399024009705
hepatic B-Disease 1 0.9995394945144653
cirrhosis I-Disease 1 0.9981531500816345
develops O 0 0.00035247739288024604
because O 0 3.944478976336541e-06
phlebotomy O 0 0.01039944775402546
therapy O 0 0.0008918525418266654
can O 0 4.1929292819986586e-06
avert O 0 0.014862621203064919
serious O 1 0.999373733997345
chronic O 1 0.9999960660934448
disease O 1 0.9955386519432068
and O 0 3.0804153539065737e-06
can O 0 2.9026830361544853e-06
even O 0 1.0002537464970374e-07
lead O 0 3.069354548301817e-08
to O 0 6.308098488005953e-09
normal O 0 6.595492152428051e-08
life O 0 3.480935220068204e-07
expectancy O 0 5.270475753604842e-07
. O 0 6.0695755088602255e-09
. O 0 4.192142455394787e-08

Prevalence O 0 0.0006128880777396262
of O 0 8.917894867011e-09
the O 0 6.763033244538974e-09
I1307K O 0 4.701052773725678e-07
APC B-Disease 0 2.3328433940150717e-07
gene O 0 3.733258324700728e-08
variant O 0 2.0574356085489853e-07
in O 0 3.9601237844522075e-09
Israeli O 0 4.860708031628747e-07
Jews O 0 1.2967989349021991e-08
of O 0 1.562483059602826e-10
differing O 0 4.1941081718732676e-09
ethnic O 0 1.081160050375729e-09
origin O 0 7.231555798625777e-08
and O 0 4.1985683196799073e-07
risk O 0 3.2657513656886294e-05
for O 0 0.004452177789062262
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999991655349731
. O 0 8.903811976779252e-05

BACKGROUND O 0 0.0008932893979363143
& O 0 6.168363142933231e-06
AIMS O 0 2.0676758083482127e-07
Israeli O 0 3.475356038507016e-07
Jews O 0 2.1968682872852696e-08
of O 0 4.1074654788531006e-10
European O 0 1.335733088581037e-07
birth O 0 1.327756490354659e-05
, O 0 9.66069535479619e-09
i O 0 4.210244526348106e-07
. O 0 1.8600586348949122e-10
e O 0 1.1440581815236328e-09
. O 0 2.542447086195665e-10
, O 0 1.380871111900106e-10
Ashkenazim O 0 1.3240265772651583e-08
, O 0 5.764878019398623e-10
have O 0 1.448365161138554e-08
the O 0 1.929633981490042e-06
highest O 1 0.9999493360519409
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
incidence O 1 0.9957820177078247
of O 0 1.1193016291599633e-08
any O 0 8.941845663912318e-08
Israeli O 0 1.7746740923030302e-05
ethnic O 0 1.5884008064404043e-07
group O 0 1.5577955991830095e-06
. O 0 2.6530295826887595e-07

The O 0 3.1957847568264697e-07
I1307K O 0 2.0795064301637467e-06
APC B-Disease 0 5.583797815233993e-07
gene O 0 1.9458019551166217e-07
variant O 0 3.4175241125922184e-06
was O 0 1.3918056538386736e-06
found O 0 1.1251670173351158e-07
in O 0 3.310317708837829e-08
6 O 0 1.6503402093803743e-06
. O 0 1.2611326383193955e-06

1 O 0 1.055165483876408e-07
% O 0 1.1544901701299182e-09
of O 0 1.2323489451127045e-10
American O 0 8.29111179712072e-09
Jews O 0 1.2871048227225401e-08
, O 0 4.4757716977095185e-10
28 O 0 3.642359747146884e-10
% O 0 7.001731833211622e-11
of O 0 2.8001187479809175e-10
their O 0 0.0003581133496481925
familial O 1 0.9999992847442627
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
cases O 0 0.00021118848235346377
, O 0 3.443052420948334e-08
but O 0 1.9283259433677813e-08
not O 0 4.1616199375482665e-09
in O 0 3.0670999073834082e-09
non O 0 2.23107647912002e-08
- O 0 5.2914925618097186e-05
Jews O 0 1.2380018006297178e-06
. O 0 2.7059030571763287e-07

We O 0 1.1220503211006871e-06
assessed O 0 4.855741053688689e-07
the O 0 4.686582677493334e-09
I1307K O 0 1.0884873518079985e-06
prevalence O 0 3.066314320676611e-06
in O 0 2.819370070739069e-09
Israeli O 0 2.727169885474723e-07
Jews O 0 1.316210873625323e-08
of O 0 1.4917937718461616e-10
differing O 0 5.677648573509941e-09
ethnic O 0 2.123209608129173e-09
origin O 0 6.013654996195328e-08
and O 0 3.308178122551908e-07
risk O 0 2.4123444745782763e-05
for O 0 0.014024551957845688
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
. O 0 0.0002206871286034584

METHODS O 0 7.647898883078597e-07
DNA O 0 4.5309977281249303e-07
samples O 0 6.156334819706899e-08
from O 0 1.0841068043276891e-09
500 O 0 5.435926708763361e-10
unrelated O 0 2.4543339804949937e-08
Jews O 0 9.79439196413523e-09
of O 0 4.6121528818332536e-10
European O 0 2.271650600960129e-08
or O 0 2.4286521238536807e-08
non O 0 4.181456070284639e-09
- O 0 1.5053598190206685e-06
European O 0 1.7538695828989148e-08
origin O 0 1.3373666618576863e-08
, O 0 3.968643191853971e-10
with O 0 5.869795760560237e-10
or O 0 1.831282148145874e-08
without O 0 3.066544129737281e-09
a O 0 4.035950684766476e-09
personal O 0 2.9603818347823108e-06
and O 0 3.4625309126568027e-06
/ O 0 1.9828337372018723e-06
or O 0 7.337175134125573e-08
family O 0 2.899893658536712e-08
history O 0 1.0030293928764422e-08
of O 0 4.727278568594784e-09
neoplasia B-Disease 0 0.002936729695647955
, O 0 2.2501840390987127e-08
were O 0 3.01467615315687e-08
examined O 0 2.1041260822585173e-07
for O 0 7.607214858040834e-10
the O 0 1.9581425370063243e-09
I1307K O 0 8.424910191706658e-08
variant O 0 4.5892019073789925e-08
by O 0 7.778100385991138e-10
the O 0 6.105441929804556e-09
allele O 0 1.600884758090615e-07
- O 0 1.6915277001317008e-07
specific O 0 7.601099305531989e-09
oligonucleotide O 0 1.930523467308376e-05
( O 0 1.985591069342263e-08
ASO O 0 0.00010038368782261387
) O 0 3.070752541134425e-09
method O 0 3.923398850247395e-08
. O 0 8.094063019825626e-08

RESULTS O 0 1.6194253475987352e-05
In O 0 2.4586823244021616e-08
persons O 0 8.933285222667564e-09
at O 0 5.2218251056501686e-08
average O 0 1.4266837752074935e-05
risk O 0 3.351835403009318e-05
for O 0 0.03828055039048195
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 1.9794158561126096e-06
I1307K O 0 3.5114273941871943e-06
was O 0 1.102767441807373e-06
found O 0 3.898975009519745e-08
in O 0 1.9215518065607284e-08
5 O 0 9.449769322600332e-08
. O 0 3.7645924066964653e-07

0 O 0 2.479413296896382e-07
% O 0 4.063883007887625e-09
of O 0 3.778817814215074e-10
120 O 0 1.1276969358320343e-09
European O 0 1.6255485846272677e-08
and O 0 3.777812551675197e-08
1 O 0 6.917318984278609e-08
. O 0 2.1999716182108386e-07

6 O 0 1.2501038781920215e-07
% O 0 1.246750036543176e-09
of O 0 9.115273813531388e-11
188 O 0 1.5543869524847764e-09
non O 0 3.428384465209433e-09
- O 0 1.2474164350351202e-06
European O 0 2.6094078009464283e-08
Jews O 0 4.903112582610447e-08
( O 0 2.462975601247308e-09
P O 0 2.0175500594632467e-06
= O 0 7.94282541960456e-08
0 O 0 1.4415707516590714e-09
. O 0 4.415821597270053e-10
08 O 0 4.787100049696846e-09
) O 0 9.846271575852938e-10
. O 0 1.962615492345776e-08

It O 0 3.0370523518286063e-07
occurred O 0 9.75469220065861e-07
in O 0 1.284791828481957e-08
15 O 0 4.548098075929374e-08
. O 0 3.2314949294232065e-07

4 O 0 1.707744701207048e-07
% O 0 5.399205527112372e-09
of O 0 5.747552989099347e-10
52 O 0 2.212561867054319e-08
Ashkenazi O 0 2.823294607878779e-06
Israelis O 0 1.4160416412778432e-06
with O 0 1.1893150713149225e-06
familial O 1 0.9994500279426575
cancer B-Disease 1 0.9740422964096069
( O 0 1.0490910540283949e-07
P O 0 0.0006309346063062549
= O 0 8.957121622188424e-07
0 O 0 2.94748114804122e-09
. O 0 9.920052557177428e-10
02 O 0 1.0661135974032732e-08
) O 0 7.649027244926998e-11
and O 0 2.8258519968460405e-09
was O 0 5.753958021159633e-07
not O 0 8.418854235969775e-08
detected O 0 2.2755896225135075e-06
in O 0 6.792453266513121e-10
51 O 0 6.536974850313015e-10
non O 0 2.417485100991712e-09
- O 0 5.812885888190067e-07
European O 0 2.2647892450322615e-08
Jews O 0 1.564581175728108e-08
at O 0 3.440944951194069e-08
increased O 0 4.543959221336991e-06
cancer B-Disease 0 0.0007215844234451652
risk O 0 1.2956912541994825e-05
. O 0 5.899883035453968e-07

Colorectal B-Disease 1 0.9988699555397034
neoplasia I-Disease 1 0.9942225813865662
occurred O 0 0.0008338132174685597
personally O 0 2.4075983674265444e-05
or O 0 5.284839943442421e-08
in O 0 2.2904185215111283e-09
the O 0 7.015798497711501e-10
families O 0 8.049086397399208e-10
of O 0 1.04662133126876e-10
13 O 0 4.854162072298607e-10
of O 0 2.1286786222596277e-10
20 O 0 3.63666941005647e-09
Ashkenazi O 0 1.0402661132502544e-07
I1307K O 0 7.753504149832224e-08
carriers O 0 7.3075909767794656e-09
, O 0 1.468309918095656e-10
8 O 0 1.266926563658899e-10
of O 0 1.886185374555538e-10
whom O 0 7.285576657523052e-07
also O 0 4.093142820238427e-07
had O 0 5.511602125807258e-07
a O 0 8.969895048949184e-08
personal O 0 3.4627519198693335e-05
or O 0 7.247047619785008e-07
family O 0 1.1537669308836485e-07
history O 0 6.52156231240042e-08
of O 0 6.100903959804782e-08
noncolonic O 0 0.016373148187994957
neoplasia B-Disease 0 0.20237022638320923
. O 0 1.7992620087170508e-06

CONCLUSIONS O 0 1.3957765986560844e-05
The O 0 5.458207397168735e-08
I1307K O 0 1.2188362461529323e-06
APC O 0 9.679822596808663e-07
variant O 0 5.70007432543207e-06
may O 0 1.3042411239894136e-07
represent O 0 1.68568203839925e-09
a O 0 3.0663350969462044e-08
susceptibility O 0 9.23818297451362e-05
gene O 0 3.8401935853471514e-07
for O 0 1.140800804932951e-06
colorectal B-Disease 1 0.9999998807907104
, I-Disease 0 2.374775021962705e-06
or I-Disease 0 2.0746840334595618e-07
other I-Disease 0 7.774841215280048e-09
, I-Disease 0 2.378264838398536e-07
cancers I-Disease 0 0.013182304799556732
in O 0 6.658565325778909e-07
Ashkenazi O 0 2.012759978242684e-05
Jews O 0 1.4917005728420918e-06
, O 0 3.730347231112319e-08
and O 0 3.521671132489246e-08
partially O 0 1.8982271967615816e-06
explains O 0 5.964011506875977e-08
the O 0 1.9658552563583953e-09
higher O 0 4.529528894181567e-07
incidence O 0 0.010952663607895374
of O 0 0.0059961904771625996
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
in O 0 9.982437404687516e-06
European O 0 2.4240509901574114e-06
Israelis O 0 2.257069900224451e-05
. O 0 1.3280551911520888e-06

Systematic O 0 2.6021150461019715e-06
analysis O 0 4.5414844862534665e-07
of O 0 1.8652830391374664e-08
coproporphyrinogen O 0 0.0003489417431410402
oxidase O 0 0.00013009495160076767
gene O 0 0.0001810807443689555
defects O 1 0.9296035766601562
in O 0 4.5492348021980433e-07
hereditary B-Disease 0 0.47226107120513916
coproporphyria I-Disease 0 0.16054818034172058
and O 0 2.1595644739136333e-06
mutation O 0 0.00011369561980245635
update O 0 1.1436460226832423e-05
. O 0 7.338111913668399e-07

Hereditary B-Disease 1 0.9891624450683594
coproporphyria I-Disease 1 0.5315574407577515
( O 0 7.235519206005847e-06
HC B-Disease 1 0.644639253616333
) O 0 1.539400216188369e-07
is O 0 4.223129224101285e-07
an O 0 6.331434633466415e-06
acute O 1 0.9998056292533875
hepatic B-Disease 1 0.9999344348907471
porphyria I-Disease 1 0.9999743700027466
with O 0 0.0024076870176941156
autosomal O 1 0.9994860887527466
dominant O 0 0.18674011528491974
inheritance O 0 0.48527225852012634
caused O 0 0.00195346144028008
by O 0 5.924488277742057e-07
deficient B-Disease 0 0.00020777012105099857
activity I-Disease 0 4.088226646103976e-08
of I-Disease 0 2.6295865485082004e-09
coproporphyrinogen I-Disease 0 0.00461300415918231
III I-Disease 0 0.002692286390811205
oxidase I-Disease 0 9.961819159798324e-06
( O 0 2.1160870389280717e-08
CPO O 0 1.2105731912015472e-05
) O 0 1.0000055006287312e-08
. O 0 5.352482546072679e-08

Clinical O 0 0.0001100646986742504
manifestations O 0 3.315021240268834e-05
of O 0 4.456048330325757e-08
the O 0 1.0668280083336867e-05
disease O 0 0.041961584240198135
are O 0 8.093336845149679e-08
characterized O 0 1.585400605108589e-05
by O 0 1.1005465239577461e-05
acute O 0 0.2754577100276947
attacks O 0 0.1499481350183487
of O 0 2.6645879188436083e-05
neurological B-Disease 1 0.9999723434448242
dysfunction I-Disease 1 0.9158985614776611
often O 0 6.29754913461511e-06
precipitated O 0 6.138962362456368e-06
by O 0 1.4685802796066127e-08
drugs O 0 9.344754658968668e-08
, O 0 3.9123522199702165e-09
fasting O 0 5.0973604004411754e-08
, O 0 5.10119013696908e-09
cyclical O 0 1.7060114259948023e-05
hormonal O 0 0.0003307349106762558
changes O 0 1.23649925853897e-07
, O 0 6.963970378137674e-08
or O 0 4.559927765512839e-05
infectious B-Disease 0 0.42818889021873474
diseases I-Disease 0 0.003306166036054492
. O 0 1.5705437590440852e-06

Skin O 1 0.9990641474723816
photosensitivity O 1 0.9991269707679749
may O 0 0.000619803206063807
also O 0 1.3269672649585118e-07
be O 0 5.273089342949788e-08
present O 0 2.3973154839040944e-07
. O 0 5.931742066422885e-07

The O 0 1.3946953458798816e-07
seven O 0 9.75970593231068e-09
exons O 0 2.1997996668687847e-07
, O 0 6.2469474038096e-10
the O 0 7.201666485379121e-10
exon O 0 1.8804488490786753e-06
/ O 0 3.075968777466187e-07
intron O 0 1.1673153039737372e-06
boundaries O 0 4.477106241296269e-09
and O 0 1.0920823134696889e-09
part O 0 3.961775907335152e-10
of O 0 8.161828851660502e-11
3 O 0 4.073666959314437e-10
noncoding O 0 2.093357487353842e-08
sequence O 0 4.835172817685418e-10
of O 0 3.5392411223966747e-11
the O 0 8.570724685519338e-10
CPO O 0 1.132067950493365e-06
gene O 0 3.789465630177347e-09
were O 0 4.202804770869761e-09
systematically O 0 4.1957104457424066e-08
analyzed O 0 1.6219591003618916e-08
by O 0 1.9957419050697922e-10
an O 0 5.308130046621784e-10
exon O 0 6.593291459466855e-07
- O 0 4.845184776058886e-06
by O 0 5.6835240513919416e-08
- O 0 4.7876746975816786e-05
exon O 0 1.3910751476942096e-05
denaturing O 0 1.8910210201283917e-05
gradient O 0 1.5323854313464835e-05
gel O 0 0.00012807764869648963
electrophoresis O 0 1.3997061614645645e-05
( O 0 6.5104499569201835e-09
DGGE O 0 4.357710622571176e-06
) O 0 1.0756736473771511e-10
strategy O 0 8.34329938470546e-10
followed O 0 8.676232648996418e-11
by O 0 2.0311053186561345e-11
direct O 0 3.0024391306504583e-10
sequencing O 0 6.418787723561081e-09
in O 0 2.15794559998983e-09
seven O 0 1.944260974440226e-09
unrelated O 0 1.8641078440850833e-06
heterozygous O 0 5.561208672588691e-05
HC B-Disease 1 0.7471269369125366
patients O 0 9.786680266188341e-07
from O 0 4.798364727776061e-08
France O 0 9.928746294463053e-05
, O 0 4.2749071837988595e-08
Holland O 0 4.157031526119681e-06
, O 0 1.0468199640456533e-08
and O 0 1.1295535529143308e-07
Czech O 0 0.0034194360487163067
Republic O 0 5.562534624914406e-06
. O 0 1.0981025297951419e-06

Seven O 0 3.04393012129367e-07
novel O 0 6.131106147222454e-07
mutations O 0 9.296182724938262e-06
and O 0 9.548982937701567e-09
two O 0 2.4541784160447833e-09
new O 0 6.844506117431592e-08
polymorphisms O 0 9.856655378825963e-05
were O 0 4.177279606665252e-06
detected O 0 0.0022768594790250063
. O 0 1.2446845403246698e-06

Among O 0 3.5447058621684846e-07
these O 0 1.4329472719509795e-08
mutations O 0 2.2759492424029304e-07
two O 0 2.3503088364407176e-09
are O 0 3.47202111505851e-09
missense O 0 2.479019167367369e-05
( O 0 5.257440705008776e-09
G197W O 0 3.298953572539176e-07
, O 0 2.0461436989194226e-09
W427R O 0 8.233782011757285e-08
) O 0 2.356299599881595e-10
, O 0 1.5244029649696955e-10
two O 0 5.151247761681077e-10
are O 0 1.756356837745443e-08
nonsense O 0 2.8131730687164236e-06
( O 0 1.1215706141598503e-09
Q306X O 0 4.645264795044568e-08
, O 0 7.953945835303955e-10
Q385X O 0 2.310885882650382e-08
) O 0 1.407703398292881e-10
, O 0 7.217793723812704e-11
two O 0 2.431857493156997e-10
are O 0 6.44955089335042e-10
small O 0 1.4104158951866452e-09
deletions O 0 7.136706585697539e-07
( O 0 1.8681018953969897e-09
662de14bp O 0 1.677172178915498e-07
; O 0 1.1471872340962364e-09
1168del3bp O 0 1.0041897979817804e-07
removing O 0 3.625622468916845e-09
a O 0 3.995623831798412e-09
glycine O 0 2.0344957363249705e-07
at O 0 2.611378002725928e-09
position O 0 1.2507187285848431e-08
390 O 0 1.0753029577870166e-09
) O 0 2.0827616020735462e-10
, O 0 1.0941063333103074e-10
and O 0 1.1803992228109905e-09
one O 0 2.34205255189579e-09
is O 0 1.0381679960147494e-09
a O 0 1.1112565090343196e-08
splicing O 0 4.546658374238177e-07
mutation O 0 5.288338797981851e-07
( O 0 7.07948810685366e-10
IVS1 O 0 6.754631613148376e-06
- O 0 4.741937573271571e-06
15c O 0 7.407587645502645e-07
- O 0 2.5318117877759505e-06
- O 0 1.3891011803934816e-05
> O 0 2.1404066785635223e-07
g O 0 1.1738123930626898e-06
) O 0 1.2505767255088784e-10
which O 0 5.950848147584509e-10
creates O 0 2.15344342358037e-09
a O 0 2.8218447578609585e-09
new O 0 5.562695193361833e-09
acceptor O 0 3.6244419021613794e-08
splice O 0 1.5486193660763092e-06
site O 0 2.177766191380215e-06
. O 0 2.8895587433908076e-07

The O 0 2.4001658971428697e-07
pathological O 0 6.474993824667763e-06
significance O 0 2.1293310226155882e-07
of O 0 1.6131990188128498e-09
the O 0 2.0148129831198958e-09
point O 0 7.969686066644499e-08
mutations O 0 2.921351551776752e-07
G197W O 0 1.6755046772232163e-07
, O 0 4.3985889930375777e-10
W427R O 0 2.018926359426132e-08
, O 0 2.352016081896835e-10
and O 0 2.8962646170249684e-10
the O 0 4.926843932828717e-10
in O 0 6.04133632009507e-09
- O 0 5.227024757914478e-06
frame O 0 0.0031328408513218164
deletion O 0 6.9221096055116504e-06
390delGly O 0 1.1886539823535713e-06
were O 0 1.8552627878420935e-08
assessed O 0 9.41427114042881e-09
by O 0 2.2820884071350633e-10
their O 0 1.5999521707499298e-09
respective O 0 4.924009200379942e-09
expression O 0 2.572679491663621e-08
in O 0 1.3278498300905994e-09
a O 0 4.17955803300174e-09
prokaryotic O 0 8.707790044581998e-09
system O 0 6.292404375329852e-09
using O 0 8.97043861414204e-09
site O 0 4.776868536282564e-07
- O 0 1.2165578482381534e-06
directed O 0 4.087665956831188e-07
mutagenesis O 0 6.80418306728825e-05
. O 0 2.923464137438714e-07

These O 0 1.1009446865273276e-07
mutations O 0 2.2676736080029514e-06
resulted O 0 1.0263028826784648e-07
in O 0 3.4944169780004586e-09
the O 0 2.767745810317024e-09
absence O 0 6.520368600604343e-08
or O 0 1.2595933185366448e-08
a O 0 1.0521425508613902e-08
dramatic O 0 2.05198352887237e-06
decrease O 0 1.481857680118992e-06
of O 0 6.73402045237026e-09
CPO O 0 0.00014982068387325853
activity O 0 3.5011441923415987e-07
. O 0 6.393497642420698e-08

The O 0 1.0041782871894611e-07
two O 0 7.473840213378935e-09
polymorphisms O 0 1.5489174984395504e-05
were O 0 6.731403345838771e-08
localized O 0 3.056830792047549e-06
in O 0 2.528319420491698e-08
noncoding O 0 6.922135185050138e-07
part O 0 3.1546973922047528e-09
of O 0 7.784760336360108e-11
the O 0 3.604171128213096e-10
gene O 0 3.5973530820854194e-09
1 O 0 5.629809396445751e-10
) O 0 6.844495803459694e-11
a O 0 3.72081814248304e-08
C O 0 1.0703989573812578e-05
/ O 0 1.1468463299024734e-06
G O 0 3.665449912659824e-05
polymorphism O 0 1.2068937394360546e-05
in O 0 1.3349864325107319e-08
the O 0 2.6559403565329376e-08
promotor O 0 8.613713725935668e-05
region O 0 3.0038286524813884e-08
, O 0 5.231410304951112e-10
142 O 0 5.413247072816318e-10
bp O 0 5.87583954825277e-08
upstream O 0 5.975870909225023e-10
from O 0 3.418690677770009e-11
the O 0 4.420049395936765e-11
transcriptional O 0 1.3815514288140207e-09
initiation O 0 1.3887427874337277e-09
site O 0 3.534692893936153e-08
( O 0 3.7863573387753036e-10
- O 0 3.5932200148636184e-07
142C O 0 3.28662508763955e-07
/ O 0 7.431121389345208e-07
G O 0 3.8026923903089482e-06
) O 0 1.0682171813769514e-10
, O 0 5.2741880307571876e-11
and O 0 3.037413653927956e-10
2 O 0 3.771113699091444e-10
) O 0 4.5921631081080605e-11
a O 0 4.080885851465155e-09
6 O 0 1.1735462379647288e-08
bp O 0 2.925243336449057e-07
deletion O 0 6.023630305662664e-08
polymorphism O 0 3.19911941915052e-06
in O 0 5.2785207316219385e-09
the O 0 1.943867955489509e-09
3 O 0 4.666833586242092e-09
noncoding O 0 9.447624904623808e-08
part O 0 1.1049070547386464e-09
of O 0 1.6785393908147483e-10
the O 0 4.027530309258509e-09
CPO O 0 4.5075271373207215e-06
gene O 0 1.140231109530987e-08
, O 0 2.982411262397733e-10
574 O 0 7.310100524904328e-09
bp O 0 6.969258947719936e-08
downstream O 0 9.95504123579849e-10
of O 0 3.831338371562687e-11
the O 0 7.122367695622245e-10
last O 0 1.2368431612230779e-08
base O 0 2.776687102468145e-09
of O 0 4.341988227296589e-11
the O 0 1.2973176977126855e-09
normal O 0 2.9749203989126727e-08
termination O 0 7.892115405638833e-08
codon O 0 3.542886872764939e-08
( O 0 7.095250498245775e-10
+ O 0 1.481262046354459e-08
574 O 0 8.95013911872411e-08
delATTCTT O 0 1.3485058616424794e-06
) O 0 1.5325090529927365e-08
. O 0 8.604441603665691e-08

Five O 0 3.244297488436132e-07
intragenic O 0 3.3194311981787905e-05
dimorphisms O 0 3.4571454307297245e-05
are O 0 1.3272276611075995e-08
now O 0 3.720809216289922e-09
well O 0 3.992835395649763e-09
characterized O 0 3.171501816723321e-07
and O 0 1.6996297702576157e-08
the O 0 1.0030561270468752e-08
high O 0 2.312151963224096e-07
degree O 0 1.6044085171529332e-08
of O 0 2.98166047407733e-10
allelic O 0 1.802452970878221e-06
heterogeneity O 0 9.088253136724234e-06
in O 0 1.1225715752516408e-06
HC B-Disease 0 0.3161424696445465
is O 0 7.018187488938565e-07
demonstrated O 0 4.435413814007916e-07
with O 0 1.4687615568220735e-09
seven O 0 7.900798904003636e-10
new O 0 1.0159252328278967e-09
different O 0 3.2294025786860914e-10
mutations O 0 6.3788658799524e-09
making O 0 1.573269847732206e-10
a O 0 1.1877820949024454e-09
total O 0 4.0765038566981104e-10
of O 0 9.238959597368535e-10
nineteen O 0 1.2702580534096342e-06
CPO O 0 0.00017664977349340916
gene B-Disease 0 8.294478902826086e-06
defects I-Disease 0 0.3615656793117523
reported O 0 1.2437625400707475e-06
so O 0 6.86901415747343e-08
far O 0 7.494113418715642e-08
. O 0 3.955497973606725e-08
. O 0 3.6905393585584534e-07

Coincidence O 0 1.0731483598647173e-05
of O 0 9.756616847766963e-09
two O 0 3.5540119736054976e-09
novel O 0 1.2616423816780298e-07
arylsulfatase O 0 6.8046815613342915e-06
A O 0 1.806595264497446e-07
alleles O 0 1.009557450970533e-07
and O 0 3.018404726162771e-08
mutation O 0 2.0283575850044144e-06
459 O 0 2.940369085990824e-07
+ O 0 2.750253145222814e-07
1G O 0 0.00010619256499921903
> O 0 3.9257272987924807e-07
A O 0 3.981551444098841e-08
within O 0 6.001824037760173e-10
a O 0 8.830156161820923e-08
family O 0 9.664381650509313e-07
with O 0 1.621440242161043e-05
metachromatic B-Disease 1 0.9999974966049194
leukodystrophy I-Disease 1 0.9999879598617554
: O 0 4.639305473119748e-08
molecular O 0 1.7266263796500425e-07
basis O 0 2.2827861823060402e-09
of O 0 3.564099237962637e-09
phenotypic O 0 1.8920745787909254e-05
heterogeneity O 0 0.0006495332345366478
. O 0 1.1037163858418353e-05

In O 0 2.991675671637495e-07
a O 0 4.4796966136573246e-08
family O 0 2.2688620759936384e-08
with O 0 3.6912550793744003e-09
three O 0 2.3276514937720094e-08
siblings O 0 3.675376774481265e-06
, O 0 2.853229652544087e-09
one O 0 2.359818118691237e-09
developed O 0 7.862066553343539e-08
classical O 0 1.6498256627528463e-06
late O 0 0.00030610995600000024
infantile O 1 0.9996963739395142
metachromatic B-Disease 1 0.9999957084655762
leukodystrophy I-Disease 1 0.9999936819076538
( O 0 6.787227448512567e-06
MLD B-Disease 1 0.9999521970748901
) O 0 5.340171860268583e-09
, O 0 3.0842590703628048e-09
fatal O 0 1.0041061614174396e-05
at O 0 1.439571661876471e-07
age O 0 4.507672315412492e-07
5 O 0 1.0994312127365902e-08
years O 0 1.435779353187172e-07
, O 0 4.6657295804664045e-09
with O 0 3.26677564999045e-07
deficient O 0 0.0029207360930740833
arylsulfatase O 0 4.799834641744383e-05
A O 0 3.3309765967715066e-06
( O 0 2.240163254896288e-08
ARSA O 0 3.8361420592991635e-05
) O 0 3.8314276751272303e-10
activity O 0 2.7487487841426628e-09
and O 0 1.7604577795538034e-09
increased O 0 1.1615747297355483e-07
galactosylsulfatide O 0 0.00013748160563409328
( O 0 1.8014786462572374e-07
GS O 1 0.9999586343765259
) O 0 1.7635370497259828e-08
excretion O 0 5.342242843653366e-07
. O 0 1.7373496064010396e-07

The O 0 3.8716592598575517e-08
two O 0 2.192764414488124e-09
other O 0 1.3547108990152879e-09
siblings O 0 7.671237085560279e-07
, O 0 6.781298189650897e-09
apparently O 0 7.542092816947843e-07
healthy O 0 2.112425434575016e-08
at O 0 1.1954233158917305e-09
12 O 0 6.737768676323697e-10
( O 0 7.195827267381105e-11
1 O 0 7.605619467554448e-10
/ O 0 2.1356349577672518e-08
2 O 0 8.168016263354616e-10
) O 0 6.883930925294379e-11
and O 0 1.364562907113509e-09
15 O 0 1.1320457904417935e-09
years O 0 2.9749658736477613e-08
, O 0 1.5403532893643046e-09
respectively O 0 8.877169932475226e-08
, O 0 9.529181888012772e-10
and O 0 4.080029647468564e-09
their O 0 1.9085410585262252e-08
father O 0 1.3815957572660409e-05
, O 0 1.1287906609425136e-08
apparently O 0 7.504926884394081e-07
healthy O 0 4.0774331466764124e-08
as O 0 1.1976141189862233e-09
well O 0 2.9907636367454415e-09
, O 0 9.947374035590428e-10
presented O 0 2.402996983619232e-07
ARSA O 0 0.00020262051839381456
and O 0 7.78443563831388e-07
GS O 1 0.9998855590820312
values O 0 3.718724883583491e-08
within O 0 1.5058128355338596e-10
the O 0 1.2008394278950618e-09
range O 0 1.1471281169406211e-07
of O 0 2.331115354081703e-07
MLD B-Disease 1 0.9999827146530151
patients O 0 1.0087823284266051e-05
. O 0 1.3421680478131748e-06

Mutation O 0 0.00015315032214857638
screening O 0 1.965325736819068e-06
and O 0 1.5341234060883835e-08
sequence O 0 1.9961474251317668e-08
analysis O 0 8.505653070756125e-09
disclosed O 0 2.0808862188914645e-07
the O 0 6.971060395599693e-10
involvement O 0 2.6730518243311963e-08
of O 0 2.781085084446744e-10
three O 0 3.3182177006096936e-09
different O 0 9.000842737805215e-09
ARSA O 0 0.00033608049852773547
mutations O 0 7.090845883794827e-07
being O 0 9.645413356906829e-09
the O 0 6.069549307596844e-10
molecular O 0 5.017433579723729e-08
basis O 0 1.3966933165576734e-09
of O 0 9.793826860615695e-10
intrafamilial O 0 3.4224205592181534e-05
phenotypic O 0 2.4399696485488676e-05
heterogeneity O 0 0.00038356828736141324
. O 0 5.819452780997381e-06

The O 0 5.02252760270494e-07
late O 0 7.240668765007285e-06
infantile O 1 0.757436990737915
patient O 0 0.0012086095521226525
inherited O 0 0.001272064633667469
from O 0 2.165244161744795e-08
his O 0 2.391428779446869e-07
mother O 0 5.502723524841713e-06
the O 0 1.3740092397185322e-09
frequent O 0 8.932590134236307e-08
0 O 0 2.5566103900587223e-08
- O 0 9.598105862096418e-06
type O 0 0.00012117723963456228
mutation O 0 1.6324343050655443e-06
459 O 0 5.087084531396613e-08
+ O 0 2.7268180602391112e-08
1G O 0 7.2901057137642056e-06
> O 0 6.816573261403391e-08
A O 0 1.058029326372889e-07
, O 0 8.458683198320216e-10
and O 0 1.6541598091279752e-09
from O 0 1.1196640281596615e-09
his O 0 3.498520584344078e-07
father O 0 5.022775894758524e-06
a O 0 6.367064742107686e-08
novel O 0 2.8807642493688945e-08
, O 0 3.0401667294732704e-10
single O 0 4.743662795902992e-09
basepair O 0 2.5718605911606573e-07
microdeletion O 0 7.270723756391817e-08
of O 0 5.641781486431796e-11
guanine O 0 9.008330970061706e-09
at O 0 3.7934627661329046e-10
nucleotide O 0 8.59384208240499e-09
7 O 0 4.3264156146527455e-10
in O 0 5.245718304180969e-10
exon O 0 1.0545816166995792e-06
1 O 0 1.9288885155788194e-08
( O 0 2.1478316902800998e-09
7delG O 0 2.04333468900586e-06
) O 0 1.5583715651246166e-08
. O 0 9.864174899121281e-08

The O 0 2.3901475287857465e-07
two O 0 7.673367719007729e-08
clinically O 0 0.00013478542678058147
unaffected O 0 6.911365926498547e-05
siblings O 0 1.4088861917116446e-06
carried O 0 2.6436040911903547e-07
the O 0 6.203232594259589e-09
maternal O 0 5.35889512320864e-06
mutation O 0 3.3949467592719884e-07
459 O 0 1.605688879635636e-07
+ O 0 7.325582629391647e-08
1G O 0 2.312308606633451e-05
> O 0 2.1605829658710718e-07
A O 0 2.365313065411101e-07
and O 0 4.034544431874565e-08
, O 0 1.075378897041901e-09
on O 0 9.804055345341567e-09
their O 0 1.1808975131089028e-08
paternal O 0 1.7168586055049673e-05
allele O 0 1.3167763768251461e-07
, O 0 1.3962478395690425e-10
a O 0 1.046829511963665e-09
novel O 0 7.947944524744344e-09
cytosine O 0 3.8165307358895006e-08
to O 0 4.582785817497381e-10
thymidine O 0 1.492331023200677e-07
transition O 0 4.335719783199465e-09
at O 0 6.184846523815679e-10
nucleotide O 0 4.010239251783787e-08
2435 O 0 2.4641286699988996e-07
in O 0 1.5420288379530689e-09
exon O 0 8.501195338794787e-07
8 O 0 2.9658838940349597e-08
, O 0 3.270974047175912e-10
resulting O 0 2.2651811537599542e-09
in O 0 2.1417720375005445e-10
substitution O 0 1.010726058403577e-09
of O 0 2.3171507768093846e-10
alanine O 0 4.558311559321737e-07
464 O 0 5.646440826012622e-08
by O 0 5.118248225244315e-08
valine O 0 0.00012279806833248585
( O 0 1.029046714506876e-08
A464V O 0 4.674916453950573e-07
) O 0 6.172346189714517e-09
. O 0 5.617255283141276e-08

The O 0 8.290670052701898e-07
fathers O 0 3.768280976146343e-06
genotype O 0 8.866971620591357e-05
thus O 0 7.164653226254813e-08
was O 0 1.8027643022833217e-07
7delG O 0 8.359995263163e-06
/ O 0 5.643846634484362e-06
A464V O 0 7.51062179915607e-06
. O 0 2.914250103458471e-07

Mutation O 0 0.0004825812648050487
A464V O 0 1.745661757013295e-05
was O 0 6.538557499879971e-07
not O 0 5.865814944883141e-09
found O 0 1.9306407139652038e-08
in O 0 2.823439970711661e-08
18 O 0 2.576102531293145e-07
unrelated O 0 0.005006704945117235
MLD B-Disease 1 0.999997615814209
patients O 0 2.920698534580879e-06
and O 0 6.041084077423875e-08
50 O 0 2.2665005872113397e-08
controls O 0 2.4940270577644696e-06
. O 0 1.2347180700089666e-06

A464V O 0 8.138664998114109e-05
, O 0 8.712844845604195e-08
although O 0 1.450778785994089e-08
clearly O 0 3.8466918539370454e-08
modifying O 0 2.978168822664884e-07
ARSA O 0 0.0005075894296169281
and O 0 1.1196068953722715e-05
GS O 1 0.9999969005584717
levels O 0 1.4366780305863358e-05
, O 0 4.148345666976638e-09
apparently O 0 3.894909923474188e-07
bears O 0 2.1903125002609158e-07
little O 0 8.801797624080621e-10
significance O 0 2.547035249378382e-09
for O 0 1.3156956635285155e-09
clinical O 0 1.0512182058164399e-07
manifestation O 0 9.23822426557308e-06
of O 0 1.1354499065419077e-06
MLD B-Disease 1 0.9999973773956299
, O 0 1.3780221763681766e-07
mimicking O 0 4.614630597643554e-06
the O 0 1.791848625032344e-08
frequent O 0 1.1385107427486219e-05
ARSA O 0 0.018384916707873344
pseudodeficiency O 0 0.0004821639449801296
allele O 0 3.7176105252001435e-05
. O 0 5.310252504386881e-07

Our O 0 8.118304322124459e-07
results O 0 5.68742741791084e-08
demonstrate O 0 6.461007728830737e-08
that O 0 2.7079301023746893e-09
in O 0 7.109338673316756e-10
certain O 0 6.378890304858942e-09
genetic O 0 1.5256722690537572e-05
conditions O 0 0.0004159566306043416
MLD B-Disease 1 0.9999797344207764
- O 0 0.0002051469055004418
like O 0 1.278238300983503e-06
ARSA O 0 0.00033080996945500374
and O 0 5.444886710392893e-07
GS O 1 0.9999595880508423
values O 0 4.4395315512701927e-07
need O 0 4.336182968245339e-09
not O 0 1.4060270725479995e-09
be O 0 4.694157840212654e-10
paralleled O 0 7.150002367950492e-09
by O 0 9.105416864940707e-08
clinical O 0 0.02822617068886757
disease O 0 0.03429640829563141
, O 0 9.294481628785434e-09
a O 0 9.73011893279363e-08
finding O 0 5.1057483574368234e-08
with O 0 8.26386425956116e-08
serious O 0 4.3784613808384165e-05
diagnostic O 0 3.22058804158587e-05
and O 0 2.541704134273459e-06
prognostic O 0 0.000393352413084358
implications O 0 2.2593505491386168e-05
. O 0 8.128739636958926e-07

Moreover O 0 2.948797555291094e-05
, O 0 2.4481627391992333e-08
further O 0 1.7712972422145867e-08
ARSA O 0 0.0002936098608188331
alleles O 0 7.459942708010203e-07
functionally O 0 8.391230039705988e-07
similar O 0 2.300735246762997e-08
to O 0 4.017096433273082e-09
A464V O 0 1.3933833997725742e-06
might O 0 2.66648356728183e-07
exist O 0 3.30106182389045e-08
which O 0 3.333206821665158e-09
, O 0 8.302687010131038e-11
together O 0 1.6071634301173532e-10
with O 0 1.4827763461511267e-09
0 O 0 2.233235107951259e-08
- O 0 9.211098222294822e-05
type O 0 0.0023182996083050966
mutations O 0 2.4116612621583045e-05
, O 0 4.6313839874301266e-08
may O 0 3.7996001083229203e-06
cause O 0 5.406655873230193e-06
pathological O 0 0.0023399232886731625
ARSA O 1 0.5107716917991638
and O 0 0.00021271851437631994
GS O 1 0.9999983310699463
levels O 0 5.935447916272096e-06
, O 0 1.7260518569983674e-09
but O 0 5.5858726533131176e-09
not O 0 1.4658936287048618e-08
clinical O 0 1.4792313152156567e-07
outbreak O 0 3.0734557299183507e-07
of O 0 1.9210451007722895e-09
the O 0 1.4859517705190228e-06
disease O 0 8.666494250064716e-05
. O 0 5.802844071922664e-08
. O 0 3.902993341853289e-07

Human O 0 0.005520153325051069
MLH1 O 1 0.9976612329483032
deficiency O 1 0.9989905953407288
predisposes O 0 0.003641977207735181
to O 0 5.799552582175238e-06
hematological B-Disease 1 0.9968731999397278
malignancy I-Disease 1 0.9995026588439941
and O 0 0.00015496271953452379
neurofibromatosis B-Disease 1 0.9985338449478149
type I-Disease 0 0.00083933025598526
1 I-Disease 0 2.243230483145453e-06
. O 0 1.3873993793822592e-06

Heterozygous O 0 0.000710290449205786
germ O 0 0.012974653393030167
- O 0 0.0009240175131708384
line O 0 4.915950285067083e-06
mutations O 0 5.796339337393874e-07
in O 0 1.0090983604271742e-09
the O 0 1.925755555021169e-09
DNA O 0 1.7099500837503e-05
mismatch O 0 0.2534187436103821
repair O 0 0.0009304526029154658
genes O 0 2.580649152150727e-07
lead O 0 3.985617240687134e-07
to O 0 1.725248466755147e-06
hereditary B-Disease 1 0.9999359846115112
nonpolyposis I-Disease 1 0.9999947547912598
colorectal I-Disease 1 1.0
cancer I-Disease 1 0.9999991655349731
. O 0 0.0006822989671491086

The O 0 1.4766274944122415e-05
disease O 0 0.00012864290329162031
susceptibility O 0 0.0001749982766341418
of O 0 3.222877253961087e-08
individuals O 0 3.0038373211027647e-07
who O 0 6.712621598126134e-06
constitutionally O 0 2.7518548449734226e-05
lack O 0 1.812665004763403e-07
both O 0 9.215610496937643e-09
wild O 0 9.214811029778502e-07
- O 0 8.046962466323748e-05
type O 0 3.478223879938014e-05
alleles O 0 1.803477687190025e-07
is O 0 6.88273260607275e-08
unknown O 0 1.4034710602572886e-06
. O 0 1.1824959500472687e-07

We O 0 1.1849269867525436e-06
have O 0 1.4654602864538901e-08
identified O 0 3.2072829725393603e-08
three O 0 1.5670982289606172e-09
offspring O 0 9.234563691506992e-08
in O 0 9.408974932512137e-09
a O 0 2.3939666789374314e-05
hereditary B-Disease 1 0.9999759197235107
nonpolyposis I-Disease 1 0.9999994039535522
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 0.02101442776620388
who O 0 2.19966586882947e-05
developed O 0 1.4316095075628255e-05
hematological B-Disease 1 0.5922290086746216
malignancy I-Disease 0 0.46213987469673157
at O 0 4.161915612144185e-08
a O 0 2.5007707904478593e-08
very O 0 4.400632747092459e-08
early O 0 1.8089674824750546e-07
age O 0 4.6546927023882745e-07
, O 0 7.357769393756541e-10
and O 0 1.57537549672071e-09
at O 0 8.700332121414078e-10
least O 0 8.640198972953428e-11
two O 0 8.481555041628397e-11
of O 0 1.5688200738495084e-10
them O 0 2.1293660168453243e-09
displayed O 0 4.253372480889084e-06
signs O 0 7.978231337801844e-07
of O 0 1.1105826480672931e-08
neurofibromatosis B-Disease 0 0.4713970422744751
type I-Disease 0 9.309620509156957e-05
1 I-Disease 0 2.1733295341164194e-07
( O 0 5.3694876100962574e-08
NF1 B-Disease 0 4.497789268498309e-05
) O 0 1.2192596265947486e-08
. O 0 7.527133760731886e-08

DNA O 0 4.362646450317698e-06
sequence O 0 1.6696537841198733e-07
analysis O 0 4.1280863172232785e-08
and O 0 4.491432115116822e-09
allele O 0 1.86315546102378e-07
- O 0 4.2366428942841594e-07
specific O 0 4.171084366788591e-09
amplification O 0 9.55399286795e-07
in O 0 5.453688167733617e-09
two O 0 7.895485154563175e-09
siblings O 0 3.7190627608651994e-06
revealed O 0 4.471578904485796e-06
a O 0 5.543018914977438e-07
homozygous O 0 0.0015640499768778682
MLH1 O 0 0.36016711592674255
mutation O 0 2.9550075851147994e-05
( O 0 5.202913211377336e-09
C676T O 0 4.238032715875306e-07
- O 0 8.147890912368894e-05
- O 0 0.000715568894520402
> O 0 3.357793275426957e-06
Arg226Stop O 0 2.015226345974952e-05
) O 0 1.5885378346069956e-08
. O 0 1.2312909802858485e-07

Thus O 0 2.857915205822792e-06
, O 0 1.697650198195788e-08
a O 0 2.8093335657786156e-08
homozygous O 0 2.532636972318869e-05
germ O 1 0.5823977589607239
- O 0 0.06397252529859543
line O 0 0.00034546919050626457
MLH1 O 0 0.01793859899044037
mutation O 0 1.686715222604107e-05
and O 0 6.5499477841513e-08
consequent O 0 0.0005392393213696778
mismatch O 1 0.999638557434082
repair O 1 0.9998878240585327
deficiency O 1 0.9996732473373413
results O 0 3.207092277079937e-06
in O 0 6.553683817855926e-08
a O 0 3.6495860058494145e-06
mutator O 0 0.23537585139274597
phenotype O 0 0.016565561294555664
characterized O 0 2.6290310415788554e-05
by O 0 8.861283276928589e-06
leukemia B-Disease 1 0.9994364380836487
and O 0 0.00011173894017701969
/ O 1 0.5358095169067383
or O 1 0.9843930602073669
lymphoma B-Disease 1 1.0
associated O 0 0.0007047319086268544
with O 0 1.435641388525255e-05
neurofibromatosis B-Disease 1 0.9985951781272888
type I-Disease 0 0.002180668292567134
1 I-Disease 0 3.491547602152423e-07
. O 0 8.978230425782385e-08
. O 0 5.368175948206044e-07

Missense O 0 0.020635101944208145
mutations O 0 0.00035656418185681105
in O 0 3.988247954112012e-08
the O 0 1.733164389783326e-09
most O 0 7.769633270093834e-10
ancient O 0 1.3525635722544394e-08
residues O 0 6.825121090514585e-08
of O 0 4.1859304911184836e-10
the O 0 1.661620174786549e-08
PAX6 O 0 2.563594898674637e-05
paired O 0 1.2696681324086967e-06
domain O 0 1.5823921728497226e-07
underlie O 0 1.2659695585170994e-06
a O 0 6.043262601451715e-08
spectrum O 0 5.356564997782698e-06
of O 0 2.575358450940257e-07
human O 0 0.005988425575196743
congenital B-Disease 1 0.9999927282333374
eye I-Disease 1 0.9997890591621399
malformations I-Disease 1 0.9998856782913208
. O 0 0.00023604057787451893

Mutations O 0 0.0001037122929119505
of O 0 2.4907837570253832e-08
the O 0 4.512144968771281e-08
human O 0 7.405560609186068e-07
PAX6 O 0 0.027846552431583405
gene O 0 0.0007797349244356155
underlie O 1 0.9932767152786255
aniridia B-Disease 1 0.9999983310699463
( O 0 0.00020727902301587164
congenital B-Disease 1 0.9998867511749268
absence I-Disease 0 2.657445975273731e-06
of I-Disease 0 6.286886122808255e-09
the I-Disease 0 3.946779258967581e-07
iris I-Disease 0 0.39550188183784485
) O 0 1.5466778080508448e-08
, O 0 1.668265969811955e-09
a O 0 1.247633747425425e-07
rare O 0 5.314076042850502e-05
dominant O 0 0.001943105598911643
malformation B-Disease 1 0.8786141276359558
of I-Disease 0 7.120065959043131e-08
the I-Disease 0 1.343579356216651e-06
eye I-Disease 0 0.14324700832366943
. O 0 5.059196610091021e-06

The O 0 1.26281847201426e-07
spectrum O 0 5.75461683638423e-07
of O 0 6.856707202018697e-09
PAX6 O 0 0.0006459433934651315
mutations O 0 8.321536734001711e-05
in O 0 1.4068801874600467e-06
aniridia B-Disease 1 0.9999954700469971
patients O 0 3.303069661342306e-06
is O 0 1.985291753214824e-08
highly O 0 3.3743589256118867e-08
biased O 0 1.5740546643883135e-08
, O 0 1.546584804668072e-10
with O 0 2.0545466716814786e-10
92 O 0 1.4848112739329622e-09
% O 0 1.313856939910707e-10
of O 0 9.773835213389148e-11
all O 0 1.1875336269895342e-08
reported O 0 7.2305110734305345e-06
mutations O 0 5.163106493455416e-07
leading O 0 2.8981464339494778e-08
to O 0 5.7862079572146285e-09
premature O 0 1.9187909572337958e-07
truncation O 0 2.018129308112293e-08
of O 0 1.1022079776656923e-10
the O 0 6.434870858385011e-09
protein O 0 1.361041910286076e-07
( O 0 1.5000775066553729e-09
nonsense O 0 6.496546802736702e-07
, O 0 3.682076865629824e-10
splicing O 0 7.772364973845924e-09
, O 0 2.3185037223427685e-10
insertions O 0 4.587722912674508e-08
and O 0 1.2832090945380514e-09
deletions O 0 2.6674392472614272e-08
) O 0 2.232738716134719e-10
and O 0 4.732941816243397e-10
just O 0 9.678248202860118e-10
2 O 0 3.7687047926837636e-10
% O 0 1.4910285506264387e-10
leading O 0 7.159743353746251e-10
to O 0 8.743530899302243e-11
substitution O 0 3.4152253247654585e-10
of O 0 6.814315084424649e-11
one O 0 5.660952595576418e-09
amino O 0 2.1975292696652104e-09
acid O 0 4.082995719301152e-09
by O 0 3.7826972110188706e-10
another O 0 4.849151835628618e-08
( O 0 2.8510280358773343e-08
missense O 0 3.227052729926072e-05
) O 0 3.948201765524573e-08
. O 0 1.57360076968871e-07

The O 0 4.796598673806329e-08
extraordinary O 0 7.969321558221054e-08
conservation O 0 5.496525012915754e-09
of O 0 9.34964466958732e-11
the O 0 6.413473641053713e-10
PAX6 O 0 2.014114670600975e-06
protein O 0 8.75336780836733e-09
at O 0 7.061403684005541e-10
the O 0 8.23019485896026e-10
amino O 0 1.1918517728304323e-08
acid O 0 2.4149564126219047e-08
level O 0 1.0490887270009353e-08
amongst O 0 5.294048310844346e-09
vertebrates O 0 3.343916432640981e-07
predicts O 0 1.4553013443219243e-06
that O 0 1.5227685778995692e-08
pathological O 0 2.7288446290185675e-05
missense O 0 0.0008225332130677998
mutations O 0 2.1211248167674057e-05
should O 0 1.0160133001591021e-07
in O 0 4.947129372823156e-09
fact O 0 3.7003648145628176e-08
be O 0 1.6635806332487846e-07
common O 0 5.9170467636704416e-08
even O 0 3.8072315078352403e-08
though O 0 2.771497875642126e-08
they O 0 6.871711200062691e-09
are O 0 2.978888025140236e-09
hardly O 0 4.368469319615542e-07
ever O 0 2.6259999685862567e-07
seen O 0 2.235933749261676e-07
in O 0 8.630114933794175e-08
aniridia B-Disease 1 0.9999321699142456
patients O 0 6.397891411324963e-06
. O 0 5.240773930381692e-07

This O 0 1.1236272001724501e-07
indicates O 0 1.7529907836433267e-07
that O 0 1.3343314231306636e-09
there O 0 6.221168580289316e-10
is O 0 9.713645443554242e-10
a O 0 1.8440371007955036e-08
heavy O 0 3.290742461103946e-05
ascertainment O 0 4.6195713366614655e-05
bias O 0 6.864547685836442e-07
in O 0 1.1679898159755453e-09
the O 0 1.1271072269947169e-10
selection O 0 1.9095733327922915e-10
of O 0 3.4468203291559973e-10
patients O 0 1.4772498779791476e-08
for O 0 4.151527566165214e-09
PAX6 O 0 0.0002878921804949641
mutation O 0 3.0899777812010143e-06
analysis O 0 1.5109614892594436e-08
and O 0 3.2122768889308873e-09
that O 0 3.4112037639033588e-09
the O 0 9.713630788610317e-09
missing O 0 7.151571935537504e-06
PAX6 O 0 0.0014627971686422825
missense O 0 0.0019538472406566143
mutations O 0 0.00016722358122933656
frequently O 0 8.68523602548521e-06
may O 0 1.0915914572251495e-05
underlie O 0 6.651254807366058e-05
phenotypes O 0 2.2732883735443465e-05
distinct O 0 1.6175201267287775e-07
from O 0 3.3979981139964366e-07
textbook O 0 0.030062299221754074
aniridia B-Disease 1 0.9999555349349976
. O 0 6.701543497911189e-06

Here O 0 2.0753700482600834e-06
we O 0 1.6029831684249984e-08
present O 0 1.890335221688133e-09
four O 0 9.670756417889947e-10
novel O 0 9.510506515653105e-08
PAX6 O 0 0.00020884565310552716
missense O 0 0.0003887746133841574
mutations O 0 3.138308602501638e-05
, O 0 4.629862271343654e-09
two O 0 2.6002648922940352e-09
in O 0 1.0816705042770991e-07
association O 0 2.6485443171964107e-08
with O 0 3.930409420149772e-08
atypical O 0 0.00019482706557027996
phenotypes O 0 0.00023684540065005422
ectopia B-Disease 0 0.0018717857310548425
pupillae I-Disease 0 0.00040496952715329826
( O 0 1.3017254829605918e-08
displaced B-Disease 0 8.423287312098182e-08
pupils I-Disease 0 3.159486539061618e-07
) O 0 4.2546034251245146e-08
and O 0 2.813403625623323e-05
congenital B-Disease 1 0.9999624490737915
nystagmus I-Disease 0 0.0030495449900627136
( O 0 1.651836889493552e-08
searching B-Disease 0 2.6954771215059736e-07
gaze I-Disease 0 7.573261245852336e-05
) O 0 1.2806685711908017e-09
, O 0 5.558661864135672e-10
and O 0 3.6073364295674537e-09
two O 0 2.8961446574271577e-09
in O 0 5.171434480644166e-08
association O 0 3.4862281950154284e-09
with O 0 2.7093249865828284e-09
more O 0 2.2981607727956543e-08
recognizable O 0 0.0010612108744680882
aniridia B-Disease 1 0.9999481439590454
phenotypes O 0 0.0004806517099495977
. O 0 6.285131917138642e-07

Strikingly O 0 0.00024385587312281132
, O 0 1.3283267819019784e-08
all O 0 4.389319741004982e-10
four O 0 3.676162929622251e-09
mutations O 0 4.91129299007298e-07
are O 0 1.850042785633832e-09
located O 0 7.2999291056419224e-09
within O 0 4.998964020508367e-10
the O 0 5.515123024935065e-09
PAX6 O 0 7.907808139862027e-06
paired O 0 2.5464640884820255e-07
domain O 0 2.0525824595551967e-08
and O 0 6.859270929027161e-09
affect O 0 9.163535708012205e-09
amino O 0 4.608567305552924e-09
acids O 0 3.267820458674464e-09
which O 0 1.9861809974486277e-09
are O 0 4.204454284728598e-10
highly O 0 2.4019959354859566e-09
conserved O 0 2.889822603435732e-08
in O 0 2.1533734795298187e-09
all O 0 4.0801911849186467e-10
known O 0 5.463891561419132e-09
paired O 0 2.9341617846512236e-07
domain O 0 1.1644440434110948e-07
proteins O 0 5.623065746362954e-08
. O 0 7.962908910030819e-08

Our O 0 6.108927550485532e-07
results O 0 3.781568835847793e-08
support O 0 3.685275640208374e-09
the O 0 5.983307183043962e-10
hypothesis O 0 3.100882750572964e-08
that O 0 2.307060792405835e-10
the O 0 1.2322902420702775e-10
under O 0 2.5942952230906258e-09
- O 0 3.5023330724470725e-07
representation O 0 4.339840042888454e-09
of O 0 9.308723236678418e-10
missense O 0 0.00012515098205767572
mutations O 0 6.596998446184443e-06
is O 0 2.6829814814277597e-08
caused O 0 6.278332875808701e-08
by O 0 1.4101879663996897e-08
ascertainment O 0 0.0001923925447044894
bias O 0 1.2835757843276951e-05
and O 0 9.303477099820157e-08
suggest O 0 5.0671939533231125e-08
that O 0 7.304423732534815e-10
a O 0 1.8542645197072716e-09
substantial O 0 1.9099831050084504e-08
burden O 0 2.1597004433715483e-06
of O 0 5.934755353820265e-09
PAX6 B-Disease 0 0.002263458212837577
- I-Disease 0 0.03433096781373024
related I-Disease 0 0.00012904538016300648
disease I-Disease 0 0.0012065913761034608
remains O 0 3.446203322710062e-07
to O 0 2.861721304370235e-09
be O 0 8.645503157822532e-08
uncovered O 0 3.1873634725343436e-05
. O 0 5.573733119490498e-08
. O 0 1.3139940335804567e-07

The O 0 1.888354859147512e-07
chromosomal O 0 7.815982826286927e-05
order O 0 1.1806633004596279e-08
of O 0 1.0021223850742444e-09
genes O 0 8.364530401649972e-08
controlling O 0 5.283031327962817e-07
the O 0 3.940325044027304e-08
major O 0 7.690817369621072e-07
histocompatibility O 0 0.0008474477799609303
complex O 0 1.3079519476377754e-06
, O 0 1.524397941210509e-09
properdin O 0 1.595992898728582e-06
factor O 0 3.046717722554604e-08
B O 0 1.757855727646529e-07
, O 0 1.8560124548372414e-09
and O 0 8.500206263306609e-07
deficiency B-Disease 0 0.0001419183099642396
of I-Disease 0 1.5158266308823443e-10
the I-Disease 0 3.086648492356403e-09
second I-Disease 0 2.5291202021548997e-08
component I-Disease 0 1.7971641952385653e-08
of I-Disease 0 1.0516786330683203e-09
complement I-Disease 0 4.4318917957753e-07
. O 0 2.3922180503177515e-07

The O 0 1.1208616967905982e-07
relationship O 0 9.378645415836218e-08
of O 0 6.191704371438789e-10
the O 0 1.3150986966081746e-09
genes O 0 1.071468958002697e-08
coding O 0 5.9570318455826055e-08
for O 0 6.920532480414465e-10
HLA O 0 2.7921811351916404e-07
to O 0 1.090881163179347e-09
those O 0 1.5796181029870127e-09
coding O 0 1.3951789945565451e-08
for O 0 2.2821843026488153e-10
properdin O 0 2.4735422812227625e-06
Factor O 0 8.270862217329977e-09
B O 0 2.913576579999244e-08
allotypes O 0 2.7827837811855716e-07
and O 0 5.705526273658279e-09
for O 0 2.7701343441322024e-08
deficiency B-Disease 0 8.435523341177031e-06
of I-Disease 0 9.375109022435879e-11
the I-Disease 0 8.245090166170144e-10
second I-Disease 0 9.777947340694482e-09
component I-Disease 0 6.027409238384962e-09
of I-Disease 0 1.684376249588837e-10
complement I-Disease 0 1.2833987739213626e-07
( O 0 1.4383635615899948e-08
C2 O 0 3.126893352600746e-05
) O 0 3.2455438336853604e-10
was O 0 1.007147574227929e-07
studied O 0 5.1876956064234037e-08
in O 0 3.8652383516080135e-09
families O 0 2.100664087123505e-09
of O 0 5.667261770980758e-09
patients O 0 1.3557245210904512e-06
with O 0 8.375644938496407e-06
connective O 1 0.9998188614845276
tissue O 1 0.9999796152114868
disorders O 1 0.9994947910308838
. O 0 1.596397123648785e-05

Patients O 0 2.2165351765579544e-05
were O 0 3.862203712401424e-08
selected O 0 1.4679137017026278e-08
because O 0 1.2647692670952893e-08
they O 0 3.3040961078256714e-09
were O 0 1.120333248394445e-08
heterozygous O 0 2.733557380452112e-07
or O 0 2.2110816644271836e-07
homozygous O 0 0.0008224384509958327
for O 0 0.023488454520702362
C2 B-Disease 1 0.9999997615814209
deficiency I-Disease 1 0.9999974966049194
. O 0 1.2878146662842482e-05

12 O 0 3.5712670864995744e-07
families O 0 4.053016766647488e-08
with O 0 2.679926947024569e-09
15 O 0 6.636008187399511e-09
matings O 0 1.597618575033266e-05
informative O 0 0.0001677394175203517
for O 0 0.15933120250701904
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999995231628418
were O 0 2.755844070634339e-05
found O 0 1.0615020073601045e-05
. O 0 1.7691518223728053e-06

Of O 0 8.986917521269788e-08
57 O 0 9.377929188758571e-08
informative O 0 4.233984896018228e-07
meioses O 0 1.1495463695609942e-05
, O 0 5.877133779641497e-10
two O 0 1.5020666654930181e-10
crossovers O 0 7.748300845378253e-08
were O 0 4.3940318050772476e-08
noted O 0 2.732638826330458e-08
between O 0 3.4566333795282844e-08
the O 0 0.017210911959409714
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999938011169434
gene O 0 1.3483384009305155e-07
and O 0 3.846213125768827e-09
the O 0 5.582411422011546e-09
HLA O 0 8.421216989518143e-06
- O 0 9.034445974975824e-05
B O 0 3.3820336398093787e-07
gene O 0 6.50441744909358e-09
, O 0 1.0476618877985899e-10
with O 0 5.637414493553372e-11
a O 0 1.6061314500603885e-09
recombinant O 0 3.518077829056665e-09
fraction O 0 7.211099273263244e-09
of O 0 1.0369113345731762e-09
0 O 0 1.9961690611580707e-07
. O 0 2.368297060684199e-07

035 O 0 0.06137416139245033
. O 0 5.877655348740518e-05

A O 0 2.8275358090468217e-06
lod O 0 0.0001403505157213658
score O 0 2.012072108925622e-08
of O 0 2.2252731601835052e-10
13 O 0 1.872893395926667e-09
was O 0 1.4087792266082033e-08
calculated O 0 1.0847820419712662e-07
for O 0 2.426965295398986e-09
linkage O 0 0.005653921980410814
between O 0 0.36156630516052246
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.999998927116394
and O 0 4.075863273556024e-07
HLA O 0 1.1669674677250441e-05
- O 0 5.55800688744057e-05
B O 0 8.41683061025833e-08
at O 0 4.725320135179345e-10
a O 0 1.5982503098754819e-09
maximum O 0 8.065103251908567e-09
likelihood O 0 3.1765483576862152e-09
value O 0 1.816093664341878e-10
of O 0 5.669502194105558e-12
the O 0 6.684796466371878e-11
recombinant O 0 1.436424423850724e-09
fraction O 0 3.630161948819932e-09
of O 0 9.490184194049789e-10
0 O 0 7.798087153787492e-08
. O 0 1.0929814209248434e-07

04 O 0 0.002703459467738867
. O 0 9.124642019742168e-06

18 O 0 6.770727623006678e-07
families O 0 1.0210133183363723e-08
with O 0 2.240145180465447e-09
21 O 0 2.3954442873730386e-09
informative O 0 2.4991877012325858e-08
matings O 0 3.5084012779407203e-06
for O 0 2.2003223687505624e-09
both O 0 2.714331870379283e-09
properdin O 0 2.5378107238793746e-05
Factor O 0 1.4250429281048582e-08
B O 0 3.6117857149520205e-08
allotype O 0 1.7934117124696058e-07
and O 0 6.667688179362585e-09
HLA O 0 8.695942028680292e-07
- O 0 4.11574546888005e-05
B O 0 1.1535571502463426e-06
were O 0 4.6535028275229706e-08
found O 0 4.017865364858153e-07
. O 0 3.6749312926076527e-07

Of O 0 9.408547896327946e-08
72 O 0 1.3874281989956216e-07
informative O 0 4.341605972513207e-07
meioses O 0 3.889949221047573e-05
, O 0 2.2146717792992376e-09
three O 0 5.787584855809769e-10
recombinants O 0 7.169723176048137e-06
were O 0 1.539191742949697e-07
found O 0 1.7153314502138528e-07
, O 0 1.8992718509025508e-10
giving O 0 7.333050833224775e-11
a O 0 2.129787318727594e-10
recombinant O 0 1.4508584333938757e-09
fraction O 0 3.043568286287268e-09
of O 0 9.026867586747755e-10
0 O 0 1.1228580376609898e-07
. O 0 1.6087237497686147e-07

042 O 0 0.0016893502324819565
. O 0 1.8643797375261784e-05

A O 0 4.3924746933043934e-06
lod O 0 0.00022624469420406967
score O 0 1.3360104134108042e-08
of O 0 3.654921088003249e-10
16 O 0 9.225964436865297e-10
between O 0 2.349085148622976e-09
HLA O 0 9.583765859133564e-06
- O 0 6.15903118159622e-05
B O 0 1.6186682216812187e-07
and O 0 8.2191192740666e-10
Factor O 0 1.4693416483524402e-09
B O 0 1.1647955489024753e-08
allotypes O 0 5.3023779145178196e-08
was O 0 1.1545941980273255e-08
calculated O 0 7.516284483699565e-09
at O 0 1.7492239601235582e-10
a O 0 1.2069932830982566e-09
maximum O 0 8.930406636409316e-09
likelihood O 0 6.0206075680468985e-09
value O 0 5.074674569449655e-10
of O 0 1.5096167371719815e-11
the O 0 1.5410224485368218e-10
recombinant O 0 1.6975489902648633e-09
fraction O 0 4.61112614758008e-09
of O 0 1.1446955605620701e-09
0 O 0 1.3501527007520053e-07
. O 0 1.5941326125812338e-07

04 O 0 0.003356745932251215
. O 0 1.3873867828806397e-05

A O 0 1.4731621433838882e-07
crossover O 0 4.086402896064101e-07
was O 0 6.317432053037919e-07
shown O 0 4.6953445576036756e-08
to O 0 9.695505509554891e-10
have O 0 1.1400854482701561e-08
occurred O 0 3.243832935595492e-08
between O 0 3.077746391078051e-10
genes O 0 1.0165474018108966e-09
for O 0 1.9016570262930799e-10
Factor O 0 4.4975272395220145e-09
B O 0 1.1848253933521846e-08
and O 0 5.766794597406033e-09
HLA O 0 2.3273953502211953e-06
- O 0 0.00024495061370544136
D O 0 0.008495197631418705
, O 0 1.2232889146090997e-09
in O 0 7.940303414777361e-10
which O 0 3.02375759986262e-08
HLA O 0 5.7115780691674445e-06
- O 0 0.0002811934391502291
D O 0 0.0005624102195724845
segregared O 0 2.20475726564473e-06
with O 0 1.2343591926367026e-08
HLA O 0 2.043759423031588e-06
- O 0 5.17724538440234e-06
A O 0 6.544752864101611e-07
and O 0 8.352332656613726e-07
B O 0 5.968705409031827e-06
. O 0 1.2662663095852622e-07

These O 0 1.0022839092016511e-07
studies O 0 2.9119822997358824e-08
suggest O 0 1.3923346919852975e-08
that O 0 3.593668140844386e-10
the O 0 1.2489272116500416e-10
genes O 0 1.1428630264376238e-09
for O 0 3.085899313859386e-10
Factor O 0 8.384657235183113e-08
B O 0 0.00031020655296742916
and O 0 0.23620304465293884
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999992847442627
are O 0 1.3156562062022203e-08
located O 0 3.252901947803366e-09
outside O 0 3.3503335661322353e-09
those O 0 5.478864584240739e-10
for O 0 7.287515590981286e-10
HLA O 0 1.1347614190526656e-06
, O 0 6.336445257382195e-10
that O 0 5.893084353836286e-10
the O 0 2.714992952679296e-10
order O 0 1.698539225936102e-10
of O 0 3.6985668000477645e-11
genese O 0 9.072415423361235e-07
is O 0 1.5297281219517345e-09
HLA O 0 3.84248970419776e-08
- O 0 5.975859949103324e-07
A O 0 1.6545951098123624e-07
, O 0 3.8481133834977754e-09
- O 0 4.169952262600418e-06
B O 0 1.1699160751277304e-07
, O 0 8.907283244319331e-10
- O 0 3.360182972755865e-06
D O 0 3.392593134776689e-05
, O 0 5.216503895510982e-10
Factor O 0 3.784185409472229e-09
B O 0 2.7500433930072177e-07
allotype O 0 0.0002879086823668331
, O 0 0.0021377750672399998
C2 B-Disease 1 0.9999998807907104
deficiency I-Disease 1 0.9999971389770508
, O 0 3.4003231341728224e-09
that O 0 5.612740827665164e-10
the O 0 1.6626021670518298e-09
genes O 0 5.7638285255734445e-08
coding O 0 2.430537506370456e-06
for O 0 0.00033880514092743397
C2 B-Disease 1 0.9999998807907104
deficiency I-Disease 1 0.9999979734420776
and O 0 1.2837818985644844e-07
Factor O 0 3.4150463790183494e-08
B O 0 3.830255224102075e-08
allotypes O 0 6.682562059268093e-08
are O 0 1.2518176772946532e-10
approximately O 0 4.917875134902161e-11
3 O 0 2.7725419182722533e-10
- O 0 3.583768091175443e-07
- O 0 1.1317764574414468e-06
5 O 0 5.566746508200993e-10
centimorgans O 0 5.867820362936982e-08
from O 0 2.4260107811535647e-10
the O 0 1.3614301908049242e-09
HLA O 0 5.68048335480853e-07
- O 0 1.3124803217579029e-06
A O 0 5.8631329125091725e-08
and O 0 5.025172100658892e-08
HLA O 0 1.811519041439169e-06
- O 0 1.0740503967099357e-05
B O 0 6.669014140925356e-08
loci O 0 4.1570262787615775e-09
, O 0 6.44353792544905e-10
and O 0 1.295685558844184e-09
that O 0 1.098212965011669e-09
the O 0 1.0409915152109761e-09
apparent O 0 9.457573924009921e-07
lack O 0 1.711046770935809e-08
of O 0 1.210919697847146e-10
recombinants O 0 8.956770329859864e-07
between O 0 4.3555689610563775e-10
the O 0 1.486003986528317e-09
Factor O 0 1.103593305629147e-08
B O 0 1.4879368848141894e-07
gene O 0 3.137139401587774e-07
and O 0 0.027608299627900124
C2 B-Disease 1 0.9999998807907104
deficiency I-Disease 1 0.999996542930603
gene O 0 6.550528723892057e-07
suggests O 0 5.278462822388974e-08
that O 0 8.138655305245379e-10
these O 0 1.451245096317777e-10
two O 0 9.244177645584273e-10
genes O 0 7.801389045880569e-08
lie O 0 6.39356039755512e-06
in O 0 8.192266420792294e-09
close O 0 1.7272251184863308e-08
proximity O 0 4.8574456457117776e-08
to O 0 9.228574349151586e-09
one O 0 4.813875165154968e-08
another O 0 2.4368333129132225e-07
. O 0 5.5153623179649e-07

Distribution O 0 6.360571660479764e-07
of O 0 1.4442575135831248e-08
emerin O 0 4.745271144201979e-05
and O 0 9.935322964338411e-08
lamins O 0 0.00023446802515536547
in O 0 1.403241522979215e-08
the O 0 3.139117055184215e-08
heart O 0 0.00010217359522357583
and O 0 8.900566683678335e-08
implications O 0 1.2954484418514767e-07
for O 0 2.0444202775138365e-08
Emery B-Disease 0 0.0011447278084233403
- I-Disease 1 0.9968476891517639
Dreifuss I-Disease 1 0.9995884299278259
muscular I-Disease 1 0.9996637105941772
dystrophy I-Disease 1 0.9997918009757996
. O 0 1.6406092981924303e-05

Emerin O 0 0.00030247209360823035
is O 0 5.783694945193929e-08
a O 0 2.2945561894971434e-08
nuclear O 0 7.287728294613771e-06
membrane O 0 3.3316912322334247e-06
protein O 0 1.3567341738962568e-07
which O 0 1.3760294237386006e-08
is O 0 9.471978756891986e-09
missing O 0 2.2962140633353556e-07
or O 0 1.8819760327914992e-07
defective O 0 2.4025295715546235e-05
in O 0 2.759688015885331e-07
Emery B-Disease 0 0.004959333688020706
- I-Disease 1 0.9997149109840393
Dreifuss I-Disease 1 0.9999188184738159
muscular I-Disease 1 0.9999574422836304
dystrophy I-Disease 1 0.9999454021453857
( O 0 4.902487125946209e-05
EDMD B-Disease 1 0.9999855756759644
) O 0 5.159326406101172e-07
. O 0 3.7416421605485084e-07

It O 0 1.2878984989583842e-07
is O 0 6.063419988322494e-09
one O 0 1.1047341930137122e-09
member O 0 5.96000360175708e-10
of O 0 1.4303980222507562e-10
a O 0 9.776701404007326e-08
family O 0 1.425164555257652e-07
of O 0 3.5193998826343886e-09
lamina O 0 0.004834834951907396
- O 0 0.0020589532796293497
associated O 0 1.763574886126662e-07
proteins O 0 1.4636801770606667e-09
which O 0 6.187217960196278e-10
includes O 0 1.5638523809258231e-09
LAP1 O 0 1.8089578588842414e-05
, O 0 6.009043040933193e-09
LAP2 O 0 1.3086858416500036e-05
and O 0 4.34187903408656e-08
lamin O 0 6.497387221315876e-05
B O 0 1.2626212537725223e-06
receptor O 0 1.0203317515333765e-06
( O 0 9.033834658112028e-08
LBR O 0 0.005307163577526808
) O 0 2.4637003548377834e-08
. O 0 1.0194393951223901e-07

A O 0 4.563883635455568e-07
panel O 0 5.426805316233185e-08
of O 0 1.5564607380724738e-09
16 O 0 1.0819485751767388e-08
monoclonal O 0 1.2820008805647376e-06
antibodies O 0 6.401138307410292e-06
( O 0 1.2280562344813006e-08
mAbs O 0 6.281925948314893e-07
) O 0 7.33115346207569e-10
has O 0 4.1909893333524906e-09
been O 0 1.0229000757533413e-08
mapped O 0 3.955320607929025e-06
to O 0 2.3310668950671243e-09
six O 0 6.796599949510096e-10
specific O 0 6.450805445368246e-10
sites O 0 1.7545679353858645e-09
throughout O 0 2.079570127211383e-10
the O 0 4.0783315613523996e-10
emerin O 0 1.9083778113326844e-07
molecule O 0 5.905735012134983e-09
using O 0 1.7011047015458303e-09
phage O 0 7.906428578507985e-08
- O 0 4.712903205472685e-07
displayed O 0 3.038816771550046e-07
peptide O 0 3.801020653781961e-08
libraries O 0 7.202518026439009e-10
and O 0 1.6518172385460161e-09
has O 0 2.3155040107525338e-09
been O 0 3.0887803426082883e-09
used O 0 1.1002892819078625e-08
to O 0 3.1346580886548736e-09
localize O 0 2.836562089214567e-06
emerin O 0 3.989418109995313e-05
in O 0 1.2564427720462845e-08
human O 0 2.6241163908480303e-08
and O 0 2.6794509722094517e-07
rabbit O 0 0.0037253382615745068
heart O 0 0.0003534104616846889
. O 0 1.5307816738641122e-06

Several O 0 5.000170517632796e-07
mAbs O 0 1.207521290780278e-05
against O 0 4.2719566550886157e-08
different O 0 8.025788034160541e-09
emerin O 0 1.9388942746445537e-05
epitopes O 0 0.00037091446574777365
did O 0 7.484284765268967e-07
not O 0 9.00568508654942e-09
recognize O 0 1.8909204868577945e-08
intercalated O 0 3.629970422025508e-07
discs O 0 1.9631941086117877e-06
in O 0 6.771423421980671e-09
the O 0 2.5855138474639716e-08
heart O 0 8.267309021903202e-05
, O 0 1.0027233265930136e-08
though O 0 1.6481234155207858e-08
they O 0 9.53662393499144e-09
recognized O 0 4.3148560280315e-09
cardiomyocyte O 0 5.980825790175004e-07
nuclei O 0 1.3561331115852227e-06
strongly O 0 5.584565698768529e-08
, O 0 3.204173315562997e-10
both O 0 2.4759366779036895e-10
at O 0 2.0069619299789565e-09
the O 0 1.3620561345462079e-09
rim O 0 1.8130533518956327e-08
and O 0 7.72415731375986e-09
in O 0 6.622024262270543e-09
intranuclear O 0 3.964573352277512e-06
spots O 0 2.865011197172862e-07
or O 0 6.033921806647413e-08
channels O 0 5.163524861018232e-07
. O 0 2.8715049893435207e-07

A O 0 3.173006689394242e-06
polyclonal O 0 7.153100159484893e-05
rabbit O 0 5.426643474493176e-05
antiserum O 0 2.359711106691975e-05
against O 0 2.424575029635889e-07
emerin O 0 0.00010824044875334948
did O 0 3.4658302183743217e-07
recognize O 0 2.7396218627018243e-08
both O 0 1.8683372626782102e-09
nuclear O 0 1.3557576494349632e-05
membrane O 0 1.0608355296426453e-06
and O 0 2.067304549768778e-08
intercalated O 0 2.119748614859418e-06
discs O 0 4.787349553225795e-06
but O 0 6.290508558493002e-09
, O 0 5.982539463822434e-11
after O 0 2.084498268439816e-10
affinity O 0 5.7450351143018e-09
purification O 0 1.0198045963250024e-08
against O 0 3.904986556335643e-09
a O 0 2.7796824397796627e-08
pure O 0 5.152432436261734e-07
- O 0 5.668313679052517e-05
emerin O 0 3.812482191278832e-06
band O 0 1.405001004428641e-08
on O 0 1.5854375590151903e-09
a O 0 1.9379149396314688e-09
western O 0 3.83293530248352e-09
blot O 0 7.657600690436084e-06
, O 0 3.5888345628620755e-09
it O 0 1.5893008020739785e-09
stained O 0 3.0033244911464863e-05
only O 0 3.777428592144361e-09
the O 0 6.3070877409643344e-09
nuclear O 0 9.179226253763773e-06
membrane O 0 2.581257149358862e-06
. O 0 2.483689627297281e-07

These O 0 3.0462295796951366e-08
results O 0 4.662120289822269e-08
would O 0 8.111136651223205e-09
not O 0 1.4211118948281865e-09
be O 0 2.1607216016406028e-09
expected O 0 3.2533860050421026e-09
if O 0 5.828308946576044e-09
immunostaining O 0 9.45917918215855e-07
at O 0 2.4974946555289534e-09
intercalated O 0 6.12412861755729e-07
discs O 0 4.188125330983894e-06
were O 0 7.240983279643842e-08
due O 0 9.974280956726034e-09
to O 0 4.2302431002561036e-10
a O 0 3.2865474786092364e-09
product O 0 1.916079295227746e-09
of O 0 3.756122843312504e-11
the O 0 1.2311467401104892e-09
emerin O 0 3.933780590159586e-06
gene O 0 1.5388534890803385e-08
and O 0 1.2441756958025962e-08
, O 0 1.7154049292145146e-09
therefore O 0 1.625408252436955e-09
, O 0 8.129559525560381e-11
cast O 0 1.1371378283442368e-09
some O 0 4.1850582027658234e-11
doubt O 0 1.1799625720954054e-09
upon O 0 2.535792964497574e-10
the O 0 6.632575599851975e-10
hypothesis O 0 1.9601918666012352e-07
that O 0 2.3627295320238773e-07
cardiac B-Disease 0 0.060760747641325
defects I-Disease 1 0.9981826543807983
in O 0 0.00017029453010763973
EDMD B-Disease 1 0.9999998807907104
are O 0 4.3681338866008446e-06
caused O 0 5.28119244336267e-07
by O 0 6.244949002365274e-09
absence O 0 6.999177770694587e-08
of O 0 2.434341395129991e-09
emerin O 0 6.261566886678338e-05
from O 0 4.2717442028106234e-08
intercalated O 0 0.00015789658937137574
discs O 0 0.0001310904190177098
. O 0 8.176843948604073e-07

Although O 0 1.17658521503472e-06
emerin O 0 2.646039501996711e-05
was O 0 1.2777748281678214e-07
abundant O 0 1.5238986961207956e-08
in O 0 1.8008863289509236e-09
the O 0 5.656481394389345e-10
membranes O 0 8.294910713857462e-08
of O 0 6.479574099493846e-10
cardiomyocyte O 0 1.0110089533554856e-05
nuclei O 0 7.846141670597717e-06
, O 0 6.720175971253184e-09
it O 0 2.6701663102812745e-09
was O 0 2.93279924790113e-07
absent O 0 1.4141960491542704e-08
from O 0 1.3990576752664907e-10
many O 0 1.4421200345005047e-10
non O 0 6.358033655118334e-09
- O 0 4.730645741801709e-06
myocyte O 0 4.8657630031812005e-06
cells O 0 5.244292822226271e-08
in O 0 2.644514829341915e-09
the O 0 2.200625814907653e-08
heart O 0 0.00012203417281853035
. O 0 1.0493677109479904e-06

This O 0 2.8159213627532154e-08
distribution O 0 5.13261610990412e-09
of O 0 5.173185213536158e-10
emerin O 0 1.1171025107614696e-05
was O 0 1.952780621650163e-07
similar O 0 8.851467114823208e-09
to O 0 5.84318815555207e-10
that O 0 4.03445765684296e-09
of O 0 5.143707682009335e-10
lamin O 0 1.3437698726193048e-05
A O 0 1.6976750885078218e-06
, O 0 1.8405222901307638e-09
a O 0 6.282055320383506e-09
candidate O 0 1.66840749216135e-07
gene O 0 1.2675731575484406e-08
for O 0 8.546254814945087e-10
an O 0 3.0208294532485525e-08
autosomal O 0 0.0007237558602355421
form O 0 5.791471721749986e-06
of O 0 3.5710668271349277e-06
EDMD B-Disease 1 0.9999978542327881
. O 0 4.341776002547704e-05

In O 0 2.3469195298275736e-07
contrast O 0 2.683381126189488e-06
, O 0 6.730478929739547e-08
lamin O 0 0.0007070606225170195
B1 O 1 0.559753954410553
was O 0 1.0446437954669818e-06
absent O 0 1.2172444030511542e-07
from O 0 1.160886942130901e-09
cardiomyocyte O 0 3.459863592070178e-06
nuclei O 0 4.974931471224409e-06
, O 0 6.027041088429996e-09
showing O 0 1.1315821666357806e-06
that O 0 3.0021675456737285e-07
lamin O 0 0.001949559897184372
B1 O 0 0.13693420588970184
is O 0 1.8524872302805306e-08
not O 0 1.177136943475432e-09
essential O 0 1.436982893787686e-10
for O 0 7.807674645698981e-11
localization O 0 1.2464820287050316e-08
of O 0 2.4192228775810065e-10
emerin O 0 4.647839887184091e-06
to O 0 5.727201379812641e-09
the O 0 4.359072036663747e-08
nuclear O 0 0.002134636975824833
lamina O 0 0.0013196177314966917
. O 0 3.681835210045392e-07

Lamin O 1 0.7859477400779724
B1 O 1 0.9666255116462708
is O 0 3.5955852695224166e-07
also O 0 1.939335980694068e-08
almost O 0 9.619508745117855e-09
completely O 0 1.0569783626124263e-07
absent O 0 2.56102310913775e-07
from O 0 5.0569017417956275e-08
skeletal O 0 0.0007884484366513789
muscle O 0 0.0002324524539289996
nuclei O 0 0.004547746852040291
. O 0 2.4546955046389485e-06

In O 0 5.328430688678054e-06
EDMD B-Disease 1 0.9998530149459839
, O 0 5.508415501509489e-09
the O 0 1.4063507303152534e-10
additional O 0 4.876824499788768e-10
absence O 0 1.0613294243455584e-08
of O 0 4.831644417890857e-09
lamin O 0 0.0040504601784050465
B1 O 0 0.439134806394577
from O 0 1.5318856583235174e-07
heart O 0 0.00012822625285480171
and O 0 9.86422833193501e-07
skeletal O 0 0.05576445907354355
muscle O 0 0.00012750079622492194
nuclei O 0 0.0009117172448895872
which O 0 1.099575911212014e-06
already O 0 3.0926349836590816e-07
lack O 0 1.2690178152752196e-07
emerin O 0 0.00039598264265805483
may O 0 6.255573339331022e-07
offer O 0 7.915821886861352e-10
an O 0 1.2385889536226102e-10
alternative O 0 2.534643384066726e-09
explanation O 0 3.1963740543261565e-09
of O 0 1.4199705300477206e-10
why O 0 3.743576471038068e-08
these O 0 7.670887813837624e-10
tissues O 0 2.182351863666554e-07
are O 0 3.1651121723541564e-09
particularly O 0 4.2740101235949624e-08
affected O 0 2.012839850351611e-08
. O 0 2.0393105870653017e-08
. O 0 1.373046529806743e-07

Genetic O 0 3.312594344606623e-05
mapping O 0 3.183518401783658e-06
of O 0 9.139063728014207e-09
the O 0 1.1393251497793244e-07
copper B-Disease 1 0.6736437678337097
toxicosis I-Disease 1 0.5351359248161316
locus O 0 3.410528370295651e-05
in O 0 9.091412067618876e-08
Bedlington O 0 2.8384178222040646e-05
terriers O 0 2.862319342966657e-05
to O 0 2.8813795793780628e-08
dog O 0 0.0004645755689125508
chromosome O 0 0.0002964323794003576
10 O 0 1.706041174998063e-08
, O 0 1.7611495595204474e-09
in O 0 5.011931314413687e-09
a O 0 2.1289818619152356e-07
region O 0 1.230719419709203e-07
syntenic O 0 2.688041058718227e-05
to O 0 1.5554524779304302e-08
human O 0 8.32432718311793e-08
chromosome O 0 1.997275830945e-05
region O 0 2.838938826243975e-07
2p13 O 0 1.2220706594234798e-05
- O 0 0.00014511897461488843
p16 O 0 8.107364010356832e-06
. O 0 3.5447834534352296e-07

Abnormal O 1 0.7578151822090149
hepatic B-Disease 1 0.9781604409217834
copper I-Disease 1 0.7900851964950562
accumulation I-Disease 0 0.000228716351557523
is O 0 1.3162491541152121e-07
recognized O 0 3.198851672436831e-08
as O 0 3.5526852570910705e-08
an O 0 2.0852276065852493e-05
inherited B-Disease 1 1.0
disorder I-Disease 1 0.9999995231628418
in O 0 5.333506123861298e-05
man O 0 0.030682692304253578
, O 0 3.144354465689503e-08
mouse O 0 2.5791016469156602e-06
, O 0 2.8600693369185137e-08
rat O 0 9.891031368169934e-05
and O 0 2.603085533792182e-07
dog O 0 0.0014392923330888152
. O 0 9.918222758642514e-07

The O 0 1.863423761960803e-07
major O 0 1.0102566250225209e-07
cause O 0 2.073472842312185e-06
of O 0 5.512906398053019e-08
hepatic B-Disease 1 0.5530868172645569
copper I-Disease 1 0.9830541014671326
accumulation I-Disease 0 0.00011514608195284382
in O 0 9.389366795176102e-08
man O 0 0.00011116672976640984
is O 0 3.195211206730164e-08
a O 0 1.4532858472193766e-07
dysfunctional O 0 1.839302603912074e-05
ATP7B O 0 0.0005584094324149191
gene O 0 1.5221258991005016e-06
, O 0 4.453006852145336e-08
causing O 0 2.0444556867005304e-05
Wilson B-Disease 0 0.2679458558559418
disease I-Disease 0 0.007180776912719011
( O 0 6.868725677122711e-07
WD B-Disease 1 0.9849832653999329
) O 0 2.7250251832811045e-07
. O 0 4.382957854431879e-07

Mutations O 0 0.000218493165448308
in O 0 4.925768237740158e-08
the O 0 7.168464044582379e-09
ATP7B O 0 7.09655141690746e-05
genes O 0 8.777530524639587e-08
have O 0 1.8616683306049708e-08
also O 0 1.3060976300494076e-08
been O 0 4.9534392587702314e-08
demonstrated O 0 3.1301971148423036e-07
in O 0 1.9358694203219784e-08
mouse O 0 6.724584181938553e-06
and O 0 8.699408908796613e-07
rat O 0 0.01198400929570198
. O 0 1.450556851523288e-06

The O 0 1.3123684539095848e-07
ATP7B O 0 1.4984967492637224e-05
gene O 0 2.634443205806747e-07
has O 0 1.4740807685598156e-08
been O 0 3.0467743883377807e-09
excluded O 0 4.909904038896684e-09
in O 0 4.107018891641445e-10
the O 0 7.863589224221812e-10
much O 0 1.9135164563977014e-08
rarer O 0 1.8950217054225504e-05
human O 0 2.519924009902752e-06
copper B-Disease 1 0.9227779507637024
overload I-Disease 0 0.43054160475730896
disease O 0 7.232113421196118e-05
non B-Disease 0 7.566646331724769e-08
- I-Disease 0 0.0011396169429644942
Indian I-Disease 0 5.591082299361005e-07
childhood I-Disease 0 0.0017533269710838795
cirrhosis I-Disease 0 0.000489643367473036
, O 0 1.2008972483101843e-08
indicating O 0 1.962823489520815e-06
genetic O 0 5.802500709251035e-06
heterogeneity O 0 4.693152368417941e-05
. O 0 1.853294861575705e-06

By O 0 1.2833680784751778e-07
investigating O 0 1.108015112549765e-06
the O 0 1.1712143788145113e-07
common O 0 9.825624147197232e-06
autosomal O 1 0.9380906224250793
recessive O 1 0.9990474581718445
copper B-Disease 1 0.9999034404754639
toxicosis I-Disease 1 0.9995742440223694
( O 0 2.3455547193407256e-07
CT B-Disease 0 0.09103839844465256
) O 0 4.15645562412692e-09
in O 0 6.78585232449791e-09
Bedlington O 0 3.423063753871247e-05
terriers O 0 0.00027768180007115006
, O 0 3.6783880830171256e-08
we O 0 1.3022644296256658e-08
have O 0 3.945384463577284e-09
identified O 0 1.1117016640582733e-08
a O 0 4.669201913998222e-09
new O 0 3.221467981262549e-09
locus O 0 5.077188234281493e-07
involved O 0 1.609982263062193e-07
in O 0 5.104042884340743e-06
progressive O 1 0.9992077946662903
liver B-Disease 1 0.9999997615814209
disease I-Disease 1 0.999996542930603
. O 0 2.9677128623006865e-05

We O 0 4.985885766473075e-07
examined O 0 1.0380377943874919e-06
whether O 0 2.3067945775778753e-08
the O 0 8.519681848895289e-09
WD B-Disease 0 0.0034209720324724913
gene O 0 3.928124385765841e-07
ATP7B O 0 6.641988147748634e-05
was O 0 1.7092992266043439e-07
also O 0 3.6897980226768823e-09
causative O 0 4.729878355647088e-07
for O 0 1.6659478241365377e-09
CT B-Disease 0 0.06692592054605484
by O 0 2.2933178911443974e-08
investigating O 0 6.809048613831692e-07
the O 0 1.258515567315044e-07
chromosomal O 0 0.07795482128858566
co O 0 7.274693780345842e-05
- O 0 1.9475635781418532e-05
localization O 0 5.452785103443603e-07
of O 0 1.7937626939357187e-09
ATP7B O 0 2.9228523999336176e-05
and O 0 9.469937722883515e-09
C04107 O 0 3.9051670341905265e-08
, O 0 1.0426542962349572e-10
using O 0 4.757895744056384e-10
fluorescence O 0 5.909275841986528e-07
in O 0 3.084871025293978e-09
situ O 0 2.7816057013296813e-07
hybridization O 0 9.046128468526149e-08
( O 0 3.90413745776641e-09
FISH O 0 1.1213598583026396e-07
) O 0 9.14089426373721e-09
. O 0 1.1156402734968651e-07

C04107 O 0 4.324709516367875e-05
is O 0 2.95963378249553e-08
an O 0 1.6080718978628283e-09
anonymous O 0 5.2759968838245186e-08
microsatellite O 0 5.887163570150733e-05
marker O 0 9.127830708166584e-05
closely O 0 1.9650371996249305e-06
linked O 0 2.0763474822160788e-05
to O 0 2.3050317565775913e-07
CT B-Disease 1 0.9890039563179016
. O 0 5.372854957386153e-06

However O 0 4.826277290703729e-06
, O 0 8.890487634971578e-08
BAC O 0 1.7681735471342108e-06
clones O 0 1.4023804340013157e-07
containing O 0 9.180613602666199e-08
ATP7B O 0 7.911547436378896e-05
and O 0 1.7897651360954114e-08
C04107 O 0 1.4654135327418771e-07
mapped O 0 1.461873921471124e-06
to O 0 3.1856255411355505e-09
the O 0 8.727411682230013e-09
canine O 0 0.00034541069180704653
chromosome O 0 0.000155556364916265
regions O 0 2.966653234182104e-08
CFA22q11 O 0 1.3811504686600529e-05
and O 0 3.809868687199014e-08
CFA10q26 O 0 1.1804136192949954e-05
, O 0 1.676837779740481e-09
respectively O 0 1.2946759220255899e-08
, O 0 5.013659487573818e-10
demonstrating O 0 1.1773508390433562e-08
that O 0 5.875200770333322e-08
WD B-Disease 0 0.29978322982788086
cannot O 0 4.3818633344017144e-07
be O 0 2.1812389672248855e-09
homologous O 0 2.9835693027280286e-08
to O 0 5.118521784197583e-08
CT B-Disease 1 0.9260261654853821
. O 0 2.5151391582767246e-06

The O 0 6.558347536156361e-07
copper O 0 7.878234464442357e-05
transport O 0 1.644820457613605e-07
genes O 0 1.2871311128037632e-07
CTR1 O 0 1.2334962775639724e-05
and O 0 1.4524400349102962e-08
CTR2 O 0 3.9216498407768086e-05
were O 0 5.3842967417949694e-08
also O 0 4.432700873024942e-09
excluded O 0 3.1761366869886842e-09
as O 0 1.437457097797079e-10
candidate O 0 4.9094825982365364e-09
genes O 0 6.820351505787414e-10
for O 0 6.414953568345538e-10
CT B-Disease 1 0.5171101689338684
since O 0 1.2438242720236303e-06
they O 0 5.722331497537425e-09
both O 0 7.793559131386019e-10
mapped O 0 7.1145250331028365e-06
to O 0 5.142339531971629e-08
canine O 0 0.004438887350261211
chromosome O 0 0.0008161359000951052
region O 0 2.4474888959957752e-06
CFA11q22 O 0 0.0004267707117833197
. O 0 6.847639610896294e-07

2 O 0 1.3518369996745605e-06
- O 0 5.977302134851925e-05
22 O 0 6.807049430790357e-07
. O 0 2.6674626951717073e-07

5 O 0 2.7893893275177106e-05
. O 0 3.1660547392675653e-06

A O 0 2.55996326359309e-07
transcribed O 0 2.1641011471729144e-07
sequence O 0 3.670944792588671e-08
identified O 0 1.947178773775704e-08
from O 0 2.41073355722321e-10
the O 0 3.119506875037814e-10
C04107 O 0 3.039544367311464e-07
- O 0 2.414584514554008e-06
containing O 0 6.876531983834866e-07
BAC O 0 5.468452400236856e-06
was O 0 2.231519715678587e-07
found O 0 4.393291952453637e-09
to O 0 2.6931765151338993e-10
be O 0 4.496463645864424e-09
homologous O 0 6.753314352181405e-09
to O 0 1.7248209527309655e-09
a O 0 2.5722036056663455e-08
gene O 0 1.9839820453171342e-08
expressed O 0 2.609411575704712e-09
from O 0 1.164906171524649e-09
human O 0 1.6828332505269827e-08
chromosome O 0 3.5384780403546756e-06
2p13 O 0 9.830298495216994e-07
- O 0 1.620717011974193e-05
p16 O 0 2.0951596013674134e-07
, O 0 8.210125912455624e-10
a O 0 8.044517052496758e-09
region O 0 8.520168570669284e-09
devoid O 0 2.054655254823956e-07
of O 0 2.659323872222785e-10
any O 0 3.0588567234701713e-09
positional O 0 1.7526675719636842e-06
candidate O 0 2.75613183475798e-06
genes O 0 3.073057541769231e-07
. O 0 2.682997717329272e-07

Molecular O 0 2.380702608206775e-05
analysis O 0 1.0382026260913335e-07
of O 0 6.361208781946459e-10
the O 0 2.7018731696415443e-09
APC B-Disease 0 1.3924758945904614e-07
gene O 0 1.818303552170164e-08
in O 0 7.166710558337286e-10
205 O 0 3.6555294347095924e-09
families O 0 3.447624186136977e-09
: O 0 2.382085417806934e-09
extended O 0 2.6011642617618236e-08
genotype O 0 0.004989091772586107
- O 0 0.007128039840608835
phenotype O 0 9.409483027411625e-05
correlations O 0 7.29056455384125e-06
in O 0 6.469701219202761e-08
FAP B-Disease 0 1.5468275478269788e-06
and O 0 1.6901385180290163e-08
evidence O 0 1.724710152473108e-08
for O 0 5.311634465599013e-10
the O 0 6.196099189281767e-10
role O 0 3.0219806657072468e-09
of O 0 5.165168848186852e-10
APC B-Disease 0 1.9772319603816868e-07
amino O 0 9.040312498598269e-09
acid O 0 2.7784368583638752e-08
changes O 0 5.2480853440783903e-08
in O 0 0.0009175967425107956
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999995231628418
predisposition O 1 0.9983446598052979
. O 0 9.972716361517087e-05

BACKGROUND O 0 0.00043877633288502693
/ O 0 9.98885661829263e-06
AIMS O 0 3.420751397698041e-07
The O 0 2.0309407489094156e-09
development O 0 1.615308953262229e-08
of O 0 5.74355544813443e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 5.4569441090279724e-06
a O 0 1.2585746844706591e-06
variable O 0 2.3335005607805215e-06
range O 0 8.484945190900817e-09
of O 0 2.717781999450608e-09
extracolonic O 0 0.0013723700540140271
manifestations O 0 0.03337599337100983
in O 0 0.0022810085210949183
familial B-Disease 1 0.9999996423721313
adenomatous I-Disease 1 0.9999933242797852
polyposis I-Disease 1 0.999997615814209
( O 0 5.511557446880033e-06
FAP B-Disease 0 4.466151585802436e-05
) O 0 3.114253077640683e-09
is O 0 1.3696110912064796e-09
the O 0 2.888045358417912e-10
result O 0 1.4449685004080948e-08
of O 0 3.291564520946366e-10
the O 0 6.857364098777907e-08
dominant O 0 2.8509428375400603e-05
inheritance O 0 0.0034841527231037617
of O 0 0.00014432989701163024
adenomatous B-Disease 1 0.9999980926513672
polyposis I-Disease 1 0.999974250793457
coli I-Disease 1 0.9999773502349854
( O 0 2.472481128279469e-06
APC B-Disease 0 5.868262633157428e-06
) O 0 1.3969578382955206e-08
gene O 0 7.755795650155051e-07
mutations O 0 1.7856100384960882e-05
. O 0 1.2627441492440994e-06

In O 0 1.0380600201642665e-07
this O 0 3.410995708108544e-09
study O 0 2.4115442975869428e-09
, O 0 7.177528016377721e-11
direct O 0 5.70510971797944e-10
mutation O 0 3.7434478628028955e-08
analysis O 0 5.300006544750602e-10
of O 0 5.5651833835712594e-11
the O 0 2.001655730055063e-09
APC B-Disease 0 1.079067928344557e-07
gene O 0 1.0951053397434407e-08
was O 0 2.6794067409241507e-08
performed O 0 1.8989766203958425e-08
to O 0 9.204310091881496e-10
determine O 0 1.95594680008071e-06
genotype O 0 0.01671641133725643
- O 0 0.0029324518982321024
phenotype O 0 2.79366213362664e-05
correlations O 0 4.388868433125026e-07
for O 0 2.4036275192429457e-09
nine O 0 1.5287604071545502e-08
extracolonic O 0 1.5165667718974873e-05
manifestations O 0 2.748766291915672e-06
and O 0 2.2557056666983044e-08
to O 0 2.6190800639369627e-09
investigate O 0 1.6480298370424862e-07
the O 0 7.454965356146204e-08
incidence O 0 0.00024364462296944112
of O 0 5.451036511061602e-09
APC B-Disease 0 2.5178871965181315e-06
mutations O 0 4.132778599341691e-07
in O 0 3.018065086735078e-08
non O 0 2.317547296115663e-05
- O 1 0.9999368190765381
FAP O 1 0.9999417066574097
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999991655349731
. O 0 0.00012309559679124504

METHODS O 0 2.051613819276099e-06
The O 0 2.019234379702084e-08
APC B-Disease 0 2.6362627636444813e-07
gene O 0 4.179934620651693e-08
was O 0 3.492506195357237e-08
analysed O 0 8.713610100130609e-08
in O 0 1.6962027338252028e-09
190 O 0 3.990513253171457e-09
unrelated O 0 9.85353167948233e-08
FAP B-Disease 0 2.4280491288664052e-06
and O 0 7.81291547014007e-08
15 O 0 3.801368819722484e-08
non O 0 9.649130561228958e-07
- O 1 0.9994742274284363
FAP O 1 0.9998399019241333
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999994039535522
patients O 0 1.2926133422297426e-05
using O 0 2.5727169372657954e-07
denaturing O 0 4.5893921196693555e-05
gradient O 0 6.679336365777999e-05
gel O 0 0.00022134566097520292
electrophoresis O 0 2.4682688035682077e-06
, O 0 4.708101131178921e-10
the O 0 7.238707550039081e-11
protein O 0 8.633629922094599e-10
truncation O 0 3.52212126131235e-08
test O 0 2.2756534434620335e-08
, O 0 1.7456644463287319e-10
and O 0 2.283028904814799e-10
direct O 0 6.419240694555128e-09
sequencing O 0 2.6857316015593824e-07
. O 0 2.2202118543646066e-07

RESULTS O 0 3.466822090558708e-05
Chain O 0 7.451903456967557e-06
terminating O 0 6.88823433847574e-07
signals O 0 4.232967683037714e-07
were O 0 8.61670645946333e-09
only O 0 1.2504676183411334e-09
identified O 0 4.3990215203848493e-07
in O 0 4.335903724950185e-08
patients O 0 2.794860520793918e-08
belonging O 0 1.970515484117641e-07
to O 0 9.637285636188153e-09
the O 0 4.975331080459e-08
FAP B-Disease 0 6.723449132550741e-06
group O 0 3.50622251232835e-08
( O 0 8.917312444012282e-10
105 O 0 6.480493031091328e-09
patients O 0 8.840031284762517e-08
) O 0 1.4732093767122478e-08
. O 0 2.0819183532694296e-07

Amino O 0 4.346853074821411e-06
acid O 0 9.134237757280061e-07
changes O 0 2.7466379393104035e-08
were O 0 1.316688003072386e-08
identified O 0 1.3270205556636938e-07
in O 0 2.5239141887567484e-09
four O 0 1.708467145533632e-08
patients O 0 2.1412800421671818e-08
, O 0 7.014554492812408e-10
three O 0 1.2403501836733e-10
of O 0 5.057996244062224e-10
whom O 0 2.374584369135846e-07
belonged O 0 9.558614237903384e-07
to O 0 3.4472562582266164e-09
the O 0 8.132918338787931e-09
non O 0 2.6382119244772184e-07
- O 0 0.00021922226005699486
FAP O 0 1.5213540791592095e-05
group O 0 5.10079416926601e-07
of O 0 0.00012262171367183328
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
patients O 0 0.016819536685943604
. O 0 1.0437742275826167e-05

Genotype O 1 0.9708857536315918
- O 0 0.07189283519983292
phenotype O 0 0.0022837177384644747
correlations O 0 5.2723775297636166e-05
identified O 0 1.065729793481296e-05
significant O 0 5.4905132884641716e-08
differences O 0 2.5458548407186754e-06
in O 0 7.2114183069516e-08
the O 0 4.942149356423897e-09
nature O 0 1.0281720363991553e-07
of O 0 4.5650322411106004e-10
certain O 0 3.673751969301975e-09
extracolonic O 0 1.5565643479931168e-05
manifestations O 0 6.852716069261078e-06
in O 0 1.853654225669743e-07
FAP B-Disease 0 3.669688885565847e-05
patients O 0 8.97437857361183e-08
belonging O 0 1.1067092486882757e-07
to O 0 8.301048737280325e-09
three O 0 8.91650486778417e-08
mutation O 0 3.1187093554763123e-05
subgroups O 0 4.4222460928722285e-06
. O 0 7.172740197347593e-07

CONCLUSIONS O 0 2.0852396119153127e-05
Extended O 0 1.4556455880665453e-06
genotype O 0 0.0010962538653984666
- O 0 0.00017966239829547703
phenotype O 0 2.18333734665066e-05
correlations O 0 2.9426851142488886e-06
made O 0 1.7194743406889756e-08
in O 0 4.016039500953639e-09
this O 0 6.098062943493687e-09
study O 0 3.335459552999964e-08
may O 0 9.109722896027961e-07
have O 0 3.1038873693489677e-09
the O 0 3.5577743529024985e-10
potential O 0 4.599022496165617e-09
to O 0 9.666182299028492e-10
determine O 0 2.6008862619164574e-08
the O 0 5.076213893673298e-10
most O 0 2.950730770834298e-10
appropriate O 0 8.020887287685241e-10
surveillance O 0 8.52394421713143e-08
and O 0 8.497302417254105e-09
prophylactic O 0 8.003356924746186e-06
treatment O 0 2.843111417405453e-07
regimens O 0 3.094968690220412e-07
for O 0 2.0880208673190737e-09
those O 0 4.029269007332914e-08
patients O 0 1.932888160638413e-08
with O 0 7.895503273402937e-08
mutations O 0 2.2612321117776446e-05
associated O 0 3.5913120655095554e-07
with O 0 3.3783007324927894e-07
life O 0 0.00041210532072000206
threatening O 0 0.004162529017776251
conditions O 0 5.714534199796617e-05
. O 0 1.8397040548734367e-06

This O 0 1.9681115759340173e-07
study O 0 5.401381741876321e-08
also O 0 2.5358908306571948e-09
provided O 0 1.0765732749717927e-09
evidence O 0 6.3614669087996845e-09
for O 0 8.530571804499232e-10
the O 0 3.0544549112221375e-09
pathological O 0 2.6194268230028683e-06
nature O 0 1.0040135833833119e-07
of O 0 6.918843276082498e-10
amino O 0 1.3365507811613497e-08
acid O 0 6.2048775006928736e-09
changes O 0 9.43153777299699e-10
in O 0 2.63238675302091e-09
APC O 0 3.428563672969176e-07
associated O 0 9.638498887909464e-09
with O 0 2.1193982124856348e-09
both O 0 2.8506365268299305e-08
FAP B-Disease 0 6.058952749299351e-06
and O 0 2.9542206902988255e-07
non O 0 1.550439810671378e-05
- O 1 0.9999071359634399
FAP O 1 0.9999344348907471
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
patients O 0 0.0005012858309783041
. O 0 2.3311397967518133e-07
. O 0 6.775016458959726e-07

Inherited B-Disease 1 0.999841570854187
colorectal I-Disease 1 0.9999985694885254
polyposis I-Disease 1 0.9999082088470459
and O 0 0.04830729216337204
cancer B-Disease 1 0.9953991770744324
risk O 0 1.5155820619838778e-05
of O 0 6.104812655394198e-09
the O 0 7.264887358360284e-08
APC O 0 4.850310870097019e-05
I1307K O 0 1.780155798769556e-05
polymorphism O 0 0.0004206716548651457
. O 0 1.0512719654798275e-06

Germ O 0 0.050101861357688904
- O 0 0.00036460705450735986
line O 0 2.3969687390490435e-06
and O 0 5.596922036943397e-09
somatic O 0 2.328207102664237e-07
truncating O 0 1.589464545759256e-06
mutations O 0 4.022627422273217e-07
of O 0 2.7486635190143716e-10
the O 0 3.470617349066174e-09
APC B-Disease 0 2.5365702072122076e-07
gene O 0 1.7468652302454757e-08
are O 0 1.3140731836003283e-09
thought O 0 1.1205768757349688e-08
to O 0 1.805247862307624e-08
initiate O 0 0.0039832331240177155
colorectal B-Disease 1 0.9999998807907104
tumor I-Disease 1 0.9998399019241333
formation O 0 0.02513454481959343
in O 0 0.023542894050478935
familial B-Disease 1 0.9999997615814209
adenomatous I-Disease 1 0.999998927116394
polyposis I-Disease 1 1.0
syndrome I-Disease 1 0.9999990463256836
and O 0 0.00010278837726218626
sporadic O 1 0.9202333688735962
colorectal O 1 0.9999997615814209
carcinogenesis O 1 0.9996780157089233
, O 0 1.6776863049017265e-05
respectively O 0 2.5459943572059274e-05
. O 0 1.8203546687800554e-06

Recently O 0 9.565166692482308e-06
, O 0 8.030489162536014e-09
an O 0 2.4497914807852794e-09
isoleucine O 0 7.462444773409516e-05
- O 0 0.0015706903068348765
- O 0 0.003603197168558836
> O 0 1.8621087747305864e-06
lysine O 0 5.13582108396804e-07
polymorphism O 0 2.4380146896874066e-06
at O 0 7.035098725793887e-09
codon O 0 2.854118363870839e-08
1307 O 0 3.5301556522426836e-07
( O 0 1.9198134748599216e-10
I1307K O 0 9.836740311186531e-09
) O 0 1.1648293440913449e-11
of O 0 7.94308282342504e-12
the O 0 1.1876122307796777e-09
APC B-Disease 0 1.9337886669745785e-07
gene O 0 1.1147507805731038e-08
has O 0 2.5806545789208712e-09
been O 0 4.303144507389334e-09
identified O 0 2.080333771914411e-08
in O 0 8.533224127305061e-10
6 O 0 6.221895887392748e-09
% O 0 7.729133999490045e-10
- O 0 2.7155765565112233e-06
7 O 0 1.2558437845200388e-08
% O 0 1.6537142488726175e-10
of O 0 1.0222456908737243e-10
the O 0 2.6820913490155363e-08
Ashkenazi O 0 1.709199523247662e-06
Jewish O 0 2.43194392623991e-07
population O 0 4.492025951208234e-08
. O 0 7.779724597867244e-08

To O 0 1.2267292959222686e-07
assess O 0 8.511603368788201e-07
the O 0 1.573712538061045e-08
risk O 0 8.574592413879145e-08
of O 0 3.5971245426758003e-10
this O 0 3.945685111972352e-09
common O 0 3.1232609387643606e-08
APC B-Disease 0 5.35804986157018e-07
allelic O 0 2.6956311103276676e-06
variant O 0 0.00014059817476663738
in O 0 6.520713213831186e-05
colorectal O 1 0.9999995231628418
carcinogenesis O 1 0.9973637461662292
, O 0 1.6376937992390594e-06
we O 0 7.286939762707334e-08
have O 0 3.918505964151109e-09
analyzed O 0 1.5167941569416143e-08
a O 0 3.462332864856421e-09
large O 0 9.123145794376342e-09
cohort O 0 1.3577736979186739e-07
of O 0 5.652426304791902e-10
unselected O 0 1.4314457075670362e-05
Ashkenazi O 0 1.532774263068859e-06
Jewish O 0 1.91333839438812e-07
subjects O 0 4.3042300035267544e-07
with O 0 8.48232772909796e-08
adenomatous B-Disease 0 0.0014365912647917867
polyps I-Disease 0 0.00039346603443846107
and O 0 7.434048825416539e-07
. O 0 1.1165337809870834e-06
or O 1 0.9592230319976807
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, I-Disease 0 4.854148869526398e-07
for O 0 3.761410294345069e-09
the O 0 3.112211999223291e-08
APC O 0 8.962282663560472e-06
I1307K O 0 5.4293955145112704e-06
polymorphism O 0 7.000422920100391e-05
. O 0 4.917029627904412e-07

The O 0 5.272033831715817e-07
APC O 0 4.193816948827589e-06
I1307K O 0 2.5573576749593485e-06
allele O 0 1.4168399502523243e-06
was O 0 7.143053437630442e-08
identified O 0 8.608611068439131e-08
in O 0 1.8414493263563259e-09
48 O 0 1.322107978651843e-09
( O 0 8.624079922414651e-11
10 O 0 7.478766911317436e-11
. O 0 9.353925967126031e-11
1 O 0 5.252927537391372e-10
% O 0 1.594936127613522e-10
) O 0 8.374352600259982e-11
of O 0 7.993335993106143e-10
476 O 0 5.402109763963381e-06
patients O 0 2.392885107838083e-06
. O 0 1.007714217848843e-06

Compared O 0 8.200975685213052e-07
with O 0 2.414383803994724e-09
the O 0 2.6709150446890817e-09
frequency O 0 5.388507702264178e-07
in O 0 1.5022134647324492e-09
two O 0 2.994283987423074e-10
separate O 0 1.2283981831728852e-08
population O 0 3.987264296512194e-09
control O 0 3.398230674633851e-08
groups O 0 3.931965031345186e-10
, O 0 2.0160730029861185e-10
the O 0 4.0114436772320516e-10
APC O 0 8.561321607203354e-08
I1307K O 0 1.1689335366327214e-07
allele O 0 8.361595860151283e-08
is O 0 8.862577893786749e-10
associated O 0 5.813650671981918e-10
with O 0 2.5589785845880897e-10
an O 0 4.093405170380038e-09
estimated O 0 1.0984758347376555e-07
relative O 0 2.5055078367586248e-06
risk O 0 1.6952776604739483e-07
of O 0 1.832291096626193e-09
1 O 0 4.1736655020940816e-07
. O 0 9.971638519346016e-07

5 O 0 1.0345974033043603e-06
- O 0 1.6297248293994926e-05
1 O 0 1.455941003314365e-07
. O 0 2.8140482299932046e-07

7 O 0 7.92672835814301e-06
for O 0 3.41454961017007e-06
colorectal B-Disease 1 0.9999977350234985
neoplasia I-Disease 1 0.9992582201957703
( O 0 2.467783133397461e-07
both O 0 6.207152836168461e-08
P O 0 0.0576116144657135
= O 0 4.0232993342215195e-05
. O 0 1.2999737286634172e-08
01 O 0 1.056107407748641e-06
) O 0 1.0198960787022315e-08
. O 0 6.258127172031891e-08

Furthermore O 0 6.458274583565071e-06
, O 0 1.0892806656670473e-08
compared O 0 2.657541564587973e-08
with O 0 2.522730246923288e-09
noncarriers O 0 7.956655463203788e-05
, O 0 9.658668531642434e-09
APC O 0 1.0813424466959987e-07
I1307K O 0 1.0433201680370985e-07
carriers O 0 3.1267774147636374e-08
had O 0 1.545442174233358e-08
increased O 0 4.031396105830254e-09
numbers O 0 2.1675403694132456e-09
of O 0 6.026072418841011e-10
adenomas B-Disease 0 0.0003375402302481234
and O 0 0.004066447727382183
colorectal B-Disease 1 0.9999998807907104
cancers I-Disease 1 0.998854398727417
per O 0 9.215082172886468e-06
patient O 0 3.4758464607875794e-05
( O 0 2.6326491209260894e-08
P O 0 0.0005239986348897219
= O 0 1.0739096296674688e-06
. O 0 1.8243924149174973e-09
03 O 0 3.835189588130561e-08
) O 0 9.460866118304878e-11
, O 0 7.885949532271397e-11
as O 0 4.686553922716996e-10
well O 0 1.4704322204295295e-09
as O 0 2.054379333316092e-09
a O 0 9.585171056869513e-08
younger O 0 2.5927442948159296e-06
age O 0 6.489116231023218e-07
at O 0 2.510571164293651e-07
diagnosis O 0 0.0005104438168928027
. O 0 2.217275778093608e-06

We O 0 5.176892159397539e-07
conclude O 0 1.4220934474451496e-07
that O 0 1.7011079211926017e-09
the O 0 1.6030006211309455e-09
APC O 0 1.1083569262382298e-07
I1307K O 0 9.519617094611021e-08
variant O 0 4.3388951098677353e-07
leads O 0 1.6198722363469642e-08
to O 0 1.2622749956392454e-08
increased O 0 2.1405674488050863e-05
adenoma B-Disease 1 0.9999908208847046
formation O 0 1.0610925755827338e-06
and O 0 5.879558617749581e-09
directly O 0 1.8514936250824121e-09
contributes O 0 7.243669553069765e-10
to O 0 7.999157586313643e-11
3 O 0 1.957603662505747e-10
% O 0 1.8468053475384494e-10
- O 0 9.56499093263119e-08
4 O 0 9.216590268756875e-10
% O 0 1.2093663570578173e-10
of O 0 1.8248194622039193e-10
all O 0 1.0961944951759506e-07
Ashkenazi O 0 0.00569921312853694
Jewish O 1 0.976669430732727
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999984502792358
. O 0 6.822629802627489e-05

The O 0 9.805236800275452e-08
estimated O 0 9.839727255211983e-08
relative O 0 7.980407872310025e-07
risk O 0 5.092487072033691e-07
for O 0 9.381647458894804e-09
carriers O 0 1.419624823029153e-06
may O 0 5.622281946671137e-07
justify O 0 7.765996201669623e-08
specific O 0 4.1133865202880315e-09
clinical O 0 5.39527267306994e-09
screening O 0 3.959647720819248e-09
for O 0 2.195751636069332e-10
the O 0 3.357643885149031e-10
360 O 0 8.034360954312092e-10
, O 0 2.613444738397419e-10
000 O 0 6.364145876958105e-10
Americans O 0 1.0896188396003481e-09
expected O 0 1.9903751979910567e-09
to O 0 7.732378626279512e-10
harbor O 0 1.047707769430417e-06
this O 0 4.86092766038837e-09
allele O 0 6.942988761693414e-08
, O 0 4.5392020697754276e-10
and O 0 1.4699077510726966e-09
genetic O 0 8.72515144578756e-08
testing O 0 3.699016914993081e-08
in O 0 1.0071985467874356e-09
the O 0 4.712053525146587e-10
setting O 0 5.982967898887637e-09
of O 0 2.3558369144360825e-10
long O 0 7.633661880390719e-08
- O 0 3.2696480047889054e-06
term O 0 2.1432909136365197e-07
- O 0 1.1213111292818212e-06
outcome O 0 2.7725659990096574e-08
studies O 0 3.3163194412821895e-09
may O 0 2.9529351408541515e-08
impact O 0 4.0257198463677923e-08
significantly O 0 5.51063249076833e-06
on O 1 0.9906288981437683
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
prevention O 0 0.012931691482663155
in O 0 1.97237248755755e-08
this O 0 1.216817935301151e-08
population O 0 2.343474569954651e-08
. O 0 1.3917457408751943e-07

Localization O 0 5.202928605285706e-06
of O 0 9.884945306737336e-09
human O 0 1.1802123367488093e-07
BRCA1 O 0 2.2594000256503932e-05
and O 0 1.6119328094532648e-08
its O 0 6.213238368246721e-09
loss O 0 8.773711783760518e-07
in O 0 1.1172326175312719e-08
high O 0 5.701661848434014e-06
- O 0 0.006194093730300665
grade O 0 8.362275366380345e-06
, O 0 8.260047756891709e-09
non B-Disease 0 1.9460394184989127e-07
- I-Disease 0 0.47246280312538147
inherited I-Disease 1 0.9631377458572388
breast I-Disease 1 0.9998506307601929
carcinomas I-Disease 1 0.9999977350234985
. O 0 0.00011493470083223656

Although O 0 4.471211525469698e-07
the O 0 2.2064079452377428e-09
link O 0 8.516403937619543e-08
between O 0 4.895484462252853e-09
the O 0 1.9745429824524763e-07
BRCA1 O 0 0.1590661108493805
tumour B-Disease 1 0.9999847412109375
- O 0 0.00024453570949845016
suppressor O 0 4.163551420788281e-05
gene O 0 3.169155320392747e-07
and O 0 4.5339930920818006e-07
hereditary B-Disease 1 0.9994595646858215
breast I-Disease 1 0.9999979734420776
and I-Disease 1 0.9999970197677612
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
is O 0 2.4159566237358376e-05
established O 0 4.483491977680387e-08
, O 0 9.264317646362485e-10
the O 0 3.484458555025327e-10
role O 0 2.2253560771900993e-08
, O 0 1.2640909430317038e-09
if O 0 1.4607016707302023e-09
any O 0 3.967477735233871e-10
, O 0 1.343439942624869e-10
of O 0 2.562852152721007e-10
BRCA1 O 0 8.629194780951366e-06
in O 0 9.688692159670609e-08
non B-Disease 0 1.8004325283982325e-06
- I-Disease 1 0.7373462319374084
familial I-Disease 1 0.9988284707069397
cancers I-Disease 1 0.9997736811637878
is O 0 2.5474651010881644e-06
unclear O 0 2.67723908109474e-06
. O 0 2.950301336568373e-07

BRCA1 O 1 0.7029414176940918
mutations O 0 0.0010282824514433742
are O 0 3.777127943749292e-08
rare O 0 3.0585903232349665e-07
in O 0 5.6265090364604475e-08
sporadic B-Disease 0 0.0010614590719342232
cancers I-Disease 1 0.9991733431816101
, O 0 2.446380165110895e-07
but O 0 4.2783818798852735e-07
loss O 0 4.2618404449967784e-07
of O 0 3.020931504948976e-09
BRCA1 O 0 7.584883132949471e-05
resulting O 0 1.5293647948055877e-07
from O 0 8.876166468496649e-09
reduced O 0 1.736633947757582e-07
expression O 0 3.196187208232004e-07
or O 0 1.2907781865578727e-07
incorrect O 0 9.758840633367072e-07
subcellular O 0 1.1368042578396853e-06
localization O 0 1.1051272252871058e-07
is O 0 5.31403643311279e-10
postulated O 0 2.2138873845278795e-08
to O 0 4.4213077643462384e-10
be O 0 5.089993759810341e-09
important O 0 5.509863121311298e-10
in O 0 3.4617186894791985e-09
non B-Disease 0 3.27275643030589e-07
- I-Disease 0 0.34390193223953247
familial I-Disease 1 0.999550998210907
breast I-Disease 1 0.9999903440475464
and I-Disease 1 0.9999107122421265
ovarian I-Disease 1 1.0
cancers I-Disease 1 0.9999994039535522
. O 0 0.0001420875923940912

Epigenetic O 0 0.0019330434734001756
loss O 0 0.000925346917938441
, O 0 5.765499722087952e-08
however O 0 1.3820212529935816e-08
, O 0 1.035839969354413e-09
has O 0 2.7450288708763537e-09
not O 0 1.0071466993721856e-09
received O 0 2.0330415129166113e-09
general O 0 8.164215969941324e-10
acceptance O 0 3.5571400047729185e-08
due O 0 2.7936984281495825e-08
to O 0 1.0204617151288176e-09
controversy O 0 6.463583446247867e-08
regarding O 0 4.1262500083405484e-09
the O 0 7.833275694757447e-10
subcellular O 0 1.41633719863421e-07
localization O 0 9.534841360903101e-09
of O 0 2.5141788650984154e-10
BRCA1 O 0 1.9136755327053834e-06
proteins O 0 4.3008467898175695e-09
, O 0 4.526950481142933e-10
reports O 0 5.879040032574778e-10
of O 0 8.536964191119267e-11
which O 0 1.115584993272023e-07
have O 0 4.888526206059396e-08
ranged O 0 3.2052193432718923e-07
from O 0 1.1584009307341603e-09
exclusively O 0 1.959458550970794e-08
nuclear O 0 6.574709550477564e-05
, O 0 7.750465824685193e-10
to O 0 3.920791469269602e-10
conditionally O 0 5.974959549348569e-07
nuclear O 0 5.8631831052480265e-06
, O 0 2.2802175425606919e-10
to O 0 1.1266751420713206e-10
the O 0 4.8715649292319085e-09
ER O 0 1.6006715668481775e-05
/ O 0 2.788304129808239e-07
golgi O 0 2.9291786631802097e-06
, O 0 4.772665596064485e-10
to O 0 3.3662364562481173e-10
cytoplasmic O 0 6.610731873024633e-08
invaginations O 0 7.094268426044437e-07
into O 0 1.9158563624444014e-09
the O 0 7.963072867767096e-09
nucleus O 0 4.742389592138352e-07
. O 0 1.2345149968950864e-07

In O 0 4.8075804670588695e-08
an O 0 9.776618403734005e-10
attempt O 0 5.560873361787344e-08
to O 0 1.63871032299312e-08
resolve O 0 4.890125637757592e-07
this O 0 1.0662131622041215e-08
issue O 0 1.37000938593701e-07
, O 0 4.15879508608441e-09
we O 0 1.1797808951996558e-08
have O 0 7.962176695741618e-09
comprehensively O 0 8.23947357275756e-06
characterized O 0 6.695281058455294e-07
19 O 0 2.6398696562068835e-08
anti O 0 2.163235876651015e-05
- O 0 0.1143764853477478
BRCA1 O 0 0.00034988511470146477
antibodies O 0 9.767205483512953e-06
. O 0 3.459743993516895e-07

These O 0 7.161305859426648e-08
reagents O 0 1.0941490700133727e-06
detect O 0 5.8469900068303104e-06
a O 0 1.5502218175811322e-08
220 O 0 5.926995338967345e-09
- O 0 3.7826978314114967e-06
kD O 0 3.550413566699717e-06
protein O 0 1.725032561239459e-08
localized O 0 5.9266586305284363e-08
in O 0 1.485584655291916e-09
discrete O 0 2.0796561273073166e-07
nuclear O 0 2.0807043256354518e-05
foci O 0 5.574610895564547e-06
in O 0 1.108853364684137e-08
all O 0 1.4527717917545147e-09
epithelial O 0 2.601442793093156e-05
cell O 0 0.000768712256103754
lines O 0 5.24322604178451e-06
, O 0 4.5608980481226524e-10
including O 0 2.1452677134714548e-10
those O 0 2.3882498201288627e-09
derived O 0 1.6306474392990822e-08
from O 0 9.41671700616098e-08
breast B-Disease 0 0.4516213536262512
malignancies I-Disease 0 0.3193109333515167
. O 0 5.478312687046127e-06

Immunohistochemical O 0 0.0013126919511705637
staining O 0 0.00014593687956221402
of O 0 1.2197264709357114e-07
human O 0 2.3729910481051775e-06
breast O 0 0.17986205220222473
specimens O 0 0.0006600985070690513
also O 0 1.1163847375428304e-06
revealed O 0 0.000348665751516819
BRCA1 O 0 0.00033401959808543324
nuclear O 0 8.676350262248889e-05
foci O 0 0.00010810829553520307
in O 0 9.491005243944528e-07
benign O 1 0.6076125502586365
breast O 1 0.9947252869606018
, O 0 1.1534842087712605e-05
invasive B-Disease 0 0.1617826223373413
lobular I-Disease 1 0.9998691082000732
cancers I-Disease 1 0.9998658895492554
and O 0 5.5679167417110875e-05
low B-Disease 0 0.07872821390628815
- I-Disease 1 0.9574578404426575
grade I-Disease 0 0.3452061414718628
ductal I-Disease 1 0.9979275465011597
carcinomas I-Disease 1 0.9999955892562866
. O 0 8.775251626502723e-05

Conversely O 0 3.569442196749151e-05
, O 0 7.301882476440369e-08
BRCA1 O 0 1.0896529602177907e-05
expression O 0 1.9608851289376616e-06
was O 0 1.092858042284206e-06
reduced O 0 9.443193249580872e-08
or O 0 1.068874908582984e-07
undetectable O 0 1.9016898704649066e-06
in O 0 1.0751983747780969e-09
the O 0 5.388801072037097e-10
majority O 0 8.113639204943013e-10
of O 0 5.679855474838291e-10
high O 0 4.215261014905991e-06
- O 0 0.005319160874933004
grade O 0 2.4770341042312793e-05
, O 0 4.461789444576425e-07
ductal B-Disease 0 0.045895881950855255
carcinomas I-Disease 1 0.9999986886978149
, O 0 1.4114290536326735e-07
suggesting O 0 3.423675707381335e-07
that O 0 7.182506589487048e-09
absence O 0 6.7301941797381915e-09
of O 0 1.869057131287377e-09
BRCA1 O 0 0.00035342236515134573
may O 0 7.761596521049796e-07
contribute O 0 7.280930303110722e-10
to O 0 6.447939404630176e-10
the O 0 5.419324100586209e-09
pathogenesis O 0 1.3298583212417725e-07
of O 0 6.292182053169171e-11
a O 0 7.2482895241421375e-09
significant O 0 6.304658128897245e-09
percentage O 0 1.0024866270441635e-07
of O 0 1.3132762655132524e-09
sporadic B-Disease 0 0.002091482514515519
breast I-Disease 1 0.9999164342880249
cancers I-Disease 1 0.999390721321106
. O 0 2.3839786535972962e-06
. O 0 7.028971253930649e-07

